<?xml version="1.0" encoding="utf-8"?>
<?xml-stylesheet type="text/xsl" href="/html/xsl/rss2html.xsl"?>
<rss version="2.0"
xmlns:dc="http://purl.org/dc/elements/1.1/"
xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
xmlns:admin="http://webns.net/mvcb/"
xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
xmlns:content="http://purl.org/rss/1.0/modules/content/">
<channel><title>Ipsen - DKPHybrids Dashboard</title>
<link>http://ci.beaufour-ipsen.com/traction?type=np&amp;proj=*&amp;sdate=20140831&amp;edate=20140501&amp;rs=</link>
<description>DKPHybrids Dashboard</description><dc:language>en-us</dc:language><copyright>Copyright &amp;copy; 2016  All rights reserved.</copyright><category>News</category><docs>http://backend.userland.com/rss</docs><ttl>20</ttl><rating>A1</rating><image>
<title>Ipsen - DKPHybrids Dashboard</title>
<link>http://ci.beaufour-ipsen.com/traction?type=np&amp;proj=*&amp;sdate=20140831&amp;edate=20140501&amp;rs=</link>
<url>http://ci.beaufour-ipsen.com/share/tsi/logos/ipsenbaseline07.jpg</url>
<width>108</width>
<height>31</height>
</image><admin:generatorAgent rdf:resource="http://tractionsoftware.com" /><item>
<title>Yale Study Identifies Possible Anti-Bacterial Strategy to Treat IBD [dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2016</link>
<description>Yale Study Identifies Possible Anti-Bacterial Strategy to Treat IBD [dis:IBD]</description><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2016</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2016">Yale Study Identifies Possible Anti-Bacterial Strategy to Treat IBD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2016">GastroEnterology2016</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 29 August 2014 | 10:53</font><br><br><div style="margin-bottom: 10px;">Comment: Findings published Aug.<wbr>28 in the journal <EM>Cell</EM> indicate that anti-bacterial therapies for IBD were possible.<wbr> Such anti-bacterial approaches might include highly specific antibiotics, vaccines, and probiotics.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Study</STRONG> </div><div style="margin-bottom: 10px;">Researchers at Yale University focused on antibody coatings on the surface of bacteria.<wbr> In particular, the team looked at bacteria with high concentrations of an antibody coating called Immunoglobulin A (IgA).<wbr> </div><div style="margin-bottom: 10px;">The scientists confirmed a correlation between high levels of IgA coating and inflammatory responses in the human intestine.<wbr> To do this, the team collected 'good' and 'bad' bacteria from a small group of patients and transplanted them into mice.<wbr> </div><div style="margin-bottom: 10px;">While in healthy mice there was no influence on intestinal inflammation, in mice with induced colitis, those with the suspected 'bad' bacteria showed signs of excessive inflammation and other IBD symptoms.<wbr> </div><div>The team warned that more research is necessary to learn how many bacterial species fall into the "bad" category and whether those populations are common to all IBD patients or are unique to each patientwarned that more research is necessary to learn how many bacterial species fall into the "bad" category and whether those populations are common to all IBD patients or are unique to each patient.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2016">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-29T10:53:33+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Pfizer Supports Translational Research for IBD [dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2015</link>
<description>Pfizer Supports Translational Research for IBD [dis:IBD]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2015</comments><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2015</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2015">Pfizer Supports Translational Research for IBD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2015">GastroEnterology2015</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 August 2014 | 10:13</font><br><br><div style="margin-bottom: 10px;">Comment: Crohn&rsquo;s &amp; Colitis Foundation of America (CCFA) and Pfizer have entered into an agreement to identify and support the development and translation of research in the area of IBD.<wbr> This new agreement reinforces Pfizer's comitment in the field of IBD.<wbr> A couple of weeks ago, the company inked a deal with 23andME to map the DNA of 10,000 patients who have forms of the disease, in order to identify genetic similarities which could eventually guide development of new targeted drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Agreement</STRONG> </div><div style="margin-bottom: 10px;">The partners will drive translational research projects towards the clinic by using CCFA&rsquo;s expertise in the field of IBD research and CTI&rsquo;s network of academic medical centers.<wbr> </div><div style="margin-bottom: 10px;">CCFA and CTI will initially co-fund up to 4 jointly-selected research projects focused on studying validated targets in Crohn&rsquo;s Disease and ulcerative colitis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Crohn's &amp; Colitis Foundation of America (CCFA)</STRONG> </div><div style="margin-bottom: 10px;">The healthcare organization provides treatment related to Crohn's disease and ulcerative colitis.<wbr> </div><div style="margin-bottom: 10px;">It offers funds for the study at major medical institutions, nurtures investigators at the early stages of their careers.<wbr> </div><div style="margin-bottom: 10px;">CCFA owns and operates information resource center, which provides information, support and guidance on Crohn's and colitis diseases to the public, health care professionals, patients and their families.<wbr> </div><div style="margin-bottom: 10px;">The organization partners with Australia Crohn's &amp; Colitis Association, Australian Crohn's &amp; Colitis Association, Osterreichische Morbus Crohn/<wbr>Colitis Ulcerosa Vereingingung, Crohn en Colitis Ulcerosa Vereniging, and Crohn's and Colitis Foundation of Canada.<wbr> CCFA is headquartered in New York, the US.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Reference in Traction</SPAN> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2005" class="defaultlink">GastroEnterology2005: Pfizer and  23andME Ink Deal to Study Bowel Disease</a>.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2194c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Pfizer and 23andMe have expanded their IBD agreement to enable research, clinical trial recruitment for the treatment of lupus.<wbr> Nearly 4,000 patients have been enrolled in the IBD initiative since August 2014.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2194" class="commentpermalink">GastroEnterology2194</a> / <span class="date">12 January 2015</span> /
<span class="time">17:46:31 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2015">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-28T10:13:13+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Merck Serono's $105M Plant in China to be the Group's Second Largest Manufacturing Facility [mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10937</link>
<description>Merck Serono's $105M Plant in China to be the Group's Second Largest Manufacturing Facility [mkt:China]</description><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10937</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10937">Merck Serono's $105M Plant in China to be the Group's Second Largest Manufacturing Facility</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10937">PharmaWorld10937</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 28 August 2014 | 09:48</font><br><br><div style="margin-bottom: 10px;">Comment: The new pharma manufacturing facility in Nantong will focus on the bulk production and packaging of Merck Serono&rsquo;s leading products in the treatment of diabetes (Glucophage), cardiovascular diseases (Concor) and thyroid disorders (Euthyrox).<wbr> Management reported that the company is the first and only multinational in China to dedicate a large-scale investment to the production of drugs on the company's EDL.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Location and Timeline</STRONG> </div><div style="margin-bottom: 10px;">The new facility will cover an area of 40,000 square meters, with a possible 20,000 square meters extension.<wbr> </div><div style="margin-bottom: 10px;">The construction of the site is scheduled to start in 2014 and to be completed in 2016, and start commercial production in 2017.<wbr> The site will be designed to comply with the highest international quality standards.<wbr> </div><div style="margin-bottom: 10px;">The preservation of the environment will also be a critical consideration in the facility&rsquo;s construction, with a maximization of resource efficiency and minimized waste generation during the manufacturing process.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Merck Footprint in China</STRONG> </div><div>- A research center in Beijing, focused on biomarker research, including pharmacogenomics and bioanalytics, which is part of Merck Serono&rsquo;s stratified medicine approach;<BR>- Enhanced clinical development capabilities, covering over 400 key clinical study sites and having recruited over 10,000 patients accumulatively across China;<BR>- Increased commercial presence to better serve patients and healthcare providers;<BR>- An extensive network of collaborations with leading academic and medical institutions, as well as local companies; Merck Serono&rsquo;s latest collaboration agreement with a Chinese company, announced on November 13, 2013, is a second co-development and commercialization agreement with BeiGene, which will further strengthen the two companies existing collaboration in oncology.<wbr><BR>Recent investments for other divisions of the Merck group include the Merck Millipore Biopharmaceutical Technical and Training Centre and a soon to be opened Liquid Crystals manufacturing facility, both located in Shanghai.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10937">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-28T09:48:16+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Medtronic Buys Dutch Brain Stimulation Company for $200M [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7717</link>
<description>Medtronic Buys Dutch Brain Stimulation Company for $200M [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7717</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7717">Medtronic Buys Dutch Brain Stimulation Company for $200M</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7717">Neurology7717</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 August 2014 | 18:13</font><br><br><div style="margin-bottom: 10px;">Comment: The acquisition of Sapiens Steering Brain Stimulation will help Medtronic gain strength in the medical device market.<wbr> It will also allow Medtronic to take the lead in an emerging area of medicine, the modulation of brain function, and become the partner of choice for neurosurgeons and neuroscience centers around the world.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Medtronic</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company's Neuromodulation business includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity and urologic and gastrointestinal disorders.<wbr> </div><div style="margin-bottom: 10px;">Medtronic helped pioneer DBS, and more than 115,000 patients worldwide have received Medtronic DBS Therapy, which is approved in many locations around the world, including Europe and the United States, for the treatment of the disabling symptoms of essential tremor, advanced Parkinson's disease and chronic intractable primary dystonia, for which approval in the United States is under a Humanitarian Device Exemption (HDE).<wbr> </div><div style="margin-bottom: 10px;">In Europe, Canada and Australia, DBS therapy is approved for the treatment of refractory epilepsy.<wbr> DBS therapy is also approved for the treatment of severe, treatment-resistant obsessive-compulsive disorder in the European Union and Australia, and in the United States under an HDE.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sapiens Steering Brain Stimulation</FONT></STRONG> </div><div style="margin-bottom: 10px;">- founded in 2011 </div><div style="margin-bottom: 10px;">- privately held </div><div style="margin-bottom: 10px;">- Eindhoven based (the Netherlands) </div><div style="margin-bottom: 10px;">Employees at the Eindhoven facility will continue to work toward bringing this technology to market.<wbr> In the future, the site will serve as a global research and development center for Medtronic's Neuromodulation business, complementing our existing R&amp;D operations.<wbr> </div><div style="margin-bottom: 10px;">In 2013, the company raised €7.<wbr>5 m from the Dutch investment group INKEF Capital, in a further extension of their Series A financing round.<wbr> The proceeds are intended for the development of its Steering Brain Stimulation implant and procedure solutions to treat Parkinson’s disease (PD) and other functional brain disorders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Technology</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7717/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7717attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7717/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(26 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7717">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-27T18:13:31+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7717/1/ScreenCapture1.jpg" length="26581" type="image/jpeg"/></item><item>
<title>re: A Ph3 Trial Is Planned To Assess Efficacy Of Combination Enzalutamide And Radium223 in mCRPC</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9906</link>
<description>re: A Ph3 Trial Is Planned To Assess Efficacy Of Combination Enzalutamide And Radium223 in mCRPC</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9906</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9906">re: A Ph3 Trial Is Planned To Assess Efficacy Of Combination Enzalutamide And Radium223 in mCRPC</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9906">Oncology9906</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 27 August 2014 | 12:20</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">A Ph3 Trial Is Planned To Assess Efficacy Of Combination Enzalutamide And Radium223 in mCRPC</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font><br><span style="font-size: 12px;">Comment: This is a EORTC sponsored Ph3 study to evaluate if upfront combination of enzalutamide and radium223 improves radiological progression free survival compared to enzalutamide monotherapy in asymptomatic or mildly symptomatic castration resistant prostate cancer.<wbr> The study has not yet open for recruitment.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9837">...</a><br><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9837" class="commentpermalink">Oncology9837</a> / <span class="date">22 July 2014</span> /
<span class="time">18:41:32 o'clock CEST</span>
</font></div><div>A similar Ph2 trial (<SPAN style="font-size: small;"><SPAN style="text-align: left; color: #000000; text-transform: none; line-height: 22.39px; text-indent: 0px; letter-spacing: normal; font-family: arial, 'Nimbus Sans L', sans-serif; font-style: normal; font-variant: normal; font-weight: normal; word-spacing: 0px; float: none; display: inline !important; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;">NCT02225704</SPAN>)</SPAN> sponsored by All Ireland Cooperative Oncology Research Group (ICORG) is also ongoing in Ireland - primarily to determine the safety and tolerability of radium-223 in combination with enzalutamide.<wbr> Due to the primary objective is to determine safety and tolerability, the trial design is very different from the Ph3 trial as it is an open label study with single group assignment.<wbr> The total recruitment of 44 patients is expected and the study is expected to complete in Dec 2016.<wbr> The secondary outcome measure also includes time to clinical and PSA progression, time to first skeletal event, overall survival (for up to 2 years).<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9906" class="commentpermalink">Oncology9906</a> / <span class="date">27 August 2014</span> /
<span class="time">12:20:18 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9906">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9837">View thread  Oncology9837: A Ph3 Trial Is Planned To Assess Efficacy Of Combination Enzalutamide And Radium223 in mCRPC</a>]]></content:encoded><dc:date>2014-08-27T12:20:18+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>A Spanish Trial To Determine the Effectivness of Hexaminolevulinate In The Diagnosis And Treatment Of Patients With NMIBC [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9904</link>
<description>A Spanish Trial To Determine the Effectivness of Hexaminolevulinate In The Diagnosis And Treatment Of Patients With NMIBC [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9904</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9904">A Spanish Trial To Determine the Effectivness of Hexaminolevulinate In The Diagnosis And Treatment Of Patients With NMIBC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9904">Oncology9904</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 27 August 2014 | 11:11</font><br><br><div style="margin-bottom: 10px;">Comment: A <U>Spanish only</U>, post-authorization, observational study to assess efficacy and sensitivity of Hexvix for non muscle invasive bladder cancer (NMIBC) patients, is now completed.<wbr> Out of a total of 283 patients enrolled in the study, the study results show a superior overall lesion detection rate by Hexaminolevulinate + blue light cystoscopy compared to white light cystoscopy.<wbr> Hexaminolevulinate with blue light shows higher sensitivity for obtaining a correct diagnosis of bladder cancer at individual patient level.<wbr> However, lack of statistical analysis provided to assess the significance of difference is the limitation of the study.<wbr> Ipsen (led by Bryan Qvick, Medical Director, UroOncology Franchise) is currently working with one of the key Principal Investigators, Professor Palou, for a full publication manuscript.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrial.<wbr>Gov Identifier: <U><FONT color="#0066cc">NCT00634621</FONT></U> </div><div style="margin-bottom: 10px;">Study First Started: 26 Feb 2008 </div><div style="margin-bottom: 10px;">Study Completed 05 Dec 2013 </div><div style="margin-bottom: 10px;">Study results released: 24 Aug 2014 </div><div style="margin-bottom: 10px;">Total number of participants infused with 50 ML of a 2 mg/<wbr>mL Hexaminolevulinate solution = 283 </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;"><STRONG>Baseline Patient Characteristic</STRONG></SPAN>: </div><div style="margin-bottom: 10px;"><TABLE border="0" style="width: 509px; height: 200px;"><TBODY><TR><TD colspan="2"><STRONG>Age</STRONG></TD>
</TR>
<TR><TD><STRONG>&le; 18 years</STRONG></TD>
<TD><STRONG>0</STRONG></TD>
</TR>
<TR><TD><STRONG>18-65 years</STRONG></TD>
<TD><STRONG>110</STRONG></TD>
</TR>
<TR><TD><STRONG>&ge; 65 years</STRONG></TD>
<TD><STRONG>173</STRONG></TD>
</TR>
<TR><TD colspan="2"><STRONG>Gender</STRONG></TD>
</TR>
<TR><TD><STRONG>Female</STRONG></TD>
<TD><STRONG>40</STRONG></TD>
</TR>
<TR><TD><STRONG>Male</STRONG></TD>
<TD><STRONG>243</STRONG></TD>
</TR>
<TR><TD colspan="2"><STRONG>Region of Enrollment</STRONG></TD>
</TR>
<TR><TD><STRONG>Spain</STRONG></TD>
<TD><STRONG>283</STRONG></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><STRONG>Detecting the Rate of Bladder Cancer Lesions by White-Light Cystoscopy (WLC) and Blue-Light Cystoscopy (BLC) With Hexvix&reg; in the Overall Study Population by Comparison With the Diagnostic Gold Standard, i.<wbr>e.<wbr> Histological Examination of Lesions Biopsy</STRONG>.<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="data_table" style="margin-top: 0.5ex; border-bottom-color: currentColor; border-left-color: currentColor; border-bottom-width: 2px; border-left-width: 2px; border-bottom-style: ridge; border-left-style: ridge;"><TBODY><TR><TH class="brt bold_outcome_color"></TH>
<TH align="center" class="header3 brt bold_outcome_color"><SPAN style="font-size: small;"> Hexvix + WLC + BLC </SPAN></TH>
<TH align="center" class="header3 brt bold_outcome_color"><SPAN style="font-size: small;">Hexvix + WLC</SPAN></TH>
<TH align="center" class="header3 brt bold_outcome_color"><SPAN style="font-size: small;">Hexvix + BLC</SPAN></TH>
<TH align="center" class="header3 brt bold_outcome_color"><SPAN style="font-size: small;"> Multiple Normalized Biopsy </SPAN></TH>
</TR>
<TR><TH align="left" class="header3 brt bold_outcome_color" style="max-width: 50%;"><SPAN style="font-size: small;">Number of Participants Analyzed </SPAN><BR><SPAN class="body3" style="font-size: small;">[units: participants]<BR></SPAN></TH>
<TD align="center" class="header3 brt pale_outcome_color"><SPAN style="font-size: small;"> 283 </SPAN></TD>
<TD align="center" class="header3 brt pale_outcome_color"><SPAN style="font-size: small;"> 283 </SPAN></TD>
<TD align="center" class="header3 brt pale_outcome_color"><SPAN style="font-size: small;"> 283 </SPAN></TD>
<TD align="center" class="header3 brt pale_outcome_color"><SPAN style="font-size: small;"> 283 </SPAN></TD>
</TR>
<TR><TH align="left" class="header3 brt bold_outcome_color" style="max-width: 50%;"><SPAN class="body3" style="font-size: small;">No of lesions </SPAN></TH>
<TD class="brt pale_outcome_color">&nbsp;</TD>
<TD class="brt pale_outcome_color">&nbsp;</TD>
<TD class="brt pale_outcome_color">&nbsp;</TD>
<TD class="brt pale_outcome_color">&nbsp;</TD>
</TR>
<TR><TD class="header3 br bold_outcome_color" style="padding-left: 2em; max-width: 50%;">Tumor Stage-Carcinoma in situ</TD>
<TD align="center" class="header3 br pale_outcome_color">41</TD>
<TD align="center" class="header3 br pale_outcome_color">1</TD>
<TD align="center" class="header3 br pale_outcome_color">31</TD>
<TD align="center" class="header3 br pale_outcome_color">30</TD>
</TR>
<TR><TD class="header3 br bold_outcome_color" style="padding-left: 2em; max-width: 50%;">Tumor Stage-Ta</TD>
<TD align="center" class="header3 br pale_outcome_color">236</TD>
<TD align="center" class="header3 br pale_outcome_color">2</TD>
<TD align="center" class="header3 br pale_outcome_color">64</TD>
<TD align="center" class="header3 br pale_outcome_color">1</TD>
</TR>
<TR><TD class="header3 br bold_outcome_color" style="padding-left: 2em; max-width: 50%;">Tumor Stage- T1</TD>
<TD align="center" class="header3 br pale_outcome_color">127</TD>
<TD align="center" class="header3 br pale_outcome_color">0</TD>
<TD align="center" class="header3 br pale_outcome_color">9</TD>
<TD align="center" class="header3 br pale_outcome_color">2</TD>
</TR>
<TR><TD class="header3 br bold_outcome_color" style="padding-left: 2em; max-width: 50%;">Tumor Stage- T2-T4</TD>
<TD align="center" class="header3 br pale_outcome_color">29</TD>
<TD align="center" class="header3 br pale_outcome_color">3</TD>
<TD align="center" class="header3 br pale_outcome_color">2</TD>
<TD align="center" class="header3 br pale_outcome_color">1</TD>
</TR>
<TR><TD class="header3 br bold_outcome_color" style="padding-left: 2em; max-width: 50%;">Tumor could not be stage-Tx</TD>
<TD align="center" class="header3 br pale_outcome_color">36</TD>
<TD align="center" class="header3 br pale_outcome_color">0</TD>
<TD align="center" class="header3 br pale_outcome_color">4</TD>
<TD align="center" class="header3 br pale_outcome_color">2</TD>
</TR>
<TR><TD class="header3 br bold_outcome_color" style="padding-left: 2em; max-width: 50%;">TOTAL</TD>
<TD align="center" class="header3 br pale_outcome_color">469</TD>
<TD align="center" class="header3 br pale_outcome_color">6</TD>
<TD align="center" class="header3 br pale_outcome_color">110</TD>
<TD align="center" class="header3 br pale_outcome_color">36</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">Assess the Sensitivity of Standard White Light Cystoscopy (WLC) and Blue Light Cystoscopy (BLC) for Obtaining a Correct Diagnosis of Bladder Cancer at Individual Patient Level </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="data_table" style="margin-top: 0.5ex; border-bottom-color: currentColor; border-left-color: currentColor; border-bottom-width: 2px; border-left-width: 2px; border-bottom-style: ridge; border-left-style: ridge;"><TBODY><TR><TD class="header3 br bold_outcome_color" style="padding-left: 2em; max-width: 50%;">Intervention</TD>
<TD align="center" class="header3 br pale_outcome_color">% of Confirmed Lesions (95% confidence interval)</TD>
</TR>
<TR><TD class="header3 br bold_outcome_color" style="padding-left: 2em; max-width: 50%;">Hexvix + WLC</TD>
<TD align="center" class="header3 br pale_outcome_color">86.<wbr>3 <BR> ( 81.<wbr>7 to 90.<wbr>9 )</TD>
</TR>
<TR><TD class="header3 br bold_outcome_color" style="padding-left: 2em; max-width: 50%;">Hexvix + BLC</TD>
<TD align="center" class="header3 br pale_outcome_color">90.<wbr>9 <BR> ( 86.<wbr>2 to 94.<wbr>3 )</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table indent2" summary="Layout table for investigator information"><TBODY><TR><TD colspan="2" headers="name" nowrap="nowrap" style="padding: 1ex 1em 0px 0px;"><STRONG>Principal Investigators</STRONG></TD>
</TR>
<TR><TD headers="name" nowrap="nowrap" style="padding: 1ex 1em 0px 0px;">Dr.<wbr> Carlos Hern&aacute;ndez</TD>
<TD headers="affiliation" nowrap="nowrap" style="padding: 1ex 1em 0px 0px;">Gregorio Mara&ntilde;&oacute;n Hospital, Madrid</TD>
</TR>
<TR><TD headers="name" nowrap="nowrap" style="padding: 1ex 1em 0px 0px;">Dr.<wbr> Eduardo Solsona</TD>
<TD headers="affiliation" nowrap="nowrap" style="padding: 1ex 1em 0px 0px;">Valencian Institute of Oncology, Valencia</TD>
</TR>
<TR><TD headers="name" nowrap="nowrap" style="padding: 1ex 1em 0px 0px;">Dr.<wbr> Joan Palou</TD>
<TD headers="affiliation" nowrap="nowrap" style="padding: 1ex 1em 0px 0px;">Fundaci&oacute;n Puigvert, Barcelona</TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: <A href="http://www.clinicaltrial.gov">www.<wbr>clinicaltrial.<wbr>gov</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9904">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-27T11:11:33+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>re: Cologuard® Test Under Review for Detecting Colorectal Cancer</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2013</link>
<description>re: Cologuard® Test Under Review for Detecting Colorectal Cancer</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2013</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2013">re: Cologuard® Test Under Review for Detecting Colorectal Cancer</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2013">GastroEnterology2013</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 August 2014 | 20:04</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Cologuard® Test Under Review for Detecting Colorectal Cancer</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The test from Exact Sciences Corp.<wbr> and the Mayo Clinic detects more tumors than methods using blood in the stool, revealed the study.<wbr> Lead author Thomas Imperiale from Indiana U.<wbr> Medical Center in Indianapolis said the test has been to be having about as much potential as colonoscopy has for detecting colon cancer.<wbr> The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review Exact Science’s PMA application for Cologuard on March 27, 2014.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1945">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1945" class="commentpermalink">GastroEnterology1945</a> / <span class="date">19 March 2014</span> /
<span class="time">16:59:26 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">Mayo officials announced yesterday they will be the first in the US to offer patients the Cologuard test, by which patients collect their stool samples and mail them in sealed containers for DNA analysis of their colon cancer risks.<wbr> </div><div style="margin-bottom: 10px;"><P class="Text_Body"><STRONG>Cologuard Prescription &amp; Usage</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="Text_Body">Cologuard is intended for adults 50 and older who are only at average risk for colon cancer based on their health and family history.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Text_Body">After mailing in stool samples in secure packaging provided by the company, patients will learn of their results from their doctors in as little as two weeks.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="Text_Body"><STRONG>Medical Publication</STRONG></P> </div><div><P class="Text_Body">Clinical trial results published this March in the <EM>New England Journal of Medicine</EM> showed the test was 92% accurate at identifying patients with colon cancer and 69% accurate at identifying patients with the kinds of bowel lesions or polyps that indicate a high risk for cancer.<wbr></P> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2013" class="commentpermalink">GastroEnterology2013</a> / <span class="date">26 August 2014</span> /
<span class="time">20:04:02 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2013">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1945">View thread  GastroEnterology1945: Cologuard® Test Under Review for Detecting Colorectal Cancer</a>]]></content:encoded><dc:date>2014-08-26T20:04:02+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Heads of Roche and Novartis Postpone Russia Trip [mkt:Russia]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10935</link>
<description>Heads of Roche and Novartis Postpone Russia Trip [mkt:Russia]</description><category>mkt:Russia</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10935</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10935">Heads of Roche and Novartis Postpone Russia Trip</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10935">PharmaWorld10935</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 August 2014 | 19:48</font><br><br><div style="margin-bottom: 10px;">Comment: Swiss Economics Minister has decided to postpone his trip to Russia until the situation in Ukraine has settled down.<wbr> The Heads of Roche and Novartis were meant to join him, as well as representatives of about 20 other companies.<wbr> </div><div style="margin-bottom: 10px;">The visit had been scheduled for October, but as Johann Schneider-Ammann told the Swiss News Agency on Monday, it would not take place before 2015.<wbr> </div><div style="margin-bottom: 10px;">The minister said he was waiting for Russian-Ukrainian relations to improve, and for the negotiations between Russia and the European Free Trade Association &ndash; which includes Norway, Iceland, Liechtenstein and Switzerland &ndash; to continue.<wbr> </div><div style="margin-bottom: 10px;">Unlike the member countries of the EU, Switzerland has not imposed sanctions on Russia.<wbr> However, the Swiss authorities are looking into measures to prevent circumvention of the sanctions.<wbr> </div><div style="margin-bottom: 10px;">Switzerland currently holds the presidency of the Organization for Security and Co-operation (OSCE) in Europe.<wbr> As Schneider-Ammann has pointed out, adopting the EU&rsquo;s sanctions would weaken Switzerland&rsquo;s OSCE role as mediator.<wbr> </div><div><EM>Source: swissinfo.<wbr>ch and agencies</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10935">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-26T19:48:48+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Ferring to Assess Non-Inferiority of FE 999169 Vs NIFLEC® in Japan [sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2011</link>
<description>Ferring to Assess Non-Inferiority of FE 999169 Vs NIFLEC® in Japan [sub:CRCPrevention, :PharmaWorld:sub:ClinicalTrial]</description><category>sub:CRCPrevention</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2011</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2011">Ferring to Assess Non-Inferiority of FE 999169 Vs NIFLEC® in Japan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2011">GastroEnterology2011</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 August 2014 | 13:37</font><br><br><div style="margin-bottom: 10px;">Comment: Clinicaltrials.<wbr>gov is listing a new Ph3 trial to demonstrate non inferiority of 1) "FE 999169 Split Dosing Schedule" (one dose on the day before and the second dose on the day of colonoscopy) and 2) "FE 999169 Day Before Dosing Schedule" (two doses on the day before colonoscopy) to " Niflec On the Day Dosing Schedule" in subjects requiring colonoscopy or colorectal surgery.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ajinomoto's NIFLEC&reg;</STRONG> </div><div style="margin-bottom: 10px;">- launched in 1992 </div><div style="margin-bottom: 10px;">- the product is widely used in Japan for the pretreatment of colonoscopic examination as well as in pretreatment for colon surgery.<wbr> It does not require diet restrictions which are usually necessary until the day before examination.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ajinomoto's Comittment in the Gastro Field</STRONG> </div><div style="margin-bottom: 10px;">In 2008, Ajinomoto acquired the exclusive rights to develop, manufacture and market Norgine's MOVIPREP in Japan.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details J-CLEAR - </STRONG><a href="http://www.clinicaltrials.gov/ct2/show/NCT02215954?recr=Open&phase=012&fund=2&rcv_s=07%2F22%2F2014&rank=157" class="defaultlink">Ref NCT02215954</a> </div><div style="margin-bottom: 10px;">Recruitment approx.<wbr> 600 participants </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Japanese patients, age 20 to 80 years inclusive, requiring colonoscopy
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Female patients should be post-menopausal (women &ge;45 years with no menstrual period for at least 12 months without an alternative medical cause), or be surgically sterile, or be using medically approved contraception, throughout the trial period.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Fertile female patients must have a confirmed negative pregnancy test at screening and randomization
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Patients must have had more than or equal to 3 spontaneous bowel movements per week prior to the colonoscopy
</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines: Start date Sept 2014 - Completion date: March 2015 </div><div>Location: Japan (4) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2011">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-25T13:37:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Merck &amp; Co and Advaxis to Evaluate Two Novel Immunotherapy Candidates for Advanced Prostate Cancer [dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9903</link>
<description>Merck &amp; Co and Advaxis to Evaluate Two Novel Immunotherapy Candidates for Advanced Prostate Cancer [dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Prostate</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9903</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9903">Merck & Co and Advaxis to Evaluate Two Novel Immunotherapy Candidates for Advanced Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9903">Oncology9903</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 August 2014 | 12:07</font><br><br><div style="margin-bottom: 10px;">Comment: Both Advaxis' ADXS-PSA and Merck's pembrolizumab are investigational members of a new class of cancer treatments known as immunotherapies that are designed to enhance the body's own defenses in fighting cancer.<wbr> Advaxis will evaluate the use of its ADXS-PSA as a standalone treatment and also in combination with pembrolizumab in the Ph1/<wbr>Ph2 trial.<wbr> If the combination of drugs shows an added effect, the companies would likely continue their collaboration, perhaps under a licensing deal.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Agreement</STRONG> </div><div style="margin-bottom: 10px;">The Ph1 part of the trial is designed to establish a recommended dose regimen for ADXS-PSA alone and combined with pembrolizumab, and the Ph2 portion will assess the safety and efficacy of the combination.<wbr> </div><div style="margin-bottom: 10px;">Advaxis will sponsor and fund the study and Merck will provide pembrolizumab.<wbr> </div><div style="margin-bottom: 10px;">The companies will collaboratively oversee the conduct of the study, which is planned to begin in early 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Advaxis Drug</STRONG> </div><div style="margin-bottom: 10px;">- consists of a modified form of the Listeria bacterium fused to a protein called PSA that is shed by prostate tumors.<wbr> It is meant to spur creation of immune system soldiers, called T-cells, that are primed to recognize and kill prostate cancer cells.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Merck Drug</STRONG> </div><div style="margin-bottom: 10px;">- member of the PD-1 inhibitors that work by blocking the PD-1 protein, thereby taking the brakes off immune system cells and prodding them to attack tumors.<wbr> </div><div><EM>Sources: Merck &amp; Co; Advaxis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9903">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-25T12:07:46+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Expects Significant Revenues from India [comp:Allergan, prod:Botox, :PharmaWorld:mkt:India]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7715</link>
<description>Allergan Expects Significant Revenues from India [comp:Allergan, prod:Botox, :PharmaWorld:mkt:India]</description><category>comp:Allergan</category><category>prod:Botox</category><category>mkt:India</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7715</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7715">Allergan Expects Significant Revenues from India</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aIndia"><font color="#e95e0b">:PharmaWorld:mkt:India</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7715">Neurology7715</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 August 2014 | 11:35</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan India expects a more than two-fold jump in its revenues in the next 4 years due to new product launches (two to three-eye-care products every year, and skin care products from SkinMedica portfolio), and the consolidation of existing business segments.<wbr> On the cosmetics business managing director reported that it is "still at a nascent stage".<wbr> He outlined that about 20% of new users that the company is adding every year in India are men versus 5% five years ago.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Profile of Males Botox Users</STRONG> </div><div style="margin-bottom: 10px;">(source: cosmetic physician Jamuna Pai) </div><div><UL><LI>50% under 35 years old
</LI>
<LI>Models, actors, businessmen, politicians, marketing, sales personels, rich farmers from towns and villages.<wbr>
</LI>
<LI>Apart from skin tightenin, men want leaner faces and fuller lips.<wbr>
</LI>
<LI>Many of them want to control excessive sweating of the plams
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7715">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-25T11:35:24+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Botox May SlowTumor Growth in Stomach Cancer</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7714</link>
<description>re: Botox May SlowTumor Growth in Stomach Cancer</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7714</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7714">re: Botox May SlowTumor Growth in Stomach Cancer</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7714">Neurology7714</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/714">Karen ZINKEWICH-PEOTTI</a> | 25 August 2014 | 09:34</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Botox May SlowTumor Growth in Stomach Cancer</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Study results published in Science Translational Medicine demonstrated that Botox was able to slow tumour growth in animal models with stomach cancer.<wbr> A Ph2 of the method in patients with stomach cancer is now taking place in Norway.<wbr> The purpose of the study is to obtain data needed to calculate sample size in a larger controlled trial.<wbr> PE will measure change of tumour volumein the stomach.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7711">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7711" class="commentpermalink">Neurology7711</a> / <span class="date">21 August 2014</span> /
<span class="time">09:01:17 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">This recently published paper  &ldquo;<STRONG>Denervation suppresses gastric tumorigenesis&rdquo;  </STRONG>Sci Transl Med 20 August 2014, has generated much interest within Ipsen.<wbr>  The paper is elegant and demonstrates in a number of models, using different approaches (surgery, botulinum toxin administration, knock-out mice and a small molecule inhibitor of the muscarinic receptor M3) that there is cross-talk between the gastric nerves and stem cells/<wbr>cancer cells.<wbr>  These experimental results have also lead to a small clinical trial administering Botox to 10 patients with gastric cancer, unable or unwilling to be treated by other therapies.<wbr> </div><div style="margin-bottom: 10px;">Much like has been shown for blood vessels through the process of angiogenesis and for immunological cells in the tumour microenvironment, there is an interaction between neuronal cells and cancer cells, such that in some tumour types, cancer cells stimulate active nerve cell growth.<wbr>  The authours here have also clearly shown an effect on cancer stem cells.<wbr> There is also epidemiological data indicating that vagotomy which is the resection of the vagus nerve often used as a treatment of gastric ulcers, decreases the risk of gastric cancer by 50% at the second ten-year follow-up post vagotomy (but not during the first 10 year follow-up).<wbr>  This suggests, that like inflammation, nerves can contribute to conditions that favour tumour growth and survival.<wbr> </div><div style="margin-bottom: 10px;">The results in this paper point once again to the importance of the Wnt pathway in cancer.<wbr> This is a pathway that has been of much interest in the pharmaceutical industry in the past twenty years, and there are a number of inhibitors of both the Wnt and the related Notch pathways in discovery and development.<wbr>  As the Wnt family is made up of 19 different glycoproteins, and two major signaling routes (termed canonical and non-canonical) identifying the right targets to inhibit in order to minimize side effects and avoid redundancy, has not been easy.<wbr>   More importantly for this paper, a high proportion, if not all of the effects observed, are due to signaling through the muscarinic receptor M3 (which subsequently goes through the Wnt pathway).<wbr> The M3 receptor antagonist darifenacin is already in clinical use for overactive urinary bladder, and as the authours of this paper suggest, warrants being tried in gastric cancer, as an alternative to the approach being taken with Botox.<wbr> The at least additive effects with chemotherapy shown in the animal models, indicates that there is potential for combination therapy.<wbr> </div><div style="margin-bottom: 10px;">We continue to look at opportunities for botulinum toxins, either as pure agents or as TSIs, to treat cancer.<wbr> Such approaches can also be used as tools to validate a therapeutic angle that can then be addressed, in some cases, by peptides.<wbr>  A unifying theme in Oncology R&amp;D at Ipsen is the tumour microenvironment, starting with TASQ and leading to other immunomodulatory targets, and other cell types that sustain tumour growth and survival.<wbr> Emerging literature, including this publication, underline the contribution of multiple cell types such as neuronal and neuroendocrine cells, to tumourigenesis  and cancer.<wbr> </div><div style="margin-bottom: 10px;">Happy to discuss further </div><div>Karen &amp; Fabien </div><!-- Comment details --><font size="-1">Karen ZINKEWICH-PEOTTI / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7714" class="commentpermalink">Neurology7714</a> / <span class="date">25 August 2014</span> /
<span class="time">09:34:07 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7714">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7711">View thread  Neurology7711: Botox May SlowTumor Growth in Stomach Cancer</a>]]></content:encoded><dc:date>2014-08-25T09:34:07+02:00</dc:date><dc:creator>kaz87007</dc:creator></item><item>
<title>Sigma-Tau Complement its OTC Pediatric Line in the US [sub:Probiotics, :PharmaWorld:mkt:NorthAmerica, dis:IBS]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2009</link>
<description>Sigma-Tau Complement its OTC Pediatric Line in the US [sub:Probiotics, :PharmaWorld:mkt:NorthAmerica, dis:IBS]</description><category>sub:Probiotics</category><category>mkt:NorthAmerica</category><category>dis:IBS</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2009</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2009">Sigma-Tau Complement its OTC Pediatric Line in the US</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2009">GastroEnterology2009</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 August 2014 | 15:17</font><br><br><div style="margin-bottom: 10px;">Comment: Sigma-Tau Consumer Products, a division of Sigma-Tau, has signed an exclusive US license agreement with Crosscare of Dublin to market and distribute Colief<SUP>®</SUP> Infant Drops for the treatment of colic.<wbr> In a separate PR, Sigma-Tau has announced its goal to broaden consumer awarness of VSL#3 at the pharmacy shelf.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Deal with Crosscare</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Rationale for Sigma-Tau</STRONG> </div><div style="margin-bottom: 10px;">Colief<SUP>®</SUP> complements Sigma-Tau existing OTC pediatric product line marketed to pediatricians, including <A href="http://www.vsl3.com/discover.asp">VSL#3<SUP>®</SUP> JUNIOR</A>, a probiotic for the dietary management of irritable bowel syndrome and ulcerative colitis in children.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2009/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Colief<SUP>®</SUP> Infant Drops</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2009/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Colic affects approx.<wbr> one in every five infants and may be due to a number of causes including transient lactose intolerance (causing bloating and gas) (TLI).<wbr> </div><div style="margin-bottom: 10px;">Colief<SUP>®</SUP> Infant Drops, an all-natural dietary supplement available OTC, is supported by published research demonstrating the ability to reduce colic-related crying caused by TLI.<wbr> </div><div style="margin-bottom: 10px;">The active ingredient in Colief<SUP>®</SUP> is lactase.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">VSL#3 @ the Pharmacy Shelf</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2009/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">VSL#3 is a medical food probiotic, a potent proprietary formulation of 8 strains of live lactic acid bacteria.<wbr> Because it needs refrigeration, Sigma-Tau has, up until recently, relied mainly on physicians who recommend it and send patients to the pharmacy to find it.<wbr> </div><div style="margin-bottom: 10px;">Group Product Director , Sigma-Tau: " .<wbr>.<wbr>.<wbr> The introduction of pharmacy cards for VSL#3 will help alleviate any disconnect between physicians recommending VSL#3 and the patients getting lost at the shelf when they don't see the product.<wbr>" </div><div><EM>Source: Sigma-Tau</EM> </div><!-- Comment details --><a name="gastroenterology2009attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2009/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(25,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2009/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(29 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2009/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(10,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2009">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-21T15:17:35+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2009/1/ScreenCapture1.jpg" length="25915" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2009/2/ScreenCapture2.jpg" length="29696" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2009/3/ScreenCapture3.jpg" length="11122" type="image/jpeg"/></item><item>
<title>Botox May SlowTumor Growth in Stomach Cancer [class:BotulinumToxins, prod:Botox, :Oncology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7711</link>
<description>Botox May SlowTumor Growth in Stomach Cancer [class:BotulinumToxins, prod:Botox, :Oncology:news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7711</comments><category>class:BotulinumToxins</category><category>prod:Botox</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7711</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7711">Botox May SlowTumor Growth in Stomach Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7711">Neurology7711</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 August 2014 | 09:01</font><br><br><div style="margin-bottom: 10px;">Comment: Study results published in Science Translational Medicine demonstrated that Botox was able to slow tumour growth in animal models with stomach cancer.<wbr> A Ph2 of the method in patients with stomach cancer is now taking place in Norway.<wbr> The purpose of the study is to obtain data needed to calculate sample size in a larger controlled trial.<wbr> PE will measure change of tumour volumein the stomach.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Reference</FONT></STRONG> </div><div style="margin-bottom: 10px;">"Denervation suppresses gastric tumorigenesis" </div><div style="margin-bottom: 10px;"><EM><ABBR class="slug-jnl-abbrev" title="Science Translational Medicine">Sci Transl Med</ABBR> 20 August 2014: Vol.<wbr> 6, Issue 250, p.<wbr> 250ra115 Sci.<wbr> Transl.<wbr> Med.<wbr> DOI: 10.<wbr>1126/<wbr>scitranslmed.<wbr>3009569</EM>.<wbr> </div><div style="margin-bottom: 10px;"><A href="http://stm.sciencemag.org/content/6/250/250ra115.full">http:/<wbr>/<wbr>stm.<wbr>sciencemag.<wbr>org/<wbr>content/<wbr>6/<wbr>250/<wbr>250ra115.<wbr>full</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ongoing Clinical Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">Official Title: Botulinum Toxin for Stomach Cancer Treatment </div><div style="margin-bottom: 10px;">Methodology: In this pilot study Botox injections (100U) will be given by gastroscopy in both the tumor and the surrounding stomach wall.<wbr> </div><div style="margin-bottom: 10px;">Timelines: The study started in January last year with completion dates expected Dec 2015 and Feb 2016.<wbr> </div><div style="margin-bottom: 10px;">Recruitment approx.<wbr> 10 (both genders; 18 to 80 years old).<wbr> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 0ex">Patients with verified gastric adenocarcinoma but found non-resectable or inoperable after evaluation in the appropriate multidisciplinary team at St.<wbr>Olav Hospital.<wbr> Trondheim University Hospital.<wbr> The inclusion criteria for such patients are:</P> </div><div style="margin-bottom: 10px;"><OL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients who have received 1.<wbr>line and 2.<wbr> line chemotherapy but no longer respond to such therapy.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients who, due to toxicity of chemotherapy, cannot be offered such treatment.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients who, after meticulous information about chemotherapy, still do not want such treatment.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patients with performance status (ECOG) 0-2.<wbr></LI>
</OL> </div><div style="margin-bottom: 10px;">PI: Jon Erik Grønbech, MD.<wbr> PhD.<wbr> St.<wbr> Olavs Hospital.<wbr> </div><div><A href="http://clinicaltrials.gov/show/NCT01822210">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>show/<wbr>NCT01822210</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7714c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">This recently published paper  &ldquo;<STRONG>Denervation suppresses gastric tumorigenesis&rdquo;  </STRONG>Sci Transl Med 20 August 2014, has generated much interest within Ipsen.<wbr>  The paper is elegant and demonstrates in a number of models, using different approaches (surgery, botulinum toxin administration, knock-out mice and a small molecule inhibitor of the muscarinic receptor M3) that there is cross-talk between the gastric nerves and stem cells/<wbr>cancer cells.<wbr>  These experimental results have also lead to a small clinical trial administering Botox to 10 patients with gastric cancer, unable or unwilling to be treated by other therapies.<wbr> </div><div style="margin-bottom: 10px;">Much like has been shown for blood vessels through the process of angiogenesis and for immunological cells in the tumour microenvironment, there is an interaction between neuronal cells and cancer cells, such that in some tumour types, cancer cells stimulate active nerve cell growth.<wbr>  The authours here have also clearly shown an effect on cancer stem cells.<wbr> There is also epidemiological data indicating that vagotomy which is the resection of the vagus nerve often used as a treatment of gastric ulcers, decreases the risk of gastric cancer by 50% at the second ten-year follow-up post vagotomy (but not during the first 10 year follow-up).<wbr>  This suggests, that like inflammation, nerves can contribute to conditions that favour tumour growth and survival.<wbr> </div><div style="margin-bottom: 10px;">The results in this paper point once again to the importance of the Wnt pathway in cancer.<wbr> This is a pathway that has been of much interest in the pharmaceutical industry in the past twenty years, and there are a number of inhibitors of both the Wnt and the related Notch pathways in discovery and development.<wbr>  As the Wnt family is made up of 19 different glycoproteins, and two major signaling routes (termed canonical and non-canonical) identifying the right targets to inhibit in order to minimize side effects and avoid redundancy, has not been easy.<wbr>   More importantly for this paper, a high proportion, if not all of the effects observed, are due to signaling through the muscarinic receptor M3 (which subsequently goes through the Wnt pathway).<wbr> The M3 receptor antagonist darifenacin is already in clinical use for overactive urinary bladder, and as the authours of this paper suggest, warrants being tried in gastric cancer, as an alternative to the approach being taken with Botox.<wbr> The at least additive effects with chemotherapy shown in the animal models, indicates that there is potential for combination therapy.<wbr> </div><div style="margin-bottom: 10px;">We continue to look at opportunities for botulinum toxins, either as pure agents or as TSIs, to treat cancer.<wbr> Such approaches can also be used as tools to validate a therapeutic angle that can then be addressed, in some cases, by peptides.<wbr>  A unifying theme in Oncology R&amp;D at Ipsen is the tumour microenvironment, starting with TASQ and leading to other immunomodulatory targets, and other cell types that sustain tumour growth and survival.<wbr> Emerging literature, including this publication, underline the contribution of multiple cell types such as neuronal and neuroendocrine cells, to tumourigenesis  and cancer.<wbr> </div><div style="margin-bottom: 10px;">Happy to discuss further </div><div>Karen &amp; Fabien </div><font size="-1">Karen ZINKEWICH-PEOTTI / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7714" class="commentpermalink">Neurology7714</a> / <span class="date">25 August 2014</span> /
<span class="time">09:34:07 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7711">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-21T09:01:17+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Altor BioScience's Recieved $1.2m Grant From NCI To Trial ALT-803 + BCG In Non Muscle Invasive Bladder Cancer [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9902</link>
<description>Altor BioScience's Recieved $1.2m Grant From NCI To Trial ALT-803 + BCG In Non Muscle Invasive Bladder Cancer [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9902</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9902">Altor BioScience's Recieved $1.<wbr>2m Grant From NCI To Trial ALT-803 + BCG In Non Muscle Invasive Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9902">Oncology9902</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 20 August 2014 | 18:01</font><br><br><div style="margin-bottom: 10px;">Comment: Bladder cancer has long been known as 'the forgotten cancer' as no investment nor research focus was geared towards improving the lives of patients suffer from bladder cancer over decades.<wbr> Bladder cancer is known as a 'highly immunogenic' cancer due to the well established efficacy of BCG therapy in non muscle invasive bladder cancer (NMIBC).<wbr> Recent promising result of Roche's anti-PD1 presented at ASCO in Chicago this year has sparkled a light of hope for the success of a new generation of immunotherapies in metastatic bladder cancer (<A class="title" href="traction#/single&amp;proj=Oncology&amp;sort=2&amp;stickyparams=sort&amp;rec=9756"><U><FONT color="#0066cc">Roche Gains Breakthrough Designation For Its Immunotherapy Approach In Bladder Cancer</FONT></U></A>).<wbr> Furthermore, there are increasingly growing evidences of research effort focusing on 'improving' BCG's efficacy in NMIBC by trialling immunotherapy doublet (i.<wbr>e in combination with BCG).<wbr> ALT-803 (Altor BioScience) is the third candidate this year with the NCI grant support for the Ph2 study trialled in combination with BCG in NMIBC, followed by HS-401 (Heat Biologics) (<A href="traction#/single&amp;proj=Oncology&amp;rec=9861"><U><FONT color="#0066cc">Heat Biologics Amends Protocol Permitting Early Advancement Of HS-401 Into Phase 2 For NMIBC</FONT></U></A>) and CV-301 (Bavarian Nordic) (<A class="title" href="traction/permalink/Oncology9657" title="Permanent Link to Oncology9657"><U><FONT color="#0066cc">Bavarian Nordic Evaluates its Immunotherapy (CV-301) in Bladder Cancer</FONT></U></A>) .<wbr> </div><div style="margin-bottom: 10px;">Altor BioScience (Florida) announced that they have been awarded small business innovation research (SBIR) Phase II Grant by NCI for Clinical Development of its Novel IL-15 Super Agonist, ALT-803, for Non-muscle Invasive Bladder Cancer.<wbr> ALT-803 is consider as one of the most promising cancer immunotherapeutic agents by NCI, displaying robust anti-tumour responses in various preclinical models.<wbr> In particular combination approach with BCG has shown reduction of tumour burden by 46% compared to with either ALT-803 or BCG alone, 35% and 15%, respectively (Gomes-Giacoia et al.<wbr> PLOS, June 2014).<wbr> As a result, the $1.<wbr>2 million grant was awarded on August 11, 2014, and will support a multi-center Phase I/<wbr>II clinical trial to evaluate the tolerability and efficacy of ALT-803 in patients with NMIBC.<wbr> Patient enrollment for this trial has been initiated at the University of Hawaii Cancer Center (UHCC), the leading site for the study.<wbr> </div><div style="margin-bottom: 10px;">Altor also announced today that the US Patent and Trademark Office has issued a composition-of-matter patent covering ALT-803 (US Patent No.<wbr> 8,507,222, entitled &ldquo;Multimeric IL-15 Soluble Fusion Molecules and Methods of Making and Using Same&rdquo;).<wbr> Including this newly issued patent, Altor currently has five issued and allowed patents covering the composition, production and uses of ALT-803 and IL-15 derivatives.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Altor Altor's IL-15 Technology</STRONG> </div><div style="margin-bottom: 10px;">The cytokine IL-15 plays a major role in the development of cellular immune responses, driving T and natural killer cell proliferation and activation.<wbr> Altor has developed ALT-803, a novel IL-15 super agonist complex, with improved pharmacokinetic properties, long serum half-life and enhanced anti-tumor activity compared to recombinant human IL-15.<wbr> Altor is collaborating with more than twenty leading research institutes and universities in the U.<wbr>S.<wbr> to explore potential clinical utilities of ALT-803 against cancer and viral infections.<wbr> ALT-803 is currently in four clinical trials for patients with hematologic malignancies and solid tumours.<wbr> </div><div>Source: <A href="http://www.altorbioscience.com">www.<wbr>altorbioscience.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9902">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-20T18:01:28+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Salix Shares Soar On Rumoured Offer From Allergan [:GastroEnterology:news, comp:Allergan, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7710</link>
<description>Salix Shares Soar On Rumoured Offer From Allergan [:GastroEnterology:news, comp:Allergan, :PharmaWorld:sub:Acquisition]</description><category>news</category><category>comp:Allergan</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7710</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7710">Salix Shares Soar On Rumoured Offer From Allergan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7710">Neurology7710</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 August 2014 | 16:43</font><br><br><div style="margin-bottom: 10px;">Comment: The newswires are reporting that Allergan has approached 
Gastrointestinal Company Salix Pharmaceuticals about a potential takeover which 
could occur as early as next month according to the Wall St Journal.<wbr> Both 
companies have so far declined to comment on the mattter, but Allergan is known 
to be looking at acquisitions as a means to avert a $53bn hostile takeover 
by Valeant.<wbr> </div><div style="margin-bottom: 10px;">Salix recently disclosed that it generated sales of $1.<wbr>6bn in 2014.<wbr> 
After today's rise it is currently valued at around $10.<wbr>2bn </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/5/ScreenCapture5.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/7/ScreenCapture7.jpg?user-agent=rss"> </div><div>The other company that Allergan is reportedly interested in is Jazz 
Pharmaceuticals.<wbr> a manufacturer of narcolepsy, psychiatry and oncology drugs.<wbr> 
Jazz is has a similar market capitalization to Salix, at $9.<wbr>4 billion, which is 
within the range of potential acquisition by Allergan.<wbr> </div><!-- Comment details --><a name="neurology7710attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(119 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(122,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(127,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(129,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(151,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(129 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(119,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7710">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-20T16:43:35+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/1/ScreenCapture1.jpg" length="121823" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/2/ScreenCapture2.jpg" length="125663" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/3/ScreenCapture3.jpg" length="130430" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/4/ScreenCapture4.jpg" length="132642" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/5/ScreenCapture5.jpg" length="154898" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/6/ScreenCapture6.jpg" length="132124" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7710/7/ScreenCapture7.jpg" length="122022" type="image/jpeg"/></item><item>
<title>Bioniche Reports Q1 2015 Timeline for BLA Filing of MCNA [dis:Bladder, :PharmaWorld:func:BusDev]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9901</link>
<description>Bioniche Reports Q1 2015 Timeline for BLA Filing of MCNA [dis:Bladder, :PharmaWorld:func:BusDev]</description><category>dis:Bladder</category><category>func:BusDev</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9901</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9901">Bioniche Reports Q1 2015 Timeline for BLA Filing of MCNA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=func%3aBusDev"><font color="#e95e0b">:PharmaWorld:func:BusDev</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9901">Oncology9901</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 August 2014 | 11:57</font><br><br><div style="margin-bottom: 10px;">Comment: The filing is an important milestone for Bioniche as well as for the bladder cancer patients who lack a non-surgical treatment alternative.<wbr> The company has implemented a structured partnering process.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Product Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>MCNA (Mycobacterial Cell Wall-Nucleic Acid Complex) is prepared from the fractionation of a pure culture of Mycobacterium phlei a non-pathogenic organism, commonly found in soil and plants.<wbr></LI>
<LI>MCNA is a biologic immunotherapy/<wbr>immunomodulator designed for the treatment of NMIBC in humans who have failed BCG.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">BCG Failure Competition - Limited Options</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9901/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strong Commercial Opportunity</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Advantages</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9901/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Market Potential</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9901/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><EM>Source: Bioniche</EM> </div><!-- Comment details --><a name="oncology9901attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9901/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9901/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(34,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9901/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(30,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9901">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-20T11:57:43+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9901/1/ScreenCapture1.jpg" length="63096" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9901/2/ScreenCapture2.jpg" length="34950" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9901/3/ScreenCapture3.jpg" length="30903" type="image/jpeg"/></item><item>
<title>Daewoong's Luphere Depot® Trialled for Prostate Cancer in India [comp:Daewoong, prod:Leuprorelin, :Oncology:dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids256</link>
<description>Daewoong's Luphere Depot® Trialled for Prostate Cancer in India [comp:Daewoong, prod:Leuprorelin, :Oncology:dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Daewoong</category><category>prod:Leuprorelin</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids256</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=256">Daewoong's Luphere Depot® Trialled for Prostate Cancer in India</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=comp%3aDaewoong"><font color="#e95e0b">:DKPHybrids:comp:Daewoong</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=prod%3aLeuprorelin"><font color="#e95e0b">:DKPHybrids:prod:Leuprorelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids256">DKPHybrids256</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 August 2014 | 18:21</font><br><br><div style="margin-bottom: 10px;">Comment: The trial will involve approx.<wbr> 42 participants in a multicentric, open-label, randomized, three-treatment, parallel, single-dose clinical bioequivalence study of sc Luphere Depot® 11.<wbr>25mg Test-1 and Test-2 in comparison with Takeda's Lucrin Depot®.<wbr> PE will be to determine clinical bioequivalence of test drug with the reference drug (Cmax and AUC 0-42 day - timepoints: Day1,3,7,14,21,28,35 and Day 42).<wbr> </div><div style="margin-bottom: 10px;">ID Reference <A href="http://apps.who.int/trialsearch/Trial.aspx?TrialID=CTRI/2014/01/004325">http:/<wbr>/<wbr>apps.<wbr>who.<wbr>int/<wbr>trialsearch/<wbr>Trial.<wbr>aspx?TrialID=CTRI/<wbr>2014/<wbr>01/<wbr>004325</A> </div><div style="margin-bottom: 10px;"><STRONG>Intervention</STRONG> </div><div style="margin-bottom: 10px;">Intervention1: Luphere Depot (Leuprolide 11.<wbr>25 mg injection)-Batch 2: Subcutaneous 3 month depot<BR>Intervention2: Luphere Depot(Leuprolide 11.<wbr>25 mg injection)-Batch 1: Subcutaneous 3 month depot<BR>Control Intervention1: Lucrin Depot(Leuprolide 11.<wbr>25 mg): Subcutaneous 3 month depot </div><div style="margin-bottom: 10px;"><STRONG>Sites and PIs</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/256/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="dkphybrids256attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/256/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(196,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/256/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(220,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=256">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-19T18:21:33+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/256/1/ScreenCapture1.jpg" length="201454" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/256/2/ScreenCapture2.jpg" length="226003" type="image/jpeg"/></item><item>
<title>Medtronic Q1 Earnings - Key Takeaways [dis:Spasticity, dis:Dystonia, dis:Parkinson]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7709</link>
<description>Medtronic Q1 Earnings - Key Takeaways [dis:Spasticity, dis:Dystonia, dis:Parkinson]</description><category>dis:Spasticity</category><category>dis:Dystonia</category><category>dis:Parkinson</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7709</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7709">Medtronic Q1 Earnings - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7709">Neurology7709</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 August 2014 | 17:31</font><br><br><div style="margin-bottom: 10px;">Comment: Medtronic has today reported revenue growth of 4% on a constant 
currency basis with growth underpinned by a strong performance 
from Neuromodulation (DBS) and Surgical Technologies part of 
the Restorative Therapies Group.<wbr> </div><div style="margin-bottom: 10px;">Neuromodulation revenue of $479 million increased 11 percent on a 
constant currency basis or 12 percent as reported, driven by solid growth in 
Pain Stim, DBS, and Gastro/<wbr>Uro.<wbr> The business continues to see traction from the 
RestoreSensor® SureScan®<BR>MRI system, growth in Activa® deep brain stimulation 
systems as a result of both the continued referral development in the U.<wbr>S.<wbr> and 
international momentum from the EARLYSTIM data (which has demonstrated superior 
benefits for patients with early motor complications from Parkinson's disease), 
and strong implant rates for InterStim® Therapy (intrthercal baclofen 
therapy).<wbr> </div><div style="margin-bottom: 10px;">Interestingly at the June MDS meeting Cynthia Cormella was advocating that 
more cervical dystonia patients should be referred for DBS treatment  those 
for which other treatments have failed.<wbr> In this setting 40-60% improvements can 
be observed with good control up to 10 years.<wbr> (Further information on this to 
follow).<wbr> </div><div>Source: <A href="http://www.medtronic.com">www.<wbr>medtronic.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7709">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-19T17:31:48+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>A US Only Trial To Evaluate Combination of Abiraterone With Cabazitaxel In Chemo Naive mCRPC Patients [dis:Prostate, comp:SanofiAventis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9900</link>
<description>A US Only Trial To Evaluate Combination of Abiraterone With Cabazitaxel In Chemo Naive mCRPC Patients [dis:Prostate, comp:SanofiAventis]</description><category>dis:Prostate</category><category>comp:SanofiAventis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9900</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9900">A US Only Trial To Evaluate Combination of Abiraterone With Cabazitaxel In Chemo Naive mCRPC Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aSanofiAventis"><font color="#e95e0b">:Oncology:comp:SanofiAventis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9900">Oncology9900</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 19 August 2014 | 13:01</font><br><br><div style="margin-bottom: 10px;">Comment: An academia led trial by Memorial Sloan-Kettering Cancer Center is aimed to start to patient recruitment in Sept 2014 to assess radiological progression free survival up to 1 year for chemohormonal approach (Abiraterone +/<wbr>- Cabazitaxel) in chemo na&iuml;ve mCRPC patients.<wbr> Dr.<wbr> Susan Slovia MD PhD is the principal investigator from Memorial Sloan-Kettering Cancer Center collaborating with Sanofi, Thomas Jafferson University, and Duke University.<wbr> This is a Ph2 multicentre trial in US only.<wbr> </div><div style="margin-bottom: 10px;">Clinical Trial Identifier: NCT02218606; 14-046, PCCTC LOI: c12-108 </div><div style="margin-bottom: 10px;">Estimated Enrollement n=25 </div><div style="margin-bottom: 10px;">Estimated Primary Completion Date: Q3 2017 </div><div style="margin-bottom: 10px;">Study Design: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9900/1/NCT02218606%20Trial%20Design.png?user-agent=rss"> </div><div>Source: <A href="http://www.clinicaltrial.gov">www.<wbr>clinicaltrial.<wbr>gov</A> </div><!-- Comment details --><a name="oncology9900attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9900/1/NCT02218606%20Trial%20Design.png">NCT02218606 Trial Design.png</a>&nbsp;&nbsp;(29 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9900">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-19T13:01:38+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9900/1/NCT02218606%20Trial%20Design.png" length="29737" type="image/x-png"/></item><item>
<title>A PI3K Inhibitor In Combination With Enzalutamide Is Trialled For PTEN Deficient mCRPC Patients</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9899</link>
<description>A PI3K Inhibitor In Combination With Enzalutamide Is Trialled For PTEN Deficient mCRPC Patients</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9899</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9899">A PI3K Inhibitor In Combination With Enzalutamide Is Trialled For PTEN Deficient mCRPC Patients</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9899">Oncology9899</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 19 August 2014 | 12:38</font><br><br><div style="margin-bottom: 10px;">Comment: Another PI3K inhibitor (GSK2636771, GlaxoSmithKline) will be trialled for metastatic castration resistant prostate cancer (mCRPC) patients.<wbr> It appears only a proof of concept trial at this stage for combination with enzalutamide recruiting mCRPC patients who are deficient in PTEN and had been treated with a stable dose of enzalutamide.<wbr> The study is planned to start in Q4 2014.<wbr> </div><div style="margin-bottom: 10px;">GSK2636771 is a potent, orally bioavailable and selective inhibitor of PI3K&beta; (0.<wbr>89 nM), with &gt;900-fold selectivity over PI3K&alpha;/<wbr>PI3K&gamma; and &gt;10-fold over PI3K&delta;.<wbr> It inhibits AKT phosphorylation and downstream signalling measured as decrease of PRAS40-, GSK3&beta;-, and RPS6-phosphorylation in PTEN mutant cell lines.<wbr> A completed phase I/<wbr>II, first in human dose escalation study in PTEN deficient patients with advanced solid tumours demonstrated maximal tolerated dose of 400 mg QD.<wbr> PD effects on AKT and downstream proteins were observed and early efficacy signals suggest anti-tumour activity in patients with PTEN deficient tumours.<wbr> One prostate cancer patient had a RECIST partial response and 13 pts had stable disease, 6 of whom were on study for &ge;6 months (Arkenau et al.<wbr>, J Clin Oncol 32:5s, 2014).<wbr> </div><div style="margin-bottom: 10px;">Clinical Trial Identifier: <a href="http://clinicaltrials.gov/ct2/show/NCT02215096?cond=prostate+cancer&rcv_d=14&show_rss=Y&sel_rss=new14" class="defaultlink">NCT02215096</a> </div><div style="margin-bottom: 10px;">Estimated Start Date Oct 2014 </div><div style="margin-bottom: 10px;">Estimated Primary Completion Date Jan 2017 </div><div style="margin-bottom: 10px;">Primary Objective: Safety and tolerability follow up for up to 3 years; Non Progressive disease rate for 12 weeks according to PCWG2 criteria </div><div style="margin-bottom: 10px;">Secondary Objective: PK with enzalutamide (Blood samples for analysis of enzalutamide and N-desmethyl enzalutamide will be collected pre-dose and 0.<wbr>5, 1, 2, 3, 4, and 6, post-dose on the day prior to administration of GSK2636771 on Day -1 and at pre-dose and 0.<wbr>5, 1, 2, 3, 4, and 6, hrs post-dose on Day 29) </div><div style="margin-bottom: 10px;">Study Design: </div><div style="margin-bottom: 10px;">Experimental: Phase 1-Dose Escalation </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="margin-top: 0.5ex;">Subject receiving a stable dose of enzalutamide 160 mg once daily will receive GSK2636771 following a modified 3+3 dose escalation procedure (Cohort -1: 200 mg, Cohort 1: 300 mg and Cohort 2: 400 mg) to evaluate the safety and PK for each combination dose level and to guide selection of the RP2D of the combination.<wbr> If the combination doses in Cohort 1 are not tolerable, lower doses as defined in the de-escalation cohort (Cohort -1) will be evaluated.<wbr> If the de-escalation cohort (Cohort -1) is not tolerable, further dose-escalation using a continuous daily dosing schedule for both compounds simultaneously will be terminated.<wbr> Additional dose levels of GSK2636771 or alternative dosing schedules may be explored based upon ongoing assessment of safety and PK.<wbr> Dose modification decisions will be made utilizing all available data at the end of each DLT determination period (28 days).<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV class="indent2" style="margin-top: 0.5ex;">Interventions:
<UL style="margin-top: 0.5ex;"><LI class="color-bullet">Drug: GSK2636771
</LI>
<LI class="color-bullet">Drug: Enzalutamide
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin: 1ex 0.5ex;">Experimental: Phase 2- Dose Expansion</P> </div><div style="margin-bottom: 10px;"><P class="indent2" style="margin-top: 0.5ex;">Additional 20 subjects will be assigned to receive GSK2636771 at the MTD or RP2D determined in the Dose-Escalation Phase while continuing treatment with enzalutamide to evaluate the long-term safety of the combination as well as the 12-week non-PD rate</P> </div><div style="margin-bottom: 10px;"><P class="indent2" style="margin-top: 0.5ex;">Interventions:</P> </div><div><UL style="margin-top: 0.5ex;"><LI class="color-bullet">Drug: GSK2636771
</LI>
<LI class="color-bullet">Drug: Enzalutamide
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9899">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-19T12:38:46+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>NICE Agrees To A Re-review of Firmagon (degarelix) [class:Antihormonals, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9896</link>
<description>NICE Agrees To A Re-review of Firmagon (degarelix) [class:Antihormonals, dis:Prostate]</description><category>class:Antihormonals</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9896</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9896">NICE Agrees To A Re-review of Firmagon (degarelix)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9896">Oncology9896</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 August 2014 | 10:01</font><br><br><div style="margin-bottom: 10px;">Comment: following an oral hearing in London on the 25th June, a NICE panel has upheld Ferring's appeal agaiinst use of Firmagon as an option for treating advanced hormone-dependent prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">The panel decided that the way in whiich the recommedation for Firmagon was issued was unfair and lacked transparency.<wbr> </div><div style="margin-bottom: 10px;">Ferring was supported in its appeal by the BUG and Tackle Prostate Cancer.<wbr> The appeal was upheld ont wo grounds:- </div><div style="margin-bottom: 10px;">i) NICE failed to isse a second Appraisal Consultation Document following a substantial change to the preliminary recommendations; and, </div><div style="margin-bottom: 10px;">ii) The deicsion in the Final Aopprials Determination to restrict the use of Firmagon to patients with spinal compression ( as opposed to those who are "at risk" of spinal compression lacked transparency and failed to give adequate reasons.<wbr> This resitriction effectively reduced the number of patients eligible for treatment to less than a third compared to the "at tisk" population.<wbr> </div><div>Source: FirstWord </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9896">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-19T10:01:41+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>2CARE study for Huntington's Disease “Stopped for Futility” [dis:Huntington, :PharmaWorld:sub:Termination, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7706</link>
<description>2CARE study for Huntington's Disease “Stopped for Futility” [dis:Huntington, :PharmaWorld:sub:Termination, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Huntington</category><category>sub:Termination</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7706</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7706">2CARE study for Huntington's Disease “Stopped for Futility”</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aTermination"><font color="#e95e0b">:PharmaWorld:sub:Termination</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7706">Neurology7706</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 August 2014 | 15:52</font><br><br><div style="margin-bottom: 10px;">Comment: The largest ever therapeutic trial for Huntington’s disease was halted early this week because an analysis of the results to date showed that it was very unlikely to show positive results.<wbr> The study, called 2CARE, was designed to test whether a treatment called coenzyme Q10 could slow the progression of HD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for an Early Study Closure</FONT></STRONG> </div><div style="margin-bottom: 10px;">Following the most recent DSMB review of the study data, an interim analysis was conducted that showed that, given the current data, it would be very unlikely (less than a 5 in 100 chance) to see a statistically significant benefit of active treatment (coenzyme Q10, 2400 mg/<wbr>day) over placebo at the scheduled end of the trial.<wbr> </div><div style="margin-bottom: 10px;">The DSMB also noted a higher number of deaths in the coenzyme Q10 group (7%) in comparison to the placebo group (4%); most of these deaths appeared to be related to HD, which is a severe, progressive neurological disorder.<wbr> Although this number may have been due to chance, and was not statistically significant, the DSMB noted it in their decision.<wbr> </div><div style="margin-bottom: 10px;">Site investigators and coordinators have informed participants of the study closure and have encouraged each participant to schedule a final visit to the clinic.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Reference</U> <A href="http://ci.beaufour-ipsen.com/Subjects%20must%20have%20clinical%20features%20of%20HD%20and%20a%20confirmed%20family%20history%20of%20HD,%20OR%20a%20CAG%20repeat%20expansion%20≥%2036.">NCT00608881</A> </div><div style="margin-bottom: 10px;"><U>Timelines</U> Ph3 started in March 2008 with completion dates planned to finish in late 2017 </div><div style="margin-bottom: 10px;"><U>Location </U>48 sites through US and Australia </div><div style="margin-bottom: 10px;"><U>Recruitment</U> Approx 609 with early HD 
 </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subjects must have clinical features of HD and a confirmed family history of HD, OR a CAG repeat expansion ≥ 36.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">TFC &gt; 9.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must be ambulatory and not require skilled nursing care.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Age ≥ 16 years.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Women must not be able to become pregnant (e.<wbr>g.<wbr>, post menopausal, surgically sterile or using adequate birth control methods for the duration of the study).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">If psychotropic medications are taken (e.<wbr>g.<wbr>, anxiolytics, hypnotics, benzodiazepines, antidepressants), they must be at a stable dosage for four weeks prior to randomization and should be maintained at a constant dosage throughout the study, as possible.<wbr> (Note: stable dosing of tetrabenazine is allowable.<wbr>) Any changes to these medications mandated by clinical conditions will be systematically recorded and the subject will be permitted to remain in the trial.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Able to give informed consent and comply with trial procedures</LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Able to take oral medication.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">May be required to identify an informant or caregiver who will be willing and able to supervise the daily dosing of study medications and to maintain control of study medications in the home.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">
<UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">A designated individual will be identified by the subject to participate in the ongoing consent process should the subject's cognitive capacity to consent become compromised during participation in the study.<wbr></LI>
</UL> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Source: <A href="http://www.huntington-study-group.org/LinkClick.aspx?fileticket=LurnlLVT3rw%3d&amp;tabid=95">http:/<wbr>/<wbr>www.<wbr>huntington-study-group.<wbr>org/<wbr>LinkClick.<wbr>aspx?fileticket=LurnlLVT3rw%3d&amp;tabid=95</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7706">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-18T15:52:18+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Appoints New CFO [:PharmaWorld:sub:People, comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7705</link>
<description>Allergan Appoints New CFO [:PharmaWorld:sub:People, comp:Allergan]</description><category>sub:People</category><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7705</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7705">Allergan Appoints New CFO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7705">Neurology7705</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 August 2014 | 15:29</font><br><br><div style="margin-bottom: 10px;">Comment  <PERSON>Jim Hindman</PERSON> has been named Executive Vice 
President, Finance and Business Development, Chief Financial Officer, at 
Allergan with immediate effect.<wbr> He succeeds <PERSON value="APIN:0163057007">Jeff Edwards</PERSON>, who after 21 years of service to 
<ORG value="NYSE:AGN">Allergan</ORG>, has decided to step 
down from the position due to family commitments.<wbr> </div><div style="margin-bottom: 10px;">Mr.<wbr> Edwards is to remain employed by <ORG value="NYSE:AGN">Allergan</ORG> in a non-executive officer capacity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Mr Hindman's Profile</STRONG> </div><div style="margin-bottom: 10px;"><PERSON>Mr.<wbr> Hindman</PERSON> joined <ORG value="NYSE:AGN">Allergan</ORG> in 1984 and has served as Senior Vice 
President, Treasury, Risk and Investor Relations since 2002.<wbr> Prior to that, he 
served in a variety of finance positions, including Senior Vice President, 
Finance and Controller, Assistant Corporate Controller and Vice President, 
Financial Planning and Analysis.<wbr> <PERSON>Mr.<wbr> Hindman</PERSON> also serves as 
President of <ORG>The Allergan Foundation</ORG>.<wbr> Before joining <ORG value="NYSE:AGN">Allergan</ORG>, Mr.<wbr> Hindman worked at 
Deloitte, Haskins and Sells </div><div>Commenting on the appointment Mr.<wbr> Pyott stated, "We are pleased to 
name <PERSON>Jim Hindman</PERSON> as Allergan's Chief Financial Officer.<wbr> Jim has 
been an instrumental member of our organization for many years, and particularly 
during the past few months, has played an important leadership role.<wbr>" </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7705">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-18T15:29:32+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Key Figures from Medy-Tox 2Q14 Results [comp:MediTox, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7701</link>
<description>Key Figures from Medy-Tox 2Q14 Results [comp:MediTox, :PharmaWorld:sub:Finance]</description><category>comp:MediTox</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7701</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7701">Key Figures from Medy-Tox 2Q14 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aMediTox"><font color="#e95e0b">:Neurology:comp:MediTox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7701">Neurology7701</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 August 2014 | 13:22</font><br><br><div style="margin-bottom: 10px;">Comment: On an IFRS consolidated basis, Medy-Tox reported 2Q14 sales of W16.<wbr>1bn (up 44.<wbr>9% y-y), operating profit of W9.<wbr>5bn (up 73.<wbr>8% y-y), and net profit of W8.<wbr>7bn (up 110.<wbr>1% y-y).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Domestic Sales</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">Domestic sales were W6.<wbr>7bn (up 18.<wbr>8% y-y) reached a record high thanks to the launch of &lsquo;Meditoxin 150&rsquo; and &lsquo;Innotox&rsquo; (liquid botulinum toxin type A).<wbr></P> </div><div><P align="left"><EM>Sources: Shinhan Investment; Woori Investment &amp; Securities</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7701">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-18T13:22:00+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Cortendo AB to Start Ph3 for Endogenous Cushing's Syndrome</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7775</link>
<description>re: Cortendo AB to Start Ph3 for Endogenous Cushing's Syndrome</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7775</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7775">re: Cortendo AB to Start Ph3 for Endogenous Cushing's Syndrome</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7775">Endocrinology7775</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 August 2014 | 11:46</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Cortendo AB to Start Ph3 for Endogenous Cushing's Syndrome</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font><br><span style="font-size: 12px;">Comment: NormoCort (COR-003), the single 2S,4R enantiomer of ketoconazole, is to enter Ph3 in January next year.<wbr> PE will assess reduction in urinary free cortisol.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7330">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7330" class="commentpermalink">Endocrinology7330</a> / <span class="date">30 April 2013</span> /
<span class="time">19:02:58 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Last week Cortendo announced the enrollment of the first EU patient in the SONICS trial.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Investigator Meetings</STRONG> </div><div style="margin-bottom: 10px;">Cortendo successfully completed its European Investigator meeting supporting SONICS held in Barcelona, Spain on July 17-18.<wbr>  More than 35 investigators/<wbr>study coordinators, including many of the world&rsquo;s leading Cushing&rsquo;s experts from 24 study sites, were in attendance and received training for the trial.<wbr> Based on the positive feedback from the meeting, Cortendo has gained further confidence that NormoCort (COR-003) has the potential to be an important future treatment option for patients afflicted with Cushing&rsquo;s Syndrome.<wbr> </div><div style="margin-bottom: 10px;">A second US Investigator meeting is also being planned for later this year.<wbr> </div><div style="margin-bottom: 10px;">Cortendo has also further strengthened its internal as well as external teams to support the study and to position the trial for an increased recruitment rate.<wbr> In July, Cortendo added both an experienced physician and internal Clinical Operations Director to the NormoCort development team.<wbr> Cortendo, working in concert with its CROs supporting the SONICS trial, now has a team of approximately 20 personnel on the NormoCort development program.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Sites</STRONG> </div><div>The company has previously communicated its plan to meet the recruitment goal by increasing the number of study sites from 38 to 45 worldwide.<wbr> The company is at various levels of activation with more than 30 study sites to date.<wbr> Therein, Cortendo expects a large proportion of the sites to be activated by the end of the third quarter this year and remains confident that essentially all sites will be open by the end of 2014.<wbr> </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7775" class="commentpermalink">Endocrinology7775</a> / <span class="date">18 August 2014</span> /
<span class="time">11:46:36 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7775">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7330">View thread  Endocrinology7330: Cortendo AB to Start Ph3 for Endogenous Cushing's Syndrome</a>]]></content:encoded><dc:date>2014-08-18T11:46:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>NICE Has Not Recommended Abiraterone For Chemo Naive mCRPC Patients In Its Final Draft Guidance [comp:JnJ, dis:Prostate, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9894</link>
<description>NICE Has Not Recommended Abiraterone For Chemo Naive mCRPC Patients In Its Final Draft Guidance [comp:JnJ, dis:Prostate, news]</description><category>comp:JnJ</category><category>dis:Prostate</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9894</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9894">NICE Has Not Recommended Abiraterone For Chemo Naive mCRPC Patients In Its Final Draft Guidance</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9894">Oncology9894</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 15 August 2014 | 18:34</font><br><br><div style="margin-bottom: 10px;">Comment: In the final draft guidance published today by NICE in the UK, the decision not to recommend abiraterone for mCRPC patients who have not receive docetaxel is described by charity group as a "kick in the teeth" for patients.<wbr> NICE recongnises the obvious benefit for patients to have option to delay chemotherapy, however, the lack of clinical evidence to demonstrate extension of survival is the main driver for this decision.<wbr> It will be interesting to see how Astellas tackle this with NICE since enzalutamide may appear to have advantage over abiraterone with its demonstrated OS benefit from PREVAIL and lower overall treatment cost (as patients are not required to take prednisone with enzalutamide).<wbr> </div><div style="margin-bottom: 10px;">Prostate Cancer pateint group and scientists have also expressed their disappointment over the health watchdog's guidance not to recommend the drug in this circumstance.<wbr> Experts from the <A href="http://www.theguardian.com/education/institute-of-cancer-research">Institute of Cancer Research</A> (ICR) said there was clear evidence abiraterone was beneficial for patients before they underwent chemotherapy.<wbr> In final draft guidance, Nice said that the drug should not be widely used in the NHS in England to treat prostate cancer patients whose cancer has spread and who have previously received another type of hormone therapy before they are given chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">"<EM><STRONG>An inflexible Nice process plus the drug company's inability to produce all the requested data has led to this being just the latest in a string of hugely disappointing rulings on prostate cancer drugs.<wbr> Once again men in England will have to take their chances with the Cancer Drugs Fund</STRONG></EM>.<wbr>" </div><div style="margin-bottom: 10px;">"<EM><STRONG>We urge Janssen and Nice to get their act together and do whatever is necessary to get abiraterone pre-chemotherapy across the line without delay</STRONG></EM>.<wbr>" </div><div style="margin-bottom: 10px;">In the press release, NICE stated that the clinical evidence submitted by J&amp;J from COU-AA-302 indicating abiraterone could delay the progression of the disease, however <SPAN style="color: #ff0000; text-decoration: underline;">it was not clear how much abiraterone actually extended life</SPAN>.<wbr> The committee also had a number of concerns with the way the manufacturer calculated estimated cost-effectiveness.<wbr> The health economic model was particularly complex and the committee felt that this has made it difficult for the Evidence Review Group (ERG) to validate and critique the model.<wbr> However, it was clear that the drug is not cost effective at its current price.<wbr> </div><div style="margin-bottom: 10px;">Until final guidance is issued, NHS bodies should make decisions locally on the funding of specific treatments.<wbr> Once NICE issues its final guidance on a technology, it replaces local recommendations across the country.<wbr> </div><div>Source: <A href="http://www.nice.org.uk/">www.<wbr>nice.<wbr>org.<wbr>uk</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9894">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-15T18:34:51+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Teva Initiates PhII Study With Laquinimod in Huntington's Disease, Meanwhile PhII Huntexil Study May Pave The Way For Approval [dis:Huntington, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7699</link>
<description>Teva Initiates PhII Study With Laquinimod in Huntington's Disease, Meanwhile PhII Huntexil Study May Pave The Way For Approval [dis:Huntington, news]</description><category>dis:Huntington</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7699</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7699">Teva Initiates PhII Study With Laquinimod in Huntington's Disease, Meanwhile PhII Huntexil Study May Pave The Way For Approval</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7699">Neurology7699</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 August 2014 | 11:39</font><br><br><div style="margin-bottom: 10px;">Comment: Strenthening its development focus in Huntington's Disease (HD), Teva and its partner Active Biotech have announced the start of a phII efficacy and safety study with the immunomodulator Laquinimod.<wbr> Teva has to date been developing the drug for the treatment of multiple sclerosis.<wbr> Teva's other Huntington drug Huntexil (pridopidine) is also in phII development for HD but in this case the outcome of this study could determine whether the drug is licensed or not, given two large phIII trials (HEART &amp; MERMAID) have already been undertaken.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Situation With Huntexil (pridopidine)</STRONG> </div><div style="margin-bottom: 10px;">Discussions with Bernhard Landwehrmeyer the PI for the PhII Huntexil study were revealing.<wbr> He claims to have had conversations with both the EMA &amp; FDA both of whom favour approval of Huntexil as the only drug that has demonstrated any sign of clinical activity HD over the last 10 years.<wbr> The HEART &amp; MERMAID studies did observe an improvement in total motor scores (not the PE of either study) at 43mg b.<wbr>i.<wbr>d.<wbr> </div><div style="margin-bottom: 10px;">To facilitate approval, he claims, and not to make the regulatory pathway any more burdensome given two PhIII studies have been undertaken, the authorities have alluded to the conditions under which they might approve the drug based on new phII data.<wbr> </div><div style="margin-bottom: 10px;">It appears that the new phII study will explore 4 doses covering the full dose range and will have to demonstrate the following:- </div><div style="margin-bottom: 10px;">i) A higher and more significant impact on motor scores at higher doses; </div><div style="margin-bottom: 10px;">ii) A significant impact on functional activity i.<wbr>e.<wbr> a physical performance test; and, </div><div style="margin-bottom: 10px;">iii) An improvement in activities of daily living.<wbr> </div><div style="margin-bottom: 10px;">The new phII which is a global study will include 400 patients.<wbr> Recruitment started earlier in 2014 and is expected to complete before the year-end.<wbr> The observation period will be 6 months, with the projected primary completion date for the study March 2015.<wbr> </div><div style="margin-bottom: 10px;">Two posters presented at the MDS meeting on pridopidine one on the effect of renal impairment on the PK profile of the drug and the other focusing on the drug's drug-interaction profile are attached.<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-top: 1ex;" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="padding-left: 1em;"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02006472" title="Current version of study NCT02006472 on ClinicalTrials.gov">NCT02006472</A></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><STRONG>New Study With Laquinimod</STRONG> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="margin-top: 1ex;" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="padding-left: 1em;"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02215616" title="Current version of study NCT02215616 on ClinicalTrials.gov">NCT02215616</A></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;">The primary objective of this new study is to assess the efficacy of laquinimod 0.<wbr>5, 1.<wbr>0, and 1.<wbr>5 mg qd in patients with HD after 12 months of treatment using the UHDRS-TMS </div><div>The multicentre multinational randomised study will enroll 400 patients and is scheduled to start in September 2014.<wbr> Primary completion is projected to be December 2016.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7699">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-15T11:39:33+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>A Signifcant Step For Xofigo's Near Future Growth In US Market [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9892</link>
<description>A Signifcant Step For Xofigo's Near Future Growth In US Market [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9892</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9892">A Signifcant Step For Xofigo's Near Future Growth In US Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9892">Oncology9892</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 15 August 2014 | 09:56</font><br><br><div style="margin-bottom: 10px;">Comment: Xofigo (radium-223) has been approved by FDA and EMA for the treatment with patients with castration resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.<wbr> Due to its unique mechanism of action, one of the key challenges beyond regulatory approval is for Bayer to receive the appropriate licensing from the Nuclear Regulatory Commission or agreement to administer Xofigo.<wbr> Bayer has announced on 13 August 2014 that over 1,000 medical sites in the US are now licensed to administer Xofigo injection.<wbr> Following this announcement, we should expect significant growth /<wbr> market penetration from the US market.<wbr> </div><div style="margin-bottom: 10px;">During a statement made by Dr.<wbr> Joseph Germino (MD, VP of Medical Affairs, Oncology, Bayer), " <EM><STRONG>Xofigo is now available within a 50-mile travel radius to 96% of the indicated patient population in the US</STRONG></EM>" </div><div style="margin-bottom: 10px;">Xofigo is the first and only FDA-approved alpha particle-emitting radioactive therapeutic agent with an anti-tumour effect on bone metastases that has also demonstrated an improvement in overall survival compared to placebo, as shown in the pivotal Phase III ALSYMPCA trial; median overall survival (OS) was 14.<wbr>0 months with Xofigo plus best standard of care (95% CI 12.<wbr>1-15.<wbr>8) vs.<wbr> 11.<wbr>2 months with placebo plus best standard of care (95% CI 9.<wbr>0-13.<wbr>2) [HR=0.<wbr>695 (95% CI 0.<wbr>552-0.<wbr>875), p=0.<wbr>00185].<wbr> Xofigo also delayed time to first symptomatic skeletal event (SSE) compared to placebo.<wbr> The majority of events consisted of external beam radiation therapy (EBRT) to bone metastases to relieve skeletal symptoms.<wbr> </div><div style="margin-bottom: 10px;">To date, thousands of patients have received Xofigo at cancer treatment centers across the country, including top prescribing sites: </div><div style="margin-bottom: 10px;"><UL id="yui_3_16_0_1_1408088156953_1153" type="disc"><LI id="yui_3_16_0_1_1408088156953_1161">Associated Medical Professionals, Syracuse, New York
</LI>
<LI id="yui_3_16_0_1_1408088156953_1160">Carolinas HealthCare System's Carolinas Medical Center, Charlotte, North Carolina
</LI>
<LI id="yui_3_16_0_1_1408088156953_1159">Cleveland Clinic Nuclear Medicine, Cleveland, Ohio
</LI>
<LI id="yui_3_16_0_1_1408088156953_1152">Dana Farber Cancer Institute, Boston, Massachusetts
</LI>
<LI id="yui_3_16_0_1_1408088156953_1158">Memorial Sloan Kettering Cancer Center, New York, New York
</LI>
<LI id="yui_3_16_0_1_1408088156953_1157">Moffitt Cancer Center, Tampa, Florida
</LI>
<LI id="yui_3_16_0_1_1408088156953_1156">The University of Texas MD Anderson Cancer Center, Houston, Texas
</LI>
</UL> </div><div style="margin-bottom: 10px;">Full Prescribing information is available via <A href="http://labeling.bayerhealthcare.com/html/products/pi/Xofigo_PI.pdf" id="yui_3_16_0_1_1408088156953_1191" rel="nofollow" target="_blank"><U><FONT color="#0066cc">http:/<wbr>/<wbr>labeling.<wbr>bayerhealthcare.<wbr>com/<wbr>html/<wbr>products/<wbr>pi/<wbr>Xofigo_PI.<wbr>pdf</FONT></U></A>.<wbr> </div><div>Centres that are licensed to administer Xofigo are available via: <A href="http://xofigo-us.com/hcp/facility-finder/" id="yui_3_16_0_1_1408088156953_1196" rel="nofollow" target="_blank"><U><FONT color="#0066cc">http:/<wbr>/<wbr>xofigo-us.<wbr>com/<wbr>hcp/<wbr>facility-finder/<wbr></FONT></U></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9892">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-15T09:56:56+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Allergan Starts To Acquire To Fend Off Valeant Takeover [headline, :PharmaWorld:sub:DrugDelivery, :PharmaWorld:sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7698</link>
<description>Allergan Starts To Acquire To Fend Off Valeant Takeover [headline, :PharmaWorld:sub:DrugDelivery, :PharmaWorld:sub:xLicensing]</description><category>headline</category><category>sub:DrugDelivery</category><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7698</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7698">Allergan Starts To Acquire To Fend Off Valeant Takeover</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7698">Neurology7698</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 August 2014 | 18:59</font><br><br><div style="margin-bottom: 10px;">Comment: As part of its attempt to fight off a hostile takeover from Valeant 
and expand its growing urology pipeline, Allergan has agreed to paty 
$587.<wbr>5m  for a midstage drug-device combination designed to treat 
interstitial cystitis or painful bladder syndrome.<wbr> The company has paid $67.<wbr>5m 
up front for the product.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">In addition to its up-front Allergan has agreed to pay up to an aggregate of 
$295 million in development milestone payments and up to an aggregate of $225 
million in commercial milestone payments.<wbr> </div><div style="margin-bottom: 10px;">Prior to the closing of this transaction, TARIS spun out certain assets, 
including pipeline programs and intellectual property related to TARIS' platform 
technology, to a new company funded by TARIS shareholders.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the deal David Pyott was keen to emphasise that "Allergan has a 
longstanding history of delivering stockholder value by developing innovative 
medica treatment that address unmet medical needs.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>What is Liris and in what setting is it being trialed?</STRONG> </div><div style="margin-bottom: 10px;">Lyris is a lidocaine releasing intravesical system that is now being trialed 
in a phII safety tolerability and efficacy study in women with interstitial 
cystititis.<wbr> The PhII study started in March 2013 and has a primary 
completion date of December 2014.<wbr> 124 patients are due to be enrolled .<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-TOP: 1ex" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="PADDING-LEFT: 1em"><A class="study-link" href="http://clinicaltrials.gov/show/NCT01824303" title="Current version of study NCT01824303 on ClinicalTrials.gov">NCT01824303</A></TD>
</TR>
</TBODY>
</TABLE> </div><div>Source: <a href="http://www.allergan.com" class="defaultlink" title="www.allergan.com">allergan.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7698">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-14T18:59:18+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Urolplasty - The First &amp; Only Commercially Available, In-Office, Non-Surgical Treatment for iOAB [class:BotulinumToxins, dis:iOAB, dis:nOAB]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7697</link>
<description>Urolplasty - The First &amp; Only Commercially Available, In-Office, Non-Surgical Treatment for iOAB [class:BotulinumToxins, dis:iOAB, dis:nOAB]</description><category>class:BotulinumToxins</category><category>dis:iOAB</category><category>dis:nOAB</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7697</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7697">Urolplasty - The First & Only Commercially Available, In-Office, Non-Surgical Treatment for iOAB</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7697">Neurology7697</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 August 2014 | 15:39</font><br><br><div style="margin-bottom: 10px;">Comment: Uroplasty is an emerging force in the overactive bladder iOAB market 
and as such a competitor to Allergan and the use of Botox.<wbr> The profile of the 
product and its current positioning as highlighted yesterday at the Cannacord 
Genuity Investor H/<wbr>C conference is demonstrated below.<wbr> Usage for 
neurogenic OAB is not referred to currently nor do there appear to be any 
development plans to address this market segment at the present time.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/1/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/3/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/4/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/5/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/6/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/7/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/8/ScreenCapture9.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.uroplasty.com">www.<wbr>uroplasty.<wbr>com</A> </div><!-- Comment details --><a name="neurology7697attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/1/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(115,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(98 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(121,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/4/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(114,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/5/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(111,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/6/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(148,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/7/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(147,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/8/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(112,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7697">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-14T15:39:11+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/1/ScreenCapture2.jpg" length="118537" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/2/ScreenCapture3.jpg" length="100308" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/3/ScreenCapture4.jpg" length="124585" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/4/ScreenCapture5.jpg" length="116863" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/5/ScreenCapture6.jpg" length="114497" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/6/ScreenCapture7.jpg" length="151910" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/7/ScreenCapture8.jpg" length="150876" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7697/8/ScreenCapture9.jpg" length="115501" type="image/jpeg"/></item><item>
<title>Tekmira's Profile Raised By Potential Effectiveness of Its Ebola Virus Treatment. [dis:MidGutNET, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7773</link>
<description>Tekmira's Profile Raised By Potential Effectiveness of Its Ebola Virus Treatment. [dis:MidGutNET, news]</description><category>dis:MidGutNET</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7773</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7773">Tekmira's Profile Raised By Potential Effectiveness of Its Ebola Virus Treatment.<wbr></a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7773">Endocrinology7773</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 August 2014 | 15:17</font><br><br><div style="margin-bottom: 10px;">Comment: Tekmira release its 2nd quarter figures yesterday, providing and update on its development progress with its RNAi interference agents.<wbr> Whilst the group remains sharply focused on its lead development programme in GEP-NET and ACC patients, the severity of the Ebola outbreak in Africa has resulted in the company working alongside regulatory agencies and the WHO regarding the supply of its exploratory phI agent to treat infected patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Progress with the TKM-PLK1 GEP-NET/<wbr>ACC Programme</STRONG> </div><div style="margin-bottom: 10px;">Tekmira noted that it has seen an additional RECITS qualifying Partial Response, defined as a greater than 30% reduction in target tumour leisions.<wbr> This patient is continuing on therapy and has achieved a 44% recution in their target tumour mass located outside of the liver.<wbr> Furthermore, scans of the target tumour lesions demonstrate signs of necrosis, indicative of anti-tumour activity.<wbr> The company has not disclosed the underlying condition of this patient.<wbr> </div><div style="margin-bottom: 10px;">Tekmira expects to present Phase IIa interim data from thisl trial before the end of this year.<wbr> Meanwhile it has begun enrollment in an additional Phase I/<wbr>II trial targeting HCC patients.<wbr> </div><div>Source: <A href="http://www.tekmira.com">www.<wbr>tekmira.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7773">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-14T15:17:36+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>AZ Announces Positive Top-Line PhIII Gout Data</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10930</link>
<description>AZ Announces Positive Top-Line PhIII Gout Data</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10930</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10930">AZ Announces Positive Top-Line PhIII Gout Data</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10930">PharmaWorld10930</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 August 2014 | 12:40</font><br><br><div style="margin-bottom: 10px;">Comment: Yesterday AZ announced positive data from three phIII pivotal trials 
conducted with its selective uric acid re-absoprtion inhibitor (SURI) Lesinurad, 
as a combination therapy with either allopurinol or febuxistat for patients 
with sympomatic gout.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Nature Of The Pivotal Studies</STRONG> </div><div style="margin-bottom: 10px;">The CLEAR studies evaluated Lesinurad (200 &amp; 400mg once daily with the 
xanthine oxidase inhibitor allopurinol in patients not achieving target serum 
uric acid levels (sUA) on their current dose of allopurinol.<wbr> </div><div style="margin-bottom: 10px;">The CRYSTAL study evaluated lesinurad at similar doses in combination with 
the xanthine oxidase inhibitor febuxostat (80mg once dialy) in gout patients 
with visible nodules of uric acid crystals deposited in their joints and skin 
(tophi).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings</STRONG> </div><div style="margin-bottom: 10px;">In the CLEAR1 and CLEAR2 trials, both lesinurad 200mg and 400mg in 
combination with allopurinol met the primary endpoint, with a statistically 
significant higher proportion of patients reaching the target sUA goal of 
&lt;6.<wbr>0mg/<wbr>dL at month 6 compared to allopurinol alone (p&lt;0.<wbr>0001).<wbr> </div><div style="margin-bottom: 10px;">In the CRYSTAL trial, lesinurad 400mg in combination with febuxostat met the 
primary endpoint, with a statistically significant higher proportion of patients 
reaching the target sUA goal of &lt;5.<wbr>0mg/<wbr>dL at month 6 compared to febuxostat 
alone (p&lt;0.<wbr>0001).<wbr> Although lesinurad 200mg did not achieve statistical 
significance at month 6 (p=0.<wbr>13), this dose in combination with febuxostat, was 
superior to placebo plus febuxostat at all other time points (measured at months 
1 to 5, 8, 10 and 12; nominal p&lt;0.<wbr>05).<wbr> </div><div style="margin-bottom: 10px;">Safety wise the most commonly reported adverse events were upper respiratory 
tract infection, nasopharyngitis and back pain in the CLEAR studies and 
similarly, naopharyngitis, arthralgia and upper respiratory tract infection in 
the CRYSTAL study.<wbr> The incidence of renal-related AEs including stones was 
equivalent to placebo plus xanthine oxidase inhibitor at the 200mg 
dose but higher with the 400mg dose.<wbr> Further safety evaluation is 
ongoing.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">The company is proceeding with preparation of regulatory submissions 
for lesinurad (200mg) combination therapy.<wbr> </div><div>Source: <a href="http://www.astrazeneca.com" class="defaultlink" title="www.astrazeneca.com">astrazeneca.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10930">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-14T12:40:29+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>PHOTO Trial Is Planned To Compare Efficacy And Cost Effectiveness of Hexvix Versus White Light [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9891</link>
<description>PHOTO Trial Is Planned To Compare Efficacy And Cost Effectiveness of Hexvix Versus White Light [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9891</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9891">PHOTO Trial Is Planned To Compare Efficacy And Cost Effectiveness of Hexvix Versus White Light</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9891">Oncology9891</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 13 August 2014 | 17:28</font><br><br><div style="margin-bottom: 10px;">Comment: A randomized trial is being funded by National Institute for Health Research to evaluate efficacy (time to recurrence up to 3 years) and cost effectiveness of TUR under blue light (Hexvix instillation) versus white light for newly diagnosed intermediate and high risk non muscle invasive bladder cancer (NMIBC) patients.<wbr> The trial is currently opening for patient recruitment of estimated 533 patients in UK only.<wbr> Franchise's Hexvix team is closely monitoring the development of the trial.<wbr> </div><div style="margin-bottom: 10px;">PHOTO trial : PHOTO is a multi-centre randomised open parallel group non-masked superiority trial comparing the intervention of Photo dynamic diagnosis (PDD) guided guided bladder tumour resection (TUR) with standard white light resection in patients with newly diagnosed intermediate and high risk NMIBC.<wbr> Apart from initial treatment, both groups will receive standard care, including single dose intravesical mitomycin C within 24 hours of initial resection, surveillance according to risk-adjusted schedules and adjuvant therapy as indicated by current practice guidelines.<wbr> </div><div style="margin-bottom: 10px;">Anticipated Start Date 01/<wbr>09/<wbr>2014 </div><div style="margin-bottom: 10px;">Anticipated End Date 28/<wbr>02/<wbr>2017 </div><div style="margin-bottom: 10px;">ISRCTN: ISRCTN84013636 </div><div>DOI: 10.<wbr>1186/<wbr>ISRCTN84013636 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9891">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-13T17:28:56+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Sativex Recommended for Use on the NHS in Wales [dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7696</link>
<description>Sativex Recommended for Use on the NHS in Wales [dis:Spasticity]</description><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7696</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7696">Sativex Recommended for Use on the NHS in Wales</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7696">Neurology7696</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 August 2014 | 17:05</font><br><br><div style="margin-bottom: 10px;">Comment: The All Wales Medicines Strategy Group (AWMSG) has published a recommendation that Sativex be used within the NHS in Wales for the symptom of moderate to severe spasticity in people with MS.<wbr> However the recommendation needs to be approved by Ministers before Sativex is made available.<wbr>
The AWMSG recommendation suggests that Sativex becomes a treatment option for people with moderate to severe MS-related spasticity which has not been adequately controlled by other anti-spasticity medication and who demonstrate a measureable improvement in spasticity-related symptoms during an initial trial of therapy.<wbr> </div><div style="margin-bottom: 10px;">Previous research has suggested that not all recipients respond to the drug.<wbr> The manufacturer of Sativex, Bayer, has a scheme to help with the cost of identifying those who respond to Sativex by funding the first pack of treatment free of charge.<wbr> If the funding of Sativex is approved by Ministers, the cost for the second pack onwards would be covered by NHS Wales for those people who find it effective.<wbr> </div><div style="margin-bottom: 10px;">This recommendation means that Wales could be the first country in the UK to make Sativex routinely available on the NHS to people with MS-related spasticity that has not been adequately controlled by other treatments.<wbr> </div><div><EM>Source </EM><A href="http://www.mstrust.org.uk"><EM>http:/<wbr>/<wbr>www.<wbr>mstrust.<wbr>org.<wbr>uk</EM></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7696">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-13T17:05:46+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Pfizer and  23andME Ink Deal to Study Bowel Disease [dis:IBD]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2005</link>
<description>Pfizer and  23andME Ink Deal to Study Bowel Disease [dis:IBD]</description><category>dis:IBD</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2005</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2005">Pfizer and  23andME Ink Deal to Study Bowel Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2005">GastroEnterology2005</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 August 2014 | 16:44</font><br><br><div style="margin-bottom: 10px;">Comment: Under the agreement, the Google-backed home genetic testing company 23andMe will map the DNA of 10,000 patients who have forms of the disease, which include CD and UC.<wbr> The companies hope to identify genetic similarities among patients with the disease, which could eventually guide development of new targeted drugs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Details of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">Methodology: Patients will submit saliva samples using 23andMe's at-home collection kit and then fill out online questionnaires about their disease and symptoms.<wbr> </div><div style="margin-bottom: 10px;">Financial Terms: not disclosed </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">23andMe SnapShot</FONT></STRONG> </div><div style="margin-bottom: 10px;">23andMe, founded by Anne Wojcicki, is privately held.<wbr> </div><div>The company has signed 2 similar deals with Genentech and Janssen Pharm.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2005">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-13T16:44:35+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Revance Highlights Some Key Points During Its Q2 Earnings Call [sub:Aesthetics, dis:Hyperhydrosis, headline, class:BotulinumToxins]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7692</link>
<description>Revance Highlights Some Key Points During Its Q2 Earnings Call [sub:Aesthetics, dis:Hyperhydrosis, headline, class:BotulinumToxins]</description><category>sub:Aesthetics</category><category>dis:Hyperhydrosis</category><category>headline</category><category>class:BotulinumToxins</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7692</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7692">Revance Highlights Some Key Points During Its Q2 Earnings Call</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHyperhydrosis"><font color="#e95e0b">:Neurology:dis:Hyperhydrosis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7692">Neurology7692</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 August 2014 | 16:01</font><br><br><div style="margin-bottom: 10px;">Comment: Financially, Revance remains well-positioned to optimise the full 
potential of its botulinum toxin pipeline with $203m of cash at the 
end of the second quarter.<wbr> During yesterday's Earnings 
Call management made some interesting comments about the newly issued draft 
FDA guidance on development of botulinum drug products for upper 
facial lines and its phIII compliance with the recommendations.<wbr> 
Additionally, there was reference to a 25 person KOL survey 
regarding RT-002 which referred to it as a potential "game changer" 
because of its extended duration of action.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Comments in relation to new draft guidance and the outcome of 
a dispute resolution with the FDA with regards to Revance's phIII 
trial endpoint.<wbr> </STRONG> </div><div style="margin-bottom: 10px;">Management noted that Revance has historically interacted with the FDA's Division of Dermatology and Dental Products, which is the same division that issued the draft guidance.<wbr> Based on its interactions over the years, the draft guidance reflects the 
company's understanding of the agency's recommendations 
and expectations 
and development plans established for its product candidates are expected to provide the data necessary to respond to the FDA guidance.<wbr> </div><div style="margin-bottom: 10px;">However, it was noted that there is one area where the Revance program differs, namely in the measurement of the primary efficacy endpoint in crow's feet line at rest rather than at smile.<wbr> Revance believes that the scientific evidence supports that the improvement at rest is the most clinically meaningful aesthetic benefit desired by patient.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">L Daniel Brown Co-Founder noted that "Revance has had a thorough discussion with the Division of Dermatology and Dental Products of the FDA and ultimately went through a Formal Dispute Resolution process with the Office of Drug Evaluation in 2012.<wbr> The outcome of the Dispute Resolution was that the FDA agreed that we were free to proceed with Phase III trials, which we are doing now.<wbr> The FDA apparently also agreed that the crow's feet indication could be based on the primary endpoint at rest.<wbr>" </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Additionally, the FDA clarified the need to demonstrate that the mechanism of action depends on the effect of the toxins on the muscle being treated.<wbr> The agency apparently 
stated, as is usual that the final assessment will depend on the total review of the information submitted.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">L Daniel Browne stated "Although, we can't provide assurances that the FDA will ultimately approve our BLA, our program will be moved – will move forward based on the office level outcome of the Dispute Resolution.<wbr>" </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>So, what does this 
</STRONG><STRONG>mean?</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Essentially the development strategy for RT001 topical botulinum toxin in crow's feet lines remains unchanged.<wbr> </P> </div><div style="margin-bottom: 10px;"><UL><LI>
  Data from the first pivotal topical study is expected at the end of this year.<wbr> </LI>
<LI>
  The second US pivotal Phase III study and a European study are on schedule with results anticipated in 2015 and </LI>
<LI>
  The open-label safety study is ongoing, concluding in 2016 </LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="pwrapper">All of this points towards an anticipated BLA and European marketing application 
or MAA filing by the end of 2016.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Implications of New Financing</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">With its financial resource strengthened, the group is now in 
a position to complete its phIII pivotal studies for crow's feet lines in the US 
and Europe as well as a phII study in hyperhidrosis.<wbr> For its longer lasting 
injectable toxin RT-002, the additional capital enables the group to 
move forward with an active comparator trial for the treatment of 
frown lines and to move forward with additional aesthetic (e.<wbr>g.<wbr> forehead, upper lip, neck, and Décolletage) and 
therapeutic indications for topical and injectable neurotoxins.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Specific Comments About RT-002</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Daniel Brown also commented on some of 
the feedback the company has received to the RT002 data which importantly 
demonstrated good efficacy in frown lines with a duration of effect of 7.<wbr>3 
months.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">To quote he stated "We believe this nearly two-fold increase in duration versus the currently marketed products could transform the neurotoxin treatment market.<wbr>" </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"We are very encouraged by the initial reaction by physicians to the recent injectable data.<wbr> Since, the study was completed, we've had the opportunity to present our findings at multiple clinical meetings in the aesthetic medicine space, including the American Society of Aesthetic Plastic Surgery in April, the International Facial Plastic Surgery Meeting in May and the Cosmetic Surgery and Aesthetic Dermatology 
Meeting in June.<wbr> At each of those events, our injectable data was exceptionally well received.<wbr>" </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"In addition to the podium presentations, we conducted initial market research to gain feedback on the data and solicit input into the design of our RT002 clinical program.<wbr> Again, the feedback was overwhelmingly positive.<wbr> In interviews with more than <STRONG>25 key opinion leaders across four core specialties, the consistent response was that duration of effect in the six months to seven months, and I quote 
verbatim, was game changing and would cause them to change their current purchase habits.<wbr>" 
</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Many clinicians indicated that duration of six months to seven months fits into their current consumer habits of visiting the office about twice a year for other aesthetic treatment.<wbr> Since the market data show that the majority of consumers retain visible results at the six-month time point, they believe that the results were compelling enough that consumers would switch from their current injectable botulinum toxin to an injectable RT002 product.<wbr>" </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Many physicians also indicated that an injectable could expand the market along those consumers who don't want repeat treatments every three months to four months, for example, among men, who represent a relatively small portion of the market today.<wbr> Based on the results from the first injectable clinical trial and previous findings from preclinical data, <STRONG>we plan to begin a Phase II head-to-head active and placebo comparator clinical trial against the market leader BOTOX, with results expected in Q4 2015.<wbr></STRONG> The study will be powered to show longer duration and is expected to include approximately 
250 to 300 subjects.<wbr>"</P> </div><div><P class="pwrapper">Source: <A href="http://www.revance.com">www.<wbr>revance.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7692">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-13T16:01:43+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Synergy Pharm Reports Q2 Results and Progress with its Constipation Clinical Programs [dis:IBS, dis:Constipation]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2004</link>
<description>Synergy Pharm Reports Q2 Results and Progress with its Constipation Clinical Programs [dis:IBS, dis:Constipation]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2004</comments><category>dis:IBS</category><category>dis:Constipation</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2004</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2004">Synergy Pharm Reports Q2 Results and Progress with its Constipation Clinical Programs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2004">GastroEnterology2004</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 August 2014 | 13:19</font><br><br><div style="margin-bottom: 10px;">Comment: Synergy expects top-line data from its Ph2 trial of SP-333 in opioid-induced constipation (OIC) in 4Q:14.<wbr> Management plans to start Ph3 trial of Plecanatide for IBS-C in 4Q:14.<wbr> The chronic idiopathic constipation (CIC) program is underway, with a wrap up expected in 2H:15, and a launch at a very end of 2016.<wbr> Both drugs are unique analogs of the naturally occurring human GI hormone, uroguanylin.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Financial Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;">Synergy's cash, cash equivalents and available-for-sale securities balance as of June 30, 2014 was $51.<wbr>2 million as compared to $68.<wbr>1 million on December 31, 2013.<wbr> </div><div>Net loss for the three months ended June 30, 2014 was $25.<wbr>9 million or $0.<wbr>28 per share, as compared to a net loss of $10 million, or $0.<wbr>11 per share, for the quarter ended June 30, 2013.<wbr>
<EM>Source: Synergy Pharm.<wbr></EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2078c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Ph2b data presented at ACG demonstrate that plecanatide, once-daily oral tablet, significantly improved complete spontaneous bowel movement (CSBM) frequency, bowel habits, treatment satisfaction and significantly reduced abdominal pain in patients with IBS-C throughout the 12 week treatment period.<wbr> Synergy plans to initiate the pivotal phase 3 IBS-C clinical development program in Q4:14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Additional Findings</STRONG> </div><div style="margin-bottom: 10px;">Patients taking 3.<wbr>0 and 9.<wbr>0 mg plecanatide showed statistically significant improvement in the Overall Responder rate, a secondary analysis in this study and the endpoint required for FDA approval in IBS-C (41.<wbr>9% and 40%, respectively, compared to 24.<wbr>7% for placebo).<wbr> </div><div>The data were presented by lead author, Philip B.<wbr> Miner Jr.<wbr>, M.<wbr>D.<wbr>, President and Medical Director of the Oklahoma Foundation for Digestive Research.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2078" class="commentpermalink">GastroEnterology2078</a> / <span class="date">22 October 2014</span> /
<span class="time">09:59:46 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2004">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-13T13:19:40+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Tokai Files For IPO</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9889</link>
<description>Tokai Files For IPO</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9889</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9889</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9889">Tokai Files For IPO</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9889">Oncology9889</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 13 August 2014 | 09:51</font><br><br><div style="margin-bottom: 10px;">Comment: Tokai currently has galeterone being evaluated in metasatatic CRPC, in particular, preliminary evidence suggested potential benefit for patients who are refractory or show resistant to abiraterone or enzalutamide.<wbr> Now with the lead drug candidate, galeterone, on the precipice of a late stage trial, Tokai is taking the pitch to Wall Street.<wbr> </div><div style="margin-bottom: 10px;">Cambridge, MA-based Tokai has filed papers outlining plans to raise <A class="ext-link" href="http://www.sec.gov/Archives/edgar/data/1404281/000119312514305049/d705598ds1.htm#toc" rel="external" target="_blank" title=""><U><FONT color="#0066cc">up to $75 million in an IPO</FONT></U></A>.<wbr> The company will largely use the cash to fund clinical development of galeterone.<wbr> Should it go public, Tokai would trade on the Nasdaq under the ticker symbol &ldquo;TKAI.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><A class="ext-link" href="http://www.tokaipharma.com/" rel="external" target="_blank" title=""><U><FONT color="#0066cc">Tokai</FONT></U></A> was formed around work done by Angela Brodie and Vincent Njar of the University of Maryland School of Medicine.<wbr>Tokai&rsquo;s pitch is that galeterone is essentially <A href="http://www.xconomy.com/boston/2014/08/12/tokai-chasing-the-field-in-prostate-cancer-files-for-ipo/www.xconomy.com/boston/2013/02/13/tokai-looks-to-follow-fast-behind-jj-medivation-in-prostate-cancer/"><U><FONT color="#0066cc">a combination therapy in one pill</FONT></U></A>.<wbr> The drug employs tactics used by both enzalutamide (an androgen blocker) and abiraterone (which targets an enzyme called Cyp17 lyase that&rsquo;s required for androgen production), while also degrading the androgen receptor on tumor cells, in theory blocking the androgen hormones that feed prostate cancer tumors in three different ways.<wbr> Tokai believes this combination strategy might give it some efficacy advantages over other prostate cancer drugs.<wbr> And unlike abiraterone, galeterone also doesn&rsquo;t have to be administered with prednisone, an immunosuppressive steroid.<wbr> </div><div style="margin-bottom: 10px;">Given the way its drug is designed to work, and the intensely competitive field (big players such as J&amp;J and Astellas are already in the field), Tokai aims to first find a niche for itself treating prostate cancer patients whose tumor cells have an altered, &ldquo;truncated&rdquo; androgen receptor&mdash;a group that, Tokai says, may not be effectively treated by drugs like abiraterone or enzalutamide&mdash;before branching out into other subsets of prostate cancer patients.<wbr> </div><div>Tokai has raised more than $85 million in venture funding from the likes of Apple Tree Partners (49.<wbr>15 percent stake), Novartis BioVentures (28.<wbr>12 percent), and entities associated with former Goldman Sachs managing director Muneer Satter.<wbr> BMO Capital Markets, Stifel Nicolaus, William Blair, and Janney Montgomery Scott are underwriting the IPO.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9966c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Tokai was up $8.<wbr>76 (58%) to $23.<wbr>76 on its first day of trading Wednesday (17th Sept) after raising $97.<wbr>2 million through the sale of 6.<wbr>5 million shares at $15 in an IPO.<wbr> The IPO price valued the company at $327.<wbr>6 million.<wbr> Earlier this month, Tokai said it planned to sell 5.<wbr>4 million shares at $13-$15.<wbr> At $14, the offering would have raised $75.<wbr>6 million.<wbr> This IPO is the 14th in biotech for Massachusetts this year.<wbr> Next half, Tokai plans to start Phase III testing of galeterone (<A href="http://www.biocentury.com/products/tok-001" target="_blank" title="TOK-001 product news and analysis from BCIQ"><U><FONT color="#0066cc">TOK-001</FONT></U></A>) to treat castration-resistant prostate cancer (CRPC).<wbr> </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9966" class="commentpermalink">Oncology9966</a> / <span class="date">18 September 2014</span> /
<span class="time">12:10:33 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9889">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-13T09:51:01+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Evaluation of Two Probiotic Strains for IBS-C [dis:IBS, dis:Constipation, sub:Probiotics, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2003</link>
<description>Evaluation of Two Probiotic Strains for IBS-C [dis:IBS, dis:Constipation, sub:Probiotics, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:IBS</category><category>dis:Constipation</category><category>sub:Probiotics</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2003</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2003">Evaluation of Two Probiotic Strains for IBS-C</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2003">GastroEnterology2003</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 August 2014 | 17:38</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph2 study will determine if Lactobacillus paracasei HA-196 and Bifidobacterium longum R0175, are effective in helping subjects manage the symptoms of IBS-C.<wbr> PE will measure number of overall responders (FDA endpoint).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Reference</STRONG> <A href="http://clinicaltrials.gov/ct2/show/NCT02213172?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=07%2F12%2F2014&amp;rank=172">NCT02213172</A> </div><div style="margin-bottom: 10px;"><UL><LI>Sponsor: KGK Synergize Inc.<wbr></LI>
<LI>Collaborator: Lallemand Health Solutions</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> approx 285 (Male and female aged 18 years and older).<wbr> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">IBS diagnosis according to Rome III criteria and referral to this study by a clinician.<wbr> That is, recurrent abdominal pain or discomfort (i.<wbr>e.<wbr>, uncomfortable sensation other than pain) at least 3 days/<wbr>month in the last 3 months associated with 2 or more of the following: improvement with defecation, onset associated with a change in stool frequency; onset associated with a change in stool form (appearance).<wbr>Participants from the general population who have IBS-C symptoms, without a previous diagnosis, will be assessed by the Principle Investigator and included in the study if differential diagnosis confirms IBS-C.<wbr> The Principle Investigator will confirm the diagnosis of IBS-C in any potential participants who have a previous diagnosis of IBS-C.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Weekly average of the worst daily (in the past 24 hours) abdominal pain score of ≥ 3.<wbr>0 on a 11 point scale</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">An average of fewer than 3 CSBMs per week.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Absence of black color (melena) or blood in stools.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Willingness to complete questionnaires, records, and diaries associated with the study and to complete all clinic visits.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Willingness to discontinue consumption of probiotics (e.<wbr>g.<wbr> yogurts, with live, active cultures or supplements).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG>: Start date Aug 2014 with completion in Oct 2015 </div><div><STRONG>Location</STRONG> Canada </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2003">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-12T17:38:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly &amp; NET [class:SomatostatinAnalogue, dis:Acromegaly, dis:MidGutNET, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7770</link>
<description>EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly &amp; NET [class:SomatostatinAnalogue, dis:Acromegaly, dis:MidGutNET, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7770</comments><category>class:SomatostatinAnalogue</category><category>dis:Acromegaly</category><category>dis:MidGutNET</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7770</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7770">EU Clinical Trials Register Listing New PhII Study of CAM2029 In Acromegaly & NET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7770">Endocrinology7770</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 August 2014 | 15:43</font><br><br><div style="margin-bottom: 10px;">Comment: A new phII open-label randomised PK, PD efficacy &amp; safety study with CAM2029 is now listed by Camurus on the EU Clinical Trial Register.<wbr> The trial will evaluate the drug in both acromegaly and NET patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Main objective of the trial:</STRONG> </div><div style="margin-bottom: 10px;">To characterise the PK profile of octreotide after each injection of CAM2029 as compared with baseline PK Sandostatin&reg; LAR&reg; in patients with acromegaly and NETs </div><div style="margin-bottom: 10px;"><STRONG>Secondary objectives of the trial: </STRONG> </div><div style="margin-bottom: 10px;"><STRONG><EM>In acromegaly patients:<BR></EM></STRONG>&bull;To assess the safety and tolerability of CAM2029 <BR>&bull;To compare the effect of treatment and exposure with CAM2029 on the response rate of insulin-like growth factor 1 (IGF-1) at Day 84 with baseline treatment with Sandostatin LAR, ie, normalisation of IGF-1 adjusted for age and gender<BR>&bull;To compare the effect of treatment and exposure with CAM2029 on the reduction of mean growth hormone (GH) level to less than 2.<wbr>5 &micro;g/<wbr>L at Day 84 with baseline treatment with Sandostatin LAR<BR>&bull;To characterise IGF-1 profiles after treatment with CAM2029 as compared with baseline treatment with Sandostatin LAR<BR>&bull;To compare the proportions of patients who have normalised GH and IGF-1 levels at Day 84 with baseline treatment with Sandostatin LAR </div><div style="margin-bottom: 10px;"><EM>In patients with NET:-</EM> </div><div style="margin-bottom: 10px;">&bull;To assess the safety and tolerability of CAM2029 </div><div style="margin-bottom: 10px;">Additional exploratory endpoint for patients with acromegaly:<BR>&bull;Octreotide concentration vs IGF-1 and GH modeling </div><div style="margin-bottom: 10px;">Additional exploratory endpoints for patients with NETs:<BR>&bull;Symptoms of Carcinoid syndrome (bowel movements, flushing) with CAM2029 and Sandostatin LAR.<wbr><BR>&bull;Use of rescue medication </div><div style="margin-bottom: 10px;"><STRONG>Acromegaly Patient Eligibility</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Patients with acromegaly currently being treated with no medical treatment for acromegaly other than Sandostatin LAR.<wbr>
</LI>
<LI>Patients currently receiving Sandostatin LAR at a stable dose of 10 mg, 20 mg or 30 mg i.<wbr>m.<wbr> given every 28 days for at least 2 months before the start of the Last Sandostatin LAR Dose Assessment Phase (Day -28)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>NET Patient Eligibility</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Patients with functional, well-differentiated (G1 or G2) neuroendocrine tumour (NET) with symptoms of carcinoid (bowel movements and/<wbr>or flushing).<wbr>
</LI>
<LI>Patients currently receiving medical treatment with Sandostatin LAR for symptom control at stable doses of 10 mg, 20 mg or 30 mg i.<wbr>m.<wbr> given every 28 days for at least 2 months before the start of the Last Sandostatin LAR Dose Assessment Phase (Day -28).<wbr>
</LI>
<LI>Patients with controlled symptoms, i.<wbr>e.<wbr>, who do not require rescue medication with Sandostatin IR s.<wbr>c.<wbr> during Screening.<wbr>
</LI>
<LI>Patients not on treatment with any other agents for the treatment of NET (e.<wbr>g.<wbr>, interferon, chemotherapy, radiotherapy, targeted agents).<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Trial Sites/<wbr>Pt Numbers &amp; Timelines</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Three EU sites are participating with Germany and Italy known to be involved.<wbr>
</LI>
<LI>28 patients will be involved and recruitment started as of July 2014
</LI>
<LI>Follow-up is 84 days
</LI>
</UL> </div><div><STRONG>EudraCT Number</STRONG>: 2013-000533-12 </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7867c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div><EM>Clinicaltrials.<wbr>gov</EM> is listing the trial under the reference <a href="http://clinicaltrials.gov/ct2/show/NCT02299089?recr=Open&no_unk=Y&phase=012&fund=2&rcv_s=10%2F24%2F2014&rank=25" class="defaultlink">NCT02299089</a>.<wbr> It is indicated that Marianne Pavel will be the principal investigator.<wbr> Of note details have been provided on the countries and the centers.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7867" class="commentpermalink">Endocrinology7867</a> / <span class="date">24 November 2014</span> /
<span class="time">17:25:13 o'clock CET</span>
</font></div><a name="Endocrinology7948c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Status of trial <a href="https://clinicaltrials.gov/ct2/show/NCT02299089" class="defaultlink">NCT02299089</a> has changed to "recruiting" OnJan 25th, with 2 sites recruiting: CHU Rouen (France), RCCS Azienda Ospedaliera Universitaria San Martino IST (Italy) </div><font size="-1">rao36589 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7948" class="commentpermalink">Endocrinology7948</a> / <span class="date">03 February 2015</span> /
<span class="time">10:25:31 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7770">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-12T15:43:34+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Northwest  Biotherapeutics Reports Positive &amp; Unexpected Data From Its PhIII GBM Trial [class:Vaccines, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9886</link>
<description>Northwest  Biotherapeutics Reports Positive &amp; Unexpected Data From Its PhIII GBM Trial [class:Vaccines, news]</description><category>class:Vaccines</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9886</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9886">Northwest  Biotherapeutics Reports Positive & Unexpected Data From Its PhIII GBM Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9886">Oncology9886</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 August 2014 | 14:59</font><br><br><div style="margin-bottom: 10px;">Comment: NW noted that its trial with DCVax&reg;-L for Glioblastoma multiforme (GBM) is progressing on track and that 55 patients who were ineligible to enroll in the trial due to unusually rapid tumour recurrence have been included in a compassionate use (open label) arm and are showing unexpected and encouraging survival times of at least 8 months longer thant the norm.<wbr> </div><div style="margin-bottom: 10px;">DCVax&reg; is a platform technology that uses activated dendritic cells to reinvigorate and educate the immune system to attack cancers.<wbr> It is made with cancer antigens from tumor lysate (a protein extract from processed tumor cells) from the patient&rsquo;s own tumor tissue.<wbr> As such, DCVax-L incorporates the full set of tumor antigens, making it difficult for tumors to find ways around it.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New &amp; Encouraging Data</STRONG> </div><div style="margin-bottom: 10px;">Regular GBM patients survive for a median of about 14.<wbr>6 months with current standard of care.<wbr> &ldquo;Rapid progressors&rdquo; have a much shorter life expectancy, in the range of 7 to 10 months, and generally are not expected to respond much to any treatments.<wbr> </div><div style="margin-bottom: 10px;">The data on the compassionate use arm only recently received by the company includes the survival to date for all 55 patients and data relating to the progression of their cancer for 43 of the 55 patients.<wbr> </div><div style="margin-bottom: 10px;">According to initial analyses, the median Overall Survival for all 55 patients is 18 months; the median Overall Survival for the 43 patients is a little over 19 months.<wbr> The Company is in the process of further analyses of the data on these patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PhIII Trial Enrolment</STRONG> </div><div style="margin-bottom: 10px;">Separately the company has announced that the total number of patients and the number of events required from a primary endpoint perspective have been changed with the number of &ldquo;events&rdquo; counted in the statistical analysis increasing from 110 to 248, but the total enrollment in the trial only increasing from 312 to 348.<wbr> </div><div>Source: <A href="http://www.nwbio.com">www.<wbr>nwbio.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9886">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-12T14:59:05+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Chiasma Will Launch its Oral Octreotide Acetate by 2015 [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7767</link>
<description>Chiasma Will Launch its Oral Octreotide Acetate by 2015 [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7767</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7767">Chiasma Will Launch its Oral Octreotide Acetate by 2015</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7767">Endocrinology7767</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 August 2014 | 11:26</font><br><br><div style="margin-bottom: 10px;">Comment: License granted to Roche terminated last month.<wbr> Chiasma is now independently leading the drug development and commercialization.<wbr> It is looking either to partner the drug or to launch by itself.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps for Chiasma</STRONG> </div><div style="margin-bottom: 10px;">According to Chiasma CEO Roni Mamluk, "The results of the Ph3 trials were excellent, and a celebratory event was held in June to publicize them, attended by all Roche's senior executives, who were all happy and satisfied.<wbr> We were with them in all their meetings with the regulators, and we have before us all the results of the trials we conducted ourselves under their supervision.<wbr> There is no problem with the results; what is apparently involved is a strategic decision by them whether or not to become more deeply involved in the endocrinology sector (hormone-based drugs).<wbr>" </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> We are now producing the product ourselves through outsourcing, and because the product treats a rare disease, the number of doctors dealing in the field is small, and they can also be reached with a limited sales staff," Mamluk explains </div><div style="margin-bottom: 10px;">Chiasma now plans to submit the Ph3 results to the FDA, hoping to receive approval to launch its product by 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Sources</STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.fiercebiotech.com/story/roche-commits-danish-rna-lab-3b-london-incubator-hits-go-biotechs-post-ipo/2014-08-07?utm_medium=rss&amp;utm_source=rss&amp;utm_campaign=rss">http:/<wbr>/<wbr>www.<wbr>fiercebiotech.<wbr>com/<wbr>story/<wbr>roche-commits-danish-rna-lab-3b-london-incubator-hits-go-biotechs-post-ipo/<wbr>2014-08-07?utm_medium=rss&amp;utm_source=rss&amp;utm_campaign=rss</A> </div><div><A href="http://www.globes.co.il/en/article-roche-cancels-600m-chiasma-deal-1000961276">http:/<wbr>/<wbr>www.<wbr>globes.<wbr>co.<wbr>il/<wbr>en/<wbr>article-roche-cancels-600m-chiasma-deal-1000961276</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7767">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-12T11:26:23+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Bayer's New Treatment Option to Enter POC Study for Endometriosis-Associated Pelvic Pain [dis:Gynea, comp:BayerSchering, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9885</link>
<description>Bayer's New Treatment Option to Enter POC Study for Endometriosis-Associated Pelvic Pain [dis:Gynea, comp:BayerSchering, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Gynea</category><category>comp:BayerSchering</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9885</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9885">Bayer's New Treatment Option to Enter POC Study for Endometriosis-Associated Pelvic Pain</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9885">Oncology9885</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 August 2014 | 11:03</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph2b six-arm study is designed to assess the efficacy/<wbr>safety of different dose combinations of an aromatase inhibitor and a progestin in an intravaginal ring vs placebo and Lupron (leuprorelin) in approx 324 women with symptomatic endometriosis over a 12-week treatment period.<wbr> Absolute change in mean pain will be measured as PE.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Reference </STRONG><a href="http://www.clinicaltrials.gov/ct2/show/NCT02203331?term=endometriosis+AND+BAYER&recr=Open&rank=3" class="defaultlink">NCT02203331</a> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">The study is expected to start next month and complete in Dec 2015 </div><div style="margin-bottom: 10px;"><STRONG>Recruitment Criteria</STRONG> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Premenopausal women18 years and above at the time of screening.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Women with endometriosis confirmed by laparoscopy or laparotomy within the last ten years but not less than 8 weeks before the screening visit In Japan, diagnosis based on imaging (transvaginal ultrasound or MRI) also qualifies for inclusion.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Moderate to severe endometriosis-associated pelvic pain (EAPP) of &ge;5 in the last 28 days before screening visit 1 measured on the numeric rating scale (NRS; i.<wbr>e.<wbr> 4-week recall period).<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">At randomization: Adherence to the study procedures during the screening period, at least 24 diary entries of ESD item 1 during the last 28 consecutive days before the randomization visit, and a sum of the available ESD item 1 ('worst pain' on the daily NRS) entries during this period of at least 98 (corresponding to an average score of &ge; 3.<wbr>5).<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Willingness to use only ibuprofen as rescue pain medication for EAPP, if needed according to investigator's instruction.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Use of a non-hormonal barrier method (i.<wbr>e.<wbr> spermicide-coated condoms) for contraception from screening visit until the end of the study.<wbr> This is not required if adequate contraception is achieved by vasectomy of the partner
</LI>
</UL> </div><div><P class="color-bullet" style="margin-top: 0.7ex;"><STRONG>Locations</STRONG> US Canada EU</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9885">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-12T11:03:16+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Camurus' Leuprolide Acetate FluidCrystal® Injection Depot Once Monthly to Enter Ph2 for Prostate Cancer [sub:Hybrids, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :DKPHybrids:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9877</link>
<description>Camurus' Leuprolide Acetate FluidCrystal® Injection Depot Once Monthly to Enter Ph2 for Prostate Cancer [sub:Hybrids, dis:Prostate, :PharmaWorld:sub:ClinicalTrial, :DKPHybrids:news]</description><category>sub:Hybrids</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9877</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9877">Camurus' Leuprolide Acetate FluidCrystal® Injection Depot Once Monthly to Enter Ph2 for Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:DKPHybrids:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=sub%3aHybrids"><font color="#e95e0b">:Oncology:sub:Hybrids</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9877">Oncology9877</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 August 2014 | 17:33</font><br><br><div style="margin-bottom: 10px;">Comment: This Ph2 study will start this month to assess the pharmacokinetics, pharmacodynamics, efficacy and safety of Camurus' CAM2032 (Prosenze) q1m versus Eligard, in patients with prostate cancer.<wbr> PE will measure CAM2032 q1m pharmacokinetic profile (plasma concentration).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Reference</STRONG> <A href="http://ci.beaufour-ipsen.com/NCT02212197">NCT02212197</A> </div><div style="margin-bottom: 10px;"><STRONG>Timeline Completion</STRONG> date Feb 2015 /<wbr> March 2015 </div><div style="margin-bottom: 10px;"><STRONG>Recruitmen</STRONG>t Approx.<wbr> 55 </div><div style="margin-bottom: 10px;"><UL><LI>Men ≥40 and ≤85 years of age</LI>
<LI>Histological or cytological proven adenocarcinoma of the prostate requiring hormone therapy</LI>
<LI>Life expectancy over 12 months</LI>
<LI>World Health Organisation/<wbr> The Eastern Cooperative Oncology Group (WHO/<wbr>ECOG) performance status of 0, 1 or 2</LI>
<LI>Adequate and stable renal function</LI>
<LI>Adequate and stable hepatic function</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> All patients will receive leuprolide acetate (3.<wbr>75mg /<wbr> 7.<wbr>5mg) administered subcutaneously once monthly during 3 months </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> Hungary (5 sites) and Finland (4 sites) </div><div><STRONG>Principal Investigator</STRONG> Teuvo Tammela, Professor Tampere University Hospital, Department of Urology </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9877">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-11T17:33:04+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Versartis to Move Forward with a Ph3 Trial in Early 2015 with VRS-317 for PGHD [class:GrowthHormone, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7766</link>
<description>Versartis to Move Forward with a Ph3 Trial in Early 2015 with VRS-317 for PGHD [class:GrowthHormone, :PharmaWorld:sub:Finance]</description><category>class:GrowthHormone</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7766</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7766">Versartis to Move Forward with a Ph3 Trial in Early 2015 with VRS-317 for PGHD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7766">Endocrinology7766</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 August 2014 | 17:19</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside the financial results for the Q2, management also reported progress wit the initiation and enrollment in the VRS-317 extension study for AGHD.<wbr> In parallel with the planned US and European VRS-317 Ph3 program, Versartis will meet with PMDA (Japanese equivalent of the FDA) to discuss a clinical program for VRS-317 in Japanese children with GHD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Financial Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">For the second quarter ended June 30, 2014, Versartis reported a GAAP net loss attributable to common stockholders of approximately $8.<wbr>6 million, or $0.<wbr>36 per share, basic and diluted, compared to a net loss attributable to common stockholders for the second quarter ended June 30, 2013 of $3.<wbr>7 million, or $24.<wbr>74 per share, basic and diluted.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Anticipated Milestones</FONT></STRONG> </div><div style="margin-bottom: 10px;">In the second half of 2014 Versartis will discuss the Ph3 clinical program for VRS-317 in pediatric patients with the FDA and European Medicines Agency (EMA).<wbr> In the fourth quarter of 2014 the Company will provide an update on the outcome of these discussions as well as the VRS-317 Phase 3 trial design.<wbr> </div><div style="margin-bottom: 10px;">The Company's goal is to initiate the clinical program in Japan for VRS-317 in 2015.<wbr> </div><div style="margin-bottom: 10px;">The Company expects to initiate a Phase 2/<wbr>3 registration study of VRS-317 for adult GHD in the second half of 2015.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7766/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7766/1/ScreenCapture1.jpg?user-agent=rss"><EM>Source: Versartis</EM> </div><!-- Comment details --><a name="endocrinology7766attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7766/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(631 B)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7766/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(57,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7766">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-11T17:19:03+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7766/1/ScreenCapture1.jpg" length="631" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7766/2/ScreenCapture2.jpg" length="58848" type="image/jpeg"/></item><item>
<title>Key Messages from the International Society of Aesthetic Plastic Surgeons (ISAPS) Survey [sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7689</link>
<description>Key Messages from the International Society of Aesthetic Plastic Surgeons (ISAPS) Survey [sub:Aesthetics]</description><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7689</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7689">Key Messages from the International Society of Aesthetic Plastic Surgeons (ISAPS) Survey</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7689">Neurology7689</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 August 2014 | 16:53</font><br><br><div style="margin-bottom: 10px;">Comment: The report reflects international statistics, which are exclusively based on the estimated number of Plastic Surgeons in each country and the respondent sample.<wbr> This international survey is focused on physicians who are board certified (or national equivalent) Plastic Surgeons.<wbr> In the US, LatAm (Brazil, Mexico, Columbia, Venezueala, Argentina), Iran, Spain, and Germany "botulinum toxin" tops the non surgical-procedures.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Selection of Key Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Estimated Number of Plastic Surgeons by Country</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7689/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The countries that performed the most cosmetic <U>surgical and nonsurgical</U> procedures in 2013 include: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>United States - 3,996,631 – (17%) 
</LI>
<LI>Brazil- 2,141,257 – (9.<wbr>1%) 
</LI>
<LI>Mexico - 884,353 - (3.<wbr>8%) 
</LI>
<LI>Germany - 654,115 - (2.<wbr>8%) 
</LI>
<LI>Spain - 447,177 - (1.<wbr>9%)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Botulinum Procedures by Country</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7689/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The leading cosmetic <U>surgical procedures</U> performed in 2013 were: </div><div style="margin-bottom: 10px;"><UL type="disc"><LI>Breast Augmentation - (1,773,584) 
</LI>
<LI>Liposuction (1,614,031) 
</LI>
<LI>Blepharoplasty (1,379,263) 
</LI>
<LI>Lipostructure including lipofilling and stem-enhanced lipofilling (1,053,890) 
</LI>
<LI>Rhinoplasty (954,423)</LI>
</UL> </div><div style="margin-bottom: 10px;">The leading <U>nonsurgical </U>procedures performed were: </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7689/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>TOP5</STRONG> </div><div style="margin-bottom: 10px;"><OL><LI><STRONG>Botulinum Toxin</STRONG> (5,145,189) </LI>
<LI>Fillers and Resorbables (3,089,686) </LI>
<LI>Laser Hair Removal (1,440,252) </LI>
<LI>Non-Invasive Facial Rejuvenation (1,307,300) </LI>
<LI>Chemical Peel, CO2 resurfacing, dermabrasion (773,442)</LI>
</OL> </div><div><EM>Source: <A href="http://www.isaps.org/Media/Default/global-statistics/2014%20ISAPS%20Global%20Stat%20Results.pdf">The International Survey on Aesthetic/<wbr>Cosmetic Procedures Performed in 2013</A></EM> </div><!-- Comment details --><a name="neurology7689attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7689/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(110,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7689/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(57,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7689/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(20,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7689">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-11T16:53:38+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7689/1/ScreenCapture1.jpg" length="113429" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7689/2/ScreenCapture2.jpg" length="59320" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7689/3/ScreenCapture3.jpg" length="20793" type="image/jpeg"/></item><item>
<title>Auspex Reports Q2 Results and Updates Pipeline Progress [dis:Huntington, dis:Dyskinesia, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7688</link>
<description>Auspex Reports Q2 Results and Updates Pipeline Progress [dis:Huntington, dis:Dyskinesia, :PharmaWorld:sub:Finance]</description><category>dis:Huntington</category><category>dis:Dyskinesia</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7688</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7688">Auspex Reports Q2 Results and Updates Pipeline Progress</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aDyskinesia"><font color="#e95e0b">:Neurology:dis:Dyskinesia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7688">Neurology7688</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 August 2014 | 15:45</font><br><br><div style="margin-bottom: 10px;">Comment: Auspex ended 2Q14 with $111.<wbr>7 million in cash.<wbr> In Huntington's disease, management continues to anticipate top-line data for both the Ph 3 FIRST-HD and ARC-HD Switch trials to readout in Q414.<wbr> A phase 2/<wbr>3 study of SD- 809 in tardive dyskinesia has been initiated, with top-line data expected in mid- 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Financial Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">For the three months ended June 30, 2014, Auspex reported a net loss of $10.<wbr>4 million, an increase of $7.<wbr>5 million from the $2.<wbr>9 million reported for the comparable period in 2013.<wbr> </div><div style="margin-bottom: 10px;">For the six months ended June 30, 2014, the company reported a net loss of $20.<wbr>5 million, an increase of $15.<wbr>3 million from the $5.<wbr>2 million reported for the first six months of 2013 </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Update on Other Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Tourette Syndrome (TS)</U>:  The company recently initiated an eight-week open-label preliminary efficacy and safety clinical trial (Phase 1b) for the potential treatment of tics associated with TS.<wbr> This study involves adolescent subjects and the top-line data are expected in the fourth quarter of 2014.<wbr> </div><div style="margin-bottom: 10px;"><U>Idiopathic Pulmonary Fibrosis (IPF)</U>:  SD-560 (deuterium-containing form of pirfenidone) is being advanced for the potential treatment of IPF and other fibrotic orphan conditions.<wbr> Auspex is on track to initiate a Phase 1 clinical trial for SD-560 with data expected to be available by mid-2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Milestones RoadMap</FONT></STRONG> </div><div style="margin-bottom: 10px;"><EM><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7688/1/ScreenCapture1.jpg?user-agent=rss"></EM> </div><div><EM>Source: Auspex</EM> </div><!-- Comment details --><a name="neurology7688attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7688/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(124,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7688">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-11T15:45:42+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7688/1/ScreenCapture1.jpg" length="127517" type="image/jpeg"/></item><item>
<title>OncoGenex's Q2 Key Takeaway Highlighting Development Progress of Curtisen and Apaorsen In mCRPC And Bladder Cancer [dis:Prostate, dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9875</link>
<description>OncoGenex's Q2 Key Takeaway Highlighting Development Progress of Curtisen and Apaorsen In mCRPC And Bladder Cancer [dis:Prostate, dis:Bladder]</description><category>dis:Prostate</category><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9875</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9875">OncoGenex's Q2 Key Takeaway Highlighting Development Progress of Curtisen and Apaorsen In mCRPC And Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9875">Oncology9875</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 11 August 2014 | 14:42</font><br><br><div style="margin-bottom: 10px;">Comment: OncoGenex Pharmaceuticals, Inc.<wbr> announced their Q2 financial results on 7th August, and the company believes to have $60 million that will sufficiently fund their Q3 planned operations, and through 1) the expected release of final survival results from the Borealis-1 trial (metastatic 1L bladder cancer) in the Q1 2015, 2) expected completion of enrolment in 2014 and release of final results in 2015/<wbr>205 in the AFFINITY (custirsen + cabazitaxel) trial; and 3) the expected completion of enrolment for the apatorsen Spruce and Rainer clinical trials (non squamous NSCLC) in 2015.<wbr> During the call OncoGenex provided the full summary of their clinical developments /<wbr> anticipated milestones and indicated the final analysis of PFS and OS outcomes from SYNERGY trial (Ph3, custirsen + docetaxel vs docetaxel in mCRPC patients) will be presented in September 2014 during ESMO.<wbr> </div><div style="margin-bottom: 10px;">Revenue for the three and six months ended June 30, 2014 was $4.<wbr>9 million and $16.<wbr>7 million, respectively.<wbr> This compares with $6.<wbr>3 million and $11.<wbr>4 million, respectively, in the same periods in 2013.<wbr> Revenue earned in the second quarter of 2014 consists of reimbursable clinical trial, manufacturing and preclinical costs incurred by OncoGenex under the collaboration agreement with Teva.<wbr> Total operating expenses for the three and six months ended June 30, 2014 were $12.<wbr>6 million and $32.<wbr>2 million, respectively, compared with $15.<wbr>7 million and $29.<wbr>1 million, respectively, in the same periods in 2013.<wbr> The decrease in the second quarter of 2014 as compared to the same period in 2013 was due primarily to purchases of combination drugs used in the AFFINITY trial during the second quarter of 2013.<wbr>The increase for the six months ended June 30, 2014 was predominantly the result of higher clinical trial expenses associated with patient enrolment and treatment in the AFFINITY and apatorsen investigator-sponsored trials.<wbr> Net loss for the three and six months ended June 30, 2014 was $7.<wbr>0 million, or $0.<wbr>47 per diluted common share, and $15.<wbr>7 million, or $1.<wbr>05 per diluted common share, respectively.<wbr> Comparatively, net loss for the three and six months ended June 30, 2013 was $8.<wbr>4 million, or $0.<wbr>57 per diluted common share, and $15.<wbr>1 million, or $1.<wbr>03 per diluted common share, respectively.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/1/Table%201%20financial.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/2/Table%202%20financial.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="text-decoration: underline;">Clinical Developments and Anticipated Milestones</SPAN> </STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/3/Table%203%20clinical%20development.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Custirsen</STRONG>: </div><div style="margin-bottom: 10px;"><UL><LI>SYNERGY full detail analysis will be presented at ESMO - analysis indicates superior benefit in the sub mCRPC patient group with worse prognosis
</LI>
<LI>AFFINITY is designed to evaluate a survival benefit for custirsen in combination with cabazitaxel treatment as second-line chemotherapy in patients with CRPC.<wbr> Completion of enrollment of approximately 630 men is expected in the second half of 2014.<wbr>
</LI>
<LI>The ENSPIRIT Phase 3 trial is evaluating a survival benefit for custirsen in combination with docetaxel treatment as second-line chemotherapy in patients with NSCLC.<wbr> The first interim futility analysis is expected to be conducted before the end of this year.<wbr>Apatorsen
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/4/Table%204%20clinical%20development.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Apatorsen (Hsp27 inhibitor) : evidence suggesting apatorsen may have impact on downstream immune response by increasing PD-L1 expression.<wbr> The company believes this strengthen the rationale in metastatic bladder cancer although this will unlikely result in shortening the runway for early advancement to Ph3 due to financial limitation.<wbr> </STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>The OncoGenex apatorsen development program includes seven Phase 2 trials in four tumor types, including bladder, lung, pancreatic and prostate cancers.<wbr> Apatorsen is a once-weekly intravenous (IV) experimental drug that is designed to inhibit production of Hsp27 to disable cancer cells' defenses and overcome treatment resistance.<wbr> Specifically, apatorsen is being evaluated in combination with abiraterone (Zytiga) in chemo na&iuml;ve mCRPC patients.<wbr>
</LI>
<LI>The Company announced initiation of the Cedar&trade; clinical trial in July 2014, an investigator-sponsored, randomized, open-label Phase 2 trial evaluating apatorsen in previously untreated patients with advanced squamous cell lung cancer.<wbr> Cedar is being conducted and funded primarily by the UK National Cancer Research Network and the UK Experimental Cancer Medicine Network and will include approximately 20 centres in the United Kingdom.<wbr>
</LI>
<LI>The Company provided an update on timing of the randomized, placebo-controlled Phase 2 Borealis-1&trade; trial of apatorsen in combination with first-line gemcitabine and cisplatin in patients with metastatic bladder cancer.<wbr> Final results are expected to be announced in the first quarter of 2015.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/5/Table%205%20clinical%20development.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/6/Table%206%20clinical%20development.JPG?user-agent=rss"> </div><div>Source: <A href="http://www.oncogenex.com">www.<wbr>oncogenex.<wbr>com</A> </div><!-- Comment details --><a name="oncology9875attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/1/Table%201%20financial.JPG">Table 1 financial.JPG</a>&nbsp;&nbsp;(185,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/2/Table%202%20financial.JPG">Table 2 financial.JPG</a>&nbsp;&nbsp;(144,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/3/Table%203%20clinical%20development.JPG">Table 3 clinical development.JPG</a>&nbsp;&nbsp;(276,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/4/Table%204%20clinical%20development.JPG">Table 4 clinical development.JPG</a>&nbsp;&nbsp;(318,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/5/Table%205%20clinical%20development.JPG">Table 5 clinical development.JPG</a>&nbsp;&nbsp;(367,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/6/Table%206%20clinical%20development.JPG">Table 6 clinical development.JPG</a>&nbsp;&nbsp;(326,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9875">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-11T14:42:26+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/1/Table%201%20financial.JPG" length="189957" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/2/Table%202%20financial.JPG" length="148305" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/3/Table%203%20clinical%20development.JPG" length="283349" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/4/Table%204%20clinical%20development.JPG" length="326004" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/5/Table%205%20clinical%20development.JPG" length="376235" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9875/6/Table%206%20clinical%20development.JPG" length="334367" type="image/jpeg"/></item><item>
<title>CRUK Are To Join Force With Astellas To Find New Therapeutic Target For Cancer - Pancreatic Cancer is Chosen As The Priority [comp:Astellas]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9873</link>
<description>CRUK Are To Join Force With Astellas To Find New Therapeutic Target For Cancer - Pancreatic Cancer is Chosen As The Priority [comp:Astellas]</description><category>comp:Astellas</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9873</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9873">CRUK Are To Join Force With Astellas To Find New Therapeutic Target For Cancer - Pancreatic Cancer is Chosen As The Priority</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9873">Oncology9873</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 08 August 2014 | 20:50</font><br><br><div style="margin-bottom: 10px;">Comment: Cancer Research UK and its commercial arm, Cancer Research Technology, are to join forces with Astellas Pharma Inc.<wbr> (Tokyo, President &amp; CEO: Yoshihiko Hatanaka) to find new drug targets in the fight against cancer, with an initial focus on pancreatic cancer.<wbr> As part of a new collaboration, Cancer Research UK, CRT and Astellas will conduct a two-year research programme in the UK to find promising new drug targets for pancreatic cancer.<wbr> Reserch focus will initially on autophagy, the process of consuming cellular parts for energy, in order to grow.<wbr> This is part of Astellas' objective to form a global drug discovery network.<wbr> </div><div style="margin-bottom: 10px;">New treatments are desperately needed for pancreatic cancer one of the deadliest forms of cancer.<wbr> Every year 8,800 people are diagnosed with the disease in the UK but survival rates remain very low, with only three per cent of people diagnosed with pancreatic cancer surviving their disease for five years or more after their diagnosis.<wbr> </div><div style="margin-bottom: 10px;">Under the terms of the deal, the first stage aims to identify and then validate the best possible drug targets to block the autophagy pathway in pancreatic cancer cells.<wbr> This research will be carried out by Professor Kevin Ryan at the Cancer Research UK Beatson Institute and Dr Sharon Tooze at the Cancer Research UK London Research Institute.<wbr> Astellas has an exclusive license to progress the most promising candidates through further drug discovery and development, subject to certain milestone and royalty payments to CRT.<wbr> Professor Kevin Ryan, Cancer Research UK scientist based at the Cancer Research UK Beatson Institute, said: "This is an exciting opportunity to develop new drugs for pancreatic cancer where there is an urgent need for new treatments.<wbr> Research suggests that pancreatic cancer can be dependent on autophagy making it an excellent pathway to target for drug discovery" </div><div>Dr Keith Blundy, Cancer Research Technologys chief executive officer, said: "establishing this significant collaboration, the first of its kind between CRT and a Japanese pharmaceutical company, we are bringing together Cancer Research UK's world-leading target validation expertise and Astellas' proven track record on drug development.<wbr>"   </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9873">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-08T20:50:11+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Medivation's Q2 Marked by Strong US EU and Japan Performance of XTANDI [comp:Astellas, dis:Prostate, prod:MDV3100, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9869</link>
<description>Medivation's Q2 Marked by Strong US EU and Japan Performance of XTANDI [comp:Astellas, dis:Prostate, prod:MDV3100, news]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>prod:MDV3100</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9869</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9869">Medivation's Q2 Marked by Strong US EU and Japan Performance of XTANDI</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9869">Oncology9869</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 August 2014 | 14:08</font><br><br><div style="margin-bottom: 10px;">Comment: Management highlighted that for the second consecutive quarter XTANDI continues to be the drug therapy chosen most often by oncologists in the post-chemo setting.<wbr> Given the profile of the drug, it believes that XTANDI will "resonate very well with urologists".<wbr> after the approval of the pre-chemo indication (PDUFA date for the completion September 18, 2014).<wbr> Progress with the ongoing clinical programs of enzalutamide was reported in breast cancer, an entirely new market for XTANDI.<wbr> Medivation closed the second quarter with $290M in cash.<wbr> Key messages are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Overview of XTANDI Net Sales</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>US XTANDI</STRONG> net sales at the brand level, as reported by Astellas, were $143.<wbr>7 million in the second quarter 2014 (74% higher than the $82.<wbr>4 million reported in the prior year period).<wbr> </div><div style="margin-bottom: 10px;">For the six-months year-to-date period ended June 30, US XTANDI net sales were $268.<wbr>2 million (an increase of 70% over the 2013 period).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ex-US XTANDI</STRONG> net sales, as reported by Astellas, were $83.<wbr>3 million in the second quarter of 2014.<wbr> </div><div style="margin-bottom: 10px;">On a year-to-date basis, ex-US XTANDI net sales were $131 million, compared with $3.<wbr>7 million in the comparable 2013 period.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Messages From Key Selected Questions</STRONG> </div><div style="margin-bottom: 10px;">When questionned on the <STRONG>resistance pathways to XTANDI</STRONG>, Daid Hung reported " .<wbr>.<wbr>.<wbr>PREVAIL and AFFIRM data still shows that the vast majority of patients do respond to XTANDI out front.<wbr> Certainly, as with any drug, no matter how good it is, they will develop resistance pathways.<wbr> We are well aware of them, but the good news is that the vast majority of patients have very robust response to XTANDI and do well on it, some for very long period of time.<wbr><BR>But we are also cognizant of what potential escape paths there might be, and we are looking into that.<wbr> One of our first forays into that area is to work with BET Bromodomain inhibitors, but clearly we are on the lookout for any other technologies that might help us address that issue.<wbr> But we still think that, with the current franchise we have based on XTANDI, that we're providing a great benefit to the majority of patients".<wbr> </div><div style="margin-bottom: 10px;">Regarding the <STRONG>launch of XTANDI in the pre-chemo setting</STRONG>, management indicated ' .<wbr>.<wbr>.<wbr> We would anticipate launching immediately upon getting the label.<wbr> So, we are -- as I said, we're ready to go.<wbr> We are just waiting for the approval, and we would expect to be out immediately" </div><div style="margin-bottom: 10px;"><STRONG>Treatment sequencing</STRONG> was evoked, and questions were asked on the right sequence of treatment.<wbr> Some data presented at ASCO showed the right combination should be either XTANDI followed by Zytiga or a XTANDI/<wbr>Zytiga combination.<wbr> Management indicated that " .<wbr>.<wbr>.<wbr> There's already a few studies that have already shown that following XTANDI, Zytiga responses are quite low.<wbr> So, certainly you could do larger studies, I suspect the outcome would be the same.<wbr> So I think that, the bottom line is, as you know, throughout the history of ontology, first-line therapies always do better than second line therapies, who do better than third line therapies.<wbr> So whoever's first is going to have probably the longest duration of use and the greatest effects.<wbr><BR>So that's why important to get first in the market in the treatment paradigm, and we believe that, given our PREVAIL data, given our efficacy results, our safety results, and our convenience profile, we believe that we will be the preferred treatment up front.<wbr> And that's the most important consideration for us.<wbr> What other people will do in terms of trials, and I'm probably not the best person to ask about that, but it is quite clear that whoever second line is, is not going to do as well as whoever's first line".<wbr> </div><div style="margin-bottom: 10px;">On the <STRONG>competition side</STRONG>, two aspects were discussed.<wbr> </div><div style="margin-bottom: 10px;">- cost in the upcoming pre-chemo launch vs Zytiga.<wbr> Given the recent 7% price increase in July, XTANDI now is at 22% premium to Zytiga.<wbr> Management "believe the competitiveness of XTANDI really is dependent on its efficacy, safety, and convenience profile, which we think is quite extraordinary.<wbr> So, we believe that will do well.<wbr> We think that payers are going to be keen, as I said, to make a drug like that accessible to patients.<wbr> And so, we believe that will do fine".<wbr> </div><div style="margin-bottom: 10px;">- In the longer term, 2017/<wbr>2018, analyst indicated that J&amp;J is going to have a <SPAN style="background-color: #ffffff;">CYP17 </SPAN><SPAN style="background-color: #ffffff;">and an androgen receptor (AR).<wbr> Clearly, Management thinks that " .<wbr>.<wbr>.<wbr> CYP17 inhibitors have been around for a long time since Ketoconazole, and as you know, among urologists, they have not adopted CYP17 inhibitors despite their presence on the market for years.<wbr> So, we are looking, really, more forward at other, newer technologies.<wbr> " .<wbr>.<wbr>.<wbr> we recently licensed a new set of compounds from OncoFusion which target of different mechanistic pathway, which we believe -- data suggest have significant promise".<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="background-color: #ffffff;">Enzalutamide in three major subsets of breast cancer</SPAN></STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">Last June, a Ph2 trial was initiated evaluating enzalutamide as a single agent for the treatment of advanced androgen receptive positive, triple negative breast </SPAN><SPAN style="background-color: #ffffff;">cancer, known as T</SPAN><SPAN style="background-color: #ffffff;">NBC.<wbr> (preliminary topline data available by end of 2014, with a presentation probably at the San Antonio Breast Cancer symposium).<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">In December 2013, enrollment was initiated in a randomized double-blind Ph2 trial evaluating enzalutamide in combination with exemestane vs exemestane alone in approx.<wbr>240 women with advanced breast cancer that is either estrogen receptive positive or progesterone receptor positive, and HER2, normal.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="background-color: #ffffff;">A third Ph2 trial in a new breast cancer indication to evaluate the safety and efficacy of adding enzalutamide to Trastuzumab (Herceptin), is ongoing in approx.<wbr> 80 women with AR positive HER2 amplified and ER negative or PR negative advanced breast cancer who's disease has previously progressed on trastuzumab.<wbr></SPAN> </div><div><EM><SPAN style="background-color: #ffffff;">Source: Medivation call</SPAN></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9869">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-08T14:08:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Commercial Preparations of Lexicon's Telotristat Etiprate Has Begun</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7764</link>
<description>Commercial Preparations of Lexicon's Telotristat Etiprate Has Begun</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7764</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7764">Commercial Preparations of Lexicon's Telotristat Etiprate Has Begun</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7764">Endocrinology7764</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 August 2014 | 11:38</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside the presentation of the Q2:14 financial results, Lonnel Coats (new President &amp; CEO) highlighted the 'very good progress' in the recruitment of telotristat etiprate for carcinoid syndrome.<wbr> He indicated that &gt;70% of the patients needed for the trial have been enrolled, and believed completion of the enrollment by late 2014/<wbr>early 2015.<wbr> The diabetes program was largely discussed.<wbr> Key points are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Update on Telotristat Etiprate for Carcinoid Syndrome</STRONG> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><STRONG>Status</STRONG>- orphan drug designation from the FDA, and orphan drug designation from the European Medicines Agency</P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><STRONG>Rationale</STRONG> - management outlined that interviews with physicians show that the majority of patients, approximately 79%, are essentially non-adequately controlled.<wbr> This lack of control occurs in a timeframe of approximately 36 months.<wbr> There is no new therapeutic option for these patients.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="PADDING-LEFT: 30px"><STRONG>Endpoints of the TELESTAR Ph3</STRONG> - to demonstrate a reduction in bowel movement frequency in patients with inadequately controlled carcinoid syndrome.<wbr> Secondary endpoints will include urinary 5HIA, which is the biomarker of serotonin synthesis, and other symptoms of carcinoid syndrome.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG>On the commercial side</STRONG>- management said " .<wbr>.<wbr>.<wbr> what we need to continue to do is continue to become operationally in our overall clinical development efforts, and we are making those progresses every day.<wbr> </div><div style="margin-bottom: 10px;">And then last but not least, we have to start beginning to bring on the commercial capabilities that will allow Lexicon to participate in its own assets in the marketplace.<wbr> </div><div style="margin-bottom: 10px;">So those are the things that we're working on right now.<wbr> But I will simply tell you that science is good, the development is progressing, and I think we have every way right to be bullish at this moment".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Update on the Diabetes Programs Business Development</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Partnership- </STRONG>analyst asked to clarify partnership progress discussions.<wbr> Management reported that one of the company's priorities is "a partnership around a full diabetes program".<wbr> ".<wbr>.<wbr>.<wbr> we have to move forward in type 1 diabetes.<wbr> And we're planning on doing that whether we have a partnership in place or not.<wbr> And we feel very confident in the value of LX4211 in that indication and that this is something that we need to proceed with, partnership or no partnership".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Financial Figures</STRONG> </div><div style="margin-bottom: 10px;">Revenues for the 2014 second quarter: $0.<wbr>7M (an increase from $0.<wbr>2 million in the prior-year period).<wbr> </div><div style="margin-bottom: 10px;">Revenues in the first half of 2014: $1M (66% increase from $0.<wbr>6 million for the prior-year period).<wbr> </div><div><EM>Source: Lexicon call</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7764">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-08T11:38:56+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Novo To Progress Forward With LAhGH Programme [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7759</link>
<description>Novo To Progress Forward With LAhGH Programme [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7759</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7759">Novo To Progress Forward With LAhGH Programme</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7759">Endocrinology7759</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 August 2014 | 18:16</font><br><br><div style="margin-bottom: 10px;">Comment: As part of its Q2 slide presentation, Novo highlighted how it continues to expand its leadership position within the growth hormone market.<wbr> It also confirmed its intent to move its long-acting growth hormone into phIII later this year for AGHD.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7759/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7759/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Specific comments by management on its new growth hormone candidaqte were as follows: "We announced in January of this year that we completed a Phase I trial investigating the safety, tolerability, pharmacokinetics and dynamics of multiple doses of NN8640 our once weekly growth hormone derivative.<wbr> Based on the results from this trial, Novo Nordisk has decided to progress NN8640 into Phase III development late this year.<wbr>" </div><div>Source: <A href="http://www.novonordisk.com/">www.<wbr>novonordisk.<wbr>com</A> </div><!-- Comment details --><a name="endocrinology7759attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7759/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(129,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7759/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(115,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7759">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-07T18:16:34+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7759/1/ScreenCapture1.jpg" length="132840" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7759/2/ScreenCapture2.jpg" length="117960" type="image/jpeg"/></item><item>
<title>FIM of Palobiofarma's PBF-999 for Huntington's Disease [dis:Huntington, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7687</link>
<description>FIM of Palobiofarma's PBF-999 for Huntington's Disease [dis:Huntington, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Huntington</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7687</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7687">FIM of Palobiofarma's PBF-999 for Huntington's Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7687">Neurology7687</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 August 2014 | 17:06</font><br><br><div style="margin-bottom: 10px;">Comment: Safety and tolerability of PBF-999 will be assessed in healthy young male volunteers.<wbr> Number of participants with serious/<wbr>non-serious AEs will be measured as PE.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Drug Candidate</FONT></STRONG> </div><div style="margin-bottom: 10px;">PBF-999 is a dual Adenosine A2a receptor antagonist /<wbr> PDE-10 inhibitor.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Reference</STRONG> <A href="http://clinicaltrials.gov/ct2/show/NCT02208934?term=Palo+Biofarma&amp;rank=3">NCT02208934</A> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> approx.<wbr> 32 Healthy male subjects, 18-45 years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date: Sept 2014 - completion date: Nov 2014 /<wbr> Dec 2014 </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> Spain (CIM-Sant Pau) </div><div style="margin-bottom: 10px;"><P><!--generated--></P> </div><div style="margin-bottom: 10px;"><TR><TD colspan="2" style="PADDING-LEFT: 4em"><STRONG>Principal Investigator</STRONG>: Joan Martinez Colomer, MD</TD>
</TR> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Palobiofarma</FONT></STRONG> </div><div><UL><LI>Spanish biotech company</LI>
<LI>Private</LI>
<LI>Founded in 2006</LI>
<LI>CEO Julio Castro-Palomino Laria</LI>
<LI>Mission to discover new drugs based on the modulation of adenosine receptors</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7687">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-07T17:06:31+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Botulax® Non-Inferior to Botox® for Glabellar Lines [TAL:Aesthetic]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7686</link>
<description>Botulax® Non-Inferior to Botox® for Glabellar Lines [TAL:Aesthetic]</description><category>TAL:Aesthetic</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7686</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7686">Botulax® Non-Inferior to Botox® for Glabellar Lines</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=TAL%3aAesthetic"><font color="#e95e0b">:Neurology:TAL:Aesthetic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7686">Neurology7686</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 August 2014 | 15:21</font><br><br><div style="margin-bottom: 10px;">Comment: Conclusion from a double-blind, randomized non-inferiority trial in Korea strongly supports that NCT (Botulax®) is as effective as onabotulinumtoxin A (Botox®), and that both products are well tolerated.<wbr> Subjects were randomized in a 1:1 ratio to receive 20 U of the drugs.<wbr> The primary endpoint was the response rate of physicians' assessment using the Facial Wrinkle Scale at week 4.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="2"><U>Rationale</U></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2">The drug packaging units already include: 50U; 100U and 200U.<wbr></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7686/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="2">This study validates the 20U for the treatment of moderate to severe GL</FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">Response rates ( RRs) for maximum frown were 89.<wbr>3% in the NTC group and 81.<wbr>9% in the onabotulinumtoxin A group at week 4.<wbr> </div><div style="margin-bottom: 10px;">NTC also resulted in comparable results for both the response rates of the other evaluation points and incidence of adverse events compared to those of onabotulinumtoxin A.<wbr> </div><div style="margin-bottom: 10px;">In subjects' improvement assessment and photographic evaluations, NTC even demonstrated better results compared with onabotulinumtoxin A in the early phase after treatment.<wbr> </div><div style="margin-bottom: 10px;">Analysis of these results strongly supports the non-inferiority of NTC to onabotulinumtoxin A in the efficacy and safety.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT01791920?term=botulax+botox+glabellar+lines&amp;rank=1">NCT01791920</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Reference</FONT></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="cit"><EM>Eur Acad Dermatol Venereol.<wbr> 2014 Mar 5.<wbr> doi: 10.<wbr>1111/<wbr>jdv.<wbr>12408.<wbr> [Epub ahead of print].<wbr></EM></DIV> </div><div style="margin-bottom: 10px;"><DIV class="cit">- <FONT size="2">Double-blind, randomized non-inferiority trial of a novel botulinum toxin A processed from the strain CBFC26, compared with onabotulinumtoxin A in the treatment of glabellar lines.<wbr></FONT></DIV> </div><div><DIV class="auths">Kim BJ<SUP>1</SUP>, Kwon HH, Park SY, Min SU, Yoon JY, Park YM, Seo SH, Ahn JY, Lee HK, Suh DH.<wbr></DIV> </div><!-- Comment details --><a name="neurology7686attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7686/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7686">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-07T15:21:53+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7686/1/ScreenCapture1.jpg" length="58295" type="image/jpeg"/></item><item>
<title>re: Ackman/Valeant Win Support For A Special Shareholder Meeting</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7685</link>
<description>re: Ackman/Valeant Win Support For A Special Shareholder Meeting</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7685</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7685">re: Ackman/<wbr>Valeant Win Support For A Special Shareholder Meeting</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7685">Neurology7685</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 August 2014 | 10:32</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Ackman/<wbr>Valeant Win Support For A Special Shareholder Meeting</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font><br><span style="font-size: 12px;">Comment; Glass Lewis the leading, independent, governance analysis and proxy 
voting firm, serving institutional investors has backed William Ackman in 
calling for a special shareholder meeting amongst Allergan shareholders 
suggesting that shareholders would be best served by supporting Ackman's 
request.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7678">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7678" class="commentpermalink">Neurology7678</a> / <span class="date">05 August 2014</span> /
<span class="time">19:07:14 o'clock CEST</span>
</font></div><div>Institutional Shareholder Services (ISS) has added its weight behind  Ackmann &amp; Glass Lewis, advocating that shareholders  should support a special shareholder meeting.<wbr> Its report states that there appears to be significant governance issues that could be addressed by a proposed meeting.<wbr> ISIS criticises Allergan's restrictive by-laws governing special meetings which it suggests should be voted out  .<wbr> Moreover, it has implied that investors may even consider removing some Allergan directors depending on how they respond to the special meeting request and critique of its corporate bylaws.<wbr> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7685" class="commentpermalink">Neurology7685</a> / <span class="date">07 August 2014</span> /
<span class="time">10:32:24 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7685">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7678">View thread  Neurology7678: Ackman/<wbr>Valeant Win Support For A Special Shareholder Meeting</a>]]></content:encoded><dc:date>2014-08-07T10:32:24+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>GW Pharma Q3 Results - Key Takeaways [dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7682</link>
<description>GW Pharma Q3 Results - Key Takeaways [dis:Spasticity]</description><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7682</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7682">GW Pharma Q3 Results - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7682">Neurology7682</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 August 2014 | 18:27</font><br><br><div style="margin-bottom: 10px;">Comment: Revenue for the quarter ended 30 June 2014 of £7.<wbr>6 million ($13.<wbr>0 million) compared to £7.<wbr>3 million for the three months ended 30 June 2013.<wbr> Significant advances were made with Epidiolex in a number of programmes, and were a follow-on offering of ADSs on the NASDAQ Global Market raising total net proceeds after expenses of approx.<wbr> $118M.<wbr> The company continues to make strong progress across its cannabinoid pipeline, which is yielding interesting new product candidates in a wide variety of therapeutic areas.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Epidiolex<SUP><SMALL>®</SMALL></SUP> (Cannabidiol or CBD) childhood epilepsy program </STRONG> </div><div style="margin-bottom: 10px;">U.<wbr>S.<wbr> Food and Drug Administration (FDA) Authorized Physician-Led Expanded Access Program </div><div style="margin-bottom: 10px;"><UL><LI>Treatment effect data on initial patient cohort released in June 2014 with data showing promising signals of efficacy and safety</LI>
<LI>Number of children suffering from intractable epilepsy syndromes authorized for treatment with Epidiolex by FDA increased to approximately 395</LI>
<LI>Approximately 100 children now receiving treatment with Epidiolex in the U.<wbr>S.<wbr> at six hospital sites</LI>
<LI>Treatment data on additional cohort of patients to be released H2 2014<BR></LI>
</UL> </div><div style="margin-bottom: 10px;">Dravet syndrome development program </div><div style="margin-bottom: 10px;">Orphan Drug Designation, Fast Track Designation granted and Investigational New Drug Application (IND) opened with the FDA for Epidiolex in the treatment of Dravet Syndrome </div><div style="margin-bottom: 10px;"><UL><LI>Phase 2/<wbr>3 Dravet syndrome trial protocol finalized and on track to commence H2 2014 </LI>
<LI>Additional Phase 3 Dravet syndrome trial on track to commence early 2015</LI>
</UL> </div><div style="margin-bottom: 10px;">Lennox-Gastaut syndrome (LGS) development program </div><div style="margin-bottom: 10px;"><UL><LI>Orphan Drug Designation granted by FDA in the treatment of LGS</LI>
<LI>FDA comments received on proposed Phase 3 trial protocols</LI>
<LI>Phase 3 trials on track to commence early 2015</LI>
</UL> </div><div style="margin-bottom: 10px;">State Programs </div><div style="margin-bottom: 10px;"><UL><LI>Initiatives announced with States of Georgia and New York to collaborate with GW on state-based Epidiolex clinical trials in epilepsy </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Sativex<SUP><SMALL>®</SMALL></SUP> program developments </STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Fast Track designation granted by FDA for Sativex in the treatment of chronic cancer pain in patients with advanced cancer who have failed to respond adequately to optimized opioid therapy</LI>
<LI>Initial top-line Phase 3 cancer pain data on track for release towards the end of 2014.<wbr> Data intended to lead to a New Drug Application (NDA) filing with the FDA in the U.<wbr>S.<wbr></LI>
<LI>Special Protocol Assessment (SPA) ongoing with the FDA for proposed Sativex Phase 3 trial in the treatment of Multiple Sclerosis (MS) spasticity<BR></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Ongoing clinical trial activity for cannabinoid pipeline </STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Advancement of Cannabidivarin (CBDV) epilepsy program with a Phase 2 trial expected to commence at end of 2014/<wbr>early 2015</LI>
<LI>Phase 2a trial of GWP42003 for the treatment of ulcerative colitis recruitment complete - data expected H2 2014</LI>
<LI>Phase 2b 12-week randomized, double blind, placebo controlled trial of GWP42004 in type-2 diabetes commenced in March 2014 with expected completion in H2 2015</LI>
<LI>Phase 2a trial of GWP42003 for the treatment of schizophrenia commenced in March 2014 with expected completion in H2 2015</LI>
<LI>Phase 1b/<wbr>2a trial of GWP42002:GWP42003 in the treatment of glioma ongoing with safety data on an initial cohort due in 2014</LI>
</UL> </div><div><EM>Source: GW Pharm</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7682">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-06T18:27:44+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Highlights of Leerink Swann's 2Q14 Cosmetic Survey [sub:Aesthetics, comp:Allergan, comp:Merz, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7679</link>
<description>Highlights of Leerink Swann's 2Q14 Cosmetic Survey [sub:Aesthetics, comp:Allergan, comp:Merz, :PharmaWorld:mkt:NorthAmerica]</description><category>sub:Aesthetics</category><category>comp:Allergan</category><category>comp:Merz</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7679</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7679">Highlights of Leerink Swann's 2Q14 Cosmetic Survey</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7679">Neurology7679</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 August 2014 | 13:05</font><br><br><div style="margin-bottom: 10px;">Comment: Respondents (31 dermatologists and 30 plastic surgeons) still expect Botox to capture approx.<wbr> 70% of the overall toxin market in 2015 and 2016.<wbr> Overall, topical botulinum toxin, ATX-101 (injection for submental fat removal) and Merz products continue to hold the highest new product interest.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Respondent Distribution</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7679/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Results Suggest Xeomin to Take Share</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7679/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strong Early Uptake of Juvederm Voluma</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7679/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Product Interest</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7679/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><EM>Source: MEDACorp Survey, “Trends in Cosmetic Procedures in 2Q:14," August 2014</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7679">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-06T13:05:41+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Cosmo's &quot;Game Changer&quot; Product Available for Licensing [news, sub:CRCPrevention, :PharmaWorld:func:BusDev, :PharmaWorld:sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2001</link>
<description>Cosmo's &quot;Game Changer&quot; Product Available for Licensing [news, sub:CRCPrevention, :PharmaWorld:func:BusDev, :PharmaWorld:sub:xLicensing]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2001</comments><category>news</category><category>sub:CRCPrevention</category><category>func:BusDev</category><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2001</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2001">Cosmo's "Game Changer" Product Available for Licensing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=func%3aBusDev"><font color="#e95e0b">:PharmaWorld:func:BusDev</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2001">GastroEnterology2001</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 August 2014 | 11:45</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its 1H financial results, management has highlighted that the licensing process of SIC 8000, a sub-mucosal injectable composition for the extraction of polyps in the colon, will commence in Q4 2014.<wbr> SIC 8000 is classified as a medical device with a very short regulatory approval path.<wbr> Cosmo expects therefore to be able to launch the product in North America and the EU in H1 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development Timing</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2001/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Product Description &amp; MoA</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1976" class="defaultlink">GastroEnterology1976: Cosmo Unveils New Colonoscopy Product</a>.<wbr> </div><div><EM>Source: Cosmo</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="GastroEnterology2524c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>FDA has approved Cosmo's request for marketing authorization of SIC 8000.<wbr> According to the company, SIC 8000 will allow endoscopists to do their resection procedures safer and faster than before.<wbr> Management now intends to conduct two marketing trials in order to have the product ready for marketing by the beginning of 2016.<wbr> In the EU the request for marketing authorization filing was made on July 31<SUP>st</SUP> 2015 and with an approval expected in early 2016.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2524" class="commentpermalink">GastroEnterology2524</a> / <span class="date">07 September 2015</span> /
<span class="time">12:16:45 o'clock CEST</span>
</font></div><a name="gastroenterology2001attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2001/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2001">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-06T11:45:28+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/2001/1/ScreenCapture1.jpg" length="59286" type="image/jpeg"/></item><item>
<title>Corcept's Korlym Is Gaining In Acceptance &amp; Next Generation Drug Is About To Start PhI Development [dis:Cushing, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7754</link>
<description>Corcept's Korlym Is Gaining In Acceptance &amp; Next Generation Drug Is About To Start PhI Development [dis:Cushing, news]</description><category>dis:Cushing</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7754</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7754">Corcept's Korlym Is Gaining In Acceptance & Next Generation Drug Is About To Start PhI Development</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7754">Endocrinology7754</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 August 2014 | 10:41</font><br><br><div style="margin-bottom: 10px;">Comment: Corcept reported a 33% increase in revenues vs.<wbr> the prior quarter based on strong uptake of Korlym&reg; for the treatment of Cushing's syndrome.<wbr> The group's net loss narrowed to $0.<wbr>07 per share and the company reiterated its 2014 revenue guidance of $25-29m and currently has a cash balance of $34m.<wbr> Some interesting comments were made about the group's pipeline progress and the application of next generation drugs within the oncology space.<wbr> </div><div style="margin-bottom: 10px;">Commenting on its Cushing's business Joseph K Belanoff CEO noted that "the group's Cushing syndrome business grew broadly last quarter.<wbr>" </div><div style="margin-bottom: 10px;">He suggested that as experience with the drug grows the difference being seen in patients lives is convincing them to prescribe the drug more widely and that definitely more in-roads are being made into the group of patients who have less severe Cushing's syndrome.<wbr> Moreover,, ong-term data presented at the ENDO meeting in June provided tangible evidence that Korlym's benefits are maintained over time.<wbr> </div><div style="margin-bottom: 10px;">Belanoff also noted that one of the places that the group is going to expand over the course of the year is to add additional sales reps.<wbr> He stated "We have found that this is a market that has got doctors treating patients in more disparate areas than we did think initially.<wbr> And what we have found is that by adding salespeople, as we have done in the first part of this year, we have added revenues and treated more patients, and we're going to follow up on that by adding additional salespeople over the course of the year, to make sure that all of our ground is covered, and we're really getting to any patient who might have a chance to be positively affected by Korlym.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Pipeline Progress</STRONG> </div><div style="margin-bottom: 10px;">Belanoff explained that the group has developed a large portfolio of proprietary next-generation cortisol receptor antagonists that, unlike mifepristone, do not block the progesterone receptor, and so do not terminate pregnancy.<wbr> Some of these compounds have performed better than mifepristone in animal and in vitro models of human disease, including triple-negative breast cancer.<wbr> In the coming quarters, the group plans to advance several of these proprietary molecules to the clinic, and will gather the data we need to determine the illnesses for which they hold the most potential.<wbr> It will start by moving its first next generation glucocorticoide antagonists CORT125134 into phI development this month.<wbr> </div><div style="margin-bottom: 10px;">These next generation anagonists apparently have the valuable characteristic of behaving differently from each other in important respects.<wbr> Some of the compounds get into the brain, some do not, some have potent metabolic effects, others are even more effective than mifepristone in animal models of triple-negative breast cancer.<wbr> Whilst the group has not selected which indications its plans to study, Cushing's syndrome and triple-negative breast cancer are high on our list.<wbr> A trial with Korlym in triple negative breast cancer is currently ongoing and will generate results in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Prostate Cancer Study</STRONG> </div><div style="margin-bottom: 10px;">Independently a trial is being run by the University of Chicago, where Corcept is providing the mifepristone for a combination study with enzalutamide in patients with castrate-resistant metastatic prostate cancer.<wbr>.<wbr><BR><BR>Belanoff stated "one of the things, and there was actually an editorial about this in the New England Journal of Medicine, in March, is that essentially in enzalutamide resistant tumors you begin to see an increasing numbers receptors for cortisol, the GR receptor.<wbr> As a consequence, that GR receptor then becomes the growth factor for tumors.<wbr> In some sense, enzalutamide resistance is actually the advancement of cortisol activity through the GR receptor, and the idea of the study, again it's an investigator study, but one where we understand the science, and are supporting it, is that if you use the drugs in combination, perhaps you can prevent that escape and people can actually maintain without their tumors advancing.<wbr>"<BR><BR>We'll find out whether that's true or not.<wbr> But there really is an interesting body of science pulled out of Sloan Kettering a year ago, and out of the University of Chicago that speak to these questions.<wbr> </div><div>Source: <A href="http://www.corcept.com">www.<wbr>corcept.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7754">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-06T10:41:51+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Ackman/Valeant Win Support For A Special Shareholder Meeting [:PharmaWorld:sub:Acquisition, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7678</link>
<description>Ackman/Valeant Win Support For A Special Shareholder Meeting [:PharmaWorld:sub:Acquisition, news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7678</comments><category>sub:Acquisition</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7678</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7678">Ackman/<wbr>Valeant Win Support For A Special Shareholder Meeting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7678">Neurology7678</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 05 August 2014 | 19:07</font><br><br><div style="margin-bottom: 10px;">Comment; Glass Lewis the leading, independent, governance analysis and proxy 
voting firm, serving institutional investors has backed William Ackman in 
calling for a special shareholder meeting amongst Allergan shareholders 
suggesting that shareholders would be best served by supporting Ackman's 
request.<wbr> </div><div style="margin-bottom: 10px;">The report could be seen as a win for Ackman in the increasingly bitter 
battle with Allergan </div><div style="margin-bottom: 10px;">Glass Lewis took care to note that shareholders would not explicity throw 
their weight behind a takeover by participating in the process to call a special 
meeting.<wbr> </div><div style="margin-bottom: 10px;">This opinion comes only a few days after Allergan sued Ackman and Valeant 
accusing them of breaking insider trading regulations by having worked out 
possible details of a takeover bid as the $15bn hedge fund was building its 
stake in Allergan.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7685c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Institutional Shareholder Services (ISS) has added its weight behind  Ackmann &amp; Glass Lewis, advocating that shareholders  should support a special shareholder meeting.<wbr> Its report states that there appears to be significant governance issues that could be addressed by a proposed meeting.<wbr> ISIS criticises Allergan's restrictive by-laws governing special meetings which it suggests should be voted out  .<wbr> Moreover, it has implied that investors may even consider removing some Allergan directors depending on how they respond to the special meeting request and critique of its corporate bylaws.<wbr> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7685" class="commentpermalink">Neurology7685</a> / <span class="date">07 August 2014</span> /
<span class="time">10:32:24 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7678">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-05T19:07:14+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Botox Assessed for Prophylactic Treatment of Chronic Migraine [dis:Migraine, prod:Botox, comp:Allergan, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7677</link>
<description>Botox Assessed for Prophylactic Treatment of Chronic Migraine [dis:Migraine, prod:Botox, comp:Allergan, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Migraine</category><category>prod:Botox</category><category>comp:Allergan</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7677</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7677">Botox Assessed for Prophylactic Treatment of Chronic Migraine</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7677">Neurology7677</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 August 2014 | 18:29</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph4 study will evaluate the efficacy, safety and tolerability of BOTOX® compared to topiramate in adults with chronic migraine.<wbr> PE will measure percentage of participants with a ≥ 50% decrease from baseline in the frequency of headache days.<wbr> <A href="http://www.topamax.com/">Topamax</A> is a daily treatment prescribed for preventing migraine headaches.<wbr> The drug side effects include tiredness, dizziness, coordination problems, speech problems, changes in vision and sensory distortion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Reference</STRONG> <A href="http://clinicaltrials.gov/ct2/show/NCT02191579?term=botulinum&amp;phase=0123&amp;fund=2&amp;rcv_s=07%2F05%2F2014&amp;rank=4">NCT02191579</A> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> approx.<wbr> 400 both genders (18 to 65 years old)
 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">History of chronic migraine</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">More than 15 headache days in a 28 day period (headaches that last more than 4 hours and/<wbr>or require treatment with prescription medication).<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Completion dates January 2017 /<wbr> June 2017</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Dosage</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.<wbr></LI>
<LI>Topiramate up to a maximum oral dose of 100 mg/<wbr>day.<wbr></LI>
</UL> </div><div><STRONG>Location</STRONG> USA </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7677">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-05T18:29:22+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Merz Russia Has Started Comparative Trial of Xeomin vs Botox® in Pediatric Cerebral Palsy [comp:Merz, dis:Palsy, :PharmaWorld:mkt:Russia, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7675</link>
<description>Merz Russia Has Started Comparative Trial of Xeomin vs Botox® in Pediatric Cerebral Palsy [comp:Merz, dis:Palsy, :PharmaWorld:mkt:Russia, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Merz</category><category>dis:Palsy</category><category>mkt:Russia</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7675</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7675">Merz Russia Has Started Comparative Trial of Xeomin vs Botox® in Pediatric Cerebral Palsy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aPalsy"><font color="#e95e0b">:Neurology:dis:Palsy</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7675">Neurology7675</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 August 2014 | 18:07</font><br><br><div style="margin-bottom: 10px;">Comment: Started this month, the Ph2 study will assess the clinical and neurophysiological efficacy of Xeomin® vs.<wbr> Botox® in children with spastic equine and equinovarus foot deformation in pediatric cerebral palsy, and the safety of Xeomin® in this patient population.<wbr> PE will measure Changes from baseline in the degree of spasticity in gastrocnemius according to modified Ashworth scale (AS).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Reference</STRONG> <A href="http://clinicaltrials.gov/ct2/show/NCT02188277?cond=spasticity+OR+prostate+OR+botulinum+OR+acromegaly+OR+neuroendocrine+OR+growth+hormone+deficiency+OR+Huntington&amp;phase=0123&amp;fund=2&amp;rcv_s=07%2F05%2F2014&amp;rank=7">NCT02188277</A> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> approx.<wbr> 64 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Children from 2 through 12 years of age, of both sexes, suffering from spastic paraplegia or hemiparesis in pediatric cerebral palsy.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Equine and equinovarus foot posture.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Gastrocnemius spasticity of 2 points and greater, by modified Ashworth scale.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patient can walk unassisted or with a support.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Mental development of patients is normal or mildly retarded.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Previous course of spasticity treatment with BTA products was completed earlier than at 6 months before this trial or never administered before</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> completion date is December 2015 </div><div style="margin-bottom: 10px;"><STRONG>Dosages</STRONG> </div><div style="margin-bottom: 10px;"><UL dir="ltr" style="MARGIN-RIGHT: 0px"><LI>Xeomin® 4-8 units per kg body weight (single inj cycle)</LI>
<LI>Botox® 4-6(8) units per kg body weight (single inj cycle)</LI>
</UL> </div><div><STRONG>Location</STRONG>: 2 sites in the Russian Federation </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7675">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-05T18:07:59+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Taiho Terminated Their Ph3 Hepatocellular Carcinoma Programme</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9868</link>
<description>Taiho Terminated Their Ph3 Hepatocellular Carcinoma Programme</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9868</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9868">Taiho Terminated Their Ph3 Hepatocellular Carcinoma Programme</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9868">Oncology9868</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 05 August 2014 | 16:59</font><br><br><div style="margin-bottom: 10px;">Comment: Hepatocellular carcinoma (HCC) is one of the highest unmet need cancer featured by lack of success of several Ph3 candidates (including brivanib, sunitinib, erlotinib, and linifanib).<wbr> Reasons for failure are heterogeneous, including lack of understanding of critical drivers of tumour progression, liver toxicity, flaws in trial design or marginal antitumoral potency.<wbr> Taiho's angiogenesis inhibitor, orantinib, Ph3 development programme for HCC will be terminated based on an independent data monitoring committee's recommendation.<wbr> </div><div style="margin-bottom: 10px;">The trial was a randomized, double blind trial of HCC patients who were treated by transcatheter arterial chemoembolization (TACE), comparing orantinib +TACE versus placebo + TACE.<wbr> A total of 889 patients were enrolled from Dec 2010 to Nov 2013 and the trail was conducted in Japan, South Korea, and Taiwan.<wbr> The interim analysis indicated the pre-determined standard related to the primary endpoint of overall survival was not met.<wbr> </div><div style="margin-bottom: 10px;">This is the second disappointment for Taiho as they announced S-1 did not statistically extend overall survival compared to placebo in patients with advanced HCC who had failed sorafenib monotherapy.<wbr> </div><div>Source: <a href="http://www.taiho.co.jp" class="defaultlink" title="www.taiho.co.jp">taiho.co.jp</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9868">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-05T16:59:52+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Raptor's Huntington Drug Receives ODD from the EU Commission [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7674</link>
<description>Raptor's Huntington Drug Receives ODD from the EU Commission [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7674</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7674">Raptor's Huntington Drug Receives ODD from the EU Commission</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7674">Neurology7674</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 August 2014 | 16:25</font><br><br><div style="margin-bottom: 10px;">Comment: The decision follows a positive recommendation from the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) in June.<wbr> The company will release 2Q financials results on Aug.<wbr> 7th.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">RP103 Slows HD Progression</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7674/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7674attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7674/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(111 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7674">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-05T16:25:26+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7674/1/ScreenCapture1.jpg" length="113656" type="image/jpeg"/></item><item>
<title>GTx Challening Times As The Company Seeks Route For Commercialisation Of Enobosarm Whilst PhII CRPC Programme Is Ongoing [class:Antihormonals, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9866</link>
<description>GTx Challening Times As The Company Seeks Route For Commercialisation Of Enobosarm Whilst PhII CRPC Programme Is Ongoing [class:Antihormonals, dis:Prostate]</description><category>class:Antihormonals</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9866</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9866">GTx Challening Times As The Company Seeks Route For Commercialisation Of Enobosarm Whilst PhII CRPC Programme Is Ongoing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9866">Oncology9866</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 05 August 2014 | 15:27</font><br><br><div style="margin-bottom: 10px;">Comment: GTx figures for the second quarter report a loss of $10.<wbr>9m vs $12.<wbr>8 for the same period in 2013.<wbr> The company has 3 development programmes ongoing with a filing for marketing authorisation fo Enobosarm for the treatment of muscle wasting in the process of evaluation and a phII study with GTx-758 in secondary hormonal therapy for CRPC ongoing.<wbr> Positive data reported at ASCO for Enobosarm in AR/<wbr>ER+ metastatic breast cancer merits further development for this indication, however, this will be subject to the ability of the company to find further funding.<wbr> Its cash position currently stands at $17.<wbr>3m.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>GTx-758 (Capesaris</STRONG><SUP><STRONG>&reg;</STRONG></SUP><STRONG>) </STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Is being studied for secondary hormonal therapy in men with castration-resistant prostate cancer and, potentially, as a secondary hormonal treatment for advanced prostate cancer used in combination with ADT</STRONG> </div><div style="margin-bottom: 10px;">GTx is continuing to enroll patients in an open-label, Phase 2 clinical study of GTx-758 to treat men with <STRONG>metastatic and non-metastatic</STRONG> <STRONG>CRPC </STRONG>and is evaluating the safety and efficacy of two doses (125 mg and 250 mg oral daily dosing) of GTx-758.<wbr> The primary endpoint of the study is the proportion of patients with a &ge; 50% decline from baseline in serum PSA by Day 90.<wbr> </div><div style="margin-bottom: 10px;">Enrollment in the 125 mg arm has been completed and, after a pre-specified safety review by the independent Data Safety Monitoring Board identified no safety concerns, the Company commenced enrollment in the 250 mg arm.<wbr> </div><div style="margin-bottom: 10px;"><P class="bwlistitemmargb">The Company is enrolling the 250 mg arm and expects enrollment to be completed in 2014 and top-line results to be available during thefirst quarter of 2015.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="bwlistitemmargb"><STRONG>Enobosarm</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="bwlistitemmargb">In a meeting with FDA earlier this year, the FDA confirmed that the current data from the POWER trials are insufficient to support the filing of a new drug application, as the POWER trials did not meet the pre-specified statistical criterion for the co-primary endpoints of lean body mass and stair climb power, using responder analyses, as agreed upon with the FDA.<wbr> The Company is evaluating options for further development of enobosarm 3 mg in the US</P> </div><div><P class="bwlistitemmargb">GTx met with representatives from two member countries to the EMA in January 2014 to review and discuss the results of the POWER trials to determine an appropriate path forward for submitting a MAA in the EU for enobosarm 3 mg for the prevention and treatment of muscle wasting in patients with advanced NSCLC.<wbr> The Company has retained experts in both the US and EU to work with its internal team to explore the option of submitting a MAA for enobosarm 3 mg in the more narrow indication of the prevention and treatment of muscle wasting in patients with advanced NSCLC treated with platinum plus taxane chemotherapy</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9866">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-05T15:27:59+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Heat Biologics Amends Protocol Permitting Early Advancement Of HS-401 Into Phase 2 For NMIBC [dis:Bladder, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9861</link>
<description>Heat Biologics Amends Protocol Permitting Early Advancement Of HS-401 Into Phase 2 For NMIBC [dis:Bladder, news]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9861</comments><category>dis:Bladder</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9861</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9861">Heat Biologics Amends Protocol Permitting Early Advancement Of HS-401 Into Phase 2 For NMIBC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9861">Oncology9861</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 05 August 2014 | 11:26</font><br><br><div style="margin-bottom: 10px;">Comment: Heat Biologics has now amended its Phase 1/<wbr>2 study protocol for HS-401 (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9505" class="defaultlink">Oncology9505: Heat Biologics Commences Dosing of First Patient in Phase 1/<wbr>2 Study of HS-410 for The Treatment of Non Muscle Invasive Bladder Cancer</a><A class="title" href="traction/permalink/Oncology9505" title="Permanent Link to Oncology9505"><U><FONT color="#0066cc">)</FONT></U></A> to permit Heat Biologics to advance directly into Ph2 following enrolment of a single cohort of Ph1 study.<wbr> The amended protocol changes the treatment regimen from HS-401 (vesigenurtacel-L) monotherapy post BCG to combination with BCG.<wbr> This will also allow HS-401 to be evaluated in the earlier setting for non-muscle invasive bladder cancer (NMIBC).<wbr> </div><div style="margin-bottom: 10px;">HS-410 (vesigenurtacel-L) is an investigation biologic originating from Heat Biologics ImPACT platform - allogeneic cell lines designed to activate a T-cell mediated pan-antigen immune response.<wbr> The original Phase 1/<wbr>2 bladder cancer trial protocol called for evaluation of two doses of monotherapy after BCG induction to assess initial safety and determine the maximum tolerated dose (MTD) to advance to Phase 2.<wbr> The amended protocol facilitates a more robust dose response analysis and will permit Heat Biologics to advance directly into Phase 2 trials.<wbr> The Phase 1 portion of the study is expected to complete enrolment in Q3 2014 and phase 2 will commence in the Q4 2014.<wbr> </div><div>ClinicalTrials.<wbr>Gov Identifier NCT02010203 </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9999c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The company has dosed the ninth and final patient required in the Ph1 portion of its Phase 1/<wbr>2 clinical study for Vesigenurtacel-L (HS-410) in patients with high-risk non-muscle invasive bladder cancer.<wbr> It now expects to commence the Ph2 portion of the bladder cancer clinical trial during Q4:14 (a full quarter sooner that originally reported).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Timelines</STRONG> </div><div style="margin-bottom: 10px;">Patient enrollment and dosing in the Vesigenurtacel-L Ph2 study for the treatment of bladder cancer is expected to be completed in the third quarter of 2015.<wbr> </div><div>Heat then anticipates reporting top-line recurrence-free survival results in the third quarter of 2016 after the protocol's twelve-month patient observation period ends.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9999" class="commentpermalink">Oncology9999</a> / <span class="date">03 October 2014</span> /
<span class="time">14:04:36 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9861">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-05T11:26:52+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Sales of Lupron Decrease During 2Q14 [prod:Lupron, :PharmaWorld:func:Sales]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9860</link>
<description>Sales of Lupron Decrease During 2Q14 [prod:Lupron, :PharmaWorld:func:Sales]</description><category>prod:Lupron</category><category>func:Sales</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9860</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9860">Sales of Lupron Decrease During 2Q14</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aLupron"><font color="#e95e0b">:Oncology:prod:Lupron</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=func%3aSales"><font color="#e95e0b">:PharmaWorld:func:Sales</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9860">Oncology9860</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 August 2014 | 11:17</font><br><br><div style="margin-bottom: 10px;">Comment: AbbVie reported revenue of $4.<wbr>926bn, an increase of 5% over 2Q13.<wbr> Global Lupron sales were $186M, down 5.<wbr>2% on an operational basis.<wbr> However management indicated that the drug continues to hold a leadership position and maintains significant share of the market.<wbr> Pipeline continues to advance, with Ph3 data readout of elagolix (endometriosis) over the next 6-9 months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Growth Drivers</FONT></STRONG> </div><div style="margin-bottom: 10px;">Humira delivered global sales of nearly $3.<wbr>3 billion, up 25.<wbr>4% on an operational basis and 26.<wbr>2% on a reported basis.<wbr> </div><div style="margin-bottom: 10px;">Total company sales growth was also driven by strong growth from key products including Synthroid, Sevoflurane and Duodopa.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9860/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the New AbbVie</FONT></STRONG> </div><div style="margin-bottom: 10px;">The combination of AbbVie and Shire will create a well-positioned specialty-focused global biopharmaceutical company with a strong product portfolio and sustainable leadership positions within high-value market segments of significant patient need.<wbr> </div><div style="margin-bottom: 10px;">It is intended that the New AbbVie shares will be listed on the New York Stock Exchange.<wbr> As a result, management expects that New AbbVie will be included in the S&amp;P 500.<wbr> </div><div style="margin-bottom: 10px;">More information to come next quarter.<wbr> </div><div><EM>Source: AbbVie</EM> </div><!-- Comment details --><a name="oncology9860attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9860/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(97,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9860">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-05T11:17:32+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9860/1/ScreenCapture1.jpg" length="99511" type="image/jpeg"/></item><item>
<title>re: Allergan's R&amp;D Recognised With Three Nominations For The 2014 US Prix Galien Awards</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7673</link>
<description>re: Allergan's R&amp;D Recognised With Three Nominations For The 2014 US Prix Galien Awards</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7673</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7673">re: Allergan's R&D Recognised With Three Nominations For The 2014 US Prix Galien Awards</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7673">Neurology7673</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/431">Alexandre BENOIN</a> | 04 August 2014 | 22:52</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan's R&D Recognised With Three Nominations For The 2014 US Prix Galien Awards</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The three nominations for these presitgious 
awards are in different categories but include Botox for Chronic Migraine.<wbr> 
Recipients will be announced in the fall.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7669">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7669" class="commentpermalink">Neurology7669</a> / <span class="date">04 August 2014</span> /
<span class="time">18:24:55 o'clock CEST</span>
</font></div><div>More noise on migraine.<wbr>.<wbr>.<wbr> </div><!-- Comment details --><font size="-1">Alexandre BENOIN / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7673" class="commentpermalink">Neurology7673</a> / <span class="date">04 August 2014</span> /
<span class="time">22:52:08 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7673">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7669">View thread  Neurology7669: Allergan's R&D Recognised With Three Nominations For The 2014 US Prix Galien Awards</a>]]></content:encoded><dc:date>2014-08-04T22:52:08+02:00</dc:date><dc:creator>alb02123</dc:creator></item><item>
<title>PTC Therapeutics Wins Conditional EU Approval For The 1st Approved Duchenne Muscular Dystrophy Drug [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7671</link>
<description>PTC Therapeutics Wins Conditional EU Approval For The 1st Approved Duchenne Muscular Dystrophy Drug [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7671</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7671">PTC Therapeutics Wins Conditional EU Approval For The 1st Approved Duchenne Muscular Dystrophy Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7671">Neurology7671</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 04 August 2014 | 18:44</font><br><br><div style="margin-bottom: 10px;">Comment: PTC Therapeutics has been granted EU conditional marketing 
authorisation for Translarna (ataluren) for the treatment of nonsense mutation 
DMD in ambulatory patients aged 5 years and over in 28 countries that are 
members of the EU.<wbr> </div><div style="margin-bottom: 10px;">The DMD communinity has been waiting a long time for treatment options and 
this conditional approval marks an important day for many patients.<wbr> </div><div style="margin-bottom: 10px;">As part of the approval process, PTC Therapeutics is obligated to complete 
its confirmatory phIII trial in nmDMD </div><div style="margin-bottom: 10px;"><STRONG>Basis For Approval</STRONG> </div><div style="margin-bottom: 10px;">Approval has been based on the safety and efficacy results from one 
randomised double-blind multicentre study undertaken in 174 nmDMD patients for 
48 weeks and additional retrospective analysis of study data.<wbr> The primary 
endpoint of the study was change in the six minute walking distance.<wbr> </div><div style="margin-bottom: 10px;">Post-hoc analysis demonstrated that from baseline to week 48 patients 
receiving Tanslarna (40mg/<wbr>kg.<wbr>day given in 3 doses) had a 12.<wbr>9 metre mean decline 
in 6MWD compared to a 44.<wbr>1 metre decline in patients taking placebo (p=0.<wbr>056).<wbr> 
Moreover, in less severely affected patients whose baseline 6MWD was less than 
350 metres, the mean change observed in the Translarna arm was 68 metres.<wbr> </div><div style="margin-bottom: 10px;">Patients treated also trended better in terms of secondary enpoints such as 
stair climb and descend time-functions tests, which the CHMP found to suggest 
slowing of nmDMD progression relative to placebo.<wbr> </div><div style="margin-bottom: 10px;">Translarna was generally well tolerated with the most frequent AEs being, 
nausea, vomiting and headache which generally did not require medical 
intervention or cause discontinuation of treatment.<wbr> </div><div>Source: <A href="http://www.ptcbio.com">www.<wbr>ptcbio.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7671">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-04T18:44:50+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Merz to Initiate POC Trial of Xeomin for Arm Tremors [comp:Merz, prod:Xeomin, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7670</link>
<description>Merz to Initiate POC Trial of Xeomin for Arm Tremors [comp:Merz, prod:Xeomin, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Merz</category><category>prod:Xeomin</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7670</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7670">Merz to Initiate POC Trial of Xeomin for Arm Tremors</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7670">Neurology7670</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 August 2014 | 18:41</font><br><br><div style="margin-bottom: 10px;">Comment: The prospective, randomized, double-blind, placebo-controlled, parallel-group trial will assess efficacy and safety of 200U of Xeomin in the unilateral treatment of essential tremor of the upper limb.<wbr> PE will measure change from baseline to week 4 in maximum angular tremor amplitude of the wrist (injected limb).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details - </FONT></STRONG><A href="http://clinicaltrials.gov/ct2/show/NCT02207946?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=07%2F11%2F2014&amp;rcv_e=08%2F04%2F2014&amp;rank=97"><STRONG><FONT size="3">NCT02207946<BR></FONT></STRONG><BR></A>Recruitment approx.<wbr> 30
 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
Diagnosis of 'definite essential tremor' in accordance with the TRIG criteria, as follows:
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Bilateral postural tremor with or without kinetic tremor, involving hands and forearms, that is visible and persistent.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">It is to be noted that:</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Tremor of other body parts may be present in addition to upper limb tremor.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Bilateral tremor may be asymmetric.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Tremor is reported by patient to be persistent, although the amplitude may fluctuate.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Tremor may or may not produce disability.<wbr></LI>
</UL></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">First diagnosis of essential tremor at least 5 years before screening.<wbr> Moderate-to-marked upper-limb postural and/<wbr>or kinetic tremor.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Tremor causing moderate to severe functional disability in activities of daily living.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Root-mean-square angular tremor amplitude in kinematic analysis of the injected limb, within defined limits.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Stable concomitant anti-tremor medication and no clinically relevant findings in routine laboratory examinations.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div>Start date Aug 2014 - Completion date Dec 2014 /<wbr> April 2014 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7670">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-04T18:41:00+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan's R&amp;D Recognised With Three Nominations For The 2014 US Prix Galien Awards [class:BotulinumToxins, dis:Migraine, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7669</link>
<description>Allergan's R&amp;D Recognised With Three Nominations For The 2014 US Prix Galien Awards [class:BotulinumToxins, dis:Migraine, prod:Botox]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7669</comments><category>class:BotulinumToxins</category><category>dis:Migraine</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7669</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7669">Allergan's R&D Recognised With Three Nominations For The 2014 US Prix Galien Awards</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7669">Neurology7669</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 04 August 2014 | 18:24</font><br><br><div style="margin-bottom: 10px;">Comment: The three nominations for these presitgious 
awards are in different categories but include Botox for Chronic Migraine.<wbr> 
Recipients will be announced in the fall.<wbr> </div><div style="margin-bottom: 10px;">The Allergan products that have been nominated are: </div><div style="margin-bottom: 10px;"><UL><LI>
  <STRONG>Best Biotechnology Product Nominee - </STRONG>BOTOX® 
  (onabotulinumtoxinA) for Chronic Migraine patients </LI>
<LI>
  <STRONG>Best Pharmaceutical Agent Nominee - </STRONG>OZURDEX® 
  (dexamethasone intravitreal implant) 0.<wbr>7 mg </LI>
<LI>
  <STRONG>Best Medical Technology Nominee - </STRONG>SERI® Surgical Scaffold 
  </LI>
</UL> </div><div>“For more than 64 years, Allergan has remained committed to developing 
innovative products to address unmet medical needs,” said David E.<wbr>I.<wbr> Pyott, 
Chairman and Chief Executive Officer, Allergan.<wbr> “We are proud to be recognized 
for our R&amp;D efforts by the Prix Galien Committee and especially honored to 
be the only company to receive nominations in all three of the 2014 Prix Galien 
Award categories </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7673c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>More noise on migraine.<wbr>.<wbr>.<wbr> </div><font size="-1">Alexandre BENOIN / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7673" class="commentpermalink">Neurology7673</a> / <span class="date">04 August 2014</span> /
<span class="time">22:52:08 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7669">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-04T18:24:55+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Astellas Q1 Results FY2014 - Key Takeaways [class:Antihormonals, comp:Astellas, dis:Prostate, :Neurology:dis:nOAB]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9859</link>
<description>Astellas Q1 Results FY2014 - Key Takeaways [class:Antihormonals, comp:Astellas, dis:Prostate, :Neurology:dis:nOAB]</description><category>class:Antihormonals</category><category>comp:Astellas</category><category>dis:Prostate</category><category>dis:nOAB</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9859</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9859">Astellas Q1 Results FY2014 - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9859">Oncology9859</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 04 August 2014 | 18:19</font><br><br><div style="margin-bottom: 10px;"><BR>Comment: Astellas has reported strong first quarter results with sales 
+9.<wbr>5% (including FX) and operating profit up 48.<wbr>2% and 
growth underpinned by by US and European demand for Xtandi (CRPC) 
and Miragebron (OAB).<wbr> There are several new pipeline developments of interest, 
including the initiation of a phI pediatric programme with mirabegron in 
neurogenic OAB.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Q1 Sales Performance</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/1/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Key Product Performance </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Included in its webex presentation were several comments to the effect that 
Xtandi's performance is exceeding internal expectations, particularly in 
Europe.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/5/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/3/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Pipeline Progress </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/4/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In addition to its slide presentation, Astellas also provided an updated 
pipeline analysis amongst which there are some interesting observations.<wbr> </div><div style="margin-bottom: 10px;">i) Astellas's own GnRH antagonists ASP1707 is currenly in phII development in 
Europe and Japan for endometriosis and in phI in Europe for prostate cancer.<wbr> </div><div style="margin-bottom: 10px;">ii) Astellas filed for approval in July in Japan for ramosetron a 5HT3 
antagonist for the treatment of IBS with diarrhea in female patients.<wbr> </div><div style="margin-bottom: 10px;">iii) Ferring's degarelix remains in phIII development in Japan but the 
impression is given that it is a new 3M formulation that is being evaluated.<wbr> </div><div style="margin-bottom: 10px;">iv) New in terms of phI development is the start of a clinical programme with 
miragebron in neurogenic OAB in pediatric patients, plus two new osteoarthritis 
programmes focused on ASP7962 and ASP3700.<wbr> </div><div>Source: <A href="http://www.astellas.com">www.<wbr>astellas.<wbr>com</A> </div><!-- Comment details --><a name="oncology9859attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/1/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(122,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(143,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/3/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(151,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/4/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(194,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/5/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(112,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9859">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-04T18:19:48+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/1/ScreenCapture2.jpg" length="125706" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/2/ScreenCapture3.jpg" length="146785" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/3/ScreenCapture5.jpg" length="155097" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/4/ScreenCapture6.jpg" length="199085" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9859/5/ScreenCapture7.jpg" length="115412" type="image/jpeg"/></item><item>
<title>Phase Ib Study of HMPL-012 (Sulfatinib) in NETS [:PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7753</link>
<description>Phase Ib Study of HMPL-012 (Sulfatinib) in NETS [:PharmaWorld:sub:ClinicalTrial]</description><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7753</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7753">Phase Ib Study of HMPL-012 (Sulfatinib) in NETS</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7753">Endocrinology7753</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 August 2014 | 18:03</font><br><br><div style="margin-bottom: 10px;">Comment: In the interim results for the 6 months ended 30 June 2014, management of Hutchison MediPharma highlighted that sulfatinib has the potential "to revolutionise the treatment of NET", and reported that it is currently expanding the Ph1 study to enrol further NET patients.<wbr> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px"><STRONG><FONT size="3">Data Published @ ASCO</FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><P dir="ltr" style="MARGIN-RIGHT: 0px">The Ph1 results on sulfatinib were published in May 2014 at ASCO.<wbr>  It shows ORR of 33% and DCR of 100% among 12 NET patients.<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>Sutent (Pfizer) and Afinitor (Novartis) are both approved only in pancreatic NET and have ORR of &lt;10% and DCR approximately 70%.<wbr>  </LI>
<LI>Octreotide (Novartis) has ORR of 6% and DCR around 35-45%.<wbr>  </LI>
<LI>Chemotherapy combinations are now being studied for NET, such as Capecitabine (Roche) plus Temozolomide (a generic), and are showing encouraging ORR/<wbr>DCRs, but tolerability and toxicity will be a challenge with these combinations for long-term use.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Information</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="1">(source Pharma e Track)</FONT> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7753/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7753attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7753/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7753">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-04T18:03:58+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7753/1/ScreenCapture1.jpg" length="53934" type="image/jpeg"/></item><item>
<title>Takeda's 1Q is on the Weak Side in Terms of Sales [comp:Takeda, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9857</link>
<description>Takeda's 1Q is on the Weak Side in Terms of Sales [comp:Takeda, :PharmaWorld:sub:Finance]</description><category>comp:Takeda</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9857</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9857">Takeda's 1Q is on the Weak Side in Terms of Sales</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9857">Oncology9857</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 August 2014 | 15:56</font><br><br><div style="margin-bottom: 10px;">Comment: Q1 results show a temporary slowdown in sales growth as a result of the biennual Japanese national health insurance downwards price revisions as well as reductions of inventories at wholesalers in emerging markets (EMs).<wbr> However management confirms that emerging market revenue growth for the FY is expected to be in double digits, as it was last year.<wbr> The ongoing transformation "Project Summit" has yeld JPY5b savings in the quarter.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9857/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">TOP 10 Products</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9857/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Postionning in EMs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>in Russia</STRONG> </div><div style="margin-bottom: 10px;">Management reported that " .<wbr>.<wbr>.<wbr> the Russian situation has nothing to do with any political situation in any country, apart from what I mentioned in Venezuela or in Ukraine.<wbr> In the Russia the situation is totally different.<wbr> We had for some time, for several years a rather high level of inventory with the wholesalers in Russia.<wbr> And there are two reasons for it.<wbr> One of them is the fact that we have moved from exports to local manufacturing after we built the plant in Russia and the transfer required some higher level of inventory.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>in Mexico</STRONG> </div><div>Management indicated that " .<wbr>.<wbr>.<wbr> There is nothing either linked to any new political situation whatsoever.<wbr> But in Mexico one wholesaler which has a significant market share is having some financial tensions.<wbr> And we decided to have a more stringent policy in terms of credit from a credit point of view and, therefore, to reduce the inventory level globally in the country.<wbr> So it's a very specific situation which should come back to normal over time.<wbr> So these are pure one-off that happened in Q1 and they're not likely to happen again in the future.<wbr> </div><!-- Comment details --><a name="oncology9857attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9857/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(27,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9857">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-04T15:56:08+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9857/1/ScreenCapture1.jpg" length="28595" type="image/jpeg"/></item><item>
<title>TSK Laboratory Europe B.V. Introduces a New BoNT Injection Syringe [class:BotulinumToxins, :PharmaWorld:sub:Devices]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7668</link>
<description>TSK Laboratory Europe B.V. Introduces a New BoNT Injection Syringe [class:BotulinumToxins, :PharmaWorld:sub:Devices]</description><category>class:BotulinumToxins</category><category>sub:Devices</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7668</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7668">TSK Laboratory Europe B.<wbr>V.<wbr> Introduces a New BoNT Injection Syringe</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aDevices"><font color="#e95e0b">:PharmaWorld:sub:Devices</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7668">Neurology7668</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 August 2014 | 14:18</font><br><br><div style="margin-bottom: 10px;">Comment: During the AMWC meeting in Monaco, TSK Laboratory Europe B.<wbr>V.<wbr> introduced a new BoNT injection syringe, the 3Dose™ Dose Injection Syringe.<wbr> The adjustable clicker system allows easy and precise dose injection (0.<wbr>025ml; 0.<wbr>04ml and 0.<wbr>05ml).<wbr> Settings and cost are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Details and Characteristics</FONT></STRONG> </div><div style="margin-bottom: 10px;">If we refer to the company's website (<A href="http://www.tsklab.nl/shop/aesthetics">http:/<wbr>/<wbr>www.<wbr>tsklab.<wbr>nl/<wbr>shop/<wbr>aesthetics</A>), cost is featured as below : </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The 3Dose™ syringe has a plunger that can be turned to select the desired injection volumes of 0.<wbr>025ml, 0.<wbr>04ml and 0.<wbr>05ml, and every click administers a precise selected dose without the risk of over/<wbr>under dose injection.<wbr> </div><div style="margin-bottom: 10px;"><U>Ease of Use</U> </div><div style="margin-bottom: 10px;">After filling the syringe and setting the desirable dose volume, the focus can be on the patient instead of the syringe.<wbr> An audible and tactile click gives feedback when one precise dose is injected, and the procedure can be repeated without having to reference the ml scale on the syringe.<wbr>  The display conveniently shows how many units remain in the syringe.<wbr> </div><div style="margin-bottom: 10px;"><U>Minimum Product Loss</U> </div><div style="margin-bottom: 10px;">Leakage or pop-off is prevented by a perfect press fit between the secure luer lock connection and the needle hub.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Settings</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About TSK Laboratory</FONT></STRONG> </div><div style="margin-bottom: 10px;">The medical needles are produced in Japan by TSK Laboratory Japan.<wbr> </div><div style="margin-bottom: 10px;">Since 1973 this company has been part of a larger group of companies in Japan that manages several factories and schools, and has grown into the largest employer in Tochigi, a province north of Tokyo.<wbr> </div><div>The company’s first established abroad was opened in Canada in 1989 and is responsible for the North American market.<wbr> The new office in the Netherlands gives TSK Laboratory the required European representation to further expand internationally.<wbr> </div><!-- Comment details --><a name="neurology7668attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(19,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(23,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(8,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(56 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(67,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7668">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-04T14:18:44+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/1/ScreenCapture1.jpg" length="19700" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/2/ScreenCapture2.jpg" length="23655" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/3/ScreenCapture3.jpg" length="9063" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/4/ScreenCapture4.jpg" length="57347" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7668/5/ScreenCapture5.jpg" length="68968" type="image/jpeg"/></item><item>
<title>Key Takeaways from AstraZeneca's Results and Activities in China [comp:AstraZeneca, :PharmaWorld:mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9855</link>
<description>Key Takeaways from AstraZeneca's Results and Activities in China [comp:AstraZeneca, :PharmaWorld:mkt:China]</description><category>comp:AstraZeneca</category><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9855</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9855">Key Takeaways from AstraZeneca's Results and Activities in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9855">Oncology9855</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 August 2014 | 12:20</font><br><br><div style="margin-bottom: 10px;">Comment: Revenue in 2Q was $6,454M (up 4% CER), and 1H revenue up 3% driven by the 5 growth platforms (Brilinta, Diabetes, Respiratory, EMs, and Japan).<wbr> The emerging markets grew in double digits, with <FONT style="BACKGROUND-COLOR: #ffffff">China </FONT>being the key driver at 23% (and 26% growth in Russia).<wbr> On the pipeline side, management highlighted its immuno-oncology portfolio with &gt;15 planned sponsored and/<wbr>or pivotal studies.<wbr> In September, AstraZeneca will present key data readouts at the ESMO meeting in Madrid.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Activities in China</FONT></STRONG> </div><div style="margin-bottom: 10px;">China now accounts for nearly 40% of AZ's total EMs business, with growth driven by Crestor (choloesterol drug), Nexium (PPI), asthma and COPD treatment Symbicort, Pumicort and beta-blocker Seloken.<wbr> </div><div style="margin-bottom: 10px;">The strength of AstraZeneca 's respiratory portfolio in China will be bolstered further by the buying of Almirall 's respiratory franchise.<wbr> </div><div style="margin-bottom: 10px;">New drug launches are now prioritized for China: </div><div style="margin-bottom: 10px;"><DIV class="div1 changeFontSize" style="BORDER-BOTTOM: 0px; BORDER-LEFT: 0px; LINE-HEIGHT: 24px; MARGIN-TOP: 0px; BORDER-TOP: 0px; BORDER-RIGHT: 0px">
<P class="contentMain">- regulatory filings for IBS drug linaclotide and T2DM drug Onglyza (saxagliptin) during 2015.<wbr> </P>
<P class="contentMain">- Olaparib (ovarian cancer), roxadustat (anemia in chronic kidney disease), and Falsodex (fulvestrant; first-line breast cancer) are expected to be filed during 2016.<wbr></P>
<P class="contentMain"><STRONG><FONT size="3">Details of the Growth Platforms</FONT></STRONG></P></DIV> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9855/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Emerging Markets</FONT></STRONG> </div><div style="margin-bottom: 10px;">AZ is the fatest growing multi national company in China YTD </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9855/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Immuno-Oncology Progressing Well</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9855/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ESMO Highlights</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9855/6/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Potential Submission 2014-2016</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9855/4/ScreenCapture4.jpg?user-agent=rss"> </div><div><STRONG><FONT size="4">Full Presentation is attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140831&edate=20140501&rs=/link%20Oncology9856%405" class="defaultlink">@5</a> and Pipeline Update <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140831&edate=20140501&rs=/link%20Oncology9856%407" class="defaultlink">@7</a></FONT></STRONG> </div><!-- Comment details --><a name="oncology9855attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9855/5/AZ%5f2Q%20and%201H%202014%20Results.pdf">AZ_2Q and 1H 2014 Results.pdf</a>&nbsp;&nbsp;(1,3 MB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9855/7/AZ%5fpipeline%20Update%20June%2030%202014.pdf">AZ_pipeline Update June 30 2014.pdf</a>&nbsp;&nbsp;(86,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9855">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-08-04T12:20:47+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9855/5/AZ%5f2Q%20and%201H%202014%20Results.pdf" length="1403465" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9855/7/AZ%5fpipeline%20Update%20June%2030%202014.pdf" length="88218" type="application/pdf"/></item><item>
<title>Incyte Announces Clinical Trial Agreement With Roche to Evaluate Combination of Two Novel Cancer Immunotherapies</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9853</link>
<description>Incyte Announces Clinical Trial Agreement With Roche to Evaluate Combination of Two Novel Cancer Immunotherapies</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9853</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9853">Incyte Announces Clinical Trial Agreement With Roche to Evaluate Combination of Two Novel Cancer Immunotherapies</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9853">Oncology9853</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 31 July 2014 | 18:37</font><br><br><div style="margin-bottom: 10px;">Comment: Incyte has entered a clinical trial agreement with Roche to evaluate the safety, tolerability and preliminary efficacy of Incyte's IDO inhibitor in combination with Roche's anti-PDL1 in patients with NSCLC.<wbr> Both agents belong to a new class of immunotherapies.<wbr> This collaboration with Genentech is a further illustration of the therapeutic value of IDO inhibitors and the increased research focus on combination approach for immunotherapy doublet.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><SPAN style="background-color: #ffcc00;">Scientific Rationale</SPAN></STRONG> </div><div style="margin-bottom: 10px;">There is a growing body of evidence to suggest that IDO1 inhibitor-based combination immunotherapy may improve clinical response.<wbr> INCB24360 has been shown to be active in mouse models of cancer as a single agent and in combination with cytotoxic and immunotherapy agents, and its ability to reduce tumour growth is dependent on a functional immune system &ndash; consistent with its proposed mechanism of action.<wbr> Preliminary clinical data from an ongoing Phase I/<wbr>II trial evaluating INCB24360 in combination with the approved immunotherapy checkpoint inhibitor Yervoy<SUP><FONT size="2">&reg;</FONT></SUP> (ipilimumab) in metastatic melanoma, recently presented at the 50<SUP><FONT size="2">th</FONT></SUP> Annual Meeting of the American Society of Clinical Oncology (ASCO), suggest anti-tumor synergy between the two agents, establishing proof of concept for the combination.<wbr> Thus far, 42 percent of the immunotherapy-na&iuml;ve patients receiving INCB24360 combined with ipilimumab achieved an objective response and 75 percent achieved disease control.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9853/1/Picture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9853attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9853/1/Picture1.jpg">Picture1.jpg</a>&nbsp;&nbsp;(32,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9853">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-31T18:37:39+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9853/1/Picture1.jpg" length="33061" type="image/jpeg"/></item><item>
<title>New Device To Be Trialed In Spinal Cord Spasticity [dis:Spasticity, dis:Dystonia]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7667</link>
<description>New Device To Be Trialed In Spinal Cord Spasticity [dis:Spasticity, dis:Dystonia]</description><category>dis:Spasticity</category><category>dis:Dystonia</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7667</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7667">New Device To Be Trialed In Spinal Cord Spasticity</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7667">Neurology7667</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 31 July 2014 | 18:33</font><br><br><div style="margin-bottom: 10px;">Comment: ClinicalTrials.<wbr>gov is listing a new study which will evaluate 
extracorporeal shock wave therapy (Storz Medical's Duolith® SD 1 "T-Top" 
device for the treatment of focal spasticity in patients with spinal 
cord injury.<wbr> </div><div style="margin-bottom: 10px;">The purpose of this study is to investigate the effect of a one-time ESWT on 
lower limb spasticity in patients with an incomplete spinal cord injury.<wbr> </div><div style="margin-bottom: 10px;">The primary outcome measure for this interventional study will be severity of 
spasticity (0-2hr) as measured on the Ashworth scale.<wbr> Secondary measures 
will be personal goal attainments at day 0,1,3 and 5) and walking sitance 
and speed (pre and post intervention.<wbr> Several other scales will be deployed to 
measure the severity of spasticity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Enrolment Nos, Timelines &amp; Study Location</STRONG> </div><div style="margin-bottom: 10px;">20 patients will be enrolled with the study scheduled to start this 
month and complete in May 2016.<wbr> The study is to be undertaken by the Swiss 
Paraplegic Centre in Notwil.<wbr> </div><div style="margin-bottom: 10px;">Reference is also made to recent studies which have reported 
positive effects of extracorporeal shock wave therapy on spasticity in patients 
with stroke, focal limb dystonia and cerebral palsy.<wbr> We will look to identify 
these papers.<wbr> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-TOP: 1ex" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">
      <P>ClinicalTrials.<wbr>gov Identifier:</P></TD>
<TD headers="colData" style="PADDING-LEFT: 1em"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02203994" title="Current version of study NCT02203994 on ClinicalTrials.gov">NCT02203994</A> 
  </TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7667">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-31T18:33:33+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Boehringer Ingelheim Has Planned A Ph1 Trial to Evaluate Combination of Anti-IGF With Enzalutamide For mCRPC Patients (Post-Docetaxel Setting)</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9852</link>
<description>Boehringer Ingelheim Has Planned A Ph1 Trial to Evaluate Combination of Anti-IGF With Enzalutamide For mCRPC Patients (Post-Docetaxel Setting)</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9852</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9852">Boehringer Ingelheim Has Planned A Ph1 Trial to Evaluate Combination of Anti-IGF With Enzalutamide For mCRPC Patients (Post-Docetaxel Setting)</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9852">Oncology9852</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 31 July 2014 | 18:11</font><br><br><div style="margin-bottom: 10px;">Comment: Boehringer Ingelheim has planned a Ph1 trial to investigate their experimental drug BI-836845, an insulin growth factor inhibitor, in combination with enzalutamide for the treatment of mCRPC patients who progress beyond docetaxel and abiraterone.<wbr> A Phase 1b expansion cohort will proceed once the maximum tolerated dose has been determined.<wbr> This will the follow by the randomised ph2 trial with parallel group study design in a 1:1 ratio to compare BI836845+ Enzalutamide vs Enzalutamide monotherapy.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov Identifier: <a href="https://clinicaltrials.gov/ct2/show/NCT02204072?rcv_s=07%2F28%2F2014&rank=45" class="defaultlink">NCT02204072</a> </div><div style="margin-bottom: 10px;">Estimated Enrolment = 160 </div><div style="margin-bottom: 10px;">Study start date : Sept 2014 </div><div style="margin-bottom: 10px;">Estimated Completion date : Nov 2017 </div><div>Source: <A href="http://www.clinicaltrial.gov">www.<wbr>clinicaltrial.<wbr>gov</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9852">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-31T18:11:46+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Acorda Q2 - Key Takeaways - Stroke Trial Now Planned To Start By Year-End</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7666</link>
<description>Acorda Q2 - Key Takeaways - Stroke Trial Now Planned To Start By Year-End</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7666</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7666">Acorda Q2 - Key Takeaways - Stroke Trial Now Planned To Start By Year-End</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7666">Neurology7666</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 31 July 2014 | 18:08</font><br><br><div style="margin-bottom: 10px;">Comment: Acorda's sales of AMPYRAin the second quarter were 
strong prompting the company to reiterate its net sales guidance for 
the year of $328-335m.<wbr> However, the company has now received eight Paragraph IV 
Certification Notice Letters advising that companies have submitted ANDAs to 
the <ORG>FDA requesting permission to manufacture and market a generic 
version of AMPYRA in July 2017</ORG> </div><div style="margin-bottom: 10px;"><STRONG>Status Of The Patent Challenge</STRONG> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px">The Company has filed patent infringement suits 
against all ANDA filers to date, triggering a 30-month statutory stay period 
that restricts <ORG>FDA</ORG> from approving an ANDA until <CHRON>July 
2017</CHRON> at the earliest, unless a district court issues a decision adverse 
to all of Acorda’s asserted Orange Book patents prior to that date.<wbr> The 30-month 
stay starts from <CHRON>January 22, 2015</CHRON>, which is the end of the new 
chemical entity (NCE) exclusivity period.<wbr> AMPYRA is currently protected by five 
Orange Book-listed patents, four of which extend into 2025, 2026 and 2027, 
respectively.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px"><STRONG>Acorda Looks Forward To A New Formulation 
As A Means Of Protection - Inclusion In Ph3 Stroke Study Is Planned</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px">Meanwhile, the company expects to initiate a 
Phase 3 clinical trial by the end of this year studying the use of dalfampridine 
administered twice-daily (BID) to improve walking in people who have experienced 
a stroke.<wbr> The start of this study is delayed compared to previous estimates but 
we note that the group is working with external partners to develop a 
new once-daily (QD) formulation that could be included in future studies.<wbr></P> </div><div><P style="MARGIN-BOTTOM: 10px">Source: <A href="http://www.acorda.com">www.<wbr>acorda.<wbr>com</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7666">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-31T18:08:37+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Valeant Q2 Earnings Figures - Transparency Markedly Enhanced As Allergan's Criticisms Are Addressed [comp:Allergan, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7664</link>
<description>Valeant Q2 Earnings Figures - Transparency Markedly Enhanced As Allergan's Criticisms Are Addressed [comp:Allergan, :PharmaWorld:sub:Acquisition]</description><category>comp:Allergan</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7664</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7664">Valeant Q2 Earnings Figures - Transparency Markedly Enhanced As Allergan's Criticisms Are Addressed</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7664">Neurology7664</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 31 July 2014 | 17:37</font><br><br><div style="margin-bottom: 10px;">Comment: Valeant has reported an accelerating growth picture and revenues seemingly in line with consensus.<wbr> Increased transparency is apparent and shows how diversified the business is with the group's top 20 global brands generating 31% of revenue ($1.<wbr>2bn) growing 22% y/<wbr>y and 124% year to date.<wbr> Guidance has been lowered to reflect the sale of facial injectables to Galderma, where revenues interestingly appear to be above market consensus at $230m.<wbr> </div><div style="margin-bottom: 10px;">Valeant has provided 2015-16 guidance under two scenarios: debt repayment and acquisition.<wbr> What is notable is that even without acquisition Valeant is expecting high-single organic growth and cash EPS of &gt;15% and #20% in 2015 and 2016, suggesting that it is forecasting strong underlying growth in the business.<wbr> </div><div style="margin-bottom: 10px;">The slides below highlight some of the key points made in the presentation, and data that in certain instances effectively counters Allergan's accusations.<wbr> Details of the next steps in the acquisition process are also outlined plus indications given on how the integration process may take place if Valeant is successful.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/1/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/3/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/4/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/5/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/6/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/7/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/8/ScreenCapture9.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/9/ScreenCapture10.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7664attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/1/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(98,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(91,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(102,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/4/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(83,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/5/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(80,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/6/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(90,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/7/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(101,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/8/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(93,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/9/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(80,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7664">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-31T17:37:47+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/1/ScreenCapture2.jpg" length="101138" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/2/ScreenCapture3.jpg" length="93377" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/3/ScreenCapture4.jpg" length="105116" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/4/ScreenCapture5.jpg" length="85606" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/5/ScreenCapture6.jpg" length="82591" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/6/ScreenCapture7.jpg" length="92888" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/7/ScreenCapture8.jpg" length="104241" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/8/ScreenCapture9.jpg" length="95957" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7664/9/ScreenCapture10.jpg" length="82308" type="image/jpeg"/></item><item>
<title>Eligard 6M Now Reimbursed In Italy [class:Antihormonals, comp:Astellas, :PharmaWorld:mkt:Italy]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9851</link>
<description>Eligard 6M Now Reimbursed In Italy [class:Antihormonals, comp:Astellas, :PharmaWorld:mkt:Italy]</description><category>class:Antihormonals</category><category>comp:Astellas</category><category>mkt:Italy</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9851</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9851">Eligard 6M Now Reimbursed In Italy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aItaly"><font color="#e95e0b">:PharmaWorld:mkt:Italy</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9851">Oncology9851</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 31 July 2014 | 16:17</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Michela Maraschi (Uro-Oncology Franchise Marketing), we 
understand that Eligard 6M is now officially reimbursed in Italy.<wbr> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US"><FONT face="Calibri">In the Official Journal n.<wbr> 
179 of  29.<wbr>7.<wbr>2014 the authorisation for the reimbursement of Eligard 6 
months has been published.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US"><FONT face="Calibri">Official prices, at the gros 
of the mandatory discount,  are:</FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="IT" style="mso-ansi-language: IT; mso-fareast-font-family: Calibri"><SPAN style="mso-list: Ignore"><FONT face="Calibri">-</FONT>          
</SPAN></SPAN><FONT face="Calibri"><SPAN lang="IT" style="mso-ansi-language: IT; mso-fareast-language: IT">PP  : € 
815,76</SPAN></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="IT" style="mso-ansi-language: IT; mso-fareast-font-family: Calibri"><SPAN style="mso-list: Ignore"><FONT face="Calibri">-</FONT>          
</SPAN></SPAN><FONT face="Calibri"><SPAN lang="IT" style="mso-ansi-language: IT; mso-fareast-language: IT">Ex-factory: 
€494,28</SPAN></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><SPAN lang="EN-US" style="mso-ansi-language: EN-US; mso-fareast-language: IT">Official 
prices at the net of the mandatory discounts (-5%; -5%) are </SPAN></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="IT" style="mso-ansi-language: IT; mso-fareast-font-family: Calibri"><SPAN style="mso-list: Ignore"><FONT face="Calibri">-</FONT>          
</SPAN></SPAN><FONT face="Calibri"><SPAN lang="IT" style="mso-ansi-language: IT; mso-fareast-language: IT">PP : €736,22</SPAN></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="IT" style="mso-ansi-language: IT; mso-fareast-font-family: Calibri"><SPAN style="mso-list: Ignore"><FONT face="Calibri">-</FONT>          
</SPAN></SPAN><FONT face="Calibri"><SPAN lang="IT" style="mso-ansi-language: IT; mso-fareast-language: IT">Ex-factory: 
€446,09</SPAN></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="mso-ansi-language: EN-US; mso-fareast-language: IT"><FONT face="Calibri">Astellas has agreed with HAs an additional undisclosed 
discount.<wbr></FONT></SPAN> </div><div><SPAN lang="EN-US" style="mso-ansi-language: EN-US; mso-fareast-language: IT"><FONT face="Calibri">Official price, at the gros of the undisclosed discount, is twice 
the price of the 3 months formulation.<wbr></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9851">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-31T16:17:57+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Bayer Q2 Figures-Key Takeaways [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9850</link>
<description>Bayer Q2 Figures-Key Takeaways [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9850</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9850">Bayer Q2 Figures-Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9850">Oncology9850</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 July 2014 | 18:53</font><br><br><div style="margin-bottom: 10px;">Comment: Bayer today reported strong demand for its top five new drugs 
including its prostate cancer drug Xofigo (Alphardin), whilst total 
sales and profits were dampened by the strength of the Euro.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9850/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Pharmaceuticals generated an impressive 10% sales growth to almost EUR 3.<wbr>0 
billion.<wbr> The growth was driven by the group's launch products, 
Xarelto, Eylea, Stivarga, Xofigo and Adempas, which collectively posted sales of 
EUR 702 million.<wbr> Sales of Xarelto maintained the strong growth momentum of prior 
quarters.<wbr> Eylea grew strongly as well, mainly in Western Europe and the 
group's cancer drugs, Stivarga and Xofigo (€43m), made encouraging 
contributions to the sales development.<wbr> </div><div style="margin-bottom: 10px;">The performance of the group's established Pharma products 
was more mixed in the quarter.<wbr> </div><div style="margin-bottom: 10px;">On the positive side, sales of Nexavar rose by 3% with particular 
contributions from the emerging markets and the U.<wbr>S.<wbr> Mirena recorded sales gains 
of 13%, mainly as a result of price increases in the U.<wbr>S.<wbr>, and Aspirin Cardio 
experienced a substantial increase in demand, especially in China, resulting in 
overall sales growth of 9%.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">On the negative side, Kogenate sales declined by 17%, mainly 
due to capacity constraints that were caused by utilization of existing 
manufacturing capacity for the development of the group's next generation 
hemophilia product.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Sales of Betaferon receded by 16% mainly due to increased 
competition in the U.<wbr>S.<wbr> Sales of the YAZ family contracted by 3% and sales 
growth in the U.<wbr>S.<wbr> only partly compensated for the revenue decline in Western 
Europe due to generic competition.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Xofigo Update</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Xofigo now is approved in 38 countries and launched in 
18, and in Europe that includes Germany, Austria, U.<wbr>K.<wbr>, Ireland, France, 
Netherlands and a set of smaller countries.<wbr> It's very early days but it is 
perceived to be going well.<wbr> So far about 4,100 U.<wbr>S.<wbr> patients have 
received Xofigo since launch and in Europe it is getting close to 
1,000 patients.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG>Pipeline Update</STRONG> </div><div style="margin-bottom: 10px;">Bayer has five focus projects in its pipeline.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Molidustat, which is a therapy for kidney disease, has three 
  Phase II studies ongoing and results are expected during the second 
  half of 2014.<wbr> </LI>
<LI>Copanlisib, a PI3K inhibitor PhII results are expected in 
  the first half of 2015.<wbr> </LI>
<LI>Vilaprisan a progesterone receptor antagonist targeting uterine 
  fibroids.<wbr> A PhII clinical trial is ongoing and primary study 
  completion is expected during 2016.<wbr></LI>
<LI>
  Finerenone has two studies ongoing 
  looking at different indications.<wbr> One is in worsening chronic heart 
  failure and the second diabetic neuropathy.<wbr> Results are 
  expected during the second half of 2014.<wbr></LI>
<LI>
  Vericiguat which is a sGC modulator which part 
  of a partnership with Merck;  is being evlauted in worsening 
  CHF in two different populations: one with reduced injection fraction and the 
  other with preserved injection fraction and results are exected by 
  first part of 2015.<wbr></LI>
</UL> </div><div><P class="pwrapper"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9850/2/ScreenCapture2.jpg?user-agent=rss"></P> </div><!-- Comment details --><a name="oncology9850attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9850/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(51,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9850/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(229,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9850">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-30T18:53:08+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9850/1/ScreenCapture1.jpg" length="52322" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9850/2/ScreenCapture2.jpg" length="234825" type="image/jpeg"/></item><item>
<title>PhII ATL1103 Acromegaly Study Results Expected By End August [dis:Acromegaly]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7751</link>
<description>PhII ATL1103 Acromegaly Study Results Expected By End August [dis:Acromegaly]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7751</comments><category>dis:Acromegaly</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7751</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7751">PhII ATL1103 Acromegaly Study Results Expected By End August</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7751">Endocrinology7751</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 July 2014 | 18:26</font><br><br><div style="margin-bottom: 10px;">Comment: Antisense Therapeutics has reported completion of enrolment in its 26 patient phII acromegaly trial with results now expected by the end of August 2014.<wbr> </div><div style="margin-bottom: 10px;">So far there have been no patient withdrawals or reports of any serious adverse events related to dosing with ATL1103.<wbr> Patients will continue to be monitored for two months after their last dose.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Primary Study Endpoint</STRONG> </div><div style="margin-bottom: 10px;">The primary efficacy endpoint of this trial is percentage reduction from baseline in each patients serum IGF-1 levels to their levels one week after the last dose.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Interim Results</STRONG> </div><div style="margin-bottom: 10px;">Interim data was reported back in December 2013 from 8 patients who had completed their dosing.<wbr> Their results provided indicative data of efficacy with ATL1103, with reductions in IGF-1 in line with what could be therapeutically effective in the treatment of acromegaly.<wbr> </div><div>Source: <A href="http://www.antisensetherapeutics.com">www.<wbr>antisense.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7784c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">The company has reported that the Ph2 trial met its primary efficacy endpoint, showing a statistically significant average reduction in the serum insulin-like growth factor levels of 26% from baseline.<wbr> Management plans to conduct a small study at a higher dose than 400mg for potential use in a Ph3 trial.<wbr> </div><div style="margin-bottom: 10px;">Preparation for the Ph3 </div><div>Preparatory work for a Ph3 trial of 6-12 months of treatment includes manufacture and formulation of drug product and further animal toxicology studies which the company plans to undertake with a future development Partner.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7784" class="commentpermalink">Endocrinology7784</a> / <span class="date">03 September 2014</span> /
<span class="time">17:18:31 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7751">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-30T18:26:09+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Merck Serono's Anti-PD1 Is Being Evaluated In A Ph1 Trial Including mCRPC Patients</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9849</link>
<description>Merck Serono's Anti-PD1 Is Being Evaluated In A Ph1 Trial Including mCRPC Patients</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9849</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9849">Merck Serono's Anti-PD1 Is Being Evaluated In A Ph1 Trial Including mCRPC Patients</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9849">Oncology9849</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 29 July 2014 | 18:50</font><br><br><div style="margin-bottom: 10px;">Comment: Merck Serono announced the initiation of an international Ph2 study to assess the efficacy and safety of MSB0010718C (anti PDL1) in patients with metastatic Merkel Cell carcinoma (a rare and aggressive type of skin cancer).<wbr> The PD-L1/<wbr>PD-1 pathway is implicated as a major mechanism by which tumours evade elimination by the immune system.<wbr> In addition to this new study, MSB0010718C is also being explored in a Ph1 dose escalation study and the study is currently recruiting patients into expansion cohorts in 7 cancer types including castration resistant prostate cancer, colorectal cancer, gastric/<wbr>gastroeophogeal cancer, melanoma, metastatic breast cancer, non small cell lung cancer, and ovarian cancer.<wbr> </div><div style="margin-bottom: 10px;">The development of anti-PD1/<wbr>PDL1 monoclonal antibody was the hottest topic in ASCO this year, and this is certainly reflected by the size of the audience during the presentation.<wbr> Merck Serono is slightly behind the race, however, MSB-0010718C is the first anti-PD1 to be evaluated for the treatment of mCRPC patients.<wbr> Currently mCRPC patients are being recruited as the secondary cohorts only.<wbr> Given the previous negative results of ipilimumab (another immune oncology agent, BMS) in heavily treated mCRPC patients, the success of anti-PD1 in mCRPC will remain elusive and require further investigation.<wbr> The fate of anti-PD1/<wbr>PDL1 will probably become clearer once we learn more from the trial outcome of ipilimumab in chemo na&iuml;ve mCRPC setting.<wbr> </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="0" cellspacing="0" style="width: 458px;"><COLGROUP><COL width="259">
</COLGROUP>
<COLGROUP><COL width="199">
</COLGROUP>
<TBODY><TR height="17"><TD height="17" style="text-align: center;" width="259"><SPAN style="color: #000000;"><STRONG><FONT size="2">Anti-PD1/<wbr>PDL1 Monoclonal Antibody in Clinical Development </FONT></STRONG></SPAN></TD>
<TD style="text-align: center;" width="199"><SPAN style="color: #000000;"><STRONG><FONT size="2">Company/<wbr>Manufacture</FONT></STRONG></SPAN></TD>
<TD style="text-align: center;" width="199"><SPAN style="color: #000000;"><STRONG><FONT size="2">Highest Development Phase</FONT></STRONG></SPAN></TD>
</TR>
<TR height="17"><TD height="17" style="text-align: left;" width="259"><FONT size="2">pembrolizumab</FONT></TD>
<TD style="text-align: left;" width="199"><FONT size="2">Merck &amp; Co.<wbr>, Inc.<wbr> (MSD)</FONT></TD>
<TD style="text-align: center;" width="199"><FONT size="2">Pre-Registration</FONT></TD>
</TR>
<TR height="17"><TD height="17" style="text-align: left;"><FONT size="2">nivolumab</FONT></TD>
<TD style="text-align: left;"><FONT size="2">BMS/<wbr>Ono</FONT></TD>
<TD style="text-align: center;"><FONT size="2">Japan Approved /<wbr>ROW Pre-Registration</FONT></TD>
</TR>
<TR height="17"><TD height="17" style="text-align: left;"><FONT size="2">MEDI-4736</FONT></TD>
<TD style="text-align: left;"><FONT size="2">Medimmune/<wbr>AZ</FONT></TD>
<TD style="text-align: center;"><FONT size="2">III</FONT></TD>
</TR>
<TR height="17"><TD height="17" style="text-align: left;"><FONT size="2"><FONT size="2">MPDL3280A</FONT></FONT></TD>
<TD style="text-align: left;"><FONT size="2">Roche</FONT></TD>
<TD style="text-align: center;"><FONT size="2">II</FONT></TD>
</TR>
<TR height="17"><TD height="17" style="text-align: left;"><FONT size="2">MSB-0010718C</FONT></TD>
<TD style="text-align: left;"><FONT size="2">Merck KGaA (Merck Serono)</FONT></TD>
<TD style="text-align: center;"><FONT size="2">II</FONT></TD>
</TR>
<TR height="17"><TD height="17" style="text-align: left;"><FONT size="2">Pidilizumab</FONT></TD>
<TD style="text-align: left;"><FONT size="2">CureTech Ltd.<wbr></FONT></TD>
<TD style="text-align: center;"><FONT size="2">II</FONT></TD>
</TR>
<TR height="17"><TD height="17" style="text-align: left;"><FONT size="2">BMS-936559</FONT></TD>
<TD style="text-align: left;">
<P><FONT size="2">BMS</FONT></P>
</TD>
<TD style="text-align: center;"><FONT size="2">I</FONT></TD>
</TR>
<TR height="17"><TD height="17" style="text-align: left;"><FONT size="2">MEDI-0680</FONT></TD>
<TD style="text-align: left;">
<P><FONT size="2"><FONT size="2">Medimmune/<wbr>AZ</FONT></FONT></P>
</TD>
<TD style="text-align: center;"><FONT size="2">I</FONT></TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><SPAN class="hit_org" style="font-weight: bold; background-color: #ffeedd;">Trial Details: <SPAN style="background-color: #ffffff;">NCT01772004 (expected enrolment = 590)</SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN class="hit_org" style="font-weight: bold; background-color: #ffeedd;">MSB0010718C</SPAN> (anti PD-L1) will be administered in study location using a protocol-defined dose escalation scheme until confirmed progression, unacceptable toxicity, or if any criterion for withdrawal from the trial or investigational medicinal product occurs.<wbr> After determination of the dose and regimen for Expansion Phase, <SPAN class="hit_org" style="font-weight: bold; background-color: #ffeedd;">MSB0010718C</SPAN> will be administered to subjects divided into 3 primary cohorts of non-small cell lung cancer (NSCLC), gastric/<wbr>gastroesophageal junction (GEJ) cancer and metastatic breast cancer (MBC); and 4 secondary cohorts of colorectal cancer (CRC), castrate-resistant prostate cancer (CRPC), melanoma, and ovarian cancer.<wbr> </div><div>source: Pharma eTrack; clinicaltrial.<wbr>gov </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9849">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-29T18:50:37+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Zealand Pharma Concludes $402m Peptide Deal With Boehringer Ingelheim [dis:Diabetes, class:GLP1]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7750</link>
<description>Zealand Pharma Concludes $402m Peptide Deal With Boehringer Ingelheim [dis:Diabetes, class:GLP1]</description><category>dis:Diabetes</category><category>class:GLP1</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7750</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7750">Zealand Pharma Concludes $402m Peptide Deal With Boehringer Ingelheim</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aGLP1"><font color="#e95e0b">:Endocrinology:class:GLP1</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7750">Endocrinology7750</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 July 2014 | 18:12</font><br><br><div style="margin-bottom: 10px;">Comment: Zealand Pharma has signed a second collaboration agreement with 
Boehringer Ingelheim to advance a novel peptide medicine for an undisclosed 
cardio-metabolic indication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Zealand is eligible to receive up to €295m in potential milestone payments 
for the first commercialised product plus research funding and roylaties.<wbr> </div><div style="margin-bottom: 10px;">In return Boehringer will obtain global exclusive development and 
commercialisation rights to products under the agreement, with Zealnd retaining 
co-commercialisation rights in Scandanavi.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Existing Collaboration</STRONG> </div><div style="margin-bottom: 10px;">The first agreement, between both comapnies was signed in June 2011.<wbr> The 
collaboration is ongoing for the development and commercialization of novel 
glucagon/<wbr>GLP-1 dual-acting peptide therapeutics to treat patients with Type 2 
diabetes and/<wbr>or obesity.<wbr> </div><div style="margin-bottom: 10px;">Zealand has a partnering strategy for the development and commercialization 
of its products and in addition to its license agreement with Sanofi in 
Type 2 diabetes covering the marketed product Lyxumia<SUP>®</SUP> , the 
company has  a collaboration with Lilly in diabetes and obesity, one with 
Helsinn Healthcare in chemotherapy induced diarrhea and a license agreement with 
AbbVie in acute kidney injury.<wbr> </div><div>Source: <A href="http://www.zealandpharma.com">www.<wbr>zealandpharma.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7750">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-29T18:12:10+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Glide Pharma In-licenes Novel Diagnostic Technology For Prostate Cancer [sub:Diagnostic, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9848</link>
<description>Glide Pharma In-licenes Novel Diagnostic Technology For Prostate Cancer [sub:Diagnostic, dis:Prostate]</description><category>sub:Diagnostic</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9848</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9848">Glide Pharma In-licenes Novel Diagnostic Technology For Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=sub%3aDiagnostic"><font color="#e95e0b">:Oncology:sub:Diagnostic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9848">Oncology9848</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 July 2014 | 17:59</font><br><br><div style="margin-bottom: 10px;">Comment: Glide has acquired an exclusive worldwide licence to an 
innovative prostate cancer diagnostic technology from FScan Ltd, a Durham 
University spin-out company, a technology that it hopes one day may replace PSA 
measurements.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the agreement, Glide Pharma will pay an upfront fee, 
development and commercial milestone payments, and royalties on future product 
sales.<wbr> Glide Pharma has also taken an option for additional exclusive licences 
to FScan diagnostic technologies, for use in other conditions.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What Does The Technology Involve?</STRONG> </div><div style="margin-bottom: 10px;">The licensed technology pioneers the use of lanthanide complexes for the 
non-invasive, rapid and accurate measurement of citrate levels in seminal fluid.<wbr> 
The link between citrate levels and prostate cancer is well documented, 
providing the opportunity to develop an effective diagnostic test.<wbr> Further 
clinical validation of this approach is currently underway in studies 
co-ordinated by Professor Mark Emberton, Consultant Urologist at University 
College London.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Limitations Of Existing PSA Measurements</STRONG> </div><div style="margin-bottom: 10px;">The current routinely-used prostate-specific antigen (PSA) diagnostic has 
major limitations, with inaccurate results leading to large numbers of patients 
undergoing unnecessary additional testing and biopsy.<wbr> A rapid, accurate, 
non-invasive test would meet a major unmet clinical need, and consequently has 
significant commercial potential.<wbr> According to Glide Pharma,  approximately 
24 million PSA tests are conducted each year in the US alone, with the worldwide 
market valued at more than $2 billion.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Glide Pharma plans to provide the technology initially as an analyte specific 
reagent in the USA.<wbr> In the longer-term, the company intends to develop a 
prostate cancer diagnostic test, and to pursue regulatory approval in the US and 
Europe.<wbr> </div><div>Source: <A href="http://www.glidepharma.com">www.<wbr>glidepharma.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9848">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-29T17:59:09+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Reckitt Benckiser To Create Stand-Alone Pharmaceutical Business [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10924</link>
<description>Reckitt Benckiser To Create Stand-Alone Pharmaceutical Business [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10924</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10924">Reckitt Benckiser To Create Stand-Alone Pharmaceutical Business</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10924">PharmaWorld10924</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 July 2014 | 17:01</font><br><br><div style="margin-bottom: 10px;">Comment: Reckitt Benckiser yesterday announced its intentions to create 
a stand-alone pharmaceutical business based around the treatment of addiction in 
its many forms.<wbr> Included was reference to a derivative of the spasticity 
drug Arbaclofen which it is developing for alchohol addicition.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">Right from January 2012 onwards, Reckitt management have stated that RBP 
is not core to RB.<wbr> Having waited to see the impact of generic entry on the 
business it is now in a better position to assess prospects and a valuation for 
the business.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">What RB has created is a global leadership position in the world of 
addiction treatment, which is fast-growing, under-served market.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/5/ScreenCapture5.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/6/ScreenCapture6.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/7/ScreenCapture7.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">RB management are not ruling out selling this business.<wbr> 
The preparations for a separation of RBP from RB are to a large extent common, 
whatever the form of the separation.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">It believes RBP will be a magnet for interesting business 
development opportunities particularly in the under-served, fast-growing and 
large area of addiction treatment.<wbr> This is the reason 
why it is going to pursue the de-merger with full energy.<wbr> </P> </div><div style="margin-bottom: 10px;"><DIV>

<DIV class="speaker"><STRONG>Pipeline Perspective</STRONG></DIV>

<DIV class="speaker"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/8/ScreenCapture8.jpg?user-agent=rss"></DIV>

</DIV> </div><div><DIV>

<P class="pwrapper">From a pipeline perspective, Shaun Thaxter 
President &amp; CEO of RBP  noted that the group has moved 
on considerably over the last two years.<wbr> It has in-licensed  two 
new technologies, one, is arbaclofen placarbil, for the treatment of alcohol 
use, use disorders, and the other is Nasal Naloxone, which is an overdose rescue 
medication.<wbr> And there are more opportunities moving forward.<wbr> RBP 
is continuing to look for opportunities in cocaine/<wbr>methamphetamine and 
cannabis addiction.<wbr></P>
<P class="pwrapper"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/9/ScreenCapture9.jpg?user-agent=rss"></P>
<P class="pwrapper"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/10/ScreenCapture10.jpg?user-agent=rss"></P>
<P class="pwrapper"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/11/ScreenCapture11.jpg?user-agent=rss"></P>
<P class="pwrapper">Source: <A href="http://www.reckittbenckiser.com">www.<wbr>reckittbenckiser.<wbr>com</A></P>
<P class="pwrapper">.<wbr></P></DIV> </div><!-- Comment details --><a name="pharmaworld10924attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(50,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(41,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(53,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(71,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(48,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(92,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(64,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(68,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(61,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(63,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(76,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10924">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-29T17:01:38+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/1/ScreenCapture1.jpg" length="51700" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/2/ScreenCapture2.jpg" length="42076" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/3/ScreenCapture3.jpg" length="55087" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/4/ScreenCapture4.jpg" length="72833" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/5/ScreenCapture5.jpg" length="49589" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/6/ScreenCapture6.jpg" length="94374" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/7/ScreenCapture7.jpg" length="65611" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/8/ScreenCapture8.jpg" length="69908" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/9/ScreenCapture9.jpg" length="63173" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/10/ScreenCapture10.jpg" length="64824" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10924/11/ScreenCapture11.jpg" length="77930" type="image/jpeg"/></item><item>
<title>Bioniche To File NDA For Bladder Cancer Drug MCNA [dis:Bladder, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9847</link>
<description>Bioniche To File NDA For Bladder Cancer Drug MCNA [dis:Bladder, news]</description><category>dis:Bladder</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9847</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9847">Bioniche To File NDA For Bladder Cancer Drug MCNA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9847">Oncology9847</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 July 2014 | 10:47</font><br><br><div style="margin-bottom: 10px;">Comment: Bioniche Life Sciences Inc.<wbr> has provided an update on its 
flagship Phase 3 program, Mycobacterial Cell Wall-Nucleic Acid Complex (MCNA) 
sterile suspension for the treatment of patients with BCG refractory high grade 
non-muscle invasive bladder cancer (NMIBC), noting that it will now file 
for US approval and seek external partners for commercialisation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Outcome Of Regulatory Discussions</STRONG> </div><div style="margin-bottom: 10px;">Following several months of active dialogue with the U.<wbr>S FDA, concerning the 
most appropriate regulatory pathway for MCNA approval in the United States, 
Bioniche has received written guidance.<wbr> This guidance provides regulatory 
clarity and permits the submission of an MCNA Biological License Application 
(BLA) for U.<wbr>S.<wbr> marketing approval review based on Bioniche's existing clinical 
trial data set.<wbr> </div><div style="margin-bottom: 10px;">In accordance with this feedback and in preparation for a timely and 
efficient submission of its MCNA BLA, Bioniche has engaged a top-tier global 
regulatory consulting firm that will help in the review and final preparation of 
the BLA.<wbr> Bioniche will provide guidance on the anticipated timelines of this BLA 
submission following the completion of a full assessment of the regulatory tasks 
required to complete all BLA requirements.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on this development Dr.<wbr> Michael Berendt, CEO of Bioniche 
Life Sciences Inc.<wbr> stated</STRONG> </div><div style="margin-bottom: 10px;">"This is the beginning of a new and significant transformative path for BCG 
refractory bladder cancer patients as well as for Bioniche and its shareholders.<wbr> 
We are excited to have the opportunity to file a BLA for MCNA based upon our 
existing regulatory dossier and are determined and committed to making MCNA 
available to high grade non-muscle invasive bladder cancer patients who have 
failed BCG treatment and who are in dire need of treatment options beyond 
cystectomy.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Focus Now On Increasing Awareness of MCNA and Partnering 
Discussions</STRONG> </div><div style="margin-bottom: 10px;">With regulatory clarity in hand, Bioniche is now in a position to advance 
discussions  with potential partners who have demonstrated a commercial 
interest in MCNA for both the  U.<wbr>S.<wbr> and other world-wide markets.<wbr> </div><div style="margin-bottom: 10px;">In parallel and in further support of its MCNA partnering discussions and so 
as to increase MCNA visibility within the broader urology community, Bioniche 
and its collaborators have prepared a clinical manuscript, describing MCNA Phase 
3 results and post-study analyses, that is being submitted to a top-tier urology 
journal.<wbr> </div><div>Source: <A href="http://www.bioniche.com">www.<wbr>bioniche.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9847">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-29T10:47:28+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Soft Intelligence Regarding Sun Pharma's Activities With Octreotide [sub:Hybrids, prod:Octreotide, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7749</link>
<description>Soft Intelligence Regarding Sun Pharma's Activities With Octreotide [sub:Hybrids, prod:Octreotide, news]</description><category>sub:Hybrids</category><category>prod:Octreotide</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7749</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7749">Soft Intelligence Regarding Sun Pharma's Activities With Octreotide</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=sub%3aHybrids"><font color="#e95e0b">:Endocrinology:sub:Hybrids</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7749">Endocrinology7749</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 25 July 2014 | 17:53</font><br><br><div style="margin-bottom: 10px;">Comment: External intelligence has established that no clinical development 
activity has yet been initiated in the US or the EU with SPARC's (Sun Pharma) 1M 
or 3M formulations of octreotide.<wbr> Sun Pharma was hoping to utilise Indian data 
for approval but no such agreement has been reached with either the EMA or FDA 
suggesting an abreviated clinical trial programme will be required.<wbr> The group's 
1M octreotide formulation was launched in India Q12009 and the 3M formulation is 
expected to be approved in India Q42014, having been filed in February this 
year.<wbr> </div><div style="margin-bottom: 10px;">Whilst it is not clear to SPARC what the FDA or EMA will actually 
require, one source speculated a clinical development timeframe of 17-18 
months for the 1M and 25-30 months for the 3M (assuming a combined short phI/<wbr>II 
followed by a phIII).<wbr> An alternative could be that the authorities accept Indian 
phI/<wbr>II data but require a phIII study for registration.<wbr> </div><div style="margin-bottom: 10px;">Based on the last public communicaton by SPARC on this topic in March 
2013, an IND filing for either the 1M or 3M or both could be made in FY2015 
(in or before Q116) </div><div style="margin-bottom: 10px;">One benchmark that could potentially be used as a comparison is the groups's 
paclitaxel injection concentrate for nanodispersion PICN, publically disclosed 
timelines for which are avaiable.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Q2 2011 PICN IND filed - 505(b)2 regualtory route to be used</LI>
<LI>Q4 2013 Successful PICN phII meeting with the FDA announced</LI>
<LI>Q3 2014 PhIII protocol to be submitted to the FDA</LI>
<LI>Q4  2014 PhIII trial to be initiated.<wbr></LI>
<LI>2018 target filing.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">One final point to be confirmed, was that SPARC has not yet succeeded in 
finding a development partner for either the 1M or 3M formulation.<wbr> </div><div>Source: DIG Worldwide </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7749">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-25T17:53:00+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Roche Q2 Figures- Key Takeaway Octreolin Development Is Stopped</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7748</link>
<description>re: Roche Q2 Figures- Key Takeaway Octreolin Development Is Stopped</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7748</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7748">re: Roche Q2 Figures- Key Takeaway Octreolin Development Is Stopped</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7748">Endocrinology7748</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/204">rao36589</a> | 25 July 2014 | 10:49</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Roche Q2 Figures- Key Takeaway Octreolin Development Is Stopped</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Roche has reported a solid performance with sales being driven by growth of the group's new breast cancer drugs (Perjeta and Kaldyca) and by strong sales of diagnostics.<wbr> Octreolin phIII data was highlighted, as was the decision NOT to proceed further with a submission following interaction with the regulatory authorities in the second quarter.<wbr> Meanwhile, Roche's ant-PDL1 immunotherapy will apparently move into phIII development for bladder cancer before the year end, with a phII study having started in Q214 in locally advanced and metastatic patients.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7742">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7742" class="commentpermalink">Endocrinology7742</a> / <span class="date">24 July 2014</span> /
<span class="time">14:09:04 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">An addition to that news: according to one answer(*) from of Alan Hippe (CFO) in the Q&amp;A session, the impairment charge related to the decision not to pursue octreolin development accounts for 64mEUR (CHF78million).<wbr> </div><div style="margin-bottom: 10px;">Facial value of the Roche Chiasma deal was USD595m, incl USD65m upfront.<wbr> </div><div><EM>"(*)Yes.<wbr> The question on -- and we have outlined this in fact on Page 65 in our half year report, and because, well, the question is the impairment charges totaling CHF 166 million [136.<wbr>5mEUR], what was it related to? That was the question.<wbr> Is that just bito and MetMab, and my answer is no.<wbr> One point I can outline here is oral octreotide is part of these charges of the CHF 166 million with the CHF 78 million which I mentioned here.<wbr>"</EM> </div><!-- Comment details --><font size="-1">rao36589 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7748" class="commentpermalink">Endocrinology7748</a> / <span class="date">25 July 2014</span> /
<span class="time">10:49:03 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7748">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7742">View thread  Endocrinology7742: Roche Q2 Figures- Key Takeaway Octreolin Development Is Stopped</a>]]></content:encoded><dc:date>2014-07-25T10:49:03+02:00</dc:date><dc:creator>rao36589</dc:creator></item><item>
<title>Ono and BMS Has Entered An Agreement For Co-Developing And Commercialising BMS' Immuno-Oncology Assests</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9845</link>
<description>Ono and BMS Has Entered An Agreement For Co-Developing And Commercialising BMS' Immuno-Oncology Assests</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9845</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9845">Ono and BMS Has Entered An Agreement For Co-Developing And Commercialising BMS' Immuno-Oncology Assests</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9845">Oncology9845</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 24 July 2014 | 18:02</font><br><br><div style="margin-bottom: 10px;">Comment: Following Ono's announcement for Opdivo (nivolumab)'s approval in Japan <a href="http://ci.beaufour-ipsen.com/traction#/single&proj=Oncology&rec=9821" class="defaultlink">(Oncology9821:The First Anti-PD-1 Has been Approved In Japan)</a>, BMS and Ono Pharm Co,.<wbr>Ltd, have now entered a collaboration agreement to develop and commercialize multiple immunotherapies as single agents and combination regimens as treatment of cancer in Japan, South Korea and Taiwan.<wbr> Under the agreement, Ono Pharma and BMS will develop and commercialize Opdivo (nivolumab) and ipilimumab (outside Japan Yervoy) across a broad range of tumor types in Japan, South Korea and Taiwan.<wbr> </div><div style="margin-bottom: 10px;">The agreement also includes additional early-stage clinical immuno-oncology assets from Bristol-Myers Squibb: </div><div style="margin-bottom: 10px;"><UL><LI>Lirilumab, an antibody that blocks the KIR receptor on natural killer cells
</LI>
<LI>Urelumab, an agonist of the CD137 co-stimulatory receptor
</LI>
<LI>BMS-986016, a LAG3 immune checkpoint inhibitor.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">Development costs and commercial profits  are shared equally when Opdivo is used in combination with any Bristol-Myers Squibb compound (Ipilimumab, lirilumab, urelumab, BMS-986016).<wbr> When Opdivo is used as a single agent, ONO will fund the substantial majority of development costs and receive the substantial majority of commercial profits.<wbr> For a Bristol-Myers Squibb compound used as monotherapy, or two Bristol-Myers Squibb compounds used in a combination regimen, Bristol-Myers Squibb will fund the substantial majority of development costs and receive the substantial majority of commercial profits.<wbr> </div><div style="margin-bottom: 10px;">Ipilimumab, a CTLA-4 immune checkpoint inhibitor, is approved in Taiwan for the treatment of patients with advanced melanoma who have received prior therapy, and is in late stage development as a potential treatment option for melanoma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) in Japan.<wbr> </div><div style="margin-bottom: 10px;">Ono Pharmaceutical Co.<wbr> Ltd.<wbr> is specialized in the production and sale of prescription pharmaceuticals and diagnostic reagents.<wbr> Ono currently has marketed products for the treatment of </div><div style="margin-bottom: 10px;"><UL><LI>type II diabetes;
</LI>
<LI>chemotherapy-induced nausea and vomiting;
</LI>
<LI>osteoporosis
</LI>
<LI>Alzheimer&rsquo;s disease;
</LI>
<LI>OAB
</LI>
<LI>peripheral circulatory disorder;
</LI>
<LI>bronchial asthma and allergic rhinitis;
</LI>
<LI>diabetic peripheral neuropathy;
</LI>
<LI>chronic pancreatitis
</LI>
<LI>postoperative reflux esophagitis;
</LI>
<LI>tachyarrhythmia during and post operation
</LI>
<LI>RA
</LI>
</UL> </div><div style="margin-bottom: 10px;">Opdivo will be Ono's first oncology marketed  product.<wbr> The company operates in Japan, South Korea, the UK and the US.<wbr> Ono Pharmaceutical is headquartered in Chuo ku, Osaka, Japan and currently has co-promoting partnership with : </div><div><UL><LI>Merck &amp;Co
</LI>
<LI>Valeant Pharm North America
</LI>
<LI>BMS
</LI>
<LI>Novartis
</LI>
<LI>Helsinn Healthcare
</LI>
<LI>Palon AG
</LI>
<LI>Progenics Pharm Inc
</LI>
<LI>Kadmon Corp LLC
</LI>
<LI>Onyx Pharm
</LI>
<LI>Les Laboratoires Servier
</LI>
<LI>Amgen
</LI>
<LI>Merck KGaA
</LI>
<LI>Eial
</LI>
<LI>AstraZeneca
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9845">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-24T18:02:03+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Roche Q2 Figures- Key Takeaway Octreolin Development Is Stopped [dis:Acromegaly, prod:Octreotide, headline, :Oncology:dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7742</link>
<description>Roche Q2 Figures- Key Takeaway Octreolin Development Is Stopped [dis:Acromegaly, prod:Octreotide, headline, :Oncology:dis:Bladder]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7742</comments><category>dis:Acromegaly</category><category>prod:Octreotide</category><category>headline</category><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7742</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7742">Roche Q2 Figures- Key Takeaway Octreolin Development Is Stopped</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7742">Endocrinology7742</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 24 July 2014 | 14:09</font><br><br><div style="margin-bottom: 10px;">Comment: Roche has reported a solid performance with sales being driven by growth of the group's new breast cancer drugs (Perjeta and Kaldyca) and by strong sales of diagnostics.<wbr> Octreolin phIII data was highlighted, as was the decision NOT to proceed further with a submission following interaction with the regulatory authorities in the second quarter.<wbr> Meanwhile, Roche's ant-PDL1 immunotherapy will apparently move into phIII development for bladder cancer before the year end, with a phII study having started in Q214 in locally advanced and metastatic patients.<wbr> </div><div style="margin-bottom: 10px;">Daniel O'Day's (COO of Roche Pharmaceuticals) specific comments in relation to octreolin were as follows:- </div><div style="margin-bottom: 10px;">"On Oral Octreotide we had some additional Phase III data plus some regulatory interactions in the second quarter.<wbr> And we've decided to not move that program ahead so additional Phase III data, plus some regulatory interactions in the second quarter, and we decided to not move that program ahead.<wbr> So we&rsquo;ll be removing that program from our Phase III list.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Key Highlights Of Roche's Q2 Financial Performance</STRONG><BR><BR> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Whilst sales growth may be strong and newsflow positive for Avastin in terms of recent priority review designations for ovarian and cervical cancer, newsflow for high-risk carcinoid disease and newly diagnosed glioblastoma has not been so good (see below).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Product Pipeline Developments</STRONG> </div><div style="margin-bottom: 10px;">Key developments with Roche drugs in bladder, pancreatic, prostate and HCC are highlighted below, Commenting on its immunotherapy programme Daniel O'Day  made the following remarks:- </div><div style="margin-bottom: 10px;">It was terrific year at ASCO this year for our cancer immunotherapy program.<wbr> Those of you that you were able to attend the Roche event where, we highlighted the fact that we have now 20 projects in the clinic or pre-clinically for cancer immunotherapy.<wbr> We presented of course on our bladder cancer anti- PDL1 ph1 data, which was one of the highlights of the ASCO meeting this year, that received breakthrough therapy designation.<wbr> We also presented on anti-CSF-1R.<wbr> And we started to expose you to other compounds we have like anti-OX40 anti-CD40  and our immunotherapy combinations which again, if you remember the cancer immunotherapy cycle, you know we remain convinced that it is extremely important to approach cancer immunotherapy with multiple ways of approaching a cancer immunotherapy cycle and with biomarker strategies to determine which patients might be able to best respond.<wbr> And we continue to make good progress there.<wbr><BR><BR>I remind you we have the -- another cancer type, so this would be the fifth cancer type for Roche for cancer immunotherapy and anti-PDL1 that we'll disclose in the second half of this year.<wbr> <BR><BR>Just because I can't get away from this data on the right-hand side here, it was extremely encouraging for bladder cancer patients; remember these are patients that are generally over the age of 65, quite compromised.<wbr> The only available therapy today is chemotherapy and surgery and many of these patients cannot tolerate that.<wbr> And what we saw in our Phase 1 single arm is a 43% response rate at six weeks.<wbr> And when you looked at that data at 12 weeks we had a 52% response rate.<wbr> This is partial response and complete response; of that around 7% were complete responses.<wbr><BR><BR>So as you know with the breakthrough therapy status, with discussions with regulatory authorities, we're now moving very aggressively into our larger Phase 2 that's already enrolling and planning for a Phase 3 trial in bladder cancer.<wbr>  <img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/4/ScreenCapture4.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology7748c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">An addition to that news: according to one answer(*) from of Alan Hippe (CFO) in the Q&amp;A session, the impairment charge related to the decision not to pursue octreolin development accounts for 64mEUR (CHF78million).<wbr> </div><div style="margin-bottom: 10px;">Facial value of the Roche Chiasma deal was USD595m, incl USD65m upfront.<wbr> </div><div><EM>"(*)Yes.<wbr> The question on -- and we have outlined this in fact on Page 65 in our half year report, and because, well, the question is the impairment charges totaling CHF 166 million [136.<wbr>5mEUR], what was it related to? That was the question.<wbr> Is that just bito and MetMab, and my answer is no.<wbr> One point I can outline here is oral octreotide is part of these charges of the CHF 166 million with the CHF 78 million which I mentioned here.<wbr>"</EM> </div><font size="-1">rao36589 / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7748" class="commentpermalink">Endocrinology7748</a> / <span class="date">25 July 2014</span> /
<span class="time">10:49:03 o'clock CEST</span>
</font></div><a name="endocrinology7742attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(105,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(94,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(89,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(117,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(115,9 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(116,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(63,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(111,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(76,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(87,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7742">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-24T14:09:04+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/1/ScreenCapture1.jpg" length="107961" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/2/ScreenCapture2.jpg" length="96643" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/3/ScreenCapture3.jpg" length="91389" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/4/ScreenCapture4.jpg" length="120065" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/5/ScreenCapture5.jpg" length="118720" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/6/ScreenCapture6.jpg" length="119506" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/7/ScreenCapture7.jpg" length="64777" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/8/ScreenCapture8.jpg" length="113956" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/9/ScreenCapture9.jpg" length="78226" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7742/10/ScreenCapture10.jpg" length="89807" type="image/jpeg"/></item><item>
<title>xxxxx</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7663</link>
<description>xxxxx</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7663</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7663">xxxxx</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7663">Neurology7663</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 24 July 2014 | 14:08</font><br><br><div>xxxxx </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7663">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-24T14:08:45+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Xtandi's Got NICE Thumbs Up This Morning [comp:Astellas, prod:MDV3100, dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9838</link>
<description>Xtandi's Got NICE Thumbs Up This Morning [comp:Astellas, prod:MDV3100, dis:Prostate, headline]</description><category>comp:Astellas</category><category>prod:MDV3100</category><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9838</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9838">Xtandi's Got NICE Thumbs Up This Morning</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9838">Oncology9838</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 23 July 2014 | 15:17</font><br><br><div style="margin-bottom: 10px;"><P style="font: 12px/normal Arial; margin: 0px; font-size-adjust: none; font-stretch: normal;"><SPAN style="font-family: arial,helvetica,sans-serif;">Comment: Cost regulators for the NHS in England and Wales issued guidance recommending the use of Xtandi (enzalutamide) for prostate cancer this morning.<wbr> The use of Xtandi has been given a green light to treat patients with prostate cancer in post-docetaxel setting.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;"><P style="font: 12px/normal Arial; margin: 0px; font-size-adjust: none; font-stretch: normal;"><SPAN style="font-family: arial,helvetica,sans-serif;">Xtandi costs &pound;2734.<wbr>67 for one pack of 112 x 40mg capsules, which equates to an average treatment cost of &pound;25,269 (based on 160 mg for a treatment duration for 8.<wbr>5 months).<wbr> Astellas has agreed a patient access scheme but the level of discount remains confidential.<wbr> The Committee accepted that the cost per QALY for Xtandi compared with Johnson &amp; Johnson's Zytiga (abiraterone) is associated with some degree of uncertainty.<wbr> But it was satisfied that it would remain below &pound;30,000 per QALY gained, and so represents value for money for the NHS.<wbr></SPAN></P> </div><div><SPAN style="font-family: arial,helvetica,sans-serif;">Source: <A href="http://www.nice.org.uk/Guidance/TA3">http:/<wbr>/<wbr>www.<wbr>nice.<wbr>org.<wbr>uk/<wbr>Guidance/<wbr>TA3</A></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9838">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-23T15:17:42+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>A Ph3 Trial Is Planned To Assess Efficacy Of Combination Enzalutamide And Radium223 in mCRPC [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9837</link>
<description>A Ph3 Trial Is Planned To Assess Efficacy Of Combination Enzalutamide And Radium223 in mCRPC [dis:Prostate]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9837</comments><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9837</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9837">A Ph3 Trial Is Planned To Assess Efficacy Of Combination Enzalutamide And Radium223 in mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9837">Oncology9837</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 22 July 2014 | 18:41</font><br><br><div style="margin-bottom: 10px;">Comment: This is a EORTC sponsored Ph3 study to evaluate if upfront combination of enzalutamide and radium223 improves radiological progression free survival compared to enzalutamide monotherapy in asymptomatic or mildly symptomatic castration resistant prostate cancer.<wbr> The study has not yet open for recruitment.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov Identifier: <A class="study-link" href="http://clinicaltrials.gov/show/NCT02194842" style="font: 14px/19.6px arial, 'Nimbus Sans L', sans-serif; text-align: left; color: #1a3d85; text-transform: none; text-indent: 0px; letter-spacing: normal; text-decoration: none; word-spacing: 0px; border-bottom-width: 1px; border-bottom-style: dotted; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;" title="Current version of study NCT02194842 on ClinicalTrials.gov">NCT02194842</A> (PEACE III) </div><div style="margin-bottom: 10px;">Expected Enrollment = 560 </div><div style="margin-bottom: 10px;">Target Patient Population: asymptomatic or mildly symptomatic (i.<wbr>e.<wbr> no opioids and brief pain inventory score) with metastases to bone (&ge; 2 bone mets) and progressive castration resistant prostate cancer </div><div style="margin-bottom: 10px;">Study Expected Start Date December 2014 </div><div style="margin-bottom: 10px;">Study Estimated Primary Completion Date Oct 2018 </div><div style="margin-bottom: 10px;">Primary outcome: radiological PFS (time frame = 46 months after first patient entry) </div><div style="margin-bottom: 10px;">Secondary Outcome: Overall Survival, First symptomatic skeletal event, time to next systemic therapy, second PFS in sequential regimen, Time to pain progression, adverse events, time to use of opioid analgesics, quality of life </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9837/3/PEACEIII%20trail%20design.png?user-agent=rss"> </div><div>Source: <A href="http://www.clinicaltrials.gov">www.<wbr>clinicaltrials.<wbr>gov</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9906c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>A similar Ph2 trial (<SPAN style="font-size: small;"><SPAN style="text-align: left; color: #000000; text-transform: none; line-height: 22.39px; text-indent: 0px; letter-spacing: normal; font-family: arial, 'Nimbus Sans L', sans-serif; font-style: normal; font-variant: normal; font-weight: normal; word-spacing: 0px; float: none; display: inline !important; white-space: normal; font-size-adjust: none; font-stretch: normal; background-color: #ffffff; -webkit-text-stroke-width: 0px;">NCT02225704</SPAN>)</SPAN> sponsored by All Ireland Cooperative Oncology Research Group (ICORG) is also ongoing in Ireland - primarily to determine the safety and tolerability of radium-223 in combination with enzalutamide.<wbr> Due to the primary objective is to determine safety and tolerability, the trial design is very different from the Ph3 trial as it is an open label study with single group assignment.<wbr> The total recruitment of 44 patients is expected and the study is expected to complete in Dec 2016.<wbr> The secondary outcome measure also includes time to clinical and PSA progression, time to first skeletal event, overall survival (for up to 2 years).<wbr> </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9906" class="commentpermalink">Oncology9906</a> / <span class="date">27 August 2014</span> /
<span class="time">12:20:18 o'clock CEST</span>
</font></div><a name="oncology9837attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9837/1/PEACEIII%20trail%20design.png">PEACEIII trail design.png</a>&nbsp;&nbsp;(13,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9837/2/PEACEIII%20trail%20design.png">PEACEIII trail design.png</a>&nbsp;&nbsp;(13,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9837/3/PEACEIII%20trail%20design.png">PEACEIII trail design.png</a>&nbsp;&nbsp;(13,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9837">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-22T18:41:32+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9837/1/PEACEIII%20trail%20design.png" length="14204" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9837/2/PEACEIII%20trail%20design.png" length="14204" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9837/3/PEACEIII%20trail%20design.png" length="14204" type="image/x-png"/></item><item>
<title>Allergan Initiates PhIII Crow's Feet Lines Trial In China [sub:Aesthetics, prod:Botox, :PharmaWorld:mkt:China, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7662</link>
<description>Allergan Initiates PhIII Crow's Feet Lines Trial In China [sub:Aesthetics, prod:Botox, :PharmaWorld:mkt:China, headline]</description><category>sub:Aesthetics</category><category>prod:Botox</category><category>mkt:China</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7662</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7662">Allergan Initiates PhIII Crow's Feet Lines Trial In China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7662">Neurology7662</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 July 2014 | 17:38</font><br><br><div style="margin-bottom: 10px;">Comment ClinialTrials.<wbr>gov is listing a new Allergan sponsored phIII aesthetic 
study in China which is due to commence in October 2014.<wbr> This is the first such 
regulatory study Allergan has undertaken in China.<wbr> </div><div style="margin-bottom: 10px;">This study will evaluate the safety and efficacy of BOTOX® compared with 
placebo in patients with moderate to severe crow's feet lines (lateral canthal 
lines) and was listed for the first time late last week.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Endpoints</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="body3">Primary Outcome Measures: 
<UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Investigator's Assessment of Crow's Feet Lines (CFL) Severity 
  at Maximum Smile Using the 4-point Facial Wrinkle Scale (FWS-A) 
  [ Time Frame: Day 30 ] <BR></LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">Secondary Outcome Measures: </DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Investigator's Assessment of CFL Severity at Rest Using the 
  4-point FWS-A [ Time Frame: Day 30 ] 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject's Global Assessment of Change in CFL Using a 7-point 
  Scale [ Time Frame: Day 30 ] 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject's Assessment of CFL Severity at Maximum Smile Using 
  the 4-point FWS-A [ Time Frame: Day 30 ] 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject's Assessment of Age-related Facial Appearance as 
  Measured by the Self-Perception of Age Questionnaire 
  [ Time Frame: Day 30 ] </LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex"><STRONG>Enrollment &amp; Timelines</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">400 
patients will be recruited with expected study completion according to the 
primary endpoint in August 2015.<wbr></P> </div><div><TABLE border="0" cellpadding="0" cellspacing="0" class="layout_table" style="MARGIN-TOP: 1ex" summary="Layout table for additional information"><TBODY><TR valign="top"><TD headers="colTitle">ClinicalTrials.<wbr>gov Identifier:</TD>
<TD headers="colData" style="PADDING-LEFT: 1em"><A class="study-link" href="http://clinicaltrials.gov/show/NCT02195687" title="Current version of study NCT02195687 on ClinicalTrials.gov">NCT02195687</A></TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7662">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-22T17:38:18+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Combination Approach of Two Cancer Vaccines Received FDA Breakthrough Designation</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9836</link>
<description>Combination Approach of Two Cancer Vaccines Received FDA Breakthrough Designation</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9836</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9836">Combination Approach of Two Cancer Vaccines Received FDA Breakthrough Designation</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9836">Oncology9836</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 22 July 2014 | 17:16</font><br><br><div style="margin-bottom: 10px;">Comment: CRS-207 and GVAX combination has received breakthrough therapy designation for treatment of metastatic pancreatic patients.<wbr> Both therapeutic vaccines are developed by Aduro Biotech Inc.<wbr>, a private biotechnology company focusing primarily on development of immunotherapy for cancer.<wbr> </div><div style="margin-bottom: 10px;">The designation was based on findings from a Ph2 randomized, controlled, multicentre study, which enrolled 93 patients who failed or refused prior therapy.<wbr> The findings were presented at the GI ASCO and demonstrated a statistically significant survival benefit in patients receiving GVAX + CRS 207 versus GVAX alone.<wbr> The median overall survival of patients receiving the combination was 6.<wbr>1 months compared to 3.<wbr>9 months (GVAX alone) with a hazard ration of 0.<wbr>59 (one sided p=0.<wbr>0172).<wbr> </div><div style="margin-bottom: 10px;">Aduro is currently conducting a 240 patient Phase 2b clinical trial (ECLIPSE; <a href="http://clinicaltrials.gov/show/NCT02004262" class="defaultlink">NCT02004262</a>) in metastatic pancreatic cancer patients who have progressed after at least one line of therapy.<wbr> The randomized, controlled 3-arm trial will involve over 20 clinical trial sites in the U.<wbr>S.<wbr> and Canada and will evaluate the safety, immune response and efficacy of the combination immunotherapy of GVAX Pancreas and CRS-207 compared to chemotherapy or to CRS-207 alone.<wbr> The primary endpoint of the trial is overall survival.<wbr> </div><div>Source: <A href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.adurobiotech.com&amp;esheet=50908639&amp;newsitemid=20140721005263&amp;lan=en-US&amp;anchor=www.adurobiotech.com&amp;index=3&amp;md5=b85e013f632f536a22d0bf6652d473aa" rel="nofollow"><U><FONT color="#0066cc">www.<wbr>adurobiotech.<wbr>com</FONT></U></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9836">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-22T17:16:03+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Glide Pharma Completes Pre-Clinical POC With Novel Solid Dose Formulation Of Octreotide [headline, dis:Acromegaly, dis:pNET, :PharmaWorld:sub:DrugDelivery]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7738</link>
<description>Glide Pharma Completes Pre-Clinical POC With Novel Solid Dose Formulation Of Octreotide [headline, dis:Acromegaly, dis:pNET, :PharmaWorld:sub:DrugDelivery]</description><category>headline</category><category>dis:Acromegaly</category><category>dis:pNET</category><category>sub:DrugDelivery</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7738</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7738">Glide Pharma Completes Pre-Clinical POC With Novel Solid Dose Formulation Of Octreotide</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7738">Endocrinology7738</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 July 2014 | 16:02</font><br><br><div style="margin-bottom: 10px;">Comment: Glide Pharma, a pharmaceutical development and device company focused on solid dose formulations of therapeutics and vaccines, has announced that its solid formulation of octreotide acetate achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Sandostatin&reg;).<wbr> A clinical POC is planned to complete in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Route To The Clinic</STRONG> </div><div style="margin-bottom: 10px;">Based on these results, the company intends to transfer the formulation production process to a contract manufacturing organisation (CMO), and to advance Glide octreotide delivered with the needle-free Glide solid dose injector (SDI&reg;) into clinical trials in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pre-Clinical Findings</STRONG> </div><div style="margin-bottom: 10px;">The pre-clinical study compared the pharmacokinetic profile of the most widely used clinical dose of Sandostatin (100 mcg) with that of Glide&rsquo;s octreotide solid dose formulation.<wbr> The results demonstrated that there was no statistical difference between the two profiles (p&lt;0.<wbr>05).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Dr Mark Carnegie-Brown, Glide Pharma&rsquo;s CEO, commented</STRONG>, &ldquo;These results represent a significant milestone, both in the development of our final clinical formulation for Glide octreotide and of our scale-up capabilities.<wbr> Together, these enable us to transfer the formulation manufacturing process to a CMO later in the year.<wbr> This progress is mirrored in our device scale-up programme, and as a result we plan to complete an octreotide clinical proof-of-concept study with our Glide SDI&reg; device in 2015.<wbr>&rdquo; </div><div style="margin-bottom: 10px;"><STRONG>What Is The Profile Of The New Formulation &amp; How Is It Administered</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Glide Pharma's SSDI&reg; </STRONG>is an innovative, patented drug delivery system for the injection of drugs and vaccines in solid doses.<wbr> </div><div style="margin-bottom: 10px;">The Glide SDI&reg; comprises two main components: </div><div style="margin-bottom: 10px;"><UL><LI>The reusable Glide actuator powered by a mechanical spring
</LI>
<LI>The disposable cassette pre-loaded with the drug formulation
</LI>
</UL> </div><div style="margin-bottom: 10px;">All components, apart from the reusable actuator are sterile.<wbr> </div><div style="margin-bottom: 10px;">The core of Glide technology is a tiny, solid dose of active pharmaceutical.<wbr> This is supplied contained in a disposable, plastic cassette in sterile packaging.<wbr> Just prior to use, the cassette is inserted into the mechanical reuseable actuator.<wbr> The spring powered actuator is primed by being pushed against the skin.<wbr> It then automatically triggers at a preset spring force and delivers the implant through the skin into the body.<wbr> </div><div style="margin-bottom: 10px;">The dosing process is completed in a fraction of a second.<wbr> The solid dose is 4 mm in length and pointed at one end.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7738/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7738/3/ScreenCapture4.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Glide's Development Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7738/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Glide recently made two new appointments, that of Richard Bungay as Chief Financial Officer and Tony Mills as Director of Business Development.<wbr> Both Mr Bungay and Dr Mills have extensive experience of the life sciences industry.<wbr> </div><div style="margin-bottom: 10px;">Richard Bungay has over 20 years&rsquo; corporate experience of the biotechnology and pharmaceutical sectors.<wbr> His recent roles include CFO at Verona Pharma Plc and CEO of Chroma Therapeutics, prior to which he was Chroma&rsquo;s CFO.<wbr> Previously, he was Director of Corporate Communications and Strategic Planning at Celltech, following a period as Finance Director for AstraZeneca&rsquo;s Respiratory and Inflammation Therapy Area.<wbr> He also held a number of finance positions at Celltech, including Financial Controller.<wbr> He qualified as a Chartered Accountant at Deloitte.<wbr> </div><div style="margin-bottom: 10px;">Tony Mills brings over 25 years&rsquo; commercial experience of the life sciences industry to Glide.<wbr> He joins the company from the drug delivery company Q Chip Ltd where he was Chief Commercial Officer.<wbr> He was also Vice President, Business Development at BioVex Ltd, and held several roles at BTG International including Vice President, Genomics and Proteomics.<wbr> He holds a PhD in Virology from Liverpool University.<wbr> </div><div style="margin-bottom: 10px;">Glide Pharma is privately owned.<wbr> Investors include Invesco Perpetual, Oxford Technology 3 VCT plc, Oxford Technology 4 VCT plc, Hygea VCT plc, Oxford Capital Partners, business angels and management </div><div>Source: <A href="http://www.glidepharma.com">www.<wbr>glidepharma.<wbr>com</A> </div><!-- Comment details --><a name="endocrinology7738attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7738/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(41,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7738/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(15 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7738/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(24,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7738">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-22T16:02:21+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7738/1/ScreenCapture1.jpg" length="42131" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7738/2/ScreenCapture3.jpg" length="15400" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7738/3/ScreenCapture4.jpg" length="25226" type="image/jpeg"/></item><item>
<title>Valeant Complains To The Regulators About Allergan's Misleading Statements [comp:Allergan, prod:Botox, :PharmaWorld:sub:Acquisition, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7660</link>
<description>Valeant Complains To The Regulators About Allergan's Misleading Statements [comp:Allergan, prod:Botox, :PharmaWorld:sub:Acquisition, :PharmaWorld:sub:Finance]</description><category>comp:Allergan</category><category>prod:Botox</category><category>sub:Acquisition</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7660</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7660">Valeant Complains To The Regulators About Allergan's Misleading Statements</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7660">Neurology7660</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 July 2014 | 19:05</font><br><br><div style="margin-bottom: 10px;">Comment: Valeant has complained to the financial regulator in Quebec and the US SEC about false and misleading statements Allergan has made about its business.<wbr> It issued a slide presentation on Friday highlighting some of the inaccuracies and outlining the growth it has achieved with Bausch &amp; Lomb since the business was acquired, something Allergan has and continues to dispute.<wbr> It is interesting to note the level of cost synergies Valeant has planned versus the cost savings announced by Allergan today ($2.<wbr>7bn by an unspecified timeline vs.<wbr> $475m in 2015).<wbr> </div><div style="margin-bottom: 10px;">A selection of the key slides is highlighted below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Allergan's response to new Bausch &amp; Lomb Growth Figures</STRONG> </div><div style="margin-bottom: 10px;">David Pyott stated today "On July 18, Valeant pre-announced sales figures for Bausch &amp; Lomb for Q2.<wbr> We were impressed by some of the eye-popping growth numbers, which are outside any range of normal growth of these global ophthalmic market segments.<wbr> We would encourage investors to ask Valeant [ph] about in-market growth relative to inventory changes as well as any rebating or promotional programs.<wbr> Finally, we also look forward to Bausch &amp; Lomb growth figures for Q3 so the trends can be monitored.<wbr>" </div><div>Source: <a href="http://www.valeant.com" class="defaultlink" title="http://www.valeant.com">valeant.com</a> </div><!-- Comment details --><a name="neurology7660attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(228,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(90,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(160,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(88,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(168,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(99,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(198,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(155,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(172,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(182,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(165,1 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(195,4 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(153,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(202,1 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(133 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7660">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-21T19:05:57+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/1/ScreenCapture1.jpg" length="234418" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/2/ScreenCapture2.jpg" length="92509" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/3/ScreenCapture3.jpg" length="164266" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/4/ScreenCapture4.jpg" length="90707" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/5/ScreenCapture5.jpg" length="172204" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/6/ScreenCapture6.jpg" length="102044" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/7/ScreenCapture7.jpg" length="203327" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/8/ScreenCapture8.jpg" length="159124" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/9/ScreenCapture9.jpg" length="176403" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/10/ScreenCapture10.jpg" length="187110" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/11/ScreenCapture11.jpg" length="169106" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/12/ScreenCapture12.jpg" length="200130" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/13/ScreenCapture13.jpg" length="157288" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/14/ScreenCapture14.jpg" length="206956" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7660/15/ScreenCapture15.jpg" length="136174" type="image/jpeg"/></item><item>
<title>Allergan Cuts Costs - Challenging What More Valeant Could Achieve [headline, prod:Botox, :PharmaWorld:sub:Acquisition, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7659</link>
<description>Allergan Cuts Costs - Challenging What More Valeant Could Achieve [headline, prod:Botox, :PharmaWorld:sub:Acquisition, :PharmaWorld:sub:Finance]</description><category>headline</category><category>prod:Botox</category><category>sub:Acquisition</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7659</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7659">Allergan Cuts Costs - Challenging What More Valeant Could Achieve</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7659">Neurology7659</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 July 2014 | 18:52</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside its Q2 earnings figures, Allergan has announced that 
it will cut its global workforce by 13% (1500 jobs) as a part of a 
restructuring programme intended to boost profilt growth over the next six years 
and achieve what maybe Valeant was planning to do but on its own.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Restructuring Programme</STRONG> </div><div style="margin-bottom: 10px;">The scope of the cost-cutting programme is more than analysts had been 
anticipating (range 5-10%).<wbr> It will create savings of $475m in 2015 and 
enhance earnings per share by around $10 per share.<wbr> Some of the detail of what 
is planned is highlighted in the slides below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/3/ScreenCapture4.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/4/ScreenCapture5.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/5/ScreenCapture6.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/6/ScreenCapture7.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/7/ScreenCapture8.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/8/ScreenCapture9.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/9/ScreenCapture10.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Key Takeaways From Q2 Figures</STRONG> </div><div style="margin-bottom: 10px;">Allergan has posted the strongest increase in absolute dollar sales in 
any quarter in its history with strong contributions from nearly all 
of its businesses and major products.<wbr> </div><div style="margin-bottom: 10px;">Overall sales increased 15.<wbr>9% in dollars and by 16.<wbr>3% in local currencies 
reflecting strong underlying demand and the impact of many regulatory approvals 
all over the world.<wbr> </div><div style="margin-bottom: 10px;"><P class="pwrapper">The upswing in earnings was even more notable than the 
growth in sales with non-GAAP EPS $1.<wbr>51, +23.<wbr>8% versus Q2 of 
2013.<wbr> EPS.<wbr> The revised outlook for EPS for full year 2014 is now in the range of 
20% to 22% growth versus 2013.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Individual Business Performances</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Ophthalmic Pharmaceuticals.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Q2 sales year-over-year grew strongly at 14.<wbr>8% in local 
currencies and 14.<wbr>5% in dollars.<wbr> Year-to-date growth has been diversified with 
every operating region growing double digits, namely North America, Europe, 
Africa and Middle East, Latin America, and Asia-Pacific.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Botox Performance</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Q2 sales increased year over year by 13.<wbr>7% in local 
currencies, with double digit performance in both the therapeutic and aesthetic 
categories by 12.<wbr>9% in dollars.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">In the U.<wbr>S.<wbr>, a strong upswing in sales for chronic migraine 
and the two approved bladder conditions were observed as we have continued to 
enhance our patient access programs, physician training, and practice efficiency 
support.<wbr> In addition with the benefit of the upper limb spasticity indication, 
and what it claimes is weakened competition, sales are growing double digit 
in the neuro rehabilitation channel.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Regarding overactive bladder mangement 
are excited by a new print campaign entitled "Calm Your Bladder" and 
which will be initiated on TV in August.<wbr> The American Urology 
Association and the society for Euro dynamics and female urology updated their 
guidelines in May that established BOTOX as the only standard, third-line 
treatment after firstly, behavioral therapy and secondly pharmacological 
treatment typically anticholinergics drugs.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Recent regulatory approvals for BOTOX, </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Allergan now has lower limb spasticity approval in 10 of 
the 14 countries through the mutual recognition procedure in Europe and 
with this approval in all of the major western European markets it claims to be 
growing BOTOX therapeutic in Western markets at over 10%.<wbr>  </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Additionally, overactive bladder was approved in France, 
Taiwan, and Ecuador and neurogenic bladder in Malaysia.<wbr> </P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Aesthetic Performance</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Allergan estimate, based on survey data, that the U.<wbr>S.<wbr> 
market year to date grew high single digits in the quarter with its sales 
growth being further boosted by our 3% price increase posted in January.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">BOTOX market share remained high in June with over 77% 
Xeomin's re-entry has resulted in it now having a 7% share whil 
Dysport it claims has lost one point to 16% In Europe, it 
suggests it is successfully holding share in a growing market as it deals 
with price competition from Galderma and Merck's.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">To quote Allergan the "blowout in the quarter with 
46% growth in local currencies and in dollars was its filler 
range propelled by the launch of VOLUMA in the U.<wbr>S.<wbr> but also by the 
introduction of VOLBELLA and VOLIFT in many foreign markets.<wbr> Every operating 
region recorded huge growth.<wbr></P> </div><div><P class="pwrapper">Source: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A></P> </div><!-- Comment details --><a name="neurology7659attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(99 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(191,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(101,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/4/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(156,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/5/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(185,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/6/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(101 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/7/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(130,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/8/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(157,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/9/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(125,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7659">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-21T18:52:27+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/1/ScreenCapture1.jpg" length="101343" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/2/ScreenCapture3.jpg" length="196074" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/3/ScreenCapture4.jpg" length="103607" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/4/ScreenCapture5.jpg" length="159929" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/5/ScreenCapture6.jpg" length="190292" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/6/ScreenCapture7.jpg" length="103444" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/7/ScreenCapture8.jpg" length="133531" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/8/ScreenCapture9.jpg" length="160876" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7659/9/ScreenCapture10.jpg" length="128266" type="image/jpeg"/></item><item>
<title>AbbVie Successfully Acquires Shire [sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10921</link>
<description>AbbVie Successfully Acquires Shire [sub:Acquisition]</description><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10921</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10921">AbbVie Successfully Acquires Shire</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10921">PharmaWorld10921</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 July 2014 | 16:15</font><br><br><div style="margin-bottom: 10px;">Comment: AbbVie succeeded today in buying Dublin-based Shire for &pound;32 billion in a deal that will allow it to slash its tax bill by relocating to Britain.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">London listed Shire which makes medicines to treat rare diseases, fought off four earlier bids from AbbVie until the U.<wbr>S.<wbr> firm raised its price to 52.<wbr>48 pounds per share - made up of 24.<wbr>44 pounds in cash and 0.<wbr>8960 new AbbVie shares.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rational For AbbVie</STRONG> </div><div style="margin-bottom: 10px;">Chicago-based AbbVie is buying Shire to cut both its U.<wbr>S.<wbr> tax bill and its reliance on arthritis drug Humira, the world's top selling medicine which loses U.<wbr>S.<wbr> patent protection in 2016.<wbr> </div><div style="margin-bottom: 10px;">AbbVie, which generates nearly 60 percent of its revenue from Humira, had until today to announce a firm offer for Shire, extend the deadline or walk away under UK takeover rules.<wbr> It now plans to create a combined company incorporated in Jersey, the Channel Islands, which will pay an effective tax of about 13 percent, sharply lower than its current rate of about 22 percent, making the deal one of the biggest driven by the tactic known as tax inversion.<wbr> </div><div style="margin-bottom: 10px;">AbbVie's agreed price represents a premium of about 53 percent to Shire's share price on May 2, the last business day before AbbVie's first offer, which was rebuffed by Shire.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10921">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-18T16:15:02+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Alkermes Sets Sight On Biogen Idec's Tecfidera [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7658</link>
<description>Alkermes Sets Sight On Biogen Idec's Tecfidera [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7658</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7658">Alkermes Sets Sight On Biogen Idec's Tecfidera</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7658">Neurology7658</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 July 2014 | 16:08</font><br><br><div style="margin-bottom: 10px;">Comment Alkermes has announced that it is moving a  new drug candidate 
into phI development for multiple sclerosis.<wbr> The drug ALKS 8700 is 
novel and designed to convert into monomethyl fumarate (MMF).<wbr> Biogen-Idec 
currently markets a twice daily formulation of MMF (Tecfidera) which 
is reaching blockbuster status as a therapy for MS.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Design</STRONG> </div><div style="margin-bottom: 10px;">Alkermes is initiating a 125 patient randomised phI trial to determine safety 
and tolerability of multiple formulations and doses of the new oral drug </div><div style="margin-bottom: 10px;"><STRONG>Differentiating Properties</STRONG> </div><div style="margin-bottom: 10px;">The company believes it has a shot at developing a successor that will allow 
for once-a-day dosing with fewer side effects.<wbr> </div><div style="margin-bottom: 10px;">We expect the results of this study to be highly informative and determine 
the therapeutic utility and differentiating features of ALKS 8700," Chief 
Medical Officer Elliot Ehrich said in a statement.<wbr> "ALKS 8700 leverages 
Alkermes' expertise in prodrug chemistry and oral controlled-release 
formulations to offer potential differentiated tolerability and dosing for 
patients with MS.<wbr>" </div><div>Source: <a href="http://www.alkermes.com" class="defaultlink" title="www.alkermes.com">alkermes.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7658">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-18T16:08:49+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>NET Patient Foundation Calls For Support From UK Parliamentarians [dis:MidGutNET, dis:pNET, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7737</link>
<description>NET Patient Foundation Calls For Support From UK Parliamentarians [dis:MidGutNET, dis:pNET, news]</description><category>dis:MidGutNET</category><category>dis:pNET</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7737</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7737">NET Patient Foundation Calls For Support From UK Parliamentarians</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7737">Endocrinology7737</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 July 2014 | 12:59</font><br><br><div style="margin-bottom: 10px;">Comment: The UK NET Patient Foundation is oranganising an event on the 4th 
November at the House of Commons aiming to increase awareness amongst 
parliamentairainas about NET and the challenges involved in timely 
diagnosis.<wbr> </div><div style="margin-bottom: 10px;">It also hopes to communicate the importance of NET centres of excellence and 
to bring NETs to the forefront of the cancer agenda.<wbr> </div><div style="margin-bottom: 10px;">The event will be hoseted the the MP Eric Ollerenshaw.<wbr> </div><div style="margin-bottom: 10px;">An invitation is extended to NET specialists , GPs and patients to attend 
from every region in the UK.<wbr> </div><div>Attedance can be arranged by contacting Alex on 02035421118 or at <A href="mailto:netparliamentevent@theopen-road.com">netparliamentevent@theopen-road.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7737">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-18T12:59:39+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Speculation Of Roche Buying Exelixis To Complete Its Melanoma Portfolio</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9833</link>
<description>Speculation Of Roche Buying Exelixis To Complete Its Melanoma Portfolio</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9833</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9833">Speculation Of Roche Buying Exelixis To Complete Its Melanoma Portfolio</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9833">Oncology9833</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 17 July 2014 | 18:19</font><br><br><div style="margin-bottom: 10px;">Comment: There have been some forms of <STRONG>speculative</STRONG> discussion amongst healthcare investors over the possibility of Roche buying Exelixis in order to capture the full economics of cobimetinib.<wbr> Exelixis and Roche announced the positive results for the combination trial of cobimetinib with Roche's Zelboraf (vemurafenib) in metastatic melanoma patients with BRAF mutation.<wbr> Investor estimates a potential price point of $1b bid depending on the timing.<wbr> If this becomes reality, cabozantinib could represent a higher competitive threat entry in CRPC provided if positive results are announced from Exelixis' two Ph III studies of cabozantinib.<wbr> </div><div style="margin-bottom: 10px;">Currently Exelixis has a worldwide co-development agreement with Genentech for cobimetinib, under which Exelixis received initial upfront and milestone payments for signing the agreement and submitting the IND.<wbr> Exelixis was responsible for development of cobimetinib through the end of phase 1, at which point Genentech exercised its option to further develop the compound.<wbr> Under the agreement, Exelixis is entitled to an initial equal share of U.<wbr>S.<wbr> profits and losses, which will decrease as sales increase, and will share equally in the U.<wbr>S.<wbr> marketing and commercialization costs.<wbr> Exelixis is eligible to receive royalties on any sales of the product outside the United States.<wbr> </div><div style="margin-bottom: 10px;">Cobimetinib is a potent and highly selective MEK inhibitor that has demonstrated a statistically significant improvement in PFS with Roche's Zelboraf (vemurafenib) for metastatic melanoma patients harbouring BRAF mutation.<wbr> Roche's Zelboraf is approved and becoming established in melanoma.<wbr> Analysts believe that Zelboraf will become standard of care for metastatic melanoma patients harbouring BRAF mutation.<wbr> On its own, Zelboraf is already a $400m drug worldwide and analyst forecast cobimetinib and Zelboraf combination represent a $600m - $1 billion revenue opportunity for Roche in the US alone.<wbr> Under current agreement, Exelixis is eligible for 50% profit share in the U.<wbr>S.<wbr> and a low-teens royalty overseas.<wbr> This is a lot for Roche to be giving away to Exelixis.<wbr> Although historically Roche has not acquired its cancer drug development partners, the large revenue opportunity may trigger an 'exception' decision.<wbr> </div><div style="margin-bottom: 10px;">Cometriq (cabozantinib) is currently Exelixis' only marketed product.<wbr> It has been approved for medullary thyroid cancer.<wbr> The most advanced clinical development programmes for cabozantinib are the two Ph3 (COMET-1 and COMET-2) trials in mCRPC patients who had been previously treated with abiraterone, enzalutamide or docetaxel.<wbr> Results are expected to be announced end of this year although the confidence amongst the analysts are not very high.<wbr> Despite of this, some investors believe cabozantinib could have a better shot in two other ongoing Ph3 studies in mRCC and HCC.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9833/1/cabo%20clinical%20trial.JPG?user-agent=rss"> </div><!-- Comment details --><a name="oncology9833attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9833/1/cabo%20clinical%20trial.JPG">cabo clinical trial.JPG</a>&nbsp;&nbsp;(103 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9833">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-17T18:19:38+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9833/1/cabo%20clinical%20trial.JPG" length="105445" type="image/jpeg"/></item><item>
<title>Merz To Relocate Its US HQ To Raleigh North Carolina [comp:Merz, class:BotulinumToxins, prod:Xeomin, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7657</link>
<description>Merz To Relocate Its US HQ To Raleigh North Carolina [comp:Merz, class:BotulinumToxins, prod:Xeomin, sub:Aesthetics]</description><category>comp:Merz</category><category>class:BotulinumToxins</category><category>prod:Xeomin</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7657</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7657">Merz To Relocate Its US HQ To Raleigh North Carolina</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7657">Neurology7657</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 July 2014 | 17:17</font><br><br><div style="margin-bottom: 10px;">Comment:  Merz believes the move to Raleigh from Greensboro will 
accelerate "its vision of becoming the world's most admired, trusted and 
innovative aesthetics and neurotoxin company", according to Merz's North 
American President and CEO Bill Humphries.<wbr> </div><div style="margin-bottom: 10px;">The decision to centralize around Raleigh has taken more than a year to 
conclude with various metropolitan areas considered.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Why Raleigh?</STRONG> </div><div style="margin-bottom: 10px;">Home to three Tier-One research universities, two of which have dermatology 
and neurology teaching programs, Raleigh is the heart of the country's life 
sciences industry, with more than 42,800 biotech employees and the highest 
concentration of doctorate degrees in the U.<wbr>S.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the development Michael McMyne Head of North American 
Operations stated:- </div><div style="margin-bottom: 10px;"><BR>"Our investment in Raleigh is a testament to the area's talented 
workforce, business-friendly environment and high quality of life.<wbr> We look 
forward to partnering with the state, Wake County Economic Development, Raleigh 
Economic Development and the Greater Raleigh Chamber of Commerce to invest in 
workforce development and job creation, further strengthening the Raleigh 
business community.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Timeline For The Relocation &amp; Staff 
Projections<BR></STRONG><BR>The relocation will take place in a phased approach 
over the coming year.<wbr> Merz has executed a lease at 6501 Six Forks Road for 
60,000 square feet, which will be custom-built to meet the company's needs today 
and for future growth.<wbr> The new headquarters is expected to house 250 employees, 
including 50 net new jobs to the state of North Carolina.<wbr> </div><div>Source: <A href="http://www.merzus.com">www.<wbr>merzus.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7657">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-17T17:17:33+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Novartis Q2 Figures - Key Takeaways [dis:Acromegaly, comp:Novartis, dis:Cushing, dis:MidGutNET, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7735</link>
<description>Novartis Q2 Figures - Key Takeaways [dis:Acromegaly, comp:Novartis, dis:Cushing, dis:MidGutNET, headline]</description><category>dis:Acromegaly</category><category>comp:Novartis</category><category>dis:Cushing</category><category>dis:MidGutNET</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7735</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7735">Novartis Q2 Figures - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7735">Endocrinology7735</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 July 2014 | 17:04</font><br><br><div style="margin-bottom: 10px;">Comment: Q2 sales &amp; operating figures came in below consensus due to a weak performance from the outgoing vaccines and animal health.<wbr> However, full year guidance was confirmed, with cost savings and business transformation expected to boost margins.<wbr> Comments about Sandostatin and Signifor were not particularly noteworthy although phIII results for Signifor in acromegaly were briefly highlighted and the company confirmed its expectation of both FDA &amp; CHMP action for acromegaly in the 2H2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Business Structure</STRONG> </div><div style="margin-bottom: 10px;">With the exit from vaccines and animal health plus the acquisition of GSK's oncology products, Novartis will concentrate on three "powerhouse divisions" of pharmaceuticals, eyecare and generics with a single shared back-office organisation providing support.<wbr> </div><div style="margin-bottom: 10px;">Sales are expected to grow in the low-to-mid single digit percentage range this year as the company braces itself for generic competition to Diovan to lop $2.<wbr>7bn off its top line, as Ranbaxy was granted approval for the first US generic at the end of June (see.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pharmaceuticals Performance</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Sandostatin's Performance</STRONG> </div><div style="margin-bottom: 10px;">Sandostatin sales in the second quarter grew by 3% to $417m.<wbr> US sales grew by 5% to $185m whilst sales in the ROW grew by 2% to $252m.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">In January 2014, the ICA opened an investigation to assess whether Novartis Farma S.<wbr>p.<wbr>A.<wbr> and Italfarmaco S.<wbr>p.<wbr>A.<wbr> colluded on the supply of octreotide acetate (<EM><FONT face="Arial-ItalicMT" size="2"><FONT face="Arial-ItalicMT" size="2">Sandostatin LAR </FONT></FONT></EM><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2">and Longastatina</FONT></FONT><FONT face="ArialMT" size="1"><FONT face="ArialMT" size="1">&reg;</FONT></FONT><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2">LAR, respectively) to prevent competition in tenders issued by the regions of Emilia Romagna, Veneto and Lombardia.<wbr></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left">Oncology sales amounted to USD 3.<wbr>0 billion (+4% cc).<wbr> Excluding <EM><FONT face="Arial" size="2"><FONT face="Arial" size="2">Zometa </FONT></FONT></EM><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2">(USD 76 million, -52% cc), Oncology sales were up 8% (cc).<wbr> By brand, growth was driven mainly by </FONT></FONT><EM><FONT face="Arial" size="2"><FONT face="Arial" size="2">Afinitor </FONT></FONT></EM><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2">(USD 384 million, +25% cc), </FONT></FONT><EM><FONT face="Arial" size="2"><FONT face="Arial" size="2">Tasigna </FONT></FONT></EM><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2">(USD 373 million, +18% cc) and </FONT></FONT><EM><FONT face="Arial" size="2"><FONT face="Arial" size="2">Jakavi </FONT></FONT></EM><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2">(USD 69 million, +100% cc).<wbr></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/7/ScreenCapture7.jpg?user-agent=rss"> </div><div>Source: <a href="http://www.novartis.com" class="defaultlink" title="http://www.novartis.com">novartis.com</a> </div><!-- Comment details --><a name="endocrinology7735attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(56,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(48,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(83,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(101,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(94 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(95,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(142,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(87,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7735">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-17T17:04:44+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/1/ScreenCapture1.jpg" length="57552" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/2/ScreenCapture2.jpg" length="49979" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/3/ScreenCapture3.jpg" length="85781" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/4/ScreenCapture4.jpg" length="103603" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/5/ScreenCapture5.jpg" length="96257" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/6/ScreenCapture6.jpg" length="97464" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/7/ScreenCapture7.jpg" length="146056" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7735/8/ScreenCapture8.jpg" length="89318" type="image/jpeg"/></item><item>
<title>Billionaire Investor Paulson Strongly Supports Valeant As An Acquiror of Allergan [comp:Allergan, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7656</link>
<description>Billionaire Investor Paulson Strongly Supports Valeant As An Acquiror of Allergan [comp:Allergan, :PharmaWorld:sub:Acquisition]</description><category>comp:Allergan</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7656</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7656">Billionaire Investor Paulson Strongly Supports Valeant As An Acquiror of Allergan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7656">Neurology7656</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 July 2014 | 12:54</font><br><br><div style="margin-bottom: 10px;">Comment: John Paulson on Wednesday endorsed Valeant as a "very serious 
acquiror" and predicted that Allergan will not be able to rebuff Valeant without 
making an acquisition of its own.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Paulson's Significant Holding In Allergan</STRONG> </div><div style="margin-bottom: 10px;">Paulson's hedge fund holds a roughly $1bn stake or 6 million shares in 
Allergan and announced on Wednesday his support for the Valeant bid at the CNBC 
Institutional Investor Delivering Alpha Conference.<wbr> </div><div style="margin-bottom: 10px;">Paulson called Mike Pearson, Valeant's CEO a very cost concious executive who 
has added significant value for shareholders in the last few years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ackman's Reaction To Recent Events</STRONG> </div><div style="margin-bottom: 10px;">Institutional investor Ackman who is mounting a proxy battle to try and force 
Allergan's board to discuss the Valeant bid on Wednesday accused Allergan of 
violating its fiduciary duty for not entering negotations.<wbr> </div><div style="margin-bottom: 10px;">Ackman is apparently hosting a call with investors today which will 
focus on Allergan's corporate goveranance and other aspects of its business </div><div style="margin-bottom: 10px;">Paulson earned his respect as a serious investor when he made a 
good call on the overheated housing market right in 2007.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7656">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-17T12:54:54+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Pfizer To Acquire Private US Sterile Injectable Company [sub:DrugDelivery, sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10920</link>
<description>Pfizer To Acquire Private US Sterile Injectable Company [sub:DrugDelivery, sub:Acquisition]</description><category>sub:DrugDelivery</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10920</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10920">Pfizer To Acquire Private US Sterile Injectable Company</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10920">PharmaWorld10920</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 July 2014 | 19:25</font><br><br><div style="margin-bottom: 10px;">Comment: Pfizer has announced today it will acquire Innopharm for $225m 
with up to $135m of contingent milestone payments.<wbr> The company is a specialist 
in developing complex injectable delivery forms including pens and depot 
injectables.<wbr> The acquisition is intended to strengthen the presence of Pfizer 
Injectables, part of its Global Established Pharma Business.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pfizer's Current Presence In The Sterile Injectable 
Market</STRONG> </div><div style="margin-bottom: 10px;">Pfizer's current active sterile injectable portfolio consists of 44 
products with over 190 presentations in the U.<wbr>S.<wbr> The new Pfizer portfolio of 
seventy three products will include currently marketed, as well as products 
filed with the FDA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Innopharm's Expertise</STRONG> </div><div style="margin-bottom: 10px;">Innopharm develops novel formulations of existing drugs, including 
hard-to-make products, such as those that require complex manufacturing 
capabilities or have bio-equivalency challenges, in areas such as cancer and 
central nervous disorders.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the agreement John Young group president, Pfizer Global 
Established Pharma (GEP) stated; "Today’s announcement is an important milestone 
as we continue to look for innovative growth opportunities for our sterile 
injectables portfolio, which will increase to seventy three products with this 
acquisition,” </div><div>Source: <A href="http://www.innopharmainc.com">www.<wbr>innopharmainc.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10920">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-16T19:25:14+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Sun Pharma Acquires Nucleur Medicine Specialist [sub:Diagnostic]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9832</link>
<description>Sun Pharma Acquires Nucleur Medicine Specialist [sub:Diagnostic]</description><category>sub:Diagnostic</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9832</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9832">Sun Pharma Acquires Nucleur Medicine Specialist</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=sub%3aDiagnostic"><font color="#e95e0b">:Oncology:sub:Diagnostic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9832">Oncology9832</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 July 2014 | 16:53</font><br><br><div style="margin-bottom: 10px;">Comment: Sun Pharma has acquired Pharmalucence Inc  pharmaceutical 
company.<wbr> The company develops, manufactures and supplies human injectable 
pharmaceuticals.<wbr> In particular it is a speciliast in the production of 
injectable nuclear medicines with its oncology product 
portfolio including sestamibi injection, mebrofenin, pyrophosphate 
injection, preparation of technetium tc99m disofenin, and sulfur colloid 
injection.<wbr> Deal terms have not been disclosed.<wbr> </div><div style="margin-bottom: 10px;">Pharmalucence is headquartered in Billerica, Massachusetts and employes 100 
people.<wbr> </div><div style="margin-bottom: 10px;">As of this year it has a new 70,000sq.<wbr>ft sterile fill and 
finish injectable facility making it the region's first CMO to utilize 
fully automated and isolated aseptic technology capable of producing small 
clinical fills up to full commercial scale production for markets 
worldwide.<wbr> In April 2014 it submitted its DMF with the plan that the plant 
will become operational by early Q4 2014.<wbr> The first product to be produced in 
the pl;ant will be the group's sulfur colloid injection.<wbr> </div><div style="margin-bottom: 10px;">The strategic importance of this acquisition to Sun Pharma at this point is 
not completely clear, albeit this oncology diagnostic business may well 
complement Sun Pharma's US oncology operations.<wbr> </div><div>source: <A href="http://www.sunpharma.com">www.<wbr>sunpharma.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9832">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-16T16:53:16+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>J&amp;J Q2 Earnings Presentation Key Take Away [comp:JnJ, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9830</link>
<description>J&amp;J Q2 Earnings Presentation Key Take Away [comp:JnJ, headline]</description><category>comp:JnJ</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9830</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9830">J&J Q2 Earnings Presentation Key Take Away</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9830">Oncology9830</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 15 July 2014 | 18:37</font><br><br><div style="margin-bottom: 10px;">Comment: During J&amp;J Q2 Earnings Webcast today, J&amp;J announced sales of $19.<wbr>5 billion for the second quarter of 2014, an increase of 9.<wbr>1% as compared to the second quarter of 2013.<wbr> Operational results increased 9.<wbr>4% and the negative impact of currency was 0.<wbr>3%.<wbr>  Domestic sales increased 14.<wbr>9%.<wbr>  International sales increased 4.<wbr>4%, reflecting operational growth of 5.<wbr>0% and a negative currency impact of 0.<wbr>6%.<wbr> Zytiga continues to demonstrate strong performance with Q2 sales of $562m representing &gt;40% YoY growth worldwide.<wbr> </div><div style="margin-bottom: 10px;">Focusing on their Pharmaceutical Business, worldwide sales of $8.<wbr>5 billion for the second quarter represented an increase of 21.<wbr>1% versus the prior year on a total and operational basis.<wbr>  Domestic sales increased 36.<wbr>6%.<wbr>  International sales increased 6.<wbr>8% which reflected an operational increase of 6.<wbr>9% and a negative currency impact of 0.<wbr>1%.<wbr> The newly launched products, in particular, Olysio for hepatitis C, are the main drivers of the strong sales.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/1/J%26J%20earning%20pic%201.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/2/J%26J%20earning%20pic%202.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/3/J%26J%20earning%20pic%203.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;">Zytiga and Imbruvica in oncology are also being highlighted as the significant contributors of the growth.<wbr> Joaquin Duato (Worldwide Chairman, Pharamceutical group) commented "Zytiga is the most successful oral oncology launch in history and metastatic castration sensitive registration trial is on track.<wbr>"  Zytiga continues to hold significant market share in the U.<wbr>S.<wbr> (~34% MS), gaining 1.<wbr>2 points versus the first quarter this year.<wbr> Zytiga generated second quarter sales of $562 million representing more than 40% growth year-over-year worldwide.<wbr> Nearly 60% of these sales in the quarter were outside the U.<wbr>S.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/4/J%26J%20earning%20pic%204.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/10/zytiga%20table.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;">Alex Gorsky (CEO, Johnson&amp;Jonson) reassured the continuous investment in R&amp;D in our five therapeutic areas and approximately 20% to 21% of sales will be put down for plans to file more than 10 new drugs and 25 line extensions between 2013 and 2017.<wbr> Further investment with smaller scale acquisitions and early stage licensing agreements will surface through the innovation centers.<wbr> </div><div style="margin-bottom: 10px;">J&amp;J's ambition is to </div><div style="margin-bottom: 10px;"><OL><LI lang="en-US" value="1">establish unparalleled global development capabilities and have set industry benchmark for timelines for filing submissions and productivity and also for speed to market - 14 new products launched in the past 5 years (including 3 NMEs);
</LI>
<LI lang="en-US">deliver more than 10 potential NMEs and more than 25 significant line extensions between 2013-2017.<wbr>
</LI>
</OL> </div><div style="margin-bottom: 10px;"><OL><LI lang="en-US" value="3">Enter immuno oncology where there is promising new science and have established several collaborations.<wbr>
</LI>
</OL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/5/J%26J%20earning%20pic%205.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/6/J%26J%20earning%20pic%206.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/8/J%26J%20earning%20pic%208.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/7/J%26J%20earning%20pic%207.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/9/J%26J%20earning%20pic%209.JPG?user-agent=rss"> </div><div>Source: <A href="http://www.jnj.com/">http:/<wbr>/<wbr>www.<wbr>jnj.<wbr>com/<wbr></A> </div><!-- Comment details --><a name="oncology9830attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/1/J%26J%20earning%20pic%201.JPG">J&J earning pic 1.JPG</a>&nbsp;&nbsp;(150,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/2/J%26J%20earning%20pic%202.JPG">J&J earning pic 2.JPG</a>&nbsp;&nbsp;(113,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/3/J%26J%20earning%20pic%203.JPG">J&J earning pic 3.JPG</a>&nbsp;&nbsp;(147,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/4/J%26J%20earning%20pic%204.JPG">J&J earning pic 4.JPG</a>&nbsp;&nbsp;(151,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/5/J%26J%20earning%20pic%205.JPG">J&J earning pic 5.JPG</a>&nbsp;&nbsp;(123,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/6/J%26J%20earning%20pic%206.JPG">J&J earning pic 6.JPG</a>&nbsp;&nbsp;(122,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/7/J%26J%20earning%20pic%207.JPG">J&J earning pic 7.JPG</a>&nbsp;&nbsp;(155,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/8/J%26J%20earning%20pic%208.JPG">J&J earning pic 8.JPG</a>&nbsp;&nbsp;(133,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/9/J%26J%20earning%20pic%209.JPG">J&J earning pic 9.JPG</a>&nbsp;&nbsp;(151,5 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/10/zytiga%20table.JPG">zytiga table.JPG</a>&nbsp;&nbsp;(93,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9830">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-15T18:37:07+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/1/J%26J%20earning%20pic%201.JPG" length="154565" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/2/J%26J%20earning%20pic%202.JPG" length="116200" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/3/J%26J%20earning%20pic%203.JPG" length="150981" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/4/J%26J%20earning%20pic%204.JPG" length="154915" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/5/J%26J%20earning%20pic%205.JPG" length="126127" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/6/J%26J%20earning%20pic%206.JPG" length="125535" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/7/J%26J%20earning%20pic%207.JPG" length="159365" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/8/J%26J%20earning%20pic%208.JPG" length="136975" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/9/J%26J%20earning%20pic%209.JPG" length="155128" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9830/10/zytiga%20table.JPG" length="95288" type="image/jpeg"/></item><item>
<title>Progress With The PhIII Programme For Plecanatide In Constipation [dis:Constipation, dis:IBS, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2000</link>
<description>Progress With The PhIII Programme For Plecanatide In Constipation [dis:Constipation, dis:IBS, news]</description><category>dis:Constipation</category><category>dis:IBS</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2000</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2000">Progress With The PhIII Programme For Plecanatide In Constipation</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aConstipation"><font color="#e95e0b">:GastroEnterology:dis:Constipation</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBS"><font color="#e95e0b">:GastroEnterology:dis:IBS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology2000">GastroEnterology2000</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 July 2014 | 17:31</font><br><br><div style="margin-bottom: 10px;">Comment: Synergy Pharmaceuticals has announced that it has reached the 
halfway mark for total enrollment in the first pivotal phase 3 trial of 
plecanatide in patients with chronic idiopathic constipation (CIC).<wbr> <BR> </div><div style="margin-bottom: 10px;"><STRONG>PhIII Pivotal Programme For Plecanatide</STRONG> </div><div style="margin-bottom: 10px;">The trial is currently being conducted at 180 sites and has randomized 
approximately 675 CIC patients.<wbr> This is the first of two ongoing pivotal phase 3 
trials designed to confirm the efficacy and safety of both 3.<wbr>0 mg and 6.<wbr>0 mg 
plecanatide doses versus placebo in CIC patients.<wbr> </div><div style="margin-bottom: 10px;">Synergy announced the initiation of its second phase 3 CIC trial in April 
2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About Plecanatide &amp; Additional 
Programmes<BR></STRONG><BR>Plecanatide is Synergy’s lead uroguanylin analog in 
late-stage clinical development to treat patients with CIC and IBS-C.<wbr> 
Uroguanylin is a natural gastrointestinal (GI) hormone produced by humans in the 
small intestine and plays a key role in regulating the normal functioning of the 
digestive tract through its activity on the guanylate cyclase-C (GC-C) receptor.<wbr> 
The GC-C receptor is known to be a primary source for stimulating a variety of 
beneficial physiological responses.<wbr> </div><div style="margin-bottom: 10px;">Orally administered plecanatide mimics uroguanylin's functions by binding to 
and activating the GC-C receptor to stimulate fluid and ion transit required for 
normal bowel function.<wbr> </div><div style="margin-bottom: 10px;">Synergy has successfully completed a phase 2b trial of plecanatide in 951 
patients with CIC and is currently enrolling patients in two pivotal phase 3 CIC 
trials.<wbr> </div><div style="margin-bottom: 10px;">The company also recently announced positive top-line data results from a 
phase 2b dose-ranging study with plecanatide in patients with IBS-C.<wbr> Synergy 
plans to initiate its pivotal phase 3 IBS-C program in the fourth quarter of 
2014.<wbr> </div><div>Source: <a href="http://www.synergy.com" class="defaultlink" title="www.synergy.com">synergy.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=2000">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-15T17:31:31+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>The Battle For Control Continues As Allergan Hits Back At Valeant's Assertions [comp:Allergan, headline, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7655</link>
<description>The Battle For Control Continues As Allergan Hits Back At Valeant's Assertions [comp:Allergan, headline, :PharmaWorld:sub:Acquisition]</description><category>comp:Allergan</category><category>headline</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7655</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7655">The Battle For Control Continues As Allergan Hits Back At Valeant's Assertions</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7655">Neurology7655</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 July 2014 | 17:24</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan issued a new slide deck yesterday, calling into question 
i) concerns about Valeant's  disclosure and the accuracy of its 
statements and ii) concerns about its business.<wbr> It is essentially 
challenging Valeant management to adhere to its promise of improved 
disclosure by listing a long list of items it expects disclosure 
on during the group's Q2 earnings call (31st July).<wbr> </div><div style="margin-bottom: 10px;">Key growth concerns highlighted by Allergan relate to both that of 
Bausch &amp; Lomb post acquisition and Valeant's share loss in neurotoxin and 
fillers post the Medicis acquisition.<wbr> Of course Allergan fails to mention 
its own loss of share in toxins as a result of Xeomin's gains.<wbr> </div><div style="margin-bottom: 10px;">Key slides are highlighted below with the full presentation attached:- </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/5/ScreenCapture5.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7655attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(395,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(282,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(237,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(325,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(366,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(145 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/7/investor%5fpresentation%5fju114%5f2014.pdf">investor_presentation_ju114_2014.pdf</a>&nbsp;&nbsp;(886,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7655">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-15T17:24:50+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/1/ScreenCapture1.jpg" length="404549" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/2/ScreenCapture2.jpg" length="289514" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/3/ScreenCapture3.jpg" length="243394" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/4/ScreenCapture4.jpg" length="333439" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/5/ScreenCapture5.jpg" length="375041" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/6/ScreenCapture6.jpg" length="148437" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7655/7/investor%5fpresentation%5fju114%5f2014.pdf" length="907752" type="application/pdf"/></item><item>
<title>re: The First Anti-PD-1 Has been Approved In Japan</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9829</link>
<description>re: The First Anti-PD-1 Has been Approved In Japan</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9829</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9829">re: The First Anti-PD-1 Has been Approved In Japan</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9829">Oncology9829</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 14 July 2014 | 17:55</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">The First Anti-PD-1 Has been Approved In Japan</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aBMS"><font color="#e95e0b">:Oncology:comp:BMS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font><br><span style="font-size: 12px;">Comment: BMS is slightly ahead of the race as its anti-PD1, nivolumab, has been approved for use in melanoma in Japan on 7th July 2014.<wbr> Ono Pharmaceutical has the marketing rights in Japan, Korea, and Taiwan.<wbr> Bristol-Myers Squibb retains the rights elsewhere worldwide.<wbr> Nivolumab was submitted under a rolling BLA in the US in April.<wbr> This is one of the most highly anticipated drug approvals in oncology &mdash; the product has shown unprecedented response in melanoma, as well as several other tumour types.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9821">...</a><br><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9821" class="commentpermalink">Oncology9821</a> / <span class="date">09 July 2014</span> /
<span class="time">16:45:09 o'clock CEST</span>
</font></div><div>Comment: Bristol-Myers Squibb Company announced that, following discussions with the U.<wbr>S.<wbr> Food and Drug Administration (FDA), the company is planning a Q3 submission of a Biologics Licensing Application (BLA) for Opdivo&reg; (nivolumab) for previously treated advanced melanoma.<wbr> This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.<wbr>S.<wbr> The advanced melanoma BLA is based on data from Checkmate -037, a multinational, multicenter, randomized open-label Phase 3 trial evaluating Opdivo compared to dacarbazine (DTIC) or carboplatin/<wbr>paclitaxel in patients with unresectable or metastatic melanoma who have been previously treated with Yervoy&reg; (ipilimumab) and, if BRAF-mutation positive, a BRAF inhibitor regimen.<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9829" class="commentpermalink">Oncology9829</a> / <span class="date">14 July 2014</span> /
<span class="time">17:55:46 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9829">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9821">View thread  Oncology9821: The First Anti-PD-1 Has been Approved In Japan</a>]]></content:encoded><dc:date>2014-07-14T17:55:46+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>A &quot;Potentially&quot; New Delivery System For Triptorelin</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9828</link>
<description>A &quot;Potentially&quot; New Delivery System For Triptorelin</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9828</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9828">A "Potentially" New Delivery System For Triptorelin</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9828">Oncology9828</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 14 July 2014 | 17:52</font><br><br><div style="margin-bottom: 10px;">Comment: An Iranian Group from Tehran University of Medical Sciences has published an article in Asian Journal of Pharmaceutics to evaluate a new composite of poly-lactic-co-glycolic acid (PLGA) and hyaluronic acid (HA) was designed and prepared in the form of implants containing triptorelin.<wbr> </div><div style="margin-bottom: 10px;">Impants technology have advantages over microparticles due to possibility of direct administration to the target site, requiring lower dosing frequency with longer duration.<wbr> The major drawback of implant technology mainly due to the requirement for invasive procedure as well as risk of local immunological rejection.<wbr> Omid's group utilised hyaluronic acid - a nature anionic polymer - as part of the formulation in the implants to overcome the risk of immunologic reactions at the administration site.<wbr> </div><div style="margin-bottom: 10px;">PLGA is synthetic polyester with biocompatibility and biodegradability in both crystalline and amorphous forms and offers flexibility related to processing.<wbr> Currently, triptorelin salt is encapsulated in this polymer along with other solvents.<wbr> Omid et al.<wbr> postulated that designing a composite containing both PLGA and HA in an optimized ratio could create a similar drug release pattern similar to current triptorelin's formulation.<wbr> This could also represent a promising delivery vehicle for other protein or peptides.<wbr> </div><div>Source: Design, Preparation and characterization of novel poly-lactic-co-glycolic acid hyaluronic acid implants containing triptorelin acetate.<wbr> Omid N.<wbr>J.<wbr> et al.<wbr> Asian J Pharmaceutics Vol 8 Issue 1 2014 p.<wbr>18-26.<wbr> (Full Text link is available through PEARL).<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9828">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-14T17:52:29+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Auspex Expects Financing to Bring Approx. $60M [dis:Huntington, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7654</link>
<description>Auspex Expects Financing to Bring Approx. $60M [dis:Huntington, :PharmaWorld:sub:Finance]</description><category>dis:Huntington</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7654</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7654">Auspex Expects Financing to Bring Approx.<wbr> $60M</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7654">Neurology7654</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 July 2014 | 15:20</font><br><br><div style="margin-bottom: 10px;">Comment: Auspex has  announced the pricing of its underwritten public offering of 3,150,000 shares of common stock at a price to the public of $19.<wbr>25 per share.<wbr> The company expects readouts of SD-809, a deuterium-substituted version of Xenazine (tetrabenazine), for HD in Q4:14.<wbr> Beyond SD-809, pipeline lists almost half a dozen earlier-stage, and still un-partnered additional deuterium substitution molecules in development.<wbr> These earlier-stage opportunities remain unmodeled for now, but this platform could start to make some noise following initial SD-809 clinical validation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Catalysts</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">SD-809 is being initially evaluated for the treatment of chorea associated with Huntington&rsquo;s disease.<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>
ASPX anticipates pivotal data Q414, followed by US NDA filing and a potential first commercial product by YE15.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><P align="left">SD-809 also has potential applications in tardive dyskinesia and Tourette syndrome.<wbr></P> </div><div style="margin-bottom: 10px;"><UL><LI>
SD-809's Phase 2/<wbr>3 tardive dyskinesia (TD) study is ongoing, with possible top-line data by mid-2015.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Interim Data</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Design: The ARC-HD Switch trial is an open-label study examining safety/<wbr>tolerability and chorea control in Huntington&rsquo;s Disease patients who switch from treatment with Xenazine (tetrabenazine) to ASPX&rsquo;s SD-809</P> </div><div style="margin-bottom: 10px;"><P align="left">Findings: interim analysis occurred after 12 patients were enrolled and had reached the week 1 time point.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" style="padding-left: 30px;">Mean change in total chorea score at week 1 (n=12) and week 4 (n=8) were -0.<wbr>83&plusmn;0.<wbr>51 and -0.<wbr>75&plusmn;0.<wbr>75, respectively.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Safety: No SAEs encountered in the trial </P> </div><div>See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7623" class="defaultlink">Neurology7623: Auspex -  A Late-stage Development Company With An Asset Potential In Multiple Hyperkinetic Movement Disorders</a>.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7654">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-11T15:20:23+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Shareholders in Allergan Encourage CEO to Do a Large Acquisition [comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7653</link>
<description>Shareholders in Allergan Encourage CEO to Do a Large Acquisition [comp:Allergan]</description><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7653</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7653">Shareholders in Allergan Encourage CEO to Do a Large Acquisition</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7653">Neurology7653</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 July 2014 | 14:14</font><br><br><div style="margin-bottom: 10px;">Comment: In an interview with the Financial Times (FT), CEO of Allergan has recognised that the company which has $14bn of cash on its balance sheet, is contemplating a deal, and should "act sooner than rather later if it was going to make an acquisition".<wbr> Pyott indicated to Reuters the profile for a 'suitable acquisition', which is detailed below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Suitable Acquisition /<wbr> Partner Asset</STRONG> </div><div style="margin-bottom: 10px;">- specialized, with differentiated technology </div><div style="margin-bottom: 10px;">- with great connectivity with the physicians, and customer based </div><div style="margin-bottom: 10px;">- with a growth profile (" .<wbr>.<wbr>.<wbr> acquiring a company with a 1% growth makes no sense"), and value creation </div><div style="margin-bottom: 10px;">He outlined that "if aided by tax better, but if not it's ok as well".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Speculations Around Shire Still Ongoing</STRONG> </div><div style="margin-bottom: 10px;">Some analysts have speculated that Shire could be a good partner for Allergan, with the Irish drugmaker currently considering a $51.<wbr>5-billion bid from AbbVie.<wbr> </div><div style="margin-bottom: 10px;">A top 15 shareholder in both Allergan and Shire told the FT that the UK company would be more likely to accept an offer from Allergan than from AbbVie, even at a lower price, and that he would support such a choice because of Allergan&rsquo;s faster growth prospects.<wbr> </div><div>Source: Thomson </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7653">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-11T14:14:07+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Messages from Advanced Accelerator Applications (AAA) Financial Results</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7734</link>
<description>Key Messages from Advanced Accelerator Applications (AAA) Financial Results</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7734</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7734">Key Messages from Advanced Accelerator Applications (AAA) Financial Results</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7734">Endocrinology7734</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 July 2014 | 16:31</font><br><br><div style="margin-bottom: 10px;">Comment: Sales in 2013 increased by 31.<wbr>77% to €53.<wbr>8M (from €40.<wbr>8M in 2012).<wbr>The year was marked by the continued expansion of the company's Molecular Nuclear Medicine (MNM) network, with the creation of AAA Poland and the signing of an agreement with the U.<wbr> of Warsaw to operate its production site in 2014.<wbr> Management indicated that Ph3 trial for Lu-DOTATATE (Lutathera®) is progressing as planned.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Milestones</FONT></STRONG> </div><div style="margin-bottom: 10px;">A €4.<wbr>8 million capital increase was completed in April 2013 to help fund expansion plans and finance clinical trials of a promising portfolio of MNM product candidates (See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7371" class="defaultlink">Endocrinology7371: Advanced Accelerator Applications (AAA) Reports Completion of €4.<wbr>8M Capital Increase</a>).<wbr> </div><div style="margin-bottom: 10px;">In March 2014, AAA received orphan drug designation from FDA and EMA for Gallium-68 DOTATATE for use in patients with GEP NETs </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Progress</FONT></STRONG> </div><div style="margin-bottom: 10px;">In early 2014 AAA acquired Imaging Equipment Limited (IEL) giving the Company its first direct presence in the UK and Ireland, and a strong presence in all Europe’s G5 countries.<wbr> </div><div style="margin-bottom: 10px;">AAA continued its global expansion with the opening of an office in New York to support ongoing clinical studies for Ga-68 DOTATATE and Lu-DOTATATE.<wbr> </div><div>AAA also recently started operations in its new French site in Marseille which produced and delivered its first doses of GLUSCAN® on 12 May 2014.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7734">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-10T16:31:27+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Briefing on Astellas R&amp;D Meeting [comp:Astellas, dis:Prostate, prod:Firmagon, prod:MDV3100, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9825</link>
<description>Briefing on Astellas R&amp;D Meeting [comp:Astellas, dis:Prostate, prod:Firmagon, prod:MDV3100, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9825</comments><category>comp:Astellas</category><category>dis:Prostate</category><category>prod:Firmagon</category><category>prod:MDV3100</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9825</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9825">Briefing on Astellas R&D Meeting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aFirmagon"><font color="#e95e0b">:Oncology:prod:Firmagon</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9825">Oncology9825</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 10 July 2014 | 11:57</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas hosted an R&amp;D meeting on 10 July at which it talked about its stance of accelerating new drug development via the use of external resources.<wbr> The company has been speeding up development in particular in oncology, which it has set up as its 3rd focus domain.<wbr> Management announced its FASTEN project for accelerating R&amp;D.<wbr> The pipeline section outlined that Xtandi's Ph2 results for breast cancer are due around end-2014 to early 2015.<wbr> The development of degarelix 3M is still mentioned being in Ph3/<wbr>Japan.<wbr> Key slides are provided below, and the full presentations are attached.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Oncology Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Enzalutamide - Prostate Cancer Development</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Enzalutamide - Breast Cancer Development</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Restructured Organization</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Therapeutic Areas and Novel Tech Platform</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10141c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: The global PROSPER Ph3 to investigate enzalutamide's safety and efficacy in non-metastatic CRPC (M0 CRPC) patients will also include 18 centres in China.<wbr> This appears to be sponsored by Medivation (CTR20140772).<wbr> Currently the patient recruitment has not yet started.<wbr> Source: <a href="http://www.chinadrugtrials.org.cn/eap/clinicaltrials.searchlistdetail" class="defaultlink">China Drug Trials Registry Platform</a> </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10141" class="commentpermalink">Oncology10141</a> / <span class="date">28 November 2014</span> /
<span class="time">16:43:23 o'clock CET</span>
</font></div><a name="oncology9825attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(95,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/8/Astellas%5fJuly102014%5fdrugdiscovery%5fen.pdf">Astellas_July102014_drugdiscovery_en.pdf</a>&nbsp;&nbsp;(1,7 MB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/9/Astellas%5fJuly102014%5fpipeline%5fen.pdf">Astellas_July102014_pipeline_en.pdf</a>&nbsp;&nbsp;(2,7 MB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/10/Astellas%5fuly102014%5finnovation%5fen.pdf">Astellas_uly102014_innovation_en.pdf</a>&nbsp;&nbsp;(1,5 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9825">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-10T11:57:14+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/6/ScreenCapture6.jpg" length="97461" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/8/Astellas%5fJuly102014%5fdrugdiscovery%5fen.pdf" length="1807807" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/9/Astellas%5fJuly102014%5fpipeline%5fen.pdf" length="2825107" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9825/10/Astellas%5fuly102014%5finnovation%5fen.pdf" length="1581038" type="application/pdf"/></item><item>
<title>Entremed Now CASI Pharm. Receives US ODD for its HCC Drug Candidate</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9824</link>
<description>Entremed Now CASI Pharm. Receives US ODD for its HCC Drug Candidate</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9824</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9824">Entremed Now CASI Pharm.<wbr> Receives US ODD for its HCC Drug Candidate</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9824">Oncology9824</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 July 2014 | 17:49</font><br><br><div style="margin-bottom: 10px;">Comment: The Company underwent a name change to CASI in June 2014 to reflect the Company&rsquo;s shift to a new development model that includes a focus on the Chinese pharmaceutical market.<wbr> Next steps for ENMD-2076 in HCC and/<wbr>or in fibrolamellar carcinoma are being finalized.<wbr> The drug is an orally-active, Aurora A/<wbr>angiogenic kinase inhibitor with a unique kinase selectivity profile and multiple mechanisms of action.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ENMD-2076 Profile</STRONG> </div><div style="margin-bottom: 10px;">ENMD-2076 has been shown to inhibit a distinct profile of angiogenic tyrosine kinase targets in addition to the Aurora A kinase.<wbr> Aurora kinases are key regulators of mitosis (cell division), and are often over-expressed in human cancers.<wbr> ENMD-2076 also targets the VEGFR, Flt-3 and FGFR3 kinases, which have been shown to play important roles in the pathology of several cancers.<wbr> </div><div style="margin-bottom: 10px;">ENMD-2076 has shown promising activity in Phase I clinical trials in many different solid tumor cancers including ovarian, breast, liver, renal and sarcoma, as well as in leukemia, and multiple myeloma, and is completing a Phase II clinical trial for ovarian cancer.<wbr> </div><div style="margin-bottom: 10px;">CASI is conducting a Phase II study of ENMD-2076 in triple-negative breast cancer, a Phase II study in advanced/<wbr>metastatic soft tissue sarcoma, and a Phase II study in advanced ovarian clear cell carcinomas in North America.<wbr> Pending approval by the CFDA, the Company intends to expand these trials into China.<wbr> ENMD-2076 has received orphan drug designation from the U.<wbr>S.<wbr> Food and Drug Administration for the treatment of ovarian cancer, multiple myeloma and acute myeloid leukemia.<wbr> </div><div style="margin-bottom: 10px;">ENMD-2076 has strong global intellectual property protections worldwide with patents approved or pending for approvals in the US, Canada, Japan and many other countries.<wbr> On May 6, 2013, the Chinese State Intellectual Property Office issued a patent for ENMD-2076 covering composition of matter and uses to treat various cancers.<wbr> </div><div>Source: CASI Pharm </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9824">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-09T17:49:13+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>U.S.-Based Evolus to Start POC Trial of Daewoong's BTX-A for GL [class:BotulinumToxins, sub:Aesthetics, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7650</link>
<description>U.S.-Based Evolus to Start POC Trial of Daewoong's BTX-A for GL [class:BotulinumToxins, sub:Aesthetics, headline]</description><category>class:BotulinumToxins</category><category>sub:Aesthetics</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7650</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7650">U.<wbr>S.<wbr>-Based Evolus to Start POC Trial of Daewoong's BTX-A for GL</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7650">Neurology7650</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 July 2014 | 17:16</font><br><br><div style="margin-bottom: 10px;">Comment: Approx.<wbr> three hundred and fifty subjects will be enrolled, and injected with DWP-450 over the course of the 365 day study.<wbr> PE will assess safety (incidence, severity and duration of any adverse reactions during the study period).<wbr> The trial will take place in one single site in the U.<wbr>S (ATS Clinical Research in Santa Monica, CA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">- Reference: <a href="http://www.clinicaltrials.gov/ct2/show/NCT02184988?recr=Open&no_unk=Y&phase=012&fund=2&rcv_s=06%2F09%2F2014&rank=169" class="defaultlink">NCT02184988</a> </div><div style="margin-bottom: 10px;">- Timelines: Start date August 2014 - Completion date August 2015 /<wbr> October 2015 </div><div style="margin-bottom: 10px;">- Protocol: intra-muscularly injection into a total of 5 sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim.<wbr> </div><div style="margin-bottom: 10px;">- Dosage: Each site is injected with 0.<wbr>1 ml (4U), for a total of 20 U and 0.<wbr>5 ml.<wbr> </div><div style="margin-bottom: 10px;">- Recruitment: Both genders </div><div><UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Subjects must be an adult 18 years of age or over
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Subject has moderate to severe glabellar lines on maximum frown as assessed by the investigator using the GLS
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Subject is willing and able to complete the entire course of the study
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7650">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-09T17:16:43+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>The First Anti-PD-1 Has been Approved In Japan [comp:BMS, :PharmaWorld:mkt:Japan, class:MonoclonalAntibody]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9821</link>
<description>The First Anti-PD-1 Has been Approved In Japan [comp:BMS, :PharmaWorld:mkt:Japan, class:MonoclonalAntibody]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9821</comments><category>comp:BMS</category><category>mkt:Japan</category><category>class:MonoclonalAntibody</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9821</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9821">The First Anti-PD-1 Has been Approved In Japan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aBMS"><font color="#e95e0b">:Oncology:comp:BMS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9821">Oncology9821</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 09 July 2014 | 16:45</font><br><br><div style="margin-bottom: 10px;">Comment: BMS is slightly ahead of the race as its anti-PD1, nivolumab, has been approved for use in melanoma in Japan on 7th July 2014.<wbr> Ono Pharmaceutical has the marketing rights in Japan, Korea, and Taiwan.<wbr> Bristol-Myers Squibb retains the rights elsewhere worldwide.<wbr> Nivolumab was submitted under a rolling BLA in the US in April.<wbr> This is one of the most highly anticipated drug approvals in oncology &mdash; the product has shown unprecedented response in melanoma, as well as several other tumour types.<wbr> </div><div style="margin-bottom: 10px;">Anti-PD-1/<wbr>L1 as a class has dominated the news coming out of ASCO for the last 2 years.<wbr> It has led to a huge interest in immunotherapy, and manipulation of the PD pathway in particular, and many pharmaceutical companies are investing in this research area, considered to be one of the most promising in the whole cancer field.<wbr> Cancer immunotherapies such as the anti-PD-1/<wbr>PD-L1 agents are predicted to be one of the key growth categories in the cancer immunotherapy market, which is predicted to grow from $1.<wbr>1bn in 2012 to nearly $9bn in 2022 in the US, France, Germany, Italy, Spain, UK and Japan (Decision Resources).<wbr> </div><div style="margin-bottom: 10px;">Interestingly, melanoma is very rare in Far East countries, and Ono Pharm will provide the drug free of charge as soon as it is available until the time that it is listed on the national health insurance price list.<wbr> Due to lack of sufficient patients available in Japanese clinical trials, the company is required to perform a postmarketing use/<wbr>results survey covering all cases until data on a certain minimum number of patients have been accumulated.<wbr> Although the clinical efficacy of nivolumab was first demonstrated in melanoma, it has since shown efficacy in a number of other tumor types, and Bristol-Myers Squibb has numerous studies with the drug ongoing.<wbr> In the United States, the US Food and Drug Administration has granted a fast track designation for<STRONG> melanoma</STRONG>, <STRONG>non-small-cell lung cancer</STRONG>, and <STRONG>renal cell carcinoma</STRONG>, and it was recently granted breakthrough therapy designation for the treatment of patients with Hodgkin's lymphoma after failure of autologous stem cell transplant and brentuximab.<wbr> </div><div style="margin-bottom: 10px;">BMS is very closely tailed by Merck&amp;Co (MSD)'s anti-PD1, pembrolizumab, for the treamtment of advanced melanoma.<wbr> On 1st July, the European Medicines Agency (EMA) has accepted Merck &amp; Co's filing for for the treatment of advanced melanoma, putting it in contention to be the first drug in its class to reach the EU market.<wbr> Pembrolizumab (formerly lambrolizumab; MK-3475) is one of the highlights of Merck's R&amp;D pipeline and is being evaluated across more than 30 types of cancer, with peak sales estimated to reach around $500m in melanoma alone.<wbr> Additional regulatory filings in other countries outside of Europe are planned by the end of 2014.<wbr> Pembrolizumab was filed in US in January and could be approved by the FDA as early as October.<wbr> In February 2014, Merck formed collaborations with Pfizer, Amgen and Incyte to explore the use of pembrolizumab in combination with other drugs across a variety of tumour types, including melanoma, renal cell carcinoma, non-small cell lung cancer (NSCLC) and breast cancer.<wbr> </div><div>Other anti-PD1 or anti-PDL1 drugs coming through development include Roche's MPDL-3280A, while AstraZeneca and Novartis are also active in this area.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9829c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Bristol-Myers Squibb Company announced that, following discussions with the U.<wbr>S.<wbr> Food and Drug Administration (FDA), the company is planning a Q3 submission of a Biologics Licensing Application (BLA) for Opdivo&reg; (nivolumab) for previously treated advanced melanoma.<wbr> This will mark the second tumor type for which Bristol-Myers Squibb has a regulatory submission underway for Opdivo in the U.<wbr>S.<wbr> The advanced melanoma BLA is based on data from Checkmate -037, a multinational, multicenter, randomized open-label Phase 3 trial evaluating Opdivo compared to dacarbazine (DTIC) or carboplatin/<wbr>paclitaxel in patients with unresectable or metastatic melanoma who have been previously treated with Yervoy&reg; (ipilimumab) and, if BRAF-mutation positive, a BRAF inhibitor regimen.<wbr> </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9829" class="commentpermalink">Oncology9829</a> / <span class="date">14 July 2014</span> /
<span class="time">17:55:46 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9821">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-09T16:45:09+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Synergy's Plecanatide Expected to Enter Ph3 for IBS-C in Q4:14</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1995</link>
<description>Synergy's Plecanatide Expected to Enter Ph3 for IBS-C in Q4:14</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1995</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1995">Synergy's Plecanatide Expected to Enter Ph3 for IBS-C in Q4:14</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1995">GastroEnterology1995</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 July 2014 | 15:58</font><br><br><div style="margin-bottom: 10px;">Comment: Synergy Pharm has successfully completed an end-of-Ph2 meeting with the FDA, in which the regulatory agency gave the company the goahead to proceed into Ph3 testing.<wbr> Analysts think that Salix may be interested in plecanatide as it would give it the ability to target all forms of IBS (since Salix already has Xifaxan for IBS-D).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Results from Ph2b</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">Synergy recently reported favorable results from a Ph2b trial of plecanatide in IBS-C, which appears to position the drug as a safer and equivalently efficacious option vs.<wbr> linaclotide across the board, in both chronic idiopathic constipation (CIC) as well as IBS-C.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">Complete data from this trial, including the discontinuation rate due to diarrhea, could be presented at the American College of Gastroenterology (ACG) Meeting in Philadelphia, PA in October 2014.<wbr></P> </div><div><P align="left">Also see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1972" class="defaultlink">GastroEnterology1972: Positive Top-Line Data from a 424-Patients Ph2b Trial of Plecanatide for IBS-C</a>.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1995">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-09T15:58:54+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Strategic Rationale of the Salix and Cosmo Unit Transaction [dis:Diarrhoea, headline, sub:CRCPrevention]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1993</link>
<description>Strategic Rationale of the Salix and Cosmo Unit Transaction [dis:Diarrhoea, headline, sub:CRCPrevention]</description><category>dis:Diarrhoea</category><category>headline</category><category>sub:CRCPrevention</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1993</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1993">Strategic Rationale of the Salix and Cosmo Unit Transaction</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:GastroEnterology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1993">GastroEnterology1993</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 July 2014 | 15:26</font><br><br><div style="margin-bottom: 10px;">Comment: Salix has announced it is buying the part of Cosmo that is based in Ireland in an all-stock deal to become an Irish company and lower its tax rate.<wbr> The combination makes strategic sense for Salix, as it further enhances its position as a leader to treat gastrointestinal diseases and disorders.<wbr> Cosmo is the inventor and developer of Lialda and Uceris, has three products on the market and six in clinical development.<wbr> Based on announced deal terms, analysts calculate that Salix is paying $1.<wbr>74bn for the Cosmo assets (20% of current, outstanding shares).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale for Salix</STRONG> </div><div style="margin-bottom: 10px;">The company's strategy is to take GI products to both gastroenterologists and primary care.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Product Strategy</SPAN> - One of the benefit of the transaction for Salix is the addition of 2 promising Cosmo's drugs: </div><div style="margin-bottom: 10px;"><UL><LI>rifamycin MMX
<UL><LI>in Ph3 testing for traveller diarrhea, with launch expected in H2:2017
</LI>
<LI>in Ph2 for uncomplicated diverticulitis in adults &gt;18 yeas old, with launch expected H1:2019
</LI>
</UL>

</LI>
<LI>methylene blue MMX (to aid in the detection of colon cancer (launch expected H2:2017)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Growth Strategy</SPAN>- Management noted on the call the new tax structure will make Salix more competitive for future deals.<wbr> While itmanagement indicated they are not shifting current Salix products' IP to Ireland, products acquired from Cosmo Tech will remain in the Irish subsidiary and will benefit from favorable tax rates.<wbr> Further M&amp;A/<wbr>licensing deals would benefit from lower tax rates going forward under the new company.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Financial Strategy</SPAN> - To reduce Salix effective long-term tax rate from the high 30% range to the low 20% range.<wbr> Upon the closing of the transaction, the new company will be incoporated in Ireland.<wbr> </div><div><STRONG>Please find attached the full presentation</STRONG> </div><!-- Comment details --><a name="gastroenterology1993attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1993/1/salix%2dcombines%2dwith%2dcosmo%2dpresentation.pdf">salix-combines-with-cosmo-presentation.pdf</a>&nbsp;&nbsp;(545,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1993">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-09T15:26:16+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1993/1/salix%2dcombines%2dwith%2dcosmo%2dpresentation.pdf" length="558293" type="application/pdf"/></item><item>
<title>Patent and Trial Updates on Antisense's Acromegaly Program [dis:Acromegaly, :PharmaWorld:sub:IP, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7733</link>
<description>Patent and Trial Updates on Antisense's Acromegaly Program [dis:Acromegaly, :PharmaWorld:sub:IP, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Acromegaly</category><category>sub:IP</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7733</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7733">Patent and Trial Updates on Antisense's Acromegaly Program</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aIP"><font color="#e95e0b">:PharmaWorld:sub:IP</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7733">Endocrinology7733</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 July 2014 | 11:47</font><br><br><div style="margin-bottom: 10px;">Comment: The Canadian Patent Office has allowed patent application for ATL1103, which covers its use until February 2024.<wbr> In addition, the company has confirmed that the results of the PE endpoint of the Ph2 trial are expected by the end of August 2014.<wbr> Beginning of 2014, mangement reported interest from pharma companies in partnering the Ph3 development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Patent Situation</STRONG> </div><div style="margin-bottom: 10px;">Canadian Patent Office has allowed patent application 2,517,101 entitled &ldquo;A Modified Oligonucleotide for inhibition of Growth Hormone Receptor Expression&rdquo; which covers the Company&rsquo;s growth hormone receptor (GHr) targeting drug ATL1103 and its use until February 2024.<wbr> <BR><BR>The Canadian patent forms part of the Company&rsquo;s extensive portfolio of intellectual property protecting ATL1103 and its applications in the modulation of Insulin-like Growth Factor-I (IGF-I) in the treatment of the growth disorder acromegaly and other diseases.<wbr> This portfolio includes patents that have been granted and are now registered in the United States, Japan, New Zealand and Australia.<wbr> In addition patent applications are in advanced stages of prosecution in Europe.<wbr> Additionally, International application PCT/<wbr>AU2013/<wbr>000095 has been lodged covering the use of ATL1103 in combination with the GHr antagonist Somavert, for the treatment of acromegaly and cancer.<wbr> </div><div style="margin-bottom: 10px;">In the US, patent protection covers ATL1103 until January 2025, and in Canada and other jurisdictions to February 2024.<wbr> In the US, Japan, Europe and Australia claims to ATL1103 can be extended up to a further 5 years.<wbr> The International PCT application once granted, would cover the use of ATL1103 in combination with Somavert until 2032.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Ph2 Clinical Trial Update for Acromegaly</STRONG> </div><div style="margin-bottom: 10px;">24 patients have completed the full 13 weeks of dosing in the trial.<wbr> The opportunity presented for the Company to enrol an additional 2 acromegalic patients into the trial (now 26 in total) who will receive their final dose of ATL1103 by 19 July 2014, which will mark the completion of all dosing in the trial.<wbr> </div><div style="margin-bottom: 10px;">Safety : to date there have been no treatment related patient withdrawals from the trial or reports of any treatment related serious adverse events.<wbr> <BR><BR>The Company expects to receive the results of the primary efficacy endpoint of the trial, being the statistical analysis of the change (percentage reduction) from each patient&rsquo;s baseline (start of the study) serum IGF-I levels to their levels one week after the completion of dosing with ATL1103, by the end of August 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ATL1103 Profile</STRONG> </div><div style="margin-bottom: 10px;">- second generation antisense drug designed to block growth hormone receptor (GHr) expression thereby reducing levels of the hormone insulin-like growth factor-I (IGF-I) in the blood and is a potential treatment for diseases associated with excessive growth hormone action.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Important Milestones</SPAN> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=6786" class="defaultlink">Endocrinology6786: ALT1103 Successfully Meets PhI Trial Endpoint</a> </div><div><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7552" class="defaultlink">Endocrinology7552: Positive Results from the Interim Analysis of Antisense's ATL1103 for Acromegaly</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7733">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-09T11:47:18+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ENDO Insights Part II - Key Intelligence On Pasireotide &amp; Novarits's New Cushing's Therapy LC1699 [headline, dis:Cushing, dis:Acromegaly, dis:MidGutNET, dis:pNET, comp:Novartis, :PharmaWorld:congress:ENDO]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7721</link>
<description>ENDO Insights Part II - Key Intelligence On Pasireotide &amp; Novarits's New Cushing's Therapy LC1699 [headline, dis:Cushing, dis:Acromegaly, dis:MidGutNET, dis:pNET, comp:Novartis, :PharmaWorld:congress:ENDO]</description><category>headline</category><category>dis:Cushing</category><category>dis:Acromegaly</category><category>dis:MidGutNET</category><category>dis:pNET</category><category>comp:Novartis</category><category>congress:ENDO</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7721</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7721">ENDO Insights Part II - Key Intelligence On Pasireotide & Novarits's New Cushing's Therapy LC1699</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aENDO"><font color="#e95e0b">:PharmaWorld:congress:ENDO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7721">Endocrinology7721</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 July 2014 | 18:32</font><br><br><div style="margin-bottom: 10px;">Comment:-Additional insight from ENDO focuses on Novartis''s pasiroetide both regard to timelines for approval of the acromegaly indication in the US and a future phIII NET trial, to commence in 2015.<wbr> Additionally, It was noted that development work has started with a fluid-crystal formulation of pasireotide.<wbr> PhII results for Novartis's new Cushing's therapy <SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">LC1699 were also presented, with an acknowledgement that a confirmatory phIII study LINC3 is now planned in a larger population.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><STRONG>Summary of Key Soft Intelligence:</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Pasireotide LAR has been submitted for approval both with the FDA and the EAM with an advisory board (FDA) due to meet in September and expected outcome in November 2014.<wbr></SPAN>
</LI>
<LI><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">The high costs of the drug was referenced by several speaker over the duration of the congress</SPAN>
</LI>
<LI><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">A phIII trial of pasireotide LAR in NET is expected to commence in 2015 (confirmed by George Shen Novartis USA (first author of poster SUN-0617 entitled PK/<wbr>PD analysis of pasireotide LAR and octreotide LAR support the efficacy results of the randomised , double-blind phIII study of patients with medically naive acromegaly).<wbr> Personnel at the Novartis medical booth confirmed that a clinical trial of pasireotide LAR in NET was in discussion but could not confirm the timelines.<wbr></SPAN>
</LI>
<LI><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Shen also confirmed that development work has started with a fluid crystal formulation of pasireotide and that phI studies are in discussion for all indications.<wbr></SPAN>
</LI>
<LI><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Regarding Sandostatatin LAR, confirmation was obtained that the new device will be introduced to the US market very soon.<wbr></SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><STRONG>Pasireotide</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Highlights of the key studies presented in oral and poster form.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-fareast-font-family: Calibri; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Novartis had a notable presence at the meeting with several company sponsored oral and poster presentations updating the audience on the<STRONG> results of the phIII multicentre randomised PAOLA trial (data first reported at the ECE in April</STRONG> see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7670" class="defaultlink">Endocrinology7670: Insights From The ECE Meeting & Upcoming ENDO Congress</a>).<wbr> <STRONG>Phase III multicenter, randomised study (PAOLA) clinical study demonstrating that Pasireotide LAR has superior efficacy over octreotide LAR and lanreotide ATG in patients with inadequately controlled acromegaly </STRONG>The study was presented by Annamaria Colao Italy PP17-2, SUN0591.<wbr> The following slides are from the poster preview session.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/4/ScreenCapture4.jpg?user-agent=rss"> A copy of the poster is attached.<wbr> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Poster 0615: Exploratory Data Evaluating the Effect Of Pasiroetide on GH, IGF-1, IGFBP-2, IGFBP-3, HbA1c and Glucose in Patients with Inadequately Controlled Acromegaly Enrolled in a 24-Week Study (PAOLA) </SPAN></STRONG><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">presented by HA Schmid et al</SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Results &amp; Conclusions</SPAN></STRONG><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">- Elevated GH causes insulin resistance; therefore patients with inadequately controlled acromegaly may be particularly sensitive to developing pasireotide- induced hyperglycaemia.<wbr> Given the increased glucose levels, the increase in IGFBP-2 levels was an unexpected observation.<wbr> The effects of pasireotide LAR on glucose homeostasis may be attenuated by increased insulin sensitivity due to the compensatory increase in IGFBP-2.<wbr> The approximate 50% of the population who did not receive antidiabetic medication had significantly lower baseline glucose levels than those who did, and pasireotide- induced hyperglycaemia was mild and decreased over time.<wbr> A copy of the poster is attached.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><U>Poster 0617</U></STRONG>: <STRONG style="mso-bidi-font-weight: normal;">PK and PD Analyses of Pasireotide LAR and Ocreotide LAR Support the Efficacy Results of a randomised, Double-Blind, Phase III study in patients with Medically Naive Acromegaly,</STRONG> presented by G.<wbr> Shen <EM style="mso-bidi-font-style: normal;">et al.<wbr></EM> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Summary:</SPAN></STRONG><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"> Pasireotide LAR was superior to octreotide LAR at providing biochemical control (GH and IGF-1) in patients with medically naive acromegaly in a 12 month study.<wbr> The PK/<wbr>PD of pasireotide and octreotide in these patients is reported here.<wbr> A copy of the poster is attached.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><U>Poster 0619</U></STRONG>: <STRONG style="mso-bidi-font-weight: normal;">Is clinical practice reflective of Acromegaly treatment guidelines? Results From a Survey of treating Physicians in 45 countries, </STRONG>presented by GK Stalla <EM style="mso-bidi-font-style: normal;">et al.<wbr></EM> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Summary:</SPAN></STRONG><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"> Although guidelines for the treatment of acromegaly recommend control of both GH and IGF-1, 56% of the physicians responding to this survey consider it acceptable for a patient to have IGF-1&gt;ULN, and 18% consider IGF-1&ge;1.<wbr>5xULN acceptable.<wbr> Although this lack of urgency to treat may reflect challenges in clinical practice, it suggests that many patients with acromegaly remain on the same treatment despite being inadequately controlled, which may impact on long-term patient outcomes, as well as on the cost of disease management.<wbr> A copy of the poster is attached.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><U>Poster 0726</U></STRONG>: <STRONG style="mso-bidi-font-weight: normal;">An Acromegaly, Open-Label, Multi-Center, Safety Monitoring Program for Treating Patients with SOM230 (pasireotide) LAR who have need to receive medical therapy (ACCESS),</STRONG> presented by A Glamocak <EM style="mso-bidi-font-style: normal;">et al.<wbr></EM> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Summary:</SPAN></STRONG><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"> The primary objective of the ACCESS study is to document the safety of pasireotide LAR in patients with acromegaly.<wbr> The primary endpoint of the study is the proportion of patients who experience a treatment-emergent grade 3 or 4 adverse event or a serious AE.<wbr> The trial is ongoing and results are not currently available.<wbr> A copy of the poster is attached.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><U>Poster 0715</U></STRONG>: <STRONG style="mso-bidi-font-weight: normal;">Study Design of a Phase II Trial of subcutaneous Pasireotide alone or in combination with Cabergoline in patients with Cushings Disease</STRONG>, presented by Maria Fleseriu <EM style="mso-bidi-font-style: normal;">et al.<wbr></EM> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">This study was designed to evaluate safety and efficacy of pasireotide alone or in combination with cabergoline as a stepwise approach in patients with CD.<wbr> This presentation described the study design of the phase II multicenter, prospective, international, open-label, non-comparative with patients with confirmed diagnosis of CD.<wbr> A copy of the poster is attached.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Other <STRONG style="mso-bidi-font-weight: normal;">Novartis-sponsored posters</STRONG> described reviews and patterns of pharmacologic treatments in patients with acromegaly (0592- Patterns of Pharmacologic treatment in US patients with acromegaly, JD Carmichael <EM style="mso-bidi-font-style: normal;">et al.<wbr></EM> &amp; 16399- Systemic review of real-world evidence on treatment of Acromegaly, Nellesen D <EM style="mso-bidi-font-style: normal;">et al</EM>.<wbr>) and a further three posters described the treatment patterns, clinical and economic burden of Cushings Disease (0645, 0646, &amp; 0647, all presented by T Burton <EM style="mso-bidi-font-style: normal;">et al</EM>.<wbr>) Poster 0592 is attached with some of the key data shown below.<wbr></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: 'Times New Roman'; mso-fareast-theme-font: minor-fareast; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/5/ScreenCapture5.jpg?user-agent=rss"></SPAN></SPAN> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><U>LC1699 PhII Cushing's Results</U></STRONG> </div><div style="margin-bottom: 10px;">The results from a 22-week multicenter, open-label study of <SPAN style="mso-ascii-font-family: Calibri; mso-fareast-font-family: Calibri; mso-hansi-font-family: Calibri; mso-bidi-font-family: 'Times New Roman';">LC1699 (a potent inhibitor of 11</SPAN>&beta;-hydroxylase) in patients with Cushing&rsquo;s disease were presented which demonstrated that LC1699 normalised urinary free cortisol levels in these patients (Rosario Pivonello, OR17-4).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/13/ScreenCapture13.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/14/ScreenCapture14.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7721attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(61,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(51,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(38,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(51,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(179,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(33,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(42,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(42,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(40,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(40,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(35,6 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(43,3 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(38,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(35,8 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/15/ENDO%202014%20C2402%20Colao%20poster%5fFinal.pdf">ENDO 2014 C2402 Colao poster_Final.pdf</a>&nbsp;&nbsp;(360,6 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/16/ENDO%202014%20Biomarker%20poster%5fFinal.pdf">ENDO 2014 Biomarker poster_Final.pdf</a>&nbsp;&nbsp;(434,5 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/17/ENDO%202014%20C2305%20PK%20PD%20poster%5fFinal.pdf">ENDO 2014 C2305 PK PD poster_Final.pdf</a>&nbsp;&nbsp;(323,5 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/18/ENDO%202014%20Biochemical%20control%20survey%20poster%5fFinal.pdf">ENDO 2014 Biochemical control survey poster_Final.pdf</a>&nbsp;&nbsp;(465,8 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/19/4826%5fENDO%20ACCESS%20%5fPoster%5fv3.pdf">4826_ENDO ACCESS _Poster_v3.pdf</a>&nbsp;&nbsp;(576 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/20/ENDO%202014%20B2411%20Study%20design%20poster%5fFinal.pdf">ENDO 2014 B2411 Study design poster_Final.pdf</a>&nbsp;&nbsp;(520,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7721">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-08T18:32:02+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/1/ScreenCapture1.jpg" length="62612" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/2/ScreenCapture2.jpg" length="53020" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/3/ScreenCapture3.jpg" length="39870" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/4/ScreenCapture4.jpg" length="52300" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/5/ScreenCapture5.jpg" length="184073" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/6/ScreenCapture6.jpg" length="34074" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/7/ScreenCapture7.jpg" length="43622" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/8/ScreenCapture8.jpg" length="43462" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/9/ScreenCapture9.jpg" length="41619" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/10/ScreenCapture10.jpg" length="41624" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/11/ScreenCapture11.jpg" length="36463" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/12/ScreenCapture12.jpg" length="44330" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/13/ScreenCapture13.jpg" length="39014" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/14/ScreenCapture14.jpg" length="36619" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/15/ENDO%202014%20C2402%20Colao%20poster%5fFinal.pdf" length="369232" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/16/ENDO%202014%20Biomarker%20poster%5fFinal.pdf" length="444899" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/17/ENDO%202014%20C2305%20PK%20PD%20poster%5fFinal.pdf" length="331313" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/18/ENDO%202014%20Biochemical%20control%20survey%20poster%5fFinal.pdf" length="477016" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/19/4826%5fENDO%20ACCESS%20%5fPoster%5fv3.pdf" length="589799" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7721/20/ENDO%202014%20B2411%20Study%20design%20poster%5fFinal.pdf" length="532818" type="application/pdf"/></item><item>
<title>Novartis Supports Ethical Clinical Research [:Endocrinology:comp:Novartis, :Oncology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10917</link>
<description>Novartis Supports Ethical Clinical Research [:Endocrinology:comp:Novartis, :Oncology:comp:Novartis]</description><category>comp:Novartis</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10917</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10917">Novartis Supports Ethical Clinical Research</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10917">PharmaWorld10917</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 July 2014 | 17:37</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis has released new global guidelines for Investigator Initiated Trials (IITs).<wbr> The guidelines are designed to reinforce the company's commitment to the principles of ethics, governance and transparency, and its support of ethical clinical research.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Guidelines Principles</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>"Compliance with the highest ethical and scientific standards</LI>
<LI>Robust medical and scientific governance systems within Novartis</LI>
<LI>Global training on the guidelines for Novartis associates including the rules of independence of third party investigators/<wbr>sponsors</LI>
<LI>Financial transparency on funding support</LI>
<LI>Contractual requirement of third party sponsors to publish findings and report any safety information</LI>
<LI>Ongoing tracking and monitoring within Novartis and transparent sharing of information with investigators/<wbr>sponsors"</LI>
</UL> </div><div>Source: Novartis </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10917">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-08T17:37:47+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>NHS Scotland Assessment of BOTOX® [comp:Allergan, prod:Botox, dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7648</link>
<description>NHS Scotland Assessment of BOTOX® [comp:Allergan, prod:Botox, dis:Spasticity]</description><category>comp:Allergan</category><category>prod:Botox</category><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7648</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7648">NHS Scotland Assessment of BOTOX®</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7648">Neurology7648</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 08 July 2014 | 11:32</font><br><br><div style="margin-bottom: 10px;">Comment: Botox® for spasticity is not recommended for use within NHS Scotland, but is accepted for restricted use for the management of bladder dysfunctions.<wbr> Please see details below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Spasticity</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7648/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Bladder Dysfunctions</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7648/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><A href="http://www.scottishmedicines.org.uk/files/advice/botulinum_toxin_type_A_Botox_FINAL_June_2014_for_website.pdf">http:/<wbr>/<wbr>www.<wbr>scottishmedicines.<wbr>org.<wbr>uk/<wbr>files/<wbr>advice/<wbr>botulinum_toxin_type_A_Botox_FINAL_June_2014_for_website.<wbr>pdf</A> </div><!-- Comment details --><a name="neurology7648attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7648/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(75,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7648/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(92,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7648">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-08T11:32:00+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7648/1/ScreenCapture1.jpg" length="77728" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7648/2/ScreenCapture2.jpg" length="94893" type="image/jpeg"/></item><item>
<title>New Trial of Sativex as an Add-on Therapy in Subjects With Spasticity Due to MS [dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7644</link>
<description>New Trial of Sativex as an Add-on Therapy in Subjects With Spasticity Due to MS [dis:Spasticity, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Spasticity</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7644</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7644">New Trial of Sativex as an Add-on Therapy in Subjects With Spasticity Due to MS</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7644">Neurology7644</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 July 2014 | 17:23</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph3 trial is planned to start end of Q3 2014 to determine the effective dose range and to demonstrate a non-effective dose range of Sativex compared with placebo in relieving symptoms of spasticity due to multiple sclerosis (MS).<wbr> Locations have been listed in the US and UK.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Reference</STRONG>: <A href="http://clinicaltrials.gov/ct2/show/NCT01868048?recr=Open&amp;no_unk=Y&amp;cond=spasticity+OR+prostate+OR+botulinum+OR+acromegaly+OR+neuroendocrine+OR+growth+hormone+deficiency+OR+Huntington&amp;phase=012&amp;fund=2&amp;rank=7&amp;submit_fld_opt=">NCT01868048</A> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex"><STRONG>Primary Outcomes Measures</STRONG></P> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Physician Global Impression of Change (PGIC) questionnaire [ Time Frame: This is completed by the physician at each visit whilst using the study medication.<wbr> ] [ Designated as safety issue: No ]<BR></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change in mean Modified Ashworth Scale score from baseline to the end of treatment period.<wbr> [ Time Frame: The Modified Ashworth Scale will be performed at each visit of the study ] [ Designated as safety issue: No ] All 20 muscle groups were assessed for spasticity (using a 0-4 scale): 0= no increase in muscle tone to 4=considerable increase in muscle tone, passive movement is difficult.<wbr> The score for all 20 muscle groups were added to give a total score out of 80.<wbr> A decrease in score indicates an improvement in condition.<wbr></LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG>: Approx 711 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">The subject is at least 18 years of age or older.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Diagnosed with any disease sub-type of multiple sclerosis of at least six months duration.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Spasticity due to multiple sclerosis of at least six months duration, which is not wholly relieved with current anti-spasticity therapy, and which is expected to remain stable for the duration of the study.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject must be receiving at least one of the following anti-spasticity therapies to be eligible: Baclofen, Tizanidine, Clonazepam, Diazepam, Dantrolene.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Subject is willing to maintain anti-spasticity medication at a stable dose for the duration of the study and should be stable for 30 days prior to screening.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">If the subject is currently taking disease-modifying medication, this must be at a stable dose for at least three months prior to the screening visit; the dose must also remain stable for the duration of the study.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex"><STRONG>Timelines</STRONG></P> </div><div>Start date: Sept 2014 Completion date December 2016.<wbr> </div><!-- Comment details --><a name="neurology7644attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7644/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(34,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7644">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-07T17:23:29+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7644/1/ScreenCapture1.jpg" length="34931" type="image/jpeg"/></item><item>
<title>Gustave Roussy Institute and AstraZeneca Formed Strategic Partnership in Oncology</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9819</link>
<description>Gustave Roussy Institute and AstraZeneca Formed Strategic Partnership in Oncology</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9819</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9819">Gustave Roussy Institute and AstraZeneca Formed Strategic Partnership in Oncology</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9819">Oncology9819</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 July 2014 | 17:03</font><br><br><div style="margin-bottom: 10px;">Comment: Gustave Roussy will gain access to the AZ's pipeline of novel anti-cancer molecules for pre-clinical, translational and early clinical trials.<wbr> </div><div><DIV style="BORDER-BOTTOM: medium none; TEXT-ALIGN: left; BORDER-LEFT: medium none; BACKGROUND-COLOR: #ffffff; COLOR: #000000; OVERFLOW: hidden; BORDER-TOP: medium none; BORDER-RIGHT: medium none; TEXT-DECORATION: none">
<P><STRONG><FONT size="3">About the Collaboration</FONT></STRONG></P>
<P>The collaboration includes a number of parallel and inter- connected projects that will cover pre-clinical, translational and clinical phases of drug development.<wbr> </P>
<P>The parties will also create a joint Strategic Collaboration Plan that will be supervised by a Joint Steering Committee.<wbr></P>
<P><STRONG><FONT size="3">Prior Collaboration</FONT></STRONG></P>
<P>As part of a prior alliance, AstraZeneca already has several pre- clinical and clinical projects ongoing at Gustave Roussy.<wbr></P>
<P>Souce: IGR</P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9819">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-07T17:03:29+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Insights From the WCGC Meeting in Barcelona 25th-28th June</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7717</link>
<description>Key Insights From the WCGC Meeting in Barcelona 25th-28th June</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7717</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7717">Key Insights From the WCGC Meeting in Barcelona 25th-28th June</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7717">Endocrinology7717</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 04 July 2014 | 14:25</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to Eva Pineda (Medical advisor, Comm.<wbr>Ope.<wbr> Specialty Care), we can share her report from ESMO's 16th World Congress on Gastrointestinal Cancer in Barcelona.<wbr> Key points to emerge are that the CO-OPERATE II data will be presented at ESMO, whilst RADIANT-4 data is now likely to appear next year.<wbr> Importantly, initial data from the SWOG trial of octreotide/<wbr>bevacizumab vs interferon/<wbr>octreotide has demonstrated no significant difference based on central radiology (a disappointing outcome for Roche).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Report Plus Key Slides</STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">Around 4000 Oncologist/<wbr> 70 speakers of all continents (information coming of the Technical Secretary) attended the 16<SUP>th</SUP> edition of WCGC traditionally based in Barcelona.<wbr>,</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">Medical Oncologists explained that the relevant new onco medical information is presented mainly in ASCO, congress that traditionally occurs just 3 weeks before this one.<wbr> WCGC is an adequate forum to communicate new data just when has not been possible to do it in Chicago (deadline over.<wbr>.<wbr>.<wbr>), for example, Phase III CT data of Sutent in pNETs where presented here.<wbr> They believe that ASCO (end May, Chicago) and ESMO (end of September, Europe) have to be considered as the Oncology Congresses of reference.<wbr></FONT> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><U><SPAN lang="EN-US" style="font-size: 14pt; line-height: 115%;"><FONT face="Calibri">NETs session </FONT></SPAN></U></STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">Around 2500-2800 delegates attended this General Session</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">Chairs: M Ducreux (Gustave Roussy, France) and R Salazar (Catalan Institute of Oncology, Spain)</FONT> </div><div style="margin-bottom: 10px;"><OL style="margin-top: 0cm;" type="1"><LI style="margin: 0cm 0cm 10pt; mso-list: l3 level1 lfo6;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri">Recommendations for the management of pNETs </FONT></EM></STRONG>
</LI>
</OL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">Dr Wiedenmann, planned speaker for this talk, had problems due to France air-traffic controllers strike and he was not able to attend the Congress.<wbr> Dr Ruszniewski gave the talk with Dr Wiedenmann&rsquo; slides.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">Some interesting points discussed: </FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l1 level1 lfo3;"><FONT face="Calibri">Biotherapy is the most frequent first line medical treatment for NEN in Germany (36,7%)</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/1/ScreenCapture2.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l1 level1 lfo3;"><FONT face="Calibri">Guidelines: Using current ENETs Guidelines 2012 as reference</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="circle"><LI style="margin: 0cm 0cm 10pt; mso-list: l1 level2 lfo3;"><FONT face="Calibri">for pNETs with liver metastasis without extrahepatic involvement: in those patients with bilobar liver extension of pNETs, SSA was presented as a treatment option instead to surgery but just after Chemo and, mainly, MTT.<wbr></FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l1 level2 lfo3;"><FONT face="Calibri">for pNETs with metastatic, non resectable pNET: no changes were suggested</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI style="margin: 0cm 0cm 10pt; mso-list: l1 level1 lfo3;"><FONT face="Calibri">Dr Ruszniewski mentioned Cooperate 2 data (everolimus+ LAR vs everolimus) could be presented in ESMO 2014</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/2/ScreenCapture3.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l1 level1 lfo3;"><FONT face="Calibri">Clarinet: presentation of the study design, patient distribution, PFS (overall and by subgroups).<wbr> He mentioned the clinical relevance of pNET subgroup as well as the sample size was calculated for overall population no for pNET subgroup.<wbr></FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l1 level1 lfo3;"><FONT face="Calibri">Cost: comparative of the german cost of standard chemo (998 &euro;/<wbr>month) vs temozolamida/<wbr>capecitabine (3327 &euro;/<wbr>month), everolimus (4723 &euro;/<wbr>month) and Sutininib (5630&euro;/<wbr>month) was showed.<wbr></FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><STRONG style="mso-bidi-font-weight: normal;"><SPAN lang="EN-US" style="mso-fareast-font-family: 'Times New Roman';"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/3/ScreenCapture4.jpg?user-agent=rss"></SPAN></STRONG></FONT> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri">2.<wbr> Recommendations for the management of intestinal NETs.<wbr> Dr Pavel</FONT></EM></STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">Some interesting presented data: </FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l5 level1 lfo4;"><FONT face="Calibri">A systematic review of the incidence of neuroendocrine tumours</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/4/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l5 level1 lfo4;"><FONT face="Calibri">Just 10-30% of intestinal NET are associated with carcinoid syndrome.<wbr></FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/5/ScreenCapture6.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/6/ScreenCapture7.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l5 level1 lfo4;"><FONT face="Calibri">In those refractory carcinoid syndromes: dose escalation of both SSAs was suggested as first option, after that she recommend to add IFN and PPRT treatment.<wbr> She also mentioned pasireotide and telotristat.<wbr></FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/7/ScreenCapture8.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l5 level1 lfo4;"><FONT face="Calibri">Data of phase II telotristat study was showed and information that a phase III is ongoing was given.<wbr></FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l5 level1 lfo4;"><FONT face="Calibri">RADIANT 4 recruitment is over: data could be presented next year</FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l5 level1 lfo4;"><FONT face="Calibri">&ldquo;Wait and see&rdquo; still is an alternative for those patients with stable disease and/<wbr>or low Ki67.<wbr> She recommends image test/<wbr>6 months and, as soon as growth is detected (no RECIST criteria required), to start treatment.<wbr> PROMID Overal Survival data (ASCO 2013) were used to justify this positioning.<wbr></FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l5 level1 lfo4;"><FONT face="Calibri">Very nice comparative between PROMID and CLARINET designs.<wbr> Data of CLARINET global PFS, midgut and subgroups were discussed</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/8/ScreenCapture10.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/9/ScreenCapture11.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l1 level1 lfo3;"><FONT face="Calibri">Guidelines: Using current ENETs Guidelines 2012 as reference</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="circle"><LI style="margin: 0cm 0cm 10pt; mso-list: l1 level2 lfo3;"><FONT face="Calibri">She mentioned Octreotide LAR is described at ENETs Guidelines as the standard of treatment for well differentiated midgut NET.<wbr></FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/10/ScreenCapture12.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI>
<UL style="margin-top: 0cm;" type="circle"><LI style="margin: 0cm 0cm 10pt; mso-list: l1 level2 lfo3;"><FONT face="Calibri">for midgut NETs with liver metastasis without extrahepatic involvement: SSA could be the first treatment option instead of surgery in those patients with bilobar liver extension</FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l1 level2 lfo3;"><FONT face="Calibri">for midgut NETs with metastatic, non resectable disease: SSAs can be a first option not only for G1 with low tumor burden but also G2 with Ki67&lt;10% and high tumour burden</FONT>
</LI>
</UL>

</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l1 level1 lfo3;"><FONT face="Calibri">Review of the ongoing CT in midgut NETs</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/11/ScreenCapture13.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/12/ScreenCapture14.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;">3.<wbr> Liver directed therapy for liver mestastases</EM></STRONG>.<wbr> Dr Ruszniewski</FONT> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l8 level1 lfo9;"><FONT face="Calibri">Chemoembolization is a potential treatment of refractory carcinoid syndrome</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri">4.<wbr> Efficacy and toxicity of PRRT.<wbr> Dr Kwekkeboom (Rotterdam)</FONT></EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri">Some burning data: </FONT></EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/13/ScreenCapture15.jpg?user-agent=rss"></FONT></EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/14/ScreenCapture16.jpg?user-agent=rss"></FONT></EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/15/ScreenCapture17.jpg?user-agent=rss"></FONT></EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/16/ScreenCapture18.jpg?user-agent=rss"></FONT></EM></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/17/ScreenCapture19.jpg?user-agent=rss"></FONT></EM></STRONG> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri">On going clinical trial: Chemosensitisation with Capecitabine before PRRT</FONT></EM> </div><div style="margin-bottom: 10px;"><UL><LI><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri">Lutathera results avaialable data in 2016</FONT></EM>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><FONT face="Calibri"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri">Prospective trial of the neoadjucant use of Lutathera in patients with nonfunctioning pancreatic NETS proposed by Kweekboom in which predeined cirteria of tumor resectability should be incorporated</FONT></EM></FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><EM style="mso-bidi-font-style: normal;"><FONT face="Calibri">5.<wbr> Q&amp; A</FONT></EM></STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">1 to Prof Pavel about wait and see positioning</FONT> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">2 Dr Ruzsniewsky, and in an unrequested situation, commented: &ldquo;To be honest, no differences between both SSAs should exists&rdquo;.<wbr> In that moment , already out of time, no more than 200 delegates where at the session room</FONT> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><U><SPAN lang="EN-US" style="font-size: 14pt; line-height: 115%;"><FONT face="Calibri">Posters</FONT></SPAN></U></STRONG> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="mso-fareast-font-family: 'Times New Roman';"><FONT face="Calibri">Just five NETs posters where presented:</FONT></SPAN> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l4 level1 lfo2;"><SPAN lang="EN-US" style="mso-fareast-font-family: 'Times New Roman';"><FONT face="Calibri">Presentation of insulinoma in developing countries: experience of 7 insulinomas in India</FONT></SPAN>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l4 level1 lfo2;"><SPAN lang="EN-US" style="mso-fareast-font-family: 'Times New Roman';"><FONT face="Calibri">Most prevalent of pNETs in everyday clinical practice: review of papers published in different platforms (Brazil)</FONT></SPAN>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l4 level1 lfo2;"><SPAN lang="EN-US" style="mso-fareast-font-family: 'Times New Roman';"><FONT face="Calibri">Retrospective study of the prognostic value of various pathological and immunohistochemical features in tissue samples of patients with pNETs: 37 patients, Australia</FONT></SPAN>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l4 level1 lfo2;"><SPAN lang="EN-US" style="mso-fareast-font-family: 'Times New Roman';"><FONT face="Calibri">Gastric NET: a single center experience: 25 patients, Greece</FONT></SPAN>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l4 level1 lfo2;"><SPAN lang="EN-US" style="mso-fareast-font-family: 'Times New Roman';"><FONT face="Calibri">Efficacy of LA SSA in patients with highly differentiated GEP NETs: 44 patients, Russia (just abstract available, no poster presented)</FONT></SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><U><SPAN lang="EN-US" style="font-size: 14pt; line-height: 115%;"><FONT face="Calibri">Exhibit Area</FONT></SPAN></U></STRONG> </div><div style="margin-bottom: 10px;"><U><FONT face="Calibri">Booths/<wbr>Stands: </FONT></U> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0cm;" type="disc"><LI style="margin: 0cm 0cm 10pt; mso-list: l6 level1 lfo1;"><FONT face="Calibri">Merck- Serono, Roche, Sirtex, Bayer (all of them Platino Sponsors)</FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l6 level1 lfo1;"><FONT face="Calibri">Celgene, Amgen, Lilly , Sanofi (all of them Bronze Sponsors)</FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l6 level1 lfo1;"><FONT face="Calibri">Taiho, Nordic (Contributors)</FONT>
</LI>
<LI style="margin: 0cm 0cm 10pt; mso-list: l6 level1 lfo1;"><FONT face="Calibri">Nutricia: just exhibitor</FONT>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><FONT face="Calibri">No booth of Novartis, neither Pfizer.<wbr> </FONT> </div><div><FONT face="Calibri">Novartis Oncology was the sponsor of Ciber caf&eacute;</FONT> </div><!-- Comment details --><a name="endocrinology7717attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/1/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(54,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(133,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(50,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/4/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(58,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/5/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(109,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/6/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(96,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/7/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(118,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/8/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(122,6 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/9/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(143 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/10/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(137,2 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/11/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(120,2 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/12/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(151,3 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/13/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(101,8 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/14/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(75 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/15/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(138,7 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/16/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(72,8 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/17/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(117,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7717">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-04T14:25:22+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/1/ScreenCapture2.jpg" length="55400" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/2/ScreenCapture3.jpg" length="136552" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/3/ScreenCapture4.jpg" length="51592" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/4/ScreenCapture5.jpg" length="60312" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/5/ScreenCapture6.jpg" length="112480" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/6/ScreenCapture7.jpg" length="98690" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/7/ScreenCapture8.jpg" length="121337" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/8/ScreenCapture10.jpg" length="125532" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/9/ScreenCapture11.jpg" length="146446" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/10/ScreenCapture12.jpg" length="140463" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/11/ScreenCapture13.jpg" length="123089" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/12/ScreenCapture14.jpg" length="154926" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/13/ScreenCapture15.jpg" length="104219" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/14/ScreenCapture16.jpg" length="76830" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/15/ScreenCapture17.jpg" length="142043" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/16/ScreenCapture18.jpg" length="74523" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7717/17/ScreenCapture19.jpg" length="120490" type="image/jpeg"/></item><item>
<title>Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of Prostate Cancer [dis:Prostate, sub:Diagnostic, :PharmaWorld:sub:IP, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9817</link>
<description>Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of Prostate Cancer [dis:Prostate, sub:Diagnostic, :PharmaWorld:sub:IP, :PharmaWorld:mkt:NorthAmerica]</description><category>dis:Prostate</category><category>sub:Diagnostic</category><category>sub:IP</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9817</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9817">Rosetta Genomics Receives Notice of Allowance for U.<wbr>S.<wbr> Patent for the Prognosis and Treatment of Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=sub%3aDiagnostic"><font color="#e95e0b">:Oncology:sub:Diagnostic</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aIP"><font color="#e95e0b">:PharmaWorld:sub:IP</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9817">Oncology9817</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2014 | 16:22</font><br><br><div style="margin-bottom: 10px;">Comment: The patent claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer.<wbr> In addition, this biomarker, over-expressed in primary prostate tumors could be used as a therapeutic target for prostate cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Patent Reference</FONT></STRONG> </div><div style="margin-bottom: 10px;">Patent Application No.<wbr> 13/<wbr>390,995, entitled "Compositions and Methods for Prognosis and Treatment of Prostate Cancer.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">- leader in the field of microRNAs </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Technology</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/4/ScreenCapture4.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9817attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(73,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(38,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(46,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(89 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9817">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-03T16:22:21+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/1/ScreenCapture1.jpg" length="74973" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/2/ScreenCapture2.jpg" length="39810" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/3/ScreenCapture3.jpg" length="47571" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9817/4/ScreenCapture4.jpg" length="91114" type="image/jpeg"/></item><item>
<title>Bayer Inks Strategic Research Alliance for Endometriosis and Uterine Fibroids [comp:BayerSchering, dis:Gynea]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9816</link>
<description>Bayer Inks Strategic Research Alliance for Endometriosis and Uterine Fibroids [comp:BayerSchering, dis:Gynea]</description><category>comp:BayerSchering</category><category>dis:Gynea</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9816</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9816">Bayer Inks Strategic Research Alliance for Endometriosis and Uterine Fibroids</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aGynea"><font color="#e95e0b">:Oncology:dis:Gynea</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9816">Oncology9816</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2014 | 14:52</font><br><br><div style="margin-bottom: 10px;">Comment: Bayer and the University of Oxford will share responsibilities from basic research to early clinical trials in these two diseases.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Alliance</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG> </div><div style="margin-bottom: 10px;">Joint research projects will be performed at the University of Oxford and at the Bayer HealthCare R&amp;D Center in Berlin, Germany.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Duration</STRONG> </div><div style="margin-bottom: 10px;">The collaboration will be for an initial period of 2 years but is open for extension for up to 5 years.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Development</STRONG> </div><div style="margin-bottom: 10px;">Bayer is eligible to license both targets and potential drug candidates exclusively and will then be responsible for any subsequent clinical development and commercialization.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financials</STRONG> </div><div>The University of Oxford will receive undisclosed milestone and royalty payments depending on the successful development and approval of potential drug candidates </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9816">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-03T14:52:28+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>BINDS Therapeutics Ends Nanotechnology Collaboration with Amgen [comp:Amgen, class:KinaseInhibitors, :PharmaWorld:sub:Termination]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9815</link>
<description>BINDS Therapeutics Ends Nanotechnology Collaboration with Amgen [comp:Amgen, class:KinaseInhibitors, :PharmaWorld:sub:Termination]</description><category>comp:Amgen</category><category>class:KinaseInhibitors</category><category>sub:Termination</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9815</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9815">BINDS Therapeutics Ends Nanotechnology Collaboration with Amgen</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAmgen"><font color="#e95e0b">:Oncology:comp:Amgen</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aTermination"><font color="#e95e0b">:PharmaWorld:sub:Termination</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9815">Oncology9815</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2014 | 14:45</font><br><br><div style="margin-bottom: 10px;">Comment: The goal of this research collaboration was to optimize a specific therapeutic payload from Amgen.<wbr> Despite achieving the objective of high tumor concentrations, the results were not sufficiently compelling to proceed forward and both companies have agreed that the program will not be continued.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Amgen Collaboration</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=8714" class="defaultlink">Oncology8714: Amgen and BIND Biosciences Sign $180M Nanomedicine Deal</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Partnership Ongoing with Leading Pharma Companies</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/2/ScreenCapture2.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">- with Pfizer (<A href="http://ir.bindtherapeutics.com/releasedetail.cfm?ReleaseID=791529">http:/<wbr>/<wbr>ir.<wbr>bindtherapeutics.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=791529</A>) - BIND and Pfizer have entered into a global collaboration agreement to develop and commercialize Accurins™ utilizing select small-molecule targeted therapies.<wbr> The collaboration aims to employ BIND's Medicinal Nanoengineering® platform to impart tissue and cellular targeting capabilities to molecularly targeted drugs.<wbr> </div><div style="margin-bottom: 10px;">- with AstraZeneca (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=8906" class="defaultlink">Oncology8906: AZ &  BIND Therapeutics Announce Worldwide Development & Commercialisation Agreement For Cancer Nanomedicine</a>).<wbr> </div><div>- with Roche (<A href="http://ir.bindtherapeutics.com/releasedetail.cfm?ReleaseID=855513">http:/<wbr>/<wbr>ir.<wbr>bindtherapeutics.<wbr>com/<wbr>releasedetail.<wbr>cfm?ReleaseID=855513</A>) - BIND and Roche have entered into a research agreement to discover novel nanomedicines.<wbr> This collaboration will focus on combining BIND’s Accurin™ technology with Roche’s proprietary therapeutic payloads and targeting ligands to create Accurins for the treatment of diseases in a number of therapeutic areas outside of oncology.<wbr> </div><!-- Comment details --><a name="oncology9815attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(15,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(631 B)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(5,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(17,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9815">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-03T14:45:48+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/1/ScreenCapture1.jpg" length="16060" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/2/ScreenCapture2.jpg" length="631" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/3/ScreenCapture3.jpg" length="5568" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9815/4/ScreenCapture4.jpg" length="17574" type="image/jpeg"/></item><item>
<title>New Guidelines Presented at the 47th Annual Meeting of the ESPGHAN (June 9-12) [dis:Diarrhoea, sub:Probiotics, :PharmaWorld:congress:OTHERS, :PharmaWorld:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1987</link>
<description>New Guidelines Presented at the 47th Annual Meeting of the ESPGHAN (June 9-12) [dis:Diarrhoea, sub:Probiotics, :PharmaWorld:congress:OTHERS, :PharmaWorld:news]</description><category>dis:Diarrhoea</category><category>sub:Probiotics</category><category>congress:OTHERS</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1987</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1987">New Guidelines Presented at the 47th Annual Meeting of the ESPGHAN (June 9-12)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aOTHERS"><font color="#e95e0b">:PharmaWorld:congress:OTHERS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1987">GastroEnterology1987</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 July 2014 | 11:50</font><br><br><div style="margin-bottom: 10px;">Comment: The new guidelines were discussed at The European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN).<wbr> ESPGHAN and the European Society for Paediatric Infectious Diseases (ESPID) have closely worked on this production, with Evidence-Based Medicine (EBM) methodology.<wbr> <FONT size="2"><SPAN style="FONT-SIZE: 11pt"><FONT size="2"><SPAN lang="en-US" style="FONT-SIZE: 8.5pt"><FONT size="2">It was highlighted that Racecadotril, specific probiotics and also Smecta are recommended “weakly” based on “moderate quality evidence” to manage acute gastroenteritis in children, while gelatinne tannate is not recommended due to lack of evidence of efficacy.<wbr></FONT> </SPAN></FONT></SPAN></FONT>Thanks to Hélène Mathiex (Primary Care; Medical Development) please find below the main interesting points.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-SIZE: 11pt"><STRONG><FONT size="3">Main Points for Ipsen</FONT></STRONG></SPAN> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">Pr Alfredo Guarino was the Chairman and introduced the session .<wbr> </FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 36pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">- <STRONG>Pathogens - epidemiology</STRONG></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px 0px 0px 36pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">New rotavirus strain, and Norovirus are the more frequent</FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px 0px 0px 36pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">It seems that Rotavirus vaccination has not be able to decrease the number of acute gastroenteritis, and there is an important increase of Norovirus.<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px 0px 0px 36pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">Salmonella is decreasing.<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 36pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">- <STRONG>Management of Acute diarrhoea</STRONG></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px 0px 0px 36pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">A phone call to the pediatrician or general physician would be appropriate to appreciate the severity, and the need of medical consultation ( which could be frequently avoided if correct phone contact).<wbr> The Doctor could give the advice for the treatment.<wbr> ORS is the 1<SUP>st</SUP> line treatment in children should be always available at home.<wbr> </FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 36pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">- <STRONG>Drug treatment</STRONG></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 72pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">o Loperamide : NOT recommended (safety issues).<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 72pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">o Diosmectite : 2 news RCTs - may be considered : weak reco, moderate quality evidence.<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 72pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">o Racecadotril : 9 RCTs- may be considered : weak reco, moderate quality evidence (idem Smecta).<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 72pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">o Bismuth ; NOT recommended (safety issues).<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 72pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">o Zn : not recommended in EU (developed countries) as lack of evidence of efficacy.<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 72pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">o Probiotics : only 2 strains may be considered : weak reco, moderate quality evidence: Lactobacillus GG and S.<wbr> Boulardii, some are NOT recommended (safety issues++), other are simply not sufficiently efficient.<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 72pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">o Prebiotics : not recommended as lack of evidence of efficacy.<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 72pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">o Synbiotics : not recommended as lack of evidence of efficacy.<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 72pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">o Gelatinne Tannate : not recommended as lack of evidence of efficacy.<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px 0px 0px 36pt"><SPAN style="FONT-SIZE: 11pt"><FONT size="2">The wording “ may be considered” refers to the difference between ORS which is mandatory and the drug which is not.<wbr></FONT></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="TEXT-INDENT: -18pt; MARGIN: 0px 0px 0px 36pt"><FONT face="Calibri,sans-serif" size="2"><SPAN style="FONT-SIZE: 11pt">- <FONT face="Verdana" size="2">In case of hospitalization, the potential treatments in addition to rehydration could be probiotics (which decrease the hospitalization by 1 day) or the immunoglobulins.<wbr></FONT></SPAN></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px 0px 0px 36pt"><SPAN style="FONT-SIZE: 11pt"><B><FONT size="2">Conclusion</FONT></B></SPAN></DIV> </div><div style="margin-bottom: 10px;"><UL><LI><SPAN style="FONT-SIZE: 11pt"><B><FONT size="2">Smecta and racecadotril are on the same level, as probiotics.<wbr> But these last have the advantage to be also considered during hospitalization.<wbr> </FONT></B></SPAN></LI>
<LI><SPAN style="FONT-SIZE: 11pt"><B><FONT size="2">To be also highlighted : the position on Zn, which is not WHO position (WHO being focused on developing countries).<wbr></FONT></B></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><SPAN style="FONT-SIZE: 11pt"><SPAN lang="en-US" style="FONT-SIZE: 18pt"><STRONG><FONT size="3">Reference of the Publication</FONT></STRONG></SPAN></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><SPAN style="FONT-SIZE: 11pt"><SPAN lang="en-US" style="FONT-SIZE: 18pt"><FONT size="2"><STRONG>European Society for Paediatric Gastroenterology, Hepatology, and Nutrition/<wbr>European Society for Paediatric Infectious Diseases Evidence-based Guidelines for the Management of Acute Gastroenteritis in Children in Europe: Update 2014</STRONG>.<wbr></FONT></SPAN></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><SPAN style="FONT-SIZE: 11pt"><SPAN lang="en-US" style="FONT-SIZE: 8.5pt"><FONT size="2"><U>Authors</U> Guarino Alfredo; Ashkenazi Shai; Gendrel Dominique; Vecchio Andrea Lo; Shamir Raanan; Szajewska Hania </FONT></SPAN></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><SPAN style="FONT-SIZE: 11pt"><SPAN lang="en-US" style="FONT-SIZE: 8.5pt"><FONT size="2">Affiliation *Department of Pediatrics, University of Naples Federico II, Naples, Italy .<wbr>dag.<wbr>Schneider Children's Medical Center, Petach-Tikva, and Felsenstein Medical Research Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel .<wbr>dbldag.<wbr>University Paris 5 and Necker-Enfants-Malades, Paris, France Schneider Children's Medical Center, Petach-Tikva, and Institute of Gastroenterology, Nutrition, and Liver Diseases, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel , Medical University of Warsaw, Department of Pediatrics, Warsaw, Poland.<wbr>, Europe; Italy; France; Israel; Poland; </FONT></SPAN></SPAN></DIV> </div><div><DIV style="MARGIN: 0px"><SPAN style="FONT-SIZE: 11pt"><SPAN lang="en-US" style="FONT-SIZE: 8.5pt"><FONT size="2"><U>Source</U> Journal of pediatric gastroenterology and nutrition, (2014 Mar 31) .<wbr> (Electronic Publication Date: 31 Mar 2014) .<wbr> Jul 2014 ; vol.<wbr> 59: iss.<wbr> 1: pp 132-152E-ISSN: 1536-4801.<wbr> L-ISSN: 0277-2116.<wbr>, 2014, 10.<wbr>1097/<wbr>MPG.<wbr>0000000000000375</FONT></SPAN></SPAN></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1987">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-03T11:50:51+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Rottapharm Madaus Sets Price Range for IPO [:PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1986</link>
<description>Rottapharm Madaus Sets Price Range for IPO [:PharmaWorld:sub:Finance]</description><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1986</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1986">Rottapharm Madaus Sets Price Range for IPO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1986">GastroEnterology1986</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 July 2014 | 17:53</font><br><br><div style="margin-bottom: 10px;">Comment: The company, focused on research in areas like anti-inflammatory-anti-rheumatic, bone metabolism, menopause &amp; gastrointestinal disorders, intends to use the net proceeds from the offering to fund new acquisitions, launch new products and expand into new markets.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Financial Details of the IPO</FONT></STRONG> </div><div style="margin-bottom: 10px;"><P class="story-body-text">Rottapharm said that it expected an IPO of its shares later this month to value the company at up to 1.<wbr>8 million euros (about $2.<wbr>46 billion).<wbr></P> </div><div style="margin-bottom: 10px;"><P class="story-body-text">Rottapharm, which operates under the name Rottapharm|Madaus, said that it expected to price its offering of 50 million shares at €7.<wbr>25 to €9 a share.<wbr> The bottom end of the price range would value the company at about €1.<wbr>45 billion.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="story-body-text">The offering represents about 25 percent of Rottapharm’s share capital, and it expects to list on the Mercato Telematico Azionario of the Borsa Italiana exchange in Milan</P> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company's Top10</FONT></STRONG> <STRONG><FONT size="3">Products</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1986/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">With the acquisition of the German Madaus Pharma, specialized in the production of natural pharmaceutics, Rottapharm strengthened a route already undertaken by many of its brands: from natural origin to active principle.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">Rottapharm|Madaus's strategy is set on growth not only through continuous investment in R&amp;D and the consequent launching of new and innovative products, but also through possible new acquisitions in foreign countries.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ongoing Trials</FONT></STRONG> </div><div>Please see <A href="http://clinicaltrials.gov/ct2/results?recr=Open&amp;spons=Rottapharm">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>results?recr=Open&amp;spons=Rottapharm</A> </div><!-- Comment details --><a name="gastroenterology1986attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1986/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(55,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1986/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(56 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1986/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(131,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1986">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-02T17:53:32+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1986/1/ScreenCapture1.jpg" length="57066" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1986/2/ScreenCapture2.jpg" length="57384" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1986/3/ScreenCapture3.jpg" length="134881" type="image/jpeg"/></item><item>
<title>Raptor Pharmaceuticals Enters Into $70m Financing Traction With HealthCare Royalty Partners</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10911</link>
<description>Raptor Pharmaceuticals Enters Into $70m Financing Traction With HealthCare Royalty Partners</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10911</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10911">Raptor Pharmaceuticals Enters Into $70m Financing Traction With HealthCare Royalty Partners</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10911">PharmaWorld10911</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 July 2014 | 17:52</font><br><br><div style="margin-bottom: 10px;">Comment: Orphan Drug Company Raptor has entered into an agreement with HC 
Royalty Partners for $70m in funding which includes $60m in new convertivle 
senior notes.<wbr> The new capital will be used for expansion of the company's 
manufacturing capacity, for expansion of commercial operations in Europe for 
Procysbi (a drug expected to generate global net revenue of $55-65m this 
year) and the advancement of the company's development programs which 
include's RP-103 for Huntington's Disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the agreement</STRONG> </div><div style="margin-bottom: 10px;">Under the terms of the financing agreement, the convertible notes to be 
issued to HC Royalty and its affiliates will pay interest quarterly at a rate of 
8.<wbr>0% per year.<wbr> The notes mature on August 1, 2019 unless earlier converted, 
redeemed or repurchased in accordance with their terms prior to such date.<wbr> Prior 
to August 1, 2019 the notes are convertible into shares of Raptor common stock 
at an initial conversion rate of 57.<wbr>14 shares per $1,000 principal amount of 
notes, subject to adjustment, which is equivalent to a conversion price of 
$17.<wbr>50 per share, representing a 49.<wbr>6% premium over the closing price of 
Raptor's common stock of $11.<wbr>70 per share on July 1, 2014.<wbr> In addition, the 
notes are subject to automatic conversion into shares of Raptor common stock or 
redemption, at Raptor's election subject to certain conditions, if Raptor's 
share price is at or above 175% of the conversion price over a 30 consecutive 
day period.<wbr> Any payment of the principal amount of the notes will be subject to 
a 10% payment premium.<wbr> </div><div style="margin-bottom: 10px;">The terms of the loan agreement signed December 20, 2012 have been revised to 
provide for an additional $10 million in funding.<wbr> The base interest rate has 
been revised to an annual fixed rate of 8.<wbr>0% compared to the original 10.<wbr>75%.<wbr> 
The Synthetic Royalty variable rate has been consolidated and revised to 8.<wbr>0% on 
the first $50 million of revenue, from the original two-tier rate of 12.<wbr>25% on 
the first $25 million and 6.<wbr>0% on the second $25 million of net revenue.<wbr> The 
second tier of 2.<wbr>0% on net sales above $50 million remains unchanged.<wbr> The 
scheduled maturity date of the term loans under the loan agreement is March 31, 
2020.<wbr>  Starting on June 30, 2015, the term loans are scheduled to be repaid 
in equal quarterly principal payments of $3 million, with the remaining 
principal paid on the scheduled maturity date.<wbr> All amounts owed under 
the loan agreement will continue to be secured by substantially all assets of 
the company.<wbr> </div><div style="margin-bottom: 10px;">With the new financing, Raptor will have $120m in cash on its balance 
sheet.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Perspectives</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the agreement Raptor's CEO stated "This financing with HC 
Roylaty demsontrates their belief in Raptor's future prospects, provides balance 
sheet strength, and reduces the cost of capital of our debt facility.<wbr>" </div><div style="margin-bottom: 10px;">Clark Futch Founding Managing Director of HC Royalty  notes that:- 
"TheRaptor's franchise which includs PROCYBI is an asset of significant value 
that has performed above our expectations.<wbr> We continue to believe cystinosis 
continues to present a significant global market opportunity for the 
company".<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Development Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/4/ScreenCapture4.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.raptor.com">www.<wbr>raptor.<wbr>com</A> </div><!-- Comment details --><a name="pharmaworld10911attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(191,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(232,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(303,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(206,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10911">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-02T17:52:52+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/1/ScreenCapture1.jpg" length="195702" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/2/ScreenCapture2.jpg" length="238415" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/3/ScreenCapture3.jpg" length="310891" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10911/4/ScreenCapture4.jpg" length="211267" type="image/jpeg"/></item><item>
<title>Novartis to Start Registration Trial with LC1699 for Cushing's Disease [dis:Cushing, :PharmaWorld:sub:ClinicalTrial, comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7714</link>
<description>Novartis to Start Registration Trial with LC1699 for Cushing's Disease [dis:Cushing, :PharmaWorld:sub:ClinicalTrial, comp:Novartis]</description><category>dis:Cushing</category><category>sub:ClinicalTrial</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7714</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7714">Novartis to Start Registration Trial with LC1699 for Cushing's Disease</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7714">Endocrinology7714</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 July 2014 | 17:16</font><br><br><div style="margin-bottom: 10px;">Comment: This pivotal trial intends to support the registration of LCI699 for the treatment of patients with Cushing's disease in the EU, Japan, and other countries.<wbr> It is running in parallel with another trial started in March 2011 which will determine whether the drug can safely reduce the level of urinary free cortisol in patients with Cushing's disease (NCT01331239).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Registration Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><FONT size="2"><A href="http://clinicaltrials.gov/ct2/show/NCT02180217?term=LCI699&amp;recr=Open&amp;rank=1&amp;submit_fld_opt=">NCT02180217</A></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><FONT size="2">Recruitment: approx 132</FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><FONT size="2">Timelines start date July 2014 /<wbr> Completion May 2018</FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV class="identifier"><FONT size="2">PE: Proportion of randomized patients with: mUFC &lt;/<wbr>= ULN [ Time Frame: Week 34 (8 weeks) ]</FONT></DIV> </div><div style="margin-bottom: 10px;"><P class="identifier"><STRONG><FONT size="3">Recent Reference</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">Conclusion from a multi-center, POC study has recently shown that LCI699, a potent 11&beta;-hydroxylase inhibitor, was efficacious and well tolerated in patients with Cushing's disease.<wbr> </div><div style="margin-bottom: 10px;"><EM>J Clin Endocrinol Metab</EM>.<wbr> 2014 Apr;99(4):1375-83. doi: 10.<wbr>1210/<wbr>jc.<wbr>2013-2117.<wbr> Epub 2013 Dec 11.<wbr> - <FONT size="2">LCI699, a potent 11&beta;-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing's disease: results from a multicenter, proof-of-concept study.<wbr></FONT> </div><div><DIV class="auths">Bertagna X<SUP>1</SUP>, Pivonello R, Fleseriu M, Zhang Y, Robinson P, Taylor A, Watson CE, Maldonado M, Hamrahian AH, Boscaro M, Biller BM.<wbr></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7714">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-02T17:16:56+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Trial Evaluating Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies [sub:Diagnostic, dis:MidGutNET, dis:pNET]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7712</link>
<description>New Trial Evaluating Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies [sub:Diagnostic, dis:MidGutNET, dis:pNET]</description><category>sub:Diagnostic</category><category>dis:MidGutNET</category><category>dis:pNET</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7712</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7712">New Trial Evaluating Gallium-68 DOTA-TOC Imaging of Somatostatin Receptor Positive Malignancies</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3apNET"><font color="#e95e0b">:Endocrinology:dis:pNET</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=sub%3aDiagnostic"><font color="#e95e0b">:Endocrinology:sub:Diagnostic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7712">Endocrinology7712</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 July 2014 | 16:26</font><br><br><div style="margin-bottom: 10px;">Comment: The University of California is sponsoring a new phII 
efficacy study to determine if Gallium-68 labeled DOTA-TOC PET/<wbr>C 
T will result in the delineation of more lesions in patients with SSA 
receptor positivie malignancies than with conventional imaging with 
Octreoscan.<wbr> </div><div style="margin-bottom: 10px;">The conditions to be evaluated include neuroendocrine tumours, 
paranganglioma, carcinoid tumours and neuroblastoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Numbers &amp; Timelines</STRONG> </div><div style="margin-bottom: 10px;">The 120 patient study started in June and is due to collect in terms of 
primary outcome measures in June 2016 </div><div style="margin-bottom: 10px;"><STRONG>Primary Outcome Measures:</STRONG> </div><div style="margin-bottom: 10px;"><UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Number 
  of lesions visualized [ Time Frame: 24 hours from injection of 
  DOTA-TOC ] </LI>
</UL> </div><div><STRONG>ClinicalTrials Identifier</STRONG>:- NCT02177773 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7712">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-02T16:26:45+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Allergan Sponsored Aesthetic Trial Evaluating Combined Facial Treatment - HARMONY Study [sub:Aesthetics, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7643</link>
<description>New Allergan Sponsored Aesthetic Trial Evaluating Combined Facial Treatment - HARMONY Study [sub:Aesthetics, news]</description><category>sub:Aesthetics</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7643</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7643">New Allergan Sponsored Aesthetic Trial Evaluating Combined Facial Treatment - HARMONY Study</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7643">Neurology7643</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 July 2014 | 15:59</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan is listing in ClinicalTrials.<wbr>gov a new US phIV patient 
satisfaction study which will evaluate the aesthetic and psychological impact of 
comined treatment with BOTOX® Cosmetic, JUVÉDERM® ULTRA XC, JUVÉDERM® ULTRA PLUS 
XC, JUVÉDERM® VOLUMA® XC, and LATISSE® (bimatoprost ophthalmic solution) for 
facial rrhytides, crow's feet lines, glabellar line and nasolabial fold.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Patients Nos and Timelines</STRONG> </div><div style="margin-bottom: 10px;">The study was due to start this June and complete in April 2015 and involve 
100 patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Endpoints</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="body3">Primary Outcome Measures: 
<UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change 
  from Baseline in Satisfaction with Facial Appearance Overall Using a 10-item 
  Questionnaire [ Time Frame: Baseline, Month 4 ] 
<BR></LI>
</UL></DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">Secondary Outcome Measures: </DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL style="MARGIN-BOTTOM: 1ex; MARGIN-TOP: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change 
  from Baseline in Aging Appearance Using a 7-item Questionnaire 
  [ Time Frame: Baseline, Month 4 ] 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change 
  from Baseline in Age Appraisal Using a Visual Analogue Scale (VAS) 
  [ Time Frame: Baseline, Month 4 ] [
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change 
  from Baseline in Social Confidence Using an 8-item Questionnaire 
  [ Time Frame: Baseline, Month 4 ] 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Change 
  from Baseline in Psychological Well-Being Using a 10-item Questionnaire 
  [ Time Frame: Baseline, Month 4 ] 
  </LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Patient's Self- Perception of Age Using a 3-item 
  Questionnaire [ Time Frame: Baseline, Month 4 ] 
  [ Designated as safety issue: No ]<BR></LI>
</UL></DIV> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">ClinicalTrial Identifier:- NCT02176356</P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7643">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-02T15:59:22+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Pharma Mar to Distribute GP Pharm's Politrate® (leuprorelin) in Italy [prod:Leuprorelin, :PharmaWorld:mkt:Italy, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids250</link>
<description>Pharma Mar to Distribute GP Pharm's Politrate® (leuprorelin) in Italy [prod:Leuprorelin, :PharmaWorld:mkt:Italy, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids250</comments><category>prod:Leuprorelin</category><category>mkt:Italy</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids250</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=250">Pharma Mar to Distribute GP Pharm's Politrate® (leuprorelin) in Italy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:DKPHybrids:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=prod%3aLeuprorelin"><font color="#e95e0b">:DKPHybrids:prod:Leuprorelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aItaly"><font color="#e95e0b">:PharmaWorld:mkt:Italy</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids250">DKPHybrids250</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 July 2014 | 13:01</font><br><br><div style="margin-bottom: 10px;">Comment: The agreement designates Pharma Mar S.<wbr>R.<wbr>L.<wbr> as the sole distributor of Politrate&reg; in Italy; the product will be supplied to Pharma Mar S.<wbr>R.<wbr>L.<wbr> by GP Pharm.<wbr> Pharma Mar plans to begin distributing Politrate&reg; in Italy in October.<wbr> Initially the 1M dosage will be distributed, with plans to subsequently add the 3M dose.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Presence on the French Territory</FONT></STRONG> </div><div style="margin-bottom: 10px;">End of May, the company started commercial activities, with a sales team of 14 persons </div><div style="margin-bottom: 10px;"><UL><LI>as per today, Lurate&reg;/<wbr>Politrate&reg; is not registered in France.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for Pharma Mar</FONT></STRONG> </div><div style="margin-bottom: 10px;">The agreement is synergic with PharmaMar's commercial activities in other EU countries and is part of the company's strategy of enhancing its sales network by adding other products to its portfolio.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>PharmaMar has a specialised sales team for the commercialisation in Europe.<wbr>
</LI>
<LI>Sales in the big Western European countries are covered by a sales network established for PharmaMar under an agreement with Quintiles Group organised in nine territories.<wbr>
</LI>
<LI>In the rest of Europe, promotional and sales distribution agreements have been signed with <STRONG>Swedish Orphan Biovitrum</STRONG> for the Nordic countries and Eastern Europe, and with Genesis Pharma for Greece, Cyprus and the Balkan region
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Regulatory Status of Politrate&reg;/<wbr>Lutrate&reg;</FONT></STRONG> </div><div style="margin-bottom: 10px;">Lutrate&reg; 1 month has been approved in 23 countries of the European Union, including Spain, Germany, the United Kingdom and Italy.<wbr> </div><div style="margin-bottom: 10px;">It is expected to be available shortly in the US (the registration dossier for Lutrate&reg; Depot 1 and 3 months is expected to be submitted in the US in the second half of 2014) and many other countries.<wbr> </div><div style="margin-bottom: 10px;">The registration dossier for Lutrate&reg; Depot 3 months was submitted (DCP with Spain as the reference country) in April 2014.<wbr> </div><div style="margin-bottom: 10px;">GP Pharm is currently developing Lutrate&reg; Depot 6 months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pharma Mar SnapShot</FONT></STRONG> </div><div style="margin-bottom: 10px;">PharmaMar is a Spanish member of the Zeltia Group, a leader in the development of antitumor drugs of marine origin </div><div style="margin-bottom: 10px;"><STRONG>Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/250/2/ScreenCapture2.jpg?user-agent=rss"> </div><div><EM>Source: GP Pharm /<wbr> Pharma Mar</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="DKPHybrids258c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Thanks to Michela Maraschi we have been informed that <FONT face="Calibri,sans-serif" size="2"><SPAN style="font-size: 11pt;">Politrate 1 month will reach the market in Italy from January 19th.<wbr></SPAN></FONT> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0px; font: 15px wf_segoe-ui_normal, 'Segoe UI', 'Segoe WP', Tahoma, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #212121; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><FONT face="Times New Roman,serif" size="3"><SPAN style="background-color: white; font-size: 12pt;"><FONT color="black" face="Calibri,sans-serif">Price at the NET of the mandatory discounts (-5%; -5%)</FONT></SPAN></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0px; font: 15px wf_segoe-ui_normal, 'Segoe UI', 'Segoe WP', Tahoma, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #212121; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><FONT face="Times New Roman,serif" size="3"><SPAN style="background-color: white; font-size: 12pt;"><FONT color="black" face="Calibri,sans-serif">EFP: &euro;84,83</FONT></SPAN></FONT></DIV> </div><div><DIV style="widows: 2; text-transform: none; background-color: white; text-indent: 0px; margin: 0px; font: 15px wf_segoe-ui_normal, 'Segoe UI', 'Segoe WP', Tahoma, Arial, sans-serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #212121; word-spacing: 0px; -webkit-text-size-adjust: auto; -webkit-text-stroke-width: 0px;"><FONT face="Times New Roman,serif" size="3"><SPAN style="background-color: white; font-size: 12pt;"><FONT color="black" face="Calibri,sans-serif">PP: &euro;140,01</FONT></SPAN></FONT></DIV> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids258" class="commentpermalink">DKPHybrids258</a> / <span class="date">14 January 2015</span> /
<span class="time">16:48:47 o'clock CET</span>
</font></div><a name="dkphybrids250attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/250/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(66,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/250/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(59 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=250">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-02T13:01:43+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/250/1/ScreenCapture1.jpg" length="68288" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/250/2/ScreenCapture2.jpg" length="60377" type="image/jpeg"/></item><item>
<title>Genentech Acquires Next Generation Therapy for the Treatment of Hormone-Driven Cancers [news, :Endocrinology:comp:Roche, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9813</link>
<description>Genentech Acquires Next Generation Therapy for the Treatment of Hormone-Driven Cancers [news, :Endocrinology:comp:Roche, :PharmaWorld:sub:Acquisition]</description><category>news</category><category>comp:Roche</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9813</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9813">Genentech Acquires Next Generation Therapy for the Treatment of Hormone-Driven Cancers</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9813">Oncology9813</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 July 2014 | 10:39</font><br><br><div style="margin-bottom: 10px;">Comment: The $1.<wbr>7 bn acquisition of Seragon Pharmaceuicals, will expand Genentech's pipeline in next-generation therapies that target the estrogen receptor to treat hormone-receptor positive cancer (such as ER+ breast cancer), and provide the opportunity to accelerate development of Selective Estrogen Receptor Degrader (SERD) platform.<wbr> Of note, Seragon was spun out of Aragon Pharm.<wbr> in 2013 following its acquisition by J&amp;J.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for the Deal</FONT></STRONG> </div><div style="margin-bottom: 10px;">Roche has long dominated the field of breast cancer with drugs such as Herceptin and recently won approval for Kadcyla and Perjeta, two treatments for patients whose cancer cells contain increased amounts of the protein known as HER2.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Financial Terms</FONT></STRONG> </div><div style="margin-bottom: 10px;">$725 million in cash up front along with $1.<wbr>0 billion in contingent development milestone payments.<wbr> </div><div style="margin-bottom: 10px;">The transaction is expected to close in the third quarter of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Seragon Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;">Lead candidate is <STRONG>ARN-810,</STRONG> currently in Ph1 for the treatment of endocrine-resistant breast cancer.<wbr> </div><div style="margin-bottom: 10px;">Seragon is developing a 2nd SERD compound that is chemically and pharmacologically distinct from ARN-810 that not only has potential in ER+ breast cancer but also ER+ endometrial and ovarian cancer.<wbr>
 </div><div style="margin-bottom: 10px;"><STRONG>Potential Competition</STRONG> </div><div style="margin-bottom: 10px;"><FONT size="2">Breast cancer indication of Astellas' <STRONG>Xtandi and ARN-810</STRONG> are in Ph2 and Ph1, respectively.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><FONT size="2">ARN-810 utilizes a new mechanism called SERD (selective estrogen receptor degraders), Xtandi is an oral androgen receptor blocker.<wbr></FONT> </div><div style="margin-bottom: 10px;">ARN-810 is being created by companies which boast a solid track record with ARN-509, and thus could be a potential competitor of Xtandi.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Seragon SnapShot</FONT></STRONG> </div><div style="margin-bottom: 10px;">Founded in 2013 </div><div style="margin-bottom: 10px;">Seragon is based in San Diego, CA and financed by legacy Aragon investors The Column Group, OrbiMed Advisors, Aisling Capital, TopSpin and venBio.<wbr> </div><div>Richard Heyman, former CEO of Aragon, has been named CEO of Seragon.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9813">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-02T10:39:21+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>TheraCoat Seeks Strategic Partners for its TCGel in Bladder Diseases [class:BotulinumToxins, dis:iOAB, :PharmaWorld:sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7639</link>
<description>TheraCoat Seeks Strategic Partners for its TCGel in Bladder Diseases [class:BotulinumToxins, dis:iOAB, :PharmaWorld:sub:xLicensing]</description><category>class:BotulinumToxins</category><category>dis:iOAB</category><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7639</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7639">TheraCoat Seeks Strategic Partners for its TCGel in Bladder Diseases</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7639">Neurology7639</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 July 2014 | 18:04</font><br><br><div style="margin-bottom: 10px;">Comment: TCGel is a novel Internal Cavity Drug Retention (ICDR) system via reverse thermal gelation technology.<wbr> In ongoing trials, it is assessed with mitomycin for NMIBC and BTX for use in OAB.<wbr> is in the process of raising USD 10m for a minority stake to support clinical trials in Europe and the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Theracoat Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- founded in 2004 by uro-oncologists, experts in polymer formulation and veterans in the medical device</FONT><FONT size="2">.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">- Headquarters are located in Israel with an office in US.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;">- Business Development (for partnering opportunities, Dr Sari Prutchi Sagiv at: <A href="mailto:sari.sagiv@theracoat.com">sari.<wbr>sagiv@theracoat.<wbr>com</A>) </div><div style="margin-bottom: 10px;"><UL><LI>A strategic partner, such as a pharma company with generic or therapeutic drugs in urology or bladder cancer, could be a potential investor.<wbr> Strategic players could also help take TheraCoat to market</LI>
<LI>Management could consider co-development, in-licensing and out-licensing partnerships, among others.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">From <A href="http://theracoat.com/">http:/<wbr>/<wbr>theracoat.<wbr>com</A>, see <A href="http://theracoat.com/news/in-the-press/">original source</A>.<wbr> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG>Ongoing Trials</STRONG></FONT> </div><div style="margin-bottom: 10px;">Please see <A href="http://clinicaltrials.gov/ct2/results/displayOpt?flds=a&amp;flds=b&amp;flds=f&amp;flds=c&amp;flds=k&amp;flds=n&amp;submit_fld_opt=on&amp;term=theracoat&amp;recr=Open&amp;show_flds=Y">http:/<wbr>/<wbr>clinicaltrials.<wbr>gov/<wbr>ct2/<wbr>results/<wbr>displayOpt?flds=a&amp;flds=b&amp;flds=f&amp;flds=c&amp;flds=k&amp;flds=n&amp;submit_fld_opt=on&amp;term=theracoat&amp;recr=Open&amp;show_flds=Y</A> </div><div style="margin-bottom: 10px;"><UL><LI>NCT02179099 - Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients (Phase1/<wbr>Phase2)</LI>
<LI>NCT01997983 - Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients(Phase1/<wbr>Phase2)</LI>
<LI>NCT01803295 - Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)</LI>
<LI>NCT01799499 - A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Technology</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <A href="http://theracoat.com/technology/">http:/<wbr>/<wbr>theracoat.<wbr>com/<wbr>technology/<wbr></A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7639/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7639attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7639/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(70,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7639/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(80,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7639">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-01T18:04:01+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7639/1/ScreenCapture1.jpg" length="71947" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7639/2/ScreenCapture2.jpg" length="82356" type="image/jpeg"/></item><item>
<title>Novartis About To Be Hit By The US Launch Of Generic Diovan [sub:Generics, mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10910</link>
<description>Novartis About To Be Hit By The US Launch Of Generic Diovan [sub:Generics, mkt:NorthAmerica]</description><category>sub:Generics</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10910</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10910">Novartis About To Be Hit By The US Launch Of Generic Diovan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aGenerics"><font color="#e95e0b">:PharmaWorld:sub:Generics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10910">PharmaWorld10910</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 01 July 2014 | 10:17</font><br><br><div style="margin-bottom: 10px;">Comment: The long-delayed and highly anticipated launch of generic Diovan is 
about to happen.<wbr> This represents a  potenitally significant boost for the 
Indian drugmaker Ranbaxy Laboratories and its owner Sun Pharmaceuticals but 
a significant threat to Novartis and its $1.<wbr>7bn of US Diovan sales.<wbr> </div><div style="margin-bottom: 10px;">Diovan went of patent in the US in 2012 and Ranbaxy has the 180-day 
first-to-file exclusivity on the drug.<wbr> However with bans imposed on Ranbaxy's 5 
FDA-approved plants because of quality issues it has been impossible for Ranbaxy 
to get a product to market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recent Developments</STRONG> </div><div style="margin-bottom: 10px;">Last Thursday the FDA approved Ranbaxy's Ohm Laboratories in New Jersey to 
start making valsartan the generic of Diovan in 40mg, 80mg, 160mg and 320mg 
doses.<wbr> It is the only one of Ranb axy's 5 FDA-approved plants that has escaped 
bans for sales in the US.<wbr> As soon as sufficient supplies have been manufactured 
to meet the needs of the market the generic version will be launched.<wbr> </div><div style="margin-bottom: 10px;">The delay has been a windfall for Novartis which should have been dealing 
with plunging sales but instead reported W/<wbr>W revenues of $3.<wbr>5bn of which the US 
contributed $1.<wbr>7bn.<wbr> </div><div>Source: Fiercepharma </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10910">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-01T10:17:52+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Allergan's R&amp;D Business Update Call - Mix Of Good &amp; Bad News But Nothing On Toxins [comp:Allergan, dis:Migraine, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7638</link>
<description>Allergan's R&amp;D Business Update Call - Mix Of Good &amp; Bad News But Nothing On Toxins [comp:Allergan, dis:Migraine, news]</description><category>comp:Allergan</category><category>dis:Migraine</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7638</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7638">Allergan's R&D Business Update Call - Mix Of Good & Bad News But Nothing On Toxins</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7638">Neurology7638</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 01 July 2014 | 09:45</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan hosted a short webcast yesterday to comment on three key 
R&amp;D developments: i) new information of DARPin vs Lucentis in AMD; ii) 
approval of Osurdex in a subpopulation of diabetic macular edema patients; and, 
iii) another complete response letter from the FDA on the migraine drug Levadex 
which will delay the next FDA action until at least Q215 and iv) good durability 
data on bimatoprost SR implants.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>DAPRin vs.<wbr> Lucentis Data In AMD (Age-related Macular 
Degeneration)</STRONG> </div><div style="margin-bottom: 10px;">Leerink analysts are suggesting that whilst at first sight it looks as though 
the phIII DAPRin efficacy data was numerically better at 16 weeks on second 
appraisal there is a belief that Lucentis underperformed.<wbr> The analysts 
state: "While we believe AGN's conclusion that "abicipar at the 2mg dose is at 
least as effective as monthly Lucnetis with a longer duration of action" is 
consistent with the phII data, a comparison of data in the labels for both 
Lucentis and Eylea suggests that 5.<wbr>3 letters would be a relatively poor 
performance for Lucentis.<wbr> The 10% frequency of inflammation 
also compares unfavourable to the 1 and 2% rates listed on the labels for 
Lucentis and Eylea.<wbr> Meanwhile, advancing treatments in development at Novartis 
and Regeneron as well as gene therapy options raise questions about DARPin's 
commercial potential.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Bimatoprost Glaucoma Data Looks Good</STRONG> </div><div style="margin-bottom: 10px;">Allergan has reviewed phII data and the analysis suggests efficacy that is 
comparable to daily topical bimatoprost with a duration of four to six months.<wbr> 
The data has been shared with the FDA and the agency is supportive of the 
company's decision to advance into phIII clinical development.<wbr> PhIII trials 
will be intitiated by the end of 2014.<wbr> Based on this data and the FDA response 
David Pyott suggestsed that the product may prove to be a "game-changer" in the 
treatment of glaucoma.<wbr> Apparently 20% of patients are currently not well managed 
with topical drugs and compliance remains a huge issue with patients losing 
vision as a result.<wbr> So despite the availability of generic daily formulations 
Allergan believes it will have strong pharmacoeconomic data to justify good 
reimbursment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT face="Arial">Levadex 
(Semprana) Delay Raises Questions About Allergan's Purchase of MAPP 
for $1bn</FONT> </STRONG> </div><div style="margin-bottom: 10px;"><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2"><FONT face="Arial">This is the third complete response letter from the FDA citing 
Levadex manufacturing issues.<wbr> The two specific items listed in the CRL are 
related to specifications around content uniformity, on the improved 
canister-filling process, and on standards for the device actuation.<wbr> There were 
no issues related to the clinical safety and efficacy of the product, and 
Allergan received draft labeling from the FDA for the product in June 2013.<wbr> 
Allergan plans to meet with the FDA, and we will work to fully address these 
issues to the satisfaction of the agency.<wbr> The company estimates that the next 
FDA action will occur by the end of second quarter 
2015.<wbr></FONT></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2"><FONT face="Arial"><STRONG>Osurdex Label 
Expansion</STRONG></FONT></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT face="ArialMT" size="2"><FONT face="ArialMT" size="2"><FONT face="Arial">Allergan was happy to announce the label expansion for Osurdex to 
treatment a sub-population of diabetic macular oedema patients.<wbr> </FONT></FONT></FONT> </div><div style="margin-bottom: 10px;">Ozurdex works by 
releasing the steroid dexamethasone over time to suppress inflammation, which 
plays a key role in the development of DME.<wbr> Leerink analysts believe this 
approval represents a positive but modest commercial opportunity for the 
drug of around $100-259m.<wbr> </div><div>Source: 
<a href="http://www.allergan.com" class="defaultlink" title="www.allergan.com">allergan.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7638">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-01T09:45:29+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Roche Management Emphasizes Innovation and Growth at JP Morgan EU H/C Conference [:Endocrinology:comp:Roche, dis:Bladder, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9812</link>
<description>Roche Management Emphasizes Innovation and Growth at JP Morgan EU H/C Conference [:Endocrinology:comp:Roche, dis:Bladder, dis:Prostate]</description><category>comp:Roche</category><category>dis:Bladder</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9812</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9812">Roche Management Emphasizes Innovation and Growth at JP Morgan EU H/<wbr>C Conference</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9812">Oncology9812</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 July 2014 | 09:42</font><br><br><div style="margin-bottom: 10px;">Comment: Bill Anderson (Head of Global Product Strategy and Chief Marketing Officer) started his presentation with an overview of drugs in development in hematology and cancer immunotherapy with a focus on <FONT size="2">MPDL3280A, </FONT>its anti-PDL1 program for NSCLC, renal and bladder cancer.<wbr> He highlighted an innovative and tailored business model in emerging markets that depends on market characteristics and segments.<wbr> Key slides are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Developing Markets - Multiple Approaches</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Cancer Immunotherapy at Roche</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Urothelial Bladder Carcinoma (UBC)</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Readout over the next 12 months </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/2/ScreenCapture2.jpg?user-agent=rss"> </div><div>Full presentation <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140831&edate=20140501&rs=/link%20Oncology9812%405" class="defaultlink">@5</a> </div><!-- Comment details --><a name="oncology9812attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(58 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(50,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(63,3 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(68,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/5/Roche%5fJP%20Morgan%5fJune2014.pdf">Roche_JP Morgan_June2014.pdf</a>&nbsp;&nbsp;(1,2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9812">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-01T09:42:45+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/1/ScreenCapture1.jpg" length="59378" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/2/ScreenCapture2.jpg" length="52111" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/3/ScreenCapture3.jpg" length="64789" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/4/ScreenCapture4.jpg" length="70406" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9812/5/Roche%5fJP%20Morgan%5fJune2014.pdf" length="1242818" type="application/pdf"/></item><item>
<title>Merz NA Adds Novel Retinoid Compound for Skin Conditions [:Neurology:comp:Merz, :Neurology:sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10908</link>
<description>Merz NA Adds Novel Retinoid Compound for Skin Conditions [:Neurology:comp:Merz, :Neurology:sub:Aesthetics]</description><category>comp:Merz</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10908</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10908">Merz NA Adds Novel Retinoid Compound for Skin Conditions</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10908">PharmaWorld10908</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 01 July 2014 | 09:16</font><br><br><div style="margin-bottom: 10px;">Comment: Merz North America and Brickell Biotech have signed an agreement granting Merz an exclusive NA license, with additional internationa rights, to develop a novel retinoid compound for the treatment of acne and psoriasis.<wbr> Brickell Biotech's lead compound BBI-4000<STRONG>,</STRONG> a novel topical soft anticholingeric, is being developed for the treatment of hyperhidrosis, with initial human clinical studies planned to commence during 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Agreement</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Merz NA will assume the full cost and responsibility for future development and commercialization, initially for North America </div><div style="margin-bottom: 10px;">- Terms and finanacials remain confidential </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About Brickell Biotech</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Pipeline</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10908/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Background</U> </div><div style="margin-bottom: 10px;">- founded in Nov 2009 </div><div style="margin-bottom: 10px;">- private </div><div style="margin-bottom: 10px;">- Management team <A href="http://www.brickellbio.com/company/team.htm">http:/<wbr>/<wbr>www.<wbr>brickellbio.<wbr>com/<wbr>company/<wbr>team.<wbr>htm</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About BBI-3000</FONT></STRONG> </div><div style="margin-bottom: 10px;">- novel, potent topical/<wbr>oral retinoid, acting as a highly selective RXR agonist </div><div>Source: Merz; brickell Biotech </div><!-- Comment details --><a name="pharmaworld10908attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10908/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(36,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10908">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-07-01T09:16:20+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10908/1/ScreenCapture1.jpg" length="37659" type="image/jpeg"/></item><item>
<title>Recent Event with Management Highlights the &quot;New Novartis&quot; [comp:Novartis, :Endocrinology:comp:Novartis]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9808</link>
<description>Recent Event with Management Highlights the &quot;New Novartis&quot; [comp:Novartis, :Endocrinology:comp:Novartis]</description><category>comp:Novartis</category><category>comp:Novartis</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9808</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9808">Recent Event with Management Highlights the "New Novartis"</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9808">Oncology9808</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 June 2014 | 14:24</font><br><br><div style="margin-bottom: 10px;">Comment: With 20 Novartis executives from all of the company businesses, Joseph Jimenez provided his "view of the world over the next ten years".<wbr> Chronic diseases (such as diabetes and dementia), reimbursement, innovation will have a profound impact on the H/<wbr>C industry.<wbr> Management highlighted its technologies and innovative therapies that can help manage an aging population in heart failure, oncology, dermatology, respiratory diseases, and cell therapy.<wbr> Pipeline holds promising potential for &gt;14 blockbusters by 2018.<wbr> For J Jimenez, innovation and scale are critical to "win in a future world".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Projected Blockbusters</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Planned Filings 2014 to &gt;2018</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Estimation About Chronic Diseases</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management estimates " .<wbr>.<wbr>.<wbr> there will be an additional 100 diabetics in the world bringing that total to 500 million by the year 20255.<wbr> We estimate that there will be somewhere between 50 and 100 million people with dementia by the year 2025.<wbr> Chronic disease will move from about 60% of the disease burden today to over 70% by the year 2025.<wbr> This is going to have a profound impact on the healthcare industry".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pressure on Payers and Reimbursements</FONT></STRONG> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> governments are going to have to make trade offs between other social programs; education, transportation.<wbr> That is going to put pressure on payers in the next ten years to look at reimbursement.<wbr> We believe that reimbursement, if you're incrementally better or if you're not better is going to become tougher and tougher to get reimbursement".<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr> Because governments are going to push more and more spending on to the patient.<wbr> They're going to have to take a more active role in their own healthcare".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Two Scenarios</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/1/ScreenCapture1.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;">J Jimenez reported that " .<wbr>.<wbr>.<wbr> The first one is a more negative scenario.<wbr> I call this the brutal world in which there is slow economic growth.<wbr> Healthcare is growing ahead of economic growth.<wbr> Reimbursement, the true innovators are getting reimbursement.<wbr> They're thriving in an environment like that.<wbr> But if you're not innovating, you're in trouble in this scenario.<wbr> </div><div style="margin-bottom: 10px;">A second and more positive scenario is if you look at the technologies that starting to emerge for healthcare companies, developing new and innovative therapies that can help manage an aging population in heat failure, in oncology, in respiratory disease become bigger and bigger.<wbr> New breakthroughs that we have not seen in the last ten years help payers manage an aging population.<wbr> This is a much more positive view of what can happen over the next ten years".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">New Novartis's Strategy Focuses on Three Businesses</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>Pharmaceutical business, which is over $30 billion</LI>
<LI>Alcon Eye Care business which is $10 billion</LI>
<LI>Sandoz Generics business, which is about $10 billion</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drugs with Strong Potential</FONT></STRONG> </div><div style="margin-bottom: 10px;">Potential first in class and /<wbr> or best in class </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Novartis Oncology</FONT></STRONG> </div><div style="margin-bottom: 10px;">- is pursuing personalized cellular immunotherpay with a portfolio of CARTs </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/5/ScreenCapture5.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;">- a broad pipeline, with agents covering most oncogenic pathways </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">- combinations are expected to be the future of targeted therapy </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/10/ScreenCapture10.jpg?user-agent=rss"> </div><div>Full presentation <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140831&edate=20140501&rs=/link%20Oncology9811%4012" class="defaultlink">@12</a> </div><!-- Comment details --><a name="oncology9808attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(50,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(37 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(64,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(72,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(56,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(62,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(93,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(54,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(77,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(62,5 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(79,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/12/Meet%20Novartis%20Management%5fjune%2devent.pdf">Meet Novartis Management_june-event.pdf</a>&nbsp;&nbsp;(4,1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9808">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-30T14:24:28+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/1/ScreenCapture1.jpg" length="51322" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/2/ScreenCapture2.jpg" length="37861" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/3/ScreenCapture3.jpg" length="65787" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/4/ScreenCapture4.jpg" length="74681" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/5/ScreenCapture5.jpg" length="57458" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/6/ScreenCapture6.jpg" length="63753" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/7/ScreenCapture7.jpg" length="96160" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/8/ScreenCapture8.jpg" length="56053" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/9/ScreenCapture9.jpg" length="79448" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/10/ScreenCapture10.jpg" length="63980" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/11/ScreenCapture11.jpg" length="81412" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9808/12/Meet%20Novartis%20Management%5fjune%2devent.pdf" length="4317517" type="application/pdf"/></item><item>
<title>ENDO Insights - Two Key Presentations On Oral Octreotide (Roche) &amp; Octreoide SC Depot (Novartis) [comp:Novartis, comp:Roche, dis:Acromegaly, headline, :PharmaWorld:congress:ENDO]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7706</link>
<description>ENDO Insights - Two Key Presentations On Oral Octreotide (Roche) &amp; Octreoide SC Depot (Novartis) [comp:Novartis, comp:Roche, dis:Acromegaly, headline, :PharmaWorld:congress:ENDO]</description><category>comp:Novartis</category><category>comp:Roche</category><category>dis:Acromegaly</category><category>headline</category><category>congress:ENDO</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7706</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7706">ENDO Insights - Two Key Presentations On Oral Octreotide (Roche) & Octreoide SC Depot (Novartis)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aENDO"><font color="#e95e0b">:PharmaWorld:congress:ENDO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7706">Endocrinology7706</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 June 2014 | 13:51</font><br><br><div style="margin-bottom: 10px;">Comment: Feedback from ENDO from has provided us with details of two key presentations made during one of the oral abstract sessions.<wbr> The slides provide more detail than available before and together with the Q/<wbr>A some interesting insight into perhaps some of the issues each product faces.<wbr> Notably from a safety &amp; adequate efficacy perspective with octreolin and a safety and sustained efficacy perspective for octreotide sc depot (previously known as CAM2029).<wbr> Confirmation was also obtained that octreotide sc depot is now being further evaluated in a phII European study in both NET and acromegaly patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Shlomo Melmed's Presentation On Octreolin (oral octreotide)</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT face="Times New Roman" size="3">Study Design</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">As can be seen from the slide below, the core treatment period with octreolin started at least 4 weeks after the last SSA injection.<wbr> Oral octreotide was administered <STRONG>twice daily on an empty stomach at least one hour prior to a meal or 2 hours after a meal in a step up dose of 40, 60 and 80 mg/<wbr>day</STRONG>.<wbr> Per protocol subjects entered the fixed dose period when IGF-1 levels were normalised or stable for at least 2 consecutive visits.<wbr> Subjects could revert to parenteral somatostatin analogues at any time for safety or efficacy reasons</SPAN></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/2/ScreenCapture2.jpg?user-agent=rss"></SPAN></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">Baseline characteristics are summarised below:-</SPAN></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/3/ScreenCapture3.jpg?user-agent=rss"></SPAN></FONT> Sixty three% of patients received octreotide LAR and 37% received lanreotide.<wbr> Two hundred and thirty five patients were screened and 155 were enrolled into the study as shown in the slide below.<wbr> Most patients failing to meet inclusion criteria had higher levels of IGF-1 despite being on injectable somatostatin analogues.<wbr> Following dose titration 65 subjects were on 40mg, 33 subjects were on 60mg and 57 subjects needed 80mg.<wbr> <STRONG>53 subjects discontinued the treatment.<wbr> The main reasons were treatment failure in 24 patients all having been titrated to the highest dose.<wbr></STRONG> Of the 102 subjects who completed the study, 86% elected to continue an extension period.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Key Efficacy Findings</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">91 subjects entered the fixed dose as responders and 82 ended the fixed dose period</SPAN> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><P style="margin: 0cm 0cm 10pt;">The data above shows that all 110 patients who entered the fixed dose period maintained both IGF-1 and GH levels.<wbr></P> </div><div style="margin-bottom: 10px;">Similarly, the slide below shows this graphically for both the mITT and Completers &amp; Responders population and that IGF-1 levels were unchanged between baseline and the end of the fixed dose period in both populations.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The PK profile of octreolin in a sub-set of patients during the fixed dose period is shown below and demonstrates dose propotionallity.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Safety Profile</STRONG> </div><div style="margin-bottom: 10px;">Seventeen Serious AEs were recorded during the trial.<wbr> Details of some and reasons for discontinuation due to other side-effects are shown below together with the more commonly observed side-effects consitent with the known safety profile of octreotide LAR:- </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Overall Conclusions &amp; Q&amp;A</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;">Question from the Chairperson, Anthony Heaney, USA</STRONG>: </div><div style="margin-bottom: 10px;">&ldquo;I was interested in the levels of GH with oral octreotide.<wbr>.<wbr>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;">Response-</STRONG> &ldquo;That is a good question and is one we are thinking about.<wbr> It simply may be that the drug is more effective at suppressing growth hormone, as we know from other studies that GH and IGF-1 levels are not linear, and there is a non linear relationship between GH and IGF-1.<wbr> And finally in terms of the measurement itself, the GH levels were all measured within 2 hours following the oral octreotide dose, and therefore were more reflective of the oral octreotide whereas the IGF-1 levels were more reflective of a long term sustained effect of the drug rather than the acute effect.<wbr> It is an interesting observation which emerged from the data and it is something which we will be pursuing&rdquo;.<wbr> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;">Question from AnaMaria Colao, Italy: </STRONG> </div><div style="margin-bottom: 10px;">&ldquo;Shlomo, excellent presentation and very promising data for acromegaly patients.<wbr> My question concerns the dose which was from 40-80mg/<wbr>day, this must mean that a lot of the drug is lost because it is what we may give a month with injectable octreotide.<wbr> So what cost do we expect to pay for this preparation to account for all the octreotide used?&rdquo; </div><div style="margin-bottom: 10px;">Response: &ldquo;I am just a scientist and have no idea what the cost of the medicine will be&rdquo;.<wbr> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;">Question from audience</STRONG>: </div><div style="margin-bottom: 10px;">&ldquo;Yesterday we heard that new clinical guidelines indicate that we should only use IGF-1 levels to measure efficacy of a drug and here you suggest we need to measure IGF-1 and GH levels? So what is the best course to take&rdquo;? </div><div style="margin-bottom: 10px;">Response: &ldquo;At the moment this drug has not been approved and the clinical guidelines state that the measurement of IGF-1 as an indicator of efficacy remains.<wbr> But next year or year after when the clinical guidelines are reviewed again, this drug should be approved and then this question will be taken into account.<wbr> But at the moment oral octreotide is not approved&rdquo;.<wbr> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;">Additional intelligence was obtained that the Phase 3 study of OOA in acromegaly was recently submitted to the NEJM with first author Shlomo Melmed </STRONG> </div><div style="margin-bottom: 10px;"><STRONG><U>John Roberts (Novartis PK/<wbr>PD Dept) Presentation On The PK/<wbr>PD Profile Of CAM2029</U></STRONG> </div><div style="margin-bottom: 10px;">This data was formely presented in poster form at the ECE meeting in late April </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The following advantages of the novel depot octreotide formulation were noted:- </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">A few slides described the 45 degree angle of subcutaneous administration and the formation of a gel-like crystal deposit.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Design</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;">After a 7-day washout healthy volunteers were randomised to three repeat once monthly injections of three different variations of formulations of octreotide sc depot compared to octreotide LAR, and IGF-1 levels were measured as depicted below:-</SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/16/ScreenCapture16.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 11pt; font-family: 'Calibri','sans-serif'; line-height: 115%; mso-ascii-theme-font: minor-latin; mso-fareast-font-family: Calibri; mso-fareast-theme-font: minor-latin; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: 'Times New Roman'; mso-bidi-theme-font: minor-bidi; mso-ansi-language: EN-GB; mso-fareast-language: EN-US; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/17/ScreenCapture17.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><P style="margin: 0cm 0cm 10pt;">As can be seen, there was an immediate peak in terms of IGF-1 response followed by a sustained release of drug over 28 days.<wbr></P> </div><div style="margin-bottom: 10px;">The following 2 slides show a comparison of octreotide sc depot-B (30mg) versus octreotide LAR 30mg with mean plasma concentration of octreotide and IGF-1 by sampling time respectively.<wbr> Octreotide concentrations for octreotide sc depot B equalled or exceeded those for octreotide LAR over the dosing interval on a dose-matched basis.<wbr> Higher bioavailability (nearly 500%) was observed for octreotide sc depot B versus octreotide LAR.<wbr> John Roberts stated &ldquo;<STRONG style="mso-bidi-font-weight: normal;">We believe this higher bioavailability is exciting as it gives patients more options of regimen selection.<wbr> It is a sustained release of high levels of octreotide which has not been seen via the sc route before.<wbr> This is very encouraging data&rdquo;.<wbr></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/18/ScreenCapture18.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/19/ScreenCapture19.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><P style="margin: 0cm 0cm 10pt;">Octreotide sc depot-B showed more rapid and extensive suppression of IGF-1 after the first injection compared with octreotide LAR.<wbr> Suppression was similar after the second and third injections.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0cm 0cm 10pt;"><STRONG>Safety Profile</STRONG></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0cm 0cm 10pt;">Safety and tolerability data for octreotide sc depot A, B and C formulations in healthy volunteers were more frequent overall compared with octreotide LAR.<wbr> By comparison, it will be interesting to see how acromegalic patients will respond to treatment.<wbr></P> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/20/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In terms of serious adverse events there were 2 that occurred: one possibly drug related and the other one was not, and in terms of discontinuations there were slightly more in the formulation-A group.<wbr> Most AEs were deemed mild-moderate.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Overall Conclusions and Q&amp;A</STRONG> </div><div style="margin-bottom: 10px;"><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/21/ScreenCapture21.jpg?user-agent=rss"></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>John Roberts stated:- </STRONG> </div><div style="margin-bottom: 10px;">&ldquo;Due to the high bioavailability seen with octreotide sc depot, we believe this new formulation of octreotide may provide opportunity for individualised dose/<wbr>interval and may offer enhanced convenience when administered via a prefilled syringe with a thin needle&rdquo;.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin: 0cm 0cm 10pt;"><STRONG style="mso-bidi-font-weight: normal;"><U>Questions from the audience:</U></STRONG></P> </div><div style="margin-bottom: 10px;">Alan Harris (New York): &ldquo;I would like to ask whether this new formulation of octreotide (as well as the oral octreotide) will in fact improve what has now become as a very low level of efficacy of octreotide, namely 20%.<wbr> So basically 80% of patients are no longer controlled with octreotide compared to earlier studies, so do you expect this new formulation to actually improve upon the 20% we have seen reported since 2007&rdquo;? </div><div style="margin-bottom: 10px;">Response: Because of the intervals we are presented with we can perhaps be able to use every 2 weeks and we have a lower volume and it is a smaller needle and so we have an opportunity and because of the higher bioavailability seen we expect to see higher response rates in some patients&rdquo;.<wbr> </div><div style="margin-bottom: 10px;">Question from audience (UK): &ldquo;I am not sure whether the dose and the dose interval may stay the same as the programme evolves.<wbr> I would like to challenge you on your word &ldquo;sustained&rdquo; in your conclusion, the octreotide level is varying because it is a logarithmic scale that you are showing on your graphs, there is a big difference between the peak octreotide level few days afterwards and the trough level that is present for a couple of weeks, is that going to translate into symptoms at the beginning of the treatment cycle of that month&rdquo;? </div><div style="margin-bottom: 10px;">Response: &ldquo;So we do know that from immediate release octreotide that the very high <EM style="mso-bidi-font-style: normal;">Cmax</EM> values are tolerated in patients in the earlier trials that were and in that sense we feel that it is consistent with <EM style="mso-bidi-font-style: normal;">Cmax</EM> in wash out and what&rsquo;s been really shown today is that we have to target <EM style="mso-bidi-font-style: normal;">Ctrough </EM>because it is the <EM style="mso-bidi-font-style: normal;">Ctrough</EM> that is driving IGF-1 and there is more to find out in the patient studies and how they will react to our new formulation&rdquo;.<wbr> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;"><U>Summary of Dr Dowling's (Ipsen Consultant) discussion with speaker following presentation</U></STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;">Clarification of clinical trial status of CAM2029:</STRONG> </div><div style="margin-bottom: 10px;"><STRONG style="mso-bidi-font-weight: normal;">Response:</STRONG> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN>Phase 2, initiated by Camurus, is currently ongoing in Europe.<wbr> Camurus is in control of this study (although John Roberts implied that Novartis may oversee the development of the study and have some input.<wbr> He re-iterated that Camurus had overall control of the phase 2 study).<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN>Novartis is currently in discussion on how best to proceed with the planning of phase 3 study.<wbr> The company is in contact with several health authorities.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN>Novartis is looking carefully at dosing regimens with reference to PK/<wbr>PD data.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN>John Roberts stressed the advantage of the sc depot technology in terms of ease and convenience of self-injection.<wbr> The needle is fine with a pre-filled syringe.<wbr> Compliance is the key issue.<wbr> </div><div><SPAN style="font-family: Symbol; mso-fareast-font-family: Symbol; mso-bidi-font-family: Symbol;"><SPAN style="mso-list: Ignore;">&middot; </SPAN></SPAN>He also pointed out that octreotide sc depot may provide opportunity for individualised dose/<wbr>interval regimens.<wbr> </div><!-- Comment details --><a name="endocrinology7706attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(57,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(37,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(44,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(47,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(49,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(44 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(43,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(50,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(46,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(39,8 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(42,9 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(50,7 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(46,6 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(42,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(58,4 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(48,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(57,7 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(53,5 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(49,5 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(62,5 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(57,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7706">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-30T13:51:14+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/1/ScreenCapture1.jpg" length="59294" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/2/ScreenCapture2.jpg" length="38282" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/3/ScreenCapture3.jpg" length="45219" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/4/ScreenCapture4.jpg" length="48189" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/5/ScreenCapture5.jpg" length="50650" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/6/ScreenCapture6.jpg" length="45062" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/7/ScreenCapture7.jpg" length="44139" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/8/ScreenCapture8.jpg" length="51569" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/9/ScreenCapture9.jpg" length="47753" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/10/ScreenCapture10.jpg" length="40768" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/11/ScreenCapture11.jpg" length="43922" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/12/ScreenCapture12.jpg" length="51873" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/13/ScreenCapture13.jpg" length="47762" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/14/ScreenCapture14.jpg" length="43225" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/15/ScreenCapture15.jpg" length="59825" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/16/ScreenCapture16.jpg" length="49894" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/17/ScreenCapture17.jpg" length="59065" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/18/ScreenCapture18.jpg" length="54824" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/19/ScreenCapture19.jpg" length="50687" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/20/ScreenCapture20.jpg" length="64046" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7706/21/ScreenCapture21.jpg" length="58921" type="image/jpeg"/></item><item>
<title>Endpoints of Index's Kappaproct® Reached in Ph3 for UC [dis:IBD, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1985</link>
<description>Endpoints of Index's Kappaproct® Reached in Ph3 for UC [dis:IBD, news]</description><category>dis:IBD</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1985</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1985">Endpoints of Index's Kappaproct® Reached in Ph3 for UC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1985">GastroEnterology1985</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 30 June 2014 | 12:18</font><br><br><div style="margin-bottom: 10px;">Comment: CEO of InDex expects to meet with regulatoriy agencies in EU and US to discuss path to approval.<wbr> Last April, Almirall licensed the drug for EU, where the drug obtained an orphan drug designation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Results</FONT></STRONG> </div><div style="margin-bottom: 10px;">In the COLLECT study, 131 patients with moderate to severe Ulcerative Colitis with inadequate response to conventional therapy received either Kappaproct® or placebo as an add-on to conventional treatment.<wbr> Concominant use of TNF-α inhibitors was excluded.<wbr> The study was conducted at 40 sites in seven European countries (Czech Republic, France, Germany, Hungary, Italy, Poland and the UK).<wbr> </div><div style="margin-bottom: 10px;">Kappaproct was administrated as two single rectal doses, given at week 0 and week 4.<wbr> The primary endpoint was clinical remission (Rachmilewitz/<wbr>CAI score of ≤4) measured at week 12.<wbr> </div><div style="margin-bottom: 10px;">There was an unexpectedly high remission rate in the control group and there was no statistically significant difference observed on this measure.<wbr> Statistically significant effects were demonstrated on the secondary endpoints symptomatic remission (blood in stool = none, number of stools weekly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Current Treatments in UC</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1985/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Kappaproct® MoA</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1985/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology1985attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1985/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1985/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(43,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1985">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-30T12:18:10+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1985/1/ScreenCapture1.jpg" length="31241" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1985/2/ScreenCapture2.jpg" length="44746" type="image/jpeg"/></item><item>
<title>Sanofi's Presentation at JP Morgan Highlights Business in China [:PharmaWorld:mkt:China, :Endocrinology:dis:Diabetes, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1981</link>
<description>Sanofi's Presentation at JP Morgan Highlights Business in China [:PharmaWorld:mkt:China, :Endocrinology:dis:Diabetes, news]</description><category>mkt:China</category><category>dis:Diabetes</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1981</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1981">Sanofi's Presentation at JP Morgan Highlights Business in China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1981">GastroEnterology1981</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2014 | 16:27</font><br><br><div style="margin-bottom: 10px;">Comment: Fabrice Baschiera (GM, Commercial Operation, Greater China) focused its presentation on the leading presence of the company in China, and the healthcare needs in the country.<wbr> He outlined the healthcare reform activities to have created opportunities as well as challenges and sustained pricing pressure.<wbr> The company is adressing the medical needs in China's counties with a dedicated "Primary Care Business Unit", one of its three strategic pillars for continued leadership in the H/<wbr>C Chinese market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Three Strategic Pillars for Continued Leadership in the H/<wbr>C Market in China</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Primary care Business Unit Description</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Growth of the China's Pharma Market</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sanofi Foot Print</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company is well established in China, with a fully integrated presence.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">China - A Growing Contributor to Sanofi's Leadership Position in EMs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Sanofi Lists #3 Position in China</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/2/ScreenCapture2.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology1981attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(63,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(82,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(79,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(85,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(90,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(85,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1981">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-27T16:27:51+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/1/ScreenCapture1.jpg" length="64580" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/2/ScreenCapture2.jpg" length="84090" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/3/ScreenCapture3.jpg" length="81837" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/4/ScreenCapture4.jpg" length="87764" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/5/ScreenCapture5.jpg" length="92825" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1981/6/ScreenCapture6.jpg" length="87882" type="image/jpeg"/></item><item>
<title>re: Merrimack Meets Primary Endpoint of OS In PhIII Metastatic Pancreatic Cancer Study</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9807</link>
<description>re: Merrimack Meets Primary Endpoint of OS In PhIII Metastatic Pancreatic Cancer Study</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9807</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9807">re: Merrimack Meets Primary Endpoint of OS In PhIII Metastatic Pancreatic Cancer Study</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9807">Oncology9807</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 27 June 2014 | 11:26</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Merrimack Meets Primary Endpoint of OS In PhIII Metastatic Pancreatic Cancer Study</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font><br><span style="font-size: 12px;">Comment: The NAPOLI-1 study evaluating a combination of MM-398 with 
5-fluorouracil (5-FU) and leucovorin in 2nd line metastatic pancreatic 
cancer has achieved an overall survival of 6.<wbr>1 months, a 1.<wbr>9 month 
improvement over the 4.<wbr>2 month survival demonstrated by the control arm of 5-FU 
and leucovorin alone.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9672">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9672" class="commentpermalink">Oncology9672</a> / <span class="date">01 May 2014</span> /
<span class="time">14:07:44 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Comment: Merrimack announced detailed results from NAPOLI-1 study (MM-39+5FU+leucovorin in metastatic pancreatic cancer previously treated with gemcitabine based therapy.<wbr> Detailed results were presented by Andrea Wang-Gillam MD PhD Assistant Professor of Medicine, Washington University School of Medicine during the oral session in ESMO GI held in Barcelona.<wbr> A statistically significant advantage in PFS was seen with a median of 3.<wbr>1 months compared to 1.<wbr>5 in the control arm.<wbr> A higher overall response rate of 16% was also seen in the combination arm compared to control arm (1%, p&lt;0.<wbr>001).<wbr> The most common grade 3 or above adverse events are consistent to those reported in May except neutropenia incidence (20%) was slightly higher than those reported in May.<wbr> </div><div style="margin-bottom: 10px;">Abstract #O-0003 NAPOLI-1: Randomized Phase 3 Study of MM-398 (nal-IRI), with or without 5-Fluorouracil and Leucovorin, versus 5-Fluorouracil and Leucovorin, in Metastatic Pancreatic Cancer Progressed on or Following Gemcitabine-based Therapy </div><div style="margin-bottom: 10px;">Study results for MM-398 in combination with 5-fluorouracil and leucovorin </div><div style="margin-bottom: 10px;"><UL><LI>
Patients on the combination therapy of MM-398, dosed at 80 mg/<wbr>m2 Q2W with 5-FU and leucovorin, achieved an overall survival of 6.<wbr>1 months versus 4.<wbr>2 month survival demonstrated by the control arm of 5-FU and leucovorin alone (HR=0.<wbr>67, 95% CI [0.<wbr>49-0.<wbr>92], p=0.<wbr>01).<wbr>

</LI>
<LI>
The combination arm demonstrated a statistically significant median PFS of 3.<wbr>1 months compared to 1.<wbr>5 months in the control arm (HR = 0.<wbr>56, 95% CI [0.<wbr>41-0.<wbr>75], p=0.<wbr>0001).<wbr>

</LI>
<LI>
Safety and efficacy data for patients treated with MM-398 were consistent with previously reported top line data and results from earlier MM-398 clinical studies.<wbr> Hematologic grade 3 and higher adverse events in the combination arm included neutropenia, which was observed in 20% of patients as determined by objective laboratory values, and febrile neutropenia which was observed in 2% of the patients.<wbr> The most common non-hematologic grade 3 and higher adverse events were fatigue (14%), diarrhea (13%) and vomiting (11%).<wbr>

</LI>
<LI>
The overall response rate in the combination arm was 16% versus 1% in the control arm which was statistically significant (p&lt;0.<wbr>001).<wbr>

</LI>
<LI>
A reduction of CA19-9 levels was observed in 36% of patients in the combination arm versus 12% of patients in the control arm.<wbr> The reduction of CA19-9, a pancreatic tumor marker indicative of patient response to MM-398, was defined by a greater than or equal to 50% decrease in baseline CA19-9 levels.<wbr>

</LI>
</UL> </div><div style="margin-bottom: 10px;">Study results for MM-398 as a monotherapy </div><div><UL><LI>
MM-398, dosed at 120 mg/<wbr>m2 Q3W, had a 4.<wbr>9 month median overall survival compared to 4.<wbr>2 months in the control arm (HR=0.<wbr>99, 95% CI [0.<wbr>77-1.<wbr>28], p=0.<wbr>942).<wbr>

</LI>
<LI>
Patients on the MM-398 monotherapy arm achieved a median PFS of 2.<wbr>7 months versus 1.<wbr>6 months in the control (HR = 0.<wbr>80, 95% CI [0.<wbr>62-1.<wbr>04]).<wbr>

</LI>
<LI>
Neutropenia was observed in 16% of the patients on the monotherapy arm and febrile neutropenia was observed in 4% of patients.<wbr> The most common grade 3 or higher adverse events included diarrhea (21%), vomiting (14%) and hypokalemia (12%).<wbr>

</LI>
<LI>
The overall response rate of MM-398 alone was 6% versus 1% in the control arm.<wbr>

</LI>
<LI>
A reduction of CA19-9 levels was observed in 31% of patients on the MM-398 monotherapy arm versus 12% of patients in the control arm.<wbr>

</LI>
</UL> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9807" class="commentpermalink">Oncology9807</a> / <span class="date">27 June 2014</span> /
<span class="time">11:26:19 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9807">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9672">View thread  Oncology9672: Merrimack Meets Primary Endpoint of OS In PhIII Metastatic Pancreatic Cancer Study</a>]]></content:encoded><dc:date>2014-06-27T11:26:19+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Acquisition of Ulthera is the Largest in Merz's History [comp:Merz, sub:Aesthetics, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7633</link>
<description>Acquisition of Ulthera is the Largest in Merz's History [comp:Merz, sub:Aesthetics, headline]</description><category>comp:Merz</category><category>sub:Aesthetics</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7633</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7633">Acquisition of Ulthera is the Largest in Merz's History</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7633">Neurology7633</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 27 June 2014 | 10:27</font><br><br><div style="margin-bottom: 10px;">Comment: Merz has acquired the medical device company for up to $600M, to expand its portfolio of treatment options.<wbr> The Ulthera® System is the first and only energy-based device to receive U.<wbr>S.<wbr> FDA clearance for a non-invasive aesthetic lift indication.<wbr> It is used in a procedure known as Ultherapy®, which is an FDA-cleared treatment to lift skin above the eyebrow, on the neck and under the chin.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.6">The transaction is expected to close in the third quarter of 2014.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.6"><STRONG>Marketing Status</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><DIV><SPAN style="LINE-HEIGHT: 1.6"><FONT size="3"><FONT size="2">The Ulthera® System has been available internationally since 2008, and in the US since September 2009</FONT><FONT size="2">.<wbr></FONT> </FONT></SPAN>
<P><SPAN style="LINE-HEIGHT: 1.6"><FONT size="3"><STRONG>Ulthera SnapShot</STRONG></FONT></SPAN></P></DIV> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.6">Founded in 2004 and based in Mesa, Arizona.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="LINE-HEIGHT: 1.6">Ulthera is a privately held company backed by top-tier venture capital firms New Enterprise Associates and Apposite Capital.<wbr> </SPAN> </div><div style="margin-bottom: 10px;">In March 2014, Ulthera acquired Cabochon Aesthetics.<wbr> The FDA-cleared system developed by Cabochon -- used in a procedure to improve the appearance of cellulite -- will allow Ulthera to expand its technology offerings for physician practices worldwide.<wbr> </div><div>Source: Merz </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7633">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-27T10:27:36+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>ANDA Filing By Activis For Acorda's MS Drug [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7632</link>
<description>ANDA Filing By Activis For Acorda's MS Drug [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7632</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7632">ANDA Filing By Activis For Acorda's MS Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7632">Neurology7632</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 26 June 2014 | 15:46</font><br><br><div style="margin-bottom: 10px;">Comment: Acorda Therapeutics, has announced receipt of a Paragraph IV 
Certification Notice Letter advising it that Actavis Laboratories FL, 
Inc has submitted an ANDA to the U.<wbr>S FDA requesting permission to 
manufacture and market a generic version of AMPYRA® (dalfampridine) Extended 
Release Tablets, 10 mg.<wbr> <BR> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps<BR></STRONG>Acorda is reviewing the Notice Letter and has 
45 days from the date of receipt to commence a patent infringement lawsuit 
against Actavis Laboratories FL, Inc.<wbr> in order to trigger a statutory stay 
period under the Hatch-Waxman Act.<wbr> This would restrict the FDA from approving an 
ANDA until July 2017 at the earliest, unless a district court issues a decision 
adverse to all of Acorda’s asserted Orange Book patents prior to that date.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>AMPYRA's Current IP Status<BR></STRONG>AMPYRA is currently protected 
by five patents listed in the FDA’s Approved Drugs Product List (Orange Book), 
four of which extend into 2025, 2026 and 2027, respectively.<wbr> AMPYRA also has 
Orphan Drug status, which extends into January 2017.<wbr> </div><div style="margin-bottom: 10px;">Acorda has stated that it intends to vigorously defend its intellectual 
property rights.<wbr> </div><div>Source: <A href="http://www.acorda.com">www.<wbr>acorda.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7632">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-26T15:46:06+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Eisai Files First Market Authorization for Lenvatinib (Thyroid Cancer) in Japan [:Oncology:news, :PharmaWorld:mkt:Japan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7704</link>
<description>Eisai Files First Market Authorization for Lenvatinib (Thyroid Cancer) in Japan [:Oncology:news, :PharmaWorld:mkt:Japan]</description><category>news</category><category>mkt:Japan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7704</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7704">Eisai Files First Market Authorization for Lenvatinib (Thyroid Cancer) in Japan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7704">Endocrinology7704</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 June 2014 | 14:11</font><br><br><div style="margin-bottom: 10px;">Comment: The drug has received orphan designation in EU and the US, where filings have been planned for Q3:2014.<wbr> Eisai's ambition is to establish lenvatinib as gold standard treatment for refractory thyroid cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company's Strategic Ambitions</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Submission Plans</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7704/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Thyroid Cancer Unmet Need in Japan</FONT></STRONG> </div><div style="margin-bottom: 10px;">The number of patients with thyroid cancer in Japan is estimated to be between 13,000 and 29,000.<wbr> </div><div style="margin-bottom: 10px;">Although treatment is possible for most types of thyroid cancer, there are few treatment options available once thyroid cancer has progressed, therefore it remains a disease with significant unmet medical needs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Potential Indications - Liver and Lung Cancer</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Ph3 results in HCC are expected in 2H 2015 (plan to submit in FY2016).<wbr> </div><div style="margin-bottom: 10px;">- Good Ph2 outcomes were released at ASCO in June for lenvatinib in NSCLC 3rd line), but Ph3 trial design has yet to be fixed (Eisai aims for filing in or after Q3:2019).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Detail</FONT></STRONG> </div><div style="margin-bottom: 10px;">Lenvatinib is an oral multiple receptor tyrosine kinase (RTK) inhibitor with a novel binding mode that selectively inhibits the kinase activities of various RTKs including VEGFR, FGFR, PDGFRα, KIT and RET, involved in angiogenesis and tumor proliferation </div><div><EM>Source: Esai</EM> </div><!-- Comment details --><a name="endocrinology7704attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7704/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(46,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7704">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-26T14:11:41+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7704/1/ScreenCapture1.jpg" length="47248" type="image/jpeg"/></item><item>
<title>Strategic Rationale of AbbVie Possible Acquistion of Shire [:GastroEnterology:news, :Oncology:dis:Prostate, :Oncology:prod:Lupron]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10901</link>
<description>Strategic Rationale of AbbVie Possible Acquistion of Shire [:GastroEnterology:news, :Oncology:dis:Prostate, :Oncology:prod:Lupron]</description><category>news</category><category>dis:Prostate</category><category>prod:Lupron</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10901</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10901">Strategic Rationale of AbbVie Possible Acquistion of Shire</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aLupron"><font color="#e95e0b">:Oncology:prod:Lupron</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10901">PharmaWorld10901</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 June 2014 | 11:56</font><br><br><div style="margin-bottom: 10px;">Comment: Yesterday AbbVie presented strong arguments for the Shire acquisition.<wbr> Strategic rationale reported by management include the tax inversion opportunity and the operational synergies.<wbr> On the other hand, the combined company would 1/<wbr> lower AbbVie’s risk profile in lowering dependence on Humira (threat of biosimilars around 2017-2018), 2/<wbr> have a market leading position in the gastrointestinal segment.<wbr> Please find below key messages.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background of AbbVie's offers</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>AbbVie last offer valued Shire at roughly $46bn</LI>
<LI>Shire turned down three offers from AbbVie</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Why Buy Shire ?</FONT></STRONG> </div><div style="margin-bottom: 10px;">With its speciality niche, high margins and strong single-digit compound annual sales growth potential, Shire is likely to appeal to larger pharmaceutical peers.<wbr> </div><div style="margin-bottom: 10px;">The effective corporate tax rate among the lowest in the world also makes Shire an attractive takeover candidate.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Allergan, BMS, Biogen, Amgen, AbbVie and Gilead are among those cited in the press in recent weeks as seeking “tax inversion” deals</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Rationale for AbbVie</FONT></STRONG> </div><div style="margin-bottom: 10px;">AbbVie believes the combination has strategic rationale for all shareholders.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Messages from the AbbVie Presentation</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The combination would create a leadership postition with growing therapeutic areas, a diversified portfolio of launched products, and stronger growth platforms </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Combined Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Gastrointestinal Franchise</FONT></STRONG> </div><div style="margin-bottom: 10px;">Shire has 2 key products in the Gastrointestinal unit, namely Lialda and Pentasa.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Combined sales of Lialda and Pentasa amounted to USD810m in 2013 or 16% of total revenues (below sales split in Q1 2014)</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Gastro Sales Estimates</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Gastro Pipeline</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>SHP555 is in the ph3 stage in the US and Shire is currently planning discussions with FDA to determine potential clinical development pathways.<wbr> Based on the lack of available options for the treatment of chronic constipation, and what seems to be a better cardiac profile than for Cisapride, we see a strong probability of this drug being approved by the FDA</LI>
<LI>ph3 treatments for 8 rare and devastating hepatic diseases</LI>
<LI>LUM002 for the treatment of non-alcoholic steatohepatitis could potentially also come under this business unit, if launched.<wbr></LI>
</UL> </div><div><EM>Source: Shire; AbbVie</EM> </div><!-- Comment details --><a name="pharmaworld10901attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(27,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(12,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(4,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(41,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10901">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-26T11:56:48+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/6/ScreenCapture6.jpg" length="28245" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/7/ScreenCapture7.jpg" length="13139" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/8/ScreenCapture8.jpg" length="5051" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10901/9/ScreenCapture9.jpg" length="42884" type="image/jpeg"/></item><item>
<title>re: The First Approval OF PARP Inhibitor Is Underway</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9805</link>
<description>re: The First Approval OF PARP Inhibitor Is Underway</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9805</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9805">re: The First Approval OF PARP Inhibitor Is Underway</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9805">Oncology9805</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 26 June 2014 | 10:57</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">The First Approval OF PARP Inhibitor Is Underway</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Today FDA Oncologic Drugs Advisory Committee announced that the committee is planning to discuss application submitted by AstraZeneca for olaparib on 25 June.<wbr> Olaparib is the most advanced PARP inhibitors in development, followed by rucaparib by Clovis Oncology and Niraparib by TesaroBio.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9637">...</a><br><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9637" class="commentpermalink">Oncology9637</a> / <span class="date">24 April 2014</span> /
<span class="time">13:35:23 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Comment: Yesterday FDA held the Oncologic Drugs Advisory Committee and agency advisors voted 11-2 for AstraZeneca should complete a study to confirm olaparib's benefit before an approval decision can be made.<wbr> If the FDA requires AstraZeneca to complete a confirmatory study before deciding on approval, the company is estimated to lose $150 million in sales through 2016, Bloomberg Industries said.<wbr> Most importantly, A delay also would raise questions about AstraZeneca&rsquo;s view that its experimental medicines were undervalued by Pfizer in the proposed acquisition, according to Bloomberg Industries.<wbr>.<wbr> </div><div style="margin-bottom: 10px;">After the committee meeting, Brent Logan (panel member and biostatistics professor at the medical college of Wisconsin) commented after the vote &ldquo;there are a number of issues that raise concern about the benefit of olaparib helping patients to survive without their disease progression.<wbr> That produces a magnitude of uncertainty.<wbr>&rdquo; AstraZeneca&rsquo;s reanalysis of the drug, known as Study 19, found ovarian cancer patients with the BRCA mutation who took olaparib lived 11.<wbr>2 months without their disease progressing compared with 4.<wbr>1 months for those on a placebo.<wbr> FDA staff members questioned whether the reanalysis skewed the results.<wbr> If the difference in progression-free survival isn&rsquo;t as pronounced, the risks associated with olaparib may outweigh the benefit.<wbr> Safety concerns include bone marrow suppression, fatigue, nausea and abdominal pain as well as a &ldquo;small but concern risk&rdquo; of developing a certain kind of leukemia, according to the report.<wbr> </div><div>AstraZeneca is attempting to gain accelerated approval of olaparib based on a Phase II clinical trial, the middle of three stages of trials usually required for approval.<wbr> Early FDA clearance would require the drugmaker to complete a final-phase study, called SOLO-2, to stay on the market.<wbr> Results from that study are expected to be available at the end of 2015.<wbr>The FDA is expected to decide whether to grant olaparib accelerated approval by Oct.<wbr> 3.<wbr> AstraZeneca also is studying the drug in lung and breast cancers.<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9805" class="commentpermalink">Oncology9805</a> / <span class="date">26 June 2014</span> /
<span class="time">10:57:32 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9805">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9637">View thread  Oncology9637: The First Approval OF PARP Inhibitor Is Underway</a>]]></content:encoded><dc:date>2014-06-26T10:57:32+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>CEA-Leti and Akrivis to Develop Nanomed Platform</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9804</link>
<description>CEA-Leti and Akrivis to Develop Nanomed Platform</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9804</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9804">CEA-Leti and Akrivis to Develop Nanomed Platform</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9804">Oncology9804</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 26 June 2014 | 10:57</font><br><br><div style="margin-bottom: 10px;">Comment: French CEA-Leti and US-based Akrivis intend to develop a new, more efficient and safer platform to deliver high payloads specifically to targeted cells.<wbr> The resulting targeted nanoparticles will be optimized in a first phase for research and pre-clinical <EM>in vitro</EM> and <EM>in vivo</EM> applications.<wbr> Then, in a second phase, they will be further developed clinically for <EM>in vitro</EM> diagnostics, <EM>in vivo</EM> imaging and targeted therapy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Details of the Deal</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Technology</U> </div><div style="margin-bottom: 10px;">The new platform will be based on Akrivis Technologies' proprietary Z-TECT technology that targets and detects unusually low levels of proteins and molecular targets and Leti's Lipidot nanovector delivery capability.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><A href="http://akrivis.com/targeted-drug-delivery/">Z-TECT combines nanotechnology</A>, molecular detection and immunology to provide high sensitivity and detection levels across multiple immunoassays and other assay formats, from colorimetric to fluorescent detection <EM>in vitro</EM> and imaging <EM>in vivo</EM>.<wbr></LI>
<LI>The Lipidot technology is a versatile nano-delivery platform based on very small droplets of oil that encapsulate and carry drugs, fluorescent imaging agents or any other lipophilic payload to targeted cells for diagnosis or treatment.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Rationale</U> </div><div style="margin-bottom: 10px;"><UL><LI>New theranostic platform will Combine ultrasensitive detection, high payloads and more efficient cell targeting.<wbr></LI>
</UL> </div><div>Source: CEA-Leti; Akrivis </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9804">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-26T10:57:29+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan Tests BOTOX for Myofascial Pelvic Pain (MPP) [class:BotulinumToxins, comp:Allergan, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7630</link>
<description>Allergan Tests BOTOX for Myofascial Pelvic Pain (MPP) [class:BotulinumToxins, comp:Allergan, :PharmaWorld:sub:ClinicalTrial]</description><category>class:BotulinumToxins</category><category>comp:Allergan</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7630</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7630">Allergan Tests BOTOX for Myofascial Pelvic Pain (MPP)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7630">Neurology7630</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 25 June 2014 | 17:59</font><br><br><div style="margin-bottom: 10px;">Comment: The BotoxMPP Ph1 study, sponsored by the University Hospital Case Medical Center will determine whether or not injections with onabotulinumtoxinA (Botox) improve symptoms of pain and tenderness.<wbr> The PE will measure efficacy at 1 month post treatment versus placebo.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale</STRONG> </div><div style="margin-bottom: 10px;">Chronic pelvic pain affects 15-20% of the female population aged 18-50 years and accounts for up to 10% of gynecologic visits each year resulting in a cost of 2.<wbr>8 billion dollars annually to the health care system.<wbr> It is defined as non-menstrual (non-cyclic) pain that occurs on an average of two weeks per month for at least six months' duration; localized to the anatomic pelvis, anterior abdominal wall below the umbilicus, buttocks, or lumbosacral back.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">Reference <a href="http://www.clinicaltrials.gov/ct2/show/NCT02173405?recr=Open&fund=2&rcv_s=05%2F25%2F2014&rank=325" class="defaultlink">NCT02173405</a> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Principal Investigator</SPAN> Sangetta Mahajan, MD </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Recruitment</SPAN>: approx 40 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Females age 18 years to 65 years
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">MPP for at least 6 months with pain ranked &gt; 7/<wbr>10 by VAS
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;"><SPAN style="text-decoration: underline;">Timeline</SPAN> This Ph1 has been planned to start this month and complete Sept 2015 /<wbr> Sept 2016</P> </div><div style="margin-bottom: 10px;"><SPAN style="text-decoration: underline;">Design of the two-arm study</SPAN> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="margin-top: 0.7ex;">Treatment Group : 20 patients randomly assigned to receive 100 U onabotulinumtoxinA reconstituted in 20 ml saline sequentially injected bilaterally into the pubococcygeus, iliococcygeus, coccygeus, obturator internus, and piriformis muscles.<wbr></P> </div><div>Placebo Group: 20 patients randomly assigned to receive 20 ml of saline bilaterally into the same pelvic floor muscles<BR><BR><SPAN style="text-decoration: underline;">Location</SPAN>: USA (2 sites) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7630">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-25T17:59:55+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: ASIS Device for Botox in ULS and in Chronic Migraine</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7629</link>
<description>re: ASIS Device for Botox in ULS and in Chronic Migraine</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7629</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7629">re: ASIS Device for Botox in ULS and in Chronic Migraine</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7629">Neurology7629</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 June 2014 | 17:27</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">ASIS Device for Botox in ULS and in Chronic Migraine</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aDevices"><font color="#e95e0b">:PharmaWorld:sub:Devices</font></a>]</font></font><br><span style="font-size: 12px;"><SPAN style="FONT-FAMILY: arial,helvetica,sans-serif; FONT-SIZE: small"><FONT face="Verdana" size="2">Comment: ASIS Corporation has been developing </FONT><a href="http://www.asis-inc.com/product.html" class="defaultlink">Automatic Subdermal Injection System</a><FONT face="Verdana" size="2"> for the correct injection of almost every Injectable products into a bloodless space just outside of the fascia, which exists subdermally (between the skin and muscle), or interfascially (between the deeper muscles).<wbr> Two Ph1/<wbr>2 will be starting in Q2:14 with details provided below.<wbr></FONT></SPAN></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7440">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7440" class="commentpermalink">Neurology7440</a> / <span class="date">03 March 2014</span> /
<span class="time">18:16:42 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">A new trial has been added for cervical dystonia (CD).<wbr> The purpose of the study is to assess the safety and efficacy of Botox (onabotulinumtoxinA) administered intramuscularly and subdermally </div><div style="margin-bottom: 10px;"><STRONG>Reference ASIS in CD</STRONG> <a href="http://www.clinicaltrials.gov/ct2/show/NCT02074293?term=NCT02074293&rank=1" class="defaultlink">NCT02074293</a> </div><div style="margin-bottom: 10px;">Over 6 months usage will demonstrate ASIS device's consistent performance on 60 adult subjects with cervical dystonia in which Gadolinium will be injected with ASIS subdermally in 30 subjects or conventional intramuscularly in other 30 subjects for these 7 muscle groups: Splenius, Scalene, Sterno-cleido-mastoid, Levator scapulae, Semispinalis, Trapezius, and Longissimus.<wbr> An MRI will be taken immediately after Gadolinium injection, as starting reference, to which subsequent MRI taken at 6 hrs, 12 hrs, and 24 hrs later will be compared for Persistent %.<wbr> </div><div style="margin-bottom: 10px;">Over 12 months usage of Botox, instead of Gadolinium, will demonstrate the advantages of ASIS device subdermally over intramuscularly, for the same 60 adult subjects with cervical dystonia, on these particular 7 muscle groups: Splenius, Scalene, Sterno-cleido-mastoid, Levator scapulae, Semispinalis, Trapezius, and Longissimus.<wbr> </div><div style="margin-bottom: 10px;">A total of 60 subjects are planned to be enrolled in the study </div><div>Timelines Start date June 2014 - Completion date June 2015 /<wbr> June 2016 </div><!-- Comment details --><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7629" class="commentpermalink">Neurology7629</a> / <span class="date">24 June 2014</span> /
<span class="time">17:27:14 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7629">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7440">View thread  Neurology7440: ASIS Device for Botox in ULS and in Chronic Migraine</a>]]></content:encoded><dc:date>2014-06-24T17:27:14+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>DNA Vaccines Enters Ph2 for Prostate Cancer Before ADT</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9800</link>
<description>DNA Vaccines Enters Ph2 for Prostate Cancer Before ADT</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9800</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9800">DNA Vaccines Enters Ph2 for Prostate Cancer Before ADT</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9800">Oncology9800</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 June 2014 | 17:07</font><br><br><div style="margin-bottom: 10px;">Comment: Madison Vaccines, a clinical stage biopharmaceutical company, has announced enrollment begun in the expansion of a Ph2 trial of its lead product candidate MVI-816 (pTVG-HP).<wbr> MVI-816 targets prostatic acid phosphatase (PAP), and can be delivered to patients by simple intradermal injection.<wbr> The Vaccine is readily manufactured in a cost-effective manner, and is highly stable compared to protein or peptide vaccines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">Recruitment: The expansion will add 50 patients to the original cohort of 56 patients.<wbr> </div><div style="margin-bottom: 10px;">Criteria: The trial is enrolling non-metastatic prostate cancer patients who have rising PSA after their primary treatment (surgery or radiation), but before patients require androgen deprivation therapy (castration therapy).<wbr> </div><div style="margin-bottom: 10px;">Objective: The trial is seeking clinical evidence that MVI-816 can delay the onset of metastatic disease in these patients.<wbr> </div><div style="margin-bottom: 10px;">Sponsor/<wbr>Collaborator: The trial is funded by the company, with patient recruitment currently underway at the University of Wisconsin, and future enrollment anticipated at the University of California, San Francisco and at least one other site later this year.<wbr> </div><div><EM>Source: MVI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9800">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-24T17:07:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>AntiAndrogen May Also Have A Role In Triple Negative Breast Cancer [class:Antihormonals, comp:Astellas, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9798</link>
<description>AntiAndrogen May Also Have A Role In Triple Negative Breast Cancer [class:Antihormonals, comp:Astellas, :PharmaWorld:sub:ClinicalTrial]</description><category>class:Antihormonals</category><category>comp:Astellas</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9798</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9798">AntiAndrogen May Also Have A Role In Triple Negative Breast Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9798">Oncology9798</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 24 June 2014 | 16:00</font><br><br><div style="margin-bottom: 10px;">Comment: A new study being presented today at the Endocrine Society Annual Meeting shows that even triple negative breast cancer (TNBC) expressing very low levels of androgen receptor may benefit from antiandrogen therapy.<wbr> TNBCs were recently divided into further subtypes including a subtype with high androgen receptor expression (Lehmann, JCI 2011).<wbr> Recent work shows that while these cancers lack oestrogen receptors, progesterone receptors, and aren&rsquo;t driven by the gene HER2, up to a third of these tumours express the androgen receptor.<wbr> Currently there is an ongoing phase 2 study to evaluate safety and efficacy of enzalutamide in TNBC patients who express the androgen receptor (<a href="http://clinicaltrials.gov/ct2/show/NCT01889238?term=androgen+triple-negative+breast+cancer&rank=1" class="defaultlink">NCT01889238</a>).<wbr> </div><div style="margin-bottom: 10px;">Triple Negative Breast Cancer patients historically represent a subset of breast cancer patients with worst prognosis.<wbr> They do not respond to HER2 targeted therapy and neither to hormonal treatment due to their phenotype of HER2 negative, and lack of oestrogen and progesterone receptors.<wbr> Lehmann (2011) published an article in JCI and showed that TNBCs include a subtype with high androgen receptor expression.<wbr> Based on these findings, Barton and colleagues treated cell lines with the drug enzalutamide and with shRNAs designed to knock down androgen receptor levels to find out how different subtypes could respond differently to anti-androgen receptor therapy.<wbr> We all know that enzalutamide is in wide use for prostate cancer as prostate cancer is mainly driven by and dependent on androgen receptor.<wbr> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 11pt;"><SPAN style="font-size: small;">&ldquo;<EM>This line of work is starting to change our thinking about who and when </EM><EM>&ndash;</EM><EM> the timing and patient selection for anti-androgen receptor therapy in triple-negative breast cancer</EM>,&rdquo; says Valerie Barton, the study&rsquo;s first author and PhD candidate in the lab of CU Cancer Center investigator Jennifer Richer, PhD.<wbr></SPAN></P> </div><div style="margin-bottom: 10px;">In vitro models showed that not only does anti-androgen receptor therapy reduce the ability of androgen-receptor-expressing triple-negative breast cancers to proliferate, migrate and invade, but for these cells, androgen receptor seems essential to survival.<wbr> When Barton and colleagues blocked androgen receptor in these cells, the cells died.<wbr> Interestingly, but it was not <EM>only </EM>the high androgen-receptor-expressing cells that were affected.<wbr> However, this is still early data and requires clinical evidence to support the future development.<wbr> </div><div style="margin-bottom: 10px;">Currently Medivation/<wbr>Astellas is recruiting for a Ph2 study to evaluate enzalutamide in triple negative breast cancer patients.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="info-title">ClinicalTrials.<wbr>gov Identifier: NCT01889238</DIV> </div><div style="margin-bottom: 10px;"><DIV class="info-title">Expected Enrolment = 95</DIV> </div><div style="margin-bottom: 10px;"><DIV class="info-title">Estimated Primary completion Date May 2015</DIV> </div><div><DIV class="info-title">Experimental Arm: 160 mg administered as four 40 mg soft gelatin capsules orally once daily</DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9798">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-24T16:00:44+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>6-Month Ped Ph2 Data of Versartis' Monthly hGH and OPKO/Prolor's Lagova (hGH-CTP) Presented @ ENDO [class:GrowthHormone]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7703</link>
<description>6-Month Ped Ph2 Data of Versartis' Monthly hGH and OPKO/Prolor's Lagova (hGH-CTP) Presented @ ENDO [class:GrowthHormone]</description><category>class:GrowthHormone</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7703</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7703">6-Month Ped Ph2 Data of Versartis' Monthly hGH and OPKO/<wbr>Prolor's Lagova (hGH-CTP) Presented @ ENDO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7703">Endocrinology7703</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 June 2014 | 15:24</font><br><br><div style="margin-bottom: 10px;">Comment: Versartis reported that the data are reinforcing the attractive profile of the drug and are viable for a Ph3 trial (design to be discussed with FDA in August).<wbr> OPKO  indicated the study allows selection of a dose for a Ph3 study, which is due to start in 2015 (adult Ph3 interim data are expected end of 2015).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">VRS-317 - Efficacy and Safety Data</FONT></STRONG> </div><div style="margin-bottom: 10px;">The monthly dose showed a smaller decrease versus semi-monthly.<wbr> Annualized growth rates at six months were: 5.<wbr>0 mg/<wbr>kg monthly: 7.<wbr>9 cm/<wbr>yr vs.<wbr> 8.<wbr>15 cm/<wbr>yr at three months.<wbr> 2.<wbr>5 mg/<wbr>kg semi-monthly: 8.<wbr>7 cm/<wbr>yr vs.<wbr> 9.<wbr>21 cm/<wbr>yr at three months.<wbr> 1.<wbr>35 mg/<wbr>kg weekly: 7.<wbr>6 cm/<wbr>yr vs.<wbr> 7.<wbr>8 cm.<wbr>yr at three months.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Safety at six months was very clean, with the vast majority of AEs reported as mild.<wbr> Specifically, no nodules or lipoatrophy were seen at injections sites.<wbr> More than 80% of patients had two or fewer occurrences of injection site reactions.<wbr> One investigator stated that simply changing the injection site completely resulted in zero injection site reactions in one of his patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">hGH-CTP - Efficacy and Safety Data</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management highlighted that ' .<wbr>.<wbr>.<wbr> very good safety profile of our product.<wbr> Without any evidence for any problems with injection site reaction.<wbr> And this is actually aligned with our technology which enables us to inject our product into very small volumes and high concentration using a single injection and using a <STRONG>30 1G needle</STRONG> which you are all familiar from the insulin product.<wbr> So we really feel comfortable with the data and then we are actually going to move forward with that into our ph3 study'.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT size="3"><STRONG><FONT style="BACKGROUND-COLOR: #fdfd00">Competition</FONT> - OPKO/<wbr>Prolor 6-Month Data</STRONG></FONT> </div><div style="margin-bottom: 10px;"><UL><LI>Specifically, <STRONG>base height and age</STRONG> are keys for predicting growth trends with daily GH, with differences making cross trial comparisons tricky and often inaccurate.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;">Versartis Management reported " .<wbr>.<wbr>.<wbr> there's a 2 year difference almost between their <STRONG>mean age</STRONG> and our mean age and our study.<wbr> That effect alone can account for several centimeters per year different in growth rates just because of the difference in age.<wbr> </div><div style="margin-bottom: 10px;">The other major difference when one tries to compare against trials is the <STRONG>height standard deviation score</STRONG>.<wbr> And because as I understand it, their trial was conducted in Eastern Europe and other parts of where growth hormone's not available, their height standard deviation scores were closer to minus 4 and our were obviously minus 2.<wbr>5.<wbr> </div><div style="margin-bottom: 10px;">So they have a lot more growing to do, and if we had done our study in Eastern Europe, we probably would have gotten similar height velocity results.<wbr> But we thought it was appropriate to actually do a study in where we plan to market this product, which is in the United States".<wbr> </div><div style="margin-bottom: 10px;"><UL><LI><U>Prolor </U>conducted its Ph2 study in Eastern Europe, where patients are severely growth hormone deficient, which is well known to give very high growth rates.<wbr> </LI>
<LI><U>Versartis</U> conducted its Phase 2 study in US patients, who are more representative of the normal population.<wbr></LI>
</UL> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7703attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(65,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(68,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(36,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(75,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7703">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-24T15:24:24+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/1/ScreenCapture1.jpg" length="66757" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/2/ScreenCapture2.jpg" length="70289" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/3/ScreenCapture3.jpg" length="37363" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7703/4/ScreenCapture4.jpg" length="77457" type="image/jpeg"/></item><item>
<title>Shire's &quot;10 x 20&quot; Strategic Plan Presented to Investors [:GastroEnterology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10897</link>
<description>Shire's &quot;10 x 20&quot; Strategic Plan Presented to Investors [:GastroEnterology:news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10897</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10897">Shire's "10 x 20" Strategic Plan Presented to Investors</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10897">PharmaWorld10897</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 24 June 2014 | 13:07</font><br><br><div style="margin-bottom: 10px;">Comment: Shire has hosted an investor call in response to AbbVie's unsolicited offers.<wbr> Management has reported that $10bn in product sales by 2020 (even before additional M&amp;A and in-licensing) will come from rare diseases, neurosciences and GI franchises.<wbr> Positions in "attractive" adjacent therapeutic such as ophthalmology and hematology/<wbr>oncology will be delivering superior outcomes and sustainable growth.<wbr> Key messages and slides are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ambitions of the Plan</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management believes that Shire now has the key elements in place with the right strategy, the right team, enhanced pipeline, and future investment opportunities, to deliver sustainable growth and strong returns on investment.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Leading Positions in Three TAs</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Management indicated that " .<wbr>.<wbr>.<wbr> The broader GI market is estimated to grow 5% from 2013 through 2020.<wbr> We have the number-one position in the 5-ASA market.<wbr> Our substantial commercial expertise, including the number-two ranked GI sales force will enable us to promote additional products, such as liver disease treatments acquired from Lumena to the benefits of patients and shareholders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Lialda</STRONG> remains the largest product in this franchise, and has a formulation patent that expires in June of 2020.<wbr> In order for a generic version of Lialda to be commercialized, a generic manufacturer must accomplish the following: Number one, it must successfully address the Orange Book listed formulation patent.<wbr> Number two, it must get its ANDA approved by the FDA, and number three, if not the first filer, the generic manufacturer must wait until the first filer's exclusivity period has lapsed.<wbr> As a result, we expect the GI franchise to remain a sizeable portion of our business, with over $1.<wbr>3 billion in net product sales in 2020 .<wbr>.<wbr>.<wbr>).<wbr> </div><div style="margin-bottom: 10px;"><U>Adjacent Therapeutic Areas</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Potential Upside</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>The acquisition of Lumena, with two moleculed targets in cholestatic liver disease (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10856" class="defaultlink">PharmaWorld10856: Shire To Acquire Lumena For $260m</a>)</LI>
<LI>The recently-announced Fibrotech transaction (yet to be closed)</LI>
<LI>Future M&amp;A and licensing</LI>
</UL> </div><div style="margin-bottom: 10px;"><U>Existing Pipeline</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U>Product Acquisitions</U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/4/ScreenCapture4.jpg?user-agent=rss"> </div><div><STRONG><FONT size="3">Full presentation available <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140831&edate=20140501&rs=/link%20PharmaWorld10900%408" class="defaultlink">@8</a></FONT></STRONG> </div><!-- Comment details --><a name="pharmaworld10897attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(64,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(58,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(82,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(88,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(93,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(77,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(37,4 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/8/10x20%5fShireJune2014.pdf">10x20_ShireJune2014.pdf</a>&nbsp;&nbsp;(2,1 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10897">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-24T13:07:25+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/1/ScreenCapture1.jpg" length="66229" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/2/ScreenCapture2.jpg" length="60246" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/3/ScreenCapture3.jpg" length="84028" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/4/ScreenCapture4.jpg" length="90725" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/5/ScreenCapture5.jpg" length="96078" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/6/ScreenCapture6.jpg" length="79555" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/7/ScreenCapture7.jpg" length="38269" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10897/8/10x20%5fShireJune2014.pdf" length="2202766" type="application/pdf"/></item><item>
<title>Real World Pattern of Use of BOTOX® for the Management of UI in Patients with iOAB [class:BotulinumToxins, comp:Allergan, dis:iOAB, prod:Botox, :PharmaWorld:sub:ClinicalTrial, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7627</link>
<description>Real World Pattern of Use of BOTOX® for the Management of UI in Patients with iOAB [class:BotulinumToxins, comp:Allergan, dis:iOAB, prod:Botox, :PharmaWorld:sub:ClinicalTrial, headline]</description><category>class:BotulinumToxins</category><category>comp:Allergan</category><category>dis:iOAB</category><category>prod:Botox</category><category>sub:ClinicalTrial</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7627</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7627">Real World Pattern of Use of BOTOX® for the Management of UI in Patients with iOAB</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7627">Neurology7627</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 June 2014 | 17:10</font><br><br><div style="margin-bottom: 10px;">Comment: The PE of the GRACE trial will assess change from baseline in number of urinary incontinence episodes.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02161159?recr=Open&amp;fund=2&amp;rcv_s=05%2F23%2F2014&amp;rank=176">NCT02161159</A> </div><div style="margin-bottom: 10px;">Recruitment approx.<wbr> 500 </div><div style="margin-bottom: 10px;">Timelines </div><div style="margin-bottom: 10px;">Start date June 2014 /<wbr> Completion Oct 2016 /<wbr> Feb 2017 </div><div>Location Germany (2 sites) </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7627">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-23T17:10:11+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Sanofi to Fund PMS of Oral Enterogermina® for Diarrhea Among LatAm Children [dis:Diarrhoea, sub:Probiotics, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1978</link>
<description>Sanofi to Fund PMS of Oral Enterogermina® for Diarrhea Among LatAm Children [dis:Diarrhoea, sub:Probiotics, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Diarrhoea</category><category>sub:Probiotics</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1978</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1978">Sanofi to Fund PMS of Oral Enterogermina® for Diarrhea Among LatAm Children</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aDiarrhoea"><font color="#e95e0b">:GastroEnterology:dis:Diarrhoea</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=sub%3aProbiotics"><font color="#e95e0b">:GastroEnterology:sub:Probiotics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1978">GastroEnterology1978</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 June 2014 | 17:00</font><br><br><div style="margin-bottom: 10px;">Comment: The objective of the CadiLAc Ph4 trial is to demonstrate the effectiveness of Bacillus clausii probiotic strain (Enterogermina®) in combination with oral rehydration therapy (ORT) for a period of 5 days, in the duration of acute community-acquired diarrhea in Latin American children.<wbr> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG><FONT size="3">About the product</FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1978/2/ScreenCapture2.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1978/1/ScreenCapture1.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex"><STRONG><FONT size="3">Trial Details</FONT></STRONG></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02169817?recr=Open&amp;fund=2&amp;rcv_s=05%2F23%2F2014&amp;rank=60">NCT02169817</A></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Recruitment approx.<wbr> 759</P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Infants or children with acute community-acquired diarrhea (≥3 liquid or watery stools occurring in a 24-hour period):</P> </div><div><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">with less than 48 hours duration</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">aged between 6 months and 5 years of age</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">whose parents or legal guardians have given their written informed consent</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">with clinical indication for ORT per formula of World Health Organization</LI>
</UL> </div><!-- Comment details --><a name="gastroenterology1978attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1978/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1978/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(21,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1978">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-23T17:00:42+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1978/1/ScreenCapture1.jpg" length="22423" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1978/2/ScreenCapture2.jpg" length="22418" type="image/jpeg"/></item><item>
<title>Ex-Ipsen Joins Versartis [class:GrowthHormone, :PharmaWorld:sub:People]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7702</link>
<description>Ex-Ipsen Joins Versartis [class:GrowthHormone, :PharmaWorld:sub:People]</description><category>class:GrowthHormone</category><category>sub:People</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7702</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7702">Ex-Ipsen Joins Versartis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7702">Endocrinology7702</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 June 2014 | 16:42</font><br><br><div style="margin-bottom: 10px;">Comment: Bert Bakker has been appointed Sr VP, Medical Affairs.<wbr> With George Bright, MD heading the clinical development, the company expects adding significant value to the regulatory and commercialization plans of VRS-317 (GHD in adults/<wbr>children).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Bakker's Background</FONT></STRONG> </div><div style="margin-bottom: 10px;">Dr.<wbr> Bakker was Global Brand Medical Director, Global Medical Affairs at Novartis Oncology where he led and developed the global medical affairs strategy for the use of two somatostatin analogs in neuro-endocrine tumors and oversaw a number of early clinical development studies.<wbr> </div><div style="margin-bottom: 10px;">At <STRONG>Ipsen</STRONG>, he was Vice President Medical Affairs and led all activities of the US Endocrine Medical Affairs group which scientifically supported the company's products.<wbr> </div><div style="margin-bottom: 10px;">At Genentech, he was a key contributor as Medical Director in the Clinical Development group, where he covered all four stages of drug development, from early clinical development to post marketing studies for products including human growth hormone, anti CD-20 and anti-VEGF.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Education</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>began his medical career as a pediatric endocrinologist and Assistant Professor at the <ORG>Academic Medical Center</ORG>, <ORG>University of Amsterdam</ORG>, the Netherlands.<wbr> </LI>
<LI>received his MD from the <ORG>Medical School</ORG> at the <ORG>University of Leiden</ORG>, <LOCATION value="LC/nl">the Netherlands</LOCATION> and his PhD in Medical Sciences, from the <ORG>University of Amsterdam</ORG>, the Netherlands.<wbr> </LI>
<LI>was a Pediatric Endocrinology Fellow at <ORG>Stanford University</ORG> and the <ORG>University of Utrecht, the Netherlands</ORG>, where he also completed his pediatric residency.<wbr> </LI>
<LI>Is widely published and while at <ORG value="ACORN:4015175934">Genentech</ORG> was one of the lead authors of the National Cooperative Growth Study Registry.<wbr> His most cited publication is on the first year growth results with daily growth hormone in pediatric growth hormone deficiency.<wbr></LI>
</UL> </div><div><EM>Source: Versartis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7702">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-23T16:42:00+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Valeant Responds to Allergan's Assertions</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7625</link>
<description>Valeant Responds to Allergan's Assertions</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7625</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7625">Valeant Responds to Allergan's Assertions</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7625">Neurology7625</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 23 June 2014 | 14:18</font><br><br><div style="margin-bottom: 10px;">Comment: Valeant has responded today to what it claims are the many inaccurate and missleading comments made by Allergan in its presentation of the 11th June arguing against the Valeant takeover.<wbr> Valeant launched a hostile exchange offer for Allergan last Thursday.<wbr> The offer is scheduled to expire at 5:00 p.<wbr>m.<wbr>, New York City time, on August 15, 2014, unless the offer is extended </div><div style="margin-bottom: 10px;"><STRONG>Valeant's Claim About The Inaccuracies </STRONG>has stated the following:- </div><div style="margin-bottom: 10px;"><H2>"Allergan has based most of their analysis on IMS's US prescription data, including products that we do not own and missing many products, geographies and businesses that we do own.<wbr></H2> </div><div style="margin-bottom: 10px;">US IMS data will cover less than 30% of Valeant&rsquo;s business and, for that portion of Valeant&rsquo;s business IMS covers, the IMS data will not properly collect sales through a numbers of channels (e.<wbr>g.<wbr>, specialty pharmacy, physician dispensed sales, corporate accounts, and alternative fulfillment).<wbr> </div><div style="margin-bottom: 10px;">Given the information being used, the conclusions from Allergan&rsquo;s analysis are both inaccurate and based on a fraction of our overall business" </div><div style="margin-bottom: 10px;">The full facts are included in the lengthy Word Document attached.<wbr> </div><div>Source: <A href="http://www.valeant.com">www.<wbr>valeant.<wbr>com</A> </div><!-- Comment details --><a name="neurology7625attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7625/1/Valeant%20Counter%20Response%20June%2023rd.pdf">Valeant Counter Response June 23rd.pdf</a>&nbsp;&nbsp;(449,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7625">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-23T14:18:50+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7625/1/Valeant%20Counter%20Response%20June%2023rd.pdf" length="459974" type="application/pdf"/></item><item>
<title>China's Luye Pharm to Attempt Relisting [:GastroEnterology:news, mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10895</link>
<description>China's Luye Pharm to Attempt Relisting [:GastroEnterology:news, mkt:China]</description><category>news</category><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10895</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10895">China's Luye Pharm to Attempt Relisting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10895">PharmaWorld10895</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 June 2014 | 09:58</font><br><br><div style="margin-bottom: 10px;">Comment: Luye Pharma Group Ltd.<wbr> is seeking to raise up to $764M in an IPO in Hong Kong, after it delisted from the Singapore stock exchange in 2012.<wbr> The company's core products include CMNa® (the only cancer radiotherapy sensitizer in the PRC), Lipusu® (the first Paclitaxel Liposome product which has independent intellectual property in PRC).<wbr> Of note, the company sells SAILIMAI, a smectite dispersible tablet.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the IPO</FONT></STRONG> </div><div style="margin-bottom: 10px;">The Chinese drug company, partly owned by 3 Chinese private-equity firms, is selling 999.<wbr>6 million shares, of which 33.<wbr>2% are from existing shareholders.<wbr> </div><div style="margin-bottom: 10px;">The deal's indicative price range is HK$5.<wbr>38 to HK$5.<wbr>92 a share, according to a term sheet seen by The <EM>Wall Street Journal</EM> <EM>Monday</EM>, which represents 24.<wbr>2 times to 26.<wbr>6 times the company's 2014 forecast earnings.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">What is SALIMAI ?</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see @ <A href="http://www.luye.cn/en/products/?fid=1109&amp;id=68">http:/<wbr>/<wbr>www.<wbr>luye.<wbr>cn/<wbr>en/<wbr>products/<wbr>?fid=1109&amp;id=68</A> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10895/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Important Strategic Milestone for the Company</FONT></STRONG> </div><div style="margin-bottom: 10px;">2013, obtained the GMP certificate issued by EU.<wbr> </div><div style="margin-bottom: 10px;">2009, passed Chinese GMP accreditation, and obtained Australian TGA certification.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company launched around 30 products in oncology, cardiovascular, orthopaedics, gastroenterology and central nervous system areas with independent in </div><div style="margin-bottom: 10px;">These products marketed in a vast majority of chinese provinces, autonomous regions and municipalities, and have encompassed over 8,000 hospitals and exported to a number of foreign countries and regions.<wbr> </div><div><EM>Source: Luye Pharm; WSJ</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10895">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-23T09:58:00+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Zytiga Is The 10th Top Selling Oncology Drug in 2013 Globally</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9797</link>
<description>Zytiga Is The 10th Top Selling Oncology Drug in 2013 Globally</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9797</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9797">Zytiga Is The 10th Top Selling Oncology Drug in 2013 Globally</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9797">Oncology9797</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 20 June 2014 | 18:04</font><br><br><div style="margin-bottom: 10px;">Comment: According to EvaluatePharma's sales data, J&amp;J's abiraterone (Zytiga) is the 10th top selling oncology drugs in 2013 globally with the sales of $1.<wbr>70 billion.<wbr> On the top 10 list includes Mabthera (rituximab), followed by Avastin (bevacizumab), Herceptin (trastuzumab), Gleevec (imatinib), and Neulasta (pegfilgrastim).<wbr> One thing to note is that Alimta (pemetrexed, Eli Lilly) and Zytiga are the only two drugs from the top 10 list with one indication only (NSCLC, and Prostate, respectively).<wbr> A quick comparison of the global figures and US figures reveals that the United States accounts for a large portion of global sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Table : Global Top 10 Selling Oncology Drugs in 2013.<wbr> (Source: Evaluate Pharma, Medscape).<wbr></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9797/1/Sales%20DAta.PNG?user-agent=rss"> </div><div style="margin-bottom: 10px;">The top 5 best sellers in the United States match up closely with the global list.<wbr> The top-selling cancer drug in the United States in 2013 was also rituximab, with sales of $3.<wbr>59 billions.<wbr> That was followed by bevacizumab at $2.<wbr>78 billion, lenalidomide at $2.<wbr>49 billion, imatinib at $1.<wbr>94 billion, and trastuzumab $1.<wbr>93 billion.<wbr> </div><div style="margin-bottom: 10px;">The implications to learn from this include: </div><div><OL><LI>US will remain a main strategic market for big phamra organisations.<wbr> The success in the US market can increase the chance of success globally.<wbr>
</LI>
<LI>The success in one big indication could ensure the success of the drug, however, the risk could remain high due to fast evolving therapy landscape.<wbr>
</LI>
<LI>Zytiga is one of the latest launched drug on the top 10 list - this demonstrated a unique clinical profile that revolutionises disease paradigm could guarantee the launching success
</LI>
</OL> </div><!-- Comment details --><a name="oncology9797attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9797/1/Sales%20DAta.PNG">Sales DAta.PNG</a>&nbsp;&nbsp;(31,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9797">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-20T18:04:43+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9797/1/Sales%20DAta.PNG" length="32450" type="image/x-png"/></item><item>
<title>Astellas Funded A Randomised Controlled Study of Degarelix vs GnRH Agonist + Bicalutamide In Japan [dis:Prostate, class:Hormonals]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9795</link>
<description>Astellas Funded A Randomised Controlled Study of Degarelix vs GnRH Agonist + Bicalutamide In Japan [dis:Prostate, class:Hormonals]</description><category>dis:Prostate</category><category>class:Hormonals</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9795</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9795">Astellas Funded A Randomised Controlled Study of Degarelix vs GnRH Agonist + Bicalutamide In Japan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9795">Oncology9795</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 20 June 2014 | 17:16</font><br><br><div style="margin-bottom: 10px;">Comment: An exploratory Ph2 trial was registered in 12th June to evaluate degarelix monotherapy and complete androgen blockade (CAB) with GnRH agonist + bicalutamide for metastatic hormone sensitive patients.<wbr> Japan is the only country and led by Clinical Research Support Center Kyushu.<wbr> </div><div style="margin-bottom: 10px;">Trial ID: KYUCOG-1401 (unblended) </div><div style="margin-bottom: 10px;">Anticipated Start date: 01/<wbr>July/<wbr>2014 </div><div style="margin-bottom: 10px;">Expected last follow-up date: 1/<wbr>March/<wbr>2019 </div><div style="margin-bottom: 10px;">Primary Objective: safety and efficacy </div><div style="margin-bottom: 10px;">Primary endpoint: PSA PFS </div><div style="margin-bottom: 10px;">Secondary endpoint: Time to CAB Treatment failure, OS, PFS in image diagnosis, rPFS, change of PSA, effect on hormone dynamics, change of bone metabolic markers, effect on lipid metabolism, adverse event </div><div style="margin-bottom: 10px;">Intervention arm: degarelix 240 mg sc at day1 and thereafter every 4 weeks (in the case of PSA recurrence, bicalutamide 80 mg daily is offered) </div><div style="margin-bottom: 10px;">Comparison arm: leuprorelin or goserelin sc + bicalutamide 80 mg daily </div><div>Source: <FONT color="#6a5acd"><A href="https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr.cgi?function=brows&amp;action=brows&amp;recptno=R000016585&amp;type=summary&amp;language=E">https:/<wbr>/<wbr>upload.<wbr>umin.<wbr>ac.<wbr>jp/<wbr>cgi-open-bin/<wbr>ctr/<wbr>ctr.<wbr>cgi?function=brows&amp;action=brows&amp;recptno=R000016585&amp;type=summary&amp;language=E</A></FONT> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9795">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-20T17:16:24+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Enzalutamide and Everolimus for Post-Chemo mCRPC [comp:Novartis, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9794</link>
<description>Enzalutamide and Everolimus for Post-Chemo mCRPC [comp:Novartis, dis:Prostate, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Novartis</category><category>dis:Prostate</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9794</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9794">Enzalutamide and Everolimus for Post-Chemo mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9794">Oncology9794</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 June 2014 | 16:44</font><br><br><div style="margin-bottom: 10px;">Comment: In collaboration with Novatis, SCRI will sponsor this first in man study to determine the safety/<wbr>efficacy of the combination.<wbr> PE will measure escalating doses of everolimus with standard dose of enzalutamide.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://clinicaltrials.gov/ct2/show/NCT02125084?recr=Open&amp;no_unk=Y&amp;cond=spasticity+OR+prostate+OR+botulinum+OR+acromegaly+OR+neuroendocrine+OR+growth+hormone+deficiency&amp;phase=012&amp;fund=2&amp;rank=169">NCT02125084</A> </div><div style="margin-bottom: 10px;">Recruitment: approx 43 </div><div style="margin-bottom: 10px;"><U>Timelines</U> </div><div>Start date: July 2014 - Completion date: May 2016 /<wbr> May 2017.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9794">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-20T16:44:24+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Insights From The MDS Congress Part 1 -  New Spasticity Data &amp; Merz Development Programme [class:BotulinumToxins, dis:Spasticity, headline, :PharmaWorld:congress:MDS]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7624</link>
<description>Key Insights From The MDS Congress Part 1 -  New Spasticity Data &amp; Merz Development Programme [class:BotulinumToxins, dis:Spasticity, headline, :PharmaWorld:congress:MDS]</description><category>class:BotulinumToxins</category><category>dis:Spasticity</category><category>headline</category><category>congress:MDS</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7624</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7624">Key Insights From The MDS Congress Part 1 -  New Spasticity Data & Merz Development Programme</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aMDS"><font color="#e95e0b">:PharmaWorld:congress:MDS</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7624">Neurology7624</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 June 2014 | 17:28</font><br><br><div style="margin-bottom: 10px;">Comment: The spasticity content of the meeting was minimal compared to other topics but some of the data on the posters is worth noting and importantly soft intelligence was gained on a new development programme that Merz has planned to treat paratonia in Alzheimer's disease.<wbr> A patent was aparently filed last week with discussions now ongoing about a large phII POC study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The SPACE Trial</STRONG> </div><div style="margin-bottom: 10px;">Interim Results Of Merz's SPACE trial were presented in poster form covering the analysis of 648 patients who had completed 1 treatment cycle with incobotulinumtoxin Xeomin (67.<wbr>1%), onabotulinumtoxin (Botox) (21.<wbr>3%) or abobotulinumtoxin A (Dysport) (11.<wbr>6%).<wbr> The one poster on display focused on patient-rated and investigator -rated assessments of efficacy (PGAE &amp; IGAE respectively) and investigator-rated global assessment of tolerability (IGAT).<wbr> The other poster from the SPACE study on QOL assessments was only provided in abstract form.<wbr> We belive SPACE was set up in the UK with the idea of trying to demonstrate a difference in antibody formation between the different toxins.<wbr> To date no such evidence has been found.<wbr> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">.<wbr> </SPAN><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/1/ScreenCapture1.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/2/ScreenCapture2.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/7/ScreenCapture7.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/8/ScreenCapture8.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/3/ScreenCapture3.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/4/ScreenCapture4.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/5/ScreenCapture5.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Another poster Merz elected to show was that based on two satisfaction surveys undertaken in post-stroke spasticity patients and physicians.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/6/ScreenCapture6.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/9/ScreenCapture9.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/15/ScreenCapture15.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/17/ScreenCapture17.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/10/ScreenCapture10.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/11/ScreenCapture11.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/16/ScreenCapture16.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Merz's other key poster display on the spasticity poster day was one focusing on the safety of higher dosages (see below).<wbr> It appears as though it could be the data that has supported the evaluation of higher doses in the phIII TOWER study, which Merz will utilise for filing purposes alongside the PLUS &amp; PURE data.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/19/ScreenCapture19.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/20/ScreenCapture20.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">The conclusions of this study are of interest in that they potentially point to future studies in patients with more severe hyperactivity conditions.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/21/ScreenCapture21.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/18/ScreenCapture18.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Outside of the company sponsored posters, interesting data was presented by Dr<SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"> Kleiner-Fisman </SPAN>on a preliminary small proof of principal study undertaken in 10 patients in a Toronto care home.<wbr> As shown below, the data demonstrated a positive outcome with regards to careburden in incobotulinumtoxin A patients.<wbr> Many such patients are in care homes with little focus on this condition which if rectified could ease the burden of care for these patients.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/12/ScreenCapture12.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/13/ScreenCapture13.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/14/ScreenCapture14.jpg?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">The PI of the study volunteered that Merz was "excited by the data" and as of that day had a filed a patent covering the indication.<wbr> She also noted that plans are underway to conudct a larger POC study with around 50-100 patients.<wbr> Discussions are apparently ongoing with the FDA/<wbr>EMA regarding the study design.<wbr> Before this starts there needs to be further validation of the careburden scale undertaken as the scale used in the study is an adapted scale to cover both arms.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Dr Kleiner-Fisman noted that Allergan had also expressed interest in this potential indication focusing more on the lower limbs but that there had been some difficulty in defining an appropriate scale for a primary endpoint.<wbr> Whether it has suceeded and this is the new undisclosed phII indication it has referred to remains to be seen.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">She stated that this is potentially a big commercial opportunity for toxin usage bearing in mind demongraphic trends and the huge increase in the no of Alzheimer patients expected over the next 30 years and the careburden associated with that.<wbr></SPAN> </div><div><SPAN style="font-size: 12pt; font-family: 'Times New Roman','serif'; line-height: 115%; mso-fareast-font-family: 'Times New Roman'; mso-ansi-language: EN-GB; mso-fareast-language: EN-GB; mso-bidi-language: AR-SA;">Source: MDS Congress</SPAN> </div><!-- Comment details --><a name="neurology7624attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(111,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(53,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(59,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(59,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(72,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(94,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(38,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(56,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(34 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(17,5 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(83,1 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(118,6 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(157,3 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(90,7 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(73,3 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(68 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(48,6 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(93,4 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(637 B)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(110,7 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(43 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7624">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-19T17:28:37+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/1/ScreenCapture1.jpg" length="114447" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/2/ScreenCapture2.jpg" length="54720" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/3/ScreenCapture3.jpg" length="60593" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/4/ScreenCapture4.jpg" length="60874" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/5/ScreenCapture5.jpg" length="74081" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/6/ScreenCapture6.jpg" length="96715" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/7/ScreenCapture7.jpg" length="39155" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/8/ScreenCapture8.jpg" length="57590" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/9/ScreenCapture9.jpg" length="34832" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/10/ScreenCapture10.jpg" length="17871" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/11/ScreenCapture11.jpg" length="85115" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/12/ScreenCapture12.jpg" length="121451" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/13/ScreenCapture13.jpg" length="161089" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/14/ScreenCapture14.jpg" length="92910" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/15/ScreenCapture15.jpg" length="75072" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/16/ScreenCapture16.jpg" length="69618" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/17/ScreenCapture17.jpg" length="49793" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/18/ScreenCapture18.jpg" length="95614" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/19/ScreenCapture19.jpg" length="637" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/20/ScreenCapture20.jpg" length="113315" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7624/21/ScreenCapture21.jpg" length="44001" type="image/jpeg"/></item><item>
<title>NICE to Conduct an Oral Appeal Hearing for Ferring's Firmagon [prod:Firmagon, :PharmaWorld:mkt:UK, :PharmaWorld:sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9792</link>
<description>NICE to Conduct an Oral Appeal Hearing for Ferring's Firmagon [prod:Firmagon, :PharmaWorld:mkt:UK, :PharmaWorld:sub:Pricing]</description><category>prod:Firmagon</category><category>mkt:UK</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9792</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9792">NICE to Conduct an Oral Appeal Hearing for Ferring's Firmagon</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aFirmagon"><font color="#e95e0b">:Oncology:prod:Firmagon</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aUK"><font color="#e95e0b">:PharmaWorld:mkt:UK</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9792">Oncology9792</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2014 | 16:35</font><br><br><div style="margin-bottom: 10px;">Comment: Ferring has confirmed that its drug Firmagon (degarelix) will be the subject of an appeal hearing by NICE on June 25.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9390" class="defaultlink">Oncology9390: UK's NICE Backs Ferring's Firmagon for PCa Subgroup</a>.<wbr> </div><div style="margin-bottom: 10px;">The original Appraisal Consultation Document (ACD) recommended the use of Firmagon for patients "at risk" of spinal cord compression.<wbr> </div><div style="margin-bottom: 10px;">However, the Final Appraisal Determination (FAD) in April restricted the use of Firmagon to prostate cancer patients who present with "signs and symptoms of spinal cord compression", rather than those considered at risk –thereby reducing the number of patients to less than a third of those eligible for treatment per the ACD.<wbr> </div><div><DIV id="editorContent">
<P><STRONG><FONT size="3">Drug Status in the UK and Scotland</FONT></STRONG></P>
<P>Firmagon has been available in the UK since 2009 but was only reviewed by the NICE as part of a Single Technological Appraisal (STA) in 2014.<wbr> </P>
<P>Firmagon has been previously reviewed and recommended by the Scottish Medicines Consortium (SMC) in 2011 and by the All Wales Medicine Strategy Group (AWMSG) in 2012 for all patients with prostate cancer.<wbr> </P>
<P>Whilst the FAD will not change the guidance in Scotland, the FAD guidance would supersede the current recommendation from AWMSG and reduce the approved availability of this treatment for men in Wales.<wbr></P></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9792">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-19T16:35:28+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Auspex -  A Late-stage Development Company With An Asset Potential In Multiple Hyperkinetic Movement Disorders [dis:Huntington]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7623</link>
<description>Auspex -  A Late-stage Development Company With An Asset Potential In Multiple Hyperkinetic Movement Disorders [dis:Huntington]</description><category>dis:Huntington</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7623</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7623">Auspex -  A Late-stage Development Company With An Asset Potential In Multiple Hyperkinetic Movement Disorders</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7623">Neurology7623</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 19 June 2014 | 13:11</font><br><br><div style="margin-bottom: 10px;">Comment: At the Jefferies H/<wbr>C Conference last week, Auspex 
Pharmaceuticals presented some key data illustrating the PK profile and 
potential therapeutic application of its novel analogue of tetrabenazine 
(Xenazine), a drug used quite widely to treat Huntington's disease (sales of 
$253m in 2013.<wbr>) PhIII SD-809 data in Huntington's disease is due in 
Q414.<wbr> </div><div style="margin-bottom: 10px;">SD-809 which is in phIII development for Huntington's disease is a deuterated 
form of tetrabenazine (Xenazine Lundbeck).<wbr> The latter has some limitations in 
terms of its side-effect profile, which hopefully SD-809 will overcome.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/16/ScreenCapture16.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/17/ScreenCapture17.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7623attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(121,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(147,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(137,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(116,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(88,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(115,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(72,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(115,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(115,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(75,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(132,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(130,8 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(104,4 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(155,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(143,6 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(125,3 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(121,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7623">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-19T13:11:20+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/1/ScreenCapture1.jpg" length="124667" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/2/ScreenCapture2.jpg" length="151114" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/3/ScreenCapture3.jpg" length="140477" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/4/ScreenCapture4.jpg" length="118987" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/5/ScreenCapture5.jpg" length="90628" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/6/ScreenCapture6.jpg" length="118700" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/7/ScreenCapture7.jpg" length="74388" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/8/ScreenCapture8.jpg" length="118157" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/9/ScreenCapture9.jpg" length="117925" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/10/ScreenCapture10.jpg" length="77197" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/11/ScreenCapture11.jpg" length="135558" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/12/ScreenCapture12.jpg" length="133970" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/13/ScreenCapture13.jpg" length="106858" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/14/ScreenCapture14.jpg" length="159073" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/15/ScreenCapture15.jpg" length="147079" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/16/ScreenCapture16.jpg" length="128307" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7623/17/ScreenCapture17.jpg" length="124137" type="image/jpeg"/></item><item>
<title>Takeda Ends WW Development of Orteronel for Prostate Cancer [comp:Takeda, dis:Prostate, prod:Orteronel, :PharmaWorld:sub:Termination]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9789</link>
<description>Takeda Ends WW Development of Orteronel for Prostate Cancer [comp:Takeda, dis:Prostate, prod:Orteronel, :PharmaWorld:sub:Termination]</description><category>comp:Takeda</category><category>dis:Prostate</category><category>prod:Orteronel</category><category>sub:Termination</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9789</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9789">Takeda Ends WW Development of Orteronel for Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aOrteronel"><font color="#e95e0b">:Oncology:prod:Orteronel</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aTermination"><font color="#e95e0b">:PharmaWorld:sub:Termination</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9789">Oncology9789</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 June 2014 | 12:31</font><br><br><div style="margin-bottom: 10px;">Comment: The decision follows the results of 2 Ph3 in mCRPC.<wbr> The studies found while orteronel+prednisone could extend the time patients lived before their cancer progressed, it did not extend OS in these patients.<wbr> The suspension of TAK-700 (orteronel) has not come to a surprise, and may have few implications for share price.<wbr> </div><div style="margin-bottom: 10px;">After careful consideration of the data from these trials, the company has determined that the drug has not demonstrated a clinical profile sufficient to move forward in mCRPC, given the availability of other therapies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background - Drug Failure</FONT></STRONG> </div><div style="margin-bottom: 10px;">On May 14, 2014, Takeda announced results from <STRONG>ELM-PC4</STRONG>, a pivotal, international, double blind, randomized Ph3 trial in men with mCRPC who had not received chemotherapy, which showed that orteronel plus prednisone improved radiographic progression free survival (rPFS) compared to prednisone alone, one of the study’s two primary endpoints, but did not show a statistically significant improvement in the study’s second primary endpoint of OS.<wbr> </div><div style="margin-bottom: 10px;">A previously reported Ph3 trial, <STRONG>ELM-PC5</STRONG>, in men with mCRPC that had progressed during or following chemotherapy, was unblinded in 2013 after a pre-specified interim analysis indicated that orteronel plus prednisone would likely not meet the primary endpoint of improved overall survival when compared to the control arm.<wbr> The interim analysis did show an advantage for orteronel plus prednisone for the secondary endpoint, radiographic progression-free survival over the control arm.<wbr> There were no significant safety concerns in either study.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>
Feddback from ASCO &gt; Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9773" class="defaultlink">Oncology9773: ASCO Highlight 1 - Progress On Development of New Anti-Androgenic Agents</a>.<wbr></LI>
</UL> </div><div><EM>Source: Takeda</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9789">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-19T12:31:16+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>OPKO Update On Its Long-acting hGH [class:GrowthHormone, dis:GrowthHormoneDeficiency]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7700</link>
<description>OPKO Update On Its Long-acting hGH [class:GrowthHormone, dis:GrowthHormoneDeficiency]</description><category>class:GrowthHormone</category><category>dis:GrowthHormoneDeficiency</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7700</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7700">OPKO Update On Its Long-acting hGH</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7700">Endocrinology7700</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 June 2014 | 17:06</font><br><br><div style="margin-bottom: 10px;">Comment: At the recent Jefferies H/<wbr>C Confernece, OPKO provided slides demonstrating the current status of its long-acting hGH development programme both in adults and children which is based around a proprietary CTP technology platform.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7700/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7700/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7700/3/ScreenCapture3.jpg?user-agent=rss"> </div><div>Source: <A href="http://www.opko.com">www.<wbr>opko.<wbr>com</A> </div><!-- Comment details --><a name="endocrinology7700attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7700/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(247,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7700/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(189 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7700/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(207,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7700">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-18T17:06:14+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7700/1/ScreenCapture1.jpg" length="253164" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7700/2/ScreenCapture2.jpg" length="193494" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7700/3/ScreenCapture3.jpg" length="212879" type="image/jpeg"/></item><item>
<title>BOTOX® for Scleroderma-Associated Raynaud's Syndrome [prod:Botox, :PharmaWorld:sub:ClinicalTrial, comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7622</link>
<description>BOTOX® for Scleroderma-Associated Raynaud's Syndrome [prod:Botox, :PharmaWorld:sub:ClinicalTrial, comp:Allergan]</description><category>prod:Botox</category><category>sub:ClinicalTrial</category><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7622</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7622">BOTOX® for Scleroderma-Associated Raynaud's Syndrome</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7622">Neurology7622</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 18 June 2014 | 16:53</font><br><br><div style="margin-bottom: 10px;">Comment: This randomized, doubled-blinded Ph3 trial has been planned to start in September 2014.<wbr> The trial will be sponsored by the Johns Hopkins U.<wbr> in collaboration with Allergan.<wbr> The primary outcome measure is blood flow to the fingers, as measured by non-invasive laser Doppler imaging.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Raynaud Syndrome</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7622/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">In this syndrome, the fingers of both hands are very sensitive to cold, and they remain cold and blue-colored after exposure to low temperatures.<wbr> This occurs in nearly all cases of scleroderma, both limited and diffuse.<wbr> It is caused by abnormal changes in small blood vessels.<wbr> These changes cause the vessels to narrow, and blood flow is temporarily interrupted, usually in the fingers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">PI: Scott D Lifchez M.<wbr>D </div><div style="margin-bottom: 10px;"><STRONG>Reference</STRONG> <A href="http://clinicaltrials.gov/ct2/show/NCT02165111?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F18%2F2014&amp;rank=220">NCT02165111</A> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Study participants at the first study visit will complete study questionnaires, their hands will be assessed clinically for digital ulceration, and their hands will undergo non-invasive laser Doppler imaging to assess blood flow.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">After this initial assessment, the patients will undergo peri-arterial injection of Botulinum toxin A in one hand, and of sterile saline solution (placebo) in the other, in a randomized, blinded manner.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">Patient will report the severity of their Raynaud's symptoms weekly over the four month study period.<wbr> At one month post-injection, the patient will complete study questionnaires, their hands will be assessed clinically for digital ulceration, and their hands will undergo non-invasive laser Doppler imaging.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-TOP: 0ex; MARGIN-BOTTOM: 1ex">At four months post-injection, the patient will again complete study questionnaires, their hands will be assessed clinically for digital ulceration, and their hands will undergo non-invasive laser Doppler imaging.<wbr> In addition, patient will be given the option of one week post-injection visit, at which point the same assessment will be performed.<wbr></P> </div><div style="margin-bottom: 10px;"><P><STRONG>Recruitment</STRONG> approx 40
<!--generated--></P> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Aged 18 years and older</LI> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Diagnosed with scleroderma.<wbr></LI> </div><div style="margin-bottom: 10px;"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Symptoms of Raynaud's syndrome affecting both hands (not necessarily to equal extents)</LI> </div><div><P><STRONG>Timelines</STRONG>: completion date Sept 2016 /<wbr> Dec 2016</P> </div><!-- Comment details --><a name="neurology7622attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7622/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(27,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7622">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-18T16:53:00+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7622/1/ScreenCapture1.jpg" length="28533" type="image/jpeg"/></item><item>
<title>Key Takeaways From Novartis's Investor Update [class:SomatostatinAnalogue, comp:Sandoz, comp:Novartis, dis:Cushing, dis:Acromegaly, dis:MidGutNET]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7697</link>
<description>Key Takeaways From Novartis's Investor Update [class:SomatostatinAnalogue, comp:Sandoz, comp:Novartis, dis:Cushing, dis:Acromegaly, dis:MidGutNET]</description><category>class:SomatostatinAnalogue</category><category>comp:Sandoz</category><category>comp:Novartis</category><category>dis:Cushing</category><category>dis:Acromegaly</category><category>dis:MidGutNET</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7697</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7697">Key Takeaways From Novartis's Investor Update</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aSandoz"><font color="#e95e0b">:Endocrinology:comp:Sandoz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7697">Endocrinology7697</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 18 June 2014 | 15:40</font><br><br><div style="margin-bottom: 10px;">Comment: Novartis has this week hosted a 2-day investor event focusing on the "New Novartis - A More Focused Company".<wbr> Whilst the full-day presentation covers all aspects of the businesss and additionally Novartis's approach to resource allocation, the event is unusual in format.<wbr> Breakout sessions have been organised for smaller groups to facilitate more interactive sessions with management and these have not been broadcast.<wbr> Amongst the headlines, Sandostatin LAR still features as one of the pharma business's blockbusters both now and as of 2018, whilst Signifor (pasireotide) is described as a potential "best in class agent".<wbr> No reference is made to the development of the fluid crystal octreotide formulation.<wbr> </div><div style="margin-bottom: 10px;">Key slides are highlighted below:=- </div><div style="margin-bottom: 10px;"><STRONG>Product Orientated Highlights/<wbr>Key Development Programmes</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Novartis's Approach To Resrouce Allocation</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/18/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/19/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/20/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/21/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Sandoz's Performance </STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/22/ScreenCapture22.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/23/ScreenCapture23.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/24/ScreenCapture24.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/25/ScreenCapture25.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/26/ScreenCapture26.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/27/ScreenCapture27.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/28/ScreenCapture28.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/29/ScreenCapture29.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Research &amp; Development</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/30/ScreenCapture30.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/31/ScreenCapture31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/32/ScreenCapture32.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/33/ScreenCapture33.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/34/ScreenCapture34.jpg?user-agent=rss"> </div><div><STRONG>Source: <A href="http://www.novartis.com">www.<wbr>novartis.<wbr>com</A></STRONG> </div><!-- Comment details --><a name="endocrinology7697attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(239,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(187,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(175,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(246,1 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(220,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(238,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(142,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(200,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(180,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(262,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(301,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(304,4 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(274,7 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(245,2 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(166,6 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(149 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(127,2 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(113,7 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(134,7 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(199,3 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(209,1 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/22/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(245,7 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/23/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(191,1 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/24/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(142,3 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/25/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(180,7 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/26/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(182,2 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/27/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(189,8 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/28/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(145,9 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/29/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(145,1 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/30/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(120,4 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/31/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(186,1 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/32/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(153,4 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/33/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(220,6 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/34/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(366,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7697">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-18T15:40:20+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/1/ScreenCapture1.jpg" length="244880" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/2/ScreenCapture2.jpg" length="192275" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/3/ScreenCapture3.jpg" length="179312" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/4/ScreenCapture4.jpg" length="251967" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/5/ScreenCapture5.jpg" length="225578" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/6/ScreenCapture6.jpg" length="244522" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/7/ScreenCapture7.jpg" length="146061" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/8/ScreenCapture8.jpg" length="204928" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/9/ScreenCapture9.jpg" length="184516" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/10/ScreenCapture10.jpg" length="268428" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/11/ScreenCapture11.jpg" length="308609" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/12/ScreenCapture12.jpg" length="311742" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/13/ScreenCapture13.jpg" length="281283" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/14/ScreenCapture14.jpg" length="251094" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/15/ScreenCapture15.jpg" length="170589" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/16/ScreenCapture16.jpg" length="152556" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/17/ScreenCapture17.jpg" length="130214" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/18/ScreenCapture18.jpg" length="116466" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/19/ScreenCapture19.jpg" length="137907" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/20/ScreenCapture20.jpg" length="204104" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/21/ScreenCapture21.jpg" length="214073" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/22/ScreenCapture22.jpg" length="251637" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/23/ScreenCapture23.jpg" length="195682" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/24/ScreenCapture24.jpg" length="145728" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/25/ScreenCapture25.jpg" length="185084" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/26/ScreenCapture26.jpg" length="186541" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/27/ScreenCapture27.jpg" length="194387" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/28/ScreenCapture28.jpg" length="149448" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/29/ScreenCapture29.jpg" length="148631" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/30/ScreenCapture30.jpg" length="123327" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/31/ScreenCapture31.jpg" length="190555" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/32/ScreenCapture32.jpg" length="157060" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/33/ScreenCapture33.jpg" length="225863" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7697/34/ScreenCapture34.jpg" length="375535" type="image/jpeg"/></item><item>
<title>Valeant Retaliates Regarding Allergan's Misrepresentations [class:BotulinumToxins, comp:Allergan, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7620</link>
<description>Valeant Retaliates Regarding Allergan's Misrepresentations [class:BotulinumToxins, comp:Allergan, :PharmaWorld:sub:Acquisition]</description><category>class:BotulinumToxins</category><category>comp:Allergan</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7620</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7620">Valeant Retaliates Regarding Allergan's Misrepresentations</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7620">Neurology7620</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 17 June 2014 | 18:28</font><br><br><div style="margin-bottom: 10px;">Comment: Valeant hosted another business update call today to address the " the erroneous statements and misrepresentations that have been made not only by Allergan, but also by others" and discuss its next steps in its bid to acquire Allergan </div><div style="margin-bottom: 10px;">Mike Pearson &amp; colleagues focused on the following key points about value creation, next steps and misrepresentations noting that a more exhaustive response will be issued later this week.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Value Creation</STRONG> </div><div style="margin-bottom: 10px;">Allergan shareholders stand to realize over 90% accretion in stock price from the unaffected stock price prior to announcement, and Valeant shareholders would realize a 45% increase based on the unaffected Valeant stock price prior to announcement.<wbr> </div><div style="margin-bottom: 10px;">Goldman Sachs rated Allergan a neutral with a $125 stock target as the analyst at Goldman saw limited near-term pipeline catalysts for the company.<wbr> The transaction creates enormous value for shareholders, and we believe there is a clear path to allow shareholders to express their views and to complete a transaction.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Process Going Forward Breaks Down Into Four Steps.<wbr> </STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Step one,</STRONG> we expect to launch our exchange offer this week.<wbr> Pershing Square is concurrently pursuing a process to call special meeting to remove six of Allergan instructors.<wbr> They filed their solicitation materials with the SEC two weeks ago, and should be in a position to mail up the proxies in the near-term.<wbr> Pershing has also commenced litigation in order to clarify that actions in connection with requesting that meeting will not trigger the poison pill.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Step two</STRONG>, once Pershing reaches a 25% threshold to call for meeting, they will move forward to solicit support for removable of Directors at the special meeting as soon as possible.<wbr> We could be in a position to hold a special meeting as early as August if Allergan looks up the date we suggest, but in any event it should be by the end of the year.<wbr> </div><div style="margin-bottom: 10px;">At that special meeting, we believe shareholders will support Pershing&rsquo;s resolution to remove directors.<wbr> And Pearson will propose independent replacement directors who will act in the interest of Allergan&rsquo;s shareholders.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Step three</STRONG>, after the special meeting, assuming we have successfully removed our directors, an application will be made to the Delaware Court to order a shareholder meeting to elect replacement directors.<wbr> Shareholders holding 10% of the organic shares can make that application.<wbr> So, given Pearson&rsquo;s ownership, this will only require shareholders only an additional 0.<wbr>3% to make that application.<wbr> We think that needs to be able to be held within approximately two months of the court application.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Step four</STRONG>, as a final step, we would expect the new Board of Directors to engage with Valeant, so that the terms of the transaction can be negotiated and obstacles to closing are removed.<wbr> At that time, this change applicant be completed and the transaction closed.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Product &amp; Revenue Growth Misrepresentations</STRONG> </div><div style="margin-bottom: 10px;">I am pleased to update all of you that our business is continuing to perform well.<wbr> I find it very odd that Allergan continues to suggest that our Q2 and in particularly our Q3 results will demonstrate weakness.<wbr> I am very confident that we will meet expectations in Q2 and the rest of the year.<wbr> </div><div style="margin-bottom: 10px;">Organic growth and cash flow will continue to improve over the course of the year.<wbr> We are now on a path to deliver organic growth of greater than 10%, and I am confident that we will continue to do so for the rest of the year.<wbr> In short, our business is strong.<wbr> And I can assure you our operating model is both durable and sustainable.<wbr> </div><div style="margin-bottom: 10px;">In the Allergan&rsquo;s investor presentation dated June 10, 2014, they asserted that Valeant has experienced volume decreases in 11 of its top 15 worldwide pharmaceutical products.<wbr> First, the products listed in the presentation are not Valeant&rsquo;s top 15 products by revenue, only six of the products illustrated are in Valeant&rsquo;s top 15 products.<wbr> The presentation also claim that most of our products are not growing, but in fact 13 of our top 15 products are growing and 9 of the top 15 are growing by volume, not just price.<wbr> </div><div style="margin-bottom: 10px;">Next, the Allergan slide imply that all of the products worldwide, but in fact we only have worldwide rates on 11 of the 15 products listed, in other parts of the world these products are sold by other companies.<wbr> So it is unclear as to what data Allergan was using.<wbr> </div><div style="margin-bottom: 10px;">Finally, Allergan continue to represent that IMS Health is an accurate proxy for both volume and price increases or decreases realized by our products.<wbr> IMS Health does capture retail and pharmacy sales product information.<wbr> However, it does not capture revenue that flows through specialty pharmacies, alternate fulfillment channels and physician dispensaries, thus significantly under reporting the true revenue figures for many of our dermatology RX products.<wbr> We expect to go through each and every one of the other mischaracterizations later this week and will post the facts to our website.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Accounting Misrepresentations That Were Partially Addressed &amp; Will Be Elaborated on Later This Week</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Number one</STRONG>; that the assets of acquired companies are written down at the date of acquisition in order to benefit earnings in future periods.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Number two;</STRONG> that normal operating expenses are classified as one-time acquisition related, restructuring or integration expenses.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Number three</STRONG>; the Valeant&rsquo;s disclosure regarding these expenses are inadequate.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Number four;</STRONG> that existing royalties paid to Galderma were classified as one-time acquisition related cost at the time of Medicis acquisition.<wbr> </div><div>Source: <A href="http://www.valeant.com/">www.<wbr>valeant.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7620">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-17T18:28:52+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Clovis Oncology Enrolled First Patient To Evaluate Their PARP Inhibitor For Metastatic Pancreatic Cancer [class:KinaseInhibitors, news, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9784</link>
<description>Clovis Oncology Enrolled First Patient To Evaluate Their PARP Inhibitor For Metastatic Pancreatic Cancer [class:KinaseInhibitors, news, :PharmaWorld:sub:ClinicalTrial]</description><category>class:KinaseInhibitors</category><category>news</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9784</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9784">Clovis Oncology Enrolled First Patient To Evaluate Their PARP Inhibitor For Metastatic Pancreatic Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9784">Oncology9784</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 17 June 2014 | 13:07</font><br><br><div style="margin-bottom: 10px;">Comment: Clovis Oncology announced first patient enrolled in RUCAPANC study to evaluate their PARP inhibitor, rucaparib, as treatment for locally advanced or metastatic pancreatic cancer with BRCA mutation.<wbr> All the PARP inhibitors in clinical development are being evaluated in ovarian cancer or breast cancer as BRCA mutation is found most prominent in ovarian and breast cancer (<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9400" class="defaultlink">Oncology9400: PARP Inhibitors Are Bouncing Back in Oncology</a>).<wbr> </div><div style="margin-bottom: 10px;">Dr Susan Domchek (MD, Director of the Basser Research Center for BRCA in the Abramson Cancer Center, and PI of the PUCAPANC study) stated that given pancreatic cancer represents a very difficult-to-treat disease with limited options following disease progression and BRCA mutations do exist in other cancer than ovarian or breast cancer, the rationale to explore rucaparib in the treatment of BRCA mutant driven pancreatic cancer is apparent.<wbr> </div><div style="margin-bottom: 10px;"><DIV class="info-title">ClinicalTrials.<wbr>gov Identifier: <a href="http://www.clinicaltrials.gov/ct2/show/NCT02042378?term=rucaparib%2C+pancreatic&amp;rank=1" class="defaultlink">NCT02042378</a></DIV> </div><div style="margin-bottom: 10px;"><DIV class="info-title">Study Expected Completion Date: April 2017</DIV> </div><div style="margin-bottom: 10px;"><DIV class="info-title">Primary Completion Data: August 2016</DIV> </div><div style="margin-bottom: 10px;">RUCAPANC Study is a Phase 2, open-label study exploring rucaparib monotherapy in patients with locally advanced or metastatic pancreatic cancer and a known deleterious BRCA mutation (including both germline or somatic) who have progressed on 1-2 prior therapies (i.<wbr>e.<wbr> 2L+ patients).<wbr> The study is expected to enrol up to 100 patients with the primary endpoint of overall response rate, and secondary endpoints including duration of response, PFS, OS, and safety.<wbr> </div><div style="margin-bottom: 10px;">Previous data shown that several patients treated with rucaparib showed a few notable responses.<wbr> Patients with a BRCA2 mutation experienced a robust partial response to rucaparib therapy following failed 1L FOLFIRINOX treatment.<wbr> The best response observed was with a 52% target lesion shrinkage at cycle 6.<wbr> In addition, one patient who failed previous 1L gemcitabine based therapy achieved a best response of 43% target lesion shrinkage at cycle 4.<wbr> PFS for these patients was 7.<wbr>5 and 5.<wbr>9 months, respectively.<wbr> Note that no significant toxicity was observed in these two patients.<wbr> </div><div style="margin-bottom: 10px;">These results provided a good rationale to evaluate rucaparib in a larger Ph2 trial.<wbr> From Clovis Oncology perspective, pursuing rucaparib in metastatic pancreatic cancer could lead to a potential accelerated submission path should the data from this study support it.<wbr> </div><div>Source: <A href="http://www.rucapanc.com/">http:/<wbr>/<wbr>www.<wbr>rucapanc.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9784">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-17T13:07:54+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Update on TTY Biopharm's Leuprolide Launch [headline, :Oncology:dis:Prostate, prod:Leuprorelin, :Oncology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids244</link>
<description>Update on TTY Biopharm's Leuprolide Launch [headline, :Oncology:dis:Prostate, prod:Leuprorelin, :Oncology:news]</description><category>headline</category><category>dis:Prostate</category><category>prod:Leuprorelin</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids244</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=244">Update on TTY Biopharm's Leuprolide Launch</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:DKPHybrids:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=prod%3aLeuprorelin"><font color="#e95e0b">:DKPHybrids:prod:Leuprorelin</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids244">DKPHybrids244</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 June 2014 | 12:19</font><br><br><div style="margin-bottom: 10px;">Comment: TTY aims to develop liposomes containing leuprolide acetate (Leuprolide) for prostate cancer.<wbr> The company expects to launch in EU and the US in FY15 and FY16 respectively.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Leuprol (leuprorelin) Presence</FONT></STRONG> </div><div style="margin-bottom: 10px;">Presence on the market has been identified in Greece (March 2012, for Leuprol 3.<wbr>75 mg; September 2012, for Leuprol 11.<wbr>25 mg).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">TTY Biopharm's Global Deployment is Gradually Taking Shape</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company looks to ink new licensing deals with a few multinational pharmaceutical heavyweights this year, further solidifying its foothold in the international landscape in FY15-16.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/244/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About TTY Biopharm</FONT></STRONG> </div><div style="margin-bottom: 10px;">Principally engaged in the manufacturing, processing and distribution of drugs.<wbr> </div><div style="margin-bottom: 10px;">The Company provides cardiovascular medicines, orthopedics medicines, gastrointestinal medicines, anti-infection medicines and tumor medicines, among others, including oral solutions and pastes.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
 </div><div style="margin-bottom: 10px;"><P>The Company's products include Lipo-Dox, UFUR, Thado, Oxalip, Asadin, Gemmis, Epicin, Tyxan, Irino, Anazo, Zobonic, Cubicin, Maxtam, Exacin, Metacin and Flusine, among others.<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;">The Company distributes its products primarily in Taiwan and the rest of Asia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About PharmaEngine</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Development arm of TYY Biopgharm.<wbr> </div><div style="margin-bottom: 10px;">- PharmaEngine is a biopharmaceutical company established in Taipei, Taiwan in 2003.<wbr> </div><div style="margin-bottom: 10px;">- Business model: “<STRONG>no research, development only</STRONG>”.<wbr> </div><div style="margin-bottom: 10px;">- Focus on the development of new drugs for the treatment of cancer and Asian prevalent diseases.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
 </div><div style="margin-bottom: 10px;"><P>The company licensed the Asian and European rights of PEP02 (nanoliposomal irinotecan, aka MM-398) to Merrimack Pharmaceuticals, Inc.<wbr>, which is in a global ph3 study for the treatment of metastatic pancreatic cancer.<wbr> In addition, the company licensed the Asia-Pacific rights of PEP503 (crystalline hafnium oxide, aka NBTXR3) from Nanobiotix, Inc.<wbr> which is in a ph1 clinical trial in France.<wbr></P></BLOCKQUOTE> </div><div><EM>Source: TTY Biopharm; PharmaEngine; Fubon Research Report</EM> </div><!-- Comment details --><a name="dkphybrids244attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/244/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(123 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=244">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-17T12:19:12+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/244/1/ScreenCapture1.jpg" length="125917" type="image/jpeg"/></item><item>
<title>Revance Announces Proposed Public Offering of Common Stock [news, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7619</link>
<description>Revance Announces Proposed Public Offering of Common Stock [news, sub:Aesthetics]</description><category>news</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7619</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7619">Revance Announces Proposed Public Offering of Common Stock</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7619">Neurology7619</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 17 June 2014 | 10:33</font><br><br><div style="margin-bottom: 10px;">Comment: Revance will offer 3,000,000 shares of its common stock.<wbr> The company recently completed an IPO, and raised approx.<wbr> $98.<wbr>7M.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Next Milestones</FONT></STRONG> </div><div style="margin-bottom: 10px;">results from the RT001 U.<wbr>S.<wbr> Ph3 pivotal study for the treatment of crow's feet lines in the second half of 2014.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Management</FONT></STRONG> </div><div style="margin-bottom: 10px;">Revance appointed Mark Prygrocki to the board.<wbr> He is a well-known pharmaceutical executive, and his experience gained at Medicis will be a good addition to Revance.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7619attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(71,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(45,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(62,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(57 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7619">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-17T10:33:14+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/1/ScreenCapture1.jpg" length="73015" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/2/ScreenCapture2.jpg" length="46238" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/3/ScreenCapture3.jpg" length="64032" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7619/4/ScreenCapture4.jpg" length="58334" type="image/jpeg"/></item><item>
<title>Medtronic To Acquire Covidien To Accelerate Its Growth Strategies [:PharmaWorld:sub:Acquisition, dis:Dystonia, dis:Huntington, dis:Parkinson, dis:Spasticity]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7617</link>
<description>Medtronic To Acquire Covidien To Accelerate Its Growth Strategies [:PharmaWorld:sub:Acquisition, dis:Dystonia, dis:Huntington, dis:Parkinson, dis:Spasticity]</description><category>sub:Acquisition</category><category>dis:Dystonia</category><category>dis:Huntington</category><category>dis:Parkinson</category><category>dis:Spasticity</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7617</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7617">Medtronic To Acquire Covidien To Accelerate Its Growth Strategies</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aDystonia"><font color="#e95e0b">:Neurology:dis:Dystonia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7617">Neurology7617</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 16 June 2014 | 19:27</font><br><br><div style="margin-bottom: 10px;">Comment: This $42.<wbr>9bn transaction is all about access to cash, the future of device distribution and Medtronic's structural position according to analysts from Morgan Stanley.<wbr> It takes advantage of the Irish tax inversion process and creates some synergies for Medtronic in terms of key growth areas namely its Peripheral Vascular Business &amp; Neuroscience strategy (examples of which were evident at the MDS meeting in Stockholm last week).<wbr>.<wbr> </div><div style="margin-bottom: 10px;">This deal is seen as potentially the first of many in the device sector.<wbr> Structural pressures have it is claimed made it more critical for device companies to use their balance sheets to achiev lower tax rates, drive cost synergies, or return greater cash to shareholders.<wbr> In addition, large cap companies may need to gain scale and expand geographically to compete more effectively in the future environment.<wbr> The deal excludes Covidien's pharmaceutical business, which was spun -off in June 2013 to form Mallinckrodt Inc Medtronic already has an agreement in place with Mallinckrodt covering its intrathecal baclofen technology and assets (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7343" class="defaultlink">Neurology7343: New Deal To Focus On Increased Awareness & Adoption Of Intrathecal Therapies For Pain & Spasticity</a>) </div><div style="margin-bottom: 10px;"><P align="left">Evidence of Medtronic's neuroscience expansion strategy was seen last week at the MDS meeting in Stockholm, where application of its Deep Brain Stimulation technology was highlighted in terms of its application in Parkinson's disease, Dystonia, Cervical Dystonia, Tourettes and Huntington's Disease.<wbr> Further details on this will be reported in the MDS Insight Reviews.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/5/ScreenCapture5.jpg?user-agent=rss"></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left"><FONT face="Arial" size="2"><FONT face="Arial" size="2">The sldies below highlight the key aspects about the deal.<wbr></FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/1/ScreenCapture1.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/2/ScreenCapture2.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/3/ScreenCapture3.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P align="left"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/4/ScreenCapture4.jpg?user-agent=rss"></P> </div><div><P align="left"><FONT face="Arial"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/6/ScreenCapture6.jpg?user-agent=rss"></FONT></P> </div><!-- Comment details --><a name="neurology7617attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(177,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(159,7 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(144,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(154,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(139,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(130 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7617">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-16T19:27:13+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/1/ScreenCapture1.jpg" length="181511" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/2/ScreenCapture2.jpg" length="163525" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/3/ScreenCapture3.jpg" length="148055" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/4/ScreenCapture4.jpg" length="158228" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/5/ScreenCapture5.jpg" length="142775" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7617/6/ScreenCapture6.jpg" length="133070" type="image/jpeg"/></item><item>
<title>Valeant Adds Restylane® Silk to its Range of Dermal Fillers [sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7615</link>
<description>Valeant Adds Restylane® Silk to its Range of Dermal Fillers [sub:Aesthetics]</description><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7615</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7615">Valeant Adds Restylane® Silk to its Range of Dermal Fillers</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7615">Neurology7615</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 June 2014 | 17:15</font><br><br><div style="margin-bottom: 10px;">Comment: Restylane® Silk Injectable Gel with 0.<wbr>3% Lidocaine has been cleared by the US FDA.<wbr> It is a device indicated for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Restylane® Silk Description</FONT></STRONG> </div><div style="margin-bottom: 10px;">Crystal clear injectable gel composed of hyaluronic acid, a natural substance that already exists in the body.<wbr> Restylane® Silk is non-animal based and free from animal protein.<wbr> Allergy pretesting is not necessary.<wbr> </div><div style="margin-bottom: 10px;">Restylane® Silk contains 0.<wbr>3% lidocaine, which was added to reduce the discomfort associated with the treatment.<wbr> </div><div style="margin-bottom: 10px;">A clinical study was conducted with Restylane® Silk to evaluate the safety and effectiveness of injections to enhance lip fullness and to improve the wrinkles around the lips.<wbr> The study included 221 mostly female subjects and evaluated subjects with light and dark skin.<wbr> Subjects with very dark skin were not studied.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>98% of subjects reported improvement in their lip fullness 14 days after injection and 76% of the subjects still had lip improvement 6 months after their injection.<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;">The majority of adverse events were mild in intensity and the most common symptoms were lip swelling, contusion, and lip pain.<wbr> The incidence of adverse event decreased significantly after the second treatment.<wbr> </div><div><EM>Source: Valeant</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7615">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-16T17:15:56+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New J&amp;J Sponsored Study With Androgen Receptor Antagonist [comp:JnJ, dis:Prostate, :PharmaWorld:mkt:Japan, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9782</link>
<description>New J&amp;J Sponsored Study With Androgen Receptor Antagonist [comp:JnJ, dis:Prostate, :PharmaWorld:mkt:Japan, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:JnJ</category><category>dis:Prostate</category><category>mkt:Japan</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9782</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9782">New J&J Sponsored Study With Androgen Receptor Antagonist</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9782">Oncology9782</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 June 2014 | 16:09</font><br><br><div style="margin-bottom: 10px;">Comment: Janssen Pharmaceutical K.<wbr>K.<wbr> will initiate a first in man study evaluating ARN-509 (JNJ-56021927) in Japanese subjects with mCRPC.<wbr> PE will assess DLT.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/study/NCT02162836?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F16%2F2014&amp;rank=90#contacts">NCT02162836</A> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> approx.<wbr> 12 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features, with metastatic disease</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Castration-resistant prostate cancer (CRPC) demonstrated during continuous androgen deprivation therapy (ADT)/<wbr>post orchiectomy</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Maintain castrate levels of testosterone (less than [&lt;] 50 nanogram per deciliter (ng/<wbr>dL) [1.<wbr>72 nanomol per liter {nmol/<wbr>L}]) within 4 weeks before enrollment</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Prostate-specific antigen (PSA) evidence for progressive prostate cancer consists of a PSA level of at least greater than or equal to (&gt;=) 2 nanogram per milliliter (ng/<wbr>mL) within 2 weeks before enrollment which has risen on at least 2 successive occasions, at least 1 week apart.<wbr> If the confirmatory PSA value is less than the last PSA value, then an additional test for rising PSA will be required to document progression</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Participants who received a first generation anti-androgen [for example, bicalutamide, flutamide, nilutamide (not approved in Japan)] as part of an initial combined androgen blockade therapy or as second-line hormonal therapy must show continuing disease progression off the anti-androgen for at least 4 weeks prior to the first dose of study drug</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Protocol</STRONG> </div><div><DIV class="indent1" style="MARGIN-TOP: 3ex">
<DIV class="indent2" style="MARGIN-TOP: 2ex">
<DIV class="indent3">
<DIV class="body3">
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex">The study consists of 4 parts: Screening (28 days before study commences on Day 1), pharmacokinetic week (PK), Continuous daily dosing, Extension and Safety follow-up period.<wbr> In PK week participants will receive a single oral capsule of JNJ-56021927 at a dose of 240 milligram (mg) on Day 1 and will be monitored for 1 week.<wbr> After Week 1, in continuous daily dosing period, participants will receive continuous daily therapy at the same dose for 4 weeks (Cycle 1).<wbr> After Cycle 1 participants, who will not meet the criteria for discontinuation listed such as progressive disease (PD) or unacceptable toxicity, will continue in safety follow-up period and will receive continuous daily therapy at the same dose up to cycle 13.<wbr> Primarily dose limiting toxicity (DLT) will be evaluated.<wbr> Participants' safety will be monitored throughout.<wbr></P>
<P style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><STRONG>Timelines </STRONG>Start date June 2014 /<wbr> Completion date: September 2018</P></DIV></DIV></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9782">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-16T16:09:23+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Update of Daewoong's Nabota in Thailand [class:BotulinumToxins, :DKPHybrids:comp:Daewoong, TAL:Aesthetic, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7612</link>
<description>Update of Daewoong's Nabota in Thailand [class:BotulinumToxins, :DKPHybrids:comp:Daewoong, TAL:Aesthetic, headline]</description><category>class:BotulinumToxins</category><category>comp:Daewoong</category><category>TAL:Aesthetic</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7612</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7612">Update of Daewoong's Nabota in Thailand</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=comp%3aDaewoong"><font color="#e95e0b">:DKPHybrids:comp:Daewoong</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=TAL%3aAesthetic"><font color="#e95e0b">:Neurology:TAL:Aesthetic</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7612">Neurology7612</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 13 June 2014 | 16:37</font><br><br><div style="margin-bottom: 10px;">Comment: According to Daewoong, Nabota received approval last month in Thailand.<wbr> A launching symposium is slated to open in August, targeting about 300 Thai experts.<wbr> The company intends to focus messages on the 'high purity' of its drug to differentiate from competitors.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Daewoong's Growing Ambitions in Asia</FONT></STRONG> </div><div style="margin-bottom: 10px;">To take the 'top spot as undisputed N°1 leader in major cosmetic surgery markets' in Asia.<wbr> </div><div style="margin-bottom: 10px;">Daewoong will leverage the synergic effects of Nabota with dermal filler Perfectha (top-selling product in Thailand).<wbr> </div><div style="margin-bottom: 10px;">The company has set a target of approx.<wbr> KRW10 billion in sales from the Thai market by 2015.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7612/1/ScreenCapture1.jpg?user-agent=rss"> </div><div><EM>Source: Daewoong</EM> </div><!-- Comment details --><a name="neurology7612attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7612/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7612">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-13T16:37:49+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7612/1/ScreenCapture1.jpg" length="21552" type="image/jpeg"/></item><item>
<title>Lilly's Cyramza Misses PhIII Endpoint In HCC Trial [class:MonoclonalAntibody, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9780</link>
<description>Lilly's Cyramza Misses PhIII Endpoint In HCC Trial [class:MonoclonalAntibody, news]</description><category>class:MonoclonalAntibody</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9780</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9780">Lilly's Cyramza Misses PhIII Endpoint In HCC Trial</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9780">Oncology9780</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 June 2014 | 11:54</font><br><br><div style="margin-bottom: 10px;">Comment: Lilly has announced this week that top-line results from the PhIII REACH HCC with Cyramza (ramucirumab) did not meet the primary endpoint of the study of a statistically significant improvement in overall survival.<wbr> However, encouraging single-agent CYRAMZA activity was observed, with meaningful improvements in key secondary endpoints of progression-free survival, overall response rate and time to progression.<wbr> The global, randomized, double-blind REACH trial compared CYRAMZA plus best supportive care to placebo plus best supportive care as a second-line treatment in patients with hepatocellular carcinoma (HCC) after being treated with sorafenib in the first-line setting.<wbr> </div><div style="margin-bottom: 10px;">The top-line safety data were consistent with what was seen in previous single-agent CYRAMZA studies.<wbr> The most common ( &gt; 5% incidence) grade &gt; /<wbr>=3 adverse events occurring at a higher rate on the CYRAMZA arm compared to the control arm were hypertension and asthenia (fatigue).<wbr> </div><div style="margin-bottom: 10px;">Commenting on the study findings Richard Gaynor MD, SVP of Product Development &amp; Medical Affairs at Lilly stated:- </div><div style="margin-bottom: 10px;">"Although the REACH study did not achieve statistical significance for survival, we are encouraged by the efficacy seen overall, especially in specific subpopulations.<wbr> We plan to discuss these results with regulatory authorities".<wbr> </div><div style="margin-bottom: 10px;">In the HCC review article published on Traction earlier this year, ramucirumab was highlighted amongst a number of late stage-trials that was probably unlikely to succeed (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9453" class="defaultlink">Oncology9453: Alternative To Recent PhIII HCC Failures - What Does The Future Hold - ASCO GU Presentation</a> ).<wbr> </div><div>Source: <A href="http://www.lilly.com">www.<wbr>lilly.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9780">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-13T11:54:22+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Cyclacel's Seliciclib (CYC202, R-roscovitine) to Enter POC Trial for Cushing [dis:Cushing, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7694</link>
<description>Cyclacel's Seliciclib (CYC202, R-roscovitine) to Enter POC Trial for Cushing [dis:Cushing, :PharmaWorld:sub:ClinicalTrial]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7694</comments><category>dis:Cushing</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7694</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7694">Cyclacel's Seliciclib (CYC202, R-roscovitine) to Enter POC Trial for Cushing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7694">Endocrinology7694</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2014 | 17:07</font><br><br><div style="margin-bottom: 10px;">Comment: Shlomo Melmed (Cedars-Sinai Medical Center) is the principal investigator of this trial.<wbr> PE is to assess efficacy of seliciclib, an inhibitor of cyclin-dependent kinases 2, 7 and 9, causing cell cycle changes and apoptosis in cancer cells.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02160730?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F12%2F2014&amp;rank=260">NCT02160730</A> </div><div style="margin-bottom: 10px;"><STRONG>Rationale</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<P style="margin-top: 1ex; margin-bottom: 1ex;">The investigators hypothesize that R-roscovitine will suppress pituitary corticotroph tumor ACTH production and normalize urinary free cortisol levels in patients with Cushing disease.<wbr></P>
<P style="margin-top: 1ex; margin-bottom: 1ex;">Recruitment approx 16</P>
</DIV> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Male &amp; female patients at least 18 years old
</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Patients with confirmed pituitary origin of excess adrenocorticotropic hormone (ACTH) production:
<UL style="margin-top: 1ex; margin-bottom: 1ex;"><LI class="color-bullet" style="margin-top: 0.7ex;">Persistent hypercortisolemia established by two consecutive 24 h UFC levels at least 2x the upper limit of normal
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Normal or elevated ACTH levels
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Pituitary macroadenoma (&gt;1 cm) on MRI OR
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Inferior Petrosal Sinus Sampling (IPSS) central to peripheral ACTH gradient &gt;2 at baseline and &gt;3 after CRH stimulation
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Recurrent or persistent Cushing disease is defined as pathologically confirmed resected pituitary ACTH-secreting tumor, and 24 hour UFC above the upper limit of normal reference range beyond post-surgical week 6
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Patients receiving ketoconazole and/<wbr>or pasireotide before the study entry are required to discontinue the drug for 2 weeks before receiving R- roscovitine.<wbr>
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Patients receiving strong CYP3A4 inducers or inhibitors before the study entry are required to discontinue the drug for 2 weeks before receiving R- roscovitine
</LI>
</UL>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date May 2014 - Completion date June 2017 </div><div style="margin-bottom: 10px;">Location: USA </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Information</FONT></STRONG> </div><div style="margin-bottom: 10px;"><EM>(source: Cyclacel)</EM> </div><div style="margin-bottom: 10px;">To date, seliciclib has been evaluated in several Ph1 and Ph2 studies and has shown early signs of anti-cancer activity in approximately 240 patients.<wbr> </div><div style="margin-bottom: 10px;">Studies included a Phase I study in which single agent seliciclib was administered to patients with advanced NSCLC and two Ph2a studies in which seliciclib was administered in combination with gemcitabine and cisplatin as first-line treatment and with docetaxel as second-line treatment in NSCLC.<wbr> </div><div>Seliciclib was also evaluated in a non-Cyclacel Pharmaceuticals sponsored Ph1 study in patients with nasopharyngeal cancer (NPC) with evidence of tumor shrinkage and concomitant reduction in copy counts of the EBV virus that is causally associated with the pathogenesis of NPC.<wbr> Seliciclib is also being evaluated in a Phase 2 study as a single agent in patients with nasopharyngeal cancer.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology8131c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Cyclacel Pharmaceuticals has announced today that the first patient has been dosed in an investigator sponsored trial of CDK inhibitor, seliciclib in Cushing Disease (CD).<wbr> Researchers at the Cedars-Sinai were awarded a grant from the NIDDK to evaluate seliciclib, a CDK2/<wbr>9 inhibitor currently in clinical development to treat certain cancers, as a potential therapy for CD.<wbr> This molecule has a unique mechanism of action with a dual effect, impacting tumor growth by decreasing the levels and activity of cyclin E, as well as inhibiting ACTH production.<wbr> If successful, this could lead to a potential dramatic improvement to CD treatment for patients.<wbr> </div><font size="-1">Giorgia VICENTINI / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology8131" class="commentpermalink">Endocrinology8131</a> / <span class="date">02 July 2015</span> /
<span class="time">15:16:23 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7694">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-12T17:07:38+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Octreopharm's 68Gallium-labeled Radiopharmaceutical to Enter Ph1/2 Trial for the Diagnostic of GEP NET [news, comp:Novartis, :PharmaWorld:sub:ClinicalTrial, sub:Diagnostic]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7693</link>
<description>Octreopharm's 68Gallium-labeled Radiopharmaceutical to Enter Ph1/2 Trial for the Diagnostic of GEP NET [news, comp:Novartis, :PharmaWorld:sub:ClinicalTrial, sub:Diagnostic]</description><category>news</category><category>comp:Novartis</category><category>sub:ClinicalTrial</category><category>sub:Diagnostic</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7693</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7693">Octreopharm's 68Gallium-labeled Radiopharmaceutical to Enter Ph1/<wbr>2 Trial for the Diagnostic of GEP NET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=sub%3aDiagnostic"><font color="#e95e0b">:Endocrinology:sub:Diagnostic</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7693">Endocrinology7693</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2014 | 16:53</font><br><br><div style="margin-bottom: 10px;">Comment: Newly listed on <EM>clinicaltrials.<wbr>gov</EM> the open-label, micro-dosing study will evaluate safety, biodistribution, dosimetry and efficacy of 2 single doses of OPS202 for the diagnostic imaging of somatostatin receptor-positive GEP NET using PET/<wbr>CT.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Reference <A href="http://clinicaltrials.gov/ct2/show/NCT02162446?recr=Open&amp;no_unk=Y&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F12%2F2014&amp;rank=9">NCT02162446</A> </div><div style="margin-bottom: 10px;">Recruitment: approx 12 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">diagnostic CT or MRI of the tumor region within the previous 6 months prior to dosing day is available.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">A somatostatin receptor scan with results in the previous 6 months prior to dosing day.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">At least 2 lesions detected by the previous somatostatin receptor scan.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Not exceeding 15 lesions /<wbr> organ detected by the previous somatostatin receptor scan.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Blood test results as follows (WBC: ≥ 3*109/<wbr>L, Hemoglobin: ≥ 8.<wbr>0 g/<wbr>dL, Platelets: ≥ 50x109/<wbr>L, ALT, AST, AP: ≤ 5 times ULN, Bilirubin: ≤ 3 times ULN)</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">ECG: any abnormalities have to be clarified by a cardiologist.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Serum creatinine: within normal limits or &lt; 120 μmol/<wbr>L for patients aged 60 years or older.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Calculated GFR ≥ 45 mL/<wbr>min.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Negative pregnancy test in women capable of child-bearing</LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Timelines</P> </div><div style="margin-bottom: 10px;">Start date: June 2014 /<wbr> Competion date Dec 2014 /<wbr> March 2015 </div><div style="margin-bottom: 10px;">Location: Switzerland (U Hospital Basel) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Link with Novartis</FONT></STRONG> </div><div><DIV class="i" id="endocrinology7583.09i">
<DIV class="ii" id="endocrinology7583.09ii">In Oct 2011, OctreoPharm Sciences GmbH received the WW exclusive license for the development and commercialization of OPS202 (SOMscan), from Novartis.<wbr></DIV>

<DIV class="ii">Under the terms of the agreement, Novartis is to receive an upfront payment and milestone payments upon regulatory approvals, as well as royalties.<wbr></DIV>

<DIV class="ii">Novartis has the right to re-acquire the rights to SOMscan on pre-agreed financial terms.<wbr></DIV></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7693">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-12T16:53:09+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Teva's Manufacturing Sites Could be Halved [func:MSO]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10893</link>
<description>Teva's Manufacturing Sites Could be Halved [func:MSO]</description><category>func:MSO</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10893</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10893">Teva's Manufacturing Sites Could be Halved</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=func%3aMSO"><font color="#e95e0b">:PharmaWorld:func:MSO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10893">PharmaWorld10893</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2014 | 16:23</font><br><br><div style="margin-bottom: 10px;">Comment: At the Goldman Sachs H/<wbr>C Conference, CFO E Desheh confirmed the Teva's intention to reduce the 75 manufacturing facilities by half.<wbr> This cut is part of the announced plan to slash annual spending by $2bn by 2017.<wbr> The cost-cutting programme is an opportunity for the company to build up its specialty business in pain treatment and have room to grow in emerging markets (EMs).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Target of the Cost-Cutting Programme</FONT></STRONG> </div><div style="margin-bottom: 10px;">Most of the cost reduction program is designed to hit the generic business.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Building Up the Specialty Business</FONT></STRONG> </div><div style="margin-bottom: 10px;">Last week Teva acquired Labrys Biologics (for $825M) to add an investigational migraine treatment to its portfolio (mAb LBR-101 in Ph2).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Reshaping Operations in EMs</FONT></STRONG> </div><div style="margin-bottom: 10px;">The plans to reshape operations include moving some production to Eastern EU countries, and growing operations in Brazil, Mexico, South East Asia, and Russia (where the company is building a plant).<wbr> </div><div><EM>Source: BioPharma</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10893">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-12T16:23:14+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>RIEMSER GmbH Announces Takeover of French  Pharma Keocyt [:Oncology:dis:Prostate, :Endocrinology:news, sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10892</link>
<description>RIEMSER GmbH Announces Takeover of French  Pharma Keocyt [:Oncology:dis:Prostate, :Endocrinology:news, sub:Acquisition]</description><category>dis:Prostate</category><category>news</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10892</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10892">RIEMSER GmbH Announces Takeover of French  Pharma Keocyt</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10892">PharmaWorld10892</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 12 June 2014 | 11:47</font><br><br><div style="margin-bottom: 10px;">Comment: Keocyt was founded in 2007 by 2 former employees of Pfizer and markets the drugs Zanosar, Estracyt, Prodilantin and Dilantin used for the treatment of certain pancreatic endocrine tumors, prostate cancer and status epilepticus, respectively.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for REIMSER</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>extension of its oncological portfolio in France</LI>
<LI>opening possibilities of developing niche markets in the neurological sector in the future</LI>
<LI>strengthening its position on the French and Southern European markets.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">REIMSER Mini Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>headquartered in Greifswald (Germany)</LI>
<LI>midsize pharmaceutical company </LI>
<LI>specialized in marketing and sophisticated life cycle management of specialty drugs for treatment of highly complex and niche disease areas.<wbr></LI>
<LI>targets European markets</LI>
<LI>products are distributed worldwide</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Keocyt Mini Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Internet home page <A href="http://www.keocyt.com/index_en.html">http:/<wbr>/<wbr>www.<wbr>keocyt.<wbr>com/<wbr>index_en.<wbr>html</A></LI>
<LI>Founders: Jean-Francois Auffret and Christophe Pasik</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10892/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>Activities: to market established products treating diseases with high medical need.<wbr> The company has put a special emphasis on building long-term and reliable partnerships with doctors, scientists and patients' associations.<wbr></LI>
<LI><U>Products</U></LI>
</UL> </div><div><UL><LI>Estracyt (estramustin) for prostate cancer</LI>
<LI>Zanosar (streptozocin) for NETs</LI>
</UL> </div><!-- Comment details --><a name="pharmaworld10892attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10892/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(32,3 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10892/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(8,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10892">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-12T11:47:19+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10892/1/ScreenCapture1.jpg" length="33098" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10892/2/ScreenCapture2.jpg" length="8367" type="image/jpeg"/></item><item>
<title>Novartis' FGFR Inhibitor to Enter POC for Cholangiocarcinoma [:Oncology:news, :Oncology:comp:Novartis, comp:Novartis, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7692</link>
<description>Novartis' FGFR Inhibitor to Enter POC for Cholangiocarcinoma [:Oncology:news, :Oncology:comp:Novartis, comp:Novartis, :PharmaWorld:sub:ClinicalTrial]</description><category>news</category><category>comp:Novartis</category><category>comp:Novartis</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7692</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7692">Novartis' FGFR Inhibitor to Enter POC for Cholangiocarcinoma</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7692">Endocrinology7692</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 11 June 2014 | 16:53</font><br><br><div style="margin-bottom: 10px;">Comment: In addition to cholangiocarcinoma, BGJ398 has been listed in eight trials for different indications such as glioblastoma, tumor with alterations of the FGF-R and melanoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Profile</FONT></STRONG> </div><div style="margin-bottom: 10px;">Highly specific fibroblast growth factor receptor (FGFR) inhibitor that Novartis is exploring in a variety of FGFR-driven solid tumors.<wbr> </div><div style="margin-bottom: 10px;">A Ph1 study provides the first clinical evidence of activity against cancers that are driven by dysregulation of the FGFR pathway.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02150967?recr=Open&amp;phase=012&amp;fund=2&amp;rcv_s=05%2F11%2F2014&amp;rank=167">NCT02150967</A> </div><div style="margin-bottom: 10px;">PE: ORR </div><div style="margin-bottom: 10px;">Recruitment: approx 55 </div><div style="margin-bottom: 10px;">Of these 55 patients, 40 patients will have cholangiocarcinoma with identified FGFR2 gene fusions and up to 15 patients may have other FGFR genetic alterations.<wbr> All patients will receive oral BGJ398, once daily, on a three weeks on (21 days), one week off (7 days) schedule.<wbr> One treatment cycle will consists of 28 days </div><div style="margin-bottom: 10px;">Timelines </div><div style="margin-bottom: 10px;">Start date: June 2014 /<wbr> Completion date: July 2018 </div><div style="margin-bottom: 10px;">Locations </div><div>USA; France; Rusian Fed.<wbr>; Singapore; Spain; Thailand.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7692">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-11T16:53:23+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Dendreon Changes Of Leadership [:Oncology:dis:Prostate, sub:People]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10889</link>
<description>Dendreon Changes Of Leadership [:Oncology:dis:Prostate, sub:People]</description><category>dis:Prostate</category><category>sub:People</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10889</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10889">Dendreon Changes Of Leadership</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10889">PharmaWorld10889</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 11 June 2014 | 12:09</font><br><br><div style="margin-bottom: 10px;">Comment: Dendreon Board has elected Douglas G.<wbr> Watson, Dendreon’s lead independent director, as chairman of the Board.<wbr> As a result, Dendreon rose 1.<wbr>9 percent to $2.<wbr>15 at 4:47 p.<wbr>m.<wbr> in New York trading.<wbr> This decison was said to be based on personal reason, however, the shares have fallen 45 percent in the past 12 months.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Background</FONT></STRONG> </div><div style="margin-bottom: 10px;">Mr.<wbr> Watson has served as one of Dendreon's independent directors since February 2000.<wbr> He is chief executive officer of Pittencrieff Glen Associates, a consulting firm that he founded in 1999.<wbr> </div><div style="margin-bottom: 10px;">Prior to that, Mr.<wbr> Watson's career spanned 33 years with Geigy/<wbr>Ciba-Geigy/<wbr>Novartis, during which time he held a variety of positions in the UK, Switzerland and the U.<wbr>S.<wbr> </div><div style="margin-bottom: 10px;">Mr.<wbr> Watson was president of Ciba U.<wbr>S.<wbr> Pharmaceuticals Division from 1986-1996, when he was appointed president and chief executive officer of Ciba-Geigy U.<wbr>S.<wbr> Corporation.<wbr> </div><div>Mr.<wbr> Watson also served as president and chief executive officer of Novartis U.<wbr>S.<wbr> Corporation from 1997-1999.<wbr> Mr.<wbr> Watson currently serves as chairman of OraSure Technologies, Inc.<wbr> and is a director of Wright Medical Group, Inc.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10889">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-11T12:09:32+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Allergan - Get Ready For A Long Battle For Control [:PharmaWorld:sub:Acquisition, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7611</link>
<description>Allergan - Get Ready For A Long Battle For Control [:PharmaWorld:sub:Acquisition, headline]</description><category>sub:Acquisition</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7611</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7611">Allergan - Get Ready For A Long Battle For Control</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7611">Neurology7611</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 11 June 2014 | 09:12</font><br><br><div style="margin-bottom: 10px;">Comment : Yesterday, Allergan categorically rejected Valeant's revised offer 
of $53bn, highlighting on a further business update call its reasons why it 
believes the bid continues to undervalue the business, is associated with risk 
and will not provide the best return to shareholders.<wbr> Its retalliatory process 
continues to focus more questions on Valeant and how it runs its business and 
what is its value </div><div style="margin-bottom: 10px;">Allergan's cautious stance is based on Valeant's operational model which 
it believes is unsustainable, focused on  serial acquisitions, aggressive 
pricing and operational cost cutting.<wbr> It claims Valeant does not provide 
sufficient detail about the performance of its key product sales, something even 
Allergan is not open about when it comes to indication growth.<wbr> Valeant's last 
presentation certainly provided more clarity on this topic than it has done 
hitherto.<wbr> </div><div style="margin-bottom: 10px;">The battle for control is now likely to turn hostile and hinge on a special 
AGM called by Valeant that most likely will not take place until November.<wbr> 
Allergan's shares which currently lie below the Valeant offer price of $177 
suggests the market still believes Valeant's offer is too low to 
suceed.<wbr> </div><div style="margin-bottom: 10px;">The slides below illustrate the key sentiments expressed, whilst the 
full slide-set is attached </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/8/ScreenCapture8.jpg?user-agent=rss"> </div><div>Source: <a href="http://www.Allergan.com" class="defaultlink" title="www.Allergan.com">Allergan.com</a> </div><!-- Comment details --><a name="neurology7611attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(178,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(138,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(118,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(113,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(169,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(115,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(188,2 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(164,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7611">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-11T09:12:47+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/1/ScreenCapture1.jpg" length="183009" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/2/ScreenCapture2.jpg" length="142199" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/3/ScreenCapture3.jpg" length="120979" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/4/ScreenCapture4.jpg" length="116402" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/5/ScreenCapture5.jpg" length="173634" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/6/ScreenCapture6.jpg" length="117929" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/7/ScreenCapture7.jpg" length="192737" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7611/8/ScreenCapture8.jpg" length="168395" type="image/jpeg"/></item><item>
<title>ASCO Highlight 2 - Progress On Combination Strategy In Prostate Cancer [class:Hormonals, dis:Prostate, news, :PharmaWorld:congress:ASCO]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9776</link>
<description>ASCO Highlight 2 - Progress On Combination Strategy In Prostate Cancer [class:Hormonals, dis:Prostate, news, :PharmaWorld:congress:ASCO]</description><category>class:Hormonals</category><category>dis:Prostate</category><category>news</category><category>congress:ASCO</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9776</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9776">ASCO Highlight 2 - Progress On Combination Strategy In Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9776">Oncology9776</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 10 June 2014 | 19:50</font><br><br><div style="margin-bottom: 10px;">Comments: Despite of availability of new generation of hormonal therapies, survival of mCRPC patients still remain short (&lt; 3 years).<wbr> Various efforts have been made to look into the best combination strategy not only in mCRPC, but also evaluating combination of chemotherapy with ADT in earlier setting.<wbr> During ASCO this year, two oral abstracts were presented during the oral session to evaluate two different combination strategies with docetaxel in earlier setting.<wbr> Dr.<wbr> Eleni Efstathious also presented preliminary finding from the first combination trial of abiraterone and enzalutamide.<wbr> Although this is still a proof of concept trial, the findings should lead to a maker driven strategy for allocation of androgen targeted therapy in mCRPC.<wbr> Other Phase 3 /<wbr>4 trials (ALLIANCE and PLATO) are currently ongoing to evaluate the efficacy of the combination and determine the sequence of two agents in mCRPC setting.<wbr> </div><div style="margin-bottom: 10px;"><BR> <img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/1/pic%201.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>SWOG S0925 Ph2 ADT + Cixutumumab vs ADT in mHSPC</STRONG><BR>Cixutumumab is a fully recombinant monoclonal antibody of IgG1 that targets IGF-1R for internalisation.<wbr> Preclinical data implicates the role of IGF-1R in AR- mediated signalling in absence of androgens.<wbr> Xenograft models showed a significant reduction of tumour volume with addition of Cixutumumab (A12) following castration.<wbr>  Cixutumumab also demonstrated activity as a monotherapy in the Ph2 study, where 9/<wbr>31 (29%) patients had stable disease  &ge; 6 months.<wbr> Mild 1/<wbr>2 AEs of fatigue and hyperglycemia was observed.<wbr> This has provided the basis of designing the Ph2 trial (SWOG S0925) to evaluate the activity when adding cixutumumab to ADT versus ADT alone in metastatic hormone sensitive prostate cancer.<wbr> Dr Evan Yu presented the finding during oral abstract session - <BR> &bull; Despite the scientific rationale and activity demonstrated as a monotherapy in mCRPC patients, cixutumumab + ADT did not significantly improve the undetectable PSA rate (&le;0.<wbr>2 ng/<wbr>ml) at 28 weeks.<wbr><BR> &bull; IGF-IR biomarkers did not correlate with undetectable PSA rate, there were not significant changes from baseline to week 12 between treatment arm .<wbr> <BR><EM><STRONG> Dr Evan Yu commented " however, this is being challenged by the small sample size evaluated.<wbr> Patients will continue to be followed for overall survival to validate the prognostic model of undetectable PSA from S9346" </STRONG></EM><BR><EM><STRONG> Dr Scott Tagawa commented during discussion session " this is a well designed trial, unfortunately the result is negative"</STRONG></EM> </div><div style="margin-bottom: 10px;"><EM><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/2/pic%202.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/21/pic20.png.emf?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/22/pic21.png.emf?user-agent=rss"></STRONG></EM> </div><div style="margin-bottom: 10px;"><STRONG>Early Chemo (docetaxel+estramustine) in combination with ADT in localised high risk prostate cancer  (French GETUG 12 Phase III)</STRONG><BR>During oral abstract session, Dr Karim Fizazi presented the results of the French GU Tumour group sponsored Ph3 trial to evaluate combination of ADT with docetaxel and estramustine in localised high risk prostate cancer patients.<wbr> Previous finding from a meta-analysis in Ph2 trial (2001) showed possible OS improvement activity when combining docetaxel and estramustine in metastatic setting.<wbr> Goserelin was the LHRH agonist of choice and was given 3 years in both arms.<wbr> Aspirin was also co-administered in the treatment arm of docetaxel+estramustine (DE) for thrombo-prophylaxis .<wbr> A total of 413 patients accrued between 2002 and 2006.<wbr> </div><div style="margin-bottom: 10px;">The findings include: </div><div style="margin-bottom: 10px;">&bull; Toxicity is significantly associated with older age although no apparent long term toxicity of docetaxel-estramustine was observed.<wbr> <BR> &bull; Efficacy is associated with patient with T3,  a gleason score &le; 7 and high PSA producing cancer PSA&gt;20) <BR>  "<EM><STRONG>Why is this ? We can only speculate Gleason score 7 and 8 are biologically different and associate with choemosensitivity or 4 cycles of docetaxel is simply not enough for pts with high disease burden GS 8-10.<wbr> Similar differential activity of docetaxel was seen in anther Ph3 trial in hormone na&iuml;ve metastatic prostate cancer (GETUG15</STRONG></EM>).<wbr>" Dr Fizazi </div><div style="margin-bottom: 10px;"><EM><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/3/pic%203.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/4/pic%204.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/6/pic%206.png?user-agent=rss"></STRONG></EM> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/7/pic%207.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Early Chemo in combination with ADT in hormone sensitive metastatic prostate cancer (CHAARTED)</STRONG><BR>The first major advance for managing patients with hormone sensitive prostate cancer occurred in 1941 with the observation that testosterone suppression resulted in prostate cancer regression.<wbr> Because of its clear benefit, placebo controlled trial was not required and ADT has been standard of care for more than 70 years.<wbr> Recently, the stage migrated was reported with the PSA era has resulted in longer OS.<wbr> It is also clear that some patients live longer with ADT while other patients had a outlook that is measured in months.<wbr> It has been shown that patients with visceral disease or bone metastases beyond axial skeleton had shorter responses.<wbr> Evidences shown that there are testosterone independent clones occur in most patients who had responded to ADT at a variable time.<wbr> Argument with early usage of chemotherapy in ADT includes attacking de novo testosterone independent clone and therefore allowing longer remission.<wbr> Delaying chemotherapy will result in some patients would become to frail for chemotherapy at the time of progression.<wbr> However, the other side of the argument is that ADT will cause cell cycle arrest and therefore will be less responsive to cytotoxics.<wbr> Also there are patients who respond very well to ADT and may never need chemotherapy.<wbr> Dr.<wbr> Christopher Sweeney (Dana Faber Cancer Institute, US) presented the results of the randomised Ph3 trial to answer this question during the plenary session .<wbr> </div><div style="margin-bottom: 10px;">790 men accrued between July 2006 to Nov 2012.<wbr> Patients with high volume of disease were particular an interest for this study.<wbr> High volume disease is defined as ECOG definition (visceral metastases and/<wbr>or &ge; 4 bone metastases).<wbr>  In Jan 2014 median follow up of 29 months showed 136 deaths in ADT alone arm vs 101 deaths in ADT + Docetaxel arm.<wbr> <BR> &bull; The combination of ADT and 6 cycles of docetaxel significantly improve OS  in men with mHSPC (57.<wbr>6 m vs 44.<wbr>0 m; HR=0.<wbr>61, p=0.<wbr>0003)<BR> &bull; This could present as an appropriate option for patients who are suitable for docetaxel<BR> &bull; Clear benefit in high disease volume patients - 17 months improvement of median OS<BR><EM><STRONG>" Benefit in low volume disease patients is yet remained inconclusive as the data is still immature.<wbr>" Dr Sweeney</STRONG></EM> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/8/pic%208.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/9/pic%209.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/10/pic%2010.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/11/pic%2011.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/12/pic%2012.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Progress to understand sequencing and combination strategy in mCRPC</STRONG> <BR>Dr Efstathiou (MD Anderson, US) presented the update of the combination study of abiraterone and enzalutamide in bone metastatic castration resistant prostate cancer during oral abstract session.<wbr> Adaptive androgen signalling is the driver in mCRPC and is a valid therapeutic target.<wbr> It was found previously that following abiraterone treatment, there is a depletion of androgens not only in circulation but also in the tumour microenvironment.<wbr> However, there is an increase in androgen receptor copy numbers.<wbr> On the other hand, following enzalutamide treatment, despite of inhibition of nucleus localisation of androgen receptor, there is an increase of testosterone both  in the blood and tumour microenvironment.<wbr> Hence, these  findings point to the theory of there is two compartments in the system which are responsible for benefit we have seen from abiraterone and enzalutmide but also implicated in growing resistance to those.<wbr> The combination trial is to test this hypothesis that combining two agents would overcome the feedback.<wbr><BR> &bull; There was no unexpected side effects observed so therefore combination could be developed safely <BR> &bull; No evidence of meaningful drug-drug interaction therefore limiting pharmacokinetics (PK) interaction is not expected <BR> &bull; Adaptive responses reported with individual agents were not seen with combination - combination of androgen biosynthesis inhibition and AR blockade does not result in disruptive PK interaction <BR> &bull; Molecular characterisation showed that AR splice variant 7 (ARv7) is associated with primary resistance to enzalutamide<BR> &bull; C/<wbr>N terminal ratio of AR expression enhanced the predictive performance of androgen signalling characterization in mCRPC treated with androgen signalling inhibitors - promising development of biomarker for AR targeted therapy.<wbr> </div><div style="margin-bottom: 10px;"><EM><STRONG>Dr Mary-Ellen Taplin commented during discussion session " this is clearly an important trial as we all know mCRPC patients survival is still less than 3 years despite availability of new agents.<wbr> However, it is important to note that the toxicity was seen in 73% of patients with grade 1-3 fatigue (Prevail:36%, COU-AA-302: 40%).<wbr> We need to see how this pan out in a large ph3 trial which is underway.<wbr>"</STRONG></EM> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/13/pic%2013.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/15/pic%2015.png?user-agent=rss"> </div><div>There are more other combination and sequencing trials in progress.<wbr> Dr Taplin commented ALLIANCE trial probably takes 3 years to recruit and encourged the audience to recommend patients to enroll in the trial.<wbr><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/16/pic%2016.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/17/pic%2017.png?user-agent=rss"> </div><!-- Comment details --><a name="oncology9776attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/1/pic%201.jpg">pic 1.jpg</a>&nbsp;&nbsp;(933,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/2/pic%202.png">pic 2.png</a>&nbsp;&nbsp;(393,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/3/pic%203.png">pic 3.png</a>&nbsp;&nbsp;(300,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/4/pic%204.png">pic 4.png</a>&nbsp;&nbsp;(397,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/5/pic%205.png">pic 5.png</a>&nbsp;&nbsp;(246,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/6/pic%206.png">pic 6.png</a>&nbsp;&nbsp;(227,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/7/pic%207.png">pic 7.png</a>&nbsp;&nbsp;(323,3 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/8/pic%208.png">pic 8.png</a>&nbsp;&nbsp;(495,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/9/pic%209.png">pic 9.png</a>&nbsp;&nbsp;(303,9 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/10/pic%2010.png">pic 10.png</a>&nbsp;&nbsp;(484,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/11/pic%2011.png">pic 11.png</a>&nbsp;&nbsp;(381,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/12/pic%2012.png">pic 12.png</a>&nbsp;&nbsp;(309,2 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/13/pic%2013.png">pic 13.png</a>&nbsp;&nbsp;(156,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/14/pic%2014.emf">pic 14.emf</a>&nbsp;&nbsp;(1,6 MB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/15/pic%2015.png">pic 15.png</a>&nbsp;&nbsp;(586,1 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/16/pic%2016.png">pic 16.png</a>&nbsp;&nbsp;(359,3 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/17/pic%2017.png">pic 17.png</a>&nbsp;&nbsp;(457,1 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/18/pic%2016.png">pic 16.png</a>&nbsp;&nbsp;(359,3 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/19/pic%2016.png">pic 16.png</a>&nbsp;&nbsp;(359,3 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/20/pic20.png.emf">pic20.png.emf</a>&nbsp;&nbsp;(1,6 MB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/21/pic20.png.emf">pic20.png.emf</a>&nbsp;&nbsp;(1,6 MB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/22/pic21.png.emf">pic21.png.emf</a>&nbsp;&nbsp;(1,6 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9776">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-10T19:50:21+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/1/pic%201.jpg" length="956187" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/2/pic%202.png" length="402563" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/3/pic%203.png" length="307438" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/4/pic%204.png" length="406985" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/5/pic%205.png" length="252442" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/6/pic%206.png" length="232530" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/7/pic%207.png" length="331036" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/8/pic%208.png" length="507263" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/9/pic%209.png" length="311168" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/10/pic%2010.png" length="495970" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/11/pic%2011.png" length="390637" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/12/pic%2012.png" length="316611" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/13/pic%2013.png" length="159889" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/14/pic%2014.emf" length="1722164" type=""/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/15/pic%2015.png" length="600128" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/16/pic%2016.png" length="367930" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/17/pic%2017.png" length="468026" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/18/pic%2016.png" length="367930" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/19/pic%2016.png" length="367930" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/20/pic20.png.emf" length="1649520" type=""/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/21/pic20.png.emf" length="1649520" type=""/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9776/22/pic21.png.emf" length="1680968" type=""/></item><item>
<title>Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in mCRPC patients [dis:Prostate, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9775</link>
<description>Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in mCRPC patients [dis:Prostate, news]</description><category>dis:Prostate</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9775</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9775">Karyopharm Announces Initiation of Phase 2 Study of Selinexor (KPT-330) in mCRPC patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9775">Oncology9775</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 10 June 2014 | 09:57</font><br><br><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Comment: Karyopharm Therapeutics Inc.<wbr> today announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with metastatic hormon.<wbr> The study, referred to as the SHIP (Selinexor in Hormone Refractory Indications in Prostate Cancer) study, is led by Drs.<wbr> Christopher J.<wbr> Logothetis and John Araujo of the M.<wbr>D.<wbr> Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr"><A href="http://clinicaltrial.gov/"><FONT face="Helvetica">ClinicalTrial.<wbr>Gov</FONT></A><FONT face="Helvetica"><FONT face="Helvetica">: NCT02146833</FONT></FONT></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Target Patient Population: mCRPC patients following progression of at least one abiraterone or enzalutamide ; n=50</P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Primary Outcome Measures: Estimate clinical benefit as characterized by stable disease (SD), partial response (PR), or complete response (CR) per Response Evaluation Criteria in Solid Tumors</P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Secondary Outcome Measures: Estimate the prostate-specific antigen (PSA) response.<wbr> PSA response rate determined by a 30% drop in PSA at 12 weeks compared to baseline</P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Karyopharm Therapeutics Inc.<wbr> is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, announced the initiation of a Phase 2 trial of its novel, oral Selective Inhibitor of Nuclear Export (SINE) compound Selinexor (KPT-330) in patients with mCRPC.<wbr> The study, referred to as the SHIP (Selinexor in Hormone Refractory Indications in Prostate Cancer) study, is led by Drs.<wbr> Christopher J.<wbr> Logothetis and John Araujo of the M.<wbr>D.<wbr> Anderson Cancer Center at the University of Texas in Houston and is being funded in part by a grant from the Prostate Cancer Foundation.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left" dir="ltr">Phase 1 data demonstrated 88% disease control rate, meaning stable disease or better, in 8 patients with heavily pretreated prostate cancer.<wbr> These patients all had progressive disease upon entering the study and had exhausted available therapies including taxane-based chemotherapy, and many had received newer agents such as enzalutamide and/<wbr>or abiraterone.<wbr> Based on the encouraging finding from Ph1 study, a Phase 2 study (SHIP) to further evaluate Selinexor's potential in patients with treatment-resistant prostate cancer.<wbr>" The primary goal of the study is to determine the disease control rate assessed according to RECIST criteria and the prevention of new bone lesions.<wbr> The secondary goal of the study is to evaluate the prostate-specific antigen (PSA) response relative to baseline.<wbr> In the ongoing Ph1 trial, Selinexor demonstrates disease control rate in the prostate cancer patients with significant bone disease as well as its single-agent activity against a variety of both localized and disseminated prostate cancer in preclinical mouse models.<wbr></P> </div><div>Source:<A href="http://www.karyopharm.com/"><FONT face="Helvetica">www.<wbr>karyopharm.<wbr>com</FONT></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9775">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-10T09:57:49+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>ASCO Highlight 1 - Progress On Development of New Anti-Androgenic Agents [:PharmaWorld:congress:ASCO, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9773</link>
<description>ASCO Highlight 1 - Progress On Development of New Anti-Androgenic Agents [:PharmaWorld:congress:ASCO, headline]</description><category>congress:ASCO</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9773</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9773">ASCO Highlight 1 - Progress On Development of New Anti-Androgenic Agents</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9773">Oncology9773</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 09 June 2014 | 02:42</font><br><br><div style="margin-bottom: 10px;">Comment: Over the past 7 decades, efforts have been focused on testing different treatment strategies for metastatic prostate cancer hormone dependent disease including orchiectomy vs medical castration with LHRH agonists, combined androgen deprivation vs monotherapy, gonadal suppression vs peripheral blockade, LHRH agonist vs antagonist, intermittent androgen deprivation (IAD) vs continuous androgen deprivation (CAD).<wbr> Despite of an initial high response rate, majority of patients will eventually progress to castrate resistance with the median survival of approximately 4 years.<wbr> </div><div style="margin-bottom: 10px;">With the discovery of novel "antiandrogenic agents" (e.<wbr>g.<wbr> abiraterone, enzalutamide.<wbr>.<wbr> etc), the treatment paradigm has evolved.<wbr> Given the approval of abiraterone followed by enzalutamide in both post-docetaxel and chemo naïve setting, the success of future "antiandrogenic agents" remain unknown.<wbr> During ASCO this year, data from new "antiandrogenic" agents were presented, including Orteronel (ELM-PC4) , and updated progress of galeterone,ARN-509, and ODM201 were presented during the oral abstract and general poster session.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/1/pic%201.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>New Development in Chemo Naïve CRPC</STRONG><BR>Among the molecular alternations in CRPC is the upregulation of biosynthesis enzymes , leading to an increase in intratumoral androgen concentrations and androgen receptor signalling.<wbr> The role of androgens and androgen receptor signalling pathway in CRPC has been demonstrated by the success of abiraterone and enzalutamide.<wbr> Since then, there are many other similar candidates targeting AR signalling pathway.<wbr> TAK-700 (Orteronel), similar to abiraterone, is a selective inhibitor of CYP17, which is involved in the synthesis of testosterone.<wbr> The difference is that orteronel is a non-steroidal selective inhibitor of 17,20-lyase </div><div style="margin-bottom: 10px;">.<wbr> <img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/2/pic%202.png?user-agent=rss"> </div><div style="margin-bottom: 10px;">Orteronel has demonstrated safety and activity in mCRPC patients in previous Ph1 and Ph2 trials.<wbr> Two phase 3 trials were conducted based on the positive activity in post-docetaxel CRPC setting (ELM-PC5) and chemo naïve setting (ELM-PC4).<wbr> During ASCO GU 2014, data reported from ELM-PC4 showed Orteronel demonstrated improved radiographic progression free survival (rPFS) but not overall survival in men with mCRPC post docetaxel.<wbr> It was noted that there was a regional difference where OS improved was observed in non-European/<wbr>non-north American population.<wbr> <BR>"However, this is most likely due to availability of abiraterone and other agents as we do not see the same regional difference in the chemo naïve setting.<wbr>" Dr.<wbr> de Wit (NL)<BR>During Oral Abstract Session on 2nd June, Dr Ronald de Wit (Erasmus University Medical Centre, NL) presented orteronel's data in chemo naïve setting (ELM-PC4).<wbr> This is an updated rPFS at the final OS analysis (1051 rPFS events).<wbr> </div><div style="margin-bottom: 10px;">" The study was amended due to changing treatment landscape and increasing availability of alternate therapies.<wbr> Protocol was amended to conduct final analysis at 600 OS events".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/3/pic%203.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/4/pic%204.png?user-agent=rss"> </div><div style="margin-bottom: 10px;">He concluded: <BR>• Orteronel + prednisone demonstrated statistically significant improvement in rPFS but OS improvement was not demonstrated.<wbr> Unlike ELM-PC5 trial, there was not regional difference in terms of OS endpoints.<wbr> <BR>• Median testosterone levels in both treatment groups were drastically reduced by 12 weeks and through 24 weeks<BR>• Improvements in rates of PSA response and circulating tumour cell conversion were observed<BR>• High discontinuation rate due to toxicity and therefore " there is still room for new agents"<BR>• No further benefit can be concluded in the sub-analysis </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/5/pic%205.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/6/pic%206.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/7/pic%207.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/8/pic%208.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/9/pic%209.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/14/pic%2014.png?user-agent=rss"> </div><div style="margin-bottom: 10px;">"<EM>Do we really need another CYP17 inhibition in this setting?" "Do more selectivity matters ? - maybe it is more imporant in earlier setting!"</EM> Dr.<wbr> Scott Tagawa (Associate Professor, Weill Cornell Medical College).<wbr> </div><div style="margin-bottom: 10px;">There are other ongoing trials enrolling patients to evaluate the activity of Orteronel in men with rising PSA and no evidence of metastatic disease (M0) as well as in combination with docetaxel.<wbr> A randomized phase II study with the European Organisation for Research and Treatment of Cancer GenitoUrinary Cancers Group is comparing orteronel to bicalutamide in patients with mCRPC failing fırst-line treatment with LHRH agonists or surgical castration.<wbr> The plan is to enroll 200 patients.<wbr> The SWOG is also conducting a phase III trial of LHRH agonists plus bicalutamide compared with LHRH agonists plus orterenol for metastatic hormone sensitive prostate cancer with an estimated enrollment of 1,486 patients.<wbr> </div><div style="margin-bottom: 10px;">Galeterone (ARMOR 2 Study presented by Dr.<wbr> Robert B.<wbr> Montgomery,University of Washington, Seattle, WA; <BR>Galeterone inhibits prostate cancer growth by multiple mechanisms.<wbr> Preclinical studies have shown that galeterone selectively inhibits CYP17 lyase to prevent testosterone synthesis, antagonizes testosterone binding to the AR, and degrades the AR protein.<wbr> Galeterone was evaluated in four studies testing pharmacokinetics and formulation optimization in normal, healthy volunteers supporting development for all stages of prostate cancer and in a clinical proof-of-concept study in patients with CRPC.<wbr> ARMOR1 was a phase I, open-label, dose escalation trial of chemotherapy-naive CRPC patients.<wbr> However, the drug formulation used in ARMOR1 exhibited inconsistent gastrointestinal absorption Galeterone was reformulated as a spray dried dispersion (SDD), which mitigated the food effect for the ARMOR2 study.<wbr> ARMOR2 is a two-part phase II study designed to confırm the dose of the SDD formulation and demonstrate safety and effıcacy in four distinct cohorts of patients with CRPC.<wbr> Dr Montgomery presented interim results in four distinct patient groups from the ARMOR2 study during Poster Highlight Session.<wbr> Response was seen at 2550 mg in all tx groups, including decreases in PSA.<wbr> In the most mature dataset of 24 M1 TN pts, PSA decreases of 30% (92%), and 50% (83%) were reached.<wbr> Data on the M1 group showed encouraging preliminary objective responses (ORR) in 7 of 8 (86%) evaluable pts at 3 months.<wbr> No major safety concerns as 94% of all adverse events (AE) were gr1 or 2 in severity.<wbr> Most common &lt; gr 2 AEs were GI (nausea, diarrhea), fatigue and pruritis with no mineralocorticoid excess (ME) or seizures.<wbr> Note that signifıcant improvements were seen in PSA response at 12 weeks as compared with M1-treated patients on the ARMOR 1 study.<wbr> </div><div style="margin-bottom: 10px;">ARN-509<BR>ARN-509, a novel antiandrogen, has a similar mechanism of activity to enzalutamide and has undergone early evaluation in 30 patients with progressive CRPC who received continuous daily oral ARN-509 at doses between 30 mg and 480 mg.<wbr> A maximum effıcacious dose of 240 mg daily was selected for phase II.<wbr> A phase II trial will enroll approximately 127 patients in three cohorts; M0 CRPC, M1 abiraterone-naive, and M1 biraterone-pretreated patients.<wbr> This agent should cross the blood-brain barrier less than enzalutamide and is now being studied in the SPARTAN trial for patients with M0 CRPC in a multicenter, randomized, phase III study with metastases-free survival as the primary endpoint.<wbr> Data presented by Dr.<wbr> Simith during last year's ESMO showed that ARN demonstrates a 12- and 24-week PSA response rate of 91% in M0-CRPC pts and an excellent safety profile.<wbr> Two Trial In Progress posters were being presented to update two ongoing trials with ARN-509 including: </div><div style="margin-bottom: 10px;"><UL><LI>Dr.<wbr> Smith presented during general poster session indicating an independent data monitoring committee is commissioned to conduct reviews of the safety and efficacy data.<wbr> Approximately 300 sites in 24 countries will participate.<wbr> Pts are being screened and enrolled as of September 2013.<wbr> </LI>
<LI>Dr.<wbr> Dana E.<wbr> Rathkopf (Memorial Sloan-Kettering Cancer Centre) presented during general poster session the concept of targeting reciprocal feedback inhibition in the clinic by using ARN509 and PI3K pathway inhibition in patients with mCRPC.<wbr> Next-generation androgen receptor (AR) targeted agents provide dramatic benefit to patients with mCRPC, but the durability of response can be limited by intrinsic and acquired resistance to these drugs.<wbr> Studies in xenograft CRPC and PTEN-deficient prostate cancer models have shown synergistic anti-tumor activity of next-generation anti-androgens such as ARN509 when combined with mTOR or PI3K/<wbr>mTOR inhibitors such as everolimus.<wbr> The primary endpoint is to determine the safety, pharmacokinetics, and the recommended phase 2 dose (RP2D) of the combination.<wbr> Approximately 12 patients with progressive mCRPC will be treated with 240 mg/<wbr>day of ARN509 (RP2D) and 5-10 mg/<wbr>day of everolimus depending on the safety seen during dose escalation.<wbr> </LI>
<LI>Dr.<wbr> Dana E.<wbr> Rathkopf (Memorial Sloan-Kettering Cancer Centre) presented ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.<wbr> The trial enrolled pts included 25 mCRPC and 21 post-AA mCRPC pts with median age of 68 yrs (range 48-91).<wbr> ARN-509 is safe and well tolerated, with evidence of activity in chemo-naïve mCRPC, including in 24% of pts who have received prior AA </LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/10/pic%2010.png?user-agent=rss"> </div><div style="margin-bottom: 10px;">ODM-201<BR>ODM-201 is a new generation AR antagonist that is structurally dissimilar from enzalutamide and ARN-509.<wbr> It inhibits AR function by blocking nuclear translocation and does not enter the brain in nonclinical models, unlike other antiandrogens.<wbr> ODM-201 has no agonist activity when the AR is overexpressed and has extremely high affınity for the AR.<wbr> It has no CYP inhibition or induction with therapeutic doses.<wbr> In the phase I/<wbr>II ARADES trial PSA response at 12 weeks was evaluated at doses of 200 mg, 400 mg and 1,400 mg.<wbr> At the 1,400 mg dose: six out of seven patients (86%) had a 50% or greater decrease in PSA.<wbr> The greatest activity was seen in patients who were chemotherapy- and CYP17i-naive, although responses were also seen postchemotherapy and CYP17i.<wbr>46 An open, phase I trial assessed the bioavailability, and the effect of food on the bioavailability of ODM-201 600 mg tablets compared with a 600 mg capsule formulation.<wbr> ODM-201 600 mg twice daily as tablets has comparable pharmacokinetics to capsules used in the phase II ARADES trial.<wbr>47,48 A trial is planned in patients with M0 CRPC.<wbr> Dr Christophe Massard (Gustave Roussy, France) presented long-term efficacy and safety of androgen receptor inhibitor ODM-201 in ARADES phase I/<wbr>II trial during general poster session and concluded that these data are in line with 12-wk efficacy and safety data reported previously, and show high anticancer activity and favourable tolerability of ODM-201.<wbr> A Ph3 trial in non-metastatic CRPC patients is currently being planned.<wbr> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/11/pic%2011.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/12/pic%2012.png?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/13/pic%2013.png?user-agent=rss"> </div><!-- Comment details --><a name="oncology9773attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/1/pic%201.png">pic 1.png</a>&nbsp;&nbsp;(461,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/2/pic%202.png">pic 2.png</a>&nbsp;&nbsp;(466 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/3/pic%203.png">pic 3.png</a>&nbsp;&nbsp;(461,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/4/pic%204.png">pic 4.png</a>&nbsp;&nbsp;(466 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/5/pic%205.png">pic 5.png</a>&nbsp;&nbsp;(439,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/6/pic%206.png">pic 6.png</a>&nbsp;&nbsp;(386,1 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/7/pic%207.png">pic 7.png</a>&nbsp;&nbsp;(446,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/8/pic%208.png">pic 8.png</a>&nbsp;&nbsp;(337,5 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/9/pic%209.png">pic 9.png</a>&nbsp;&nbsp;(411 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/10/pic%2010.png">pic 10.png</a>&nbsp;&nbsp;(8,7 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/11/pic%2011.png">pic 11.png</a>&nbsp;&nbsp;(44,3 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/12/pic%2012.png">pic 12.png</a>&nbsp;&nbsp;(62,4 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/13/pic%2013.png">pic 13.png</a>&nbsp;&nbsp;(48,3 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/14/pic%2014.png">pic 14.png</a>&nbsp;&nbsp;(411 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9773">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-09T02:42:26+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/1/pic%201.png" length="472291" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/2/pic%202.png" length="477215" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/3/pic%203.png" length="472291" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/4/pic%204.png" length="477215" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/5/pic%205.png" length="450315" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/6/pic%206.png" length="395343" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/7/pic%207.png" length="457267" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/8/pic%208.png" length="345604" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/9/pic%209.png" length="420888" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/10/pic%2010.png" length="8893" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/11/pic%2011.png" length="45350" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/12/pic%2012.png" length="63939" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/13/pic%2013.png" length="49436" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9773/14/pic%2014.png" length="420888" type="image/x-png"/></item><item>
<title>Nanobiotix Scores A Hit At ASCO [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9771</link>
<description>Nanobiotix Scores A Hit At ASCO [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9771</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9771">Nanobiotix Scores A Hit At ASCO</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9771">Oncology9771</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 06 June 2014 | 16:48</font><br><br><div style="margin-bottom: 10px;">Comment : A proof-of-principle study reported at ASCO and undertaken in patients with inoperable, advanced soft tissue sarcoma has demonstrated that they were able to successfully undergo surgical resection after neoadjuvant radiotherapy and following the novel heavy metal nanoparticle, NBTXR3.<wbr> </div><div style="margin-bottom: 10px;">NBTXR3 is a nanoparticle consisting of hafnium oxide crystals, that has been developed by Nanobiotix, a spin-off of the State University of New York at Buffalo and now based in Paris, France.<wbr> </div><div style="margin-bottom: 10px;">Apparently, about 60% of patients have unresectable tumours and their standard-of-care for these patients is to receive radiotherapy to debulk the tumour mass prior to surgery.<wbr> If the radiotherapy is optimal, then the surgeon can remove the mass with clean margins.<wbr> However, if the tumour is not sufficiently debulked, the surgeon has to take it out in pieces, and this greatly increases the patient&rsquo;s risk for developing metastases from residual tumour cells.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Findings With NBTXR3</STRONG> </div><div style="margin-bottom: 10px;">In a Phase I study of NBTXR3, 17 patients with advanced soft tissue sarcoma had their tumours treated with nanoparticles prior to external beam radiation therapy.<wbr> After five weeks of radiotherapy, all patients underwent successful resection with wide surgical margins.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>How Does NBTXR3 work</STRONG> </div><div style="margin-bottom: 10px;">NBTXR3 is not a radio-sensitiser, there is no systemic delivery here because this is not a biological treatment.<wbr> What is happening is a purely physical effect".<wbr> The particle intensifies the effects of radiation through localised amplification, and this, as opposed to radio-sensitisers, spares the surrounding healthy tissue during radiotherapy.<wbr> </div><div style="margin-bottom: 10px;">Furthermore, hafnium is inert in the human body, and therefor eis not viewed, in the regulatory sense, as a drug.<wbr> The European designation for NBTXR3 is as a medical device.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ASCO Feedback</STRONG> </div><div style="margin-bottom: 10px;">Commenting on the study results, Emiliano Calvo, a panel member on ASCO&rsquo;s scientific committee for developmental therapeutics, acknowledged the potential of this approach.<wbr> &ldquo;It seems to have a real synergistic effect with the radiation therapy administered to patients with unresectable and, usually, highly resistant, sarcomas, including some very impressive tumour remissions in these patients.<wbr> And this is not at the expenses of higher toxicity, since its tolerance profile seems to be quite favorable as well.<wbr>&rdquo; </div><div>Source: PharmaTimes </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9771">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-06T16:48:25+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>NorthWest Biotherapeutics Seeks to Out-License DCVax for Prostate Cancer [class:Vaccines, dis:Prostate, :PharmaWorld:func:BusDev, :PharmaWorld:sub:xLicensing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9770</link>
<description>NorthWest Biotherapeutics Seeks to Out-License DCVax for Prostate Cancer [class:Vaccines, dis:Prostate, :PharmaWorld:func:BusDev, :PharmaWorld:sub:xLicensing]</description><category>class:Vaccines</category><category>dis:Prostate</category><category>func:BusDev</category><category>sub:xLicensing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9770</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9770">NorthWest Biotherapeutics Seeks to Out-License DCVax for Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=func%3aBusDev"><font color="#e95e0b">:PharmaWorld:func:BusDev</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3axLicensing"><font color="#e95e0b">:PharmaWorld:sub:xLicensing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9770">Oncology9770</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 June 2014 | 14:57</font><br><br><div style="margin-bottom: 10px;">Comment: DCVax-Prostate (dendritic cellls + recombinant prostate cancer biomarker) currently is in a 600-patients Ph3 trial previously cleared by FDA.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Slides Presented on June 4th @ Jeffries 2014 Global H/<wbr>C Conference</FONT></STRONG> <img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9770/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Late Stage Trials </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9770/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9770attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9770/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(115,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9770/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(29,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9770/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(32,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9770">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-05T14:57:12+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9770/1/ScreenCapture1.jpg" length="118172" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9770/2/ScreenCapture2.jpg" length="30586" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9770/3/ScreenCapture3.jpg" length="33093" type="image/jpeg"/></item><item>
<title>Highlights from Revance Presentation at Jefferies 2014 [headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7609</link>
<description>Highlights from Revance Presentation at Jefferies 2014 [headline]</description><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7609</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7609">Highlights from Revance Presentation at Jefferies 2014</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7609">Neurology7609</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 June 2014 | 12:42</font><br><br><div style="margin-bottom: 10px;">Comment: Dan Brown CEO of Revance commented on the different needs addressed by RT001 and RT002, the potential future applications, and gave an overview of the pipeline and timelines for each drug.<wbr> To be noted, the US BLA and the EU MAA filing of RT001 for CFL in 2016, and the report of the Ph2 results for HH in 2015.<wbr> The company expects 3 launches beginning in 2017.<wbr> More information regarding the granted and pending patents are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Intellectual Property</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Different Needs Addressed</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Potential Future Applications</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/7/ScreenCapture7.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Multiple Indications in Development</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">RT001 - Process </FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">RT001 -</FONT></STRONG> <FONT size="3"><STRONG>EU/<wbr>US Approval/<wbr>Launch</STRONG></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">RT001 Patient Pool Expansion in 2 Dimensions</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Timelines</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/8/ScreenCapture8.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7609attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(111,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(88,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(117,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(86,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(124,3 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(74,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(87,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(96,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(107,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7609">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-05T12:42:45+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/1/ScreenCapture1.jpg" length="114264" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/2/ScreenCapture2.jpg" length="90170" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/3/ScreenCapture3.jpg" length="120184" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/4/ScreenCapture4.jpg" length="88681" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/5/ScreenCapture5.jpg" length="127323" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/6/ScreenCapture6.jpg" length="76087" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/7/ScreenCapture7.jpg" length="89897" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/8/ScreenCapture8.jpg" length="98695" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7609/9/ScreenCapture9.jpg" length="109923" type="image/jpeg"/></item><item>
<title>Generic Competition of Zytiga (abiraterone) to Impact BTG's Revenues [:PharmaWorld:sub:IP]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9769</link>
<description>Generic Competition of Zytiga (abiraterone) to Impact BTG's Revenues [:PharmaWorld:sub:IP]</description><category>sub:IP</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9769</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9769">Generic Competition of Zytiga (abiraterone) to Impact BTG's Revenues</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aIP"><font color="#e95e0b">:PharmaWorld:sub:IP</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9769">Oncology9769</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 June 2014 | 12:06</font><br><br><div style="margin-bottom: 10px;">Comment: End of last month, BTG highlighted the potential for generic competition in the US from its 2016/<wbr>2017 financial year.<wbr> The 'licensing segment' of the company increased by 40% vs the previous year (+68% for Zytiga).<wbr> The abiraterone composition of matter patent expired on 18 February 2014, and its US exclusivity period ends on 28 April 2016.<wbr> BTG has a manufacturing process patent with a priority date of 24 August 2004.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">BTG Revenues by Segment</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9769/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9769/1/ScreenCapture1.jpg?user-agent=rss"></FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Acetate Manufacturing Process Easy to Copy</FONT></STRONG> </div><div style="margin-bottom: 10px;">Abiraterone acetate is synthesised in a 4-step process from a single starting material (<EM>Source: CHMP assessment report, ref: EMEA/<wbr>H/<wbr>C/<wbr>002321</EM>).<wbr> </div><div style="margin-bottom: 10px;">A 4-step process could be relatively straight-forward and low cost for a generic company to copy, and patents are not " .<wbr>.<wbr>.<wbr> insurmountable: a good chemist can often find a synthetic route that has been omitted from a patent".<wbr> </div><div>Source: BTG Plc </div><!-- Comment details --><a name="oncology9769attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9769/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(101 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9769/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(61,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9769">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-05T12:06:19+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9769/1/ScreenCapture1.jpg" length="103373" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9769/2/ScreenCapture2.jpg" length="63089" type="image/jpeg"/></item><item>
<title>Allergan Initiates Two New Upper Limb Spasticity Studies</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7608</link>
<description>Allergan Initiates Two New Upper Limb Spasticity Studies</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7608</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7608">Allergan Initiates Two New Upper Limb Spasticity Studies</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7608">Neurology7608</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 05 June 2014 | 09:56</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan is launching two new registration studies in post- stroke upper arm spasticity, which appear as though they are targeting inclusion into the Botox spasticity label, shoulder and elbow injections potentially at higher doses.<wbr> We believe these will be international studies.<wbr> Feedback from the ISPRM meeting also indicates how our competitors are incresaingly nervous about our spasticity trial outcomes and timelines.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study 1 NCT02145676</STRONG> </div><div style="margin-bottom: 10px;">A randomised double-blind safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity.<wbr> </div><div style="margin-bottom: 10px;">Patient nos are 400.<wbr> Study start is May 2014 and completion in terms of primary endpoint January 2016, whilst study completion is March 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Endpoints</STRONG> </div><div style="margin-bottom: 10px;">Primary Outcome Measures: </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL><LI class="color-bullet">Change from Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Elbow Flexors Using a 6-Point Scale [ Time Frame: Baseline, Week 6 ]
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><P class="color-bullet">Secondary Outcome Measures:</P> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL><LI class="color-bullet">Change from Baseline in the MAS-B Score of Shoulder Adductors Using a 6-Point Scale [ Time Frame: Baseline, Week 6 ]
</LI>
<LI class="color-bullet">Clinical Global Impression (CGI) Of Overall Change by Physician Compared to Baseline Using a 9-Point Scale [ Time Frame: Baseline, Week 6 ]
</LI>
<LI class="color-bullet">Change from Baseline in Pain on an 11-Point Scale [ Time Frame: Baseline, Week 6 ]
</LI>
<LI class="color-bullet">Change from Baseline in the 19-Item Spasticity Impact Assessment-Upper Limb (SIA-UL) Score [ Time Frame: Baseline, Week 6 ]
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><STRONG>Study 2</STRONG> <STRONG>NCT02145689</STRONG> </div><div style="margin-bottom: 10px;">Randomised double-blind long-term safety and efficacy study of onabotulinumtoxinA in poststroke patients with upper limb spasticity - Patient Nos are 400.<wbr> Study initiation August 2014 and  Primary Endpoint &amp; Study Completion May 2017 </div><div style="margin-bottom: 10px;"><STRONG>Study Endpoints</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="body3">Primary Outcome Measures:
<UL><LI class="color-bullet">Change from Baseline in the Modified Ashworth Scale-Bohannon (MAS-B) Score of Treated Muscle Groups Using a 6-Point Scale [ Up to 60 Weeks
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">Secondary Outcome Measures:</DIV> </div><div style="margin-bottom: 10px;"><DIV class="body3">
<UL><LI class="color-bullet">Clinical Global Impression (CGI) of Overall Change by Physician Compared to Baseline Using a 9-Point Scale [Up to 60 Weeks ]
</LI>
<LI class="color-bullet">Change from Baseline in Pain on an 11-Point Scale [Up to 60 Weeks ]
</LI>
<LI class="color-bullet">Change from Baseline in the 19-Item Spasticity Impact Assessment-Upper Limb (SIA-UL) Score [Up to 60 Weeks ]
</LI>
</UL>
</DIV> </div><div style="margin-bottom: 10px;"><P class="color-bullet">Notable points of interest about these studies are the lack of inclusion of non-stroke patients.<wbr> The lack of any reference so far to the dosages to be adminsitered and the addition of pain and SIA-UL endpoints.<wbr></P> </div><div style="margin-bottom: 10px;"><STRONG>Competitive Information From ISPRM:</STRONG> </div><div style="margin-bottom: 10px;">Thanks to Philippe Picaut (Neurology Drug Development) we have also learnt that Allergan is very nervous about Ipsen's forthcoming registration of Dysport in AUL and potential other spasticity indications.<wbr> Several unknown US practitioners never wiling to give their business cards approached Philipppe asking very specific questions about our programs about recruitment, dates for data, submission dates, the need for OL data to register etc.<wbr>.<wbr> </div><div>This approach by our competitors is to be expected but it emphasises how we all need to be aware of counter-intelligence approaches and be careful not to disclose anything confidential.<wbr> In such a situation just defer to our website in terms of the company position.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7608">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-05T09:56:06+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Cosmo Unveils New Colonoscopy Product [news, sub:CRCPrevention]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1976</link>
<description>Cosmo Unveils New Colonoscopy Product [news, sub:CRCPrevention]</description><category>news</category><category>sub:CRCPrevention</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1976</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1976">Cosmo Unveils New Colonoscopy Product</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=sub%3aCRCPrevention"><font color="#e95e0b">:GastroEnterology:sub:CRCPrevention</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1976">GastroEnterology1976</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2014 | 14:33</font><br><br><div style="margin-bottom: 10px;">Comment: At the Jefferies Global Health Care Conference in New York, the company announced "SIC 8000", a new product injected under polyp during colonoscopy to make removal of polyps (specially flat polyps) faster and safer.<wbr> US approval is expected in 2015.<wbr> In addition to Methylene Blue MMX, the company will be able to fully support endoscopists.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Product Description</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>SIC</STRONG> stands for Submucosal Injectable Composition.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1976/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Mechanism of action</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1976/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">EU Development Steps</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1976/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="gastroenterology1976attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1976/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(64,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1976/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(78,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1976/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(31,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1976">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-04T14:33:40+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1976/1/ScreenCapture1.jpg" length="66039" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1976/2/ScreenCapture2.jpg" length="80641" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/gastroenterology/1976/3/ScreenCapture3.jpg" length="32134" type="image/jpeg"/></item><item>
<title>AstraZeneca Seeks to Play a Leading Role in Oncology [comp:AstraZeneca, :PharmaWorld:congress:ASCO]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9767</link>
<description>AstraZeneca Seeks to Play a Leading Role in Oncology [comp:AstraZeneca, :PharmaWorld:congress:ASCO]</description><category>comp:AstraZeneca</category><category>congress:ASCO</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9767</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9767">AstraZeneca Seeks to Play a Leading Role in Oncology</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aASCO"><font color="#e95e0b">:PharmaWorld:congress:ASCO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9767">Oncology9767</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 04 June 2014 | 11:35</font><br><br><div style="margin-bottom: 10px;">Comment: AstraZeneca hosted a briefing for analysts and investors during the ASCO 2014.<wbr> Pascal Soriot (CEO) with the leadership team of the company's oncology franchise covered the strategy in immuno-oncology (IO), the progress in small molecules, the vision to redefine the cancer treatment paradigm and the ambition to play a leadership role in oncology.<wbr> Key points are reported below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Predominence in Oncology</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company is seen as No.<wbr> 4 in a race to develop the first drug in a new class that fights cancer by unleashing the body's immune system, behind Roche, Merck &amp; Co <CLASSIFIER class="RIC" value="MRK.N">and Bristol-Myers Squibb.<wbr></CLASSIFIER> </div><div style="margin-bottom: 10px;">Filings for the company's key pipeline assets are expected between 2015 and 2017 </div><div style="margin-bottom: 10px;"><UL><LI>
Oncology drugs AZD9291 could be filed in H2 2015, MEDI4736 in 2016, olaparib in breast cancer in 2016 (a regulatory decision in ovarian cancer is expected in Q3 2014), the MEK inhibitor selumetinib in 2017, the antibody conjugate moxetumomab pasudotox in 2018 </LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">ASCO 2014 in a Nutshell</FONT></STRONG> </div><div style="margin-bottom: 10px;">AstraZeneca presented data from &gt;40 scientific abstracts for experimental cancer drugs.<wbr> </div><div style="margin-bottom: 10px;">The company had a prominent front-row exhibit booth.<wbr> </div><div style="margin-bottom: 10px;">Key Highlights </div><div style="margin-bottom: 10px;">- <STRONG>MEDI4736 (Ph3 /<wbr> NSCLC)</STRONG>, that may be safer than some rivals, allowing it to be used at higher doses in combination with other drugs.<wbr> (AZ acquired the drug in its 2007 takeover of MedImmune).<wbr> </div><div style="margin-bottom: 10px;"><DIV>
 </div><div style="margin-bottom: 10px;"><UL><LI>
it was highlighted that 1/<wbr>the engineered human nature of the drug showed no immunogenicity impacting PKPD, a key for combining it safely to other drugs 2/<wbr>the drug was active at all doses in multiple tumor types with no colitis, highgrade pneumonitis, or drug-related death observed, with durable efficacy</LI>
</UL>
 </div><div style="margin-bottom: 10px;"><P>- A study funded by the NCI which shows a <STRONG>combination of olaparib</STRONG>, which blocks a cell-repair enzyme known as PARP, <STRONG>and cediranib</STRONG>, which prevents formation of blood vessels needed by tumors - extended the length of time that ovarian cancer patients lived without getting worse.<wbr></P></DIV> </div><div style="margin-bottom: 10px;"><U>More to come by Jenny Wu - Please stay tuned.<wbr></U> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Investor and Analyst Conference</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Participants</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Mondher Mahjoubi - <SPAN style="FONT-STYLE: italic">Head, Oncology Global Portfolio and Product Strategy</SPAN></LI>
<LI>Ed Bradley - <SPAN style="FONT-STYLE: italic">Head, Innovative Medicines Oncology, MedImmune</SPAN></LI>
<LI>Rachel Humphrey - <SPAN style="FONT-STYLE: italic">Head, Immuno-Oncology, Global Medicines Development</SPAN></LI>
<LI>Susan Galbraith - <SPAN style="FONT-STYLE: italic">Head, Oncology, Innovative Medicines and Early Development</SPAN></LI>
<LI>Antoine Yver - <SPAN style="FONT-STYLE: italic">Head, Oncology, Global Medicines Development</SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Leapfrogging Competition</FONT></STRONG> </div><div style="margin-bottom: 10px;">- unique indications </div><div style="margin-bottom: 10px;">- novel combinations </div><div style="margin-bottom: 10px;"><UL><LI>
managment insisted that: 1/<wbr>PD1 and PDL1 are very different justifying developing both and that 2/<wbr>best potential combos (synergistic potential) should be: PDL1/<wbr>CTLA4; PDL1/<wbr>PD1; OX40/<wbr>CTLA4)</LI>
<LI>
first wave of combinations MEDI4736+tremelimumab</LI>
</UL> </div><div style="margin-bottom: 10px;">- speed of execution </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9767/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Four Scientific Platforms</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9767/1/ScreenCapture1.jpg?user-agent=rss"> </div><div>Full Presentation attached <a href="http://ci.beaufour-ipsen.com/traction?type=np&proj=*&sdate=20140831&edate=20140501&rs=/link%20Oncology9768%405" class="defaultlink">@5</a> </div><!-- Comment details --><a name="oncology9767attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9767/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(36,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9767/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(34,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9767/5/AZ%20Oncology%5fGaining%20Momentum%5fJune2014.pdf">AZ Oncology_Gaining Momentum_June2014.pdf</a>&nbsp;&nbsp;(2,8 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9767">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-04T11:35:25+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9767/2/ScreenCapture2.jpg" length="37834" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9767/3/ScreenCapture3.jpg" length="35431" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9767/5/AZ%20Oncology%5fGaining%20Momentum%5fJune2014.pdf" length="2962684" type="application/pdf"/></item><item>
<title>Details Of Valeants Business Update Call On The 2nd June [:PharmaWorld:sub:Acquisition, comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7607</link>
<description>Details Of Valeants Business Update Call On The 2nd June [:PharmaWorld:sub:Acquisition, comp:Allergan]</description><category>sub:Acquisition</category><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7607</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7607">Details Of Valeants Business Update Call On The 2nd June</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7607">Neurology7607</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 03 June 2014 | 17:29</font><br><br><div style="margin-bottom: 10px;">Comment: In its presentation on Monday, Valeant detailed the timetable for 
calling a special shareholders meeting, commented on talks it has already had 
with shareholders and tried to demonstrate the value of the revised offer to 
Allergan shareholders.<wbr> </div><div style="margin-bottom: 10px;">Key slides are shown below, whilst the full presentation is attached.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/5/ScreenCapture5.jpg?user-agent=rss"> </div><div><FONT face="Times New Roman" size="3">Source:www.<wbr>valeant.<wbr>com</FONT> </div><!-- Comment details --><a name="neurology7607attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(168,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(199,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(162,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(148,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(147,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/6/%5fhome%5ffundamentals%5fweb%5fsrc%5fdocs%5fcallstreet%5fproduction%5fcwa%5flink%5fevent%5f4493486%5f4493486%5fSlides%5f20140602130507.pdf">_home_fundamentals_web_src_docs_callstreet_production_cwa_link_event_4493486_4493486_Slides_20140602130507.pdf</a>&nbsp;&nbsp;(253,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7607">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-03T17:29:12+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/1/ScreenCapture1.jpg" length="172276" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/2/ScreenCapture2.jpg" length="204619" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/3/ScreenCapture3.jpg" length="166377" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/4/ScreenCapture4.jpg" length="151710" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/5/ScreenCapture5.jpg" length="150720" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7607/6/%5fhome%5ffundamentals%5fweb%5fsrc%5fdocs%5fcallstreet%5fproduction%5fcwa%5flink%5fevent%5f4493486%5f4493486%5fSlides%5f20140602130507.pdf" length="259886" type="application/pdf"/></item><item>
<title>Sweden's TLV Evaluates Xtandi (enzalutamide) Not Cost-Effective [comp:Astellas, prod:MDV3100, dis:Prostate, :PharmaWorld:sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9766</link>
<description>Sweden's TLV Evaluates Xtandi (enzalutamide) Not Cost-Effective [comp:Astellas, prod:MDV3100, dis:Prostate, :PharmaWorld:sub:Pricing]</description><category>comp:Astellas</category><category>prod:MDV3100</category><category>dis:Prostate</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9766</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9766">Sweden's TLV Evaluates Xtandi (enzalutamide) Not Cost-Effective</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9766">Oncology9766</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 June 2014 | 15:24</font><br><br><div style="margin-bottom: 10px;">Comment: Astellas' Xtandi (enzalutamide) application was rejected on the grounds of a unfavourable cost-effectiveness ratio, as the price requested by the applicant was deemed too high by the Swedish Dental and Pharmaceutical Benefits Agency (TLV).<wbr> Astellas may evaluate the possibility of undertaking a similar route as its competitor Zytiga and seek approval through a risk-sharing agreement that partially shifts costs onto the manufacturer side.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Rationale for the Rejection</FONT></STRONG> </div><div style="margin-bottom: 10px;">The cost requested for the treatment was approximately SEK1,000 ($150) per day.<wbr> </div><div style="margin-bottom: 10px;">On the basis of the health economic model submitted by the company, the TLV considers the cost per quality-adjusted life year (QALY) for Xtandi high.<wbr> </div><div style="margin-bottom: 10px;">According to the TLV, the company has not shown that the cost of Xtandi is reasonable from a medical, humanitarian and socio-economically standpoint.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Market Penetration</FONT></STRONG> </div><div style="margin-bottom: 10px;">The negative recommendation granted by the TLV is a blow for Astellas and its partner Medivation (US) as expansion of the drug on the Swedish market is likely to be significantly affected by the application refusal.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Zityga Route</FONT></STRONG> </div><div style="margin-bottom: 10px;">The TLV's decision follows a negative decision adopted for J&amp;J's Zytiga (abiraterone), in 2012.<wbr> Similarly to Xtandi, the price for Zytiga requested by the applicant for reimbursement was considered too high when compared to the benefits it brings to patients.<wbr> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=8689" class="defaultlink">Oncology8689: Swedish TLV and Janssen-Cilag Reach Risk-Sharing Agreement for Zytiga</a>.<wbr> </div><div><EM>Source: IHS Global Insight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9766">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-03T15:24:40+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>SEP's Plenaxis® (abarelix) Withdrawn from the German Market [class:Antihormonals, dis:Prostate, :PharmaWorld:mkt:Germany]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9761</link>
<description>SEP's Plenaxis® (abarelix) Withdrawn from the German Market [class:Antihormonals, dis:Prostate, :PharmaWorld:mkt:Germany]</description><category>class:Antihormonals</category><category>dis:Prostate</category><category>mkt:Germany</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9761</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9761">SEP's Plenaxis® (abarelix) Withdrawn from the German Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aGermany"><font color="#e95e0b">:PharmaWorld:mkt:Germany</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9761">Oncology9761</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 03 June 2014 | 11:47</font><br><br><div style="margin-bottom: 10px;">Comment: Thanks to the feedback from Stefan Pfeifer (BU Director Uro) we have learnt that Plenaxis has been pulled off due to the quality variations in the production.<wbr> In 2011, Speciality European Pharma (SEP) signed a deal with UK-based contract manufacturing organisation SCM Pharma to manufacture the product.<wbr> Whether this issue is temporary or not will be clarified as soon as possible.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Plenaxis in Germany</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9761/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>Launch date: February 2008</LI>
<LI>Indication: advanced and metastatic hormone responsive prostate cancer</LI>
<LI>2013 sales: €1,3M (MS: &lt; 1%)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">SEP SnapShot</FONT></STRONG> </div><div><UL><LI>Founded in April 2006 - Private</LI>
<LI>Focused upon products aimed at the urology or urogynaecology markets, primarily in Europe</LI>
<LI>January 2007 SEP acquired world-wide rights to Plenaxis®, the world’s first approved GNRH antagonist for the treatment of prostate cancer.<wbr></LI>
<LI>Commercial operations in the UK, Germany, France, Italy and the Nordic region</LI>
<LI>Business Development: the company is seeking urological and/<wbr>or urogynaecological products (drugs, devices or diagnostics), that are in phase III, registration or in-market.<wbr></LI>
</UL> </div><!-- Comment details --><a name="oncology9761attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9761/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(16,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9761">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-03T11:47:11+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9761/1/ScreenCapture1.jpg" length="16514" type="image/jpeg"/></item><item>
<title>Roche Gains Breakthrough Designation For Its Immunotherapy Approach In Bladder Cancer [dis:Bladder, headline, sub:Biomarkers]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9756</link>
<description>Roche Gains Breakthrough Designation For Its Immunotherapy Approach In Bladder Cancer [dis:Bladder, headline, sub:Biomarkers]</description><category>dis:Bladder</category><category>headline</category><category>sub:Biomarkers</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9756</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9756">Roche Gains Breakthrough Designation For Its Immunotherapy Approach In Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=sub%3aBiomarkers"><font color="#e95e0b">:Oncology:sub:Biomarkers</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9756">Oncology9756</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 June 2014 | 18:27</font><br><br><div style="margin-bottom: 10px;">Comment: Roche announced on Saturday that its investigational immunotherapy anti-PDL1 (MPD3280A) has been granted "Breakthrough Therapy Designation" in bladder cancer by the FDA.<wbr> Data reported at ASCO has demonstrated that the drug shrank tumours in 43% of people with previoulsy treated metastatic bladder cancer whose tmours were characterised as PDL-1.<wbr> Highlighting this data amongst others, Roche hosted an analyst event on Sunday evening presenting and commenting on the data in more detail even suggesting that maybe an immune doublet approach with BCG could be considered.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About the Phase I MPDL3280A Study</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>The Phase I study was a single-arm, multi-center, open-label trial with a cohort of 68 people with previously treated, metastatic bladder cancer.<wbr>
</LI>
<LI>The study included 30 patients who were identified as PD-L1 positive (immunohistochemistry [IHC] 2/<wbr>3) using an investigational PD-L1 diagnostic test being developed by Roche.<wbr>
</LI>
<LI>After six weeks of follow-up, the objective response rate (ORR) as measured by RECIST criteria was 43 percent (13/<wbr>30), and after 12 weeks, ORR was 52 percent (13/<wbr>25) in people with PD-L1-positive tumours.<wbr>
</LI>
<LI>A complete response (no radiographic evidence of tumour) was observed in 7 percent of PD-L1-positive patients (2/<wbr>30).<wbr>
</LI>
<LI>The ORR was 11 percent (4/<wbr>35) in people whose tumours were identified as PD-L1-negative (IHC 0/<wbr>1) by our investigational test.<wbr>
</LI>
<LI>People in the study experienced a median time to response of 42 days.<wbr>
</LI>
<LI>Treatment-related Grade 3 AEs occurred in 4 percent (3/<wbr>68) of people in the study and included weakness (asthenia; 2 percent), low platelet count (thrombocytopenia; 2 percent) and low phosphate levels (blood phosphorus decrease; 2 percent).<wbr>
</LI>
<LI>The most common AEs observed to date occurring in more than 5 percent of patients were decreased appetite (12 percent), fatigue (12 percent), nausea (12 percent), fever (pyrexia; 9 percent) and weakness (asthenia; 7 percent).<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">The slides below highlight these results more graphically.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/1/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/2/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/3/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/4/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/5/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/6/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/7/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/8/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/9/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/10/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">When questioned further about its developments in bladder cancer and specifically about the possibility of a combination therapy appraoch, Sandra Horning EVP Chief Medical Office and Head of Global Drug Development replied:- </div><div style="margin-bottom: 10px;">"Well I think our immediate goals are obviously to build upon the phI data and the unusually exciting signals that we've seen in the PDL1 positive patient population and to understand that further as we're doing in the large Phase II and the Phase III that were in the process of planning.<wbr>" </div><div style="margin-bottom: 10px;"><P class="pwrapper">It is interesting.<wbr>.<wbr>.<wbr>.<wbr>looking at these tumors that have responded well to checkpoint inhibitors, they tend to be same tumors that haven't done well with combination chemotherapy.<wbr> So, the path forward is very likely to the combination that are actually around the cancer immunity cycle and understanding how we would then build upon this initial observation.<wbr></P> </div><div style="margin-bottom: 10px;"><DIV>
<DIV class="speaker">One further point to make with that is that there is an effective potential combination partner and almost all <SPAN class="highlight m0-17" style="color: #ffffff; background-color: #ff0400;">bladder</SPAN> cancer patients get it and it's effectively an immunologic reactive agent and that is BCG.<wbr> This is now just being studied from the point of view of what type of immune responses are not being addressed as a consequence of BCG administration.<wbr></DIV>
<DIV class="speaker">Sandra then clarified that those included in the trial had not received BCG and that they wouldn't at this stage of the disease.<wbr> However, she did point out that BCG is known to be an effective therapy at least for bladder cancer at the earliest stages, and because of that you might want to amplify the cancer immunity cycle using a second immuno doublet.<wbr></DIV>
<DIV class="speaker"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/11/ScreenCapture12.jpg?user-agent=rss"></DIV>
<DIV class="speaker"><STRONG>About MPDL3280A (anti-PDL1)</STRONG></DIV>
</DIV> </div><div style="margin-bottom: 10px;">MPDL3280A (also known as anti-PDL1) is an investigational monoclonal antibody designed to interfere with a protein called PD-L1.<wbr> MPDL3280A is designed to target PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, preventing it from binding to PD-1 and B7.<wbr>1 on the surface of T cells.<wbr> By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.<wbr> </div><div>Source: <A href="http://www.roche.com/">www.<wbr>roche.<wbr>com</A> </div><!-- Comment details --><a name="oncology9756attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/1/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(91,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/2/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(105,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/3/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(107,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/4/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(92,9 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/5/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(108,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/6/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(94,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/7/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(72,8 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/8/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(83,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/9/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(91,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/10/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(112,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/11/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(98,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9756">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-02T18:27:13+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/1/ScreenCapture2.jpg" length="93311" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/2/ScreenCapture3.jpg" length="108485" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/3/ScreenCapture4.jpg" length="109959" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/4/ScreenCapture5.jpg" length="95093" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/5/ScreenCapture6.jpg" length="111326" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/6/ScreenCapture7.jpg" length="97044" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/7/ScreenCapture8.jpg" length="74534" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/8/ScreenCapture9.jpg" length="85308" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/9/ScreenCapture10.jpg" length="94025" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/10/ScreenCapture11.jpg" length="115633" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9756/11/ScreenCapture12.jpg" length="100632" type="image/jpeg"/></item><item>
<title>Korean Researchers Developed Screening System That May Help Find Botox Substitute [news, class:BotulinumToxins]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7603</link>
<description>Korean Researchers Developed Screening System That May Help Find Botox Substitute [news, class:BotulinumToxins]</description><category>news</category><category>class:BotulinumToxins</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7603</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7603">Korean Researchers Developed Screening System That May Help Find Botox Substitute</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7603">Neurology7603</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 June 2014 | 17:34</font><br><br><div style="margin-bottom: 10px;">Comment: The researchers have developed a low-cost screening system that may potentially help discover natural substances that will work as a substitute for materials related to neurotransmission like Botox.<wbr> The study, led by a team of researchers from the Gwangju Institute of Science and Technology (GIST), focuses on identifying the process of synaptic vesicle membrane fusion, which involves the synaptic vesicle and the neuron.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Findings</FONT></STRONG> </div><div style="margin-bottom: 10px;">Jeon’s team used engineered yeast vacuoles with neuronal SNARE ― Soluble NSF Attachment Protein Receptor ― to mediate in vitro vesicle fusion.<wbr> They found that SNARE was the key factor in the membrane fusion.<wbr> </div><div style="margin-bottom: 10px;">By discovering a new way to recreate the fusion process, the researchers are saying a mass-scale screening process on neurotransmitters is possible.<wbr> </div><div>Source: <A href="http://www.koreaherald.com/view.php?ud=20140602001436">http:/<wbr>/<wbr>www.<wbr>koreaherald.<wbr>com/<wbr>view.<wbr>php?ud=20140602001436</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7603">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-02T17:34:43+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Unexpected Twist as Valeant Raises Its Bid For Allergan Again</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7602</link>
<description>re: Unexpected Twist as Valeant Raises Its Bid For Allergan Again</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7602</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7602">re: Unexpected Twist as Valeant Raises Its Bid For Allergan Again</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7602">Neurology7602</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 June 2014 | 15:19</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Unexpected Twist as Valeant Raises Its Bid For Allergan Again</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Valeant raised its bid to acquire Allergan again late Friday, a move just 48 hours after the last revised offer.<wbr> This time it increased its offer to $72 a share in cash up 23% on Wednesday's offer, whilst the share component remained the same.<wbr> The bid now values Allergan at $53bn.<wbr> The speed with which Valeant has changed its terms  is unusual but appears to highlight its determination.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7600">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7600" class="commentpermalink">Neurology7600</a> / <span class="date">02 June 2014</span> /
<span class="time">08:00:22 o'clock CEST</span>
</font></div><div>Activist investor Pershing Square has launched a process today to convene a special meeting of Allergan's shareholders, Its intent being to overturn most of the company's board in a move designed to facilitate negotiations with Valeant.<wbr> </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7602" class="commentpermalink">Neurology7602</a> / <span class="date">02 June 2014</span> /
<span class="time">15:19:52 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7602">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7600">View thread  Neurology7600: Unexpected Twist as Valeant Raises Its Bid For Allergan Again</a>]]></content:encoded><dc:date>2014-06-02T15:19:52+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Ex-Takeda to Head Acino's Projects and Process Improvement [comp:Acino, :PharmaWorld:sub:People]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids242</link>
<description>Ex-Takeda to Head Acino's Projects and Process Improvement [comp:Acino, :PharmaWorld:sub:People]</description><category>comp:Acino</category><category>sub:People</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids242</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=242">Ex-Takeda to Head Acino's Projects and Process Improvement</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=comp%3aAcino"><font color="#e95e0b">:DKPHybrids:comp:Acino</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids242">DKPHybrids242</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 June 2014 | 13:31</font><br><br><div style="margin-bottom: 10px;">Comment: Geir Myklebust was Head of Finance Shared Service Centers Operations at Takeda.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Short Bio</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/242/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><A href="http://www.acino-pharma.com/html/index.php?id=720&amp;L=1">http:/<wbr>/<wbr>www.<wbr>acino-pharma.<wbr>com/<wbr>html/<wbr>index.<wbr>php?id=720&amp;L=1</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">References in Traction</FONT></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=239" class="defaultlink">DKPHybrids239: Two Ex-Takeda Appointed at Acino</a> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=237" class="defaultlink">DKPHybrids237: Second Ex-Takeda to Join Acino</a> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9474" class="defaultlink">Oncology9474: Ex-Takeda to Join Acino as New CEO</a> </div><div><EM>Source: Acino</EM> </div><!-- Comment details --><a name="dkphybrids242attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/242/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(4,8 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/242/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(36,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=242">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-02T13:31:06+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/242/1/ScreenCapture1.jpg" length="4874" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/dkphybrids/242/2/ScreenCapture2.jpg" length="37029" type="image/jpeg"/></item><item>
<title>Bayer In-licenses Orion's Prostate Cancer Drug [class:Antihormonals, dis:Prostate, comp:BayerSchering, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9754</link>
<description>Bayer In-licenses Orion's Prostate Cancer Drug [class:Antihormonals, dis:Prostate, comp:BayerSchering, headline]</description><category>class:Antihormonals</category><category>dis:Prostate</category><category>comp:BayerSchering</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9754</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9754">Bayer In-licenses Orion's Prostate Cancer Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9754">Oncology9754</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 June 2014 | 13:03</font><br><br><div style="margin-bottom: 10px;">Comment: Orion has announced today a deal with Bayer to develop the prostate cancer drug and androgen-receptor antagonist ODM-201 in patients with non-metastatic prostate cancer.<wbr> PhIII development is planned to start this year.<wbr> Given Bayer's existing presence in the CRPC market with Xofigo, this deal should strengthen the group's overall competitive position in this market.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">Orion and Bayer will develop the new drug together, with Bayer contributing the major share of the development costs.<wbr> Orion will receive an upfront payment of $50m and will use part of this money to finance its share of the phIII study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Perspectives On The Deal</STRONG> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG class="hugin">Dr.<wbr> Reijo Salonen,</STRONG> Senior Vice President of R&amp;D at Orion commented: <BR><BR>"Joining forces with Bayer, I believe that we have again achieved a collaboration that represents the best of all worlds," said Dr.<wbr> Reijo Salonen, SVP R&amp;D and Chief Medical Officer for Orion.<wbr> "Bayer has recently committed to developing therapies in Oncology, particularly for Prostate Cancer.<wbr>  At Orion, we continue our track record of inventing innovative molecules.<wbr> And most importantly, for patients with prostate cancer, this partnership will bring a medicine that will make an important difference to their lives.<wbr>"<BR><BR><BR><STRONG class="hugin">Dr.<wbr> Joerg Moeller</STRONG>, Member of the Bayer HealthCare Executive Committee and Head of Global Development commented:</P> </div><div style="margin-bottom: 10px;"><P class="hugin">"We see in ODM-201 a potential new treatment for patients with high risk non-metastatic castration-resistant prostate cancer and are looking forward to developing this promising compound," said Dr.<wbr> Joerg Moeller, Member of the Bayer HealthCare Executive Committee and Head of Global Development.<wbr> "From a clinical perspective, ODM-201 has the potential to complement our portfolio in prostate cancer and enables us to deliver new treatment options for patients who desperately need them.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG>Orion's Revised Financial Outlook</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="hugin">Based on the deal, Orion has revised upwards its financial guidance for the year.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG class="hugin">New full-year outlook estimate for 2014, provided on 2 June 2014</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG class="hugin"><EM class="hugin">Net sales</EM></STRONG> will be at similar level to 2013 (net sales in 2013 were EUR 1,007 million).<wbr></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG class="hugin"><EM class="hugin">Operating profit</EM></STRONG> will be at similar level to 2013 (operating profit in 2013 was EUR 268 million).<wbr> This was projected to be slightly lower than in 2013.<wbr></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><EM class="hugin"><STRONG class="hugin">The Group's capital expenditure </STRONG></EM>will be about EUR 60 million excluding substantial corporate or product acquisitions (the Group's capital expenditure in 2013 was EUR 78 million).<wbr></P> </div><div>Source: <a href="http://www.orion.com" class="defaultlink" title="http://www.orion.com">orion.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9754">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-02T13:03:53+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Oncology President at Novartis [sub:People, :Oncology:comp:Novartis, :Oncology:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10885</link>
<description>New Oncology President at Novartis [sub:People, :Oncology:comp:Novartis, :Oncology:news]</description><category>sub:People</category><category>comp:Novartis</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10885</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10885">New Oncology President at Novartis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10885">PharmaWorld10885</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 June 2014 | 12:48</font><br><br><div style="margin-bottom: 10px;">Comment: Bruno Strigini will be heading Novartis'Oncology Business.<wbr> He previously was president for EU and Canada operations at Merck Sharp &amp; Dohme (MSD).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Short Bio</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10885/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Bruno Strigini has dedicated his entire career to healthcare and is a professional with a strong international experience and perspective in the global healthcare industry.<wbr> </div><div style="margin-bottom: 10px;">He has held increasingly senior executive positions in a number of companies, including Schering-Plough, UCB-Celltech and SmithKline Beecham, and has been responsible for leading a diverse range of markets and regions around the world.<wbr> During his career, Mr Strigini has led various functions, ranging from strategy and operations, to global marketing and business development.<wbr> </div><div style="margin-bottom: 10px;">He is a board member for Intervet, a global leader in the research, development, manufacturing and sale of veterinary medicines.<wbr> </div><div style="margin-bottom: 10px;"><P class="hugin">He is a member of the Executive Committee for the European Federation of Pharmaceutical Industries &amp; Associations (EFPIA), as well as a member of the Académie Nationale de Pharmacie in France.<wbr> Bruno holds an MBA from IMD, Lausanne (Switzerland), a doctorate degree in pharmacy from the University of Montpellier (France), and a master's degree in microbiology from Heriot-Watt University (UK).<wbr></P> </div><div style="margin-bottom: 10px;"><P class="hugin"><STRONG><FONT size="3">Rationale</FONT></STRONG></P> </div><div style="margin-bottom: 10px;">- Novartis moves to bolster its oncology franchise.<wbr> </div><div>- The company recently acquired GSK's oncology division (for about $14.<wbr>5bln) See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9617" class="defaultlink">Oncology9617: Novartis to Revamp its Portfolio Via Deals with GSK and Lilly</a>.<wbr> </div><!-- Comment details --><a name="pharmaworld10885attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10885/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(5,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10885">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-02T12:48:43+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10885/1/ScreenCapture1.jpg" length="5770" type="image/jpeg"/></item><item>
<title>Role of Pasireotide for Postoperative Pancreatic Fistula [comp:Novartis, :Endocrinology:prod:Pasireotide, :Endocrinology:comp:Novartis, :Endocrinology:headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9751</link>
<description>Role of Pasireotide for Postoperative Pancreatic Fistula [comp:Novartis, :Endocrinology:prod:Pasireotide, :Endocrinology:comp:Novartis, :Endocrinology:headline]</description><category>comp:Novartis</category><category>prod:Pasireotide</category><category>comp:Novartis</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9751</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9751">Role of Pasireotide for Postoperative Pancreatic Fistula</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9751">Oncology9751</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 02 June 2014 | 09:55</font><br><br><div style="margin-bottom: 10px;">Comment: The results, newly published in the NEJM, show that perioperative treatment with pasireotide decreased the rate of clinically significant postoperative pancreatic fistula, leak, or abscess.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Results</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>The primary end point</U> occurred in 45 of the 300 patients (15%).<wbr> The rate of grade 3 or higher postoperative pancreatic fistula, leak, or abscess was significantly lower among patients who received pasireotide than among patients who received placebo (9% vs.<wbr> 21%; relative risk, 0.<wbr>44; 95% confidence interval [CI], 0.<wbr>24 to 0.<wbr>78; P=0.<wbr>006).<wbr> </div><div style="margin-bottom: 10px;">This finding was consistent among 220 patients who underwent pancreaticoduodenectomy (10% vs.<wbr> 21%; relative risk, 0.<wbr>49; 95% CI, 0.<wbr>25 to 0.<wbr>95) and 80 patients who underwent distal pancreatectomy (7% vs.<wbr> 23%; relative risk, 0.<wbr>32; 95% CI, 0.<wbr>10 to 0.<wbr>99), as well as among 136 patients with a dilated pancreatic duct (2% vs.<wbr> 15%; relative risk, 0.<wbr>11; 95% CI, 0.<wbr>02 to 0.<wbr>60) and 164 patients with a nondilated pancreatic duct (15% vs.<wbr> 27%; relative risk, 0.<wbr>55; 95% CI, 0.<wbr>29 to 1.<wbr>01).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=5725" class="defaultlink">Oncology5725: Pasireotide (SOM230) Assessed to Lower Patients' Risks After Pancreatectomy</a>.<wbr> </div><div>Reference: <EM>N Engl J Med.<wbr></EM> 2014 May 22;370(21):2014-22. doi: 10.<wbr>1056/<wbr>NEJMoa1313688.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9751">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-02T09:55:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Unexpected Twist as Valeant Raises Its Bid For Allergan Again [comp:Allergan, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7600</link>
<description>Unexpected Twist as Valeant Raises Its Bid For Allergan Again [comp:Allergan, :PharmaWorld:sub:Acquisition]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7600</comments><category>comp:Allergan</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7600</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7600">Unexpected Twist as Valeant Raises Its Bid For Allergan Again</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7600">Neurology7600</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 June 2014 | 08:00</font><br><br><div style="margin-bottom: 10px;">Comment: Valeant raised its bid to acquire Allergan again late Friday, a move just 48 hours after the last revised offer.<wbr> This time it increased its offer to $72 a share in cash up 23% on Wednesday's offer, whilst the share component remained the same.<wbr> The bid now values Allergan at $53bn.<wbr> The speed with which Valeant has changed its terms  is unusual but appears to highlight its determination.<wbr> </div><div style="margin-bottom: 10px;">The latest offer is contingent on Allergan agreeing to enter into negotiations </div><div style="margin-bottom: 10px;"><STRONG>What Triggered The Revised Offer.<wbr></STRONG> </div><div style="margin-bottom: 10px;">i) The lukewarm reaction of the market to Wednesday's offer with analysts arguing that the cash component was still not enough </div><div style="margin-bottom: 10px;">2) Mr Ackman of Pershing square relinquishing the cash component he would receive in favour of Valeant's shares.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>The Reaction So Far</STRONG> </div><div>Analysts reactoin to the revised bid still remaines mixed but Bernstein Analyst Ronny Gal who has been very vocal on the proposed deal is now cited by Reuters as saying that " it incerases the pressure on Allergan to take action and negotiate" and that "the offer now appears credible.<wbr>" He does not think this is a done deal by a long shot but does now view the likelihood of success as higher.<wbr> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7602c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Activist investor Pershing Square has launched a process today to convene a special meeting of Allergan's shareholders, Its intent being to overturn most of the company's board in a move designed to facilitate negotiations with Valeant.<wbr> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7602" class="commentpermalink">Neurology7602</a> / <span class="date">02 June 2014</span> /
<span class="time">15:19:52 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7600">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-06-02T08:00:22+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Growing Usage Of Toxin Treatment For nOAB [dis:nOAB, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7599</link>
<description>Growing Usage Of Toxin Treatment For nOAB [dis:nOAB, news]</description><category>dis:nOAB</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7599</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7599">Growing Usage Of Toxin Treatment For nOAB</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7599">Neurology7599</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 May 2014 | 18:39</font><br><br><div style="margin-bottom: 10px;">Comment: Two recent posters at the AUA meeting in Orlando begin to 
illustrate how enthusiam for and administration of onaboutlinum toxin for 
neurogenic OAB is growing in North America.<wbr> Neither study was sponsored by 
Allergan.<wbr> </div><div style="margin-bottom: 10px;">MP80-13: <A href="#"><STRONG>Intravesical 
Onabotulinumtoxin A for bladder dysfunction in “real world” clinical 
practice</STRONG> </A><BR>Richard Baverstock*, Bryce Weber, Trafford Crump, 
Daniel Yanko, Kevin Carlson, Calgary, Canada </div><div style="margin-bottom: 10px;"><DIV class="absdetail" id="loadabs7788" style="BACKGROUND: rgb(198,237,237)"><STRONG>Abstract: MP80-13</STRONG> 
<BR><STRONG>Introduction and Objectives</STRONG> <BR>Intravesical BOTOX 
(Onabotulinumtoxin A, BTA) injections for lower urinary tract dysfunction was 
first described in 1987, and has been used at our institution since 2004.<wbr> It was 
approved for use in North America for refractory neurogenic detrusor 
overactivity (NDO) in 2012, and for idiopathic detrusor overactivity (IDO) in 
Canada in October 2013.<wbr> BTA remains off-label for refractory bladder pain 
syndrome (BPS).<wbr> Few studies have been published to confirm the long-term safety 
and efficacy of intravesical BTA, nor the adherence to this form of treatment.<wbr> 
We report our long-term “real-world” clinical experience with BTA for refractory 
bladder storage dysfunction (NDO, IDO, BPS) in our high-volume institution, with 
attention to baseline data, growth in uptake, and persistence with therapy.<wbr> 
<BR><BR><STRONG>Methods</STRONG> <BR>A retrospective chart review of all 
patients injected between July 20, 2009 (when charts became available via EMR) 
and October 30, 2013 was performed.<wbr> <BR><BR><STRONG>Results</STRONG> <BR>Overall 
a total of 1265 injections were performed on 443 unique patients with mean age 
of 56 years (19 – 88).<wbr> The majority of patients (66%) were injected under local 
anesthesia only.<wbr> The number of BTA treatments ranged from 1 – 14.<wbr> 63% of 
patients have received more than 1 injection while 41% have received 3 or more, 
and 14% 6 or more.<wbr> Overall, 43% discontinued BTA at any time due to attrition, 
lack of effect, or change in bladder management.<wbr> In 2010, 207 injections 
(17/<wbr>month) were performed, while 270 were done in 2011 (23/<wbr>month), and 330 in 
2012 (28/<wbr>month).<wbr> In the first 10 months of 2013, 377 injections have been 
performed (38/<wbr>month).<wbr> Indications included NDO in 55%, IDO in 40%, BPS in 5%.<wbr> 
For the NDO group, 65% were female, compared to 86% of the IDO and 100% of the 
BPS groups.<wbr> In the NDO group, 28% had spinal cord injury (SCI), 34% multiple 
sclerosis (MS), and 38% had other causes.<wbr> Twenty percent of the entire cohort 
initiated clean intermittent catheter (CIC), 20% already performed CIC, and 16% 
had indwelling catheters.<wbr> No serious adverse events or hospital admissions were 
observed.<wbr> <BR><BR><STRONG>Conclusions</STRONG> <BR>Intravesical BTA is a 
well-tolerated and safe procedure that is performed under local anesthetic in 
the majority of cases.<wbr> Repeat treatments are common and popularity of BTA for 
patients with bladder dysfunction is growing.<wbr> A significant number of patients 
initiated CIC in our blended cohort.<wbr> Persistence with treatment is high, at 57%, 
despite the challenging nature of the patient population.<wbr> <BR></DIV> </div><div style="margin-bottom: 10px;">MP80-14: <A href="#"><STRONG>BOTULINUM TOXIN A: THE 
SHIFT TO A MINIMALLY INVASIVE MANAGEMENT OF NEUROGENIC BLADDER</STRONG> 
</A><BR>Michael Aberger*, Bradley Wilson, Andrew Arther, Tomas L.<wbr> Griebling, 
Priya Padmanabhan, Kansas City, KS </div><div><DIV class="absdetail" id="loadabs7789" style="BACKGROUND: rgb(198,237,237)"><STRONG>Abstract: MP80-14</STRONG> 
<BR><STRONG>Introduction and Objectives</STRONG> <BR>The key in management of 
neurogenic dysfunction of the lower urinary tract is the maintenance of low 
storage pressures.<wbr> First line treatment is anticholinergic therapy with 
intermittent catheterization.<wbr> Once patients are refractory to anticholinergic 
therapy, augmentation cystoplasty (AC) has traditionally been used to create a 
high capacity, low-pressure reservoir.<wbr> Yet, this procedure is associated with a 
high complication rate.<wbr> The FDA approved Botulinum toxin A (BTX-A) in August of 
2011 for the treatment of neurogenic detrusor over activity (NDO).<wbr> Multiple 
studies have shown its effectiveness in neurogenic bladders with associated 
improvements in incontinence episodes and urodynamic parameters.<wbr> Our study 
reviews how the advent of BTX-A has changed modern treatment of NDO.<wbr> 
<BR><BR><STRONG>Methods</STRONG> <BR>We performed a retrospective chart review 
from 2003-2013 of patients seen in our Urology practice with anticholinergic 
refractory NDO that underwent AC or cystectomy with urinary diversion.<wbr> We 
analyzed their charts and testing data to see how many patients would have met 
the indication for BTX-A.<wbr> Furthermore, we compared our practice since the 
incorporation of BTX-A to see how our treatment of NDO has changed.<wbr> 
<BR><BR><STRONG>Results</STRONG> <BR>59 patients met inclusion criteria for our 
study.<wbr> 34 patients underwent reconstructive surgery for NDO.<wbr> The remaining 25 
patients have been managed with BTX-A detrusor injections (available since 
August 2011).<wbr> Review of the 34 patients that underwent open surgery revealed 21 
(62%) would have met indication for BTX-A injections.<wbr> Additionally, 30 of the 34 
patients that underwent reconstructive surgery had surgery in the first 8 years 
of the study resulting in nearly 4 open surgeries for NDO per year.<wbr> After BTX-A 
was introduced in 2011 the number of open reconstructive surgeries at our 
institution was reduced to less than 2 per year.<wbr> During that same time period an 
average of 12 patients per year were managed with BTX-A.<wbr> Of the 34 
reconstructive patients, 14 (41%) had a complication with 10 (29%) requiring a 
repeat procedure.<wbr> Conversely, only one BTX-A patient (4%) had a complication for 
which further intervention was not required.<wbr> 
<BR><BR><STRONG>Conclusions</STRONG> <BR>Anticholinergic refractory NDO is a 
complex disorder that impairs quality of life and often threatens the upper 
urinary tracts.<wbr> Although it is not the answer for every patient, BTX-A has 
become an effective minimally invasive alternative to urinary reconstruction.<wbr> 
This study demonstrates how the addition of BTX-A is evolving the care of NDO 
patients.<wbr> <BR><BR></DIV> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7599">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-30T18:39:06+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Otsuka To Release Extension Trial Data With Tolvaptan In ADPKD at the ERA-EDTA Congress [class:SomatostatinAnalogue, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7689</link>
<description>Otsuka To Release Extension Trial Data With Tolvaptan In ADPKD at the ERA-EDTA Congress [class:SomatostatinAnalogue, news]</description><category>class:SomatostatinAnalogue</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7689</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7689">Otsuka To Release Extension Trial Data With Tolvaptan In ADPKD at the ERA-EDTA Congress</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7689">Endocrinology7689</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 May 2014 | 18:06</font><br><br><div style="margin-bottom: 10px;">Comment: Otsuka will release data from an extension trial of its TEMPO 3:4 trial in ADPKD patients this weekend at the European Renal Association Meeting in Amsterdam.<wbr> The new data demonstrates that continuous tolvaptan treatment confers sustained protection of renal function and that the slope of eGFR decline during treatment remains improved relative to placebo through 5 year sof therapy.<wbr> Interestingly, the meeting also includes a poster highighting the positive results seen with Lanreotide in a limited number of ADPKD patients.<wbr> </div><div style="margin-bottom: 10px;">Abstract details from the two studies are highlighted below </div><div style="margin-bottom: 10px;"><STRONG>SO016] TOLVAPTAN-TREATMENT OF ADPKD CONFERS PERSISTENT EGFR IMPROVEMENT: RESULTS FROM THE TEMPO 4:4 EXTENSION TRIAL<BR><BR></STRONG><STRONG><EM>Vicente E Torres<SUP>1</SUP>, Arlene B Chapman<SUP>2</SUP>, Olivier Devuyst<SUP>3</SUP>, Ronald T Gansevoort<SUP>4</SUP>, Eiji Higashihara<SUP>5</SUP>, Ronald D Perrone<SUP>6</SUP>, John Ouyang<SUP>7</SUP>, Susan E Shoaf<SUP>8</SUP>, Ann Dandurand<SUP>9</SUP>, Robert D Mcquade<SUP>10</SUP>, Frank S Czerwiec<SUP>11</SUP> <BR><SUP>1</SUP>Mayo Clinic, Rochester, MN;<SUP>2</SUP>Emory University Medical Center, Atlanta, GA;<SUP>3</SUP>University of Zurich, Zurich, Switzerland<SUP>4</SUP>University Medical Center Groningen, Groningen, Netherlands<SUP>5</SUP>Kyorin University School of Medicine, Tokyo, Japan<SUP>6</SUP>Tufts-New England Medical Center, Boston, MA;<SUP>7</SUP>Otsuka PDC, Rockville, MD;<SUP>8</SUP>Otsuka PDC, Rockville, MD;<SUP>9</SUP>Otsuka PDC, Princeton, NJ;<SUP>10</SUP>Otsuka PDC, Princeton, NJ;<SUP>11</SUP>Otsuka PDC, Rockville, MD.<wbr> </EM></STRONG> </div><div style="margin-bottom: 10px;">The TEMPO 3:4 trial demmonstrated that the V2-receptor antagonist tolvaptan slowed the increase in total kidney volume by 49% and the deline in kidney function (eGFR) by 26% over 3 years in CKD stage 1-3 ADPKD patients (1).<wbr> The data below shows the persistence of tolvaptan's effect on eGFR.<wbr> </div><div style="margin-bottom: 10px;">Key Findings </div><div style="margin-bottom: 10px;">Included were data from 976 ADPKD patients.<wbr> An intra-subject comparison of 304 DT subjects participating in both trials, showed a significant improvement in the eGFR slope after switching from placebo to tolvaptan (from -3.<wbr>59 to -2.<wbr>85 mL/<wbr>min/<wbr>1.<wbr>73m<SUP>2</SUP>/<wbr>yr, treatment effect 21%, p=0.<wbr>048) despite the time difference leading to an increased proportion starting in CKD 3 at TEMPO 4:4' s baseline compared to their own earlier TEMPO 3:4 baseline (37 vs.<wbr> 15%) (see Figure).<wbr> Analysis of the separation in eGFR between 512 ET and 212 DT subjects post-treatment withdrawal in TEMPO 3:4 demonstrated sustained protection of renal function during the two year open label extension (p&lt;0.<wbr>05 for 11/<wbr>12 time points, see Figure).<wbr> A third analysis indicated that the 5-year ET slope (N=554) in TEMPO 3:4 and TEMPO 4:4 combined remained significantly different from the DT placebo slope (N=422) in TEMPO 3:4 (-2.<wbr>92 vs.<wbr> -3.<wbr>63 mL/<wbr>min/<wbr>1.<wbr>73m<SUP>2</SUP>/<wbr>yr, treatment effect 20%, p&lt;0.<wbr>0001) </div><div style="margin-bottom: 10px;"><SUB><SUP>1</SUP>Torres VE et.<wbr> al.<wbr>, N Engl J Med </SUB><SUB>2012 Dec 20; 367(25):2407-18</SUB> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7689/1/ScreenCapture1.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7689/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>SP022] LANREOTIDE IN POLYCYSTIC KIDNEY DISEASE: A LIGHT AT THE END OF THE TUNNEL?<BR><BR></STRONG><STRONG><EM>Serge Treille<SUP>1</SUP>, Jean-Marie Bailly<SUP>2</SUP>, Beno&Atilde;&reg;t Guillaume<SUP>3</SUP> <BR><SUP>1</SUP>CHU de Charleroi, Charleroi, Belgium<SUP>2</SUP>CHU de Charleroi, Charleroi, Belgium<SUP>3</SUP>CHU de Charleroi, Charleroi, Belgium.<wbr> </EM></STRONG><BR>Two different mutations have been identified in ADPKD: a mutation on chromosome 16 (<EM>PKD</EM> 1), found in 85% of cases, and a mutation on chromosome 4 (<EM>PKD</EM> 2), which is found in 15% of cases .<wbr> These mutations result in the production of abnormal polycistin-1 and polycistin-2, respectively, both of which cause changes in the structure of the cilia of renal tubular epithelial cells.<wbr><BR>The consequences of these mutations -cellular proliferation, secretion of large volumes of fluid and dedifferentiation - together create a favourable climate for the development of cysts.<wbr> However, the mechanisms underpinning the formation of cysts remain unclear.<wbr> One major theory supports a continuum of dedifferentiation, maturation and apoptosis.<wbr><BR>Nephromegaly resulting from ADPKD probably plays a key role in the deterioration of kidney function and in maintaining arterial hypertension.<wbr> The CRISP study showed that in ADPKD patients at high risk of renal failure the kidney volume increased by 6.<wbr>76 &plusmn; 3.<wbr>78% per year with a parallel decrease in their glomerular filtration rate (GFR) of 5.<wbr>04 &plusmn; 5.<wbr>86 ml/<wbr>min/<wbr>year.<wbr> The secretion of large volumes of fluid into cysts and changes in the structure and mobility of the cilia of the renal tubular epithelium can lead to nephromegaly.<wbr> This in turn often causes deterioration of kidney function and arterial hypertension.<wbr> In recent clinical studies, somatostatin analogues have demonstrated efficacy in isolated polycystic liver disease and, to a lesser extent, in polycystic kidney disease.<wbr> Since the publication of these clinical studies, several patients have been referred to us for somatostatin analogue treatment.<wbr><BR><STRONG>METHODS:</STRONG> Six patients received lanreotide autogel 120 mg every 4 weeks over 6, 12 or 18 months in our centre.<wbr> All patients had kidney function with a GFR above 30 ml/<wbr>min/<wbr>1.<wbr>73 m<SUP>2</SUP>.<wbr> No-one had diabetes mellitus or symptomatic gallstones, biliary sludge.<wbr> The women observed should not be pregnant, lactating or potentially childbearing without any adequate contraception.<wbr> Those with cancer, major systemic disease or proteinuria greater than 1g/<wbr>day were not approached.<wbr> No patients had received previous treatment with a somatostatin analogue, sirolimus or vasopressin antagonist.<wbr> The potential side effects of the treatment, such as diarrhoea, abdominal pain or pain at the site of injection and potential vesicular lithiasis were discussed and were part of the patients' informed consent.<wbr><BR><STRONG>RESULTS:</STRONG> We observed a mean decrease in volume of 4%, with mild to moderate side effects.<wbr><BR><STRONG>CONCLUSIONS:</STRONG> The results obtained in this limited series seem encouraging, and might offer a new perspective for patients with ADPKD.<wbr> It is notable that we observed a decrease in volume that persisted over 18 months, though these findings need to be confirmed in larger controlled clinical studies.<wbr> If these data are confirmed on a larger scale and since lanreotide has an acceptable tolerance profile, this treatment might offer a new strategy for the treatment of ADPKD patients.<wbr> Is there any light at the end of the tunnel? </div><div>Source: 51st ERA-EDTA Congress Amsterdam 31st May - 3rd June </div><!-- Comment details --><a name="endocrinology7689attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7689/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(631 B)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7689/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(47,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7689">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-30T18:06:07+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7689/1/ScreenCapture1.jpg" length="631" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7689/2/ScreenCapture2.jpg" length="48201" type="image/jpeg"/></item><item>
<title>GSK To Divest 50 Older Products [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10882</link>
<description>GSK To Divest 50 Older Products [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10882</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10882">GSK To Divest 50 Older Products</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10882">PharmaWorld10882</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 30 May 2014 | 10:10</font><br><br><div style="margin-bottom: 10px;">Comment: Sky News reported yesterday that GSK has invited private equity firms to consider bids for a range of 50 older drugs sold in Western markets.<wbr> </div><div style="margin-bottom: 10px;">Meanwhile, Reuters is quoting three people with direct knowlege of the matter as the source of the disclosuire.<wbr> </div><div style="margin-bottom: 10px;">The news tallies with a statement by CEO Andrew Witty last month that the company could dispose of individual medicines or a broader portfolio of older established products.<wbr> </div><div style="margin-bottom: 10px;">GSK is apparently being advised by Lazards on the divestment </div><div style="margin-bottom: 10px;"><STRONG>What does the older established portfolio (EP) contain?</STRONG> </div><div style="margin-bottom: 10px;">GSK in its Q1 results this year, highlighted for the first time the sales performance of some of its major "established products", however, there are clearly a number of others that make up the &pound;290m in Other sales.<wbr> The biggest drugs amonst the grouping are the anti-epileptic Lamictal and the lipid regulator Lovaza.<wbr> Other well known products are the migraine drug Imigran, the Parkinson's drug Requip and the antidepressant Paxil.<wbr> The majority of the EP group are facing generic competition and declining sales.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Q114 Sales Figures</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Total USA Europe Emerging Markets Japan</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>&pound;m CER% &pound;m CER% &pound;m CER% &pound;m CER% &pound;m </STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10882/1/ScreenCapture2.jpg?user-agent=rss"> </div><div>GSK is believed to be in "no rush" to dispose of the 50 or so older medicines in the division and notably it does plan to retain rights to most of the products in emerging markets, where they form an important part of its business.<wbr> </div><!-- Comment details --><a name="pharmaworld10882attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10882/1/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(67,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10882">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-30T10:10:57+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10882/1/ScreenCapture2.jpg" length="69007" type="image/jpeg"/></item><item>
<title>New Tourette's Drug Has A Promising Profile For Pediatric Patients [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7597</link>
<description>New Tourette's Drug Has A Promising Profile For Pediatric Patients [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7597</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7597">New Tourette's Drug Has A Promising Profile For Pediatric Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7597">Neurology7597</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 May 2014 | 16:28</font><br><br><div style="margin-bottom: 10px;">Comment: Psyadon has announced the start of its first phIIb study with its lead product ecopipam in patients with Tourette's Syndrome aged 7-17.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>What is Exopipam? </STRONG> </div><div style="margin-bottom: 10px;">Ecopipam is a first-in class molecules that selectively blocks the action of dopamine at its receptor Ecopiipam blocks dopamine at D1 receptors in contrast to all currently marketed dopamine blockers which block the D2 receptors.<wbr> </div><div style="margin-bottom: 10px;">Previous significant results from an open-label study in adults were encouragin enough for the FDA to grant the drug orphan designation to treat Tourette's Syndrome in children ages 7-17.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>PhIIb Study Design</STRONG> </div><div style="margin-bottom: 10px;">Study PSY302 is a multicentre, double-blind, placebo-controlled randomised two-way crossover study designed to assess the efficacy and safety in subjects with Tourett's Syndrome.<wbr> Patients will take ecopipam 50 or 100mg/<wbr>day or placebo over an 8-week treatment period comprised of two four-week treatment periods.<wbr> </div><div style="margin-bottom: 10px;">Efficacy will be measured using the Yale Global Tic Severity Scale.<wbr> </div><div style="margin-bottom: 10px;">Four sites are currently open and enrolling patients with further sites expected to open soon.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrials Identifier NCT02102698 n=30 </div><div style="margin-bottom: 10px;"><STRONG>About Psyadon Pharmaceuticals</STRONG> </div><div style="margin-bottom: 10px;">Psyadon is a company dedicated to the discovery &amp; development of drugs for serious neurological &amp; psychiatric disorders.<wbr> The company is focusing its efforts on orphan drug products for diseases with high unmet need.<wbr> </div><div style="margin-bottom: 10px;">The US Montgomery County company is a private venture backed organisation.<wbr> </div><div style="margin-bottom: 10px;">Source:- <A href="http://www.psyadonrx.com">www.<wbr>psyadonrx.<wbr>com</A> </div><div><FONT size="3"><FONT size="3">.<wbr> </FONT></FONT> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7597">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-29T16:28:24+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Good News For Takeda Re UC &amp; Crohn's Drug [dis:IBD, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1975</link>
<description>Good News For Takeda Re UC &amp; Crohn's Drug [dis:IBD, news]</description><category>dis:IBD</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1975</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1975">Good News For Takeda Re UC & Crohn's Drug</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:GastroEnterology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1975">GastroEnterology1975</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 29 May 2014 | 15:56</font><br><br><div style="margin-bottom: 10px;">Comment: Takeda announced yesterday that the EMA had granted approval across 
all its member states and other EU markets for the group novel gut-selective mAb 
Entyvio (vedolizumab).<wbr> The drug has been approved to treat patients with 
moderate to severe ulcerative colitis or moderate to severe Crohn's disease.<wbr> </div><div style="margin-bottom: 10px;">This positive news follows the announcment on May 20th that the drug was 
approvable in the US to treat the same types of patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Specific Labelling</STRONG> </div><div style="margin-bottom: 10px;">Specifically, the EMA and FDA labels position Entyvio for UC and CD patients 
who have failed, lost response to, or are intolerant to the standard therapies, 
including corticosteroids, purine analog immunosuppressants, and/<wbr>or TNF 
blockers.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Entyvio Has A Differentiated Profile</STRONG> </div><div style="margin-bottom: 10px;">A key strength of Entyvio is it is the first biologic with gut sepcificity.<wbr> 
There are other "me-too" drugs in the pipeline and interestingly Roche's 
etrolizumab jumped from phIIa to an accelerated phIII development  
programme earlier in May upon promising phII results.<wbr> </div><div style="margin-bottom: 10px;">The drug also appears to offer a good safety profile relative to the TNF 
blockers, something that is likely to appeal given the costs that can be 
incurred with managing such side-effect issues.<wbr> </div><div>Source; <A href="http://www.takeda.com">www.<wbr>takeda.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1975">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-29T15:56:54+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Hikma Pharmaceuticals Completes Transformation Deal By Acquiring Bedford Labs From Boehringer Ingelheim [sub:Generics, mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10879</link>
<description>Hikma Pharmaceuticals Completes Transformation Deal By Acquiring Bedford Labs From Boehringer Ingelheim [sub:Generics, mkt:NorthAmerica]</description><category>sub:Generics</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10879</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10879">Hikma Pharmaceuticals Completes Transformation Deal By Acquiring Bedford Labs From Boehringer Ingelheim</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aGenerics"><font color="#e95e0b">:PharmaWorld:sub:Generics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10879">PharmaWorld10879</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 May 2014 | 18:03</font><br><br><div style="margin-bottom: 10px;">Comment: Hikma's purchase of leading US generic injectable supplier Bedford labs for $300m propells it into the big league in this space, particularly in oncology.<wbr> As a MENA partner of GP Pharms for its branded leuprolide Lutrate-1M, there could be potential for extension of this partnership into the US.<wbr> </div><div style="margin-bottom: 10px;">Hikma has been gradually expanding its partnership with GP Pharm to a broader range of territories (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9185" class="defaultlink">Oncology9185: Hikma Expands License and Supply Agreement for GP Pharm's Lutrate® in Germany and Portugal</a>).<wbr> We know that GP Pharm is keen to conclude a US agreement and as such speculation may start to focus on Hikma as a potential partner that now has a much wider geographic footprint and critical mass.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/3/ScreenCapture3.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/4/ScreenCapture4.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/5/ScreenCapture5.jpg?user-agent=rss"></FONT> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="pharmaworld10879attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(157,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(99,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(123 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(80 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(69 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(117,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10879">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-28T18:03:13+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/1/ScreenCapture1.jpg" length="161430" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/2/ScreenCapture2.jpg" length="101791" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/3/ScreenCapture3.jpg" length="125933" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/4/ScreenCapture4.jpg" length="81884" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/5/ScreenCapture5.jpg" length="70667" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10879/6/ScreenCapture6.jpg" length="119952" type="image/jpeg"/></item><item>
<title>Valeant Sells All Toxin &amp; Filler Assets To Nestle For $1.4bn in cash [class:BotulinumToxins, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7595</link>
<description>Valeant Sells All Toxin &amp; Filler Assets To Nestle For $1.4bn in cash [class:BotulinumToxins, :PharmaWorld:mkt:NorthAmerica, :PharmaWorld:sub:Acquisition]</description><category>class:BotulinumToxins</category><category>mkt:NorthAmerica</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7595</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7595">Valeant Sells All Toxin & Filler Assets To Nestle For $1.<wbr>4bn in cash</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7595">Neurology7595</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 May 2014 | 17:05</font><br><br><div style="margin-bottom: 10px;">Comment: <ORG value="NYSE:VRX">Valeant Pharmaceuticals has 
announced that it has entered into an agreement with </ORG><ORG value="OTC-PINK:NSRGY">Nestle S.<wbr>A.<wbr></ORG> to sell all rights to Restylane, Perlane, 
Emervel, Sculptra, and Dysport owned or held by Valeant for <MONEY>$1.<wbr>4 
billion</MONEY> in cash (5x sales).<wbr> Valeant notes that 
"the agreement dovetails well with its proposed acquisition of 
Allergan".<wbr> <ORG></ORG> Of course if this was succesful, this is something 
the SEC would insist upon for monopolistic reasons.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>First Step In The Transaction</STRONG> </div><div style="margin-bottom: 10px;">Nestle expects to complete its acquisition of <ORG>Galderma S.<wbr>A.<wbr></ORG> in 
July and would then expect to operate the acquired assets through 
Galderma.<wbr>  The acquisition is attractive for Galderma in enabling 
it to extend Galderma's aesthetic franchise throughout North America.<wbr> </div><div style="margin-bottom: 10px;">The transaction is subject to customary closing conditions, including 
clearance or early expiration of the waiting period under the Hart-Scott-Rodino 
(HSR) Act and is not contingent upon a successful transaction with 
<ORG>Allergan, Inc.<wbr></ORG> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on the transaction Michael Pearson Chairman &amp; CEO 
stated:-</STRONG> </div><div style="margin-bottom: 10px;">"We are pleased to enter into this transaction.<wbr> Galderma, under the 
leadership of <PERSON>Humberto Antunes</PERSON>, CEO of Galderma, not only has a 
history of building strong businesses, but is firmly committed to the aesthetic 
dermatology.<wbr>  It is a clear testament to the performance of Valeant's 
aesthetic commercial team that Galderma recognizes their efforts and the value 
of the franchise they have developed.<wbr>  Galderma has already built a strong 
franchise with Restylane, Perlane, Dysport and Emervel outside <LOCATION value="LB/nam">North America</LOCATION> and, with the 
addition of Sculptra, will now have the ability bring their expertise to the 
U.<wbr>S.<wbr> and <LOCATION value="LC/ca;LB/nam">Canada</LOCATION>.<wbr>" </div><div>Source: <A href="http://www.valeant.com">www.<wbr>valeant.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7595">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-28T17:05:53+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Valeant Raises Its Offer For Allergan Including The Cash Component [comp:Allergan, :PharmaWorld:sub:Acquisition, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7593</link>
<description>Valeant Raises Its Offer For Allergan Including The Cash Component [comp:Allergan, :PharmaWorld:sub:Acquisition, headline]</description><category>comp:Allergan</category><category>sub:Acquisition</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7593</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7593">Valeant Raises Its Offer For Allergan Including The Cash Component</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7593">Neurology7593</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 28 May 2014 | 16:15</font><br><br><div style="margin-bottom: 10px;">Comment: Valeant has raised its offer for Allergan to $166.<wbr>16 per share, 8.<wbr>6% higher than its previous bid of $153 and valuing the company at $49.<wbr>44bn.<wbr> Its offer includes $58.<wbr>30 per Allergan share in cash $10 higher than previously.<wbr> In a webcast following the announcement, Valeant defended its business model by giving clear examples of its growth businesses, the people involved and their depth of experience in big pharma and their commitment to the Valeant business model.<wbr> CEO Mike Pearson provided an effective rebuttal against most of Allergan's accusations and highlighted the need for a different pharmaceutical model better adapted to the current more challenging competitive environment.<wbr> </div><div style="margin-bottom: 10px;">In a very lengthy 176 slide presentation, Valeant provided a very open in-depth perspective of its geographic activities, pipeline activities and acquisition driven growth.<wbr> It also challenged many of the assumptions made by Allergan in its prior day presentation.<wbr> </div><div style="margin-bottom: 10px;">The slides below firstly highlight Valeant's rebuttal to Allergan's accusations, next the adaptation of the Valeant decentralised model to the new industry environment, and then provide insight by geography/<wbr>business area into some of its key operational growth themes.<wbr> </div><div style="margin-bottom: 10px;">Amongst all 10 presentors, there was a common theme on how different the working model feels compared to big pharma from the perspective of accountability, empowerment and the drive for growth.<wbr> To quote one presentor "It looks scary from the outside but it is exciting from the inside".<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/28/ScreenCapture34.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/29/ScreenCapture36.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/30/ScreenCapture37.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/31/ScreenCapture38.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/32/ScreenCapture39.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/33/ScreenCapture40.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/34/ScreenCapture41.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/35/ScreenCapture42.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/36/ScreenCapture43.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/37/ScreenCapture44.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><U>How The Industry Needs To Change To Adapt To The Current Paradigm</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><U>Business Orientated Presentations</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/16/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/17/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/18/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/19/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><U><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/43/ScreenCapture50.jpg?user-agent=rss"></STRONG></U> </div><div style="margin-bottom: 10px;"><U><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/44/ScreenCapture51.jpg?user-agent=rss"></STRONG></U> </div><div style="margin-bottom: 10px;"><U><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/45/ScreenCapture52.jpg?user-agent=rss"></STRONG></U> </div><div style="margin-bottom: 10px;"><U><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/46/ScreenCapture53.jpg?user-agent=rss"></STRONG></U> </div><div style="margin-bottom: 10px;"><U><STRONG><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/47/ScreenCapture54.jpg?user-agent=rss"></STRONG></U> </div><div style="margin-bottom: 10px;"><U><STRONG>R&amp;D Counter Claims Vs Allergan</STRONG> </U> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/48/ScreenCapture55.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/20/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/49/ScreenCapture56.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/21/ScreenCapture25.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><U>Financial &amp; Operational Perspective On The Bausch &amp; Lomb Acquisition</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/22/ScreenCapture28.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/23/ScreenCapture29.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/24/ScreenCapture30.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/25/ScreenCapture31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/38/ScreenCapture45.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/39/ScreenCapture46.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/40/ScreenCapture47.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/41/ScreenCapture48.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/42/ScreenCapture49.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><U>Value Of The Newly Revised Offer</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/26/ScreenCapture32.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/27/ScreenCapture33.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7593attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(197,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(173,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(133,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(135,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(93,1 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(90,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(84,9 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(96,3 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(94,3 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(144,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(127,9 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(88,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(96,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(152,3 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(94,8 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/16/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(133,7 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/17/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(79,3 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/18/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(154,8 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/19/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(126,8 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/20/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(131 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/21/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(129,8 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/22/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(84,6 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/23/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(175,9 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/24/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(75,7 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/25/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(165,6 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/26/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(119,2 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/27/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(102,6 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/28/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(156,2 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/29/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(132 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/30/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(123,5 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/31/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(180,8 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/32/ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(73,3 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/33/ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(133,2 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/34/ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(173,8 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/35/ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(82 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/36/ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(159,7 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/37/ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(113 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/38/ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(137,1 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/39/ScreenCapture46.jpg">ScreenCapture46.jpg</a>&nbsp;&nbsp;(142,4 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/40/ScreenCapture47.jpg">ScreenCapture47.jpg</a>&nbsp;&nbsp;(161,4 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/41/ScreenCapture48.jpg">ScreenCapture48.jpg</a>&nbsp;&nbsp;(158 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/42/ScreenCapture49.jpg">ScreenCapture49.jpg</a>&nbsp;&nbsp;(136,9 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/43/ScreenCapture50.jpg">ScreenCapture50.jpg</a>&nbsp;&nbsp;(120 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/44/ScreenCapture51.jpg">ScreenCapture51.jpg</a>&nbsp;&nbsp;(137,2 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/45/ScreenCapture52.jpg">ScreenCapture52.jpg</a>&nbsp;&nbsp;(149,6 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/46/ScreenCapture53.jpg">ScreenCapture53.jpg</a>&nbsp;&nbsp;(94,7 KB)<br>&nbsp;&nbsp;47.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/47/ScreenCapture54.jpg">ScreenCapture54.jpg</a>&nbsp;&nbsp;(125,8 KB)<br>&nbsp;&nbsp;48.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/48/ScreenCapture55.jpg">ScreenCapture55.jpg</a>&nbsp;&nbsp;(124,7 KB)<br>&nbsp;&nbsp;49.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/49/ScreenCapture56.jpg">ScreenCapture56.jpg</a>&nbsp;&nbsp;(150,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7593">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-28T16:15:23+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/1/ScreenCapture1.jpg" length="202188" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/2/ScreenCapture2.jpg" length="177508" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/3/ScreenCapture3.jpg" length="136383" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/4/ScreenCapture4.jpg" length="138751" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/5/ScreenCapture5.jpg" length="95358" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/6/ScreenCapture6.jpg" length="92319" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/7/ScreenCapture7.jpg" length="86967" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/8/ScreenCapture8.jpg" length="98596" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/9/ScreenCapture9.jpg" length="96578" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/10/ScreenCapture10.jpg" length="147904" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/11/ScreenCapture11.jpg" length="130984" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/12/ScreenCapture12.jpg" length="90265" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/13/ScreenCapture13.jpg" length="98429" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/14/ScreenCapture14.jpg" length="155965" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/15/ScreenCapture15.jpg" length="97071" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/16/ScreenCapture17.jpg" length="136930" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/17/ScreenCapture18.jpg" length="81200" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/18/ScreenCapture19.jpg" length="158533" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/19/ScreenCapture20.jpg" length="129871" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/20/ScreenCapture21.jpg" length="134145" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/21/ScreenCapture25.jpg" length="132887" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/22/ScreenCapture28.jpg" length="86583" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/23/ScreenCapture29.jpg" length="180082" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/24/ScreenCapture30.jpg" length="77534" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/25/ScreenCapture31.jpg" length="169584" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/26/ScreenCapture32.jpg" length="122109" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/27/ScreenCapture33.jpg" length="105032" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/28/ScreenCapture34.jpg" length="159926" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/29/ScreenCapture36.jpg" length="135133" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/30/ScreenCapture37.jpg" length="126500" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/31/ScreenCapture38.jpg" length="185096" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/32/ScreenCapture39.jpg" length="75109" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/33/ScreenCapture40.jpg" length="136408" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/34/ScreenCapture41.jpg" length="177999" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/35/ScreenCapture42.jpg" length="84019" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/36/ScreenCapture43.jpg" length="163513" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/37/ScreenCapture44.jpg" length="115726" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/38/ScreenCapture45.jpg" length="140392" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/39/ScreenCapture46.jpg" length="145789" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/40/ScreenCapture47.jpg" length="165239" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/41/ScreenCapture48.jpg" length="161801" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/42/ScreenCapture49.jpg" length="140182" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/43/ScreenCapture50.jpg" length="122882" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/44/ScreenCapture51.jpg" length="140528" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/45/ScreenCapture52.jpg" length="153208" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/46/ScreenCapture53.jpg" length="97005" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/47/ScreenCapture54.jpg" length="128824" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/48/ScreenCapture55.jpg" length="127723" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7593/49/ScreenCapture56.jpg" length="153973" type="image/jpeg"/></item><item>
<title>re: New Information On Allergan's Pipeline Including Medy-Tox's BTX-A</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7592</link>
<description>re: New Information On Allergan's Pipeline Including Medy-Tox's BTX-A</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7592</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7592">re: New Information On Allergan's Pipeline Including Medy-Tox's BTX-A</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7592">Neurology7592</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/551">Anne-Gaelle BENOIT</a> | 28 May 2014 | 09:41</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">New Information On Allergan's Pipeline Including Medy-Tox's BTX-A</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Subsequent to Allergan's Business Update Call, it has become apparent that Allergan shared a different version of its presentation with some of the buy-side analysts, which included more material on its early stage pipeline.<wbr> Interestingly, the in-licensed Medytox formulation, assumed to be the liquid formulation, is cited as in PhII confirmatory development both for aesthetics and therapeutics (no trials are listed in ClinicalTrials.<wbr>gov).<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7585">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7585" class="commentpermalink">Neurology7585</a> / <span class="date">27 May 2014</span> /
<span class="time">14:24:56 o'clock CEST</span>
</font></div><div>It is interesting to see that the development in Masseter is confirmed in Allergan.<wbr> </div><!-- Comment details --><font size="-1">Anne-Gaelle BENOIT / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7592" class="commentpermalink">Neurology7592</a> / <span class="date">28 May 2014</span> /
<span class="time">09:41:13 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7592">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7585">View thread  Neurology7585: New Information On Allergan's Pipeline Including Medy-Tox's BTX-A</a>]]></content:encoded><dc:date>2014-05-28T09:41:13+02:00</dc:date><dc:creator>anb20624</dc:creator></item><item>
<title>Debiopharm Extends Commercialisation Of Triptorelin Through Agreement With Orient EuroPharma [news, comp:Debiopharm]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9749</link>
<description>Debiopharm Extends Commercialisation Of Triptorelin Through Agreement With Orient EuroPharma [news, comp:Debiopharm]</description><category>news</category><category>comp:Debiopharm</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9749</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9749">Debiopharm Extends Commercialisation Of Triptorelin Through Agreement With Orient EuroPharma</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aDebiopharm"><font color="#e95e0b">:Oncology:comp:Debiopharm</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9749">Oncology9749</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 May 2014 | 18:46</font><br><br><div style="margin-bottom: 10px;">Comment: Orient EuroPharma Co.<wbr> Ltd a specialty pharmaceutical company focused 
on marketing and commercialisation of products across Hong Kong, Malaysia, 
Signapore &amp; Phillipines has announced a distribution agreement for 
Pamorelin®  (triptorelin) with Debiopharm covering South East Asia.<wbr> 
Alongside the agreement, the launch of Pamorelin®  in Signapore has 
been announced today.<wbr> </div><div style="margin-bottom: 10px;">Commenting on the collaboration Thierry Mauverany Dekegate of the board of 
Debiopharm Group stated "The collaborations opens up an important new market for 
our backbone therapy of advanced prostate cancer (locally and metastatic.<wbr> After 
successful launch in 74 countreis, we look forard to bringing Pamorelin®  
to several South East Asian markets.<wbr>together with Orient Europharma.<wbr>" </div><div style="margin-bottom: 10px;"><TABLE width="100%"><TBODY><TR align="left"><TD>
      <DIV class="article_body"><BR>Source: <a href="http://www." class="defaultlink" title="www."></a> debiopharm.<wbr>com<BR></DIV>
      </TD>
</TR>
</TBODY>
</TABLE> </div><div><TABLE width="100%"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9749">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-27T18:46:03+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Takeda Has Initiated A Ph1 Japanese Trial To Evaluate Relugolix In ADT Treatment Naive Prostate Cancer Patients [comp:Takeda, dis:Prostate, class:Hormonals]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9747</link>
<description>Takeda Has Initiated A Ph1 Japanese Trial To Evaluate Relugolix In ADT Treatment Naive Prostate Cancer Patients [comp:Takeda, dis:Prostate, class:Hormonals]</description><category>comp:Takeda</category><category>dis:Prostate</category><category>class:Hormonals</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9747</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9747">Takeda Has Initiated A Ph1 Japanese Trial To Evaluate Relugolix In ADT Treatment Naive Prostate Cancer Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9747">Oncology9747</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 27 May 2014 | 16:35</font><br><br><div style="margin-bottom: 10px;">Comment: Takeda has planned to initiate a Phase 1, open label, multicentre, multiple-dose, placebo-controlled, randomized, single arm assignment study to evaluate the tolerability, safety, PK and efficacy of TAK-385 (relugolix) with androgen deprivation treatment na&iuml;ve nonmetastatic prostate cancer.<wbr> This trial is registered with ClinicalTrials.<wbr>gov (NCT02141659) and approved by Japan Ministry of Health, Labor and Welfare.<wbr> It is currently a Japan only trial.<wbr> </div><div style="margin-bottom: 10px;">The study consists of two parts - Part A is a dose escalation study and Part B will be an expansion phase.<wbr> A total of 30 patients are planned for enrolment in the study.<wbr> </div><div style="margin-bottom: 10px;">Expected Completion Date: 1 July 2017 (Duration planned - 3 years 2 months) </div><div style="margin-bottom: 10px;">Primary Outcome Measures include: </div><div style="margin-bottom: 10px;"><UL><LI>Does-limiting toxicity(DLT): Does resing phase - Up to 48 weeks
</LI>
<LI>Percentage of participants with markedly abnormal advers events - Up to 48 weeks
</LI>
<LI>An Adverse Event (AE) is defined as any untoward medical occurrence in a clinical investigation participant administered a drug
</LI>
<LI>DLT, adverse events, clinical laboratory tests, vital signs, and 12-lead ECGs
</LI>
</UL> </div><div style="margin-bottom: 10px;">Secondary Outcome Measures include: </div><div><UL><LI>Serum prostate-specific antigen (PSA) - Up to 48 weeks
</LI>
<LI>Plasma concentration of TAK-385 - Up to 48 weeks
</LI>
<LI>Serum testosterone concentration - Up to 48 weeks
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9747">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-27T16:35:06+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Another Antibody-Drug Conjugate Candidate - ADCT-401 - Targeting Prostate Specific Membrane Antigen (PSMA) Is Progressed Into Clinical Trial For Prostate Cancer [comp:AstraZeneca, dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9746</link>
<description>Another Antibody-Drug Conjugate Candidate - ADCT-401 - Targeting Prostate Specific Membrane Antigen (PSMA) Is Progressed Into Clinical Trial For Prostate Cancer [comp:AstraZeneca, dis:Prostate]</description><category>comp:AstraZeneca</category><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9746</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9746">Another Antibody-Drug Conjugate Candidate - ADCT-401 - Targeting Prostate Specific Membrane Antigen (PSMA) Is Progressed Into Clinical Trial For Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9746">Oncology9746</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 27 May 2014 | 16:01</font><br><br><div style="margin-bottom: 10px;">Comment: Medimmune has entered into a collaboration agreement with ADC Therapeutics to jointly develop two ADC Development Programmes in Oct 2003.<wbr> ADC Therapeutics, an oncology drug development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, announced that it has selected its first IND candidate under its joint development agreement with MedImmune, the global biologics research and development arm of AstraZeneca.<wbr> <BR><BR>Earlier this year, Progenics Pharmaceuticals presented positive data from their Ph2 trial of PSMA ADC in post-docetaxel setting <a href="http://ci.beaufour-ipsen.com/traction#/single&proj=Oncology&rec=9641" class="defaultlink">(Oncology9641: Progenics Pharmaceuticals Announces the Completion of Enrolment of Chemotherapy Naive Cohort in Phase II Trial of PSMA Antibody Drug Conjugate)</a>.<wbr> ADC Therapeutics and Medimmune announced that their first IND, ADCT-401, is entering clinical trial.<wbr> ADCT-401 targets Prostate-Specific Membrane Antigen (PSMA) a cell-surface antigen specifically expressed by prostate cancer cells based on encouraging pre-clinical data in a number of <EM>in vivo </EM>models for prostate cancer.<wbr> This will be second ADC targeting PSMA entering clinical development in CRPC.<wbr> Note that Roche is also investigating ADC technology in prostate cancer, with a different target strategy - STEAP which is a six-transmembrane epithelial antigen of the prostate and it is overexpressed in prostate cancer.<wbr> </div><div>ADCT-401 comprises an anti-PSMA monoclonal antibody coupled with a pyrrolobenzodiazepine (PBD) warhead using a proprietary linker licensed from London-based Spirogen <a href="http://ci.beaufour-ipsen.com/traction#/single&proj=Oncology&rec=9224" class="defaultlink">(Oncology8224:AstraZeneca to Bolster its Portfolio with a New Type of Cancer Therapy)</a>, a wholly owned subsidiary of MedImmune.<wbr> Initial clinical studies will focus on hormone-refractory prostate cancer and an IND filing is anticipated in 2015.<wbr> This will be ADCT&rsquo;s second ADC program into the clinic from its pipeline of eleven programs with an IND filing expected in the first of these programs by the end of this year.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9746">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-27T16:01:31+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Allergan Fights Back In Advance Of A Potentially Raised Offer From Valeant [comp:Allergan, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7589</link>
<description>Allergan Fights Back In Advance Of A Potentially Raised Offer From Valeant [comp:Allergan, :PharmaWorld:sub:Acquisition]</description><category>comp:Allergan</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7589</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7589">Allergan Fights Back In Advance Of A Potentially Raised Offer From Valeant</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7589">Neurology7589</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 May 2014 | 15:21</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan has just filed a presentation with the SEC, ahead 
of an Investor meeting it has scheduled tomorrow.<wbr> Essentially it 
has retained two nationally-recognized financial consultants and forensic 
accountants, Alvarez &amp; Marsal and FTI Consulting, to evaluate certain 
concerns about the inherent value of Valeant's business model and stock.<wbr> The 
presentation fully outlines the risks.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Background</STRONG> </div><div style="margin-bottom: 10px;">Apparently, Allergan has taken this action in response to feedback from 
numerous Allergan stockholders and analysts.<wbr> Allergan and its legal and 
financial advisors carefully analyzed publicly available data on Valeant and the 
opaque nature of Valeant's pro-forma driven financial reporting.<wbr> </div><div style="margin-bottom: 10px;">The presentation raises a number of important issues about Valeant's business 
model and stock value that Allergan's stockholders need to be aware of.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>What is Valeant's real organic growth?</LI>
<LI>How have its two largest acquisitions performed under Valeant's 
  ownership?</LI>
<LI>Does Valeant have any experience promoting products of Allergan's 
  scale?</LI>
<LI>How stable is Valeant's management team?</LI>
<LI>Can Valeant cut $2.<wbr>7bn of Allergan's expenses without disrupting the 
  performance of the business?</LI>
<LI>What is the relative distribution strength of Allergan vs Valeant in the 
  important emerging markets?</LI>
<LI>Is Valeant's low tax rate sustainable?</LI>
<LI>Are Valeant's accounting practices clearly consistent with others in the 
  industry?</LI>
<LI>Is a business model centered on serial acquisitions and a cost cutting 
  strategy sustainable?</LI>
</UL> </div><div style="margin-bottom: 10px;">Several of the key slides from the presentation are highlighted below with 
the full presentation attached.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3">Source: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A></FONT> </div><div><PRE>    </PRE> </div><!-- Comment details --><a name="neurology7589attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(181,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(146,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(152,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(174,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(148 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(158,8 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(108,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(132,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(189 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(183,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(229,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(171 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/13/investor%2dpresentation%2dmay%2d27%2d2014.pdf">investor-presentation-may-27-2014.pdf</a>&nbsp;&nbsp;(1,2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7589">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-27T15:21:06+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/1/ScreenCapture1.jpg" length="185582" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/2/ScreenCapture2.jpg" length="149604" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/3/ScreenCapture3.jpg" length="155858" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/4/ScreenCapture4.jpg" length="178767" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/5/ScreenCapture5.jpg" length="151507" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/6/ScreenCapture6.jpg" length="162574" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/7/ScreenCapture7.jpg" length="111287" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/8/ScreenCapture8.jpg" length="135273" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/9/ScreenCapture9.jpg" length="193511" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/10/ScreenCapture10.jpg" length="187671" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/11/ScreenCapture11.jpg" length="235229" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/12/ScreenCapture12.jpg" length="175086" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7589/13/investor%2dpresentation%2dmay%2d27%2d2014.pdf" length="1289532" type="application/pdf"/></item><item>
<title>New Information On Allergan's Pipeline Including Medy-Tox's BTX-A [headline, prod:Botox, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7585</link>
<description>New Information On Allergan's Pipeline Including Medy-Tox's BTX-A [headline, prod:Botox, sub:Aesthetics]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7585</comments><category>headline</category><category>prod:Botox</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7585</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7585">New Information On Allergan's Pipeline Including Medy-Tox's BTX-A</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7585">Neurology7585</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 May 2014 | 14:24</font><br><br><div style="margin-bottom: 10px;">Comment: Subsequent to Allergan's Business Update Call, it has become apparent that Allergan shared a different version of its presentation with some of the buy-side analysts, which included more material on its early stage pipeline.<wbr> Interestingly, the in-licensed Medytox formulation, assumed to be the liquid formulation, is cited as in PhII confirmatory development both for aesthetics and therapeutics (no trials are listed in ClinicalTrials.<wbr>gov).<wbr> </div><div style="margin-bottom: 10px;">Other new indications or programmes are highlighted in red and for toxins include:- </div><div style="margin-bottom: 10px;"><STRONG>Aesthetic</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>PhIII Forehead lines
</LI>
<LI>PhII Masseter indication (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7307" class="defaultlink">Neurology7307: Allergan to Test BOTOX® for Bilateral Masseter Muscle Hypertrophy (MMH)</a>)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><BR><STRONG>Therapeutic</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>PhII New indication (unspecified)
</LI>
<LI>Pre-clinical AGN-1867 Migraine
</LI>
<LI>Pre-clinical BTX-X potential for higher dose and or longer duration going into PhI.<wbr> Whilst not newly highlighted the specificity about its status is new.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7585/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Allergan is due to provide a further update to investors tomorrow presumably in response to a revised offer from Valeant.<wbr> </div><div>Source: Leerink Analyst Report May 20th </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7592c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>It is interesting to see that the development in Masseter is confirmed in Allergan.<wbr> </div><font size="-1">Anne-Gaelle BENOIT / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7592" class="commentpermalink">Neurology7592</a> / <span class="date">28 May 2014</span> /
<span class="time">09:41:13 o'clock CEST</span>
</font></div><a name="neurology7585attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7585/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(125,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7585">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-27T14:24:56+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7585/1/ScreenCapture1.jpg" length="128662" type="image/jpeg"/></item><item>
<title>Pfizer Abandons Bid For AstraZeneca [sub:Acquisition, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10878</link>
<description>Pfizer Abandons Bid For AstraZeneca [sub:Acquisition, news]</description><category>sub:Acquisition</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10878</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10878">Pfizer Abandons Bid For AstraZeneca</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10878">PharmaWorld10878</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 27 May 2014 | 10:21</font><br><br><div style="margin-bottom: 10px;">Comment: Late yesterday, Pfizer finally abandoned its pursuit of 
AstraZeneca stating that it "did not intend to make a further offer" after AZ's 
board rejected its most recent offer which it felt was compelling and 
attractively valued AZ's business prospects.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Limitations Now In Place</STRONG> </div><div style="margin-bottom: 10px;">Pfizer cannot propose another offer for the company now for the next six 
months under UK takeover regulations.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>AstraZeneca's  Perspective</STRONG> </div><div style="margin-bottom: 10px;">Following the release of Pfizer's statement, AstraZeneca chairman Leif 
Johansson said "we welcome the opportunity to continue building on the momentum 
we have already demonstrated as an independent company.<wbr>" He further highlighted 
AstraZeneca's "attractive growth prospects and a rapidly progressing pipeline," 
adding that "in the coming months, we anticipate positive news flow across our 
core therapeutic areas, which underpins our confidence in the long-term 
prospects of the business.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG>Implications For AZ</STRONG> </div><div style="margin-bottom: 10px;">AstraZeneca will now be under a lot of pressure to deliver on its pipeline 
hopes having predicted that its 71 drugs in development could generate peak 
sales of as much as $63bn.<wbr> This may, it is predicted, lead to an acceleration of 
partnerships designed to fast-track some of these programmes.<wbr> </div><div>Source: Firstword </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10878">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-27T10:21:43+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Negative Opinion from the CHMP for AB Science's Masitinib in Pancreatic Cancer</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9745</link>
<description>Negative Opinion from the CHMP for AB Science's Masitinib in Pancreatic Cancer</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9745</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9745">Negative Opinion from the CHMP for AB Science's Masitinib in Pancreatic Cancer</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9745">Oncology9745</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 May 2014 | 15:03</font><br><br><div style="margin-bottom: 10px;">Comment: CHMP of the European Medicine Agency has adopted a negative opinion on the conditional marketing authorization for Masiviera (Masitinib mesylate) for the first line treatment of non resectable locally advanced or metastat ic pancreatic cancer.<wbr> This decision is on the appeal filed by the cmpany following a previous negative opinion adopted by the CHMP in January 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Rationale for the Decision</STRONG> </div><div style="margin-bottom: 10px;"><P align="left">The evidences presented in the pain and in the genetic subgroups were very promising, but the benefit was not sufficiently demonstrated since the data were derived from subgroup analysis.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Company's Next Actions</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">AB Science intends to file for marketing authorization with data from the phase 3 confirmatory<BR>study to be initiated in the first line treatment of non resectable locally advanced or metastatic pancreatic<BR>cancer.<wbr></P> </div><div><P align="left"><EM>Source: AB Sciences</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9745">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-23T15:03:48+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>XTANDI Launched in Japan for Castration-Resistant Prostate Cancer [comp:Astellas, prod:MDV3100, :PharmaWorld:mkt:Japan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9743</link>
<description>XTANDI Launched in Japan for Castration-Resistant Prostate Cancer [comp:Astellas, prod:MDV3100, :PharmaWorld:mkt:Japan]</description><category>comp:Astellas</category><category>prod:MDV3100</category><category>mkt:Japan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9743</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9743">XTANDI Launched in Japan for Castration-Resistant Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aJapan"><font color="#e95e0b">:PharmaWorld:mkt:Japan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9743">Oncology9743</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 23 May 2014 | 09:13</font><br><br><div style="margin-bottom: 10px;"><FONT size="2">Comment: In Japan, Astellas' strategy is to maximize the sales of its products and compensate the impact of the generics.<wbr> XTANDI will be part of the the company's uro/<wbr>oncology franchise which includes Harnal, Vesicare, Tarceva, Eligard and Gonax.<wbr> </FONT> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Approval Indication</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="2">The approval of XTANDI in Japan is for post-chemo.<wbr></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2">However, as Japan's subjects have been included in the PREVAIL trial, Astellas is looking to amend the label.<wbr></FONT> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9743/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9743attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9743/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(64,7 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9743">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-23T09:13:07+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9743/1/ScreenCapture1.jpg" length="66293" type="image/jpeg"/></item><item>
<title>BIND Therapeutics-Key Takeaways From The UCB Conference Highlighting The Enhanced Therapeutic Profile That Accurin Nanotechnology Can Confer [:PharmaWorld:sub:DrugDelivery, dis:Prostate, class:Cytotoxics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9740</link>
<description>BIND Therapeutics-Key Takeaways From The UCB Conference Highlighting The Enhanced Therapeutic Profile That Accurin Nanotechnology Can Confer [:PharmaWorld:sub:DrugDelivery, dis:Prostate, class:Cytotoxics]</description><category>sub:DrugDelivery</category><category>dis:Prostate</category><category>class:Cytotoxics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9740</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9740">BIND Therapeutics-Key Takeaways From The UCB Conference Highlighting The Enhanced Therapeutic Profile That Accurin Nanotechnology Can Confer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aCytotoxics"><font color="#e95e0b">:Oncology:class:Cytotoxics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aDrugDelivery"><font color="#e95e0b">:PharmaWorld:sub:DrugDelivery</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9740">Oncology9740</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 22 May 2014 | 18:42</font><br><br><div style="margin-bottom: 10px;">Comment: BIND Therapeutics focused not only on the Accurin technology and how its application results in therapeutics with improved profiles but also some of the key data that has started to emerge with its drug BIND-014 and AstraZeneca's new aurora kinase inhibitor, ongoing development of which had been limited by the drug's low therapeutic index.<wbr> This has now been resolved and the efficacy and safety profile of the drug significantly enhanced.<wbr> Similarly, the docetaxel profile that could emerge in terms of BIND-014's mCRPC activity could be quite different to the drug's current profile.<wbr> </div><div style="margin-bottom: 10px;">Management explained how small molecules traffic throughout the body easily but are often non-specific in terms of their targeting, whilst Accurin technology can confer tissue specificity typically only see with a biologic.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/1/ScreenCapture1.jpg?user-agent=rss">.<wbr> </div><div style="margin-bottom: 10px;">Accurins start with a polymeric backbone and then have a PEG coating to form a hydration shell which is essentially ignored by the body's immune system.<wbr> On the surface are placed targeting ligands e.<wbr>g.<wbr> peptides aptamers and then the therapeutic payload is contained within.<wbr> </div><div style="margin-bottom: 10px;">Accurins use two forms of targeting, biophysical and ligand targeted binding.<wbr> By comparison with ADCs which use a toxin payload of low single digit numbers and require cellualar uptake, Accurin nanoparticles don't require cellular uptake and can deliver high multiples of payload.<wbr> They can also work with a broad range of payloads and ligands and are significantly less costly to produce.<wbr> </div><div style="margin-bottom: 10px;">BIND's first product BIND-014 targets PSMA and inside contains a docetaxel payload.<wbr> Since </div><div style="margin-bottom: 10px;">BIN-014 targetst PSMA and drug inside is docetaxel.<wbr> As the outer shell doesn't acutally bind to docetaxel, registration of such a product can take advantage of the 505 B 2 regulatory route as the particles are essentially viewed as excipients to docetaxel.<wbr> </div><div style="margin-bottom: 10px;">BIND has completed two phase I studies the results of which are shown below </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">These findings have helped to guide the choice of the next phII study the group plans to undertake in bladder, choliangocarcinoma, NET and cervical cancer.<wbr> </div><div style="margin-bottom: 10px;">However, initial studies are being undertaken in NSCL and mCRPC.<wbr> Topline results of which will be known by the year-end.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/8/ScreenCapture8.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Commenting on the profile of BIND-014 vs docetaxel, it was noted that docetaxel is quickly excreted.<wbr> It very quickly reaches peak concn in the tumours and then quickly dissapates.<wbr> </div><div style="margin-bottom: 10px;">BIND-014 by contrast shows a slow sustained release over a longer time period and results in a prolonged response giving a 5-7 fold higher concentration resulting in a higher AUC </div><div style="margin-bottom: 10px;">In a prostate Xenograft model BIND has shown that BIND-014 is active one month after administration and no re-growth is seen, whereas re-growth occurs almost immediately you stop docetaxel therapy.<wbr> </div><div style="margin-bottom: 10px;">The focus of the presentation then turned to the 3 partnerships BIND has announced, all involving situations where the partner has taken the product into clinic seen a promising efficacy signal but a low therapeutic index and has curtailed ongoing development but then sought assistance from BIND to try and overcome this.<wbr> </div><div style="margin-bottom: 10px;">Amgen and Pfiser have not disclosed the drug involved but AZ has and highlighted the results it has seen at the recent AACR meeting with its aurora kinaase inhibitor AZD1152.<wbr> </div><div style="margin-bottom: 10px;">As a class all aruora kinase inhibitors are associated with a high level of bone marrow toxicity </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/13/ScreenCapture13.jpg?user-agent=rss"> </div><div>souce: <A href="http://www.bind.com">www.<wbr>bind.<wbr>com</A> </div><!-- Comment details --><a name="oncology9740attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(145,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(147,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(113,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(153,2 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(139,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(142,7 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(683 B)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(180,8 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(90,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(102,5 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(143,7 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(185,8 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(129,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9740">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-22T18:42:36+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/1/ScreenCapture1.jpg" length="148614" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/2/ScreenCapture2.jpg" length="150816" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/3/ScreenCapture3.jpg" length="116137" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/4/ScreenCapture4.jpg" length="156903" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/5/ScreenCapture5.jpg" length="142550" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/6/ScreenCapture6.jpg" length="146119" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/7/ScreenCapture7.jpg" length="683" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/8/ScreenCapture8.jpg" length="185108" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/9/ScreenCapture9.jpg" length="92771" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/10/ScreenCapture10.jpg" length="104965" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/11/ScreenCapture11.jpg" length="147188" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/12/ScreenCapture12.jpg" length="190208" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9740/13/ScreenCapture13.jpg" length="132393" type="image/jpeg"/></item><item>
<title>re: Nymox Reports Top-Line Results From Localised Prostate Cancer Study</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9739</link>
<description>re: Nymox Reports Top-Line Results From Localised Prostate Cancer Study</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9739</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9739</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9739">re: Nymox Reports Top-Line Results From Localised Prostate Cancer Study</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9739">Oncology9739</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 22 May 2014 | 17:37</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Nymox Reports Top-Line Results From Localised Prostate Cancer Study</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font><br><span style="font-size: 12px;">Comment T<FONT face="Arial" size="2"><FONT face="Arial" size="2">op-line results from the Nymox's 146 patient NX03-0040 Phase 2 U.<wbr>S.<wbr> prostate cancer study indicate an overall benefit in terms of reduced progression in patients with low grade localized (T1c) prostate cancer treated with a single injection of NX-1207.<wbr> However, results have been overshadowed because of the high percentage of false negative biopsies in the untreated group which meant that the study overall was unable to achieve its main goal of showing a higher number of patients with undetectable PCa after 45 days of treatment.<wbr>  Nymox is actively pursuing potential partnerships with pharmaceutical companies for US and global marketing agreements for this indication.<wbr></FONT></FONT></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9670">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9670" class="commentpermalink">Oncology9670</a> / <span class="date">01 May 2014</span> /
<span class="time">13:05:06 o'clock CEST</span>
</font></div><div>Comment: Nymox Pharmaceutical Corporation reported new positive data confirming the advantageous side effect profile of the Company's lead compound NX-1207.<wbr> Results from the Brief Male Sexual Function Questionnaire (BMSF) in the Company's recently completed NX03-0040 trial of NX-1207 2.<wbr>5 mg and 15 mg for the treatment of low grade localized prostate cancer indicate that targeted treatment with NX-1207 at either dose had no significant effect on reported sexual function score post-treatment.<wbr> Current approved drugs for prostate enlargement (BPH or benign prostatic hyperplasia) can produce significant sexual side effects such as impotence, decreased libido, ejaculation disorders, and male breast enlargement.<wbr> NX-1207 has been shown not to have these sexual drawbacks in results to date.<wbr> As well, certain of the approved BPH drugs, including the combination drug therapies, are also associated with an increased risk of high-grade prostate cancer.<wbr> By contrast, the area of the prostate targeted with NX-1207 treatment showed less prostate cancer progression with less radiation and surgery due to cancer progression as compared to controls in the recent NX03-0040 trial.<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9739" class="commentpermalink">Oncology9739</a> / <span class="date">22 May 2014</span> /
<span class="time">17:37:49 o'clock CEST</span>
</font><br><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9941c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: Nymox Pharmaceutical Corporation announced on 10th Sept their new positive outcome results for their prostate cancer Ph2 US trial.<wbr> The new findings extend the previously reported study results which showed that patients with NX-1207 treatment after 2 months had less clinical progression and significantly less Gleason grade progression, lower average PSA levels, lower numbers of biopsy cores showing greater malignancy, and lower total volume of more malignant cancer compared to controls.<wbr> NX-1207 is now in Phase 3 development in the US and Europe for benign prostatic hyperplasia (BPH).<wbr> </div><div style="margin-bottom: 10px;">146 patients were enrolled in the NX03-0040 Phase 2 U.<wbr>S.<wbr> trial and either randomized to one of two doses of NX-1207 (2.<wbr>5 mg or 15 mg) or to active surveillance.<wbr> The drug was injected into the area of the prostate where the cancer was detected and repeat biopsies were then performed on all patients, drug treated and controls.<wbr> The patients in the active surveillance group in the study who were eligible could elect crossover drug treatment after their first follow-up rebiopsy.<wbr> Follow-up studies are being conducted of all consenting patients in the study to continue to monitor outcome and safety data.<wbr> </div><div style="margin-bottom: 10px;">To date, NX-1207 has had an excellent safety profile as both a treatment for benign prostatic hyperplasia (BPH) and localized low-risk prostate cancer.<wbr> In the current trial, a new high dose of drug (15 mg) was safely used without drug-related adverse effects.<wbr> NX-1207 has shown safety in repeat injection studies (NX02-0020 and NX02-0022).<wbr> The drug does not lead to immune responses such as antibody formation which can cause significant drug toxicity and/<wbr>or limit usage to single treatments due to drug neutralizing effects.<wbr> </div><div>Clinical outcomes were determined at 8 months from the initial treatments.<wbr> A controlled comparison was conducted of patients who required and received radiation and surgery treatments for their cancer based on blinded post-treatment upgraded evaluations of their pre-treatment initially positive lower grade cancers.<wbr> The study found after 8 months for NX-1207 single-injection treated patients that there was a statistically significant reduction compared to controls of more than 75% (p=.<wbr>002) in the proportion of patients who had upgraded blinded biopsy and laboratory results and went on to require and receive radiation therapy and/<wbr>or surgery.<wbr> The new results also indicated that the NX-1207 treated patients had 67% less progression to surgery and/<wbr>or radiotherapy compared to controls (p=.<wbr>008) for all reasons (including elective surgery and/<wbr>or radiotherapy with no biopsy or laboratory upgrades).<wbr> </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9941" class="commentpermalink">Oncology9941</a> / <span class="date">11 September 2014</span> /
<span class="time">11:14:18 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9739">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9670">View thread  Oncology9670: Nymox Reports Top-Line Results From Localised Prostate Cancer Study</a>]]></content:encoded><dc:date>2014-05-22T17:37:49+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>SOTIO Announced First Patient Enrolled in its Ph3 VIABLE Study for DCVAC/PCa in Combination With Chemotherapy [dis:Prostate, class:Vaccines]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9737</link>
<description>SOTIO Announced First Patient Enrolled in its Ph3 VIABLE Study for DCVAC/PCa in Combination With Chemotherapy [dis:Prostate, class:Vaccines]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9737</comments><category>dis:Prostate</category><category>class:Vaccines</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9737</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9737">SOTIO Announced First Patient Enrolled in its Ph3 VIABLE Study for DCVAC/<wbr>PCa in Combination With Chemotherapy</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9737">Oncology9737</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 22 May 2014 | 17:34</font><br><br><div style="margin-bottom: 10px;">Comment: DCVAC/<wbr>PC is an active cellular immunotherapy treatment for prostate cancer patients.<wbr> VIABLE is a randomized, double blind, multicenter, parallel-group, Phase III study to evaluate the efficacy and safety of DCVAC/<wbr>PCa as an add-on therapy to 1st line standard of care chemotherapy in men with metastatic Castration Resistant Prostate Cancer (mCRPC), which is based on overall survival (OS) in mCRPC patients treated with DCVAC/<wbr>PCa versus placebo with standard of care chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">SP005 VIABLE (Eudra CT: 2012-002814-38; IND: 015255): A Randomized, Double Blind, Multicenter, Parallel-Group, Phase III Study to Evaluate Efficacy and Safety of DCVAC/<wbr>PCa Versus Placebo in Men with Metastatic Castration Resistant Prostate Cancer Eligible for 1st Line Chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">The first patient was enrolled into the study in Hungarian Army Medical Center (Magyar Honv&eacute;ds&eacute;g Eg&eacute;szs&eacute;g&uuml;gyi K&ouml;zpont), Department of Oncology.<wbr> The VIABLE study will recruit patients through cooperation with medical centers in 20 countries: Belgium, Bulgaria, Croatia, the Czech Republic, France, Germany, Hungary, Italy, the Netherlands, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Spain, Sweden, Turkey, the United Kingdom and the United States.<wbr> The initiations of individual countries have already started and the first patients will be enrolled in the coming weeks.<wbr> SOTIO&rsquo;s aim is to enroll a total of about 1,170 prostate cancer patients in the study from Europe, Russia and the United States.<wbr> </div><div style="margin-bottom: 10px;">It is a combined chemo-immunotherapy clinical trial that explores the combination of standard care chemotherapy and dendritic cell based immunotherapy treatment with DCVAC/<wbr>PCa.<wbr> Dendritic cells are separated from patients&rsquo; monocytes and introduced to a prostate cancer cell line killed by high hydrostatic pressure.<wbr> While the chemotherapy treatment decreases tumor cell load, the cancer immunotherapy treatment with DCVAC/<wbr>PCa may induce an immune response directed against multiple tumor antigens and therefore control the growth of tumor cells.<wbr> The VIABLE study will thus test the hypothesis that the combination of two treatment modalities synergizes and leads to the prolonged survival of treated patients.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">SOTIO is the first company from the CEE region to initiate a Phase III clinical trial in the area of cellular immunotherapy.<wbr> This milestone is due to all the hard work and the cooperation of Charles University and University Hospital in Motol in Prague as well as many years of research by a dedicated group of scientists and we are now focused on delivering the results of the trial in our efforts to further the treatment of prostate cancer on a global scale.<wbr>&rdquo; </div><div>Source: <A href="http://www.sotio.com/">http:/<wbr>/<wbr>www.<wbr>sotio.<wbr>com/<wbr>,</A>  <A href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.viablestudy.com&amp;esheet=50987104&amp;newsitemid=20141119005224&amp;lan=en-US&amp;anchor=www.viablestudy.com&amp;index=1&amp;md5=dcbeed9dff81d4c45336c4677fcab7a9" id="yui_3_16_0_1_1416476271551_1602" rel="nofollow"><STRONG id="yui_3_16_0_1_1416476271551_1601"><U><FONT color="#0066cc">www.<wbr>viablestudy.<wbr>com</FONT></U></STRONG></A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10117c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>Comment: Ph3 VIABLE study for DCVAC/<wbr>PCa (a cellular immunotherapy) is enrolling the first US patient and the total target recruitment in US is 250 patients.<wbr> (Source: Satio Company Press Release) </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10117" class="commentpermalink">Oncology10117</a> / <span class="date">20 November 2014</span> /
<span class="time">10:46:06 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9737">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-22T17:34:21+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>FTIM Study of AZD5312 for Patients with Androgen Receptor Tumours [comp:AstraZeneca, dis:Prostate, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9736</link>
<description>FTIM Study of AZD5312 for Patients with Androgen Receptor Tumours [comp:AstraZeneca, dis:Prostate, headline]</description><category>comp:AstraZeneca</category><category>dis:Prostate</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9736</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9736">FTIM Study of AZD5312 for Patients with Androgen Receptor Tumours</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9736">Oncology9736</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 May 2014 | 17:06</font><br><br><div style="margin-bottom: 10px;">Comment: AZD5312 is an<A href="http:///search?q=Antisense" style="FONT-WEIGHT: bold; TEXT-DECORATION: none"> </A>antisense drug designed to treat patients with<A href="http:///search?q=Prostate+Cancer" style="FONT-WEIGHT: bold; TEXT-DECORATION: none"> </A>prostate cancer by inhibiting the production of the androgen receptor (AR).<wbr> Because the drug can inhibit the production of all known forms of AR, including variants of the AR gene, AstraZeneca believes that the drug could be an effective treatment for all stages of prostate cancer, including in patients resistant to current therapies that largely involve countering androgens by blocking ARs or removing circulating androgens.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Design</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Objective</U>: Ph1study to determine the Maximum Tolerated Dose, Recommended Ph2 dose, safety, tolerability and Pharmacokinetics of AZD5312 </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: Approximately 90 patients </div><div style="margin-bottom: 10px;"><U>Timelines</U> </div><div style="margin-bottom: 10px;"><U>Start date</U>: May 2014 - Completion dates: May 2016 </div><div style="margin-bottom: 10px;"><U>Location</U>: USA; UK </div><div style="margin-bottom: 10px;">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02144051?cond=spasticity+OR+prostate+OR+botulinum+OR+acromegaly+OR+neuroendocrine+OR+growth+hormone+deficiency+OR+huntington&amp;fund=2&amp;rcv_s=04%2F22%2F2014&amp;rank=21">NCT02144051</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Alliance with Isis Pharm</FONT></STRONG> </div><div style="margin-bottom: 10px;">In 2012, Isis entered into a collaboration with AstraZeneca to discover and develop antisense drugs to treat cancer.<wbr> </div><div style="margin-bottom: 10px;">On June 3, 2013 Isis announced that AstraZeneca has added a second development candidate, ISIS-ARRx (AZD5312), to its collaboration with Isis.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>the drug designed to treat patients with prostate cancer by inhibiting the production of the androgen receptor (AR).<wbr> AstraZeneca is planning to develop ISIS-ARRx broadly to treat patients under a variety of settings during the course of prostate cancer treatment, including both as a single agent and in combination therapy.<wbr></P></BLOCKQUOTE> </div><div>Source: AstraZeneca; Isis Pharm.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9736">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-22T17:06:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Servier And Novartis Ink Global Oncology Deal [comp:Novartis, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9734</link>
<description>Servier And Novartis Ink Global Oncology Deal [comp:Novartis, news]</description><category>comp:Novartis</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9734</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9734">Servier And Novartis Ink Global Oncology Deal</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Oncology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9734">Oncology9734</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 22 May 2014 | 10:56</font><br><br><div style="margin-bottom: 10px;">Comment: The objective of the strategic collaborative agreement is to develop and commercialize a series of novel drugs candidates issued from the Servier research programs partnered with Vernalis in oncology which are targeting the apoptosis regulation pathways.<wbr> The collaboration covers the worldwide co-development of BCL-2 selective inhibitor candidates that are now entering into clinical development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Terms of the Transaction</STRONG> </div><div style="margin-bottom: 10px;">- Financial terms: not disclosed </div><div style="margin-bottom: 10px;">- Servier will remain responsible for research activities and will share responsibilities with Novartis to conduct a clinical development program aimed at moving swiftly to a first indication for the benefit of patients.<wbr> </div><div style="margin-bottom: 10px;">- Commercialization rights to products arising from the collaboration will be allocated between the parties on a geographic basis.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Collaboration Vernalis /<wbr> Servier</STRONG> </div><div style="margin-bottom: 10px;">Vernalis first collaboration with Servier started in 2007.<wbr> </div><div style="margin-bottom: 10px;">The most advanced programme from this collaboration entered pre-clinical testing in September 2012.<wbr>Vernalis will continue to receive fees as well as research and clinical milestones on these collaboration programmes as they progress, together with a potential share in the downstream success of these programmes through royalties.<wbr> </div><div>Source: Vernalis; Servier </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9734">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-22T10:56:20+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Altor Biosciences to Evaluate Drug Candidate for BCG-naive NMIB Cancer</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9733</link>
<description>Altor Biosciences to Evaluate Drug Candidate for BCG-naive NMIB Cancer</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9733</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9733">Altor Biosciences to Evaluate Drug Candidate for BCG-naive NMIB Cancer</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9733">Oncology9733</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 May 2014 | 18:04</font><br><br><div style="margin-bottom: 10px;">Comment: As a leading developer of an IL-15-based platform, Altor has created the proprietary IL-15 superagonist complex, ALT-803, with increased ability to bind IL-2R&beta;&gamma; and enhanced immunostimulatory activity compared to IL-15.<wbr> For the purpose of this Ph1b/<wbr>2 trial, BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;"><SPAN style="text-decoration: underline;">The purpose</SPAN> of this study is to evaluate the safety, identify the Maximum Tolerated Dose (MTD) of ALT-803 and determine the Recommended Dose (RD) level of ALT-803 combined with BCG in patients who have BCG-naive nonmuscle invasive bladder cancer.<wbr> The anti-tumor activity of BCG+ALT-803 will also be assessed.<wbr> In addition, the study will characterize the molecular, immunogenicity and pharmacokinetic profile of BCG+ALT-803.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;"><SPAN style="text-decoration: underline;">Protocol</SPAN> The study includes a dose escalation phase (Ph1b) and a dose expansion phase (Ph2).<wbr> The dose escalation phase is concluded when the MTD is determined.<wbr> A dose level (RD) will be designated for the expansion phase of the study.<wbr> The expansion phase consists of a noncomparative randomized design of patients receiving ALT-803 at the RD level in combination with BCG or BCG alone</P> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;">Recruitment: 18</P> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;"><SPAN style="text-decoration: underline;">Timelines</SPAN> Start date May 2014 - Completion date: May 2018 /<wbr> August 2018</P> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;">Source: <a href="https://clinicaltrials.gov/ct2/show/NCT02138734?recr=Open&no_unk=Y&phase=012&fund=2&rcv_s=04%2F21%2F2014&rank=8" class="defaultlink">NCT02138734</a></P> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0ex; margin-bottom: 1ex;"><STRONG>Ongoing Clinical Programs</STRONG></P> </div><div><P style="margin-top: 0ex; margin-bottom: 1ex;">Altor chose to focus the first Phase I/<wbr>II clinical trial on metastatic melanoma based upon a solid foundation in this disease for various immunotherapies in preclinical and clinical settings.<wbr> A Phase I/<wbr>II trial is currently underway to evaluate ALT-803 in patients with metastatic melanoma.<wbr></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9733">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-21T18:04:49+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>New Ultrasound Contrast Agent in the Assessment of Prostate Cancer [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, sub:Diagnostic]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9732</link>
<description>New Ultrasound Contrast Agent in the Assessment of Prostate Cancer [dis:Prostate, :PharmaWorld:sub:ClinicalTrial, sub:Diagnostic]</description><category>dis:Prostate</category><category>sub:ClinicalTrial</category><category>sub:Diagnostic</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9732</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9732">New Ultrasound Contrast Agent in the Assessment of Prostate Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=sub%3aDiagnostic"><font color="#e95e0b">:Oncology:sub:Diagnostic</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9732">Oncology9732</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 May 2014 | 17:49</font><br><br><div style="margin-bottom: 10px;">Comment: Bracco Diagnostics, the sponsor of the trial is the U.<wbr>S.<wbr>-based subsidiary of Bracco Imaging SpA.<wbr> The company develops and markets imaging agents for use in X-ray/<wbr>Computed Tomography (CT), Nuclear Medicine and Magnetic Resonance Imaging (MRI) in the U.<wbr>S.<wbr> and Canada.<wbr> The Ph1/<wbr>2 pilot trial will evaluate the sensitivity and specificity of BR55 targeting for prostate cancer nodules with Gleason score greater than or equal to 7.<wbr> PE to measure the sensitivity and specificity of BR55.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Trial Details</STRONG> </div><div style="margin-bottom: 10px;">Principal Investigator: Juergen Willmann M.<wbr>D Stanford U.<wbr> </div><div style="margin-bottom: 10px;">Recruitment: approx 21 </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="margin-top: 0.7ex;">Male, age between 50-70 years old
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Increased PSA level &gt;4 ng/<wbr>mL
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Known prostate cancer
</LI>
<LI class="color-bullet" style="margin-top: 0.7ex;">Scheduled for prostatectomy not earlier than 3 days and not later than 30 days following BR55 administration (with the exception of training cases where this requirement is not applicable)
</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines: start planned next month Completion date in February 2015 </div><div style="margin-bottom: 10px;">Location: USA </div><div style="margin-bottom: 10px;">Source: <a href="https://clinicaltrials.gov/ct2/show/NCT02142608?recr=Open&no_unk=Y&phase=012&fund=2&rcv_s=04%2F21%2F2014&rank=4" class="defaultlink">NCT02142608</a> </div><div style="margin-bottom: 10px;"><STRONG>Bracco's R&amp;D Strategy</STRONG> </div><div style="margin-bottom: 10px;">Bracco Imaging is focusing its efforts in some specific R&amp;D areas: </div><div><UL><LI>Cardiovascular disease: identification of patients at risk due to the presence of unstable plaque and ability to monitor response to treatment;
</LI>
<LI>Oncology: targeted agents to visualize and characterize angiogenesis in order to identify and monitor patients responding to novel anti-angiogenic therapies;
</LI>
<LI>Degenerative diseases: agents able to visualize and characterize disease progression to enable the doctor to monitor response to treatment
</LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9732">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-21T17:49:35+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>re: Progress With New Prostate Cancer Tests</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9731</link>
<description>re: Progress With New Prostate Cancer Tests</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9731</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9731">re: Progress With New Prostate Cancer Tests</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9731">Oncology9731</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 21 May 2014 | 17:25</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Progress With New Prostate Cancer Tests</span>&nbsp;<br><span style="font-size: 12px;">Comment: New data from Myriad's Prolaris test  demonstrates that the test can predict the risk of cancer recccurence following radical prostatectomy.<wbr> Meanwhile, scientists at Cambridge Universtiy have demonstrated that a test assessing the level of a protein NAALADL2 can  correctly distinguish aggressive prostate tumours.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9476">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9476" class="commentpermalink">Oncology9476</a> / <span class="date">24 February 2014</span> /
<span class="time">18:33:52 o'clock CET</span>
</font></div><div style="margin-bottom: 10px;">Commmet: Myriad Genetics Inc presneted new data from a clinical validation study of Prolaris at the AUA 2014 in Orlando on 20th May 2014.<wbr> Tis study is the largest validation study to date of any gene based prognostic test in patients with prostate cancer who were diagnosed by needle biopsy.<wbr> Prolaris test can accurately differentiate newly diagnosed patients who were likely to die from prostate cancer within 10 years from thos with lower risk disease.<wbr> This is thought to be a much stronger indicator of clinical outcomes than Gleason score or PSA.<wbr> A quote from the study investigator " <EM>currently, with standard clinical tools like Gleason Score or PSA, we can't adequately define prognosis.<wbr> The Prolaris test provides useful new information and is highly prognostic or disease specific death among men being conservatively treated</EM>.<wbr>" </div><div>The objective of the study was to validate the test score in 761 conservatively managed prostate cancer pateints diagnosed by needle biopsy.<wbr> The primary end point was prostate cancer death and the median follow up time was 9.<wbr>5 years.<wbr> The resutls showed that for each one unit increase in the PRolaris score, patients had approximately double the risk of dying from prostate cancer.<wbr>In the second study featured in AUA, 230 men who had pathologic Gleason Scores of either 3+4 or 4+3 were examined.<wbr> The Prolaris test signifcanlty outperformed the current practice of upgrading to Gleaseon 3+4 or 43 in predicting which patients would experience biochemical recurrence after a radical prostatectomy.<wbr> This finding should lead to improved initial decisions on the most effective treatment for each patient based on the patient's own riskk of disease progression.<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9731" class="commentpermalink">Oncology9731</a> / <span class="date">21 May 2014</span> /
<span class="time">17:25:26 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9731">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9476">View thread  Oncology9476: Progress With New Prostate Cancer Tests</a>]]></content:encoded><dc:date>2014-05-21T17:25:26+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>New AUA CRPC Therapeutic Guidelines [dis:Prostate]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9730</link>
<description>New AUA CRPC Therapeutic Guidelines [dis:Prostate]</description><category>dis:Prostate</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9730</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9730">New AUA CRPC Therapeutic Guidelines</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9730">Oncology9730</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 21 May 2014 | 15:45</font><br><br><div style="margin-bottom: 10px;">Commnet: The American Urological Association (AUA) as part of its recent 
meeting has announced three updates to the organization’s guideline on the 
management of castration-resistant prostate cancer (CRPC).<wbr> All the 
modifications are specific to the potential uses of radium-223 in men 
with late stage metastatic disease.<wbr> </div><div style="margin-bottom: 10px;">The three updates are as follows: </div><div style="margin-bottom: 10px;"><UL><LI>Clinicians<EM><STRONG> should</STRONG></EM> offer radium-223 to patients 
  with symptomatic, metastatic CRPC (mCRPC) with good performance status and no 
  prior docetaxel chemotherapy with symptomatic bone metastases and without 
  known visceral disease<EM> (Standard; Evidence Level Grade B).<wbr></EM> </LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Clinicians <EM><STRONG>may</STRONG></EM> offer radium-223 to patients with 
  symptomatic mCRPC with poor performance status and no prior docetaxel 
  chemotherapy with symptomatic bone metastases and without known visceral 
  disease in select casts, specifically when the performance status is directly 
  related to symptoms related to bone metastases<EM> (Expert Opinion).<wbr></EM> 
</LI>
</UL> </div><div><UL><LI>Clinicians <EM><STRONG>should</STRONG></EM> offer radium-223 to patients 
  with good performance status who received prior docetaxel chemotherapy with 
  symptomatic bone metastases and without known visceral disease<EM> (Standard; 
  Evidence Level Grade B).<wbr></EM> </LI>
</UL> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9730">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-21T15:45:41+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Celgene and ADDi Ink License Agreement for Nanotechnology-Based Approach for Bladder Cancer [dis:Bladder, :PharmaWorld:sub:ClinicalTrial, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9729</link>
<description>Celgene and ADDi Ink License Agreement for Nanotechnology-Based Approach for Bladder Cancer [dis:Bladder, :PharmaWorld:sub:ClinicalTrial, news]</description><category>dis:Bladder</category><category>sub:ClinicalTrial</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9729</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9729">Celgene and ADDi Ink License Agreement for Nanotechnology-Based Approach for Bladder Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9729">Oncology9729</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 21 May 2014 | 11:41</font><br><br><div style="margin-bottom: 10px;">Comment: AADi, a clinical stage biopharma company focused on diseases uniquely suited for nanotechnology approaches, has in-licensed ABI-009 from Celgene.<wbr> The drug candidate is the nanoparticle albumin-bound (nab®) version of the mTOR inhibitor sirolimus or rapamycin.<wbr> AADi is currently raising capital in an initial round and plans to seek additional financing to fund its research programs through the end of ph 2 clinical studies.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ongoing Trial in NMIBC</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>status</U>: enrollment of the first three patients in the new multi-center phase 1/<wbr>2 clinical trial for the treatment of non-muscle invasive bladder cancer.<wbr> </div><div style="margin-bottom: 10px;"><U>collaboration</U>: trial is funded in-part through a Fast-Track STTR grant awarded to AADi from the National Cancer Institute of the National Institutes of Health.<wbr> </div><div style="margin-bottom: 10px;">Columbia University, with its expertise in bladder cancer, is a consortium partner for AADi as part of the awarded grant and will be the primary clinical trial site.<wbr>  Vanderbilt University will also be involved in the clinical trial.<wbr> </div><div style="margin-bottom: 10px;"><U>rationale</U>: strong scientific and biological rationale for the use of ABI-009 in bladder cancer where the mTOR activation plays a key role in progression of the disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Terms of the Transaction</FONT></STRONG> </div><div style="margin-bottom: 10px;">As part of the licensing agreement, AADi plans to develop ABI-009 initially in oncology and cardiovascular indications.<wbr> A phase 1 trial for ABI-009 has been completed in patients with advanced non-hematologic malignancies in which the drug was well tolerated with evidence of activity in heavily pretreated patients.<wbr> </div><div style="margin-bottom: 10px;">Celgene has the option to reacquire ABI-009 at various stages in development.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About AADi</FONT></STRONG> </div><div style="margin-bottom: 10px;">led by Dr.<wbr> Neil Desai, an inventor of ABRAXANE® and the nab® technology platform.<wbr> </div><div>AADi aims to develop the full potential of the albumin-bound mTOR inhibitor in diseases where the mTOR inhibitors have not or cannot be effectively exploited due to problems of effective drug delivery, safety or effective targeting to the disease site.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9729">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-21T11:41:17+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Combination of CK2 Inhibitor with Gemcitabine/Cisplatin to Enter Ph1/2 for Cholangiocarcinoma</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7688</link>
<description>Combination of CK2 Inhibitor with Gemcitabine/Cisplatin to Enter Ph1/2 for Cholangiocarcinoma</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7688</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7688">Combination of CK2 Inhibitor with Gemcitabine/<wbr>Cisplatin to Enter Ph1/<wbr>2 for Cholangiocarcinoma</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7688">Endocrinology7688</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 May 2014 | 17:50</font><br><br><div style="margin-bottom: 10px;">Comment: Senhwa Biosciences aims to develop innovative drugs through POC.<wbr> This study considers the safety and tolerability of increasing doses of CX-4945 in combination with gemcitabine plus cisplatin to determine the maximum tolerated dose (MTD), followed by a randomized study that compares antitumor activity in cholangiocarcinoma patients receiving the standard of care gemcitabine plus cisplatin versus CX-4945 at the combination MTD with gemcitabine plus cisplatin.<wbr> PE will evaluate MTD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Trial</FONT></STRONG> </div><div style="margin-bottom: 10px;">Recruitment approx.<wbr> 100 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Presence of an unresectable liver mass consistent with cholangiocarcinoma, for which treatment with gemcitabine plus cisplatin is intended.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">For patients enrolled in the Dose Escalation Phase, one or more tumors measurable on radiograph or CT scan, or evaluable disease defined as non-measurable lesions per RECIST v.<wbr> 1.<wbr>1 (e.<wbr>g.<wbr>, malignant ascites).<wbr> All patients enrolled to the Randomized Study Phase must have measurable disease only.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
Laboratory data as specified below:
<UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Hematology: Absolute neutrophil count (ANC) &gt;1,500 cells/<wbr>mm3, platelet count &gt;100,000 cells/<wbr> mm.<wbr>cu.<wbr> and hemoglobin &gt; 9 g/<wbr>dL</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Hepatic: bilirubin &lt;1.<wbr>5 X Upper Limit of Normal (ULN); alkaline phosphatase (ALP), alanine aminotransferase (ALT) or aspartate aminotransferase (AST) &lt; 5.<wbr>0 X ULN</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Renal: serum creatinine within normal limits (WNL), defined as within 25% of the institution's stated reference range, or a calculated creatinine clearance &gt;45 mL/<wbr>min/<wbr>1.<wbr>73 m.<wbr> sq.<wbr> for patients with abnormal, increased, creatinine levels.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Coagulation: International Normalized Ratio (INR) &lt; 1.<wbr>5 times normal, activated Partial Thromboplastin Time (aPTT) &lt; 1.<wbr>5 times normal.<wbr> Patients receiving therapeutic doses of anticoagulant therapy may be considered eligible for the trial if INR and aPTT are within the acceptable therapeutic limits for the institution.<wbr></LI>
</UL></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Estimated life expectancy of at least 3 months.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Eastern Cooperative Oncology Group (ECOG) Performance Status 0 - 1.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex"><STRONG>Timelines</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Start date May 2014 - Completion dates: June 2016 /<wbr> Dec 2016</P> </div><div style="margin-bottom: 10px;"><STRONG>Locations</STRONG> USA </div><div style="margin-bottom: 10px;">Source <A href="http://clinicaltrials.gov/ct2/show/NCT02128282?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=04%2F20%2F2014&amp;rank=259">NCT02128282</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Drug</FONT></STRONG> </div><div style="margin-bottom: 10px;"><B>CX-4945</B> has demonstrated favorable safety, pharmacokinetic characteristics and pharmacodynamic responses in Ph1.<wbr> Clinical observations show that CX-4945 hits the CK2 target and modulates the expected pathways without displaying toxicity.<wbr> The monitoring of circulating tumor cells demonstrates the ability of CX-4945 to kill cancer cells in patients with solid tumors.<wbr> CX-4945 achieved clinical benefit as a single agent CK2 inhibitor, demonstrating stable disease and extended duration on treatment in a several patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Company</FONT></STRONG> </div><div><A href="http://www.senhwabiosciences.com/company/">http:/<wbr>/<wbr>www.<wbr>senhwabiosciences.<wbr>com/<wbr>company/<wbr></A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7688">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-20T17:50:32+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Dr Falk to Start Registration Trial of Phosphatidylcholine for UC [dis:IBD, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1974</link>
<description>Dr Falk to Start Registration Trial of Phosphatidylcholine for UC [dis:IBD, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:IBD</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1974</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1974">Dr Falk to Start Registration Trial of Phosphatidylcholine for UC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=GastroEnterology&sdate=20140831&edate=20140501&cat=dis%3aIBD"><font color="#e95e0b">:GastroEnterology:dis:IBD</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/GastroEnterology1974">GastroEnterology1974</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 20 May 2014 | 16:50</font><br><br><div style="margin-bottom: 10px;">Comment: Two years ago the company acquired the EU rights of the drug from Lipid Therapeutics.<wbr> LT-02 is a delayed release formulation of phosphatidylcholine designed to improve the barier function of the mucosal layer of the colon.<wbr> PE will assess rate of clinical remission.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>PI</STRONG>: Alex Dignass, MD </div><div style="margin-bottom: 10px;"><STRONG>Title</STRONG>: PROTECT-1 Randomized, Double-blind, Double-dummy, Placebo-controlled, Phase III Clinical Trial on the Efficacy and Safety of a 12-weeks add-on Treatment With LT 02 vs.<wbr> Placebo in Patients With Ulcerative Colitis Refractory to Standard Treatment With Mesalamine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG> approx 762 </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Established diagnosis of ulcerative colitis</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Active ulcerative colitis disease extent ≥ 15 cm</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Active disease despite treatment with mesalamine</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines</STRONG> </div><div style="margin-bottom: 10px;">Start date June 2014 - Completion dates: Sept 2016 /<wbr> December 2016 </div><div style="margin-bottom: 10px;"><STRONG>Location</STRONG>: Germany </div><div style="margin-bottom: 10px;">Source <A href="http://clinicaltrials.gov/ct2/show/NCT02142725?recr=Open&amp;no_unk=Y&amp;fund=2&amp;rcv_s=04%2F20%2F2014&amp;rank=97">NCT02142725</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Synchronized Global Ph3 in US and EU</FONT></STRONG> </div><div style="margin-bottom: 10px;">The Ph3 trials in the US and Europe will be conducted as part of a synchronized global pivotal plan.<wbr> </div><div style="margin-bottom: 10px;">Lipid Therapeutics intends to conduct the US portion of the program with a partner, in parallel with the trials to be conducted in Europe by Lipid Therapeutics’ European licensee for LT-02, Dr.<wbr> Falk Pharma GmbH.<wbr> </div><div style="margin-bottom: 10px;">The combined clinical program will involve over 700 patients in each of two induction studies, with the objective of achieving remission based on the primary endpoint of reducing the patient’s Mayo Score.<wbr> The two induction trials will be followed by a single global maintenance trial.<wbr> </div><div style="margin-bottom: 10px;">In the planned global Ph3 program LT-02 will be tested as add-on therapy to mesalazine.<wbr> This is a significant area of high unmet medical need as approximately 40% of patients receiving the maximum dose of mesalazine, the standard 1st line therapy for ulcerative colitis, continue to experience flares of disease activity and therefore require additional treatment.<wbr> </div><div><EM>Source: Lipid Therapeutics</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=GastroEnterology&sdate=20140831&edate=20140501&rec=1974">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-20T16:50:26+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Immunomedics Reports Positive Data With Its Radiopharmaceutical In Metastatic Pancreatic Cancer [class:MonoclonalAntibody, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9728</link>
<description>Immunomedics Reports Positive Data With Its Radiopharmaceutical In Metastatic Pancreatic Cancer [class:MonoclonalAntibody, news]</description><category>class:MonoclonalAntibody</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9728</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9728">Immunomedics Reports Positive Data With Its Radiopharmaceutical In Metastatic Pancreatic Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9728">Oncology9728</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 20 May 2014 | 12:00</font><br><br><div style="margin-bottom: 10px;">Comment: Immunomedics has reported an increased survival advantage with 
patients receiving multiple cycles of its radiopharmaceutical 90Y-clivatuzumab 
tetraxetan in an early stage trial in patients with metastatic 
pancreatic cancer.<wbr> The data has been selected for presentation by the AACR for a 
special press conference on pancreatic cancer that will occur 
today.<wbr> </div><div style="margin-bottom: 10px;">Immunomedics has demonstrated  that 90Y-clivatuzumab tetraxetan, when 
used with low-dose gemcitabine, is a safe, low-side effect therapy that can 
prolong survival for at least some patients with metastatic pancreatic cancer, 
even when no chemotherapy options exist.<wbr> </div><div style="margin-bottom: 10px;">Its studies imply that radiolabeled antibodies are safe to use in advanced 
pancreatic cancer, and that it may be possible to attach other anticancer agents 
besides 90Y to clivatuzumab tetraxetan to fight pancreatic cancer.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Study Findings <BR></STRONG><BR>A total of 58 patients 
with pancreatic cancer who had received two or more prior therapies were 
enrolled in this multicenter study.<wbr> Twenty-nine patients received the 
combination of 90Y-labeled-clivatuzumab tetraxetan once-a-week for 3 weeks and 
gemcitabine given weekly for 4 weeks (Arm A) while another group of 29 patients 
were administered 4 doses of 90Y-labeled-clivatuzumab tetraxetan alone (Arm B).<wbr> 
This treatment cycle was repeated every 4 weeks until unacceptable toxicity, 
patient deterioration or patient withdrawal.<wbr> Twenty-three patients completed 
more than one cycle of treatment, with 12 patients in Arm A and 11 in Arm B.<wbr> </div><div style="margin-bottom: 10px;">Notwithstanding the late-stage setting with a difficult-to-treat cancer 
patients  the results were as follows:- </div><div style="margin-bottom: 10px;"><UL><LI>Arm A had a median overall survival (OS) of 7.<wbr>9 months, which was 
  statistically significant (p = 0.<wbr>004)</LI>
<LI>Arm B had a median overall survival (OS) of 3.<wbr>4 months in patients 
  treated repeatedly with the radiolabeled antibody alone.<wbr></LI>
<LI> Additionally, 2 patients in Arm A had a partial response and 2 
  patients are still alive 13 and 15 months after the start of their combination 
  treatment.<wbr> <BR><BR>The only clinically significant side effect was reduction 
  in blood counts, especially platelets, which was transient and manageable.<wbr> 
  </LI>
</UL> </div><div style="margin-bottom: 10px;">As a result of this data Immunomedics has launched the Phase III 
PANCRIT-1 registration trial to confirm these  results.<wbr> Patient accrual is 
planned to be complete by the middle of 2015, with top-line results 
expected in the first half of 2016.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About PANCRIT-1</STRONG> </div><div style="margin-bottom: 10px;">The PANCRIT-1 trial was designed to enroll approximately 440 patients 
with metastatic pancreatic cancer who had received at least two prior therapies.<wbr> 
A majority of these patients will be recruited at clinical trial sites across 
the U.<wbr>S.<wbr>, with additional sites in Canada, Europe and Israel participating.<wbr> 
Eligible patients will be randomized 2 to 1 to the treatment arm of 3 doses of 
90Y-clivatuzumab tetraxetan plus 4 doses of gemcitabine at 200 mg/<wbr>m2 per cycle 
or placebo plus 200 mg/<wbr>m2 gemcitabine.<wbr> All patients will receive best supportive 
care.<wbr> Treatments are administered during the initial 4 weeks of each 7-week 
cycle, and may be repeated up to a maximum of 6 cycles.<wbr> </div><div>Source: <A href="http://www.immunomedics.com">www.<wbr>immunomedics.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9728">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-20T12:00:16+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Data Will Be Presented From ELM-PC4 And ARMOR2 Study In mCRPC Chemo Naive Setting During ASCO Chicago [comp:Takeda, prod:Orteronel, dis:Prostate, class:Hormonals, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9724</link>
<description>Data Will Be Presented From ELM-PC4 And ARMOR2 Study In mCRPC Chemo Naive Setting During ASCO Chicago [comp:Takeda, prod:Orteronel, dis:Prostate, class:Hormonals, news]</description><category>comp:Takeda</category><category>prod:Orteronel</category><category>dis:Prostate</category><category>class:Hormonals</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9724</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9724">Data Will Be Presented From ELM-PC4 And ARMOR2 Study In mCRPC Chemo Naive Setting During ASCO Chicago</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aOrteronel"><font color="#e95e0b">:Oncology:prod:Orteronel</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9724">Oncology9724</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 19 May 2014 | 20:28</font><br><br><div style="margin-bottom: 10px;">Comment: Abiraterone is the first agent received FDA approval in chemo na&iuml;ve mCRPC setting, since then, Enzalutamide has also demonstrated significant survival benefit from PREVAIL trial.<wbr> The positive data was presented in ASCO GU this year and European subpopulation analysis was presented as the 'late breaker' in EAU this year.<wbr> The landscape of this setting could well be rattled further as more data will be presented in ASCO Chicago this month - featured by TAK-700 (ELM-PC4 trial) and Galeterone (ARMOR2).<wbr> </div><div style="margin-bottom: 10px;">Ahead of ASCO that will take place in Chicago end of this month, Takeda announced data from ELM -PC4 , a pivotal, international, double blind, randomized Phase 3 trial comparing TAK-700 (orteronel) with prednisone alone in mCRPC patients who have not received prior chemotherapy.<wbr> TAK-700 (orteronel) plus prednisone reduced the risk of radiological progression free survival (rPFS) by 30% compared to placebo plus prednisone (median rPFS 11.<wbr>0 vs.<wbr> 8.<wbr>3 months).<wbr> Although there is a 'numerical improvement in median OS of 1.<wbr>9 months, the improvement was not statistically significant (p=0.<wbr>314).<wbr> </div><div style="margin-bottom: 10px;">Michael Vasconcelles MD, Global Head of Takeda Oncology Therapeutic Area Unit, commented during the press release "<EM> the significant rPFS advantage observed for orteronel combined with prednisone in the ELM-PC4 study is consistent with the previously reported rPFS improvement observed in ELM-PC5 study, where orteronel was also studies with prednisone in men with mCRPC who had previously received chemotherapy.<wbr><STRONG> We are carefully analysing these data to fully inform future decisions in the orteronel programme.<wbr></STRONG></EM>" </div><div style="margin-bottom: 10px;">In the third interim analysis from COU-AA-302 study, abiraterone did not demonstrate significant survival benefit (p=0.<wbr>0151) despite of significant rPFS improvement (median rPFS: 16.<wbr>5 months vs.<wbr> 8.<wbr>2 months; p&lt;0.<wbr>00001).<wbr> Although TAK-700 appears to be in the similar situation, the data may indicate that TAK-700 is inferior.<wbr> Be cautious of this comment, as there is not a result of a direct comparison trial and this is merely an indirect comparison of different patients population.<wbr> The rate of discontinuation is quite high in TAK-700 treatment arm (30% vs 18%).<wbr> This may also highlight the possible toxicity issue.<wbr> The future of TAK-700 (orteronel) is certainly a big question mark.<wbr> The detail of the data will be presented at ASCO (ab # 5008, Oral Abstract Session, Sunday 1 June).<wbr> </div><div>The other data will be presented during ASCO is updated Phase 2 clinical data on Tokai's Galeterone in advanced prostate cancer.<wbr> The results of a phase 2 ARMOR2 Study will be presented on Saturday during poster highlights session (poster board 44).<wbr> ARMOR2 study has a unique design where it includes 4 patient cohorts, Mo CRPC (non metastatic treatment na&iuml;ve), M1 CRPC (treatment na&iuml;ve), abiraterone refractory and enzalutamide refractory patients.<wbr> This is only a phase 2 study so it has a very small patient cohort.<wbr> PSA response of both M1 (n=24) and M0 (n=6) cohorts appear to be promising.<wbr> It will be very interesting to hear about the details during ASCO.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9724">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-19T20:28:02+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>TOLMAR Regains Sales &amp; Marketing Rights to ELIGARD [prod:Eligard, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9718</link>
<description>TOLMAR Regains Sales &amp; Marketing Rights to ELIGARD [prod:Eligard, :PharmaWorld:mkt:NorthAmerica]</description><category>prod:Eligard</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9718</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9718">TOLMAR Regains Sales & Marketing Rights to ELIGARD</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aEligard"><font color="#e95e0b">:Oncology:prod:Eligard</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9718">Oncology9718</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 May 2014 | 10:32</font><br><br><div style="margin-bottom: 10px;">Comment: TOLMAR, the original developer of the drug, has regained the S&amp;M rights for the drug in the U.<wbr>S and Puerto Rico.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company's Actions</FONT></STRONG> </div><div style="margin-bottom: 10px;">TOLAMR is working to ensure both physicians and patients have a continuity of product supply, and unmatched support and patient care services.<wbr> </div><div style="margin-bottom: 10px;">The company has communicated directly with distributors and prescribing physicians regarding the availability of ELIGARD.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">QLT Divestment of ELIGARD</FONT></STRONG> </div><div style="margin-bottom: 10px;">During the first quarter of 2014, "Investment and Other Income" was <MONEY>$1.<wbr>5 million</MONEY> compared to <MONEY>$0.<wbr>8 million</MONEY> for the same period in 2013.<wbr> </div><div style="margin-bottom: 10px;">For both periods, this primarily related to gains of <MONEY>$1.<wbr>5 million</MONEY> and <MONEY>$0.<wbr>8 million</MONEY>, respectively, for the Fair Value Changes in Contingent Consideration.<wbr> These fair value gains resulted from the revaluation of the Company's contingent consideration asset, which was recorded as the present value of future expected payments with respect to Eligard<SUP>®</SUP>.<wbr> The <MONEY>$0.<wbr>7 million</MONEY> increase in the Company's fair value gains is primarily due to a <MONEY>$17.<wbr>0 million</MONEY> payment (the "Sanofi Prepayment") received from <ORG>TOLMAR Holding, Inc.<wbr></ORG> on <CHRON>March 17, 2014</CHRON> in accordance with a consent and amendment agreement (the "Consent and Amendment Agreement") to the stock purchase agreement with <ORG>Tolmar</ORG> (the "2009 Stock Purchase Agreement"), under which QLT had formerly divested the Eligard product line to <ORG>Tolmar</ORG>.<wbr> </div><div style="margin-bottom: 10px;">Pursuant to the terms of the Consent and Amendment Agreement, in exchange for QLT's consent to certain transactions proposed by <ORG>Tolmar</ORG> that would affect its license agreement with <ORG>Sanofi Synthelabo Inc.<wbr></ORG> ("Sanofi License Agreement"), QLT received the Sanofi Prepayment as pre-payment and full satisfaction of the remaining contingent consideration owing with respect to royalties under the Sanofi License Agreement.<wbr> Under the Consent and Amendment Agreement, <ORG>Tolmar</ORG> and its parent corporation, <ORG>Dodley International Ltd.<wbr></ORG>, also guaranteed payment of the remaining <MONEY>$10.<wbr>0 million</MONEY> of contingent consideration owing under the 2009 Stock Purchase Agreement on or before <CHRON>November 30, 2014</CHRON>.<wbr> </div><div><EM>Source: TOLMAR; QLT USA</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9718">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-19T10:32:16+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Chinese Authorities Ramp Up Their Visits to Foreign Pharma Firms [mkt:China]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10863</link>
<description>Chinese Authorities Ramp Up Their Visits to Foreign Pharma Firms [mkt:China]</description><category>mkt:China</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10863</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10863">Chinese Authorities Ramp Up Their Visits to Foreign Pharma Firms</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10863">PharmaWorld10863</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 19 May 2014 | 10:00</font><br><br><div style="margin-bottom: 10px;">Comment: According to an article published today by <EM>Reuters</EM>, the GSK Chinese case may be just the beginning.<wbr> Drug-company executives, sales staff, lawyers and compliance experts say China's crackdown on drugmakers and other healthcare firms is intensifying as prosecutors grow bolder in the wake of the GSK case, threatening to stymie the growth of any firms caught in the crosshairs of the prolonged corruption crackdown.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ongoing Investigations</FONT></STRONG> </div><div style="margin-bottom: 10px;">Lawyers estimate that more than half of all drugmakers operating in China are being investigated in some capacity, from large multinational firms to Chinese state-owned enterprises.<wbr> </div><div style="margin-bottom: 10px;">Last year authorities visited Novartis AG <NOVN.VX>, AstraZeneca Plc <AZN.L>, Sanofi SA <SASY.PA>, Eli Lilly &amp; Co <LLY.N>and Bayer AG.<wbr><BAYGN.DE></BAYGN.DE></LLY.N></SASY.PA></AZN.L></NOVN.VX> </div><div><EM>Source: Reuter</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10863">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-19T10:00:34+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>BMS Releases Results Of Phase1b Nivolumab (Anti-PD1) As A Single Agent (Study-003) [comp:BMS, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9715</link>
<description>BMS Releases Results Of Phase1b Nivolumab (Anti-PD1) As A Single Agent (Study-003) [comp:BMS, news]</description><category>comp:BMS</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9715</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9715">BMS Releases Results Of Phase1b Nivolumab (Anti-PD1) As A Single Agent (Study-003)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aBMS"><font color="#e95e0b">:Oncology:comp:BMS</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9715">Oncology9715</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 16 May 2014 | 18:11</font><br><br><div style="margin-bottom: 10px;">Comment: Study-003 is a Phase 1b dose escalation study (n=306) to evaluate the safety, antitumour activity and pharmacokinetics of nivolumab as a single agent.<wbr> Patients recruited include advanced melanoma (n=107), NSCLC (n=129), RCC (n=34), castration resistant prostate cancer (n=17) or colorectal cancer (n=19).<wbr> The protocol was amended and survival was being included as endpoint.<wbr> </div><div style="margin-bottom: 10px;">ClinicalTrials.<wbr>gov Identifier <a href="http://clinicaltrial.gov/ct2/show/NCT00730639?term=nivolumab%2C+study+003&rank=1" class="defaultlink">NCT00730639</a> </div><div style="margin-bottom: 10px;">Nivolumab is one of the most promising anti-PD1 agents and the results being released on 15th May (Thursday) were from the advanced melanoma cohort of this Phase 1b study.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Sustained activity in heavily treated patient population: 48% and 41% of this heavily pre-treated patient population hat received nivolumab as a single agent was alive at 2 and 3 years
</LI>
<LI>No new tolerability issue was concluded with this longer follow up (treatment related adverse events were consistent with those previously reported in the publication)
</LI>
</UL> </div><div style="margin-bottom: 10px;">Although only a small cohort of CRPC patients is included within the trial and given that negative results in mCRPC post-docetaxel setting, it will be interesting to watch the development of this trial and how BMS intends to take this forward.<wbr> </div><div>On the same day, BMS also received FDA's breakthrough designation granted for nivolumab for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant followed by brentuximab.<wbr> The designation is based on data from a cohort of patients with Hodgkin lymphoma of current ongoing Phase 1b study of relapsed and refractory haematological malignancies.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9715">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-16T18:11:44+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Update on Zosano's Transdermal Microneedle Patch Delivery of Peptides [class:GrowthHormone]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7678</link>
<description>Update on Zosano's Transdermal Microneedle Patch Delivery of Peptides [class:GrowthHormone]</description><category>class:GrowthHormone</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7678</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7678">Update on Zosano's Transdermal Microneedle Patch Delivery of Peptides</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7678">Endocrinology7678</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 May 2014 | 15:41</font><br><br><div style="margin-bottom: 10px;">Comment: The company, spun out as a private company from ALZA/<wbr>J&amp;J in 2006, is advancing a pipeline of drug candidates based on the ZP Patch Technology, capable of delivering peptides, proteins, small molecules and vaccines.<wbr> Preclinical results of transdermal microneedle patch delivery of rhGH will be presented @ENDO.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Presentation @ENDO (June 23)</FONT></STRONG> </div><div style="margin-bottom: 10px;"><FONT size="3"><FONT size="2">Thanks to Mireille Bonnemaire from the Endocrinology Franchise who has forwarded the abstract below.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7678/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7678/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>ZP-PTH Lead Product</STRONG> - Zosano is pursuing a 505(b)(2) regulatory strategy that leverages existing PTH safety and efficacy data of the marketed product Forteo®.<wbr> Unlike Forteo® the ZP-PTH patch is needle-free patch that requires no refrigeration and demonstrated excellent safety and efficacy through Ph2.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Patents &amp; Publications</FONT></STRONG> </div><div style="margin-bottom: 10px;"><A href="http://www.zosanopharma.com/index.php/20091118147/Research/Patents-and-Publications/Patents-Publications.html">http:/<wbr>/<wbr>www.<wbr>zosanopharma.<wbr>com/<wbr>index.<wbr>php/<wbr>20091118147/<wbr>Research/<wbr>Patents-and-Publications/<wbr>Patents-Publications.<wbr>html</A> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div style="margin-bottom: 10px;"><P class="contentheading-newsroom">Q1:14, Zosano entered into a license agreement with Novo Nordisk to deliver Semaglutide using Zosano’s Microneedle Patch System</P> </div><div style="margin-bottom: 10px;">Q3:11 Zosano and Asahi Kasei Pharma entered exclusive licensing agreement for a weekly Transdermal Patch Formulation of Teribone™ (teriparatide acetate) for osteoporosis </div><div><EM>Source: Zosano Pharm</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7678">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-16T15:41:41+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Takeda Not Interested in M&amp;A [comp:Takeda, :DKPHybrids:comp:Acino, :DKPHybrids:news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9712</link>
<description>Takeda Not Interested in M&amp;A [comp:Takeda, :DKPHybrids:comp:Acino, :DKPHybrids:news]</description><category>comp:Takeda</category><category>comp:Acino</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9712</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9712">Takeda Not Interested in M&A</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=comp%3aAcino"><font color="#e95e0b">:DKPHybrids:comp:Acino</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:DKPHybrids:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9712">Oncology9712</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 May 2014 | 14:39</font><br><br><div style="margin-bottom: 10px;">Comment: Today, Takeda's CFO reported that the company has no interest in synergy or tax-driven M&amp;A.<wbr> However, "strategic acquisition" such as the Millennium acquisition remains still possible.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Acquisition Still Possible</FONT></STRONG> </div><div style="margin-bottom: 10px;">The recent appointments of four ex-Takeda at the leadership positions of Acino have been questionning on whether an acquisition is likely to occur between the two companies.<wbr> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=239" class="defaultlink">DKPHybrids239: Two Ex-Takeda Appointed at Acino</a> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=237" class="defaultlink">DKPHybrids237: Second Ex-Takeda to Join Acino</a> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9474" class="defaultlink">Oncology9474: Ex-Takeda to Join Acino as New CEO</a> </div><div style="margin-bottom: 10px;">Qoting F-X Roger (CFO): </div><div style="margin-bottom: 10px;">"If we go back to acquisitions we would focus again on strategic acquisitions and what they bring to us.<wbr> Millennium brought us access to oncology, so I have access to a new franchise and a better footprint in the U.<wbr>S.<wbr>" </div><div>" .<wbr>.<wbr>.<wbr> At the end of the day it's about being agile, being able to move fast, and being efficient in what you do.<wbr>" </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9712">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-16T14:39:01+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Telormedix In Search for Partnering Vesimune (Bladder Cancer) [dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9710</link>
<description>Telormedix In Search for Partnering Vesimune (Bladder Cancer) [dis:Bladder]</description><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9710</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9710">Telormedix In Search for Partnering Vesimune (Bladder Cancer)</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9710">Oncology9710</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 16 May 2014 | 12:29</font><br><br><div style="margin-bottom: 10px;">Comment: The company has completed a successful Ph2 in patients with Non-Muscle Invasive Bladder Cancer (NMIBC), and is now hoping to find a partner by the third quarter of 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">About the Study</FONT></STRONG> </div><div style="margin-bottom: 10px;">See <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=8819" class="defaultlink">Oncology8819: Telormedix' TMX-101 to Enter in the Clinic for CIS in the Bladder</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Business Development</FONT></STRONG> </div><div style="margin-bottom: 10px;">The company is in discussions with potential licensing partners with whom it hopes to run a full-scale Ph2b study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Regulatory Pathway</FONT></STRONG> </div><div style="margin-bottom: 10px;">Telormedix has met with the FDA which has confirmed that if a Ph2b trial is well-designed and the results are promising, the company can submit a new drug application on the back of those data.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Competition</FONT></STRONG> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><SPAN style="FONT-SIZE: 11pt"><SPAN style="FONT-SIZE: 12pt"><FONT size="2">Telormedix believes there is little competition for its product, either already on the market or in the pipeline.<wbr></FONT></SPAN></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><SPAN style="FONT-SIZE: 11pt"><SPAN style="FONT-SIZE: 12pt"><FONT size="2">BCG and valrubicin are the current standards of care, failing which removal of the bladder is the only option.<wbr> </FONT></SPAN></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><SPAN style="FONT-SIZE: 11pt"><SPAN style="FONT-SIZE: 12pt"><FONT size="2">Spectrum has a Ph3 candidate, apaziquone, as does ANI Pharmaceuticals, CG-0070.<wbr> </FONT></SPAN></SPAN></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><FONT size="2"><SPAN style="FONT-SIZE: 11pt"><SPAN style="FONT-SIZE: 12pt"><FONT size="2">According to the company, many of the big pharma cancer drugs have Ph2 data for bladder cancer, including Lilly's Erbitux (cetuximab),</FONT> <FONT size="2">Sanofi's Taxotere (docetaxel), and Pfizer's Sutent (sunitinib), but these drugs are at Ph2 in a number of indications and bladder cancer is unlikely to be a priority</FONT></SPAN></SPAN>.<wbr></FONT></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px"><STRONG><FONT size="3">About Telormedix</FONT></STRONG></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px">Focus: Telormedix is a biopharmaceutical company focused on targeted immunity and the role of the innate immune system in treating cancer and infectious diseases.<wbr> Telormedix is particularly interested in the role of Toll-like Receptor 7 (TLR7) for the topical treatment of cancer.<wbr></DIV> </div><div style="margin-bottom: 10px;"><DIV style="MARGIN: 0px">Pipeline</DIV> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0px"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9710/1/ScreenCapture1.jpg?user-agent=rss"> </P> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0px"><STRONG>TMX-202</STRONG> Telormedix’s TMX-202 is a novel generation of TLR7 agonists that has recently been validated for systemic and topical administration in different cancer indications.<wbr> The candidate has already successfully completed a number of in vivo studies and was discovered through collaboration with the University of California San Diego.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0px"><STRONG>TMX-201</STRONG> Telormedix is also developing TMX-201 as a potent and highly selective TLR7 agonist as a possible vaccine adjuvant.<wbr> Telormedix welcomes enquiries from vaccine developers wishing to find out more.<wbr> </P> </div><div><DIV style="MARGIN: 0px"><EM>Source: Telormedix</EM></DIV> </div><!-- Comment details --><a name="oncology9710attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9710/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(29,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9710">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-16T12:29:50+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9710/1/ScreenCapture1.jpg" length="29989" type="image/jpeg"/></item><item>
<title>re: AZ Fights Pfizer Bid by Predicting Sales Surge</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9709</link>
<description>re: AZ Fights Pfizer Bid by Predicting Sales Surge</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9709</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9709">re: AZ Fights Pfizer Bid by Predicting Sales Surge</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9709">Oncology9709</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 16 May 2014 | 12:23</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">AZ Fights Pfizer Bid by Predicting Sales Surge</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Chief Executive <TR:CATEGORY>Pascal Soriot</TR:CATEGORY> predicted sales would rise by three quarters over the next decades.<wbr> He said plunging AstraZeneca into a disruptive merger would also jeopardise its ability to deliver on the new drug pipeline, which is expected to account for 30% of the 2023 sales total.<wbr> Key slides of his presentation, titled <EM>'Delivering value for patients and shareholders'</EM> are provided below.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9680">...</a><br><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9680" class="commentpermalink">Oncology9680</a> / <span class="date">06 May 2014</span> /
<span class="time">18:18:00 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Comment: On 15th May, AstraZeneca made a press release to strengthen and reinforce company's position to operate as an 'independent company'.<wbr> Pascal Soriot (Chief Executive of AZ) made a statement " we continue to build our pipeline and we are encouraged by the progress in the development of key assets.<wbr> We have complete confidence in our strategy as an independent company and remain focused on delivering new medicines for patients, which will continue to create significant value for our shareholders".<wbr> </div><div>In particular new data from its new lung cancer drug - AZD9291 - that targets T790M.<wbr> T790M mutation is shown to develop in about 1/<wbr>2 of lung cancer patients who become resistant to EGFR inhibitors.<wbr> the results released on Wednesday showed AZD9291 shrank tumours in 51% of patients and 64% of patients harbouring T790M mutation.<wbr> Other two candidates being featured as "their exciting future in oncology" is its anti-PDL1 - MEDI4736 - that is being evaluated in NSCLC and PARP inhibitor - olaparib - that will be reviewed by FDA in Q3 2014.<wbr> Based on these positive results, AZ has forecast potential peak sales for MEDI47376 of $ 6.<wbr>5 billion and olaparib of $ 2 billion.<wbr> Overall, AZ forecasts these new products (including new treatments for diabetes asthma, rheumatoid arthritis and psoriasis) will generate $45 billions ins ales by 2023.<wbr> These promising cancer drug data will help AZ in light of Pfizer flight and provide fresh ammunition to argue that Pfizer substantially undervalues with its takeover offer.<wbr> </div><!-- Comment details --><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9709" class="commentpermalink">Oncology9709</a> / <span class="date">16 May 2014</span> /
<span class="time">12:23:33 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9709">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9680">View thread  Oncology9680: AZ Fights Pfizer Bid by Predicting Sales Surge</a>]]></content:encoded><dc:date>2014-05-16T12:23:33+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>FIM of Q-Med's Botulinum Toxin for Knee OA [class:BotulinumToxins, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7583</link>
<description>FIM of Q-Med's Botulinum Toxin for Knee OA [class:BotulinumToxins, headline]</description><category>class:BotulinumToxins</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7583</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7583">FIM of Q-Med's Botulinum Toxin for Knee OA</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7583">Neurology7583</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 May 2014 | 18:56</font><br><br><div style="margin-bottom: 10px;">Comment: Q-Med, a wholly owned subsidiary of Galderma, has started a Ph1 randomized trial of a single intra-articular injection of the drug candidate in approx 22 participants with osteoarthritis of the knee (OA).<wbr> PE will evaluate the incidence and severity of AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Inclusion criteria </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Osteoarthritis of the knee</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Fully weight bearing in the index knee with or without the need for assistive/<wbr>orthopaedic devices</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Pain score ≥40 mm of the index knee</LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Committing to continue using their assistive/<wbr>orthopaedic device throughout the study using the same regimen</LI>
</UL> </div><div style="margin-bottom: 10px;">Timelines </div><div style="margin-bottom: 10px;">The trial started in March 2014, with completion date expected in July 2014.<wbr> </div><div style="margin-bottom: 10px;">Location: UK </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02139319?recr=Open&amp;no_unk=Y&amp;cond=spasticity+OR+prostate+OR+botulinum+OR+acromegaly+OR+neuroendocrine+OR+growth+hormone+deficiency&amp;phase=012&amp;fund=2&amp;rcv_s=04%2F12%2F2014&amp;rank=9&amp;submit_fld_opt=">NCT02139319</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7583">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-15T18:56:11+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Millennium/Takeda to Start Comparison Study of its Oral GnRH Antagonist Drug Vs Degarelix [comp:Takeda, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9707</link>
<description>Millennium/Takeda to Start Comparison Study of its Oral GnRH Antagonist Drug Vs Degarelix [comp:Takeda, :PharmaWorld:sub:ClinicalTrial]</description><category>comp:Takeda</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9707</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9707">Millennium/<wbr>Takeda to Start Comparison Study of its Oral GnRH Antagonist Drug Vs Degarelix</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9707">Oncology9707</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 May 2014 | 18:49</font><br><br><div style="margin-bottom: 10px;">Comment: The Ph2 will assess safety/<wbr>efficacy of TAK-385 for patients with localized prostate cancer requiring neoadjuvant and adjuvant ADT with EBRT.<wbr> PE will evaluate the percentage of prticipants estimated to have effective castration at all scheduled visits.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: approx 100 </div><div style="margin-bottom: 10px;">Timelines: Start date May 2014 /<wbr> Completion date July 2015 </div><div style="margin-bottom: 10px;">Protocol </div><div style="margin-bottom: 10px;">TAK-385 320 mg, tablets, orally, once, on Day 1, followed by TAK-385 120 mg, orally, once daily for 24 weeks.<wbr> Each participant may have one upward dose adjustment of 40 mg for efficacy and/<wbr>or one downward dose adjustment of 40 mg for safety during the study </div><div style="margin-bottom: 10px;">Degarelix 240 mg, injection, subcutaneous, on Day 1, followed by degarelix 80 mg, injection, subcutaneous, once every four weeks, for 24 weeks </div><div style="margin-bottom: 10px;">Locations: UK; US </div><div>Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02135445?recr=Open&amp;no_unk=Y&amp;cond=spasticity+OR+prostate+OR+botulinum+OR+acromegaly+OR+neuroendocrine+OR+growth+hormone+deficiency&amp;phase=012&amp;fund=2&amp;rcv_s=04%2F12%2F2014&amp;rank=6&amp;submit_fld_opt=">NCT02135445</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9707">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-15T18:49:45+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Insights From The EAU Sessions On The Treatment Of Overactive Bladder [comp:Allergan, dis:iOAB, dis:nOAB, prod:Botox, :PharmaWorld:congress:EAU]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7581</link>
<description>Insights From The EAU Sessions On The Treatment Of Overactive Bladder [comp:Allergan, dis:iOAB, dis:nOAB, prod:Botox, :PharmaWorld:congress:EAU]</description><category>comp:Allergan</category><category>dis:iOAB</category><category>dis:nOAB</category><category>prod:Botox</category><category>congress:EAU</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7581</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7581">Insights From The EAU Sessions On The Treatment Of Overactive Bladder</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3anOAB"><font color="#e95e0b">:Neurology:dis:nOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aEAU"><font color="#e95e0b">:PharmaWorld:congress:EAU</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7581">Neurology7581</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 15 May 2014 | 17:43</font><br><br><div style="margin-bottom: 10px;">Comment: There was a considerable amount of data presented at this year's EAU 
meeting on the use of toxins to treat idiopathic OAB, coupled with a symposium 
hosted by Allergan.<wbr> Key points to emerge were the growing demand for this type 
of treatment and signs that Astellas is trying to position 
mirabegron in the middle ground between anticholinergis and 
toxins particularly given the large waiting lists emerging for 
Botox therapy.<wbr> Astellas focus is definitely going to be on producing 
more long-term/<wbr>cost-effectiveness data that can be used to challenge Botox.<wbr> 
There were some preliminary indications that consideration may also be given to 
evaluating mirabegron in neurogenic overactive bladder.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Poster Review.<wbr></STRONG> </div><div style="margin-bottom: 10px;">There were two poster review sessions held prior to the Allergan symposium.<wbr> 
One was focused on shooting for new targets in bladder overactivity and the 
other on the treatment of refractory detrusor overactivity.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>New Targets For Bladder Overactivity</STRONG> </div><div style="margin-bottom: 10px;">Key compounds of interest reviewed in the first session included.<wbr> 3 compounds 
with activity on the cannibinoid system, 3 acting on muscarinic receptors, 2 on 
prostanoids and one targeting a newly identifed Piezo-1 receptor.<wbr> </div><div style="margin-bottom: 10px;">The more interesting experimental compounds amongst them included:- </div><div style="margin-bottom: 10px;"><UL><LI>URB937 which degrades endogenous cannabinoids</LI>
<LI>F16357 (Pierre Fabre) which is in early pre-clinical development  and 
  dose dependently decreases bladder contractions.<wbr></LI>
<LI>A 5HMT metabolite of tolterodine which can inhibit caspaicin C-fibres 
  which the researcher thought may work better in nOAB than iOAB</LI>
<LI>DFL23448 a novel TRPM8 inhibitor.<wbr> TRPM8 has a functional role in the 
  bladder and is perceived as an interesting target for the future.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Refractory OAB</STRONG> </div><div style="margin-bottom: 10px;">The session started with two posters looking at adherance to anti-muscarinic 
therapy.<wbr>The first study  undertaken by Veenboer PM et al now published in 
the Journal of Urology noted mean persistence rates across 14 studies as 
12-38.<wbr>4% at 12 months and 0-16% at 3 year.<wbr> The risks of desistance were 
associated with younger age, patients on IR formulations and the use of 
oxybutinin </div><div style="margin-bottom: 10px;">The other study a long-term population based analysis of 24,319 patients 
found that 40-80% of patients drop-out within 30 days albeit theire is higher 
adherance to fesoterdine than tolteridine or oxybutin.<wbr> It was noted that there 
was potential bias in this study as no information on diagnosis was recoreded 
and potentially some people should not have even been prescribed 
anticholinergis.<wbr> </div><div style="margin-bottom: 10px;">Changing focus there were a couple of interesting abstracts on 
Astellas's mirabegron.<wbr> The first being an observational study undertaken in 
Bristol UK was of particular interest given the comments made regarding 
potential nOAB activity.<wbr> The 2nd highlighted how Astellas may be looking to 
position mirabegron as an alternative to Botox particularly for those patients 
having to wait 4-6 month for intravesical BTx-A.<wbr> It also suggests Astellas 
will plans to evaluate long-term effectiveness in these patients and the 
economic consequences of opting for miragebron vs.<wbr> Botox therapy.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">However, overall there was a larger number focused on Botox administration, 
some evaluating cost-utility, another focused on reducing the dose in 
multiple sclerosis patients and finally one on liposomal adminsitration of 
botulinum toxin for the treatment of iOAB.<wbr> Highlights are shown 
below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">This poster prompted legitimate questions about the feasibility of doing this 
as the projection would lead to a further 40,000 Botox injections per year in 
the UK.<wbr> As a member of the audience pointed out that would require a lot more 
urologists to do this than is currently available.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Finally, it was of interest to note the first results from a pilot study 
undertaken with liposomal encapsulated onabotulinumtoxin A in patients with 
iOAB </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Finally it was of interest to note the results obtained from the first 
randomised trial of Lipella's liposomal encapsulated onabotulinumtoxinA.<wbr> 
The trial was undertaken at a tertiary centre in Taiwan.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The authors conclude that intravesical Lipotoxin installation reduced 
frequency episodes at 1 month in iOAB patients and that the procedure is safe, 
without causing an increase in postvoid residual or the risk of urinary tract 
infection.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Allergan Symposium</STRONG> </div><div style="margin-bottom: 10px;">The symposium entitled "The genesis or urgency: unravelling the symptom 
complex of overactive bladder" as the title implies had some focus on the 
pathophysiology behind urgency with Karl Erik Anderson from Aaarhus University 
Denmark presenting on this topic.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/18/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/19/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/20/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">There then followed a series of 3 case histories illustrating the various 
types of presentation of iOAB, where the audience was questioned on its approach 
to treatment.<wbr> The speakers associated with this session were John Heesakkers 
(Radound University Netherlands) and Eric Rovner (University of South Carolina 
US).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/21/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/22/ScreenCapture22.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/23/ScreenCapture23.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/24/ScreenCapture24.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The EMBARK programme was discussed in the context of this patient with the 
focus on how Botox can reduce signs of urgency and how in fact that was what she 
was treated with.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/25/ScreenCapture25.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/26/ScreenCapture26.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/27/ScreenCapture27.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/28/ScreenCapture28.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/29/ScreenCapture29.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/30/ScreenCapture30.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/31/ScreenCapture31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/32/ScreenCapture32.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/33/ScreenCapture33.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/34/ScreenCapture34.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/35/ScreenCapture35.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/36/ScreenCapture36.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/37/ScreenCapture37.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/38/ScreenCapture38.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/39/ScreenCapture39.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/40/ScreenCapture40.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/41/ScreenCapture41.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/42/ScreenCapture42.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/43/ScreenCapture43.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/44/ScreenCapture44.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/45/ScreenCapture45.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/46/ScreenCapture46.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/47/ScreenCapture47.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/48/ScreenCapture48.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/49/ScreenCapture49.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/50/ScreenCapture50.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/51/ScreenCapture51.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/52/ScreenCapture52.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Finally Dirk De Ridder (Leuven Belgiu) spoke about the Emergence of choice: 
new paths in the treatment of OAB.<wbr> He made the point that there there are 
essentially three principal choices posterior tibial nerve stimulation (PTNS, 
sacral nerve modulation (SNS) and intrdetrusor Botox.<wbr> </div><div style="margin-bottom: 10px;">PTNS can provide sustained symptom relief over 3 years, however, the data 
supporting its use is difficult to interpret, there are few randomised trials 
and they have used heterogeneous measures of success.<wbr> SNS is an 
effective option he claimed for carefully selected patients but in one 
study he selected to focus upon surgical re-intervention and or 
withdrawal of the device because of treatment failure, pain, need for MRI or 
device malfunction was observed in 41% and 26% or patients 
respectively.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/53/ScreenCapture53.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/54/ScreenCapture54.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/55/ScreenCapture55.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/56/ScreenCapture56.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/57/ScreenCapture57.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/58/ScreenCapture58.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/59/ScreenCapture59.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/60/ScreenCapture60.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/61/ScreenCapture61.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/62/ScreenCapture62.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/63/ScreenCapture63.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/64/ScreenCapture64.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/65/ScreenCapture65.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7581attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(158,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(124,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(121,5 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(157,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(159,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(196,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(167 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(200 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(220,7 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(182,4 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(168,8 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(124,2 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(108,7 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(209,9 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(191 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(94,2 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(166,8 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(62,8 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(66 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(50,2 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(39,4 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/22/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(48,2 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/23/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(37,9 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/24/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(46,4 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/25/ScreenCapture25.jpg">ScreenCapture25.jpg</a>&nbsp;&nbsp;(47,2 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/26/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(51,1 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/27/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(42,8 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/28/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(43,2 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/29/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(44,2 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/30/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(36,3 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/31/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(36,9 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/32/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(57,6 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/33/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(50 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/34/ScreenCapture34.jpg">ScreenCapture34.jpg</a>&nbsp;&nbsp;(43,3 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/35/ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(35,6 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/36/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(55,6 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/37/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(38,2 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/38/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(44,9 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/39/ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(53,7 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/40/ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(46,4 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/41/ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(45 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/42/ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(43 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/43/ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(41,9 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/44/ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(55,5 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/45/ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(40,4 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/46/ScreenCapture46.jpg">ScreenCapture46.jpg</a>&nbsp;&nbsp;(36,9 KB)<br>&nbsp;&nbsp;47.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/47/ScreenCapture47.jpg">ScreenCapture47.jpg</a>&nbsp;&nbsp;(43 KB)<br>&nbsp;&nbsp;48.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/48/ScreenCapture48.jpg">ScreenCapture48.jpg</a>&nbsp;&nbsp;(61,4 KB)<br>&nbsp;&nbsp;49.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/49/ScreenCapture49.jpg">ScreenCapture49.jpg</a>&nbsp;&nbsp;(71,7 KB)<br>&nbsp;&nbsp;50.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/50/ScreenCapture50.jpg">ScreenCapture50.jpg</a>&nbsp;&nbsp;(45,4 KB)<br>&nbsp;&nbsp;51.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/51/ScreenCapture51.jpg">ScreenCapture51.jpg</a>&nbsp;&nbsp;(61,6 KB)<br>&nbsp;&nbsp;52.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/52/ScreenCapture52.jpg">ScreenCapture52.jpg</a>&nbsp;&nbsp;(76,3 KB)<br>&nbsp;&nbsp;53.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/53/ScreenCapture53.jpg">ScreenCapture53.jpg</a>&nbsp;&nbsp;(62,9 KB)<br>&nbsp;&nbsp;54.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/54/ScreenCapture54.jpg">ScreenCapture54.jpg</a>&nbsp;&nbsp;(39,9 KB)<br>&nbsp;&nbsp;55.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/55/ScreenCapture55.jpg">ScreenCapture55.jpg</a>&nbsp;&nbsp;(54,8 KB)<br>&nbsp;&nbsp;56.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/56/ScreenCapture56.jpg">ScreenCapture56.jpg</a>&nbsp;&nbsp;(62,7 KB)<br>&nbsp;&nbsp;57.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/57/ScreenCapture57.jpg">ScreenCapture57.jpg</a>&nbsp;&nbsp;(77,5 KB)<br>&nbsp;&nbsp;58.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/58/ScreenCapture58.jpg">ScreenCapture58.jpg</a>&nbsp;&nbsp;(74,3 KB)<br>&nbsp;&nbsp;59.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/59/ScreenCapture59.jpg">ScreenCapture59.jpg</a>&nbsp;&nbsp;(42,2 KB)<br>&nbsp;&nbsp;60.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/60/ScreenCapture60.jpg">ScreenCapture60.jpg</a>&nbsp;&nbsp;(62,6 KB)<br>&nbsp;&nbsp;61.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/61/ScreenCapture61.jpg">ScreenCapture61.jpg</a>&nbsp;&nbsp;(44,5 KB)<br>&nbsp;&nbsp;62.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/62/ScreenCapture62.jpg">ScreenCapture62.jpg</a>&nbsp;&nbsp;(50,6 KB)<br>&nbsp;&nbsp;63.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/63/ScreenCapture63.jpg">ScreenCapture63.jpg</a>&nbsp;&nbsp;(48 KB)<br>&nbsp;&nbsp;64.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/64/ScreenCapture64.jpg">ScreenCapture64.jpg</a>&nbsp;&nbsp;(44 KB)<br>&nbsp;&nbsp;65.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/65/ScreenCapture65.jpg">ScreenCapture65.jpg</a>&nbsp;&nbsp;(58,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7581">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-15T17:43:21+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/1/ScreenCapture1.jpg" length="162500" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/2/ScreenCapture2.jpg" length="127556" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/3/ScreenCapture3.jpg" length="124386" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/4/ScreenCapture4.jpg" length="161462" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/5/ScreenCapture5.jpg" length="163448" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/6/ScreenCapture6.jpg" length="200985" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/7/ScreenCapture7.jpg" length="170959" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/8/ScreenCapture8.jpg" length="204825" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/9/ScreenCapture9.jpg" length="226041" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/10/ScreenCapture10.jpg" length="186806" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/11/ScreenCapture11.jpg" length="172819" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/12/ScreenCapture12.jpg" length="127157" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/13/ScreenCapture13.jpg" length="111348" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/14/ScreenCapture14.jpg" length="214935" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/15/ScreenCapture15.jpg" length="195612" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/16/ScreenCapture16.jpg" length="96435" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/17/ScreenCapture17.jpg" length="170835" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/18/ScreenCapture18.jpg" length="64290" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/19/ScreenCapture19.jpg" length="67572" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/20/ScreenCapture20.jpg" length="51453" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/21/ScreenCapture21.jpg" length="40393" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/22/ScreenCapture22.jpg" length="49324" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/23/ScreenCapture23.jpg" length="38842" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/24/ScreenCapture24.jpg" length="47493" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/25/ScreenCapture25.jpg" length="48285" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/26/ScreenCapture26.jpg" length="52286" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/27/ScreenCapture27.jpg" length="43834" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/28/ScreenCapture28.jpg" length="44207" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/29/ScreenCapture29.jpg" length="45248" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/30/ScreenCapture30.jpg" length="37137" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/31/ScreenCapture31.jpg" length="37766" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/32/ScreenCapture32.jpg" length="58963" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/33/ScreenCapture33.jpg" length="51242" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/34/ScreenCapture34.jpg" length="44334" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/35/ScreenCapture35.jpg" length="36468" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/36/ScreenCapture36.jpg" length="56919" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/37/ScreenCapture37.jpg" length="39108" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/38/ScreenCapture38.jpg" length="45981" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/39/ScreenCapture39.jpg" length="55030" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/40/ScreenCapture40.jpg" length="47535" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/41/ScreenCapture41.jpg" length="46071" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/42/ScreenCapture42.jpg" length="44078" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/43/ScreenCapture43.jpg" length="42864" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/44/ScreenCapture44.jpg" length="56784" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/45/ScreenCapture45.jpg" length="41361" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/46/ScreenCapture46.jpg" length="37763" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/47/ScreenCapture47.jpg" length="44083" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/48/ScreenCapture48.jpg" length="62864" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/49/ScreenCapture49.jpg" length="73406" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/50/ScreenCapture50.jpg" length="46530" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/51/ScreenCapture51.jpg" length="63128" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/52/ScreenCapture52.jpg" length="78174" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/53/ScreenCapture53.jpg" length="64424" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/54/ScreenCapture54.jpg" length="40859" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/55/ScreenCapture55.jpg" length="56150" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/56/ScreenCapture56.jpg" length="64228" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/57/ScreenCapture57.jpg" length="79342" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/58/ScreenCapture58.jpg" length="76091" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/59/ScreenCapture59.jpg" length="43191" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/60/ScreenCapture60.jpg" length="64098" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/61/ScreenCapture61.jpg" length="45586" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/62/ScreenCapture62.jpg" length="51814" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/63/ScreenCapture63.jpg" length="49171" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/64/ScreenCapture64.jpg" length="45017" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7581/65/ScreenCapture65.jpg" length="60020" type="image/jpeg"/></item><item>
<title>More Buzzes In The Immuno-oncology Field Featured By Roche and Merck's ASCO Presentation Annoucement, BMS-Celldex And AstraZeneca-Incyte Collaboration [news, class:MonoclonalAntibody]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9703</link>
<description>More Buzzes In The Immuno-oncology Field Featured By Roche and Merck's ASCO Presentation Annoucement, BMS-Celldex And AstraZeneca-Incyte Collaboration [news, class:MonoclonalAntibody]</description><category>news</category><category>class:MonoclonalAntibody</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9703</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9703">More Buzzes In The Immuno-oncology Field Featured By Roche and Merck's ASCO Presentation Annoucement, BMS-Celldex And AstraZeneca-Incyte Collaboration</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aMonoclonalAntibody"><font color="#e95e0b">:Oncology:class:MonoclonalAntibody</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9703">Oncology9703</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 15 May 2014 | 16:46</font><br><br><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><FONT face="Verdana" size="2">Comment: Development in immune-oncology field has featured the headlines during these two days.<wbr> As ASCO, one of the biggest oncology events, is taking place in Chicago in 2 weeks, many companies are announcing their key data that will be presented in this event.<wbr> Anti-PD-1 immunotherapies are expected to steal the spotlight at ASCO 2014 as the field leaders including Roche, Merck (</FONT><a href="http://ci.beaufour-ipsen.com/traction#/single&amp;proj=Oncology&amp;rec=9687" class="defaultlink">The First Anti-PD-1, MK-3475, Will Be Reviewed Under The FDA’s Accelerated Approval Programme)</a><FONT face="Verdana" size="2"> and BMS will present data from their anti-PD-1/<wbr>L1 candidate.<wbr> They have shown great promise against advanced melanoma - the deadliest of skin cancers - as well as advanced lung and kidney cancers, with relatively mild side effects, generating excitement among researchers and investors.<wbr> Two key collaboration announcement from BMS-Celldex and AZ-Incyte to conduct one single trial will pave the way to future combination approach of two immune-modulating agents.<wbr> </FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><BR><FONT face="Verdana" size="2"><STRONG>Roche to present new data on 27 different medicines at ASCO</STRONG></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small">Roche today announced that new data on nine approved and 18 investigational medicines will be presented during the 50th American Society of Clinical Oncology (ASCO) Annual Meeting.<wbr> Of the more than 320 abstracts on Roche medicines, more than 40 have been accepted for oral presentation during the ASCO Annual Meeting.<wbr> Andra Homing (CMO and Head, global product development) highlighted the development of its anti-PDL1 as it represents Roche's most advanced investigation cancer immunotherapy.<wbr> In particular, a phase 1 study of anti-PDL1 in metastatic urothelial bladder cancer will be presented in an oral session on Saturday 31 May.<wbr> The presentation will feature important updates including; overall response rate, biomarker and safety information.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><FONT face="Verdana" size="2">MK3475, Active in Three Different Tumour Types: New Data to be Presented at the 2014 ASCO Annual Meeting</FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><FONT face="Verdana" size="2">"The data to be presented expands our understanding of the effects of monotherapy with MK-3475, and will serve as a foundation for future studies of combination therapies in an even broader set of malignancies.<wbr>” said Dr.<wbr> Roger M.<wbr> Perlmutter, president, Merck Research Laboratories.<wbr></FONT></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><EM>The company is advancing Phase 1 studies with MK-4166, an investigational anti-GITR antibody, clinical studies of immunomodulatory combination regimens, and preclinical evaluation of other immunotherapy candidates for the treatment of cancer.<wbr> Six oral presentations report MK-3475 monotherapy data across three different tumour types and multiple lines of therapy</EM></SPAN> </div><div style="margin-bottom: 10px;"><UL><LI class="bwlistitemmargb" id="yui_3_16_0_1_1400156954472_1154"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><EM id="yui_3_16_0_1_1400156954472_1153">Late-breaker presentation of long-term findings of MK-3475 in advanced melanoma, including ipilimumab-naïve and treated settings; data included in ASCO Press Program </EM></SPAN></LI>
<LI class="bwlistitemmargb" id="yui_3_16_0_1_1400156954472_1156"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><EM id="yui_3_16_0_1_1400156954472_1155">First presentation of findings evaluating MK-3475 as initial treatment of patients with advanced non-small cell lung cancer : Phase 3 studies with MK-3475 are currently ongoing in previously-treated advanced NSCLC patients, and Merck plans to initiate a Phase 3 trial in first-line treatment in 2014.<wbr></EM></SPAN> </LI>
<LI class="bwlistitemmargb" id="yui_3_16_0_1_1400156954472_1158"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><EM id="yui_3_16_0_1_1400156954472_1157">First presentation of findings of MK-3475 in recurrent/<wbr>metastatic head and neck cancer : On Sunday, June 1, the first presentation of a study evaluating MK-3475 in patients with recurrent and metastatic head and neck cancer (KEYNOTE-012) expressing PD-L1 will be featured in an oral session (Abstract #6011).<wbr> The company announced recently that a new Phase 3 study is planned in advanced head and neck cancer in 2014.<wbr></EM></SPAN> </LI>
</UL> </div><div style="margin-bottom: 10px;"><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><FONT face="Verdana" size="2">BMS and Celldex are collaborating to conduct<SPAN style="TEXT-DECORATION: underline"> a single</SPAN> clinical trial combining their respective experiment cancer immunotherapies - Nivolumab (anti-PD-1) and Varlilumab (CD-27 targeted antibody) - as a PhI/<wbr>II study to evaluate efficacy in multiple tumour types including NSCLC, melanoma, ovarian, colon and head &amp; neck cancer.<wbr> The Bristol-Celldex collaboration is somewhat unusual in that it applies only to this single clinical trial.<wbr> Bristol is paying Celldex $5 million but the cost of the study is split between the two companies.<wbr> Celldex will run the study, which is expected to start in the Q4 this year.<wbr> Celldex retains full ownership rights to varlilumab but Bristol does have a time-limited option to license the drug, if Celldex chooses to seek a full-time partner.<wbr> Celldex was spun out of Medarex - Medarex was where ipilimumab and nivolumab originates from and later acquired by BMS.<wbr> Under the new collaboration, BMS has agreed to waive some milestone payments and reduce royalty rights.<wbr></FONT></SPAN> </div><div><SPAN style="FONT-FAMILY: times new roman,times; FONT-SIZE: small"><FONT face="Verdana"><FONT size="2">Similarly, <STRONG>AstraZeneca</STRONG> and <STRONG>Incyte</STRONG> has signed a clinical study collaboration, highlighting its desire to push ahead with drug development despite an unwanted $106 billion bid approach from Pfizer.<wbr> The agreement will study a combination of two compounds - MEDI4736 (anti-PD-L1) and INCB24360 (IDO-1 inhibitor) - in a Phase I/<wbr>II clinical study against multiple tumour types, the companies also announced Wednesday.<wbr> Interestingly, both molecules are part of a new class of cancer treatments - now known as 'immune-modulating agents', which use the body's own immune system to facilitate anti-tumour immune response.<wbr> However, these two molecules work on two different pathways but in a complementary way to uncouple negative regulatory mechanisms in tumour microenvironment.<wbr> IDO is involved in immunosuppression pathway that often utilise by tumours cell to evade detection by the immune system while PD-L1 mediates the downstream immune checkpoints pathway.<wbr> Preclinical tumour model also showed <SPAN style="TEXT-ALIGN: left; LINE-HEIGHT: 17px; TEXT-TRANSFORM: none; BACKGROUND-COLOR: #ffffff; FONT-VARIANT: normal; FONT-STYLE: normal; TEXT-INDENT: 0px; DISPLAY: inline !important; WHITE-SPACE: normal; FLOAT: none; LETTER-SPACING: normal; COLOR: #000000; FONT-WEIGHT: normal; WORD-SPACING: 0px; font-size-adjust: none; font-stretch: normal; -webkit-text-stroke-width: 0px">IDO mediates human tumor cell resistance to a PARP inhibitor (olaparib), gamma radiation, cisplatin, and combined treatment with olaparib and radiation.<wbr> Therefore this is the POC trial to evaluate the combination approach of two immune-modulating agents may lead to an enhanced anti-tumour immune response.<wbr>The study will be co-funded equally by Incyte and MedImmune and conducted by Incyte.<wbr> The results of the trial is likely to pave the way to the future of this new class of molecules.<wbr>INCB24360 is currently in Phase I/<wbr>II development for metastatic melanoma in combination with ipilimumab ( <A href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=50865186&amp;newsitemid=20140513006995&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=1&amp;md5=2d59787e311bb175d06d544e1e348bbf" rel="nofollow"><U><FONT color="#0066cc">www.<wbr>clinicaltrials.<wbr>gov</FONT></U></A> Identifier: NCT01604889) and as monotherapy for ovarian cancer ( <A href="http://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.clinicaltrials.gov&amp;esheet=50865186&amp;newsitemid=20140513006995&amp;lan=en-US&amp;anchor=www.clinicaltrials.gov&amp;index=2&amp;md5=ec1880e4d1a5f1d01d79eb2915df1fa1" rel="nofollow"><U><FONT color="#0066cc">www.<wbr>clinicaltrials.<wbr>gov</FONT></U></A> Identifier: NCT01685255).<wbr> Incyte has also established a clinical agreement with Merck to combine INCB24360 with Merck’s novel anti-PD-1 immunotherapy checkpoint inhibitor, MK-3475.<wbr></SPAN></FONT></FONT></SPAN> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9703">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-15T16:46:25+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Merck Serono Q1:14 Performance Offset by Adverse Currency Effects [comp:MerckSerono, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7676</link>
<description>Merck Serono Q1:14 Performance Offset by Adverse Currency Effects [comp:MerckSerono, :PharmaWorld:sub:Finance]</description><category>comp:MerckSerono</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7676</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7676">Merck Serono Q1:14 Performance Offset by Adverse Currency Effects</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aMerckSerono"><font color="#e95e0b">:Endocrinology:comp:MerckSerono</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7676">Endocrinology7676</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 15 May 2014 | 12:23</font><br><br><div style="margin-bottom: 10px;">Comment: All four divisions and all regions (mainly the Emerging Markets region, which encompasses Latin America and Asia excluding Japan) contributed to solid organic sales growth of the Group.<wbr> Despite solid organic growth of 4.<wbr>2%, sales by the 'Merck Serono' division declined by 1.<wbr>0% to € 1,375 million (Q1 2013: € 1,389 million), since the strong euro led to negative foreign exchange effects of 5.<wbr>2%.<wbr> The 'Consumer Health' division generated sales of € 180 million (Q1 2013: € 182 million).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Currency headwinds continue</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>Organic growth across all regions</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">An Overview of the Merck Serono Division</FONT></STRONG> </div><div style="margin-bottom: 10px;">Organic growth by product was not provided, thus no data for the sales of Saizen.<wbr> </div><div style="margin-bottom: 10px;">Management reported that Gonal-f, the leading recombinant hormone used in the treatment of infertility, performed strongly in the first quarter of 2014.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">An Overview of the Consumer Healthcare Division</FONT></STRONG> </div><div style="margin-bottom: 10px;">Chief Executive of Germany's Merck KGaA, Karl-Ludwig Kley, said in a media call on Thursday there were very few takeover opportunities to make inroads into consumer health markets in the United States and Japan, given the high prices of such assets.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The slight 0.<wbr>8% decline in sales was primarily attributable to currency headwinds of 6.<wbr>5%.<wbr> Solid organic sales growth amounted to 5.<wbr>7% in the first quarter of 2014.<wbr> </div><div style="margin-bottom: 10px;">This was also driven by <STRONG>Neurobion, a vitamin B product, and Floratil, a probiotic anti-diarrheal</STRONG>, two former Merck Serono brands that were transferred to the Consumer Health division on January 1, 2014.<wbr> The mild winter season in Europe led to weaker demand for the cold treatment Nasivin and the food supplement Bion, which was offset by strong sales of Femibion and local brands in Germany.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Guidance for 2014</FONT></STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/5/ScreenCapture5.jpg?user-agent=rss"> </div><!-- Comment details --><a name="endocrinology7676attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(52,6 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(60,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(97,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(96,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(98,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7676">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-15T12:23:36+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/1/ScreenCapture1.jpg" length="53857" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/2/ScreenCapture2.jpg" length="61946" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/3/ScreenCapture3.jpg" length="99555" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/4/ScreenCapture4.jpg" length="98911" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7676/5/ScreenCapture5.jpg" length="100405" type="image/jpeg"/></item><item>
<title>Insights From The ECE Meeting &amp; Upcoming ENDO Congress [headline, class:SomatostatinAnalogue, comp:Roche, comp:Novartis, prod:Octreotide, :PharmaWorld:congress:ECE, :PharmaWorld:congress:ENDO]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7670</link>
<description>Insights From The ECE Meeting &amp; Upcoming ENDO Congress [headline, class:SomatostatinAnalogue, comp:Roche, comp:Novartis, prod:Octreotide, :PharmaWorld:congress:ECE, :PharmaWorld:congress:ENDO]</description><category>headline</category><category>class:SomatostatinAnalogue</category><category>comp:Roche</category><category>comp:Novartis</category><category>prod:Octreotide</category><category>congress:ECE</category><category>congress:ENDO</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7670</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7670">Insights From The ECE Meeting & Upcoming ENDO Congress</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aSomatostatinAnalogue"><font color="#e95e0b">:Endocrinology:class:SomatostatinAnalogue</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aRoche"><font color="#e95e0b">:Endocrinology:comp:Roche</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Endocrinology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=prod%3aOctreotide"><font color="#e95e0b">:Endocrinology:prod:Octreotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aECE"><font color="#e95e0b">:PharmaWorld:congress:ECE</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aENDO"><font color="#e95e0b">:PharmaWorld:congress:ENDO</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7670">Endocrinology7670</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 May 2014 | 15:25</font><br><br><div style="margin-bottom: 10px;">Comment: The ECE meeting was notable in terms of the first publication of the PAOLA data with pasireotide in acromegaly in abstract form and similarly a poster highlighting PK PhI data associated with Novartis's in-licensed fluid crystal octreotide formulation.<wbr> Upcoming at ENDO will be the same PAOLA poster data but importantly an oral presentation by S Melmed on the phIII efficacy data of Roche/<wbr>Chiasma's oral octreotide.<wbr> Data which is now availabe indicates that 60% of patients were controlled at the end of the study dose titration period and 55% at the end of the core treatment period (7 months).<wbr> 27% terminated the study due to treatment failure or AEs.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>ECE Update</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Thanks to Harold Dumont and Raphael Ortiz from the Endocrinology Franchise we have access to a number of the key competitive posters presented and slides from the Novartis Symposium, all of which are attached.<wbr></STRONG> </div><div style="margin-bottom: 10px;">Data from the PAOLA pasireotide acromegaly study is as expected is in line with the Endocrinology Franchise's assumptions for pasireotide of 15-20% higher efficacy in terms of control of IGF-1 &amp; GH but a worse safety profile especially in terms of glycaemic control.<wbr> </div><div style="margin-bottom: 10px;">The PAOLA PhIII study assessed the efficacy and safety of pasireotide LAR versus continued therapy with octretoide LAR and lanreotide Autogel in patients with inadequately controlled acromegaly </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The data is in line with the franchise's anticipated positioning for pasireotide meaning not replacing the SSA 1st generation but as 2nd step after failure of SSA 1st generation or as an intermediate step between SSA 1st generation and pegvisomant, or at the same level as pegvisomant and preferably in normoglycaemic patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Novartis Symposium</STRONG> </div><div style="margin-bottom: 10px;">The case history based symposium focused on both the treatment of Cushing's and Acreomegaly but did not dwell in any of the slides on the pasireotide data (presumably because of the ongoing regulatory review).<wbr> </div><div style="margin-bottom: 10px;">Some of the key highlights are shown below with the full presentations attached for you to review.<wbr> </div><div style="margin-bottom: 10px;">Case History 1 </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Post transhpenoidal surgery the patient had a recurrence as was treated initally with ketoconazole.<wbr> The slides below illustrate the treatment progression </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/10/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Case history 2 Acromegaly </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/11/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/12/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/13/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/14/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/15/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/16/ScreenCapture16.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/17/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/18/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/19/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/20/ScreenCapture20.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/21/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Novartis's CAM20209 PK/<wbr>PD Data PhI Data From Healthy Volunteer Study</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/22/ScreenCapture22.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/23/ScreenCapture23.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The data supports what we already know about the fluid crystal formulation namely:- </div><div style="margin-bottom: 10px;">It will provide a more rapid onset of effect but with similar duration.<wbr> </div><div style="margin-bottom: 10px;">May offer enhanced convenience vs.<wbr> Sandostatin LAR because of its availability as a prefilled syringe with a thin needle, sc injection with the possibility of self-administration.<wbr> </div><div style="margin-bottom: 10px;">It was noted that planning for phIII is ongoing.<wbr> As mentioned earlier this year (see Endocrinology intelligence from ENETS suggested a phIII acromegaly study was likely to start in Q314 and a NET study in Q115.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Efficacy &amp; Safety of Oral Octreotide (OOA) in Acromegaly: Results of a multicentre phIII trial in 155 patients</STRONG> </div><div style="margin-bottom: 10px;">Oral presentation in Session OR17- Genetics To Clinical Trials In Pituitary Disease </div><div style="margin-bottom: 10px;">Sunday June 22nd 12.<wbr>30pm </div><div style="margin-bottom: 10px;"><STRONG>Trial Design</STRONG> - Global mutlicentre, open-label, dose-titration, baseline-controlled study in 155 subjects </div><div style="margin-bottom: 10px;"><STRONG>Methods: </STRONG>After screening, subjects shown to be controlled (defined as IGF-I levels &lt;1.<wbr>3 ULN, and 2hr integrated GH &lt;2.<wbr>5 ng/<wbr>mL, measured centrally), while on 3 months of injectable SSA, were enrolled.<wbr> </div><div style="margin-bottom: 10px;">Following OOA pre-treatment baseline establishment and after 4 weeks from last SRL injection, subjects were switched to OOA.<wbr> </div><div style="margin-bottom: 10px;">All entered a dose escalation phase, initially receiving OOA 40 mg/<wbr>day, titrated as required to 60 mg/<wbr>day, and up to 80 mg/<wbr>day (divided into two separate daily doses), to normalize IGF-I levels.<wbr> </div><div style="margin-bottom: 10px;">This was followed by a fixed dose phase for up to a total duration of 7 months of OOA treatment (core treatment period).<wbr> Controlled patients were then offered an additional 6-month extension phase.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Results: </STRONG>Of 151 evaluable subjects that initiated OOA treatment and had at least one evaluation following first dose, 98 (65%) achieved the primary endpoint of hormonal control at their last assessment during the core treatment period, with IGF-I levels &lt;1.<wbr>3 ULN and mean 2 hr GH concentrations of &lt;2.<wbr>5 ng/<wbr>mL.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Following individual dose titration based on IGF-I levels, 61, 33, and 57 patients reached doses of 40, 60, and 80 mg, respectively.<wbr>
</LI>
<LI>Of the 91 subjects who were controlled (IGF-I &lt;1.<wbr>3 ULN) at the end of dose escalation, 83 (91%) maintained this response at the end of the core treatment period.<wbr>
</LI>
<LI>A total of 102 subjects completed the core treatment period, of whom 88 (86%) elected to continue treatment in the 6 month extension phase.<wbr>
</LI>
<LI>Twenty-four subjects (15%) were considered treatment failures due to IGF-I level &gt;1.<wbr>3 ULN and terminated prior to the end of the core period.<wbr>
</LI>
<LI>Seventeen subjects (11%) terminated for possible drug-related adverse events (AEs), consistent with known octreotide or disease-related AEs.<wbr> Ten of the early terminations were due to GI symptoms (mostly mild to moderate nausea, diarrhea, or abdominal pain).<wbr>
</LI>
<LI>Two deaths were reported: one of myocardial infarction in a patient with pancreatic carcinoma and obstructive jaundice, and another of suspected biliary obstruction and sepsis.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Conclusions: </STRONG>Oral octreotide acetate exhibits efficacy in controlling IGF-I and GH levels in acromegaly patients treated for at least 7 months, following a switch from injectable SRLs with a safety profile consistent with approved SRLs.<wbr> OOA is a viable option for administration as oral acromegaly monotherapy.<wbr> </div><div>.<wbr> .<wbr> </div><!-- Comment details --><a name="endocrinology7670attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(100 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(79,4 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(94,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(131,4 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(168,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(153,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(258 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(197,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(193,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(201,9 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/11/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(183 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/12/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(207,5 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/13/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(223,3 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/14/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(182 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/15/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(195,3 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/16/ScreenCapture16.jpg">ScreenCapture16.jpg</a>&nbsp;&nbsp;(200,1 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/17/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(172,5 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/18/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(308,3 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/19/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(171,6 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/20/ScreenCapture20.jpg">ScreenCapture20.jpg</a>&nbsp;&nbsp;(217,5 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/21/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(195,4 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/22/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(59,6 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/23/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(168,1 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/24/ECE%202014%20Roberts%20octreotide%20sc%20depot%20poster%20Final.pdf">ECE 2014 Roberts octreotide sc depot poster Final.pdf</a>&nbsp;&nbsp;(290,3 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/25/ECE%202014%20C2402%20Biomarker%20poster%20Final.pdf">ECE 2014 C2402 Biomarker poster Final.pdf</a>&nbsp;&nbsp;(464,9 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/26/ECE%202014%20C2402%20Gadelha%20poster%20Final.pdf">ECE 2014 C2402 Gadelha poster Final.pdf</a>&nbsp;&nbsp;(353,8 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/27/The%5fimportance%5fof%5ftreating%5fto%5fbiochemical%5ftargets%5fin%5facromegaly.pdf">The_importance_of_treating_to_biochemical_targets_in_acromegaly.pdf</a>&nbsp;&nbsp;(981,2 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/28/The%5fcomplexities%5fof%5fmanaging%5fCushings%5fdisease.pdf">The_complexities_of_managing_Cushings_disease.pdf</a>&nbsp;&nbsp;(972,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7670">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-14T15:25:03+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/1/ScreenCapture1.jpg" length="102397" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/2/ScreenCapture2.jpg" length="81345" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/3/ScreenCapture3.jpg" length="96668" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/4/ScreenCapture4.jpg" length="134508" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/5/ScreenCapture5.jpg" length="172522" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/6/ScreenCapture6.jpg" length="156945" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/7/ScreenCapture7.jpg" length="264233" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/8/ScreenCapture8.jpg" length="202644" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/9/ScreenCapture9.jpg" length="197866" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/10/ScreenCapture10.jpg" length="206739" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/11/ScreenCapture11.jpg" length="187352" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/12/ScreenCapture12.jpg" length="212448" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/13/ScreenCapture13.jpg" length="228610" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/14/ScreenCapture14.jpg" length="186389" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/15/ScreenCapture15.jpg" length="199989" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/16/ScreenCapture16.jpg" length="204887" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/17/ScreenCapture17.jpg" length="176678" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/18/ScreenCapture18.jpg" length="315675" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/19/ScreenCapture19.jpg" length="175727" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/20/ScreenCapture20.jpg" length="222680" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/21/ScreenCapture21.jpg" length="200044" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/22/ScreenCapture22.jpg" length="61080" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/23/ScreenCapture23.jpg" length="172173" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/24/ECE%202014%20Roberts%20octreotide%20sc%20depot%20poster%20Final.pdf" length="297309" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/25/ECE%202014%20C2402%20Biomarker%20poster%20Final.pdf" length="476028" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/26/ECE%202014%20C2402%20Gadelha%20poster%20Final.pdf" length="362282" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/27/The%5fimportance%5fof%5ftreating%5fto%5fbiochemical%5ftargets%5fin%5facromegaly.pdf" length="1004714" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7670/28/The%5fcomplexities%5fof%5fmanaging%5fCushings%5fdisease.pdf" length="995614" type="application/pdf"/></item><item>
<title>NICE Preliminary Guidance Recommends Against Use Of Abiraterone In Pre-Chemo Patients [dis:Prostate, news, comp:JnJ, prod:Zytiga]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9702</link>
<description>NICE Preliminary Guidance Recommends Against Use Of Abiraterone In Pre-Chemo Patients [dis:Prostate, news, comp:JnJ, prod:Zytiga]</description><category>dis:Prostate</category><category>news</category><category>comp:JnJ</category><category>prod:Zytiga</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9702</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9702">NICE Preliminary Guidance Recommends Against Use Of Abiraterone In Pre-Chemo Patients</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9702">Oncology9702</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 May 2014 | 12:46</font><br><br><div style="margin-bottom: 10px;">Comment: In draft guidance published yesterday, NICE has not recommended use 
of abiraterone in the earlier pre-chemo treatment setting because the 
manufacturer's own economic model did not demosntrate that the drug was 
cost-effective at this stage.<wbr> </div><div style="margin-bottom: 10px;">Zytiga which is given 4x daily costs £2,930 ($4,900) for 120 
tablets.<wbr> </div><div style="margin-bottom: 10px;">NICE state that "it hoped that during the consultation process, the 
manufacturer would use the opportunity to look again at its submission and 
provides the committee with additional information which may enable them to 
reconsider.<wbr>” </div><div style="margin-bottom: 10px;"><STRONG>The Basis For The Model</STRONG> </div><div style="margin-bottom: 10px;">The clinical evidence submitted by the manufacturer came from one trial 
(COU-AA-302).<wbr> Although the results indicated that, when compared with placebo, 
abiraterone could extend time to progression, the Committee was concerned that 
as the trial was stopped early and that the results never reached the level 
needed to prove whether abiraterone improved survival.<wbr> </div><div style="margin-bottom: 10px;">The committee also felt there were a number of issues with the way the 
manufacturer calculated estimated cost-effectiveness.<wbr> The health economic model 
was particularly complex and the committee felt that it was not transparent 
enough for the Evidence Review Group (ERG)<SUP>2</SUP> to fully validate and 
critique.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Next Steps</STRONG> </div><div style="margin-bottom: 10px;">Consultees, including the manufacturer, healthcare professionals and members 
of the public are now able to comment on the preliminary recommendations which 
are available for public consultation.<wbr> Comments received during this 
consultation will be fully considered by the committee and following this 
meeting the next draft guidance will be issued.<wbr> </div><div>Scource: <A href="http://www.nice.org.uk">www.<wbr>nice.<wbr>org.<wbr>uk</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9702">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-14T12:46:07+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Revance Q1 Earnings - Key Takeaways [sub:Aesthetics, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7576</link>
<description>Revance Q1 Earnings - Key Takeaways [sub:Aesthetics, news]</description><category>sub:Aesthetics</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7576</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7576">Revance Q1 Earnings - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7576">Neurology7576</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 May 2014 | 11:39</font><br><br><div style="margin-bottom: 10px;">Comment: Dan Brown CEO of Revance commented on the group's positive achievements in the first quarter, including a succesful IPO raising just under $99m to fund the ongoing development of RT-001 and RT-002.<wbr> The latter he quotes as being " a demonstrably different injectable toxin" that appears to have a median duration of action as demonstrated in the recent phI/<wbr>II GL study of 7.<wbr>3 months.<wbr> Results from Revance's first pivotal trial in crows feet with RT-001 are currently expected in 2H2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Company Ambition</STRONG> </div><div style="margin-bottom: 10px;">Dan Brown emphasised how the company expects to be 1st to market with a topical formulatoin for which it reatins alll rights in all geographies and in all indications.<wbr> With this product together with RT-002 the company's aim is to create a premier dermatology company.<wbr> </div><div style="margin-bottom: 10px;">It has initiated is phIII 1800 patient safety study with RT-001 which it claims represents a critical step forward in terms of its BLA &amp; MAA filings in 2016.<wbr> Interim data from this study will be available in 2015.<wbr> Its 2nd pivotal phIII study in crows feet n=170 is starting now.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Comments on RT-002</STRONG> </div><div style="margin-bottom: 10px;">There was significant reference on the call to the very compelling data generated by the PhI/<wbr>II study conducted with its injectable formulation RT-002.<wbr> </div><div style="margin-bottom: 10px;">The results of this were detailed a few weeks ago.<wbr> (see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7515" class="defaultlink">Neurology7515: Positive Results from Revance's Injectable Botulinum Toxin Ph1/<wbr>2 Study in GL</a>) but on the call it was newly sepcified that the median duration of action demonstrated with the product was 7.<wbr>3 months.<wbr> An active comparator trial focusing on this key benefit will commence this year with results expected in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Therapeutic Intent With RT-002</STRONG> </div><div style="margin-bottom: 10px;">When questioned about whether any thought had been given to therapeutic indications for this product.<wbr> Revance acknolwedged that it was giving careful consideration to this idea trying to identify the most appropriate indication where it can demonstrate value both in terms of lack of spread and duration of action.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>European Partnerhsip Potential</STRONG> </div><div style="margin-bottom: 10px;">The company is continuing to look at what it has to evaluate and what the right time to partner will be.<wbr> It was confirmed that it is certainly not at the moment.<wbr> </div><div style="margin-bottom: 10px;">Outside of its designated core areas, of North Americaa and aesthetics it will also give consideration to the concept that it is or will be a specialty pharmaceutical company.<wbr> As such, it will look at therapeutic indications with an open-mind.<wbr> considering whether it wishes to market its products in those areas as the business continues to grow.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Financial Situation</STRONG> </div><div style="margin-bottom: 10px;">Revance's balance sheet remains strong after the cash injection from the IPO with $88m in cash at the end of March.<wbr> </div><div style="margin-bottom: 10px;">Whilst the quarterly burn rate was high for the first quarter at $22m it will be lower in the remaining quarters of the year leading to a projected cash burn for the full year of $75-85m.<wbr> </div><div>The group's net loss for the quarter of $21.<wbr>4m was made up of $11.<wbr>6m of operating expenses and $9.<wbr>8m of interest expense.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7576">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-14T11:39:08+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>GSK To Be Charged With Corporate Bribery In China [mkt:China, sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10859</link>
<description>GSK To Be Charged With Corporate Bribery In China [mkt:China, sub:Finance]</description><category>mkt:China</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10859</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10859">GSK To Be Charged With Corporate Bribery In China</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10859">PharmaWorld10859</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 14 May 2014 | 10:23</font><br><br><div style="margin-bottom: 10px;">Comment: According to the FT, Police Authorities in China have 
today claimed that they have found evidence that GSK as a company has 
engaged in bribery on a "huge scale".<wbr> </div><div style="margin-bottom: 10px;">They are suggesting that the former country head ordered staff to bribe 
doctors and government officials.<wbr> </div><div style="margin-bottom: 10px;">According to the police, the drugmaker funded the bribes by inflating the 
price of medicines in China, some of which were seven times more expensive than 
in other markets.<wbr> </div><div style="margin-bottom: 10px;">Last summer GSK admitted that some of its employees in China had appeared to 
have brocken laws.<wbr> It has since scapped individual sales targets for staff in 
China as part of an overhaul of its marketing.<wbr> </div><div style="margin-bottom: 10px;">However, after a 10 month long investigation, the case is being passed to the 
prosecutors with a recommendation that the company and its executives be charged 
with corporate bribery.<wbr> </div><div>Source: Financial Times </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10859">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-14T10:23:43+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Potentially The Next Big Commercial Opportunity In the Aesthetic Market [headline, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7575</link>
<description>Potentially The Next Big Commercial Opportunity In the Aesthetic Market [headline, sub:Aesthetics]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7575</comments><category>headline</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7575</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7575">Potentially The Next Big Commercial Opportunity In the Aesthetic Market</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7575">Neurology7575</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 May 2014 | 17:27</font><br><br><div style="margin-bottom: 10px;">Comment:- Kythera Biopharmaceuticals has announced its NDA submission to the 
US FDA for the approval of ATX-101, an new injectable aesthetic product for the 
reduction of submental fat commonly known as " double chin".<wbr> Highlights of a 
recent presentation given by Kythera highlight the potential synergies with 
toxin therapy.<wbr> </div><div style="margin-bottom: 10px;">In the Q413 Trends in Cosmetic Procedures Survey undertaken by MEDACorp 
ATX-101 and Revance's topical toxin held the highes new product interest amongst 
the 62 US dermatologist and pastic surgeons surveyd.<wbr> </div><div style="margin-bottom: 10px;"><TABLE style="HEIGHT: 636px; WIDTH: 404px" width="404"><TBODY><TR align="left"><TD>
      <DIV class="article_body">Positive and consistent results from two pivotal 
      Phase III trials -- REFINE-1 and REFINE-2 -- were reported in late 2013 
      and are now providing the basis for the NDA submission.<wbr> </DIV>
      
      <DIV class="article_body">In these trials, the majority of ATX-101 patients 
      had a visible reduction in fat under the chin and reported significant 
      improvement in the visual and emotional impact of treatment.<wbr> It also 
      demonstrated an excellent safety profile <BR><BR> While the area 
      under the chin is visually important to patients, there are 
      currently no approved non-surgical options available to reduce 
      submental fat.<wbr> ATX-101 could therefore be a first-in-class 
      submental contouring injectable drug for patients seeking to reduce fat 
      under the chin.<wbr> <BR><BR>Next Steps</DIV>
      
      <DIV class="article_body">Beyond this NDA submission, KYTHERA also plans to 
      make multiple ex-U.<wbr>S.<wbr> regulatory submissions by the second quarter of 
      2015.<wbr> </DIV>
      
      <DIV class="article_body">In March of this year, KYTHERA announced it 
      acquired all rights to ATX-101 outside of the U.<wbr>S.<wbr> and Canada from Bayer 
      Consumer Care AG, to which it had licensed the commercial rights for 
      ATX-101 outside of U.<wbr>S.<wbr> and Canada in 2010.<wbr> <BR><BR><STRONG>What is 
      ATX-101?</STRONG></DIV>
      
      <DIV class="article_body">It is a proprietary formulation of a purified 
      synthetic version of deoxycholic acid, a naturally occurring molecule in 
      the body that aids in the breakdown of dietary fat.<wbr> ATX-101 treatment 
      contours the area under the chin by destroying fat cells while leaving 
      surrounding tissue largely unaffected.<wbr></DIV>
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/1/ScreenCapture1.jpg?user-agent=rss"></DIV>
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/2/ScreenCapture2.jpg?user-agent=rss"></DIV>
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/3/ScreenCapture3.jpg?user-agent=rss"></DIV>
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/4/ScreenCapture4.jpg?user-agent=rss"></DIV>
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/5/ScreenCapture5.jpg?user-agent=rss"></DIV>
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/6/ScreenCapture6.jpg?user-agent=rss"></DIV>
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/7/ScreenCapture7.jpg?user-agent=rss"></DIV>
      
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/8/ScreenCapture9.jpg?user-agent=rss"></DIV>
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/9/ScreenCapture10.jpg?user-agent=rss"></DIV>
      
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/10/ScreenCapture11.jpg?user-agent=rss"></DIV>
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/11/ScreenCapture12.jpg?user-agent=rss"></DIV>
      
      <DIV class="article_body"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/12/ScreenCapture13.jpg?user-agent=rss"></DIV>
      
      <DIV class="article_body">Scource: <A href="http://www.kytherabiopharm.com">www.<wbr>kytherabiopharm.<wbr>com</A></DIV>
      </TD>
</TR>
</TBODY>
</TABLE> </div><div><TABLE width="100%"><TBODY><TR><TD class="bb">&nbsp;</TD>
</TR>
</TBODY>
</TABLE> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7941c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>KYTHERA Biopharmaceuticals has announced that the US FDA Dermatologic and Ophthalmic Drugs Advisory Committee has voted unanimously to support approval of ATX-101 (deoxycholic acid) injection for improvement in appearance of moderate to severe convexity or fullness associated with submental fat in adults, often referred to as double chin.<wbr>If approved, ATX-101 would be first-in-class submental contouring injectable drug.<wbr> If approved by FDA, KYTHERA anticipates launching ATX-101 in second half of 2015.<wbr> It will be interesting to observe whether Kythera becomes an acquisition target based on ATX-101's approval given the high ongoing level of interest in facial aesthetic M&amp;A.<wbr> </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7941" class="commentpermalink">Neurology7941</a> / <span class="date">10 March 2015</span> /
<span class="time">18:22:23 o'clock CET</span>
</font></div><a name="neurology7575attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(167,1 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(213,2 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(185,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(236,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(132,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(135,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(121,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/8/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(184,9 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/9/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(223 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/10/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(220,3 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/11/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(204,9 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/12/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(250,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7575">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-13T17:27:37+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/1/ScreenCapture1.jpg" length="171113" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/2/ScreenCapture2.jpg" length="218331" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/3/ScreenCapture3.jpg" length="190345" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/4/ScreenCapture4.jpg" length="242126" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/5/ScreenCapture5.jpg" length="135599" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/6/ScreenCapture6.jpg" length="138477" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/7/ScreenCapture7.jpg" length="124477" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/8/ScreenCapture9.jpg" length="189288" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/9/ScreenCapture10.jpg" length="228310" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/10/ScreenCapture11.jpg" length="225579" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/11/ScreenCapture12.jpg" length="209799" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7575/12/ScreenCapture13.jpg" length="256836" type="image/jpeg"/></item><item>
<title>Good News For Santhera As DMD Trial Meets Primary Endpoint [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7574</link>
<description>Good News For Santhera As DMD Trial Meets Primary Endpoint [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7574</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7574">Good News For Santhera As DMD Trial Meets Primary Endpoint</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7574">Neurology7574</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 May 2014 | 17:07</font><br><br><div style="margin-bottom: 10px;">Comment: Santhera Pharmaceuticals has announced that its Phase III DELOS 
study of orally administered Catena®/<wbr>Raxone® (idebenone) in patients with 
Duchenne Muscular Dystrophy (DMD) met the primary endpoint and achieved its 
primary objective of delaying the loss of respiratory function compared to 
placebo </div><div style="margin-bottom: 10px;"><STRONG>Key Study Findings.<wbr></STRONG> </div><div style="margin-bottom: 10px;">The Phase III, double-blind, 
placebo-controlled DELOS study randomized 65 DMD patients who were 10-18 years 
of age and who were not using concomitant corticosteroids.<wbr> The study met the 
primary endpoint, the difference between Catena®/<wbr>Raxone® and placebo in the 
change from baseline to week 52 in Peak Expiratory Flow (p=0.<wbr>04).<wbr> Peak 
Expiratory Flow is a measure of respiratory muscle strength, the decline of 
which is a major contributing factor to morbidity and mortality in DMD.<wbr> 
Catena®/<wbr>Raxone® (900 mg/<wbr>day) was safe and well tolerated with adverse event 
rates comparable to placebo.<wbr> Other endpoint analyses are ongoing and results of 
these will be disclosed shortly.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Commenting on the results 
Santhera's CEO stated:-</STRONG> </div><div style="margin-bottom: 10px;">"We are thrilled by these results which are consistent with the findings of 
our Phase II DELPHI and DELPHI Extension studies," As acknowledged by clinicians 
and regulatory authorities, preservation of respiratory function is a major 
benefit for patients with DMD.<wbr> On the basis of these results we will approach 
the US and European authorities for discussions on the most expeditious 
regulatory pathway to approval.<wbr>" </div><div>Santhera holds global 
commercialization rights to the DMD program, which has been granted orphan drug 
designation and patent protection in the US and EU.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7574">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-13T17:07:16+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Large Stakeholding in Sanofi Could Be Up For Grabs [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10857</link>
<description>Large Stakeholding in Sanofi Could Be Up For Grabs [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10857</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10857">Large Stakeholding in Sanofi Could Be Up For Grabs</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:PharmaWorld:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10857">PharmaWorld10857</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 May 2014 | 16:56</font><br><br><div style="margin-bottom: 10px;">Comment: Adding to the mix of acquisitions and divestitures in 
pharmaceuticals.<wbr>, L'Oreal's CEO has told a German Newspaper that it is ready to 
cash in its 9% stake in Sanofi, if money is needed to fund a large takeover.<wbr> </div><div style="margin-bottom: 10px;">L'Oreal in February agreed a deal to buy back an 8% stake in its own 
capital from Swiss consuder good group Nestle giving rise to specularion that it 
maay lok to sell its stake in Sanofi to fund that deal.<wbr> </div><div style="margin-bottom: 10px;">At the time L'Oreal stated it was very happy with its role as a core 
shareholder in Sanofi.<wbr> but clearly in recent weeks further thought is being 
given as to what to do with that shareholding.<wbr> </div><div>Scource: Reuters </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10857">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-13T16:56:02+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Allergan Board Unanimously Rejects Valeant Bid</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7573</link>
<description>re: Allergan Board Unanimously Rejects Valeant Bid</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7573</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7573">re: Allergan Board Unanimously Rejects Valeant Bid</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7573">Neurology7573</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 May 2014 | 16:47</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan Board Unanimously Rejects Valeant Bid</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Earlier today Allergan announced its rejection of Valeant's $47bn 
proposed offer.<wbr> It rejected the offer based on projected EPS growth of 20-25% in 
2015 based on continued double-digit revenue growth.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7569">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7569" class="commentpermalink">Neurology7569</a> / <span class="date">12 May 2014</span> /
<span class="time">16:14:22 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Valeant has said today that it will improve on its $47bn offer for Allergan and will change the cash/<wbr>stock composition.<wbr> It sounds as though it will made the revised offer on May 28th during a webcast to outline in more detail its intentions regarding the Allergan business.<wbr> Valeant re-stated that it remains committed to getting the deal done but will be "financially disciplined".<wbr> </div><div style="margin-bottom: 10px;">In a letter to shareholders, Valeant's CEO has also stated that it will not withdraw its offer until it hears from shareholders that  they prefer Allergan's "Stay the course plan" to a combination with Valeant.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7573" class="commentpermalink">Neurology7573</a> / <span class="date">13 May 2014</span> /
<span class="time">16:47:47 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7573">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7569">View thread  Neurology7569: Allergan Board Unanimously Rejects Valeant Bid</a>]]></content:encoded><dc:date>2014-05-13T16:47:47+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Spasticity Data Presented At The European Stroke Meeting [class:BotulinumToxins, prod:Xeomin, prod:Botox, dis:Spasticity, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7571</link>
<description>Spasticity Data Presented At The European Stroke Meeting [class:BotulinumToxins, prod:Xeomin, prod:Botox, dis:Spasticity, news]</description><category>class:BotulinumToxins</category><category>prod:Xeomin</category><category>prod:Botox</category><category>dis:Spasticity</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7571</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7571">Spasticity Data Presented At The European Stroke Meeting</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aXeomin"><font color="#e95e0b">:Neurology:prod:Xeomin</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7571">Neurology7571</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 13 May 2014 | 15:13</font><br><br><div style="margin-bottom: 10px;">Comment: Last week's meeting included an interesting abstract by MF Jeddi from the Royal Berkshire Hospital (UK), detailing the group's retrospective experience with Dysport and Xeomin in treating post stroke spasticity.<wbr> Additionally, an oral presentation was given on baseline and health utility data from Allergan's MOBILITY study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botulinum Toxin Injections for post stroke spasticity: The Royal Berkshire Hospital Experience UK</STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Jeddi et al Abstract R0607</STRONG> </div><div style="margin-bottom: 10px;">Whilst most of the literature details the outcome of BTx-A injections in spasticity, The Reading Group's abstract is different in detailing the actual number of muscles injected, the most commonly inected muscles, average dosage of toxin used and the degree and patterns of spasticity amongst the 637 patients treated over a 5-year period (2009-2013).<wbr> Significantly more Dysport was used over this period than Xeomin 211445 iu of the former and 25215 of the latter.<wbr> </div><div style="margin-bottom: 10px;">A copy of the full abstract is attached </div><div style="margin-bottom: 10px;"><STRONG>Baseline demographics and evaluation of health utility in adult patients receiving BOTOX therapy for post-stroke spasticity in a prospective observation cohort study MOBILITY</STRONG> </div><div style="margin-bottom: 10px;">T Wein et al McGill University </div><div style="margin-bottom: 10px;">Wein during an oral abstract presentation, presented data from a Canadian , multi-centre observation study collecting patient reported outcome data in patients intitiatin (naive) or receving ongoing (maintenance) onabotulinum treatment Health utility was the primary outcome measure obtained from the SF12 Health Survey using the SF-6D collected at baseline, week 4 post treatment and up to 5 subsequent injection visits.<wbr> </div><div style="margin-bottom: 10px;">220 post stroke patients were enrolled and it is reported that improvement in mean HU scores from baseline were seen in both naive and maintenance cohorts at select timepoints and were generally increased and/<wbr>or maintained over time.<wbr> </div><div style="margin-bottom: 10px;">The MOBILITY study is designed to collect demographic, treatment pattern and health utility data related to the use of Botox across several indication including movement disorders, hyperhidrosis, adult focal spasticity (AFS) and cerebral palsy.<wbr> </div><div>A copy of the full abstract is attached.<wbr> </div><!-- Comment details --><a name="neurology7571attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7571/1/ESC%5fNice%5f2014%5fprogramme%5f301.pdf">ESC_Nice_2014_programme_301.pdf</a>&nbsp;&nbsp;(1,3 MB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7571/2/ESC%5fNice%5f2014%5fprogramme%5f47.pdf">ESC_Nice_2014_programme_47.pdf</a>&nbsp;&nbsp;(1,4 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7571">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-13T15:13:19+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7571/1/ESC%5fNice%5f2014%5fprogramme%5f301.pdf" length="1364954" type="application/pdf"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7571/2/ESC%5fNice%5f2014%5fprogramme%5f47.pdf" length="1441078" type="application/pdf"/></item><item>
<title>Key Insights From The Medivation &amp; Astellas Q1 Figures [class:Antihormonals, dis:Prostate, comp:Astellas, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9698</link>
<description>Key Insights From The Medivation &amp; Astellas Q1 Figures [class:Antihormonals, dis:Prostate, comp:Astellas, headline]</description><category>class:Antihormonals</category><category>dis:Prostate</category><category>comp:Astellas</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9698</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9698">Key Insights From The Medivation & Astellas Q1 Figures</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9698">Oncology9698</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 May 2014 | 22:50</font><br><br><div style="margin-bottom: 10px;">Comment: Medivation reported strong growth in Xtandi sales with revenues in Q1 reaching $125.<wbr>4m vs.<wbr>$75.<wbr>4m for the prior year period.<wbr> Surprisingly strong uptake in the post-chemo segment has prompted an upward revision in 2014 forecast sales now in the range of $540m -$575m.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Xtandi Notworthy developments</STRONG> </div><div style="margin-bottom: 10px;">Last week Medivation &amp; its partner were notified that the US sNDA for enzalutamide in pre-chemo mCRPC was accepted for filing and granted Priority Review Designation.<wbr> The FDA has set the PDUFA date for the completion of the review as Sept 18th 2014.<wbr> </div><div style="margin-bottom: 10px;">Market research reportedly shows high awareness among both oncologists and urologists, with Xtandi continuing to lead in share of voicec in oncology, the primray prescriber group for the post-chemo label.<wbr> Based upon progress in post-chemotherapy approvals ex US, Q1 sales are reported by Astellas in this region as $47.<wbr>8m.<wbr> </div><div style="margin-bottom: 10px;">Xtandi has now been launched in 19 European countries and last Friday finally received a positive recommendation for reimbursement in the UK.<wbr> Negotations are ongoing in Germany with the final result expected in June.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Xtandi Clinical Development Progress</STRONG> </div><div style="margin-bottom: 10px;">Enrollment is reported as ongoing in the PROSPER trial which was initiated in December 2013.<wbr> Both of the phase 2 trials TERRAIN &amp; Strive have now completed enrollment.<wbr> Both of these trials are head-head trials versus bicalutamide, the most commonly used anti-adnrogen therapy.<wbr> Astellas completed enrollment in TERRAIN in July last year, whilst STRIVE only recently complete enrollment in the US in March.<wbr> In total both trials have enrolled 800 patients, with TERRAIN only enrolling metastatic patients whilst STRIVE also included non-metastatic patients, so potentially this could be used to support registration in the nmCRPC setting.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>New Prostate Cancer Development</STRONG> </div><div style="margin-bottom: 10px;">In April Medivation announced a licensing agreement with OncoFusion Therapeutics , a private company based on technology developed at the University of Michigan.<wbr> The agreement provides Medivation with exclusive W/<wbr>W rights for the development and commercialisation of a new class of drugs targeting BET bromodomain protein, </div><div style="margin-bottom: 10px;">Just two weeks ago an article appeared in Nature showing that a compound designed to inhibit BET bromodomain proteins, a large family of epigenetic reguatlors, has a significant effect on inhibiting prostate cancer growth in a preclinical model.<wbr> </div><div style="margin-bottom: 10px;">Consistent with the fact that the target of BET bromodomain inhibitors is downstream of the target for current hormonal therapyis in CRPC, they demonstrated efficacy in AR-resistant cell lines, suggesting such drugs may have therapeutic potential in patients with advanced disease who have progressed on other therapies.<wbr> </div><div style="margin-bottom: 10px;">Medivation's pipeline is not the only one to feature additional prostate cancer development programmes, as the Astellas pipeline highlights below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Performance of Astellas's OAB Urology Franchise</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Astellas Group Overall Sales Performance - Eligard Sales Slowdown </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Astellas's Strategic Priorities</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/6/ScreenCapture6.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9698attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(207,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(127,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(148,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(142,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(182,4 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(182,2 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9698">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-12T22:50:51+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/1/ScreenCapture1.jpg" length="212910" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/2/ScreenCapture2.jpg" length="130701" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/3/ScreenCapture3.jpg" length="151965" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/4/ScreenCapture4.jpg" length="145922" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/5/ScreenCapture5.jpg" length="186794" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9698/6/ScreenCapture6.jpg" length="186602" type="image/jpeg"/></item><item>
<title>Allergan's Business Update Call Highlights Strong Growth Potential [comp:Allergan, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7570</link>
<description>Allergan's Business Update Call Highlights Strong Growth Potential [comp:Allergan, headline]</description><category>comp:Allergan</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7570</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7570">Allergan's Business Update Call Highlights Strong Growth Potential</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7570">Neurology7570</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 May 2014 | 17:10</font><br><br><div style="margin-bottom: 10px;">Comment: Supporting its rejection of the Valeant Bid, Allergan hosted a 
Busines Update Call today to elaborate on its strong growth outlook and record 
of innovation.<wbr> Whilst it focused on its growth trajectory and even 
suggested that some new indication for Botox may offer the greatest 
opportunities yet, there was very little mention of the key 
pipeline developments and certainly no mention of its liquid toxin 
programme.<wbr> Key slides are highlighted below with the full presentation 
attached.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/9/ScreenCapture9.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/10/ScreenCapture10.jpg?user-agent=rss"> </div><!-- Comment details --><a name="neurology7570attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(167 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(117,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(189,9 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(146,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(162,5 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(135,6 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(118 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(149 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(79,2 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/10/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(142 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/11/Allergan%5fCompany%20presentation%5fJun12.pdf">Allergan_Company presentation_Jun12.pdf</a>&nbsp;&nbsp;(2 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7570">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-12T17:10:41+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/1/ScreenCapture1.jpg" length="170993" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/2/ScreenCapture2.jpg" length="120452" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/3/ScreenCapture3.jpg" length="194455" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/4/ScreenCapture4.jpg" length="150195" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/5/ScreenCapture5.jpg" length="166408" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/6/ScreenCapture6.jpg" length="138897" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/7/ScreenCapture7.jpg" length="120835" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/8/ScreenCapture8.jpg" length="152574" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/9/ScreenCapture9.jpg" length="81078" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/10/ScreenCapture10.jpg" length="145452" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7570/11/Allergan%5fCompany%20presentation%5fJun12.pdf" length="2093332" type="application/pdf"/></item><item>
<title>Shire To Acquire Lumena For $260m [sub:Acquisition, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10856</link>
<description>Shire To Acquire Lumena For $260m [sub:Acquisition, headline]</description><category>sub:Acquisition</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10856</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10856">Shire To Acquire Lumena For $260m</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:PharmaWorld:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10856">PharmaWorld10856</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 May 2014 | 16:29</font><br><br><div style="margin-bottom: 10px;">Comment: Strengthening its focus on rare diseases Shire is to acquire the US 
private company Lumena  Pharmaceuticals for an upfront payment of $260m in 
cash.<wbr> Lumena brings to Shire two new oral therapeutic compounds; LUM001, in 
Phase 2 with four potential orphan indications and LUM002, ready to enter Phase 
2 later in 2014.<wbr> The rare cholestatic liver diseases these drugs trear are 
primarily treated by hepatologists and gastroenterologists and can be covered by 
a small, specialty sales force consistent with Shire’s model.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Strategic rationale and background on Lumena 
Pharmaceuticals</STRONG> </div><div style="margin-bottom: 10px;">The acquisition of Lumena complements Shire’s strategic focus on Rare 
Diseases and provides a future growth path for Shire’s Gastrointestinal 
business, which generated revenues of over $800 million in 2013.<wbr>   In 
acquiring Lumena, Shire is gaining experience in liver disease with the 
opportunity to leverage its existing GI commercial infrastructure.<wbr>  In 
addition, there is a good fit with Shire’s recent acquisition of Fibrotech, 
which has brought pipeline programs to address unmet patient need in other 
fibrotic conditions including renal impairment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Mechanistically What Are These Products?</STRONG> </div><div style="margin-bottom: 10px;">LUM001 and LUM002 are both inhibitors of the apical sodium-dependent bile 
acid transporter (ASBT), which is primarily responsible for recycling bile acids 
from the intestine to the liver.<wbr>  Blocking bile acid transport with ASBT 
inhibitors reduces bile acid absorption and has the potential to improve liver 
function and relieve disease symptoms (such as extreme itching associated with 
cholestatic liver diseases), and may slow disease progression.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About LUM001</STRONG> </div><div style="margin-bottom: 10px;">LUM001 is currently in Phase 2 clinical development for four rare cholestatic 
liver disease indications; two pediatric and two adult with a potential 2016 
launch.<wbr>  These potential indications are: Alagille syndrome (ALGS), 
progressive familial intrahepatic cholestasis (PFIC), primary biliary cirrhosis 
(PBC) and primary sclerosing cholangitis (PSC).<wbr> </div><div style="margin-bottom: 10px;">Some of the key characteristics of cholestatic liver diseases are elevated 
bile acids, leading to progressive liver damage that can cause liver failure, 
and pruritus, or severe itching.<wbr>  Pruritus is generally the most 
debilitating symptom afflicting children and adults with these diseases.<wbr> </div><div style="margin-bottom: 10px;">Surgical intervention, which lowers bile acid levels, has been shown to 
relieve symptoms and slow disease progression in patients with ALGS and PFIC – 
this is currently the only treatment option for these patients.<wbr> Patients with 
cholestatic liver diseases may ultimately require liver transplants.<wbr> </div><div style="margin-bottom: 10px;">By reducing serum bile acids, LUM001 may offer a novel therapeutic approach 
for alleviating the pruritus and progressive liver damage associated with 
cholestatic liver diseases.<wbr> </div><div style="margin-bottom: 10px;">The prevalence of each of the four diseases is as follows: </div><div style="margin-bottom: 10px;"><TABLE border="0" cellpadding="2" cellspacing="2" width="100%"><TBODY><TR><TD>Indication</TD>
<TD>US prevalence</TD>
<TD>EU prevalence</TD>
</TR>
<TR><TD>ALGS</TD>
<TD>3 per 100,000<BR>9476 individuals</TD>
<TD>3 per 100,000</TD>
</TR>
<TR><TD>PFIC</TD>
<TD>&lt;1 per 100,000<BR>3159 individuals</TD>
<TD>1 per 100,000</TD>
</TR>
<TR><TD>PBC</TD>
<TD>40 per 100,000<BR>126,979 individuals</TD>
<TD>30 per 100,000</TD>
</TR>
<TR><TD>PSC</TD>
<TD>14 per 100,000<BR>44,222 individuals</TD>
<TD>3 per 100,000</TD>
</TR>
</TBODY>
</TABLE> </div><div style="margin-bottom: 10px;"><EM>(Source: Lumena Pharmaceuticals Applications for Orphan 
Designation):</EM> </div><div style="margin-bottom: 10px;">LUM001 has received orphan drug designation for all four potential 
indications in both the United States and the European Union.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>About LUM002</STRONG> </div><div style="margin-bottom: 10px;">LUM002 is a novel, once daily, orally-administered, highly potent and 
selective inhibitor of ASBT, in development for the treatment of nonalcoholic 
steatohepatitis (NASH), a common and often “silent” liver disease characterized 
by fat deposits in the liver and inflammation which can progress to significant 
fibrosis.<wbr> </div><div style="margin-bottom: 10px;">While the underlying cause of liver injury in NASH is not fully known, it is 
strongly associated with obesity, Type 2 diabetes, high cholesterol and 
triglycerides, and other metabolic disorders.<wbr> Approximately 6 million 
individuals in the US are estimated to have progressed to NASH and some 600,000 
to NASH-related cirrhosis (Source: World Gastroenterology Organisation Global 
Guidelines June 2012).<wbr> </div><div style="margin-bottom: 10px;">By blocking bile acid reabsorption, LUM002 is thought to modulate colonic 
bile acid concentrations and receptor signaling on cells in the lower portion of 
the GI tract.<wbr> This signaling is believed to result in the secretion of peptides 
that regulate insulin release from the pancreas, glucose metabolism and the 
synthesis of cholesterol and fatty acids.<wbr> </div><div style="margin-bottom: 10px;">Therapeutic strategies aimed at modulating insulin resistance and normalizing 
lipoprotein metabolism have significant potential to benefit patients with 
NASH.<wbr> </div><div style="margin-bottom: 10px;">Phase 1 safety trials in healthy volunteers and a Phase 1b trial in patients 
with metabolic disease have been completed.<wbr>  The next step is to initiate a 
Phase 2 clinical trial in patients with NASH – anticipated to begin in the 
second half of 2014.<wbr> </div><div>Source: <A href="http://www.shire.com">www.<wbr>shire.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10856">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-12T16:29:14+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Allergan Board Unanimously Rejects Valeant Bid [comp:Allergan, headline, :PharmaWorld:sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7569</link>
<description>Allergan Board Unanimously Rejects Valeant Bid [comp:Allergan, headline, :PharmaWorld:sub:Acquisition]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7569</comments><category>comp:Allergan</category><category>headline</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7569</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7569">Allergan Board Unanimously Rejects Valeant Bid</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7569">Neurology7569</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 12 May 2014 | 16:14</font><br><br><div style="margin-bottom: 10px;">Comment: Earlier today Allergan announced its rejection of Valeant's $47bn 
proposed offer.<wbr> It rejected the offer based on projected EPS growth of 20-25% in 
2015 based on continued double-digit revenue growth.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Points Behind The Rebuttal</STRONG> </div><div style="margin-bottom: 10px;">Allergan also highlighted the risk to Allergan shareholders of the large 
stock component of the offer given the uncertainty surrounding Valeant's 
long-term growth potential and business model.<wbr> Valeant offered $48.<wbr>3 per share 
in cash and 0.<wbr>83 Valeant shares for each Allergan share.<wbr> </div><div style="margin-bottom: 10px;">In a letter addressed to Valeant's CEO Mike Pearson, Allergan reportedly 
stated "In particular , we question how Valean would achieve the level of cost 
cuts it is proposing without harming the long term viability and growth 
trajectory of our business" </div><div style="margin-bottom: 10px;"><STRONG>Next Steps?</STRONG> </div><div style="margin-bottom: 10px;">It will be interesting to note, whether Allergan elaborates further on its 
case with a more detailed presentation to analysts and shareholders.<wbr> </div><div>Source: Reuters </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7573c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Valeant has said today that it will improve on its $47bn offer for Allergan and will change the cash/<wbr>stock composition.<wbr> It sounds as though it will made the revised offer on May 28th during a webcast to outline in more detail its intentions regarding the Allergan business.<wbr> Valeant re-stated that it remains committed to getting the deal done but will be "financially disciplined".<wbr> </div><div style="margin-bottom: 10px;">In a letter to shareholders, Valeant's CEO has also stated that it will not withdraw its offer until it hears from shareholders that  they prefer Allergan's "Stay the course plan" to a combination with Valeant.<wbr> </div><div>Source: Reuters </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7573" class="commentpermalink">Neurology7573</a> / <span class="date">13 May 2014</span> /
<span class="time">16:47:47 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7569">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-12T16:14:22+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>EAU Highlights III - Astellas Symposium &amp;  How The Development Paradigm for PCa Trials Is Expected To Change [class:Antihormonals, comp:Astellas, dis:Prostate, prod:MDV3100, :PharmaWorld:congress:EAU]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9694</link>
<description>EAU Highlights III - Astellas Symposium &amp;  How The Development Paradigm for PCa Trials Is Expected To Change [class:Antihormonals, comp:Astellas, dis:Prostate, prod:MDV3100, :PharmaWorld:congress:EAU]</description><category>class:Antihormonals</category><category>comp:Astellas</category><category>dis:Prostate</category><category>prod:MDV3100</category><category>congress:EAU</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9694</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9694">EAU Highlights III - Astellas Symposium &  How The Development Paradigm for PCa Trials Is Expected To Change</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aAntihormonals"><font color="#e95e0b">:Oncology:class:Antihormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aMDV3100"><font color="#e95e0b">:Oncology:prod:MDV3100</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aEAU"><font color="#e95e0b">:PharmaWorld:congress:EAU</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9694">Oncology9694</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 May 2014 | 18:51</font><br><br><div style="margin-bottom: 10px;">Comment: Clashing with the Ipsen Symposium was a symposium hosted by Astellas titled "Redefining clinical practice in CRPC, new thinking new directions.<wbr>" Some of the audience reactions to the case histories presented were interesting, as it was to note that a trial comparing enzalutamide to Radium-223 in pre-chemo CRPC patients is now planned by the EORTC.<wbr> </div><div style="margin-bottom: 10px;">The Astellas symposium was chaired by Bertrand Tombal with presenters including Axel Heidenreich, Simon Chowdhury and Karl Lummer.<wbr> The large Euroauditorium was just under half-full.<wbr> </div><div style="margin-bottom: 10px;">Bertrand Tombal, the PI of the PREVAIL trial.<wbr> introduced the symposium emphasising that these are exciting but complicated times in prostate cancer and that the idea behind the symposium was to try and help clinicians understand what is changing and how to put these changes into practice.<wbr> </div><div style="margin-bottom: 10px;">Karl Pummer focused his initial presentation on the rational for targeting the adrogen receptor in CRPC, with some of his key slides being those shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/1/ScreenCapture1.jpg?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/3/ScreenCapture3.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/4/ScreenCapture4.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><FONT face="Times New Roman" size="3"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/5/ScreenCapture7.jpg?user-agent=rss"></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/6/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/7/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">What is the future of newer AR agents he questioned.<wbr> What do they bring In a given patients you are often dealing with more than one pathway at any point in time.<wbr> </div><div style="margin-bottom: 10px;">He noted that not everyone with CRPC receives chemotherapy and the typical response rates seen with 2nd line hormonal agents.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/8/ScreenCapture12.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/9/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/10/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/11/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">He then proceeded to compare the results obtained with abiraterone in the pre-chemo setting with those obtained with enzalutamide in the PREVAIL study utilising the following slides to do so.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/12/ScreenCapture17.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/13/ScreenCapture18.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/14/ScreenCapture19.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/15/ScreenCapture21.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/16/ScreenCapture22.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/17/ScreenCapture23.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/18/ScreenCapture24.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/19/ScreenCapture26.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/20/ScreenCapture27.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/21/ScreenCapture28.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/22/ScreenCapture29.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/23/ScreenCapture30.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/24/ScreenCapture31.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The programme then continued with the discussion of two case histories, where the audience were asked to respond in terms of actions or treatment choices.<wbr> The essential elements of the cases plus the audience responses are shown below:- </div><div style="margin-bottom: 10px;"><STRONG>Case History 1 Aymptomatic CRPC Patient Axel Heidenreich</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/25/ScreenCapture32.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/26/ScreenCapture33.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/27/ScreenCapture35.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/28/ScreenCapture36.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/29/ScreenCapture37.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/30/ScreenCapture38.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Two-thirds opted for a novel hormonal therapy.<wbr> It was acknowledged that Docetaxel could be considered but it was not thought to be the best choice because the patient is asymptomatic and his PSA doubling time is not that high.<wbr> Tombal was suprised by the low level of enthusiasm for Sip-T and advocating that it should at least be considered.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Case History 2 Symptomatic CRPC Patient Simon Chowdery Medical Oncologist</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/31/ScreenCapture39.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/32/ScreenCapture40.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Axel's choice was 1 &amp; 6 trying to balance prolongation of survival whilst maintinaing overall QOL.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/33/ScreenCapture41.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/34/ScreenCapture42.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/35/ScreenCapture43.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Tombal's repsonse to this question was "Its an aggressive disease high gleason extremely progressive disease, I would not choose 1 as an option and certainly not consider Sip-T as he is progressing too rapidly.<wbr> With such rapid progression the choice today should probably be between chemotherapy or novel hormonal therapy.<wbr> Ideally I would put the patient in a sequencing or combination trial.<wbr>" </div><div style="margin-bottom: 10px;">Axel's choice was chemotherpy stating.<wbr> "He would be a primary candidate for chemotherapy.<wbr> If he refused we would opt for a clinical trial or one of the new hormonal therapies".<wbr> </div><div style="margin-bottom: 10px;">Tombal also suggested going back to the pathology and looking for neuroendocrine markers that can be a sign of very aggressive disease.<wbr> </div><div style="margin-bottom: 10px;">He noted that the chemo vs hormone choice still remains a significant issue but with this patient, given he did not show a great response to 1st line hormonal therapy, he advocated treatment with chemotherapy.<wbr> </div><div style="margin-bottom: 10px;">Following the panels comments the audience was asked to vote again with the results as shown below.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/36/ScreenCapture44.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Chowdrey stated that he was pleased to see that combined treatment with an anti-androgen has gone down.<wbr> </div><div style="margin-bottom: 10px;">Tombal noted that a superiority claim between chemo vs hormonal cannot be made today.<wbr> He liked the way the audience moved and advocated an observational trial type approach to evaluate the superiority of chemo vs hormonal in this type of setting.<wbr> </div><div style="margin-bottom: 10px;">One further point that was noted is that currently there is no evidence to suggest stopping LHRH therapy when ADT fails All the registration trials have been conducted where LHRH-agonist therapy has been continued.<wbr> Whilst it has been a long-standing controversy about whether treatment should be contineud it was noted several retrospective trials have indicated that survival is better if patients do continue LHRH therapy.<wbr> </div><div style="margin-bottom: 10px;">Bertrand Tombal concluded the symposium by emphasising that one of the answers to addressing the ongoing challenges is to enter patients in clinical trials.<wbr> He advocated three trials that merit inclusion of patients, highlighting the PLATO study in particular as an important study to eveluate treatment possibilities when patient's are progressing on enzalutamide.<wbr> He also commented on the new and upcoming EORTC trial which is going to evaluate enzalutamide vs.<wbr> Radium-223 in patients with pre-chemo CRPC who are asymptomatic or minimly symptomatic.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/37/ScreenCapture45.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/38/ScreenCapture46.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/39/ScreenCapture47.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/40/ScreenCapture50.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Earlier in the day during one of the EORTC sessions, Bertrand Tombal gave a very interesting perspective on how the development paradigm for prostate cancer could change over the course of the next few years, moving away from pivotal phIII randomised trials to more observational real-life biomarker led treatment evaluations.<wbr> He suggested that we have to integrate clinical trials into the new urological business model and also look at how we are going to prescribe these new drugs in an economic environment that needs to remain stable.<wbr> </div><div style="margin-bottom: 10px;">He even went so far as to suggest that the time of head to head studies is done and that we must embark on large cohort trials where we collect a lot of biomarker data.<wbr> Some of his key slides are shown below but first a little more background on the SPECTapros trial, a trial he views as very much the way forward and one that is currently recruiting at a rate of 10 patients per day.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/41/ScreenCapture51.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/42/ScreenCapture52.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/43/ScreenCapture53.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/44/ScreenCapture55.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/45/ScreenCapture56.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/46/ScreenCapture57.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/47/ScreenCapture59.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/48/ScreenCapture60.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/49/ScreenCapture61.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/50/ScreenCapture62.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/51/ScreenCapture63.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/52/ScreenCapture64.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/53/ScreenCapture65.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/54/ScreenCapture66.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/55/ScreenCapture67.jpg?user-agent=rss"> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/56/ScreenCapture68.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9694attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(644 B)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(62,8 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(50,4 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(75,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/5/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(84,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/6/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(102,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/7/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(68,7 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/8/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(77,7 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/9/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(82,6 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/10/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(73,1 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/11/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(75,5 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/12/ScreenCapture17.jpg">ScreenCapture17.jpg</a>&nbsp;&nbsp;(84,4 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/13/ScreenCapture18.jpg">ScreenCapture18.jpg</a>&nbsp;&nbsp;(77,7 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/14/ScreenCapture19.jpg">ScreenCapture19.jpg</a>&nbsp;&nbsp;(110,5 KB)<br>&nbsp;&nbsp;15.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/15/ScreenCapture21.jpg">ScreenCapture21.jpg</a>&nbsp;&nbsp;(84,5 KB)<br>&nbsp;&nbsp;16.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/16/ScreenCapture22.jpg">ScreenCapture22.jpg</a>&nbsp;&nbsp;(67,5 KB)<br>&nbsp;&nbsp;17.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/17/ScreenCapture23.jpg">ScreenCapture23.jpg</a>&nbsp;&nbsp;(63,4 KB)<br>&nbsp;&nbsp;18.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/18/ScreenCapture24.jpg">ScreenCapture24.jpg</a>&nbsp;&nbsp;(72,7 KB)<br>&nbsp;&nbsp;19.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/19/ScreenCapture26.jpg">ScreenCapture26.jpg</a>&nbsp;&nbsp;(72,2 KB)<br>&nbsp;&nbsp;20.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/20/ScreenCapture27.jpg">ScreenCapture27.jpg</a>&nbsp;&nbsp;(70 KB)<br>&nbsp;&nbsp;21.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/21/ScreenCapture28.jpg">ScreenCapture28.jpg</a>&nbsp;&nbsp;(89,2 KB)<br>&nbsp;&nbsp;22.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/22/ScreenCapture29.jpg">ScreenCapture29.jpg</a>&nbsp;&nbsp;(70,2 KB)<br>&nbsp;&nbsp;23.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/23/ScreenCapture30.jpg">ScreenCapture30.jpg</a>&nbsp;&nbsp;(81,5 KB)<br>&nbsp;&nbsp;24.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/24/ScreenCapture31.jpg">ScreenCapture31.jpg</a>&nbsp;&nbsp;(40,1 KB)<br>&nbsp;&nbsp;25.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/25/ScreenCapture32.jpg">ScreenCapture32.jpg</a>&nbsp;&nbsp;(70 KB)<br>&nbsp;&nbsp;26.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/26/ScreenCapture33.jpg">ScreenCapture33.jpg</a>&nbsp;&nbsp;(74,6 KB)<br>&nbsp;&nbsp;27.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/27/ScreenCapture35.jpg">ScreenCapture35.jpg</a>&nbsp;&nbsp;(82,1 KB)<br>&nbsp;&nbsp;28.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/28/ScreenCapture36.jpg">ScreenCapture36.jpg</a>&nbsp;&nbsp;(71,3 KB)<br>&nbsp;&nbsp;29.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/29/ScreenCapture37.jpg">ScreenCapture37.jpg</a>&nbsp;&nbsp;(42,5 KB)<br>&nbsp;&nbsp;30.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/30/ScreenCapture38.jpg">ScreenCapture38.jpg</a>&nbsp;&nbsp;(49,7 KB)<br>&nbsp;&nbsp;31.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/31/ScreenCapture39.jpg">ScreenCapture39.jpg</a>&nbsp;&nbsp;(68,4 KB)<br>&nbsp;&nbsp;32.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/32/ScreenCapture40.jpg">ScreenCapture40.jpg</a>&nbsp;&nbsp;(51,9 KB)<br>&nbsp;&nbsp;33.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/33/ScreenCapture41.jpg">ScreenCapture41.jpg</a>&nbsp;&nbsp;(40,9 KB)<br>&nbsp;&nbsp;34.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/34/ScreenCapture42.jpg">ScreenCapture42.jpg</a>&nbsp;&nbsp;(52,1 KB)<br>&nbsp;&nbsp;35.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/35/ScreenCapture43.jpg">ScreenCapture43.jpg</a>&nbsp;&nbsp;(67,3 KB)<br>&nbsp;&nbsp;36.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/36/ScreenCapture44.jpg">ScreenCapture44.jpg</a>&nbsp;&nbsp;(76,8 KB)<br>&nbsp;&nbsp;37.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/37/ScreenCapture45.jpg">ScreenCapture45.jpg</a>&nbsp;&nbsp;(69 KB)<br>&nbsp;&nbsp;38.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/38/ScreenCapture46.jpg">ScreenCapture46.jpg</a>&nbsp;&nbsp;(71,8 KB)<br>&nbsp;&nbsp;39.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/39/ScreenCapture47.jpg">ScreenCapture47.jpg</a>&nbsp;&nbsp;(53,3 KB)<br>&nbsp;&nbsp;40.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/40/ScreenCapture50.jpg">ScreenCapture50.jpg</a>&nbsp;&nbsp;(70 KB)<br>&nbsp;&nbsp;41.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/41/ScreenCapture51.jpg">ScreenCapture51.jpg</a>&nbsp;&nbsp;(62,1 KB)<br>&nbsp;&nbsp;42.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/42/ScreenCapture52.jpg">ScreenCapture52.jpg</a>&nbsp;&nbsp;(63,2 KB)<br>&nbsp;&nbsp;43.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/43/ScreenCapture53.jpg">ScreenCapture53.jpg</a>&nbsp;&nbsp;(77,9 KB)<br>&nbsp;&nbsp;44.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/44/ScreenCapture55.jpg">ScreenCapture55.jpg</a>&nbsp;&nbsp;(59,4 KB)<br>&nbsp;&nbsp;45.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/45/ScreenCapture56.jpg">ScreenCapture56.jpg</a>&nbsp;&nbsp;(58,4 KB)<br>&nbsp;&nbsp;46.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/46/ScreenCapture57.jpg">ScreenCapture57.jpg</a>&nbsp;&nbsp;(78,2 KB)<br>&nbsp;&nbsp;47.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/47/ScreenCapture59.jpg">ScreenCapture59.jpg</a>&nbsp;&nbsp;(69,3 KB)<br>&nbsp;&nbsp;48.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/48/ScreenCapture60.jpg">ScreenCapture60.jpg</a>&nbsp;&nbsp;(69,4 KB)<br>&nbsp;&nbsp;49.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/49/ScreenCapture61.jpg">ScreenCapture61.jpg</a>&nbsp;&nbsp;(49,3 KB)<br>&nbsp;&nbsp;50.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/50/ScreenCapture62.jpg">ScreenCapture62.jpg</a>&nbsp;&nbsp;(70,4 KB)<br>&nbsp;&nbsp;51.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/51/ScreenCapture63.jpg">ScreenCapture63.jpg</a>&nbsp;&nbsp;(55,1 KB)<br>&nbsp;&nbsp;52.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/52/ScreenCapture64.jpg">ScreenCapture64.jpg</a>&nbsp;&nbsp;(54,2 KB)<br>&nbsp;&nbsp;53.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/53/ScreenCapture65.jpg">ScreenCapture65.jpg</a>&nbsp;&nbsp;(59,4 KB)<br>&nbsp;&nbsp;54.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/54/ScreenCapture66.jpg">ScreenCapture66.jpg</a>&nbsp;&nbsp;(46,8 KB)<br>&nbsp;&nbsp;55.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/55/ScreenCapture67.jpg">ScreenCapture67.jpg</a>&nbsp;&nbsp;(54,9 KB)<br>&nbsp;&nbsp;56.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/56/ScreenCapture68.jpg">ScreenCapture68.jpg</a>&nbsp;&nbsp;(37,8 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9694">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-09T18:51:27+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/1/ScreenCapture1.jpg" length="644" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/2/ScreenCapture2.jpg" length="64307" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/3/ScreenCapture3.jpg" length="51626" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/4/ScreenCapture4.jpg" length="77272" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/5/ScreenCapture7.jpg" length="86820" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/6/ScreenCapture9.jpg" length="104904" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/7/ScreenCapture11.jpg" length="70310" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/8/ScreenCapture12.jpg" length="79614" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/9/ScreenCapture13.jpg" length="84566" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/10/ScreenCapture14.jpg" length="74903" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/11/ScreenCapture15.jpg" length="77275" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/12/ScreenCapture17.jpg" length="86454" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/13/ScreenCapture18.jpg" length="79561" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/14/ScreenCapture19.jpg" length="113138" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/15/ScreenCapture21.jpg" length="86531" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/16/ScreenCapture22.jpg" length="69134" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/17/ScreenCapture23.jpg" length="64936" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/18/ScreenCapture24.jpg" length="74435" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/19/ScreenCapture26.jpg" length="73970" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/20/ScreenCapture27.jpg" length="71712" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/21/ScreenCapture28.jpg" length="91345" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/22/ScreenCapture29.jpg" length="71849" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/23/ScreenCapture30.jpg" length="83485" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/24/ScreenCapture31.jpg" length="41053" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/25/ScreenCapture32.jpg" length="71659" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/26/ScreenCapture33.jpg" length="76350" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/27/ScreenCapture35.jpg" length="84058" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/28/ScreenCapture36.jpg" length="73013" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/29/ScreenCapture37.jpg" length="43553" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/30/ScreenCapture38.jpg" length="50926" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/31/ScreenCapture39.jpg" length="70087" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/32/ScreenCapture40.jpg" length="53175" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/33/ScreenCapture41.jpg" length="41910" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/34/ScreenCapture42.jpg" length="53356" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/35/ScreenCapture43.jpg" length="68926" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/36/ScreenCapture44.jpg" length="78674" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/37/ScreenCapture45.jpg" length="70701" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/38/ScreenCapture46.jpg" length="73561" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/39/ScreenCapture47.jpg" length="54621" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/40/ScreenCapture50.jpg" length="71636" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/41/ScreenCapture51.jpg" length="63551" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/42/ScreenCapture52.jpg" length="64756" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/43/ScreenCapture53.jpg" length="79786" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/44/ScreenCapture55.jpg" length="60803" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/45/ScreenCapture56.jpg" length="59816" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/46/ScreenCapture57.jpg" length="80027" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/47/ScreenCapture59.jpg" length="70925" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/48/ScreenCapture60.jpg" length="71032" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/49/ScreenCapture61.jpg" length="50477" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/50/ScreenCapture62.jpg" length="72048" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/51/ScreenCapture63.jpg" length="56448" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/52/ScreenCapture64.jpg" length="55485" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/53/ScreenCapture65.jpg" length="60813" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/54/ScreenCapture66.jpg" length="47921" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/55/ScreenCapture67.jpg" length="56226" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9694/56/ScreenCapture68.jpg" length="38682" type="image/jpeg"/></item><item>
<title>Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9693</link>
<description>Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9693</comments><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9693</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9693">Nuvilex Signed Research Agreement to Study Development of Cannabis-Based Cancer Treatments</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9693">Oncology9693</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2014 | 18:23</font><br><br><div style="margin-bottom: 10px;">Comment: The goal of the research agreement signed with the U.<wbr> of Northern Colorado, is to develop a Cell-in-a-Box<SUP>(R)</SUP> /<wbr>cannabinoid combination that has anticancer effects coupled with low toxicity similar in concept to Nuvilex's pancreatic cancer treatment currently being prepared for Ph2b clinical trials that uses the Cell-in-a-Box<SUP>(R)</SUP> technology with low doses of the chemotherapeutic drug ifosfamide.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Initial Studies to be Performed</FONT></STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>to develop methods for the identification, separation and quantification of constituents (prodrugs) of <I id="yui_3_9_1_1_1399651707996_1160">Cannabis</I> that may be used in combination with Nuvilex's Cell-in-a-Box<SUP>(R) </SUP>technology.<wbr></LI>
<LI>to identify the appropriate cell type that can convert the selected cannabinoid prodrugs from their naturally-occurring forms into substances that are capable of killing cancer cells.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Nuvilex SnapShot</FONT></STRONG> </div><div style="margin-bottom: 10px;">Clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box<SUP>®</SUP>.<wbr> </div><div style="margin-bottom: 10px;">Nuvilex's subsidiary, Medical Marijuana Sciences, Inc.<wbr>, is dedicated to the development of cancer treatments based upon chemical constituents of marijuana known as cannabinoids.<wbr> To do so, it will examine ways to exploit the benefits of Cell-in-a-Box<SUP>®</SUP> technology in optimizing the anticancer effectiveness of cannabinoids against cancers while minimizing or eliminating the debilitating side effects usually associated with cancer treatments.<wbr> This provides Medical Marijuana Sciences a unique opportunity to develop "green" approaches to fighting deadly cancers, such as those of the pancreas, brain, breast and prostate, that affect hundreds of thousands of individuals worldwide every year.<wbr> </div><div><EM>Source: Nuvilex</EM> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology10043c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Nuvilex has submitted an application to the FDA seeking orphan drug designation for its Cell-in-a-Box treatment for pancreatic cancer.<wbr> In September, the company had submitted an application to the EMA for this treatment.<wbr> </div><div style="margin-bottom: 10px;">The company's pancreatic cancer treatment combines the Cell-in-a-Box cellulose-based live cell encapsulation technology with low doses of the anticancer prodrug ifosfamide to provide targeted chemotherapy to these patients.<wbr> </div><div>During the Cell-in-a-Box encapsulation process, cells are enclosed in pin-head-sized capsules, which convert ifosfamide into its cancer-killing form at or near the site of the tumor to increase the efficiency and effectiveness of a patient's treatment.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10043" class="commentpermalink">Oncology10043</a> / <span class="date">15 October 2014</span> /
<span class="time">18:04:31 o'clock CEST</span>
</font></div><a name="Oncology10180c"></a><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">FDA has granted Nuvilex orphan drug designation for its pancreatic cancer treatment.<wbr> Nuvilex's pancreatic cancer treatment combines Nuvilex's patented and proprietary cellulose-based encapsulation technology, known as Cell-in-a-Box<SUP>&reg;</SUP>, with the cancer prodrug ifosfamide and encapsulated live cells that convert the prodrug into its cancer-killing form.<wbr> These capsules are placed as close to the cancerous tumor as possible to enable the delivery of the highest levels of the cancer-killing drug at the source of the cancer.<wbr> </div><div style="margin-bottom: 10px;">Nuvilex is currently preparing for a Phase 2b clinical trial in advanced pancreatic cancer (the orphan indication) in Australia to gain regulatory approval from agencies like the FDA for Nuvilex's targeted chemotherapy of pancreatic cancer.<wbr> </div><div>Nuvilex's clinical trial is planned to commence in 2015.<wbr> </div><font size="-1">Brigitte DESCHAMPS / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology10180" class="commentpermalink">Oncology10180</a> / <span class="date">23 December 2014</span> /
<span class="time">11:19:31 o'clock CET</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9693">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-09T18:23:17+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>FIM of a Topical Soft Anticholingeric for Axillary Hyperhidrosis [dis:Hyperhydrosis, :PharmaWorld:sub:ClinicalTrial]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7568</link>
<description>FIM of a Topical Soft Anticholingeric for Axillary Hyperhidrosis [dis:Hyperhydrosis, :PharmaWorld:sub:ClinicalTrial]</description><category>dis:Hyperhydrosis</category><category>sub:ClinicalTrial</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7568</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7568">FIM of a Topical Soft Anticholingeric for Axillary Hyperhidrosis</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHyperhydrosis"><font color="#e95e0b">:Neurology:dis:Hyperhydrosis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7568">Neurology7568</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2014 | 16:58</font><br><br><div style="margin-bottom: 10px;">Comment: BBI-400 is the most advanced drug candidate in Brickell's pipeline, a clinical-stage pharmaceutical company focused on the acquisition, development and commercialization of innovative drug therapies for the treatment of skin diseases.<wbr> PE will assess percent change in the gravimetrically measured sweat production from baseline.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Strategic Partner</FONT></STRONG> </div><div style="margin-bottom: 10px;">Q1 13, Brickell announced $7M Series B financing; AMOREPACIFIC Group, the largest cosmetic and aesthetics company in Korea, leads financing and becomes strategic partner.<wbr> </div><div style="margin-bottom: 10px;">AMOREPACIFIC's net profit jumps 63% in the first-quarter of 2014 (source: <A href="http://www.koreatimes.co.kr/www/news/biz/2014/05/123_156857.html">http:/<wbr>/<wbr>www.<wbr>koreatimes.<wbr>co.<wbr>kr/<wbr>www/<wbr>news/<wbr>biz/<wbr>2014/<wbr>05/<wbr>123_156857.<wbr>html</A>) </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Trial Details</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Recruitment</U>: approx.<wbr> 18 males (18 to 45 years old) </div><div style="margin-bottom: 10px;"><UL style="MARGIN-TOP: 1ex; MARGIN-BOTTOM: 1ex"><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Primary axillary hyperhidrosis of at least 6 months duration.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Hyperhidrosis Disease Severity Score (HDSS) of 3 or 4 at baseline.<wbr></LI>
<LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Gravimetric test at baseline indicating at least 100mg of axillary sweat production in a 5 min period.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex"><U>Timelines</U></P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">The study is currently recruiting particpants</P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Completion date: August 2014</P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex"><U>Location</U>: Dominican Rep.<wbr> (1 site)</P> </div><div style="margin-bottom: 10px;"><P class="color-bullet" style="MARGIN-TOP: 0.7ex"><U>Principal Investigator</U>: Baisy Blanco M.<wbr>D</P> </div><div><P class="color-bullet" style="MARGIN-TOP: 0.7ex">Source: <A href="http://clinicaltrials.gov/ct2/show/NCT02058264?recr=Open&amp;cond=HYPERHIDROSIS&amp;fund=2&amp;rank=4">NCT02058264</A></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7568">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-09T16:58:42+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Preparation for FDA/EMA's Huntington's Talks Ongoing [dis:Huntington, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7566</link>
<description>Preparation for FDA/EMA's Huntington's Talks Ongoing [dis:Huntington, :PharmaWorld:sub:Finance]</description><category>dis:Huntington</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7566</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7566">Preparation for FDA/<wbr>EMA's Huntington's Talks Ongoing</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aHuntington"><font color="#e95e0b">:Neurology:dis:Huntington</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7566">Neurology7566</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2014 | 14:57</font><br><br><div style="margin-bottom: 10px;">Comment: Raptor plans to discuss the Huntington trial data with FDA in July and EMA this summer, and seek guidance from them to define the next steps toward the potential approval in the US and EU.<wbr> More color on the company's actions are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Meetings with Regulatory Agencies</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management emphasized its plans to meet both agencies in summer, highlighting this will 1/<wbr>provide a maximum advantage of the promising results from the study and 2/<wbr>move forward to potential approvals.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Publication</FONT></STRONG> </div><div style="margin-bottom: 10px;">The RP103 HD data are currently being prepared for publication.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Growth of Procysbi</FONT></STRONG> </div><div style="margin-bottom: 10px;">- achieved net sales of $12.<wbr>1 million (+20% revenue growth compared to the last quarter of 2013, all from US sales).<wbr> </div><div style="margin-bottom: 10px;">- has been launched in Germany, first European country.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>average annual per patient X-factory list price of EUR144,000, which is approximately US $200,000 with 30-day payment terms.<wbr> This price is net of compulsory government discounts at the average expected per patient dose</LI>
</UL> </div><div><EM>Source: Raptor Pharm.<wbr></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7566">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-09T14:57:40+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Provenge Sales Stabilizing in Q1:14 [class:Vaccines, dis:Prostate, :PharmaWorld:sub:Finance]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9692</link>
<description>Provenge Sales Stabilizing in Q1:14 [class:Vaccines, dis:Prostate, :PharmaWorld:sub:Finance]</description><category>class:Vaccines</category><category>dis:Prostate</category><category>sub:Finance</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9692</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9692">Provenge Sales Stabilizing in Q1:14</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aVaccines"><font color="#e95e0b">:Oncology:class:Vaccines</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9692">Oncology9692</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2014 | 14:35</font><br><br><div style="margin-bottom: 10px;">Comment: A couple of important points to highlight following the reporting of the Q1 financial results.<wbr> Firstly, Dendreon restated its plan to drive down COGS to the 30% range through increased automation and efficiency, although noted this could take several years.<wbr> Secondly, management reiterated its plans for the EU launch of Provenge (last quarter of 2014, in UK and Germany through Centers of Excellence).<wbr> Finally management acknowledged the increasing competition Zytiga and Xtandi in the pre- and post-chemo settings, but suggested that Provenge can be positioned as a complement to these drugs (70% of a panel of physicians in the <ORG><EM>European Journal of Cancer</EM></ORG> agreed that Provenge should be used prior to Xtandi and Zytiga).<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Plans for EU Launch</FONT></STRONG> </div><div style="margin-bottom: 10px;">- Using its contract manufacturing organization PharmaCell, Dendreon  anticipates making Provenge available through less than 10 “Centers of Excellence” in the UK and Germany initially, expanding beyond this once automation is approved.<wbr> </div><div style="margin-bottom: 10px;"><BLOCKQUOTE dir="ltr" style="MARGIN-RIGHT: 0px">
<P>Management expects to have the first commercial patient treated in 4Q:14.<wbr></P></BLOCKQUOTE> </div><div style="margin-bottom: 10px;">- Expand further in Europe once automation is approved.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Updated Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9692/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Provenge Sequencing with XTANDI and Zytiga</FONT></STRONG> </div><div style="margin-bottom: 10px;">The Ph2 sequencing study with Zytiga is fully enrolled.<wbr>  Management reported it is  seeing that it can be given concurrently without affecting Provenge's potency and immunological prime boost responses.<wbr> The safety profile of the drugs in combination appear to be consistent with the individual drugs' existing labels.<wbr> </div><div style="margin-bottom: 10px;">The Phase 2 sequencing study of with Xtandi is close to being fully enrolled.<wbr> A PRIME study assessing immune responses at different time points up to one year is actively enrolling patients.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Figures from the Quarter</FONT></STRONG> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px"><U>Net product revenue</U> for the quarter was <MONEY>$68.<wbr>8 million</MONEY> compared to <MONEY>$67.<wbr>6 million</MONEY> in the first quarter of 2013.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px"><U>Net loss</U> in the first quarter of 2014 was <MONEY>$36.<wbr>4 million</MONEY>, or <MONEY>$0.<wbr>24</MONEY> per share, compared to a net loss of <MONEY>$72.<wbr>0 million</MONEY>, or <MONEY>$0.<wbr>48</MONEY> per share for the same period in 2013.<wbr> </P> </div><div style="margin-bottom: 10px;"><P style="MARGIN-BOTTOM: 10px"><U>Cash, cash equivalents</U> as of <CHRON>March 31, 2014</CHRON>, <ORG value="NASDAQ-NMS:DNDN">Dendreon</ORG> had approximately <MONEY>$170 million</MONEY> in , and short-term and long-term investments.<wbr></P> </div><div style="margin-bottom: 10px;"><U>Cost of goods sold</U> was approximately <MONEY>$37 million</MONEY>, or 53% of revenue, down from approximately <MONEY>$43 million</MONEY> or 64% of revenue in the first quarter of 2013.<wbr> </div><div><EM>Source: Dendreon</EM> </div><!-- Comment details --><a name="oncology9692attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9692/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(101,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9692">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-09T14:35:15+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9692/1/ScreenCapture1.jpg" length="104023" type="image/jpeg"/></item><item>
<title>EAU Highlights II: Key takeaway for Sanofi and J&amp;J sponsored symposium [congress:EAU]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10854</link>
<description>EAU Highlights II: Key takeaway for Sanofi and J&amp;J sponsored symposium [congress:EAU]</description><category>congress:EAU</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10854</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10854">EAU Highlights II: Key takeaway for Sanofi and J&J sponsored symposium</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aEAU"><font color="#e95e0b">:PharmaWorld:congress:EAU</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10854">PharmaWorld10854</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 09 May 2014 | 12:30</font><br><br><div style="margin-bottom: 10px;">Comment: Here we provide an overview and key takeaway from Sanofi and J&amp;J sponsored symposium during EAU Stockholm 2014.<wbr> Sanofi emphasized on taxenes should remain an effective treatment as first line therapy for at least a <SPAN style="text-decoration: underline;">subse</SPAN>t of mCRPC patients.<wbr> No new data on abiraterone was presented during J&amp;J symposium as it focuses on real-life treatment management.<wbr> </div><div style="margin-bottom: 10px;"><P lang="en-US" style="margin: 16pt 0pt 0pt; color: #020b0e; font-family: Calibri; font-size: 12pt;"><STRONG>Sanofi sponsored symposium</STRONG> (chaired by Dr.<wbr> John Fitzpatrick, Ireland) featured understanding the heterogeneity of mCRPC to optimize survival and guide treatment choices.<wbr> The important emphasis of the session was on the role of docetaxel as a first line treatment in mCRPC setting still exists due to heterogeneity of mCRPC patients (i.<wbr>e.<wbr> no one treatment fits all).<wbr> First line docetaxel may not be the treatment choice for every mCRPC patients, but it should remain a valid choice for some cohorts of patients who do not respond well to first ADT or whose with high disease burden (i.<wbr>e.<wbr> high Gleason score with visceral mets).<wbr> This is supported by both clinical and scientific evidence.<wbr></P> </div><div style="margin-bottom: 10px;"><P lang="en-US" style="margin: 16pt 0pt 0pt; color: #020b0e; font-family: Calibri; font-size: 12pt;">Clinical Evidences:</P> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Calibri; font-size: 12pt; font-style: normal; font-weight: normal;">a.<wbr>) Poor response to subsequent hormonal treatments with either abiraterone or enzalutamide is observed in patients whose time to CRPC with first ADT is less than 16 months.<wbr> Response to docetaxel appears to be irrespective of length of previous ADT treatment suggesting docetaxel could be benefit who are not 'responders' to initial ADT.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Calibri; font-size: 12pt; font-style: normal; font-weight: normal;">b.<wbr>) Indirect comparison of TAX327 trial and COU-AA302 trial provides evidence of patients with high Gleason score dose not benefit from survival.<wbr></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Calibri; font-size: 12pt; font-style: normal; font-weight: normal;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/1/Table%201.png?user-agent=rss"> <img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/2/Table%202.png?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Calibri; font-size: 12pt;">Scientific evidence: similar to abiraterone and enzalutamide, taxanes (both docetaxel and cabazitaxel) also inhibit AR nuclear transport (specifically on AR translocation) although not to the same extent that observed with abiraterone and enzalutamide.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN style="font-family: Calibri; font-size: 12pt; font-style: normal; font-weight: normal;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/3/Table%203.png?user-agent=rss"></SPAN> </div><div style="margin-bottom: 10px;"><P lang="en-US" style="margin: 0in; color: #020b0e; font-family: Calibri; font-size: 12pt;">Based on this rationales, Dr.<wbr> Malik (Oncologist, Clatterbridge Cancer Centre UK) presented his real life experience in Liverpool UK with a remarkable median OS observed in patients who received cabazitaxel.<wbr></P> </div><div style="margin-bottom: 10px;"><P lang="en-US" style="margin: 0in; color: #020b0e; font-family: Calibri; font-size: 12pt;">"<STRONG><EM> Despite of new agents becoming available, cabazitaxel will still be my preferable approach</EM></STRONG>"</P> </div><div style="margin-bottom: 10px;"><P lang="en-US" style="margin: 0in; color: #020b0e; font-family: Calibri; font-size: 12pt;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/4/Table%204.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 11pt;"><STRONG>J&amp;J sponsored symposium</STRONG> focused on the key topics to consider in the management of mCRPC patients in daily clinical practice.<wbr> No new data was presented during the session.<wbr> The session is chaired by Dr.<wbr> Noel Clarke (urologist, Christie and Salford Royal hospital, UK), who stated the importance to interpret the data that are available from many Phase 3 study of many different agents in M1 CRPC patients and use the evidences from the trials to apply in daily clinical practice.<wbr> These agents with available prospective Phase 3 data for 1st line include:</P> </div><div style="margin-bottom: 10px;"><UL><LI>Docetaxel - OS available
</LI>
<LI>Sipuleucel-T - OS available
</LI>
<LI>Abiraterone - <STRONG>rPFS</STRONG> available
</LI>
<LI>Radium 223 - OS available
</LI>
<LI>Enzalutamide (abstract - PREVAIL)
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/6/Table%206.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 11pt;">Based on the data available, there are three of the clinical factors to consider include 1) comorbidities, 2) if patients have visceral metastases or not, 3) poor performance status.<wbr> It is important to weigh out different options when patients have a performance status of 2.<wbr> Other considerations include geriatric , heptic impairment or patients with CV risk.<wbr></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 11pt;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/7/Table%207.jpg?user-agent=rss"> <img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/8/Table%208.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 11pt;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/9/Table%209.jpg?user-agent=rss"> <img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/10/Table%2010.jpg?user-agent=rss"> <img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/11/Table%2011.jpg?user-agent=rss"></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 11pt;">On the final remark, Dr.<wbr> Gerhardt Attard presented the prostate cancer patient case to discuss options for an asymptomatic patient who had a rising PSA on abiraterone with liver and bone mets and later on had a radiological progression.<wbr> He asked the panel what would they do in their daily practice, and interesting response from different perspective as a urologist and oncologist.<wbr></P> </div><div style="margin-bottom: 10px;"><UL style="margin-top: 0in; margin-bottom: 0in; margin-left: 0.375in; unicode-bidi: embed; direction: ltr;" type="disc"><LI style="margin-top: 0px; margin-bottom: 0px; vertical-align: middle;"><SPAN style="font-family: Calibri; font-size: 11pt;">Prof.<wbr> Silke Gillessen (oncologist, CH): " I will switch to radium 223 or continue to use abiraterone is also an option.<wbr> However, I am not sure about switching to chemotherapy.<wbr> I would definitely not consider enzalutamide"</SPAN>
</LI>
<LI style="margin-top: 0px; margin-bottom: 0px; vertical-align: middle;"><SPAN style="font-family: Calibri; font-size: 11pt;">Prof.<wbr> Antonio Alcaraz (Urologist, Sp): " I will be little concerned by the patient's liver mets.<wbr> So I will probably switch to docetaxel as docetaxel is very effective in symptomatic patients"</SPAN>
</LI>
<LI style="margin-top: 0px; margin-bottom: 0px; vertical-align: middle;"><SPAN style="font-family: Calibri; font-size: 11pt;">Dr Gerhardt Attard (Oncologist, UK): "I would use docetaxel"</SPAN>
</LI>
<LI style="margin-top: 0px; margin-bottom: 0px; vertical-align: middle;"><SPAN style="font-family: Calibri; font-size: 11pt;">Dr Noel Clark (urologist, UK): " I would carefully evaluate options based on patients' comorbidities"</SPAN>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="margin-top: 0px; margin-bottom: 0px; vertical-align: middle;"><SPAN style="font-family: Calibri; font-size: 11pt;">Although there was no key data presented during J&amp;J sponsored symposium, an update analysis from COU-AA-302 to evaluate impact of prior endocrine therapy on radiographic progression free survival in patients with chemotherapy na&iuml;ve mCRPC was presented during poster session by Dr.<wbr> Antwerp (BE).<wbr> Dr Antwerp concluded that abiraterone + pred improved rPFS compared with prednisone alone regardless of prior duration fo treatment with a GnRH agonist or an AR inhibitor.<wbr> rPFS results are similar when duration of treatment is divided by either median or quartiles.<wbr> However, major limitation remains as duration of response to prior hormonal therapy was not captured.<wbr> <BR></SPAN></P> </div><div><P style="margin-top: 0px; margin-bottom: 0px; vertical-align: middle;"><SPAN style="font-family: Calibri; font-size: 11pt;"><SPAN style="font-family: Calibri; font-size: 11pt;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/13/Table%2013.jpg?user-agent=rss"></SPAN></SPAN></P> </div><!-- Comment details --><a name="pharmaworld10854attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/1/Table%201.png">Table 1.png</a>&nbsp;&nbsp;(133,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/2/Table%202.png">Table 2.png</a>&nbsp;&nbsp;(147,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/3/Table%203.png">Table 3.png</a>&nbsp;&nbsp;(126,8 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/4/Table%204.jpg">Table 4.jpg</a>&nbsp;&nbsp;(971,5 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/5/Table%205.jpg">Table 5.jpg</a>&nbsp;&nbsp;(842,8 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/6/Table%206.jpg">Table 6.jpg</a>&nbsp;&nbsp;(895,4 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/7/Table%207.jpg">Table 7.jpg</a>&nbsp;&nbsp;(965,5 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/8/Table%208.jpg">Table 8.jpg</a>&nbsp;&nbsp;(995 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/9/Table%209.jpg">Table 9.jpg</a>&nbsp;&nbsp;(897,8 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/10/Table%2010.jpg">Table 10.jpg</a>&nbsp;&nbsp;(1,1 MB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/11/Table%2011.jpg">Table 11.jpg</a>&nbsp;&nbsp;(935,4 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/12/Table%2012.jpg">Table 12.jpg</a>&nbsp;&nbsp;(908,1 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/13/Table%2013.jpg">Table 13.jpg</a>&nbsp;&nbsp;(994,4 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10854">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-09T12:30:42+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/1/Table%201.png" length="137153" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/2/Table%202.png" length="150862" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/3/Table%203.png" length="129864" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/4/Table%204.jpg" length="994809" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/5/Table%205.jpg" length="862981" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/6/Table%206.jpg" length="916909" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/7/Table%207.jpg" length="988696" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/8/Table%208.jpg" length="1018845" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/9/Table%209.jpg" length="919397" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/10/Table%2010.jpg" length="1101805" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/11/Table%2011.jpg" length="957852" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/12/Table%2012.jpg" length="929862" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10854/13/Table%2013.jpg" length="1018285" type="image/jpeg"/></item><item>
<title>Lundbeck to Buy Chelsea Therapeutics For $658m [:PharmaWorld:sub:Acquisition, dis:Parkinson]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7565</link>
<description>Lundbeck to Buy Chelsea Therapeutics For $658m [:PharmaWorld:sub:Acquisition, dis:Parkinson]</description><category>sub:Acquisition</category><category>dis:Parkinson</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7565</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7565">Lundbeck to Buy Chelsea Therapeutics For $658m</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aParkinson"><font color="#e95e0b">:Neurology:dis:Parkinson</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7565">Neurology7565</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 09 May 2014 | 11:18</font><br><br><div style="margin-bottom: 10px;">Comment: Lundbeck is to buy the US company Chelsea Therapeutics to gain 
access to its Neurology drug Northera for the treatment of a rare from of 
orthostatic hypertension that occurs in Parkinson's disease patients.<wbr> 
The deal represents a 59% premium to Chelsea's share price on Wednesday.<wbr> </div><div style="margin-bottom: 10px;">The drug which has had a chequered development history was recently approved 
by the FDA and is expected to be launched in the Q314.<wbr> </div><div style="margin-bottom: 10px;">Northera is seen as having the potential to become Lundbeck's most valuable 
US asset amonst its four neurological drugs, a portfolio which includes the 
Huntigton's disease product tetrabenazine.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Deal Terms</STRONG> </div><div style="margin-bottom: 10px;">The offer which was unanimously accepted by Chelsea's board but still 
requires the approval of shareholder comprised of an offering of $6.<wbr>44 per share 
in cash and contingent value rights up to $1.<wbr>50 per share.<wbr> </div><div>Source: <a href="http://www.lundbeck.com" class="defaultlink" title="www.lundbeck.com">lundbeck.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7565">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-09T11:18:13+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Key Messages from Lexicon Q1:14 Results [dis:Diabetes, :PharmaWorld:sub:Partnership]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7668</link>
<description>Key Messages from Lexicon Q1:14 Results [dis:Diabetes, :PharmaWorld:sub:Partnership]</description><category>dis:Diabetes</category><category>sub:Partnership</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7668</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7668">Key Messages from Lexicon Q1:14 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aDiabetes"><font color="#e95e0b">:Endocrinology:dis:Diabetes</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPartnership"><font color="#e95e0b">:PharmaWorld:sub:Partnership</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7668">Endocrinology7668</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2014 | 11:00</font><br><br><div style="margin-bottom: 10px;">Comment: Lexicon management emphasized again it is focusing resources on LX4211 (for diabetes) and LX1032, and is not currently planning any other clinical studies 'right now' for LX2931 and LX1033.<wbr> Pablo Lapuerta, EVP Clinical Development, CMO, gave an update on the TELESTAR ongoing pivotal study of telotristat etiprate (LX1032) for carcinoid syndrome, as well as feedback from ECE.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Update of Telotristat Etiprate</FONT></STRONG> </div><div style="margin-bottom: 10px;">TELESTAR, is a single pivotal study.<wbr> It is a Ph3 randomized and placebo-controlled.<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> We plan to recruit a minimum of 105 subjects.<wbr> They will be given double-blind treatment for 12 weeks and afterwards, there will be a long-term extension that will be open label".<wbr> </div><div style="margin-bottom: 10px;">TELESTAR aims to show that <FONT style="BACKGROUND-COLOR: #ffffff">telotristat</FONT> etiprate is effective in reducing the change from baseline in bowel movement frequency over the 12 week double-blind portion of the study.<wbr> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> The study is going well.<wbr> Our efforts have been on recruitment.<wbr> We've been satisfied that their work has been productive and the TELESTAR study is on track to complete randomization in 2014".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Feedback from ECE</FONT></STRONG> </div><div style="margin-bottom: 10px;">" .<wbr>.<wbr>.<wbr> A large audience of several hundred physicians.<wbr> They saw our long-term experience in a case series of patients who had carcinoid heart disease and were impressed with the degree of reductions in serotonin synthesis that we were able to achieve long-term.<wbr> The meeting went very well.<wbr> And speaking to physicians in general about the program, those who are participating in our Ph3 trial are very excited.<wbr> They are motivated, and once they recruit two or three patients, they want to recruit more.<wbr> So that's been a very good experience with telotristat etiprate".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Partnering LX4211</FONT></STRONG> </div><div style="margin-bottom: 10px;">Management outlined that " .<wbr>.<wbr>.<wbr> we don't have the practical ability to finance a full-scale Ph3 development program in type II diabetes except in the context of a partnership.<wbr> And we want to have a partner in place before launching a Ph3 program in that indication.<wbr> That's not necessarily the case in type I diabetes".<wbr><BR> </div><div style="margin-bottom: 10px;">"And our objective in any partnership that encompasses type II diabetes is to enable the achievement of our strategic objectives in type I diabetes indication while also enabling progression with development in type II diabetes.<wbr> So this is a long way of prefacing the answer, which is we are relatively far down the path in partnership discussions.<wbr> We are at a stage at this point where we can't offer much additional comment".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Financial Figures</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Revenues</U> were $0.<wbr>3 million, which was a decrease of 23% from $0.<wbr>4 million in the prior-year period.<wbr> The decrease was primarily due to lower revenues from our alliance with Taconic Farms.<wbr> </div><div style="margin-bottom: 10px;"><U>R&amp;D expenses</U> increased 18% to $24m from $20.<wbr>3m in the prior-year period.<wbr> </div><div style="margin-bottom: 10px;">As of March 31, 2014, Lexicon had $98.<wbr>4m in cash and investments, as compared to $129.<wbr>1m in cash and investments as of December 31, 2013.<wbr> </div><div><EM>Source: Lexicon</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7668">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-09T11:00:05+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>BIND Therapeutics Q1 Results and Pipeline Update [dis:Prostate, :Endocrinology:news, comp:AstraZeneca]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9691</link>
<description>BIND Therapeutics Q1 Results and Pipeline Update [dis:Prostate, :Endocrinology:news, comp:AstraZeneca]</description><category>dis:Prostate</category><category>news</category><category>comp:AstraZeneca</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9691</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9691">BIND Therapeutics Q1 Results and Pipeline Update</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9691">Oncology9691</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 09 May 2014 | 10:40</font><br><br><div style="margin-bottom: 10px;">Comment: BIND finished the quarter with $68.<wbr>7MM in cash and short-term investments-sufficient to fund operations into mid-2015.<wbr> Interim analysis shows promising activity in KRAS NSCLC with BIND-014, its lead candidate.<wbr> Management indicated a strong biologic rationale for the drug to be explored in bladder, cholangio and neuroendocrine cancer, as well as potential biomarkers of PSMA expression.<wbr> Data readout from Ph2 mCRPC are expected H2:14.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">mCRPC Study Details</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9118" class="defaultlink">Oncology9118: First Clinical Accurin Targets Prostate Cancer</a>.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ongoing and Future Development Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>A second signal-finding Ph2 study (also initiating in 3Q14) will evaluate BIND-014 across four solid tumor indications (cervical, bladder, cholangio and neuroendocrine tumors) where PSMA has been shown to be expressed at high levels.<wbr> In addition to antitumor activity, the trial will measure biomarker expression, tumor vascularity, and particle uptake and relate these parameters to response.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Collaboration Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Proprietary Programs</STRONG> </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/3/ScreenCapture3.jpg?user-agent=rss"> </div><!-- Comment details --><a name="oncology9691attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(30 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(5,5 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(23,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(77,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9691">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-09T10:40:51+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/1/ScreenCapture1.jpg" length="30760" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/2/ScreenCapture2.jpg" length="5621" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/3/ScreenCapture3.jpg" length="23700" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9691/4/ScreenCapture4.jpg" length="79418" type="image/jpeg"/></item><item>
<title>Valeant Starts To Try &amp; Tighten Its Grip On Allergan [comp:Allergan, sub:Aesthetics, :PharmaWorld:sub:Acquisition, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7562</link>
<description>Valeant Starts To Try &amp; Tighten Its Grip On Allergan [comp:Allergan, sub:Aesthetics, :PharmaWorld:sub:Acquisition, headline]</description><category>comp:Allergan</category><category>sub:Aesthetics</category><category>sub:Acquisition</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7562</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7562">Valeant Starts To Try & Tighten Its Grip On Allergan</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7562">Neurology7562</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 May 2014 | 18:48</font><br><br><div style="margin-bottom: 10px;">Comment: During today's Q1 webcast, Howard Schiller, Valeant's CFO made a number of comments on positive shareholder feedback on the proposed acquisition of Allergan.<wbr> He highlighted the company's next steps, in what Valeant regards as a compelling transaction and one that it is committed to consummating as quickly as possible.<wbr> </div><div style="margin-bottom: 10px;">This is the sort of talk we would expect from Valeant given its aggressive acquisitive nature, however, how much substance there is behind this rhetoric in terms of shareholder support remains to be seen.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Howard Schiller's comments were as follows:-</STRONG> </div><div style="margin-bottom: 10px;">"Since the announcement on April 22, Mike and I have done a road meeting with many of our and Allergan's top shareholders.<wbr> We have been in New York, Baltimore, Boston, Los Angeles, San Francisco, Vancouver and South Florida.<wbr>" </div><div style="margin-bottom: 10px;"><P class="pwrapper">"So far, all the feedback has been overwhelmingly positive and we look forward to meeting many more Allergan shareholders in the days and weeks to come.<wbr> During our interactions with Allergan shareholders, several things have emerged.<wbr> First, everyone agrees that the combination makes tremendous strategic sense and the combination will create substantial short and long-term value for both sets of shareholders.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Second, there has been little pushback to our claim that current and expected SG&amp;A spend is much too high and that the SG&amp;A cost structure is excessive.<wbr> There is also a general agreement that Valeant has a stronger presence in emerging markets which should allow us to sell more Allergan products in these markets.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"Finally, shareholders agreed that the Allergan team should start discussions with us as soon as possible.<wbr> While we understand their need to explore other alternatives, there is no reason that they cannot start negotiations with us.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"We are expecting to hear from the Allergan board or management team within the next few weeks and we are ready and willing to begin negotiations as soon as possible.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>Next Steps</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"In the interim, however, together with Pershing Square, we will be requesting a shareholder list from Allergan which they are required to provide under Delaware law.<wbr> <STRONG>We will then commence a shareholder referendum that will determine if the Allergan shareholders are supportive of Allergan's board engaging in negotiations with us in parallel with other efforts they may be undertaking.<wbr>"</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">"We expect that this referendum will send a clear message to the Allergan board and to us that Allergan shareholders strongly support negotiations between our two companies in parallel with their other efforts.<wbr> <STRONG>At the appropriate time, if necessary, we will also pursue holding a special meeting to remove some or all of the Allergan board members.<wbr>"</STRONG></P> </div><div style="margin-bottom: 10px;"><P class="pwrapper"><STRONG>"We are very committed to getting this deal done as we believe this combination will create an unrivaled platform for growth and value creation.<wbr></STRONG> While we pursue this transaction, we will continue to execute on our strategy of delivering strong organic growth coupled with growth through business development, thereby, maximizing shareholder value.<wbr> While we believe that speed in concluding a transaction is in the best interest of both companies' shareholders, we will be patient.<wbr> And to be very clear, we are very committed to consummating this merger.<wbr>"</P> </div><div style="margin-bottom: 10px;"><P class="pwrapper">Alongside this statement it highlighted just how many Business Develompent transactions it has completed.<wbr></P> </div><div><P class="pwrapper"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7562/1/ScreenCapture1.jpg?user-agent=rss"></P> </div><!-- Comment details --><a name="neurology7562attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7562/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(107,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7562">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-08T18:48:10+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7562/1/ScreenCapture1.jpg" length="110086" type="image/jpeg"/></item><item>
<title>Takeda F/Y 2013 Results-Key Takeaways [class:Hormonals, comp:Takeda, dis:Prostate, prod:Lupron, prod:Orteronel]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9690</link>
<description>Takeda F/Y 2013 Results-Key Takeaways [class:Hormonals, comp:Takeda, dis:Prostate, prod:Lupron, prod:Orteronel]</description><category>class:Hormonals</category><category>comp:Takeda</category><category>dis:Prostate</category><category>prod:Lupron</category><category>prod:Orteronel</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9690</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9690">Takeda F/<wbr>Y 2013 Results-Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aTakeda"><font color="#e95e0b">:Oncology:comp:Takeda</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aLupron"><font color="#e95e0b">:Oncology:prod:Lupron</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aOrteronel"><font color="#e95e0b">:Oncology:prod:Orteronel</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9690">Oncology9690</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 May 2014 | 14:27</font><br><br><div style="margin-bottom: 10px;">Comment: With new products contributing significantly to growth, notably 
Adcetris in Europe (relapsed Hodgkins Lymphoma) and Brintellix (major 
depressive disorder) in the US,  Takeda's prospects appear to be on an 
upward trend.<wbr> The transformation Project Summit is yielding good savings 
and pipeline develompents are progressing well, perhaps with a few 
exceptions potentially one being the future of its CRPC drug TAK-700 
(Orteronel).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/7/ScreenCapture7.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/9/ScreenCapture10.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Key Developments In Prostate Cancer</STRONG> </div><div style="margin-bottom: 10px;">Whilst Takeda highlighted the resilience of its base business, which includes 
leuporelin, it can be noted that its sales are under pressure with 
underlying growth -6.<wbr>8%.<wbr> The approval of a 6-M formulation in Japan potentially 
FY2015 (submission see below FY2014) may help, but the future of the 
group's prostate cancer franchise in the short to mid-term is questionable.<wbr> At 
the recent EAU meeting, the group had an exhibition stand but there was no focus 
on either leuprorelin or TAK-700, almost indicative of a company about to 
de-emphasise its promotional presence in the field.<wbr> </div><div style="margin-bottom: 10px;">Of course, the future of TAK-700 (Orteronel) hangs in the balance post a 
negative outcome in its phIII post-chemo CRPC study and is dependent on 
the outcome of its phIII chemonaive CRPC study, results for which 
are due mid-year.<wbr> Takeda's pipeline approval chart shown below 
indicates that project timelines are currently under review.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/14/ScreenCapture15.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/12/ScreenCapture13.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/13/ScreenCapture14.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">When it came to comments on the pipeline by <FONT face="Arial">Tadataka Yamada, Chief Medical &amp; Scientific Officer there was no 
mention of TAK-700 and instead much comment about many other products most 
notably <SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Contrave 
(obesity), Entyvio (ulcerative colitis and Crohns) and <SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">ixazomib, 
a new oral proteasome inhibitor for multiple myeloma (effectively a replacment 
for Velcade (for which Takeda holds global 
rights).<wbr></SPAN></SPAN></FONT> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/10/ScreenCapture11.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/11/ScreenCapture12.jpg?user-agent=rss"> </div><div>source: <a href="http://www.takeda.com" class="defaultlink" title="www.takeda.com">takeda.com</a> </div><!-- Comment details --><a name="oncology9690attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(92 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(61,6 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(87,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(59,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(48,7 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(88,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(76,1 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(118,4 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/9/ScreenCapture10.jpg">ScreenCapture10.jpg</a>&nbsp;&nbsp;(86,4 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/10/ScreenCapture11.jpg">ScreenCapture11.jpg</a>&nbsp;&nbsp;(94,6 KB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/11/ScreenCapture12.jpg">ScreenCapture12.jpg</a>&nbsp;&nbsp;(82 KB)<br>&nbsp;&nbsp;12.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/12/ScreenCapture13.jpg">ScreenCapture13.jpg</a>&nbsp;&nbsp;(267,4 KB)<br>&nbsp;&nbsp;13.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/13/ScreenCapture14.jpg">ScreenCapture14.jpg</a>&nbsp;&nbsp;(131,1 KB)<br>&nbsp;&nbsp;14.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/14/ScreenCapture15.jpg">ScreenCapture15.jpg</a>&nbsp;&nbsp;(111,1 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9690">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-08T14:27:06+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/1/ScreenCapture1.jpg" length="94235" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/2/ScreenCapture2.jpg" length="63044" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/3/ScreenCapture3.jpg" length="89176" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/4/ScreenCapture4.jpg" length="61032" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/5/ScreenCapture5.jpg" length="49914" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/6/ScreenCapture6.jpg" length="90271" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/7/ScreenCapture7.jpg" length="77949" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/8/ScreenCapture8.jpg" length="121234" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/9/ScreenCapture10.jpg" length="88445" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/10/ScreenCapture11.jpg" length="96836" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/11/ScreenCapture12.jpg" length="83969" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/12/ScreenCapture13.jpg" length="273845" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/13/ScreenCapture14.jpg" length="134241" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9690/14/ScreenCapture15.jpg" length="113791" type="image/jpeg"/></item><item>
<title>The First Anti-PD-1, MK-3475, Will Be Reviewed Under The FDA’s Accelerated Approval Programme [dis:Bladder, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9687</link>
<description>The First Anti-PD-1, MK-3475, Will Be Reviewed Under The FDA’s Accelerated Approval Programme [dis:Bladder, news]</description><category>dis:Bladder</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9687</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9687">The First Anti-PD-1, MK-3475, Will Be Reviewed Under The FDA’s Accelerated Approval Programme</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9687">Oncology9687</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 08 May 2014 | 12:29</font><br><br><div style="margin-bottom: 10px;">Comment: MSD announced that FDA has accepted for review the Biologics License Application (BLA) for MK-3475 (anti-PD1) for the treatment of unresectable or metastatic melanoma patients who previously treated with ipilimumab.<wbr> This is likely the first anti-PD1 reaching the market.<wbr> The FDA granted Priority Review designation with a PDUFA date of <STRONG>October 28, 2014</STRONG>, and the MK-3475 BLA will be reviewed under the FDA&rsquo;s Accelerated Approval program.<wbr> MSD will also be seeking to file a marketing authorization application in Europe by the end of 2014.<wbr> More than 15 company-sponsored abstracts on MK-3475 in ASCO 2014 is planned reflecting MSD's aggressive pre-launching communication strategy.<wbr> </div><div style="margin-bottom: 10px;">Following the first approval of ipilimumab (Yervoy) that revolutionise the metastatic melanoma treatment, MK-3475 is expected to start a new wave of immuno-oncology therapies that is expected to be a game changer in the oncology market.<wbr> The looming PDUFA date for MK-3475 in melanoma puts MSD on track to gain the first market entry in the field, beating out the star team at Bristol-Myers Squibb's nivolumab, who were once the leader in the field.<wbr> When the New R&amp;D chief Roger Perlmutter arrived last year, he quickly zeroed in on MK-3475 as a top prospect with wide-ranging cancer targets and made the development program a top priority, racing through studies on the way to the FDA.<wbr> </div><div style="margin-bottom: 10px;">MK-3475 is more than just <STRONG>an</STRONG> experimental drug for MSD.<wbr> It is seen as a portfolio in its own right.<wbr> The program now covers 30 tumor types, both as a monotherapy and in combination with various drugs found among other Big Pharma companies.<wbr> By the end of this year, the company projects that there will be 24 clinical trials underway with 6,000 patients, including four new Phase III trials.<wbr> There are 7 registrational studies planned for non-small cell lung cancer, advanced head &amp; neck cancer and advanced bladder cancer with 10 combo studies for advanced melanoma, advanced NSCLC, advanced renal cell carcinoma, HER2+ breast cancer and other solid tumours.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>MK-3475 Development Ongoing in 30 Tumors, as Monotherapy and in Combination</STRONG> </div><div style="margin-bottom: 10px;">Development of MK-3475 is currently ongoing in 30 tumor types as monotherapy and in combination.<wbr> It is anticipated that by the end of 2014, the MK-3475 development program will grow to more than 24 clinical trials across 30 different tumor types, enrolling an estimated 6,000 patients at nearly 300 clinical trial sites worldwide, including four new Phase 3 studies.<wbr> Ongoing and planned late-stage monotherapy and combination studies include: </div><div style="margin-bottom: 10px;"><UL><LI>
<STRONG>Seven Phase 3 registrational trials</STRONG> spanning advanced melanoma (adjuvant, ipilimumab-na&iuml;ve, and ipilimumab-refractory), advanced non-small cell lung cancer (NSCLC) (previously-treated and previously-untreated), advanced head &amp; neck cancer and <STRONG>advanced bladder cancer</STRONG>;

</LI>
<LI><STRONG>Ten combination studies</STRONG> , including advanced melanoma, advanced NSCLC, advanced renal cell carcinoma, HER2+ breast cancer and other solid tumours.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;">One thing to highlight is that some analysts were expecting MSD execs to announce that they are accelerating their R&amp;D plans for MK-3475 in lung cancer, and that didn't happen.<wbr> The next likely logical move for MSD is to focus on head &amp; neck cancer or bladder cancer as both are the two 'niche' patient population with high medical unmet need.<wbr> Currently it is the only anti-PD-1 'immune-modulating agent' targeting tumour microenvironment that has a development programme in bladder cancer.<wbr> </div><div>Source: <a href="http://www.merck.com" class="defaultlink" title="http://www.merck.com">merck.com</a> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9687">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-08T12:29:38+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>Corcept Disappoints But Cushing's Revenues Are Growing. [dis:Cushing, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7664</link>
<description>Corcept Disappoints But Cushing's Revenues Are Growing. [dis:Cushing, news]</description><category>dis:Cushing</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7664</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7664">Corcept Disappoints But Cushing's Revenues Are Growing.<wbr></a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aCushing"><font color="#e95e0b">:Endocrinology:dis:Cushing</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Endocrinology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7664">Endocrinology7664</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 May 2014 | 11:46</font><br><br><div style="margin-bottom: 10px;">Comment: Corcept shares fell 50% yesterday as the company reported both results below market expectations and the discontinuation of all further development of mifepristone for psychotic depression.<wbr> However, Korlym sales are growing and may benefit from the withdrawal from the market of J&amp;J's Nizoral (ketoconazole), a mainstay treatment for Cushing's disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>R&amp;D Setback</STRONG> </div><div style="margin-bottom: 10px;">The suspension of all further development in psychotic depression came after an independent DMC conducted an interim analysis of data from 226 patients and found once-daily oral mifeprisone was unlikely to meet the primary endpoint in its phIII study.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Korlym's Performance</STRONG> </div><div style="margin-bottom: 10px;">Meanwhile, the group reported net product revenues from the sale of Korlym (its drug to treat Cushing's syndrome) of $4.<wbr>4m up from $1.<wbr>7m in the prior year's quarter.<wbr> Because Korlym is an Orphan Drug, Corcept will have marketing exclusivity for the approved indication in the United States until February 2019.<wbr> </div><div style="margin-bottom: 10px;"><P align="left">Among the cheaper agents used off-label, ketoconazole is probably the most popular agents for long-term use of Cushing's syndrome.<wbr> Ketoconazole  inhibits steriodogenesis.<wbr> It can act on several of the p450 enzymes, including the first step in cortisol synthesis, cholesterol side chain cleavage, and conversion of 11- deoxycortisol to cortisol.<wbr> However, the FDA recently issued a new safety announcement with strong warnings that should restrict off-label use of ketoconazole in the treatment of Cushing's syndrome.<wbr> In July 2013, the FDA took several actions related to Nizoral (ketoconazole) oral tablets, including limiting the drug‟s use, warning that it can cause severe liver injuries and adrenal gland problems, and advising that it can lead to harmful drug interactions with other medications.<wbr> The FDA also suggested weekly liver function testing for patients on the drug</P> </div><div style="margin-bottom: 10px;"><P align="left">As a result of the FDA safety announcement and revised Black Boxing Warning, Johnson &amp; Johnson has stopped marketing Nizoral, which could have a positive long-term effect on Korlym sales.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Finances</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Overall the group's net loss for the quarter was $0.<wbr>14 vs.<wbr> the street estimate of $0.<wbr>09.<wbr> SG&amp;A expenses in the first quarter of 2014 were $9.<wbr>8 million, compared to $8.<wbr>4 million in the first quarter of 2013.<wbr> R&amp;D expenses in the first quarter of 2014 were $7.<wbr>3 million, compared to $4.<wbr>3 million for the comparable period in 2013, primarily due to the increased enrolment in the psychotic depression trial and additional spending to develop Corcept&rsquo;s next-generation selective GR-II antagonists.<wbr></P> </div><div style="margin-bottom: 10px;">Corcept&rsquo;s cash balance as of March 31, 2014 was $43.<wbr>6 million, compared to $54.<wbr>9 million as of December 31, 2013.<wbr> </div><div style="margin-bottom: 10px;">Despite these disappointments the company did raise its full-year sales guidance to $25-29m from its previous estimate of $24-28m.<wbr> Consensus is $26m.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Development Outlook</STRONG> </div><div style="margin-bottom: 10px;">In terms of its development outlook the company has a Phase 1 trial of mifepristone for the treatment of triple-negative breast cancer which it will now focus upon and a portfolio of selective GR antagonists that competitively block the effects of cortisol but not progesterone.<wbr> Two of these are expected to move into clinical development in 2H14, potentially one as a back up to Korlym.<wbr> </div><div style="margin-bottom: 10px;">Corcept owns extensive intellectual property covering the use of GR antagonists, including mifepristone, in the treatment of a wide variety of metabolic, psychiatric and oncologic disorders.<wbr> It also holds composition of matter patents for its selective GR antagonists.<wbr> </div><div>Source: <A href="http://www.corcept.com">www.<wbr>corcept.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7664">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-08T11:46:49+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>re: Allergan Q1 Figures - Key Takeaways</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7561</link>
<description>re: Allergan Q1 Figures - Key Takeaways</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7561</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7561">re: Allergan Q1 Figures - Key Takeaways</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7561">Neurology7561</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 08 May 2014 | 11:32</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Allergan Q1 Figures - Key Takeaways</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font><br><span style="font-size: 12px;">Comment: Allergan reported better-than-expected first quarter earnings growth +20.<wbr>4% based on strong sales of Botox and medical devices.<wbr> It continues to review the $47bn unsolicited bid from Valeant but was not prepared to comment further on this topic.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7559">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7559" class="commentpermalink">Neurology7559</a> / <span class="date">07 May 2014</span> /
<span class="time">18:24:20 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Morgan Stanley Analysts read the Valeant bid situation based on comments made by Pyott's yesterday as that Allergan will propose a go-it-alone strategy centred around the following perspectives:- </div><div style="margin-bottom: 10px;">I) The development of a new business plan :- "<FONT face="Arial" size="2"><FONT face="Arial" size="2"><FONT face="Arial" size="2">Obviously, we&rsquo;re re-looking at </FONT></FONT></FONT>our plans given the situation we are in, and, when we areready, we will report back on how we wish to move forward in terms of our organic outlook for the business.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">2) Cost cutting may take centre stage:- &ldquo;And then clearly in the past we have spoken about our ability to leverage our SG&amp;A ratios over time and obviously given the circumstances that is something we are thinking about very carefully,&rdquo; and </div><div>3) Making the case for R&amp;D - &ldquo;On R&amp;D, we have stated historically that we spent maybe even less 10% of the total on early-stage discovery&hellip;when you think back onthe productivity of R&amp;D from every survey we have seen, and this isn't us doing our own surveys, this is others doing surveys; we have always been at the very top quartile of R&amp;D productivity in terms of success rates as well as dollars spent on products produced.<wbr>&rdquo; </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7561" class="commentpermalink">Neurology7561</a> / <span class="date">08 May 2014</span> /
<span class="time">11:32:16 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7561">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7559">View thread  Neurology7559: Allergan Q1 Figures - Key Takeaways</a>]]></content:encoded><dc:date>2014-05-08T11:32:16+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Allergan Q1 Figures - Key Takeaways [comp:Allergan, dis:iOAB, dis:Migraine, dis:Spasticity, headline, prod:Botox, sub:Aesthetics]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7559</link>
<description>Allergan Q1 Figures - Key Takeaways [comp:Allergan, dis:iOAB, dis:Migraine, dis:Spasticity, headline, prod:Botox, sub:Aesthetics]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7559</comments><category>comp:Allergan</category><category>dis:iOAB</category><category>dis:Migraine</category><category>dis:Spasticity</category><category>headline</category><category>prod:Botox</category><category>sub:Aesthetics</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7559</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7559">Allergan Q1 Figures - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aiOAB"><font color="#e95e0b">:Neurology:dis:iOAB</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aMigraine"><font color="#e95e0b">:Neurology:dis:Migraine</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Neurology:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7559">Neurology7559</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 May 2014 | 18:24</font><br><br><div style="margin-bottom: 10px;">Comment: Allergan reported better-than-expected first quarter earnings growth +20.<wbr>4% based on strong sales of Botox and medical devices.<wbr> It continues to review the $47bn unsolicited bid from Valeant but was not prepared to comment further on this topic.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Sales Performance</STRONG> </div><div style="margin-bottom: 10px;">Allergan claims that the global market for neuromodulators, grew by 12% in 2013 and that as Botox was growing at the same rate it maintained market share at 76%.<wbr> Over this period the global aesthetic market grew 11% and the therapeutic +13% with Allergan gaining share in therapeutics offset by small losses in aesthetics as competitors entered the North American market.<wbr> </div><div style="margin-bottom: 10px;">In the first quarter Botox sales grew by 11.<wbr>5% underlying (9.<wbr>6% ex currency to $501.<wbr>8m.<wbr> Growth was held back at the margin by foreign currency and local issues in Venezuela &amp; Colombia respecctively, a situation expected to improve in Q2.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Botox Regulatory Approvals</STRONG> </div><div style="margin-bottom: 10px;">Regarding regulatory approvals, it was noted that that the first new national approvals for lower limb spasticity in the U.<wbr>K.<wbr> and Ireland will enable the group to expand the market as well as strengthen its competitive position.<wbr> </div><div style="margin-bottom: 10px;">Additional Botox approvals in the quarter included:- </div><div style="margin-bottom: 10px;"><UL><LI>Chronic migraine in Colombia and public reimbursement in Australia
</LI>
<LI>iOAB in Italy.<wbr>
</LI>
<LI>In South Africa, the group received several new indications, cervical dystonia, poststroke spasticity and neurogenicneurogenic bladder.<wbr>
</LI>
<LI>The European approvals of the crow's feet line indications is viewed as a new opportunities for physician training.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Specific Therapeutic Comments</STRONG> </div><div style="margin-bottom: 10px;">Regarding urology, Allergan now has 100% coverage of Medicare managed care accounts.<wbr> In the universe of 13,000 urologists and urogynecologists within about 8,000 treat incontinence, the group has established an injector base of about 4,500 physicians.<wbr> So it believes some training opportunities remain.<wbr> </div><div style="margin-bottom: 10px;">In Europe Allergan claims to be growing BOTOX in-market by over 10% driven by good performance in the base movement disorders areas and additionally by the recent reimbursed launches of chronic migraine and bladder.<wbr> In the quarter BOTOX for bladder was launched in Spain and Italy as was chronic migraine in the private nonreimbursed market in Poland and Russia.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Aesthetics</STRONG> </div><div style="margin-bottom: 10px;">Allergan estimates that the market in Q1 grew at about 10% in units, and its sales growth was further aided by the 3% price increase that it posted in the US in January.<wbr> </div><div style="margin-bottom: 10px;">BOTOX Cosmetic share in the U.<wbr>S.<wbr>it was claimed remains high.<wbr> A reduction of 3 % share points versus 2013 has been noted as Merz re-entered the market with a 6.<wbr>6 share up 3 points.<wbr> Dysport's share, it suggests, remains static at 15% share.<wbr> </div><div style="margin-bottom: 10px;">In Europe Allergan estimates the market in Q1 was growing around 10% and that BOTOX and VISTABEL are maintaining share in the face of strong price competition from both Merz and Galderma.<wbr> </div><div style="margin-bottom: 10px;">In facial aesthetics, the group is enjoying continuing strong sales, growth of 35.<wbr>6% in local currencies and 33.<wbr>1% in dollars as it benefit from the launch of VOLUMA in the U.<wbr>S.<wbr> but also the introduction around the world of the other products in the VYCROSS collection, namely Volift and VOE Bella.<wbr> </div><div style="margin-bottom: 10px;">Based on market survey, it estimates that the U.<wbr>S.<wbr> dermal filler market in Q1 grew over 10% in syringes and even higher in value due to the introduction of our premium priced product.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Two interesting questions posed and Allergan's response was as follows:-</STRONG> </div><div style="margin-bottom: 10px;">Q: Can you address a couple criticisms about the company.<wbr> i) that the majority of the R&amp;D dollars are spent on ease phase research that have not yielded returns, and that way too much money is spent away from the sales force in terms of SG&amp;A, and that amount could be easily cut without damaging the franchises.<wbr> </div><div style="margin-bottom: 10px;">David Pyott responded, "Well, first of all, on R&amp;D we've stated historically that we spent maybe even less than 10% of the total on early stage discovery.<wbr> Of course, I'd like to point out that the lion's share of that relates to neuromodulators.<wbr>.<wbr>.<wbr>.<wbr>.<wbr>I think it would be unwise for a company thinking about the long term not to think about when you can command the world's market of neurotoxins to ask yourself and not only ask yourself but do something about next generation and improvements.<wbr>" </div><div style="margin-bottom: 10px;">"We have always been in the very top quartile of R&amp;D productivity in terms of success rates as well as dollars spent on products produced.<wbr> I think also moving on to the second point about sales force, which is a quick reminder.<wbr> We actually have in terms of sales people over 3500 people on the road today, but when you reflect upon my remarks this morning, just classical share of voice details I think that's an era of the past.<wbr> Of course, I tonight want to talk about whatever excesses may have existed in the pharmaceutical industry 10 or 15 years ago, but those times are over.<wbr> If you think about our model, it's so much more sophisticated in terms of reimbursement services, hands-on physician training, direct-to-consumer.<wbr> In its essence Allergan is an amallgum of pharmaceuticals, medical devices as well as consumer goods.<wbr> Just take BOTOX as an example.<wbr> The world's most complicated biopharmaceutical in terms of molecular structure and complexity, yet in terms of how it's used is really more akin to a medical device because we have to teach the physician, once they've learned about the pharmacology, how do they actually inject it to get the maximum benefit for their patient.<wbr> Finally, of course, if we stick to BOTOX, then we've not only conducted patient education campaigns for the aestheticd -- you'll use the word customer, because they're not really patients, but also for the patient if you think about our work to build and establish the market for chronic migraine.<wbr>" </div><div style="margin-bottom: 10px;">"So I would argue that we think very careful about where we spend our money, and we believe we have great returns.<wbr> I would then ask you to just think about the growth that we have.<wbr> There are not so many companies that are growing currently.<wbr> You just look at our numbers.<wbr> 14% in the quarter based on a broad suite of products.<wbr>" </div><div style="margin-bottom: 10px;">Q: In the neuromodulator space, one of your potential competitors (Revance) had data on a potential long-acting neuromodulator and also developing a topical.<wbr> I'm wondering, what are your thoughts on these potential next generation neuromodulator products and the potential threat to your franchise? Thanks.<wbr> </div><div style="margin-bottom: 10px;">Scott M.<wbr> Whitcup responded:- "As David said in one area we spend R&amp;D dollars are early stage and focus is on neuromodulators.<wbr> So we look at not only the asset, but we have international programs that I stated before.<wbr>.<wbr>.<wbr> we do have a BOTOX X program, and we will probably get some additional details on that program second half of the year.<wbr> Our goal ourselves is to have a novel molecule with a potential for higher dose and/<wbr>or longer duration.<wbr> We look internally and continue to look on the outside as well.<wbr>" </div><div style="margin-bottom: 10px;"><STRONG><U>Outlook</U></STRONG> </div><div style="margin-bottom: 10px;">Allergan provided full year guidance for 2014 was as follows:-: </div><div style="margin-bottom: 10px;">Total product net sales between $6,775 million and $7,000 million, excluding any future anticipated revenue from the transition services agreements related to the sale of the obesity intervention business.<wbr> </div><div><UL><LI>
<UL><LI>Total specialty pharmaceuticals net sales between $5,835 million and $6,000 million.<wbr>
</LI>
<LI>Total core medical devices net sales between $930 million and $990 million.<wbr>
</LI>
<LI>ALPHAGAN<SMALL><SUP>&reg;</SUP></SMALL> franchise product net sales between $460 million and $490 million.<wbr>
</LI>
<LI>LUMIGAN<SMALL><SUP>&reg;</SUP></SMALL> franchise product net sales between $590 million and $620 million.<wbr>
</LI>
<LI>RESTASIS<SMALL><SUP>&reg;</SUP></SMALL> product net sales between $1,030 million and $1,070 million.<wbr>
</LI>
<LI>BOTOX<SMALL><SUP>&reg;</SUP></SMALL> product net sales between $2,180 million and $2,280 million.<wbr>
</LI>
<LI>LATISSE<SMALL><SUP>&reg;</SUP></SMALL> product net sales between $100 million and $110 million.<wbr>
</LI>
<LI>Breast aesthetics product net sales between $390 million and $420 million
</LI>
<LI>Facial aesthetics product net sales between $540 million and $570 million.<wbr>
</LI>
</UL>
Source: <A href="http://www.allergan.com">www.<wbr>allergan.<wbr>com</A>
</LI>
</UL> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Neurology7561c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Morgan Stanley Analysts read the Valeant bid situation based on comments made by Pyott's yesterday as that Allergan will propose a go-it-alone strategy centred around the following perspectives:- </div><div style="margin-bottom: 10px;">I) The development of a new business plan :- "<FONT face="Arial" size="2"><FONT face="Arial" size="2"><FONT face="Arial" size="2">Obviously, we&rsquo;re re-looking at </FONT></FONT></FONT>our plans given the situation we are in, and, when we areready, we will report back on how we wish to move forward in terms of our organic outlook for the business.<wbr>&rdquo; </div><div style="margin-bottom: 10px;">2) Cost cutting may take centre stage:- &ldquo;And then clearly in the past we have spoken about our ability to leverage our SG&amp;A ratios over time and obviously given the circumstances that is something we are thinking about very carefully,&rdquo; and </div><div>3) Making the case for R&amp;D - &ldquo;On R&amp;D, we have stated historically that we spent maybe even less 10% of the total on early-stage discovery&hellip;when you think back onthe productivity of R&amp;D from every survey we have seen, and this isn't us doing our own surveys, this is others doing surveys; we have always been at the very top quartile of R&amp;D productivity in terms of success rates as well as dollars spent on products produced.<wbr>&rdquo; </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7561" class="commentpermalink">Neurology7561</a> / <span class="date">08 May 2014</span> /
<span class="time">11:32:16 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7559">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-07T18:24:20+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Two Ex-Takeda Appointed at Acino [comp:Acino, :PharmaWorld:sub:People, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids239</link>
<description>Two Ex-Takeda Appointed at Acino [comp:Acino, :PharmaWorld:sub:People, headline]</description><category>comp:Acino</category><category>sub:People</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids239</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=239">Two Ex-Takeda Appointed at Acino</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=comp%3aAcino"><font color="#e95e0b">:DKPHybrids:comp:Acino</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=DKPHybrids&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:DKPHybrids:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPeople"><font color="#e95e0b">:PharmaWorld:sub:People</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/DKPHybrids239">DKPHybrids239</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 May 2014 | 18:21</font><br><br><div style="margin-bottom: 10px;">Comment: Kalle Känd has been appointed as Head of Emerging Markets &amp; Strategy.<wbr> He joins from Takeda Pharm.<wbr>, where he has been responsible for strategy and emerging markets.<wbr> Konstantin V.<wbr> Bakaykin has been named Head of Business Development.<wbr> Most recently he served in a similar function at Takeda.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Recent Appointments</FONT></STRONG> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9474" class="defaultlink">Oncology9474: Ex-Takeda to Join Acino as New CEO</a> </div><div style="margin-bottom: 10px;"><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=237" class="defaultlink">DKPHybrids237: Second Ex-Takeda to Join Acino</a> </div><div style="margin-bottom: 10px;">Konstantin Bakaykin and Kalle Känd will both join the Group on May 16, 2014, and will report to Jostein Davidsen, Acino’s new CEO, who will take up his new role the same day.<wbr> </div><div><EM>Source: Acino</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=DKPHybrids&sdate=20140831&edate=20140501&rec=239">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-07T18:21:32+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>EAU Highlights I: Overview Of Non Muscle Invasive Bladder Cancer Diagnosis and Treatment with BCG [:PharmaWorld:congress:EAU, dis:Bladder]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9685</link>
<description>EAU Highlights I: Overview Of Non Muscle Invasive Bladder Cancer Diagnosis and Treatment with BCG [:PharmaWorld:congress:EAU, dis:Bladder]</description><category>congress:EAU</category><category>dis:Bladder</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9685</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9685">EAU Highlights I: Overview Of Non Muscle Invasive Bladder Cancer Diagnosis and Treatment with BCG</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aBladder"><font color="#e95e0b">:Oncology:dis:Bladder</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aEAU"><font color="#e95e0b">:PharmaWorld:congress:EAU</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9685">Oncology9685</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 07 May 2014 | 17:59</font><br><br><div style="margin-bottom: 10px;">Comment: Non muscle invasive bladder cancer (NMIBC) is a very frequent, costly disease with a high medical unmet need as research funding is very low comparative to other cancers such as prostate cancer.<wbr> Different risk group is often used as prognostic factor for considering treatment options.<wbr> Frequent recurrence rate is the major cause of high cost management for bladder cancer.<wbr> The standard treatment of non muscle invasive bladder cancer (NMIBC) is transurethral resection of the bladder (TUR-B) with post-treatment bladder instillations of chemotherapy (MMC) or immunotherapy agents (BCG).<wbr> Here we highlight key messages and data presented during this year's EAU in Stockholm.<wbr> </div><div style="margin-bottom: 10px;">NMIBC is a disease with many events.<wbr> Around 4 million cystoscopies are estimated to be performed in the EU/<wbr>US every year.<wbr> Approximately 10 million intravesicel instillations are given annually worldwide.<wbr> At any point of time, 2.<wbr>7 million people are estimated in the follow up for bladder cancer (Ploeg et al.<wbr> 2009).<wbr> Therefore it is associated with significant high healthcare burden.<wbr> Optimisation of cost effectiveness for current diagnostic/<wbr>treatments and development of new treatment options are urgently desired.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/6/Table%206.PNG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Diagnosis of NMIBC</STRONG> includes detection of hematuria, and utilising a range of non invasive (urine tests or ultrasonography) and invasive (cystoscopy) techniques.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>Ultrasonography: very high sensitivity in tumours of more than 1 cm but decreases to 40% in tumours &lt; 5mm (EAU guidelines, Palou et al.<wbr> 1991)
</LI>
<LI>Cytological test: high specificity with sensitivity of 25-30% in low grade tumours, and 90-95% in high grade tumours
</LI>
<LI>Urinary markers: role is unclear and yet to define
</LI>
<LI>FISH: fluorescence labelled DNA probes to identify genetic alterations in pericentromeric regions of chromosomes 3,7,17, and the 9p21 locus.<wbr> This may be a marker for the followup as evidences suggest its role as a predictor of recurrence and progression after BCG treatment (Kipp et al.<wbr> 2005; Kamat et al.<wbr> 2012).<wbr> It is a very sensitive technique but problem with false positive!
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/7/Table%207.PNG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>Cystoscopy: important step in the diagnosis and management and quality of the cystoscopy is "totally" operator dependent.<wbr>
</LI>
<LI>Other tests include NMP22&reg; BladderChek&trade; (FDA approved on 28 April 2003) or tumour markers for surveillance
</LI>
</UL> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/8/Table%208.PNG?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Diagnosis of visualization techniques - White light cystoscopy vs Fluorescence light cystoscopy vs Narrow Band Imaging</STRONG> </div><div style="margin-bottom: 10px;">The objectives of TUR is to do a biopsy as well as removal of tumours.<wbr> Therefore, a good and complete TUR is important for diagnosis and prognosis.<wbr> One of the strategies to improve treatment outcome in NMIBC is to optimize the endoscopic management of T1 high grade tumour to improve the quality of TUR.<wbr> Dr.<wbr> Babjuk (Chief, EAU NMIBC guideline) talked about superiority of blue light technology during the ESU session - PDD helped us to understand there are often residual tumour cells on the surrounding and it is important to resect those tumour cells during TUR.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><EM>"T</EM></STRONG><STRONG><EM>he advantage of using PDD at TUR resulted in fewer residual tumours and longer recurrence free survival (RFS).<wbr> One of the most important thing is also to identify carcinoma in situ (CIS) as CIS is considered to be the prognostic factor for progression.<wbr>"</EM></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/1/Table%201.png?user-agent=rss"> <img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/9/Table%209.PNG?user-agent=rss"> </div><div style="margin-bottom: 10px;">In terms of sensitivity, PDD had higher sensitivity but lower specificity than white light (WLC).<wbr> However, PDD has a higher false positivity rate of 11%.<wbr> Dr.<wbr> Babjuk stressed that despite of this higher false positivity yielded with PDD, Hexvix, in particular, still has a preferential role in combination with TUR.<wbr> As this is the only technology that has demonstrated RFS so far, and false positivity can be gradually improved by accumulated experiences.<wbr> In the plenary session, Dr.<wbr> Van Rhijn gave an example how Hexvix is able to detect "the <EM><SPAN style="text-decoration: underline;">endoscopic invisible lesions</SPAN></EM>" that often could result in intravesical recurrence.<wbr> Again, he also highlighted the evidences supporting PDD with Hexvix significantly reduce recurrence rate (Burger et al.<wbr> EurUrol 2013; Stenzl et al J Uol.<wbr> 2010; Grossman et al, J Urol 2012).<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/2/Table%202.png?user-agent=rss"> <img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/3/Table%203.png?user-agent=rss"> </div><div style="margin-bottom: 10px;">Narrow Band Imaging (NBI) is the other technology is being highlighted in the Plenary Session by Dr.<wbr> Van Rhijn as recent advances in endoscopic techniques likely to improve diagnostic accuracy.<wbr> Olympus designated a large video wall for its HD NBI technology and the key communicating messages include: "it is world's first HD NBI video cystoscope, available for video cystoscopy, video ureteroscoppy, and TUR-BT.<wbr>" "NBI enhances capillary and vessel structures - allowing NMIBC resection with increasing accuracy.<wbr> " </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/10/IMG%5f2146.JPG?user-agent=rss"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/11/IMG%5f2147.JPG?user-agent=rss"> </div><div style="margin-bottom: 10px;">Dr Van Rhijn stated that two technologies work differently: </div><div style="margin-bottom: 10px;"><UL><LI>Hexvix - detection of cells that absorbed fluorescence substance
</LI>
<LI>NBI - detection of structural changes in vessel formation and thickness of the muscle
</LI>
</UL> </div><div style="margin-bottom: 10px;">NBI is the new optical image enhancement technology which narrows the bandwidth of the light to 415 and 540 nm.<wbr> These wavelengths are strongly absorbed by haemoglobin increasing visibility of capillaries and in the same way hypervascular tumour lesions.<wbr> The advantage of NBI is that there is no need for instillations and it is easier to perform.<wbr> There were clinical data suggesting NBI has a significantly higher sensitivity than WLC .<wbr> Dr Van Rhijn commented during the plenary session "<EM>I think data is very limited at this moment.<wbr> But there is a planned randomized trial that also includes recurrence as the endpoint.<wbr> Unfortunately data is not available yet.<wbr> Currently t is becoming very useful as a imaging tool for upper tract where instillation is impossible to do</EM>.<wbr>" </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/4/Table%204.png?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>BCG as standard treatment for NMIBC</STRONG> </div><div style="margin-bottom: 10px;">During ESU course of diagnosis and management of NMIBC, Dr.<wbr> Witjes and Dr.<wbr> Babuk emphasize3 years.<wbr> Intermediate risk NMIBC is defined as patients who are neither high risk nor low risk.<wbr> Intermediate risk patients should be treated with one immediate instillation of chemotherapy followed by further instillations of either chemotherapy for a maximum of 1 year or 1 year of full dose BCG.<wbr> </div><div style="margin-bottom: 10px;">An opening remark by Dr.<wbr> Kumat during Medac sponsored symposium: "<STRONG><EM> I challenged everyone in this room to find the single immunotherapy agent today to beat the result BCG has in bladder cancer .<wbr> With that being said, BCG should be used appropriately</EM>.<wbr>"</STRONG> </div><div style="margin-bottom: 10px;">Dr Kamat stated four myths around concerns with BCG needed to be cleared: </div><div style="margin-bottom: 10px;">X BCG dose not reduce progression rates (only reduces recurrences) : BCG dose reduce progression rate but only when maintenance was used (Sylvester et al; Malmstrὃm et al.<wbr> ) </div><div style="margin-bottom: 10px;">X Optimal maintenance unknown (induction alone is enough) : SWOG protocol shows clear benefit.<wbr> </div><div style="margin-bottom: 10px;">X BCG is only indicated for high risk disease: EORTC 30911 shows BCG reduces death from bladder cancer although HR of intermediate risk patients (HR=0.<wbr>35, p=0.<wbr>20) is lower than high risk patients (HR=0.<wbr>60, p=0.<wbr>39).<wbr> In the same study benefit for intermediate pts is as good as high risk patients when received 3 wk maintenance BCG (in comparison with Epirubicin) </div><div style="margin-bottom: 10px;">X Most patient cannot tolerate full course of BCG: in EORTC 30692 study, only 5.<wbr>2% patients discontinued BCG maintenance due to toxicity </div><div style="margin-bottom: 10px;"><STRONG>Other key data of </STRONG><STRONG>experimental treatment include:</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>VPM-1002 (presented by Cyrill A Rentsch (<A href="https://cortellis.thomsonreuterslifesciences.com/ngg/report/ci/sourcesConferenceDocument/1546570"><U><FONT color="#0066cc">University Hospital Basel</FONT></U></A>) during Poster Session):
</LI>
</UL> </div><div style="margin-bottom: 10px;">A genetically modified, recombinant recombinant Mycobacterium bovis BCG, to facilitates exposure of extracellular agents to MHC class I receptors.<wbr> Preclinical data suggested it resulted in activated Th17 and Th1 immune responses, with significant increases in the production of IFN-gamma and IL-17 that were greater than the effect obtained with standard BCG upon stimulation with purified tuberculin protein derivative.<wbr> No apparent differences in the toxicity profile of VPM-1002 and parental BCG.<wbr> Assessments in healthy volunteers (n = 80) included in a phase Ia, ascending-dose trial demonstrated the safety and tolerability of VP-1002, which at single, intradermal injections enhanced induction of immunity against purified protein derivative.<wbr> With this favorable profile suggestive of use as future therapeutic for non-muscle-invasive bladder cancer, further phase I/<wbr>II development is currently ongoing.<wbr> </div><div style="margin-bottom: 10px;"><UL><LI>MAGNOLIA Phase II study Update (presented by Dr.<wbr> Witjes):
</LI>
</UL> </div><div style="margin-bottom: 10px;">This is a randomized, double-blind, placebo-controlled study to assess the safety and efficacy of zastumotide (astuprotimut-R, MAGE-A3 ASCI; GlaxoSmithKline) in preventing recurrences of muscle-invasive bladder cancer after radical cystectomy.<wbr> Patients (expected n = 273) who were clinically free from residual disease after radical cystectomy for tumours expressing the MAGE-A3 antigen received intramuscular zastumotide (with AS15 as adjuvant) or placebo.<wbr> As of March 2014, 44 of 71 randomized patients were on treatment.<wbr> Data from 64 patients who had received a total of 402 injections of zastumotide during the study revealed favourable safety, with no unexpected concerns.<wbr> At randomization, 46% of patients had stage T2 disease, with 76% being free from lymph node metastases.<wbr> Many patients who screened positive for MAGE-A3-expressing bladder tumours failed to be randomized into the trial because of lack of consent, which resulted in a protocol amendment to include patients with prior neoadjuvant or adjuvant chemotherapy, and patients submitted to cystectomy up to 13 weeks prior to inclusion in order to improve enrolment.<wbr> </div><div style="margin-bottom: 10px;">Sessions covered include: </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 12pt;"><SPAN style="font-size: small;">12 April Molecular diagnostic and biomarkers of bladder cancer (10:00)</SPAN></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 12pt;"><SPAN style="font-size: small;">13 April Diagnosis and treatment of NMIBC</SPAN></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 12pt;"><SPAN style="font-size: small;">13 April Experimental therapies for bladder cancer</SPAN></P> </div><div style="margin-bottom: 10px;"><P style="margin: 0in; font-family: Calibri; font-size: 12pt;"><SPAN style="font-size: small;">14 April Diagnosis and management of NMIBC</SPAN></P> </div><div><P style="margin: 0in; font-family: Calibri; font-size: 12pt;"><SPAN style="font-size: small;">14 April Management strategies in NMIBC: from first diagnosis to recurrence (Poster Session)</SPAN></P> </div><!-- Comment details --><a name="oncology9685attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/1/Table%201.png">Table 1.png</a>&nbsp;&nbsp;(606,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/2/Table%202.png">Table 2.png</a>&nbsp;&nbsp;(563 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/3/Table%203.png">Table 3.png</a>&nbsp;&nbsp;(779,7 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/4/Table%204.png">Table 4.png</a>&nbsp;&nbsp;(732,7 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/5/Table%205.PNG">Table 5.PNG</a>&nbsp;&nbsp;(213,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/6/Table%206.PNG">Table 6.PNG</a>&nbsp;&nbsp;(65,9 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/7/Table%207.PNG">Table 7.PNG</a>&nbsp;&nbsp;(94,6 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/8/Table%208.PNG">Table 8.PNG</a>&nbsp;&nbsp;(118,2 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/9/Table%209.PNG">Table 9.PNG</a>&nbsp;&nbsp;(82 KB)<br>&nbsp;&nbsp;10.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/10/IMG%5f2146.JPG">IMG_2146.JPG</a>&nbsp;&nbsp;(3,4 MB)<br>&nbsp;&nbsp;11.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/11/IMG%5f2147.JPG">IMG_2147.JPG</a>&nbsp;&nbsp;(3,3 MB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9685">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-07T17:59:59+02:00</dc:date><dc:creator>jew60237</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/1/Table%201.png" length="620976" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/2/Table%202.png" length="576515" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/3/Table%203.png" length="798421" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/4/Table%204.png" length="750267" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/5/Table%205.PNG" length="218316" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/6/Table%206.PNG" length="67522" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/7/Table%207.PNG" length="96857" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/8/Table%208.PNG" length="121024" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/9/Table%209.PNG" length="83969" type="image/x-png"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/10/IMG%5f2146.JPG" length="3530564" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9685/11/IMG%5f2147.JPG" length="3447592" type="image/jpeg"/></item><item>
<title>OXiGENE's Combretastatin A-4 Phosphate (ZYBRESTAT®) to Enter POC Trial for GI-NET [dis:MidGutNET]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7662</link>
<description>OXiGENE's Combretastatin A-4 Phosphate (ZYBRESTAT®) to Enter POC Trial for GI-NET [dis:MidGutNET]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7662</comments><category>dis:MidGutNET</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7662</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7662">OXiGENE's Combretastatin A-4 Phosphate (ZYBRESTAT®) to Enter POC Trial for GI-NET</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aMidGutNET"><font color="#e95e0b">:Endocrinology:dis:MidGutNET</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7662">Endocrinology7662</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 May 2014 | 17:55</font><br><br><div style="margin-bottom: 10px;">Comment: The protocol of the Ph2 will investigate the safety, symptoms and biomarker response of subjects with biopsy-proven well-differentiated, low-to-intermediate-grade, unresectable, or metastatic GI-NETs with elevated biochemical markers who have relapsed during or after receiving prior standard of care therapies, including octreotide, chemotherapy or targeted therapy.<wbr> PE will assess change from one or more baseline biomarker values for each patient to each study visit and study end.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Study Details NCT02132468</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG>Recruitment</STRONG>: approx 20 participants </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Biopsy-proven well-differentiated, low-to-intermediate-grade GI-NET with elevated (&gt; ULN) biomarkers (serotonin, 5-hydroxyindoleacetic acid (5-HIAA), chromogranin A (CgA), neurokinin A, and neuron-specific enolase (NSE))</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Life expectancy &gt; 12 weeks</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Must have received or may still be receiving one or more therapies including octreotide or serotonin synthesis inhibitor (SSI) or other somatostatin analogues</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Confirmed progressive disease within 18 months of enrollment on study</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Recovered from prior radiation therapy or surgery</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Eastern Cooperative Oncology Group (ECOG) performance score 0-2</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Absolute neutrophil count (ANC) ≥ 1,500/<wbr>µL (without growth factors)</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Platelet count ≥ 100,000/<wbr>µL</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">
Adequate renal function as evidenced by serum creatinine
≤ 2.<wbr>0 mg/<wbr>dL (177 µmol/<wbr>L)</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Adequate hepatic function: serum total bilirubin ≤ 2X greater than the upper limit of normal (ULN) (≤ 3X ULN in subjects with liver metastases), AST (Aspartate aminotransferase)/<wbr>ALT (Alanine aminotransferase) ≤ 2X the ULN for the local reference lab (≤ 5X the ULN for subjects with liver metastases)</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI class="color-bullet" style="MARGIN-TOP: 0.7ex">Disease that can be assessed (evaluable) with imaging (CT, MRI, PET, radionuclide imaging or other imaging modality)</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Timelines: </STRONG>Study planned to start in July 2014, with completion in December 2016 </div><div style="margin-bottom: 10px;">Locations: USA </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Drug Development Programs</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7662/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">ZYBRESTAT® (fosbretabulin tromethamine/<wbr> combretastatin-A4 phosphate /<wbr> CA4P) is OXiGENE’s lead vascular disrupting agent (VDA) product candidate </div><div><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7662/1/ScreenCapture1.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Endocrinology8001c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div>OxiGene has announced in the 2014 financial results that they are planning to progress the Phase II study for ZYBRESTAT (fosbretabulin) in GI-NET.<wbr> More specifically the CEO stated the intention of completing the enrollment in the ongoing Phase II study <a href="https://clinicaltrials.gov/ct2/show/NCT02132468?term=fosbretabulin&rank=8&submit_fld_opt=" class="defaultlink">(NCT02132468)</a>, due to deliver data for primary outocme measures in December 2016.<wbr> </div><font size="-1">Giorgia VICENTINI / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology8001" class="commentpermalink">Endocrinology8001</a> / <span class="date">18 March 2015</span> /
<span class="time">16:05:33 o'clock CET</span>
</font></div><a name="endocrinology7662attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7662/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(83,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7662/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(66,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7662">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-07T17:55:54+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7662/1/ScreenCapture1.jpg" length="85757" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7662/2/ScreenCapture2.jpg" length="67889" type="image/jpeg"/></item><item>
<title>GW Pharma Q2 Results - Key Takeaways [dis:Spasticity, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7554</link>
<description>GW Pharma Q2 Results - Key Takeaways [dis:Spasticity, news]</description><category>dis:Spasticity</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7554</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7554">GW Pharma Q2 Results - Key Takeaways</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=dis%3aSpasticity"><font color="#e95e0b">:Neurology:dis:Spasticity</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Neurology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7554">Neurology7554</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 07 May 2014 | 17:21</font><br><br><div style="margin-bottom: 10px;">Comment: GW had an active quarter where signficant advances were made with a 
number of programmes, particularly on the epilepsy front and where a 
follow-on offering of ADSs on NASDAQ raised a total net proceeds of £56.<wbr>8 
million.<wbr>  Sativex quarterly revenues increased from £0.<wbr>4m to £1.<wbr>3 
reflecting increased shipments to partners and in-market sales volume growth of 
43% </div><div style="margin-bottom: 10px;"><STRONG>Advancement of Epidiolex® childhood epilepsy program</STRONG>: </div><div style="margin-bottom: 10px;"><UL><LI>Investigational New Drug Application (IND) authorized by the U.<wbr>S.<wbr> Food and 
  Drug Administration (FDA) for Epidiolex® (Cannabidiol or CBD) in the treatment 
  of Dravet Syndrome (announced separately today).<wbr> Phase 2/<wbr>3 trial on track to 
  commence H2 2014</LI>
<LI>Orphan Drug Designation granted by the FDA for Epidiolex to treat 
  Lennox-Gastaut syndrome (Orphan Drug Designation also granted in November 2013 
  for Dravet Syndrome)</LI>
<LI>Number of children suffering from intractable epilepsy syndromes 
  authorized for treatment with Epidiolex by FDA under Expanded Access Treatment 
  INDs increased to approximately 300 from 125 in January</LI>
<LI>Approximately 60 children now receiving treatment with Epidiolex in the 
  U.<wbr>S.<wbr></LI>
<LI>Treatment data on initial cohort of patients on track to be released 
  mid-2014</LI>
<LI>Two U.<wbr>S.<wbr> state governments have publicly expressed interest in 
  collaborating with GW on separate state-based clinical trials in 
epilepsy</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI><STRONG>Sativex<SUP>®</SUP> program developments:</STRONG></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Sativex received Fast Track designation by FDA for treatment of chronic 
  cancer pain in patients with advanced cancer who have failed to respond 
  adequately to optimized opioid therapy</LI>
<LI>Initial top-line Phase 3 cancer pain data on track for release towards the 
  end of 2014.<wbr> Data intended to lead to a New Drug Application (NDA) filing with 
  the FDA in the U.<wbr>S.<wbr></LI>
<LI>Special Protocol Assessment (SPA) ongoing with the FDA for proposed 
  Sativex Phase 3 trial in the treatment of Multiple Sclerosis (MS) 
  spasticity</LI>
<LI>Sativex now approved in 25 countries and available for use in 12 
  countries.<wbr> In-market sales volumes sold by GW’s commercial partners for the 
  six months ended 31 March 2014 increased by 40% over the prior period  
  with a particularly strong sales performance seen in Germany &amp; 
Italy.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Significant additional on-going clinical trial activity 
is underway for cannabinoid pipeline product candidates</LI>
</UL> </div><div style="margin-bottom: 10px;"><UL><LI>Phase 2a trial of GWP42003 for the treatment of ulcerative colitis ongoing 
  - data expected H2 2014</LI>
<LI>Phase 2b 12-week randomized, double blind, placebo controlled trial of 
  GWP42004 in type-2 diabetes commenced in March 2014 with expected completion 
  in H2 2015</LI>
<LI>Phase 2a trial of GWP42003 for the treatment of schizophrenia commenced in 
  March 2014 with expected completion in H2 2015</LI>
<LI>Phase 1b/<wbr>2a trial of GWP42002:GWP42003 in the treatment of glioma is 
  ongoing with safety data on an initial cohort due this year</LI>
</UL> </div><div>source:www.<wbr>gwpharma.<wbr>com </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7554">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-07T17:21:19+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>New Zealand's Pharmac Refuses Funding for Zytiga [comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:sub:Pricing]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9684</link>
<description>New Zealand's Pharmac Refuses Funding for Zytiga [comp:JnJ, dis:Prostate, prod:Zytiga, :PharmaWorld:sub:Pricing]</description><category>comp:JnJ</category><category>dis:Prostate</category><category>prod:Zytiga</category><category>sub:Pricing</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9684</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9684">New Zealand's Pharmac Refuses Funding for Zytiga</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aJnJ"><font color="#e95e0b">:Oncology:comp:JnJ</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aZytiga"><font color="#e95e0b">:Oncology:prod:Zytiga</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aPricing"><font color="#e95e0b">:PharmaWorld:sub:Pricing</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9684">Oncology9684</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 07 May 2014 | 17:02</font><br><br><div style="margin-bottom: 10px;">Comment: According to ONE News, although Pharmac's Pharmacology and Therapeutics Advisory Committee (PTAC) had previously recommended funding for Zytiga, it had assigned it low priority; despite subsequent reviews, this assignation has not changed.<wbr> </div><div style="margin-bottom: 10px;">Pharmac's director of operations, Sarah Fitt, said, "Once Pharmac has a recommendation from PTAC, we compare all the medicines funding applications that are options for investment and prioritise them, using the decision criteria and taking into account the amount of funding available.<wbr> The minutes of these later meetings are not published yet, but we can advise that the committee's low priority recommendation for funding did not change.<wbr>" </div><div style="margin-bottom: 10px;"><B>Significance</B> </div><div style="margin-bottom: 10px;">Zytiga is indicated to be used in combination with prednisone by men with metastatic castration-resistant prostate cancer (mCRPC), and it is estimated that it could potentially be of benefit for up to 1,000 men a year in New Zealand.<wbr> </div><div style="margin-bottom: 10px;">However, its high price point of NZD5,000 (USD4,320) per month – and the fact that it extends life rather than providing a definitive cure – has dissuaded Pharmac from funding its use.<wbr> </div><div style="margin-bottom: 10px;">Nevertheless, a spokesperson for Janssen said that the company will continue to try to persuade Pharmac to change the funding priority for the drug.<wbr> </div><div><EM>Source: IHS GlobalInsight</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9684">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-07T17:02:25+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>FDA Granted Astellas/Medivation Priority Review For Xtandi Capsules's License Extension In Chemo Naive mCRPC [comp:Astellas, dis:Prostate, class:Hormonals]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9682</link>
<description>FDA Granted Astellas/Medivation Priority Review For Xtandi Capsules's License Extension In Chemo Naive mCRPC [comp:Astellas, dis:Prostate, class:Hormonals]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>class:Hormonals</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9682</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9682">FDA Granted Astellas/<wbr>Medivation Priority Review For Xtandi Capsules's License Extension In Chemo Naive mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aHormonals"><font color="#e95e0b">:Oncology:class:Hormonals</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9682">Oncology9682</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/994">Jenny Wu</a> | 07 May 2014 | 10:19</font><br><br><div style="margin-bottom: 10px;">Comment: Medivation Inc.<wbr>and Astellas Pharma Inc.<wbr> reported the U.<wbr>S.<wbr> Food and Drug Administration or FDA's acceptance for filing the supplemental New Drug Application or sNDA to extend the indication for XTANDI capsules for chemo-na&iuml;ve metastatic castration-resistant prostate cancer (mCRPC).<wbr> The sNDA application was granted Priority Review designation with a stated FDA Prescription Drug User Fee Act review date of September 18, 2014.<wbr> </div><div>Currently, Enzalutamide (Xtandi) is approved to treat patients with mCRPC who have earlier received docetaxel chemotherapy.<wbr> Astellas presented positive Phase 3 PREVAIL data in ASCO GU in Feb this year.<wbr> Professor Tombal also presented European subpopulation analysis from PREVAIL in LBA session in EAU earlier this month.<wbr> The sNDA application is based on the Phase 3 PREVAIL trial results, assessing XTANDI compared with placebo in over 1,700 chemotherapy-na&iuml;ve mCRPC patients.<wbr> The FDA's acceptance of the sNDA triggers a milestone payment to Medivation under its collaboration agreement with Astellas.<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9682">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-07T10:19:11+02:00</dc:date><dc:creator>jew60237</dc:creator></item><item>
<title>AZ Fights Pfizer Bid by Predicting Sales Surge [comp:AstraZeneca, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9680</link>
<description>AZ Fights Pfizer Bid by Predicting Sales Surge [comp:AstraZeneca, headline]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9680</comments><category>comp:AstraZeneca</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9680</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9680">AZ Fights Pfizer Bid by Predicting Sales Surge</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:Oncology:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9680">Oncology9680</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2014 | 18:18</font><br><br><div style="margin-bottom: 10px;">Comment: Chief Executive <TR:CATEGORY>Pascal Soriot</TR:CATEGORY> predicted sales would rise by three quarters over the next decades.<wbr> He said plunging AstraZeneca into a disruptive merger would also jeopardise its ability to deliver on the new drug pipeline, which is expected to account for 30% of the 2023 sales total.<wbr> Key slides of his presentation, titled <EM>'Delivering value for patients and shareholders'</EM> are provided below.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Pipeline Highlights</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Impressive Growing and Accelerating Pipeline</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Key Assets with Strong Competitive Advantages</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Broad Set of Immuno-Oncology Targets</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Growth Platforms - 5 Key Levers</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Build on China Growth</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Conclusion</FONT></STRONG> </div><div>P Soriot concluded that the company has the strategy, size and focus to succeed.<wbr> Company science and innovation is at the heart of its culture.<wbr><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/7/ScreenCapture7.jpg?user-agent=rss"> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="Oncology9709c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Comment: On 15th May, AstraZeneca made a press release to strengthen and reinforce company's position to operate as an 'independent company'.<wbr> Pascal Soriot (Chief Executive of AZ) made a statement " we continue to build our pipeline and we are encouraged by the progress in the development of key assets.<wbr> We have complete confidence in our strategy as an independent company and remain focused on delivering new medicines for patients, which will continue to create significant value for our shareholders".<wbr> </div><div>In particular new data from its new lung cancer drug - AZD9291 - that targets T790M.<wbr> T790M mutation is shown to develop in about 1/<wbr>2 of lung cancer patients who become resistant to EGFR inhibitors.<wbr> the results released on Wednesday showed AZD9291 shrank tumours in 51% of patients and 64% of patients harbouring T790M mutation.<wbr> Other two candidates being featured as "their exciting future in oncology" is its anti-PDL1 - MEDI4736 - that is being evaluated in NSCLC and PARP inhibitor - olaparib - that will be reviewed by FDA in Q3 2014.<wbr> Based on these positive results, AZ has forecast potential peak sales for MEDI47376 of $ 6.<wbr>5 billion and olaparib of $ 2 billion.<wbr> Overall, AZ forecasts these new products (including new treatments for diabetes asthma, rheumatoid arthritis and psoriasis) will generate $45 billions ins ales by 2023.<wbr> These promising cancer drug data will help AZ in light of Pfizer flight and provide fresh ammunition to argue that Pfizer substantially undervalues with its takeover offer.<wbr> </div><font size="-1">Jenny Wu / <a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9709" class="commentpermalink">Oncology9709</a> / <span class="date">16 May 2014</span> /
<span class="time">12:23:33 o'clock CEST</span>
</font></div><a name="oncology9680attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(87,5 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(9,3 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(87,6 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(224,6 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(107,6 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(49,3 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(26,5 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9680">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-06T18:18:00+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/1/ScreenCapture1.jpg" length="89595" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/2/ScreenCapture2.jpg" length="9521" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/3/ScreenCapture3.jpg" length="89679" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/4/ScreenCapture4.jpg" length="229977" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/5/ScreenCapture5.jpg" length="110172" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/6/ScreenCapture6.jpg" length="50449" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9680/7/ScreenCapture7.jpg" length="27121" type="image/jpeg"/></item><item>
<title>Highlights of Leerink Swann's 1Q14 Cosmetic Survey [class:BotulinumToxins, comp:Allergan, comp:Merz, sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7553</link>
<description>Highlights of Leerink Swann's 1Q14 Cosmetic Survey [class:BotulinumToxins, comp:Allergan, comp:Merz, sub:Aesthetics, :PharmaWorld:mkt:NorthAmerica]</description><category>class:BotulinumToxins</category><category>comp:Allergan</category><category>comp:Merz</category><category>sub:Aesthetics</category><category>mkt:NorthAmerica</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7553</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7553">Highlights of Leerink Swann's 1Q14 Cosmetic Survey</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=class%3aBotulinumToxins"><font color="#e95e0b">:Neurology:class:BotulinumToxins</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aMerz"><font color="#e95e0b">:Neurology:comp:Merz</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=sub%3aAesthetics"><font color="#e95e0b">:Neurology:sub:Aesthetics</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aNorthAmerica"><font color="#e95e0b">:PharmaWorld:mkt:NorthAmerica</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7553">Neurology7553</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2014 | 16:22</font><br><br><div style="margin-bottom: 10px;">Comment: In this survey, US physicians continue to forecast Botox share of ~70%, and Juvederm Voluma share to grow from 8% currently to 15% in 2016.<wbr> Results suggest Xeomin to take share, but pace may be slowing.<wbr> Overall, topical botulinum toxin holds highest new product interest.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Respondent Distribution</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Comparing 1Q14 Survey to Historical Survey</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Treatment trends in new patients imply moderating expected Xeomin share gains </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Mean Results of Interest for New Products</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><STRONG><FONT size="3">Full Report Available on Demand to Brigitte Deschamps</FONT></STRONG> </div><!-- Comment details --><a name="neurology7553attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(90,9 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(35,1 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(43,2 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(28,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7553">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-06T16:22:45+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/1/ScreenCapture1.jpg" length="93063" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/2/ScreenCapture2.jpg" length="35962" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/3/ScreenCapture3.jpg" length="44209" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/neurology/7553/4/ScreenCapture4.jpg" length="28971" type="image/jpeg"/></item><item>
<title>Bayer AG to Buy Merck &amp; Co Consumer Business for $14.2bln [:Oncology:comp:BayerSchering, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10844</link>
<description>Bayer AG to Buy Merck &amp; Co Consumer Business for $14.2bln [:Oncology:comp:BayerSchering, headline]</description><category>comp:BayerSchering</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10844</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10844">Bayer AG to Buy Merck & Co Consumer Business for $14.<wbr>2bln</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aBayerSchering"><font color="#e95e0b">:Oncology:comp:BayerSchering</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:PharmaWorld:headline</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10844">PharmaWorld10844</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2014 | 14:19</font><br><br><div style="margin-bottom: 10px;">Comment: Moving forward with its strategy to become n°1 OTC company, Bayer AG has acquired Merck &amp; Co's non-prescription medicines business (including the global trademark and prescription rights for Coppertone®, Claritin® and Afrin® leaders in their respective categories).<wbr> In a related transaction, the companies have entered a deal potentially worth up $2.<wbr>1bln in the area of cardiovascular diseases, with a focus on sGC modulation.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Transaction Highlights</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Combined Portfolio Strengthens Global Positions and Geographic Footprint</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/9/ScreenCapture9.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/8/ScreenCapture8.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Merck's Consumer Care in a Nutshell</FONT></STRONG> </div><div style="margin-bottom: 10px;"><STRONG><U>Products</U></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><UL><LI>Claritin non-drowsy antihistamines; </LI>
<LI><U>MiraLAX</U> for relief of occasional constipation; </LI>
<LI>Coricidin HBP decongestant-free cold/<wbr>flu medicine for people with high blood pressure; </LI>
<LI>Afrin nasal decongestant spray; </LI>
<LI>Zegerid OTC treatment for frequent heartburn; </LI>
<LI>Oxytrol For Women, a treatment for overactive bladder in women.<wbr> </LI>
<LI>Dr.<wbr> Scholl’s foot care products; Lotrimin topical antifungal products; and Tinactin topical antifungal products and foot and sneaker odor/<wbr>wetness products.<wbr> </LI>
<LI>Coppertone sun care lotions, sprays and dry oils.<wbr></LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG><U>2013 Global Sales</U></STRONG> </div><div style="margin-bottom: 10px;">Global sales were $1.<wbr>9 billion in 2013, a decline of 3% compared with 2012 including a 1% unfavorable effect from foreign exchange.<wbr> </div><div style="margin-bottom: 10px;">In 2013, Merck's consumer care business generated approximately 70% of its sales in the US, where it also holds leading brand positions </div><div style="margin-bottom: 10px;">The sales decline in 2013 resulted from the termination in China of certain Consumer Care distribution arrangements and a reversal of sales previously made to these distributors, together with associated termination costs.<wbr> </div><div><EM>Source: Merck &amp; Co</EM> </div><!-- Comment details --><a name="pharmaworld10844attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(21,4 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(95,9 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(21 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(58,8 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(48,2 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(46,2 KB)<br>&nbsp;&nbsp;7.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/7/ScreenCapture7.jpg">ScreenCapture7.jpg</a>&nbsp;&nbsp;(29 KB)<br>&nbsp;&nbsp;8.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/8/ScreenCapture8.jpg">ScreenCapture8.jpg</a>&nbsp;&nbsp;(37,1 KB)<br>&nbsp;&nbsp;9.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/9/ScreenCapture9.jpg">ScreenCapture9.jpg</a>&nbsp;&nbsp;(55,3 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10844">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-06T14:19:18+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/1/ScreenCapture1.jpg" length="21944" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/2/ScreenCapture2.jpg" length="98168" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/3/ScreenCapture3.jpg" length="21546" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/4/ScreenCapture4.jpg" length="60244" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/5/ScreenCapture5.jpg" length="49316" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/6/ScreenCapture6.jpg" length="47307" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/7/ScreenCapture7.jpg" length="29657" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/8/ScreenCapture8.jpg" length="37988" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/pharmaworld/10844/9/ScreenCapture9.jpg" length="56649" type="image/jpeg"/></item><item>
<title>Update on Novo's Growth Hormone Business [class:GrowthHormone, comp:NovoNordisk, dis:GrowthHormoneDeficiency, prod:Norditropin]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7659</link>
<description>Update on Novo's Growth Hormone Business [class:GrowthHormone, comp:NovoNordisk, dis:GrowthHormoneDeficiency, prod:Norditropin]</description><category>class:GrowthHormone</category><category>comp:NovoNordisk</category><category>dis:GrowthHormoneDeficiency</category><category>prod:Norditropin</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7659</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7659">Update on Novo's Growth Hormone Business</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovoNordisk"><font color="#e95e0b">:Endocrinology:comp:NovoNordisk</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aGrowthHormoneDeficiency"><font color="#e95e0b">:Endocrinology:dis:GrowthHormoneDeficiency</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=prod%3aNorditropin"><font color="#e95e0b">:Endocrinology:prod:Norditropin</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7659">Endocrinology7659</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2014 | 12:40</font><br><br><div style="margin-bottom: 10px;">Comment: Last week, Novo provided Q1:14 financials, outlook as well as an R&amp;D update.<wbr> The companys leads the global GH market with a 29% market share measured in volume.<wbr> Pipeline lists NN8640, a once-weekly hGH drug in Ph1 for growth disorder, reported by management as being a "promising version compared to the product on the market".<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Norditropin® Data</FONT></STRONG> </div><div style="margin-bottom: 10px;">Norditropin® is the only liquid room temperature stable human GH in a prefilled device.<wbr> </div><div style="margin-bottom: 10px;">Norditropin® sales increased by 4% (in local currencies), but decreased by 2% in Danish kroner to DKK 1,500 million.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The sales growth is primarily driven by contractual wins, the support programmes that Novo Nordisk offers healthcare professionals and patients as well as the penetration of the prefilled FlexPro® device in North America.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/3/ScreenCapture3.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Global Leadership in GH Therapy</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">NN8640 Development Strategy</FONT></STRONG> </div><div style="margin-bottom: 10px;">Please see <a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7604" class="defaultlink">Endocrinology7604: Novo Nordisk's Progress With LA-GH</a>.<wbr> </div><div><EM>Source: Novo Nordisk</EM> </div><!-- Comment details --><a name="endocrinology7659attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(46,2 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(74 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(48,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(46,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7659">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-06T12:40:56+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/1/ScreenCapture1.jpg" length="47327" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/2/ScreenCapture2.jpg" length="75788" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/3/ScreenCapture3.jpg" length="49293" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/endocrinology/7659/4/ScreenCapture4.jpg" length="47695" type="image/jpeg"/></item><item>
<title>ERYTECH's POC Trial Authorized in France for Pancreatic Cancer [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9678</link>
<description>ERYTECH's POC Trial Authorized in France for Pancreatic Cancer [news]</description><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9678</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9678">ERYTECH's POC Trial Authorized in France for Pancreatic Cancer</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9678">Oncology9678</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2014 | 11:59</font><br><br><div style="margin-bottom: 10px;">Comment: Having already successfully completed a Ph1 study in late stage pancreas cancer, in which the tolerability of ERY-ASP has been confirmed, ERYTECH, a late-stage orphan oncology company, decided to continue the develoment of the drug candidate.<wbr> ANSM, French healthcare agency, has granted the authorization to start a Ph2 study in second- line treatment.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Company Snapshot</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/4/ScreenCapture4.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">The company is also developing other indications in solid tumors and certain orphan indications outside oncology.<wbr> </div><div style="margin-bottom: 10px;">The company holds orphan drug designation for ERY-ASP/<wbr>GRASPA® in ALL, AML and pancreas cancer in Europe and the USA.<wbr> </div><div style="margin-bottom: 10px;">ERYTECH has its own GMP-approved and operational manufacturing sites in Lyon (France) and Philadelphia (USA).<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Pipeline Focus</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/5/ScreenCapture5.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Technology Focus - Encapsulation of Asparaginase</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/6/ScreenCapture6.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ph1 Trial Results</FONT></STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/2/ScreenCapture2.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Ph2 Study Design</FONT></STRONG> </div><div style="margin-bottom: 10px;"><U>Objectives</U>: to evaluate efficacy in repeated doses in association with current chemotherapy and with a stratification of patients (potential responders) based on expression of ASNS.<wbr> </div><div style="margin-bottom: 10px;"><U>Lead/<wbr>Principal Investigator</U>: Professor Pascal Hammel, gastroenterologist specialized in digestive oncology at Hôpital Beaujon (Clichy-Paris, France) </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;"><STRONG>Synopsis</STRONG> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/3/ScreenCapture3.jpg?user-agent=rss"> </div><div><EM>Source: ERYTECH</EM> </div><!-- Comment details --><a name="oncology9678attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(58,7 KB)<br>&nbsp;&nbsp;2.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/2/ScreenCapture2.jpg">ScreenCapture2.jpg</a>&nbsp;&nbsp;(58 KB)<br>&nbsp;&nbsp;3.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/3/ScreenCapture3.jpg">ScreenCapture3.jpg</a>&nbsp;&nbsp;(60,1 KB)<br>&nbsp;&nbsp;4.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/4/ScreenCapture4.jpg">ScreenCapture4.jpg</a>&nbsp;&nbsp;(64,3 KB)<br>&nbsp;&nbsp;5.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/5/ScreenCapture5.jpg">ScreenCapture5.jpg</a>&nbsp;&nbsp;(49 KB)<br>&nbsp;&nbsp;6.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/6/ScreenCapture6.jpg">ScreenCapture6.jpg</a>&nbsp;&nbsp;(56,6 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9678">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-06T11:59:01+02:00</dc:date><dc:creator>brd97880</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/1/ScreenCapture1.jpg" length="60103" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/2/ScreenCapture2.jpg" length="59408" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/3/ScreenCapture3.jpg" length="61556" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/4/ScreenCapture4.jpg" length="65855" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/5/ScreenCapture5.jpg" length="50221" type="image/jpeg"/><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9678/6/ScreenCapture6.jpg" length="57943" type="image/jpeg"/></item><item>
<title>Pfizer/Astra Deal Could be Delayed by Chinese Antitrust Review [mkt:China, :Endocrinology:comp:Pfizer, :Oncology:comp:AstraZeneca, sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10843</link>
<description>Pfizer/Astra Deal Could be Delayed by Chinese Antitrust Review [mkt:China, :Endocrinology:comp:Pfizer, :Oncology:comp:AstraZeneca, sub:Acquisition]</description><category>mkt:China</category><category>comp:Pfizer</category><category>comp:AstraZeneca</category><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10843</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10843">Pfizer/<wbr>Astra Deal Could be Delayed by Chinese Antitrust Review</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aChina"><font color="#e95e0b">:PharmaWorld:mkt:China</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10843">PharmaWorld10843</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2014 | 11:04</font><br><br><div style="margin-bottom: 10px;">Comment: If a deal goes ahead, merger clearance from the Beijing authorities would be required in addition to approvals from U.<wbr>S.<wbr> and EU counterparts.<wbr> This could potentially delay proceedings of the transaction.<wbr> </div><div style="margin-bottom: 10px;">The expectation is that Pfizer and AstraZeneca's prominent position in the market will mean close scrutiny - the firms are ranked first and second place, respectively, among multinational prescription drug suppliers in China.<wbr> </div><div style="margin-bottom: 10px;">The enactment of China's anti-monopoly law 6 years ago has led to the country's regulators playing an increasingly prominent role in international deals, frequently leading to delays.<wbr> </div><div style="margin-bottom: 10px;">The country's antitrust regulators have also faced criticsm for acting as as an extension of government industrial policy.<wbr> </div><div style="margin-bottom: 10px;">Pfizer has encountered such issues before.<wbr> In June 2010, following Pfizer's previous mega merger with Wyeth in 2009, the U.<wbr>S.<wbr> firm was obliged by China's Ministry of Commerce to divest part of its China vaccines business to Harbin Pharmaceutical Group.<wbr> </div><div><EM>Source: GBI</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10843">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-06T11:04:46+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Allergan's Lagest Shareholder Urges to Negotiate with Valeant [comp:Allergan]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7549</link>
<description>Allergan's Lagest Shareholder Urges to Negotiate with Valeant [comp:Allergan]</description><category>comp:Allergan</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7549</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7549">Allergan's Lagest Shareholder Urges to Negotiate with Valeant</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7549">Neurology7549</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 06 May 2014 | 10:48</font><br><br><div style="margin-bottom: 10px;">Comment: While it makes sense for Allergan to look for a white knight, Ackman said, the company should also start talks with Valeant because its chief executive M.<wbr> Pearson has made public statements “suggesting that Valeant may be willing to improve its proposal if Allergan management and its board were to initiate discussions shortly.<wbr>” Tomorrow, alongside their Q1:14 financial results Allergan and Valeant may provide more information or comments on the future strategy.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Potential Companies with Capacity to Buy Allergan</FONT></STRONG> </div><div style="margin-bottom: 10px;">Ackman noted that the list of global pharmaceutical companies with the financial capacity to buy Allergan is limited.<wbr> </div><div style="margin-bottom: 10px;">He said “it is risky for Allergan to rely on the potential for it to negotiate a transaction with a global pharmaceutical company that is superior to the transaction proposed by Valeant.<wbr>” </div><div style="margin-bottom: 10px;">He was also critical of another scenario that has been floated – that Allergan buy a foreign company in order to make itself too big for Valeant to purchase, while reducing its tax rate by shifting some of its assets out of the US.<wbr> </div><div style="margin-bottom: 10px;"><STRONG><FONT size="3">Analysts Views</FONT></STRONG> </div><div style="margin-bottom: 10px;">Given the short list of potential acquirers and Valeant’s willingness to negotiate quickly, Reuters believe Allergan can explore its strategic alternatives and determine a course of action within a matter of weeks.<wbr> </div><div><EM>Sources: Reuters</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7549">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-06T10:48:56+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Anticipated Milestones and Events for Versartis' LA GH [class:GrowthHormone]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7658</link>
<description>Anticipated Milestones and Events for Versartis' LA GH [class:GrowthHormone]</description><category>class:GrowthHormone</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7658</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7658">Anticipated Milestones and Events for Versartis' LA GH</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=class%3aGrowthHormone"><font color="#e95e0b">:Endocrinology:class:GrowthHormone</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7658">Endocrinology7658</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 May 2014 | 19:07</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside financial results for the first quarter ended March 31, 2014 managment outlined key milestones for its long-acting form of recombinant human growth hormone.<wbr> Versartis plans to initiate the development of VRS-317 in PGHD in Japan and resume the development of VRS-317 in adult patients with GHD in 2015.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Figures for the Quarter</STRONG> </div><div style="margin-bottom: 10px;">- R&amp;D expenses for the first quarter of 2014 were $4.<wbr>9 million, compared to $3.<wbr>5 million for the first quarter of 2013.<wbr> The increase in R&amp;D expenses year-over-year was primarily due to the fully enrolled Phase 2a clinical trial for VRS-317, which was initiated in the third quarter of 2013.<wbr> </div><div style="margin-bottom: 10px;">- Cash, cash equivalents, and short-term investments were $204.<wbr>9 million as of March 31, 2014.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Data &amp; Milestones</STRONG> </div><div style="margin-bottom: 10px;">In the second half of 2014 </div><div style="margin-bottom: 10px;">- At the Endocrine Society/<wbr>International Congress on Endocrinology (ICE/<wbr>ENDO) in Chicago, Versartis will present a poster of the complete pediatric GHD Phase 1b/<wbr>2a VERTICAL clinical trial results.<wbr> The Company will host an investor conference call to discuss the findings.<wbr> </div><div style="margin-bottom: 10px;">- Versartis anticipates it will initiate discussions with the FDA and EMA following completion of the Ph2a stage of the ongoing Phase 1b/<wbr>2a VERTICAL clinical trial and in anticipation of the Ph3 clinical program for VRS-317 in pediatric patients in the US and Europe </div><div>Source: Versartis </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7658">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-05T19:07:08+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Evaluation of Astellas' Eligard 6M in Routine Clinical Practice of Uro-Onco in the Russian Federation [comp:Astellas, dis:Prostate, prod:Eligard, :PharmaWorld:mkt:Russia, :PharmaWorld:sub:ClinicalTrial, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9677</link>
<description>Evaluation of Astellas' Eligard 6M in Routine Clinical Practice of Uro-Onco in the Russian Federation [comp:Astellas, dis:Prostate, prod:Eligard, :PharmaWorld:mkt:Russia, :PharmaWorld:sub:ClinicalTrial, news]</description><category>comp:Astellas</category><category>dis:Prostate</category><category>prod:Eligard</category><category>mkt:Russia</category><category>sub:ClinicalTrial</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9677</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9677">Evaluation of Astellas' Eligard 6M in Routine Clinical Practice of Uro-Onco in the Russian Federation</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstellas"><font color="#e95e0b">:Oncology:comp:Astellas</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=prod%3aEligard"><font color="#e95e0b">:Oncology:prod:Eligard</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=mkt%3aRussia"><font color="#e95e0b">:PharmaWorld:mkt:Russia</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aClinicalTrial"><font color="#e95e0b">:PharmaWorld:sub:ClinicalTrial</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9677">Oncology9677</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 May 2014 | 18:32</font><br><br><div style="margin-bottom: 10px;">Comment: The 6-month (45 mg) formulation was approved for the Russian market in 2009.<wbr> This non-interventional study is aimed at investigating whether the efficacy and tolerability of the 6-month LA depot formulation could also be confirmed in a broad and heterogeneous patient population encountered in daily clinical practice in the Russian Federation.<wbr> This study will evaluate total serum PSA and testosterone levels (primary outcomemeasures), QoL of patients, demographic patient data, diagnosis and diagnostic findings in patients.<wbr> It will provide analysis in different subgroups of patients depending on previous hormonal treatment and anamnesis of disease.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Study Details -<a href="http://www.clinicaltrials.gov/ct2/show/NCT02128334?recr=Open&no_unk=Y&cond=PROSTATE+OR+ACROMEGALY+OR+SPASTICITY+OR+BOTULINUM&fund=2&rcv_s=04%2F05%2F2014&rank=5&submit_fld_opt=" class="defaultlink">NCT02128334</a></STRONG> </div><div style="margin-bottom: 10px;">Recruitment: 750 patients &gt; 18 years of age with advanced PCa to whom onco/<wbr>urologist decided to prescribe Eligard 45 mg </div><div style="margin-bottom: 10px;">Locations: 71 sites </div><div>Timelines: completion date expected March 2016 </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9677">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-05T18:32:28+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Key Takeaways from Pfizer's Q1:14 Results [:Endocrinology:comp:Pfizer, sub:Finance, :Oncology:comp:AstraZeneca, headline]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10839</link>
<description>Key Takeaways from Pfizer's Q1:14 Results [:Endocrinology:comp:Pfizer, sub:Finance, :Oncology:comp:AstraZeneca, headline]</description><category>comp:Pfizer</category><category>sub:Finance</category><category>comp:AstraZeneca</category><category>headline</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10839</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10839">Key Takeaways from Pfizer's Q1:14 Results</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aPfizer"><font color="#e95e0b">:Endocrinology:comp:Pfizer</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=comp%3aAstraZeneca"><font color="#e95e0b">:Oncology:comp:AstraZeneca</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=headline"><font color="#e95e0b">:PharmaWorld:headline</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aFinance"><font color="#e95e0b">:PharmaWorld:sub:Finance</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10839">PharmaWorld10839</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 May 2014 | 18:10</font><br><br><div style="margin-bottom: 10px;">Comment: Pfizer started managing its commercial operations through 3 operating segments and for the first time reported financial results for Global Innovative Pharmaceuticals (GIP), global Vaccines, Oncology, and Consumer healthcare (VOC) and Global Established Pharmaceuticals (GEP).<wbr> First quarter 2014 revenue declined 9% to $11.<wbr>4 bln.<wbr> It reflects the loss of exclusivity of Lipitor and Celebrex, the expiration and near term termination of certain collaboration agreements and continued challenging operating environment.<wbr> Merger related issues were discussed during the Q&amp;A session.<wbr> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>Discussion on the Potential Merger with AstraZeneca</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">Questions such as potential weaknesses of Astra standalone business either in terms of product mix or geographic positioning, and Pfizer's intentions assuming it acquires Astra were discussed with management.<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">- " .<wbr>.<wbr>.<wbr> In fact, most of their pipeline is licensed-in products with very view developed nationally.<wbr> But so we look at that and we look at the fit with our portfolio, especially in the immune oncology area where they have assets which stand alone are probably coming late to the market but if they were combined with our portfolio I think it strengthens their portfolio substantially.<wbr> And then when you look at their products, they fit into our categories.<wbr> So we believe that with our marketing presence and our ability in those categories, we can make more out of those products than they can standalone.<wbr> But the power of this deal for us is these three components.<wbr> It's the fit on the portfolio, it's the nice fit with the early pipeline, but it's not a pipeline story, per se.<wbr> It's also a removing of overlaps and making the organization more efficient".<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left">- " .<wbr>.<wbr>.<wbr> then the third component of value here, which is really important for Pfizer, is this ability to free the balance sheet up and get our tax rate down which would enable a lot of different strategies".<wbr></P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>GIP Segment Highlight</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">GIP is comprised of innovative new products, world-class brands as well as a pipeline that includes various high-potential late-stage candidates.<wbr> GIP intends to make targeted investments this year to drive future revenue growth:</P> </div><div style="margin-bottom: 10px;"><UL><LI>Focused promotion of the Eliquis clinical profile to cardiologists
</LI>
<LI>Reiterate Xeljanz safety and efficacy profile for treatment of adult patients with moderately to severely active rheumatoid arthritis with recently-approved U.<wbr>S.<wbr> label enhancements
</LI>
<LI>Conduct full promotional launch of Duavee in the U.<wbr>S
</LI>
<LI>Continue to pursue direct-to-consumer advertising campaigns in the U.<wbr>S.<wbr> for Lyrica, Chantix and Viagra plus investment in growth markets such as Japan
</LI>
<LI>Support ongoing Phase 3 studies for bococizumab, ertugliflozin and Xeljanz
</LI>
</UL> </div><div style="margin-bottom: 10px;"><P align="left">Q1 2014 GIP segment revenue declined 4% operationally to $3.<wbr>1 billion vs.<wbr> Q1 2013</P> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>VOC Segment Highlight</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">VOC is composed of 3 global and distinct businesses driven by an innovative pipeline and successful product launches.<wbr></P> </div><div style="margin-bottom: 10px;">Q1 2014 VOC segment revenue increased 1% operationally to $2.<wbr>2 bln vs Q1 2013: </div><div style="margin-bottom: 10px;"><UL><LI>Vaccines: Grew 2% operationally driven by the performance of Prevnar 13 in the U.<wbr>S.<wbr> and certain emerging markets
</LI>
<LI>Oncology: Increased 10% operationally, primarily due to growth from Xalkori and Inlyta
</LI>
<LI>Consumer: Declined 3% operationally due to a less severe cold/<wbr>flu incidence in the U.<wbr>S.<wbr> and Canada as well as increased competition from the return to market of certain competing analgesic brands
<BLOCKQUOTE dir="ltr" style="margin-right: 0px;">
<DIV align="left">- Pfizer received FDA approval for Nexium 24 hour for over-the-counter use.<wbr> This approval represents the first significant milestone in executing its Rx strategy.<wbr> The US launch is set for May 27th</DIV>
</BLOCKQUOTE>

</LI>
</UL> </div><div style="margin-bottom: 10px;"><P align="left"><STRONG>GEP Segment Highlight</STRONG></P> </div><div style="margin-bottom: 10px;"><P align="left">GEP is a highly-diversified operating segment with distinctive opportunities across portfolios and geographies.<wbr> GEP is comprised of three primary product groupings with different market dynamics</P> </div><div style="margin-bottom: 10px;"><UL><LI>Peri-LOE Developed -- Comprised of products in developed markets that have recently lost or are approaching loss of marketing exclusivity
</LI>
<LI>Legacy EP Developed -- Comprised of mature products in developed markets that have lost marketing exclusivity and Growth Opportunities in developed markets
</LI>
<LI>Emerging Markets -- Comprised of all products sold in emerging markets, including Growth Opportunities
</LI>
</UL> </div><div style="margin-bottom: 10px;">Q1 2014 GEP segment revenue declined 10% operationally to $6.<wbr>0 billion vs.<wbr> Q1 2013 </div><div style="margin-bottom: 10px;"><STRONG>Business Development Process Work in the Context of the New Structure</STRONG> </div><div>Management outlined " .<wbr>.<wbr>.<wbr> each business unit will have projects that they bring forward to the corporation.<wbr> Competition for capital is not necessarily -- we're not necessarily limited in capital.<wbr> There's competition for good ideas and best returns and I think the most important thing of this structure is that it puts the business leaders on the accountability side of the projects they want to get funding for".<wbr> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10839">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-05T18:10:50+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Teva Reports Business Perspectives and Immediate Priorities</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10838</link>
<description>Teva Reports Business Perspectives and Immediate Priorities</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10838</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10838">Teva Reports Business Perspectives and Immediate Priorities</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10838">PharmaWorld10838</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 May 2014 | 15:55</font><br><br><div style="margin-bottom: 10px;">Comment: Alongside Q1:14 financial results, Erez Vigodman (President &amp; CEO) has outlined the three key foundations of the comanpany being the delivery on its cost reduction program, the acceleration of its operational network transformation and the strenghtening of its global generic leadership.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Key Figures for the Quarter</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Revenues of $5.<wbr>0 billion, up 2% compared to the first quarter of 2013 ($4,9 billion)
</LI>
<LI class="bwlistitemmargb"><STRONG>U.<wbr>S</STRONG>.<wbr> generic medicine revenues increased by 17%.<wbr> Generic medicine segment profitability increased by 31%
</LI>
<LI class="bwlistitemmargb"><STRONG>OTC</STRONG> revenues amounted to $269 million in the first quarter of 2014, a decrease of 12%, or 9% in local currency terms, compared to $306 million in the first quarter of 2013, primarily due to lower sales in Eastern Europe
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Cost Reduction Program</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>Management is fully on track to deliver $1bln reduction in gross expenses by end of 2014, $2bln reduction in gross expenses by 2017, and $500M of net savings by 2017.<wbr>
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Acceleration of the Operational Network Transformation</STRONG> </div><div style="margin-bottom: 10px;">Focus on manufacturing network as a source of savings: </div><div style="margin-bottom: 10px;"><UL><LI>Plan to close or divest 11 plants already underway (16 additional plants under evaluation); Teva will be converting 4 of its Israeli factories to operate on natural gas.<wbr> This will allow the company to save millions of dollars each year
</LI>
<LI>Strategic revamp of Teva API
</LI>
</UL> </div><div style="margin-bottom: 10px;"><STRONG>Regain Focus on Generic Business</STRONG> </div><div style="margin-bottom: 10px;">Emphasis on: </div><div style="margin-bottom: 10px;"><UL><LI>Portfolio selection &amp; management
</LI>
<LI>R&amp;D and innovation
</LI>
<LI>Markets and products profitability
</LI>
<LI>
Improving profitability by at least 600 basis points by end of 2017

</LI>
</UL> </div><div><P align="left"><EM>Source: Teva Pharm</EM></P> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10838">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-05T15:55:01+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>BOTOX Approved For OAB in New Zealand [comp:Allergan, prod:Botox]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Neurology7548</link>
<description>BOTOX Approved For OAB in New Zealand [comp:Allergan, prod:Botox]</description><category>comp:Allergan</category><category>prod:Botox</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Neurology7548</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7548">BOTOX Approved For OAB in New Zealand</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=comp%3aAllergan"><font color="#e95e0b">:Neurology:comp:Allergan</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Neurology&sdate=20140831&edate=20140501&cat=prod%3aBotox"><font color="#e95e0b">:Neurology:prod:Botox</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Neurology7548">Neurology7548</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 May 2014 | 15:09</font><br><br><div style="margin-bottom: 10px;">Comment: The treatment of OAB with BOTOX involves injecting 100U of BOTOX into the detrusor muscle.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Indication</STRONG> </div><div style="margin-bottom: 10px;">The New Zealand Medicines and Medical Devices Safety Authority (Medsafe) has registered BOTOX (botulinum toxin type A), for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency and frequency, in adult patients who have an inadequate response to, or are intolerant of, an anticholinergic medication.<wbr> </div><div><EM>Source: <a href="http://www.allergan.com.au" class="defaultlink" title="www.allergan.com.au">allergan.com.au</a>.<wbr></EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Neurology&sdate=20140831&edate=20140501&rec=7548">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-05T15:09:30+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Signifor® LAR Helps Control Acromegaly [comp:Novartis, dis:Acromegaly, prod:Pasireotide, :PharmaWorld:congress:ECE]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7657</link>
<description>Signifor® LAR Helps Control Acromegaly [comp:Novartis, dis:Acromegaly, prod:Pasireotide, :PharmaWorld:congress:ECE]</description><category>comp:Novartis</category><category>dis:Acromegaly</category><category>prod:Pasireotide</category><category>congress:ECE</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7657</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7657">Signifor® LAR Helps Control Acromegaly</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=comp%3aNovartis"><font color="#e95e0b">:Endocrinology:comp:Novartis</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=dis%3aAcromegaly"><font color="#e95e0b">:Endocrinology:dis:Acromegaly</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Endocrinology&sdate=20140831&edate=20140501&cat=prod%3aPasireotide"><font color="#e95e0b">:Endocrinology:prod:Pasireotide</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=congress%3aECE"><font color="#e95e0b">:PharmaWorld:congress:ECE</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Endocrinology7657">Endocrinology7657</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/3">Brigitte DESCHAMPS</a> | 05 May 2014 | 09:21</font><br><br><div style="margin-bottom: 10px;">Comment: Results from a pivotal Ph3 trial of Signifor<SUP class="hugin" style="font-size: 0.8em; vertical-align: text-top;">&reg;</SUP> LAR (pasireotide LAR; SOM230) in patients with acromegaly for whom current standard of care provides inadequate disease control.<wbr> The study findings showed that patients taking the drug achieved greater disease control when compared to continued treatment with the standard somatostatin analogue therapies, octreotide LAR or lanreotide Autogel.<wbr> These data were presented at the 16<SUP class="hugin" style="font-size: 0.8em; vertical-align: text-top;">th</SUP> ECE (May 2014, Wroclaw, Poland).<wbr> WW regulatory filings are currently underway based on these results and separate previously published Ph3 data.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Results Presented @ECE</STRONG> </div><div style="margin-bottom: 10px;">In the trial, significantly more patients achieved biochemical control with each dose of pasireotide LAR compared to the octreotide LAR and lanreotide Autogel control arm.<wbr> Specifically, 15.<wbr>4% and 20.<wbr>0% of those with inadequately controlled acromegaly taking pasireotide LAR 40 mg and 60 mg, respectively (95% confidence interval [CI], 7.<wbr>6-26.<wbr>5; P=0.<wbr>0006; 95% CI, 11.<wbr>1-31.<wbr>8; P&lt;0.<wbr>0001), achieved biochemical control versus 0% achieving biochemical control on continued treatment with octreotide LAR or lanreotide Autogel (95% CI, 0-5.<wbr>3).<wbr> The incidence and severity of adverse events (AEs) was similar across all treatment groups, except for a higher frequency and degree of hyperglycemia in the pasireotide LAR arm </div><div style="margin-bottom: 10px;"><STRONG>About the <a href="https://clinicaltrials.gov/ct2/show/NCT01137682?term=pasireotide+AND+lanreotide&rank=1" class="defaultlink">PAOLA</a> Study</STRONG> </div><div style="margin-bottom: 10px;"><DIV class="identifier">Reference: NCT01137682</DIV> </div><div style="margin-bottom: 10px;">The multicenter Ph3 was a randomized, double-blind trial examining pasireotide LAR 40 mg or pasireotide LAR 60 mg versus continued open-label treatment with octreotide LAR 30 mg or lanreotide Autogel 120 mg (the control group) for 24 weeks.<wbr> The trial included 198 patients with inadequately controlled acromegaly on maximum approved doses of octreotide LAR or lanreotide Autogel for at least 6 months, regardless of prior surgical status.<wbr> </div><div style="margin-bottom: 10px;">The primary endpoint of this study was the proportion of patients achieving biochemical control as measured by the mean GH levels of &lt;2.<wbr>5Mu g/<wbr>L and normalized IGF-1 at 24 weeks.<wbr> </div><div style="margin-bottom: 10px;"><P class="hugin">The key secondary endpoint was the percentage of patients achieving normalized IGF-1; other secondary endpoints included the percentage of patients achieving normalized GH levels, tumor reduction and safety</P> </div><div><EM>Source: Novartis</EM> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Endocrinology&sdate=20140831&edate=20140501&rec=7657">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-05T09:21:02+02:00</dc:date><dc:creator>brd97880</dc:creator></item><item>
<title>Threshold's Pipeline Update [news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9676</link>
<description>Threshold's Pipeline Update [news]</description><category>news</category><category>A102</category><category>B88</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9676</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9676">Threshold's Pipeline Update</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9676">Oncology9676</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 May 2014 | 13:17</font><br><br><div style="margin-bottom: 10px;">Comment: During its earnings call Threshold presented an updated on 
development acitvity with its investigational hypoxia-activated pro-drug TH-302, 
PhIII development activity with which is focused on soft tissue sarcoma and 
advanced pancreatic cancer.<wbr> Additionally, there is ongoing activity in 
hematological malignancies and forthcoming data highlighting the 
drug's potential in combination with other therapies in prostate and 
glioblastoma.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Addressing the Potential New Treatment Paradigm in Pancreatic 
Cancer</STRONG> </div><div style="margin-bottom: 10px;">In March, Threshold announced that its partner Merck KGaA, had initiated 
a Phase 1 dose escalation study assessing the safety, tolerability and 
anti-tumor activity of TH-302 in combination with gemcitabine and nab-paclitaxel 
(Abraxane®) in patients with previously untreated, locally advanced unresectable 
or metastatic pancreatic adenocarcinoma.<wbr> </div><div style="margin-bottom: 10px;">Also in March, Threshold opened 
a 440-patient, randomized, double-blind, placebo-controlled Phase 2 trial of 
TH-302 in combination with pemetrexed in advanced non-squamous non-small cell 
lung cancer.<wbr> The international Phase 2 trial is designed to compare the 
combination of TH-302 and pemetrexed versus the combination of pemetrexed and 
placebo as second-line therapy in this patient population.<wbr> A TH-302 dose of 400 
mg/<wbr>m2 will be utilized in combination with full-dose pemetrexed.<wbr> Overall 
survival is the primary endpoint; secondary endpoints include safety and 
assessment of anti-tumor activity as determined by progression-free survival and 
objective response rate.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>TH-302 Recent and Upcoming Data 
Presentations</STRONG> </div><div style="margin-bottom: 10px;">In April, two posters were presented at the 
American Association for Cancer Research (AACR) Annual Meeting 2014, April 5 - 
9, San Diego, California titled "Combination hypoxia-specific chemotherapy and 
immunotherapy of prostate cancer" and "Targeting vascular endothelial growth 
factor A and tumor hypoxia combined with radiation eradicates sarcomas through 
destruction of tumor vasculature and thwarting of the hypoxic response".<wbr> </div><div style="margin-bottom: 10px;">In May, two posters will be presented at the American Association for 
Cancer Research's (AACR's) Special Conference on Pancreatic Cancer: Innovations 
in Research and Treatment, May 18-21, New Orleans, Louisiana: </div><div style="margin-bottom: 10px;">Abstract 
: Combination treatment with hypoxia-activated prodrug TH-302 and radiation 
reduce pancreatic tumor initiating cells and tumor growth in patient-derived 
xenografts; 4:30 PM - 7:00 PM Central Time on Monday, May 19, 2014 (Poster 
Session A).<wbr> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=A102"><font color="#e95e0b">:Oncology:A102</font></a>]</font></font></div><div style="margin-bottom: 10px;">Abstract : Pharmacodynamic changes from the TH-302, 
gemcitabine, and nab-paclitaxel triplet combination in a xenograft model of 
pancreatic cancer; 12:30 PM - 3:00 PM Central Time on Tuesday, May 20, 2014 
(Poster Session B).<wbr> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=B88"><font color="#e95e0b">:Oncology:B88</font></a>]</font></font></div><div style="margin-bottom: 10px;">Also in May, two posters will be presented in poster 
highlight sessions at the 2014 American Society of Clinical Oncology (ASCO) 
Annual Meeting, May 30 - June 3, Chicago, Illinois: </div><div style="margin-bottom: 10px;">Abstract #2029 
(Poster #20): Phase 1/<wbr>2 study of investigational hypoxia-targeted drug, TH-302, 
and bevacizumab in recurrent glioblastoma (GBM) following bevacizumab failure; 
1:00 PM - 4:00 PM Central Time on Friday, May 30, 2014, in E35b.<wbr> </div><div style="margin-bottom: 10px;">Abstract #8534 (Poster #14): Preliminary safety and efficacy of TH-302, 
an investigational hypoxia-targeted drug, and dexamethasone in patients with 
relapsed/<wbr>refractory multiple myeloma (RR MM); 1:00 PM - 4:00 PM Central Time on 
Friday, May 30, 2014, in S405.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Status of Pivotal 
Trials</STRONG> </div><div style="margin-bottom: 10px;">TH-302 is currently under evaluation in two Phase 3 trials: one in 
combination with doxorubicin versus doxorubicin alone in patients with soft 
tissue sarcoma, and the other in combination with gemcitabine versus gemcitabine 
and placebo in patients with advanced pancreatic cancer (MAESTRO).<wbr> Both Phase 3 
trials are being conducted under Special Protocol Agreements with the U.<wbr>S.<wbr> Food 
and Drug Administration (FDA).<wbr> The FDA and the European Commission have granted 
TH-302 Orphan Drug Designation for the treatment of soft tissue sarcoma and 
pancreatic cancer.<wbr> TH-302 is also being investigated in hematological 
malignancies and in combination with other therapies in a variety of solid 
tumors.<wbr> </div><div style="margin-bottom: 10px;"><img src="http://ci.beaufour-ipsen.com/db/attachments/oncology/9676/1/ScreenCapture1.jpg?user-agent=rss"> </div><div style="margin-bottom: 10px;">Threshold has a global 
license and co-development agreement for TH-302 with Merck KGaA, Darmstadt, 
Germany, which includes an option for Threshold to co-commercialize in the U.<wbr>S.<wbr> 
<BR> </div><div>Source:www.<wbr>thresholdpharm.<wbr>com </div><!-- Comment details --><a name="oncology9676attachments"></a>
<div style="margin-top: 10px; margin-bottom: 10px;">&nbsp;&nbsp;1.&nbsp;<a href="http://ci.beaufour-ipsen.com/db/attachments/oncology/9676/1/ScreenCapture1.jpg">ScreenCapture1.jpg</a>&nbsp;&nbsp;(82,9 KB)<br></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9676">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-02T13:17:22+02:00</dc:date><dc:creator>jac89886</dc:creator><enclosure url="http://ci.beaufour-ipsen.com/db/attachments/oncology/9676/1/ScreenCapture1.jpg" length="84929" type="image/jpeg"/></item><item>
<title>re: Pfizer Submits A Revised Bid Proposal To Acquire AstraZeneca</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10836</link>
<description>re: Pfizer Submits A Revised Bid Proposal To Acquire AstraZeneca</description><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10836</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10836">re: Pfizer Submits A Revised Bid Proposal To Acquire AstraZeneca</a></strong> </font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10836">PharmaWorld10836</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 May 2014 | 12:56</font><br><br><div style="border-left: 2px solid #8B1010; padding: 0px 0px 5px 12px; margin-bottom: 3px;"><span style="font-weight: bold; font-size: 14px;">Pfizer Submits A Revised Bid Proposal To Acquire AstraZeneca</span>&nbsp;<font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font><br><span style="font-size: 12px;">Comment:: Pfizer has today submitted a revised proposal offering £50 per 
share including 1.<wbr>845 shares in the combined company and £15.<wbr>98 in cash valuing 
the company at £63bn.<wbr> AZ has acknowledged the offer indicated that its board 
will meet to discuss and that it will make a further announcement in due 
course.<wbr></span>&nbsp;&nbsp;<a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10835">...</a><br><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10835" class="commentpermalink">PharmaWorld10835</a> / <span class="date">02 May 2014</span> /
<span class="time">11:15:00 o'clock CEST</span>
</font></div><div style="margin-bottom: 10px;">Within hours AstraZeneca has announced that it rejects Pfizer's new offer claiming it "substantially undervalues the company" and advising shareholders to take no action.<wbr> If it is to proceed, Pfizer either can raise its offer or proceed with a hostile bid targeting shareholders directly.<wbr> </div><div style="margin-bottom: 10px;">AZ's full statement reads as such: </div><div style="margin-bottom: 10px;">The financial and other terms described in the Proposal are inadequate, substantially undervalue AstraZeneca and are not a basis on which to engage with Pfizer.<wbr> The large proportion of the consideration payable in Pfizer shares and the tax-driven inversion structure remain unchanged.<wbr> Accordingly, the Board has rejected the Proposal.<wbr> </div><div>Leif Johansson, Chairman of AstraZeneca, said: &ldquo;AstraZeneca continues to invest significantly in research, development and manufacturing in the U.<wbr>K.<wbr>, Sweden and the U.<wbr>S.<wbr> We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the Board believes will deliver significant value for shareholders.<wbr> Pfizer&rsquo;s proposal would dramatically dilute AstraZeneca shareholders&rsquo; exposure to our unique pipeline and would create risks around its delivery.<wbr> As such, the Board has no hesitation in rejecting the Proposal.<wbr>&rdquo; </div><!-- Comment details --><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10836" class="commentpermalink">PharmaWorld10836</a> / <span class="date">02 May 2014</span> /
<span class="time">12:56:18 o'clock CEST</span>
</font><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10836">Add a Comment on this Article</a><br><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10835">View thread  PharmaWorld10835: Pfizer Submits A Revised Bid Proposal To Acquire AstraZeneca</a>]]></content:encoded><dc:date>2014-05-02T12:56:18+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Pfizer Submits A Revised Bid Proposal To Acquire AstraZeneca [sub:Acquisition]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10835</link>
<description>Pfizer Submits A Revised Bid Proposal To Acquire AstraZeneca [sub:Acquisition]</description><comments>http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10835</comments><category>sub:Acquisition</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10835</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10835">Pfizer Submits A Revised Bid Proposal To Acquire AstraZeneca</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=PharmaWorld&sdate=20140831&edate=20140501&cat=sub%3aAcquisition"><font color="#e95e0b">:PharmaWorld:sub:Acquisition</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10835">PharmaWorld10835</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 May 2014 | 11:15</font><br><br><div style="margin-bottom: 10px;">Comment:: Pfizer has today submitted a revised proposal offering £50 per 
share including 1.<wbr>845 shares in the combined company and £15.<wbr>98 in cash valuing 
the company at £63bn.<wbr> AZ has acknowledged the offer indicated that its board 
will meet to discuss and that it will make a further announcement in due 
course.<wbr> </div><div style="margin-bottom: 10px;">The new offer has been made following consultations with major shareholders 
in London this week.<wbr> Pfizer hopes that the increased proposal will prompt AZ to 
engage in further discussions.<wbr> </div><div style="margin-bottom: 10px;">The new offer represents a 7% premium to the initial proposal and a 39% 
premium to AZ's closing share price on January 3rd before Pfizer's interest was 
disclosed.<wbr> </div><div style="margin-bottom: 10px;">Pfizer has apparently also written to the UK Prime Minister outlining its 
commitment to the country and the lifesciences sector.<wbr> It claims it will 
complete the construction of the new Cambridge campus and employ a minimum of 
20% of the combined company's R&amp;D workforce in the UK.<wbr> Additionally, it will 
based its European HQ and regulatory HQ in the UK.<wbr> </div><div>Source: <A href="http://www.pfizer.com">www.<wbr>pfizer.<wbr>com</A> </div><!-- Comment details --><span style="font-weight: bold; font-style: italic;"><br>Comments</span><a name="PharmaWorld10836c"></a><br><div style="border: 1px solid #AAA; background-color: #FFF; margin-left: 10px; padding: 5px;"><div style="margin-bottom: 10px;">Within hours AstraZeneca has announced that it rejects Pfizer's new offer claiming it "substantially undervalues the company" and advising shareholders to take no action.<wbr> If it is to proceed, Pfizer either can raise its offer or proceed with a hostile bid targeting shareholders directly.<wbr> </div><div style="margin-bottom: 10px;">AZ's full statement reads as such: </div><div style="margin-bottom: 10px;">The financial and other terms described in the Proposal are inadequate, substantially undervalue AstraZeneca and are not a basis on which to engage with Pfizer.<wbr> The large proportion of the consideration payable in Pfizer shares and the tax-driven inversion structure remain unchanged.<wbr> Accordingly, the Board has rejected the Proposal.<wbr> </div><div>Leif Johansson, Chairman of AstraZeneca, said: &ldquo;AstraZeneca continues to invest significantly in research, development and manufacturing in the U.<wbr>K.<wbr>, Sweden and the U.<wbr>S.<wbr> We are showing strong momentum as an independent company, in particular with our exciting, rapidly progressing pipeline, which the Board believes will deliver significant value for shareholders.<wbr> Pfizer&rsquo;s proposal would dramatically dilute AstraZeneca shareholders&rsquo; exposure to our unique pipeline and would create risks around its delivery.<wbr> As such, the Board has no hesitation in rejecting the Proposal.<wbr>&rdquo; </div><font size="-1">Jacquelyne CANTLE MEYRICK / <a href="http://ci.beaufour-ipsen.com/traction/permalink/PharmaWorld10836" class="commentpermalink">PharmaWorld10836</a> / <span class="date">02 May 2014</span> /
<span class="time">12:56:18 o'clock CEST</span>
</font></div><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=PharmaWorld&sdate=20140831&edate=20140501&rec=10835">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-02T11:15:00+02:00</dc:date><dc:creator>jac89886</dc:creator></item><item>
<title>Exelixis Re-States Its Belief In Cabozantanib As A Treatment For  mCRPC [class:KinaseInhibitors, dis:Prostate, news]</title>
<link>http://ci.beaufour-ipsen.com/traction/permalink/Oncology9675</link>
<description>Exelixis Re-States Its Belief In Cabozantanib As A Treatment For  mCRPC [class:KinaseInhibitors, dis:Prostate, news]</description><category>class:KinaseInhibitors</category><category>dis:Prostate</category><category>news</category><guid isPermaLink="true">http://ci.beaufour-ipsen.com/traction/permalink/Oncology9675</guid>
<content:encoded><![CDATA[<font size="+1"><strong><a href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9675">Exelixis Re-States Its Belief In Cabozantanib As A Treatment For  mCRPC</a></strong> <font size="-1"><font color="#e95e0b">[<a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=class%3aKinaseInhibitors"><font color="#e95e0b">:Oncology:class:KinaseInhibitors</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=dis%3aProstate"><font color="#e95e0b">:Oncology:dis:Prostate</font></a></font></font><font size="-1"><font color="#e95e0b">, <a href="http://ci.beaufour-ipsen.com/traction?type=cat&proj=Oncology&sdate=20140831&edate=20140501&cat=news"><font color="#e95e0b">:Oncology:news</font></a>]</font></font></font><br><font size="-1" class="details"><a href="http://ci.beaufour-ipsen.com/traction/permalink/Oncology9675">Oncology9675</a> | Posted by <a href="http://ci.beaufour-ipsen.com/traction/profile/174">Jacquelyne CANTLE MEYRICK</a> | 02 May 2014 | 10:55</font><br><br><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Comment: 
During its earnings call management made some interesting comments about the 
IDMC decision not to stop the caboznatinib COMET-1 study at the interim analysis 
and re-affirmed its confidence in the compound.<wbr> The situation has echoes of 
the OngoGenix situation where the PhIII Custirsen trial was also 
recommended to continue at the interim analysis but where it 
was confirmed this week that it failed to meet its OS phIII trial endpoint.<wbr> 
However, as Exelixis highlighted, there are actually 3 drugs approved 
for the treatment of mCRPC that did not meet an OS endpoint at the interim 
analysis stage but did at final analysis.<wbr>  </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA"><STRONG>Key 
Comments From The Cabozantinib Update</STRONG></SPAN> </div><div style="margin-bottom: 10px;"><FONT size="2"><FONT face="Arial"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Gisela 
M.<wbr> Schwab, Chief Medical Officer noted that it is the group's </SPAN> 
highest priority for 2014 to prepare for the data readout and 
potential filing for advanced mCRPC.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2"><FONT face="Arial">As a reminder the COMET 
programme involves two trials COMET-1 is focused on overall survival and COMET-2 
on pain reponse associated with bone metastases.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2"><FONT face="Arial">COMET-1 reached its involvement target of 960 patients 
in September of 2013 and COMET-2 continues to enroll patients in the United 
States, the UK, Ireland and Australia.<wbr> </FONT></FONT> </div><div style="margin-bottom: 10px;"><FONT size="2"><FONT face="Arial">If the combined objective is achieved, Exelixis 
believes this would differentiate cabozantinib from other agents used in the 
treatment of mCRPC.<wbr></FONT></FONT> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">The 
IDMC for COMET-1 conducted the planned interim overall survival analysis for 
this study after 386 events have been reached.<wbr> </SPAN> </div><div style="margin-bottom: 10px;"><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">Its 
options at this point could have been: </SPAN> </div><div style="margin-bottom: 10px;"><OL><LI><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">To stop 
  the study for efficacy if pre-specified parameters had been met.<wbr> </SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">To 
  stop the study or recommended modifications if there had been 
  safety concerns or </SPAN></LI>
<LI><SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">To recommend that the study continue 
  unchanged.<wbr></SPAN></LI>
</OL> </div><div style="margin-bottom: 10px;">As is the case 
with most interim analysis, the COMET-1 IDMC recommended that the study continue 
to the final analysis without modifications.<wbr> And as is customary, the IDMC did 
not share any data with us and the study remains blinded.<wbr> The final analysis 
now requires 578 events a point believed to be achievable this 
year.<wbr> </div><div style="margin-bottom: 10px;">As a reminder 
the ph2 study N=144 which was similar in design to that included in 
COMET-1  observed a median overall survival of 10.<wbr>8 
months.<wbr> Additionally, clinically meaningful pain relief was reported by 57% of 
evaluable patients, reduction of this continuation of narcotic analgesics in 
55%, bone scan response in 63%, and a reduction in measurable disease in 80% of 
evaluable patients.<wbr> </div><div style="margin-bottom: 10px;">Ghisela also 
emphasied that it is important to remember that there are examples of large 
randomized pivotal study in CRPC, where a statistically significant and 
clinically meaningful improvement in overall survival was observed only at 
the final analysis although the trial did NOT meet the primary endpoint at 
the interim analysis </div><div style="margin-bottom: 10px;">.<wbr> </div><div style="margin-bottom: 10px;">After six 
pivotal trials that generated positive and statistically significant overall 
survival data in mCRPC that ultimately resulted in regulatory approval, only 
three of them at the primary endpoint at the interim analysis achieved this 
including Cougar-301 for abiraterone AFFIRM for enzalutamide and ALSYMPCA 
with Radium-223.<wbr> The others including the TAX 327 study with Docetaxel, the 
IMPACT study with sipuleucel-T and the TROPIC study with cabazitaxel were shown 
to have a significant and clinically meaningful overall survival benefit at the 
final analysis and each represented an important clinical advance that led to 
regulatory approval in mCRPC.<wbr> </div><div style="margin-bottom: 10px;"><STRONG>Status 
of Other Trials</STRONG> </div><div style="margin-bottom: 10px;"><UL><LI>
  Randomized 
  Phase 2 study evaluating different doses of cabozantinib in combination with 
  full-dose abiraterone in CRPC patient prior chemotherapy commenced in the 
  fourth quarter of 2013 and is well underway.<wbr></LI>
<LI>
  <SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">The 
  Phase 3 study in hepatocellular cancer called CELESTIAL is a 760-patient study 
  in patients, who have received a prior sorafenib.<wbr> CELESTIAL will compare 
  overall survival between patients treated with cabozantinib and those 
  receiving placebo.<wbr> This study is actively involving patients in multiple 
  continents.<wbr> </SPAN></LI>
<LI>
  <SPAN lang="EN-US" style="FONT-SIZE: 10pt; FONT-FAMILY: 'Arial','sans-serif'; mso-bidi-font-size: 12.0pt; mso-fareast-font-family: 'Times New Roman'; mso-bidi-font-family: 'Times New Roman'; mso-ansi-language: EN-US; mso-fareast-language: EN-US; mso-bidi-language: AR-SA">The 
  Phase 3 study METEOR study in renal cell cancer,  a 650-patient 
  randomized open-label study that is comparing cabozantinib with everolimus in 
  patients who have received and progressed on or 
  following at least one prior VEGFR tyrosine kinase inhibitor, i.<wbr>e.<wbr>, second or 
  later-line therapy, is also off to a good 
start.<wbr></SPAN></LI>
</UL> </div><div style="margin-bottom: 10px;"><P style="MARGIN: 0cm 0cm 0pt">Top-line data in 
RCC is expected in 2015 and HCC in 2016 and 2017 timeframe following the COMET-1 
and COMET-2 topline data that are expected in 2014.<wbr></P> </div><div>source: <A href="http://www.exelixis.com">www.<wbr>exelixis.<wbr>com</A> </div><!-- Comment details --><br><a class="showallcomments" href="http://ci.beaufour-ipsen.com/traction?type=single&proj=Oncology&sdate=20140831&edate=20140501&rec=9675">Add a Comment on this Article</a><br>]]></content:encoded><dc:date>2014-05-02T10:55:20+02:00</dc:date><dc:creator>jac89886</dc:creator></item></channel>
</rss>